

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 63.9452 Seconds  
(without alignments)  
36.290 Million cell updates/sec

Title: US-10-009-122-24  
Perfect score: 30  
Sequence: 1 OKLVFF 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : A\_Geneseq\_16Dec04:\*1: Geneseqp1980s:\*2: Geneseqp1990s:\*3: Geneseqp2000s:\*4: Geneseqp2001s:\*5: Geneseqp2002s:\*6: Geneseqp2003as:\*7: Geneseqp2003bs:\*8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	30	100.0	6	2	Aaw02313 Beta-amyl
2	30	100.0	6	2	Aaw45944 Amyloid b
3	30	100.0	6	2	Aaw29090 A-beta-bi
4	30	100.0	6	2	Aaw89377 Beta-amyl
5	30	100.0	6	4	Aab48496 Antifibri
6	30	100.0	6	5	Abg71008 Long form
7	30	100.0	6	5	Abb05156 Beta amyl
8	30	100.0	6	5	Aaul1911 Peptide #
9	30	100.0	6	8	Adj64059 Human bet
10	30	100.0	6	8	Adq37380 Amyloid-b
11	30	100.0	6	8	Adq37335 Antifibri
12	30	100.0	6	8	Adq37352 Beta-amyl
13	30	100.0	6	8	Adq37370 Amyloid-b
14	30	100.0	7	2	Aar45231 Beta amyl
15	30	100.0	7	2	Aaw02312 Beta-amyl
16	30	100.0	7	2	Aaw02311 Beta-amyl
17	30	100.0	7	2	Aaw45940 Amyloid b
18	30	100.0	7	2	Aaw89376 Beta-amyl
19	30	100.0	7	2	Aaw89375 Beta-amyl
20	30	100.0	7	5	Abg71006 Long form
21	30	100.0	7	5	Abg71007 Long form
22	30	100.0	7	5	Abb05154 Beta amyl
23	30	100.0	7	5	Abb05155 Beta amyl
24	30	100.0	7	5	Ada90153 Anti-Abet
25	30	100.0	7	6	Ada90936 Solid-pha

26	30	100.0	7	8	Adj64057 Human bet
27	30	100.0	7	8	Adj64058 Human bet
28	30	100.0	7	8	Adq37378 Amyloid-b
29	30	100.0	7	8	Adq37350 Beta-amyl
30	30	100.0	7	8	Adq37351 Beta-amyl
31	30	100.0	8	2	Aaw02310 Beta-amyl
32	30	100.0	8	2	Aaw45937 Amyloid b
33	30	100.0	8	2	Aaw89374 Beta-amyl
34	30	100.0	8	5	Abg71005 Long form
35	30	100.0	8	5	Abb05153 Beta amyl
36	30	100.0	8	8	Adj64056 Human bet
37	30	100.0	8	8	Adq37377 Amyloid-b
38	30	100.0	8	8	Adq37349 Beta-amyl
39	30	100.0	9	2	Aar45239 Mutant am
40	30	100.0	9	2	Aaw45935 Amyloid b
41	30	100.0	9	4	Aab48493 Antifibri
42	30	100.0	9	5	Abb04913 Human amy
43	30	100.0	9	5	Aaul1667 Peptide #
44	30	100.0	9	6	Abp57517 Different
45	30	100.0	9	6	Aae35436 Beta pep
46	30	100.0	9	8	Adi35874 Amyloid b
47	30	100.0	9	8	Adi35981 Amyloid b
48	30	100.0	9	8	Adp44609 Radioisot
49	30	100.0	9	8	Adq37260 Vaccine a
50	30	100.0	9	8	Adq37376 Amyloid-b
51	30	100.0	10	2	Aaw45934 Amyloid b
52	30	100.0	10	2	Aab46224 Human APP
53	30	100.0	10	4	Aab46225 Human APP
54	30	100.0	10	4	Aab46224 Human APP
55	30	100.0	10	4	Aab46223 Human APP
56	30	100.0	10	4	Aab46227 Human APP
57	30	100.0	10	4	Aab82641 All-D pep
58	30	100.0	10	5	Aau96829 Amyloid t
59	30	100.0	10	6	Abp57511 Different
60	30	100.0	10	6	Aae35455 Abeta pep
61	30	100.0	10	6	Adq37280 Vaccine a
62	30	100.0	10	8	Adq37375 Amyloid-b
63	30	100.0	10	8	Adq37371 Amyloid-b
64	30	100.0	10	8	Adq37374 Amyloid-b
65	30	100.0	10	8	Adq37374 Amyloid-b

ALIGNMENTS

RESULT 1	
Aaw02313	AAW02313 standard, peptide; 6 AA.
ID	AAW02313
XX	AAW02313;
AC	
XX	
DT	02-MAY-1997 (first entry)
XX	
DE	Beta-amylid modulator peptide #4.
XX	
XX	Beta-amylid; modulator; amyloid plaque; brain lesion; amyloidosis;
KW	cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;
KW	familial amyloid polyneuropathy; familial amyloid cardiomyopathy;
KW	isolated cardiac amyloidosis; systemic benign amyloidosis; insulinoma;
KW	bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;
KW	adult-onset diabetes; familial Mediterranean fever; therapy; deafness;
XX	scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.
OS	Synthetic.
XX	
PN	WO9628471-Al.
XX	
PD	19-SEP-1996.
XX	
PF	14-MAR-1996; 96WO-US0003492.
XX	
PR	14-MAR-1995; 95US-00404831.
PR	07-JUN-1995; 95US-00475579.

27-OCT-1995; 95US-00548998.  
(PHAR-) PHARM PEPTIDES INC.  
Findels MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
Kaaman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;  
Kubasek W, Chin J, Lee J, Kelley M;  
WPI; 1996-433762/43.  
Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
protein coupled (indirectly) to at least 1 modifying gp., useful in  
treatment of Alzheimer's disease.  
Claim 16; Page 91; 106pp; English.  
AAW2310-W02332 represent the peptide portions of the beta-amyloid  
modulator compounds of the invention. Beta-amyloid peptide is a 4  
kilodalton peptide that is the major protein component of amyloid  
plaques. Amyloid plaques are present both in the brain lesions, and in  
the walls of cerebral blood vessels in Alzheimer's disease patients. The  
amyloid modulators of the invention comprise an amyloidogenic protein or  
peptide (such as this sequence) coupled directly or indirectly to at  
least one modifying group. The modifying group is preferably a cyclic,  
heterocyclic, or polycyclic group, such as decaalin, a cholanyl group, a  
biotin containing group, or a fluorescein containing group. These  
compounds then modulate the aggregation of these sequences to natural  
amyloid proteins or peptides when contacted with the natural  
amyloidogenic proteins or peptides. The modulator compounds can be used  
in the treatment of disorders associated with amyloidosis, such as  
familial amyloid polyneuropathy, familial amyloid cardiomyopathy,  
isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,  
bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
nephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
and other types of amyloidosis. The modulators are also useful for the  
treatment of disorders associated with beta-amyloidosis, especially  
Alzheimer's disease  
Sequence 6 AA;  
Query Match 100.0%; Score 30; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QKLVFF 6  
Db 1 QKLVFF 6  
RESULT 2  
AAW45944  
ID AAW45944 standard; peptide; 6 AA.  
AC AAW45944;  
XX  
XX 25-MAR-2003 (revised)  
DT 30-JUN-1998 (first entry)  
XX  
XX Amyloid beta peptide fragment.  
DE  
DE Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
KW positron emission tomography; PET; Down's syndrome; amyloidosis.  
XX  
XX Homo sapiens.  
XX  
XX WO9721728-A1.  
XX  
XX 19-JUN-1997.  
XX  
XX 09-DEC-1996; 96WO-S0001621.  
XX  
XX 12-DEC-1995; 95SE-00004467.  
XX

29-DEC-1995; 95US-0009386P.  
(KARO-) KAROLINSKA INNOVATIONS AB.  
Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;  
WPI; 1997-332723/30.  
Use of new and known peptide(s) for inhibition of polymerisation of  
amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
Down's syndrome associated with amyloidosis.  
Example 1; Fig 2B; 31pp; English.  
This sequence represents a fragment of the amyloid beta peptide. The  
invention relates to the use of peptide compounds for inhibition of  
polymerisation of amyloid beta peptide (ABP), as model substances for  
synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a  
tool for the identification of other organic compounds with similar  
functional properties, or as ligands in positron emission tomography. The  
peptides may be used in treatment of amyloidosis, especially in treatment  
of Alzheimer's disease associated with amyloidosis, for treatment or  
prevention of demens in patients with Down's syndrome, for treatment or  
prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch  
type) or for the prevention of fibril formation of human amyloid protein.  
They can also be used for identifying other molecules with similar  
properties and/or as ligands for detection of amyloid deposits using e.g.  
positron emission tomography. (Updated on 25-MAR-2003 to correct PI  
field.)  
Sequence 6 AA;  
Query Match 100.0%; Score 30; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QKLVFF 6  
Db 1 QKLVFF 6  
RESULT 3  
AAW29090  
ID AAW29090 standard; peptide; 6 AA.  
XX  
XX AAW29090;  
XX  
XX 20-JUL-1999 (first entry)  
DT  
DE A-beta-binding peptide fragment conjugated to cyclosporin.  
XX  
XX Cyclosporin; A-beta peptide; conjugate; neurological disease; Alzheimer;  
KW multiple sclerosis; amyotrophic lateral sclerosis; ALS;  
XX non-immunosuppressive; amyloid plaque formation.  
XX  
XX Homo sapiens.  
XX  
XX Key  
FH Modified-site 6  
FT Location/Qualifiers  
FT /note= "The C-terminal is condensed onto the side chain  
FT of Lys(7) of the cyclosporin analog described in  
FT AAW29087, AAW29088, AAW29095 and AAW29097"  
XX  
XX WO9910374-A1  
XX  
XX 04-MAR-1999.  
XX  
XX 25-AUG-1998; 98WO-US017544.  
XX  
XX 26-AUG-1997; 97US-0057751P.  
XX  
XX (WISC ) WISCONSIN ALUMNI RES FOUND.  
XX



PI Rich DH, Solomon ME;  
 XX WPI; 1999-276928/23.  
 XX  
 XX New A $\beta$ -binding peptide conjugates and C $\alpha$ A analogs - useful in treatment  
 PT of neurological diseases e.g. Alzheimer's disease, Multiple Sclerosis  
 PT etc.  
 XX  
 XX Claim 5; Page 98; 129pp; English.  
 XX  
 XX New conjugates are disclosed which are of formula A-Z, in which: A is (1)  
 CC a cyclosporin A analogue described in AW29087 or (2) an FK506 binding  
 CC peptide inhibitor; and Z is a polypeptide comprising 5 or more contiguous  
 CC residues of A-beta peptide. The compounds are novel chemical inducers of  
 CC dimerization which are non-immunosuppressive and which are inhibitors of  
 CC A-beta peptide aggregation and deposition in amyloid plaques. The adverse  
 CC consequences of amyloid plaque formation can be prevented or ameliorated  
 CC by sequestering the A-beta peptide in monomeric form with a conjugate  
 CC which links the A-beta to cyclophilin or FKBP, therefore providing a  
 CC mechanism to minimize the amount of free A-beta available for fibril  
 CC formation and deposition. The compounds can be used for the treatment of  
 CC Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis  
 XX  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 30; DB 2; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 DB 1 QKLVFF 6

RESULT 4  
 ID AAW89377 standard; peptide; 6 AA.  
 XX  
 XX AAW89377;  
 XX  
 XX 02-MAR-1999 (first entry)  
 XX  
 XX Beta-amyloid peptide derivative A-beta-15-20.  
 XX  
 XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; BAP.  
 XX  
 XX Homo sapiens.  
 OS  
 XX Synthetic.  
 XX  
 XX US5854204/A.  
 XX  
 XX 29-OEC-1998.  
 XX  
 XX 14-MAR-1996; 96US-00612785.  
 XX  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX  
 XX Hundal A, Gefter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
 PI Fideis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
 PI Garnick MB, Kubasek W, Signer ER;  
 XX  
 XX WPI; 1999-094964/08.  
 XX  
 XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.

XX Example 1A; Col 64; 52pp; English.  
 PS  
 XX  
 CC The present invention describes beta-amyloid peptide (bAP) derivatives.  
 CC The bAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically bAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The bAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of bAP to  
 CC labelled bAP derivatives. Some bAP derivatives inhibit bAP aggregation  
 CC even when bAP is present in molar excess. The present sequence represents  
 CC a bAP derivative  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 30; DB 2; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 DB 1 QKLVFF 6

RESULT 5  
 ID AAB48496 standard; peptide; 6 AA.  
 XX  
 XX AAB48496;  
 XX  
 XX 02-MAR-2001 (first entry)  
 XX  
 XX Antifibrillogenic peptide #23.  
 DE  
 XX  
 XX Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.  
 XX  
 XX Homo sapiens.  
 OS  
 XX  
 XX Key Modified-site 6 Location/Qualifiers  
 FT /note="C-terminal amide"  
 XX  
 XX WO200068263-A2.  
 PN  
 XX 16-NOV-2000.  
 PD  
 XX  
 XX 04-MAY-2000; 2000WO-CA000515.  
 XX  
 XX 05-MAY-1999; 99US-0132592P.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 XX  
 XX Chalifour R, Gervais F, Gupta A;  
 PI  
 XX WPI; 2001-031852/04.  
 DR  
 XX  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 XX Claim 7; Page 26; 46pp; English.  
 PS  
 XX  
 CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein

```

XX SQ Sequence 6 AA;
Query Match 100.0%; Score 30; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 OKLVFF 6
Db 1 OKLVFF 6

RESULT 6
ID ABG71008 standard; peptide; 6 AA.
AC ABG71008;
XX 05-DEC-2002 (first entry)
DT Long form beta-amyloid protein fragment #5.
DE Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;
KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;
KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;
KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;
KW adult onset diabetes; Gerstmann-Straussler-Scheinker syndrome;
KW insuloma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;
KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;
KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;
KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;
KW hereditary non-neuropathic systemic amyloidosis;
KW familial Mediterranean Fever.
XX Homo sapiens.
OS US2002098173-A1.
XX 25-JUL-2002.
PD 04-OCT-2001; 2001US-00972475.
XX 14-MAR-1995; 95US-00404831.
PR 07-JUN-1995; 95US-00475579.
PR 27-OCT-1995; 95US-00548998.
PR 14-MAR-1996; 96US-00617267.
XX (PRAE-) PRAECIS PHARM INC.
XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;
PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;
XX WPI; 2002-697709/75.
XX Amyloid modulator useful for treating a disorder associated with
PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment
PT coupled to a modifying group.
XX Example 12; Page 35; 41pp; English.
XX The invention describes an amyloid modulator comprising an amyloidogenic
XX protein and/or peptide fragment coupled to a modifying group so that the
XX compound modulates the aggregation of natural amyloid proteins or
XX peptides. The modulator is used for treating a disorder associated with
XX amyloidosis e.g. familial amyloid polynuropathy (Portuguese, Japanese
XX and Swedish types), familial amyloid cardiomyopathy (Danish type),
XX isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine
XX spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset
XX diabetes, Gerstmann-Straussler-Scheinker syndrome, insuloma, isolated
XX atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or
XX macroglobulinaemia-associated amyloidosis, primary localised cutaneous
XX nodular amyloidosis associated with Sjogren's syndrome, reactive
XX (secondary), amyloidosis, familial Mediterranean Fever and familial
CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),
CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,
CC amyloidosis associated with long term haemodialysis, hereditary non-
CC neuropathic systemic amyloidosis (familial amyloid polynuropathy III),
CC familial amyloidosis of Finnish type, amyloidosis associated with
CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary
CC renal amyloidosis and lysozyme-associated hereditary systemic
CC amyloidosis. The compound is capable of altering and inhibiting beta-
CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins
CC or peptides when contacted with a molar excess amount of natural beta-APs
CC relative to the modulator. This sequence represents a fragment of the
CC long form of beta-amyloid used in the creation of an amyloid modulator
XX
XX SQ Sequence 6 AA;
Query Match 100.0%; Score 30; DB 5; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 OKLVFF 6
Db 1 OKLVFF 6

RESULT 7
ID ABB05156 standard; peptide; 6 AA.
XX ABB05156;
XX 02-APR-2002 (first entry)
DT Beta amyloid peptide (15-20) SEQ ID NO:8.
DE Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;
KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;
KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;
KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;
KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;
KW amyloidogenic disease; beta amyloid deposition; amyloidosis;
KW hereditary cerebral haemorrhage; familial amyloid polynuropathy.
XX Homo sapiens.
OS Synthetic.
XX US6319498-B1.
XX 20-NOV-2001.
XX 14-MAR-1996; 96US-00617267.
XX 14-MAR-1995; 95US-00404831.
PR 07-JUN-1995; 95US-00475579.
PR 27-OCT-1995; 95US-00548998.
XX (PRAE-) PRAECIS PHARM INC.
XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;
PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;
XX WPI; 2002-146668/19.
XX Amyloid modulator compound useful for treatment of an amyloidogenic
PT disease such as Alzheimer's disease comprises an aggregation core domain
PT and a modifying group attached to it.
XX Example 11; Col 63; 54pp; English.
XX The present invention describes an amyloid modulator compound (I)
XX comprising an aggregation core domain and a modifying group attached to
XX it. (I) has neurotropic, neuroprotective, immunosuppressive, antimicrobial,
XX antidiabetic, antipyretic, dermatological, cardiovascular, nephrotropic
XX and auditory activities, and can be used as a natural amyloid aggregation
CC
```

CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polynuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (II)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention

XX SQ Sequence 6 AA;

Query Match 100.0%; Score 30; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVPFF 6  
 |||||  
 Db 1 QKLVPFF 6

#### RESULT 8

AAU11911  
 ID AAU11911 standard; peptide; 6 AA.

XX AC AAU11911;

XX DT 09-APR-2002 (first entry)

XX DE Peptide #24, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.

XX KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; neurotropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX OS Synthetic.

XX FH Key Location/Qualifiers  
 FT Modified-site 6 /note= "C-terminal amide"

XX PN WO200185093-A2.

XX PD 15-NOV-2001.

XX PF 22-DEC-2000; 2000WO-IB002078.

XX PR 23-DEC-1999; 99US-0171877P.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Green AM, Gervais F;

XX DR WPI; 2002-075222/10.

PT Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.

XX PS Disclosure; Page 10; 68pp; English.

XX CC The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor

CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)

XX SQ Sequence 6 AA;

Query Match 100.0%; Score 30; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVPFF 6  
 |||||  
 Db 1 QKLVPFF 6

#### RESULT 9

ADJ64059  
 ID ADJ64059 standard; peptide; 6 AA.

XX AC ADJ64059;

XX DT 06-MAY-2004 (first entry)

XX DE Human beta-amyloid long form peptide fragment #5.

XX KW Amyloidogenic protein; therapy; amyloidosis;  
 KW familial amyloid polynuropathy; cardiomyopathy;  
 KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
 KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 KW familial mediterranean fever; urticaria; deafness;  
 KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
 KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 KW beta-amyloid peptide; human.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers  
 FT Modified-site 1 /note= "N-terminal cheryl"

XX PN US2004005307-A1.

XX PD 08-JAN-2004.

XX PF 17-JUN-2003; 2003US-00463729.

XX PR 14-MAR-1995; 95US-00404831.

XX PR 07-JUN-1995; 95US-00475579.

XX PR 27-OCT-1995; 95US-00548998.

XX PR 14-MAR-1996; 96US-00617267.

XX PR 04-OCT-2001; 2001US-00972475.

XX PA (PRAB-) PRACIS PHARM INC.

XX PI Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;

XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;

XX DR WPI; 2004-131767/13.

XX PT New amyloidogenic protein aggregation modulators useful for treating  
 PT disorder associated with amyloidosis e.g. familial amyloid  
 PT polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.

XX PS Example 12; SEQ ID NO 8; 52pp; English.

XX CC The invention relates to amyloidogenic proteins or peptide fragments  
 CC aggregation modulators. The invention is used for treating disorder  
 CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 CC (Portuguese, Japanese and Swedish types), familial amyloid-cardiomyopathy  
 CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 CC Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
 CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)

amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary localized cutaneous nodular amyloidosis associated with Sjogren's syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever and familial amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of Icelandic type, amyloidosis associated with long term haemodialysis, hereditary non-neuropathic systemic amyloidosis (familial amyloid polyneuropathy III), familial amyloidosis of Finnish type, amyloidosis associated with medullary carcinoma of the thyroid, fibrinogen associated hereditary renal amyloidosis and lysozyme-associated hereditary systemic amyloidosis. The present sequence is beta-amyloid peptide fragment used in the exemplification of the invention.

Sequence 6 AA;

Query Match 100.0%; Score 30; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QKLVFF 6  
 Db 1 QKLVFF 6

RESULT 10

ADQ37380

ID ADQ37380 standard; peptide; 6 AA.

XX AC ADQ37380;

XX DT 07-OCT-2004 (first entry)

XX DE Amyloid-beta polymerisation peptide.

XX KW amyloid-beta; amyloid-beta related disease;

XX KW amyloid-beta fibril formation; immune response; neurotropic;

XX KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

XX KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

XX KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

XX KW cardiant; antidepressant; endocrine; hypnotic;

XX KW amyloid-beta fibril formation modulator; immune system modulator;

XX KW Alzheimer's disease; mild cognitive impairment;

XX KW mild-to-moderate cognitive impairment; vascular dementia;

XX KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

XX KW senile dementia; Down's syndrome; inclusion body myositis;

XX KW age-related macular degeneration; hypothyroidism;

XX KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

XX KW behavioural dysfunction; neurological condition; psychological condition; vaccine antigen.

XX OS Synthetic.

XX XX WO2004058239-A1.

XX XX 15-JUL-2004.

XX XX 24-DEC-2003; 2003WO-CA002021.

XX XX 24-DEC-2002; 2002US-0436379P.

XX XX 23-JUN-2003; 2003US-0482214P.

XX XX (NEUR-) NEUROCHEM INT LTD.

XX XX Gervais F, Bellini F;

XX XX WPI; 2004-543342/52.

XX XX Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

XX PS Disclosure; Page 95; 143pp; English.

XX XX

The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have neurotropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; having amyloid-beta deposits. The present sequence represents an amyloid-beta polymerisation peptide which is used in the exemplification of the present invention.

Sequence 6 AA;

Query Match 100.0%; Score 30; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QKLVFF 6  
 Db 1 QKLVFF 6

RESULT 11

ADQ37335

ID ADQ37335 standard; peptide; 6 AA.

XX AC ADQ37335;

XX XX 07-OCT-2004 (first entry)

XX XX Antifibrillogenic amyloidosis inhibiting peptide.

XX DE amyloid-beta; amyloid-beta related disease;

XX KW amyloid-beta fibril formation; immune response; neurotropic;

XX KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

XX KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

XX KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

XX KW cardiant; antidepressant; endocrine; hypnotic;

XX KW amyloid-beta fibril formation modulator; immune system modulator;

XX KW Alzheimer's disease; mild cognitive impairment;

XX KW mild-to-moderate cognitive impairment; vascular dementia;

XX KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

XX KW senile dementia; Down's syndrome; inclusion body myositis;

XX KW age-related macular degeneration; hypothyroidism;

XX KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

XX KW behavioural dysfunction; neurological condition; psychological condition; vaccine antigen.

XX OS Synthetic.

XX XX WO2004058239-A1.

XX XX 15-JUL-2004.

XX XX 24-DEC-2003; 2003WO-CA002021.

XX XX 24-DEC-2002; 2002US-0436379P.

XX XX 23-JUN-2003; 2003US-0482214P.

XX XX (NEUR-) NEUROCHEM INT LTD.

XX XX Gervais F, Bellini F;

XX XX WPI; 2004-543342/52.

XX XX Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

XX PS Disclosure; Page 95; 143pp; English.

XX XX

KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

OS Synthetic.

FH Key Location/Qualifiers  
 FT Modified-site 6  
 FT /note= "amidated"

XX WO2004058239-Al.

XX 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

XX 24-DEC-2002; 2002US-0436379P.

PR 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 70; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, muscular,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, tranquiliser,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, atrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present invention represents a peptide  
 CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
 CC in the exemplification of the present invention.

XX Sequence 6 AA;

Query Match 100.0%; Score 30; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db 1 QKLVFF 6

RESULT 12

ADQ37352

ID ADQ37352 standard; peptide; 6 AA.

XX

AC ADQ37352;

XX

DT 07-OCT-2004 (first entry)

XX

DE Beta-amyloid modulator peptide.

XX

KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nootropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

XX Synthetic.

XX

PN WO2004058239-Al.

XX

PD 15-JUL-2004.

XX

PF 24-DEC-2003; 2003WO-CA002021.

XX

PR 24-DEC-2002; 2002US-0436379P.

XX

PR 23-JUN-2003; 2003US-0482214P.

XX

PA (NEUR-) NEUROCHEM INT LTD.

XX

PI Gervais F, Bellini F;

XX

DR WPI; 2004-543342/52.

XX

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 87; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,

CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a beta-  
 CC amyloid modulator peptide which is used in the exemplification of the  
 CC present invention.

XX Sequence 6 AA;

Query Match 100.0%; Score 30; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 QKLVPFF 6  
 |||||  
 Db 1 QKLVPFF 6

RESULT 13  
 ADQ37370

ID ADQ37370 standard; peptide; 6 AA.

XX ADQ37370;

XX 07-OCT-2004 (first entry)

XX Amyloid-beta polymerisation peptide.

XX amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

XX Synthetic.

XX Key Location/Qualifiers  
 FH Modified-site 1  
 FT Modified-site /note="acetylated"  
 FT Modified-site 6  
 FT Modified-site /note="amidated"

XX WO2004058239-A1.

XX 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.

PA (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX Disclosure; Page 95; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uteropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, senile dementia,  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, Down's syndrome,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents an amyloid-  
 CC beta polymerisation peptide which is used in the exemplification of the  
 CC present invention.

XX Sequence 6 AA;

Query Match 100.0%; Score 30; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 QKLVPFF 6  
 |||||  
 Db 1 QKLVPFF 6

RESULT 14

AAR45231  
 ID AAR45231 standard; peptide; 7 AA.

XX AAR45231;

XX 20-JUN-1994 (first entry)

DE Beta amyloid protein fragment.  
 XX  
 KW Amyloid precursor protein; APP; beta amyloid protein; BAP; detection;  
 KW Alzheimer's disease; Down's syndrome.  
 XX  
 OS Homo sapiens.  
 XX  
 PN AU9338358-A.  
 XX  
 XX 04-NOV-1993.  
 XX  
 XX 03-MAY-1993; 93AU-00038358.  
 XX  
 XX 01-MAY-1992; 92US-00877675.  
 XX  
 XX (AMCY ) AMERICAN CYANAMID CO.  
 XX  
 XX Vitek MP, Jacobsen JS;  
 PI  
 DR WPI; 1993-406194/51.  
 DR N-PSDB; AAQ54259.  
 XX  
 XX New mutant forms of amyloid precursor protein - for detecting cpds. that  
 PT modify activity of enzymes involved in precursor cleavage, also new  
 PT nucleic acid encoding them.  
 XX  
 XX Disclosure; Page 34; 66pp; English.  
 XX  
 CC Recombinant polypeptides produced using the coding sequences of mutant  
 CC forms of amyloid precursor proteins comprising from the 5' to the 3' end  
 CC a sequence encoding a marker and either (1) a sequence encoding the N-  
 CC terminus of an amyloid precursor protein (APP) up to, but not including,  
 CC the nucleotides encoding the beta amyloid protein (BAP) domain or (2) the  
 CC BAP domain; or the two ligated together, can be used to detect drugs or  
 CC compounds that inhibit/segment the activity of proteolytic enzymes which  
 CC cleave APP to generate BAP fragments (deposition of which occurs in  
 CC patients with Alzheimers disease and Down's syndrome). This fragment  
 CC corresponding to amino acid residues 14-20 of BAP can be altered and  
 CC affect the level of secretion of APP's containing the BAP sequence  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 DB 2 QKLVFF 7  
 RESULT 15  
 AAW02312  
 ID AAW02312 standard; peptide; 7 AA.  
 AC  
 AC AAW02312;  
 XX  
 XX 02-MAY-1997 (first entry)  
 DT  
 XX Beta-amyloid modulator peptide #3.  
 DE  
 DE Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;  
 KW cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;  
 KW bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;  
 KW adult-onset diabetes; familial Mediterranean fever; therapy; deafness;  
 KW scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.  
 XX  
 OS Synthetic.  
 XX  
 XX WO9628471-A1.  
 PN  
 XX

PD 19-SEP-1996.  
 XX  
 XX 14-MAR-1996; 96WO-US003492.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PHAR-) PHARM PEPTIDES INC.  
 XX  
 XX Findeis MA, Benjamin H, Garnick MB, Gafter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;  
 PI Kubasek W, Chin J, Lee J, Kelley M;  
 XX  
 DR WPI; 1996-433762/43.  
 XX  
 XX Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
 PT protein coupled (indirectly to at least 1 modifying gp., useful in  
 PT treatment of Alzheimer's disease.  
 XX  
 XX Claim 16; Page 91; 106pp; English.  
 XX  
 CC AAW02310-W02332 represent the peptide portions of the beta-amyloid  
 CC modulator compounds of the invention. Beta-amyloid peptide is a 4  
 CC kilodalton peptide that is the major protein component of amyloid  
 CC plaques. Amyloid plaques are present both in the brain lesions, and in  
 CC the walls of cerebral blood vessels in Alzheimer's disease patients. The  
 CC amyloid modulators of the invention comprise an amyloidogenic protein or  
 CC peptide (such as this sequence) coupled directly or indirectly to at  
 CC least one modifying group. The modifying group is preferably a cyclic,  
 CC heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a  
 CC biotin containing group, or a fluorescein containing group. These  
 CC compounds then modulate the aggregation of these sequences to natural  
 CC amyloid proteins or peptides when contacted with the natural  
 CC amyloidogenic proteins or peptides. The modulator compounds can be used  
 CC in the treatment of disorders associated with amyloidosis, such as  
 CC familial amyloid polynuropathy, familial amyloid cardiomyopathy,  
 CC isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,  
 CC bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
 CC diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
 CC nephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
 CC and other types of amyloidosis. The modulators are also useful for the  
 CC treatment of disorders associated with beta-amyloidosis, especially  
 CC Alzheimer's disease  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 DB 1 QKLVFF 6  
 RESULT 16  
 AAW02311  
 ID AAW02311 standard; peptide; 7 AA.  
 XX  
 AC AAW02311;  
 XX  
 XX 02-MAY-1997 (first entry)  
 DT  
 XX Beta-amyloid modulator peptide #2.  
 DE  
 DE Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;  
 KW cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;  
 KW bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;  
 KW adult-onset diabetes; familial Mediterranean fever; therapy; deafness;  
 KW scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.  
 XX



XX OS Synthetic.  
 XX XX WO9628471-A1.  
 XX XX 19-SEP-1996.  
 XX PF 14-MAR-1996; 96WO-US003492.  
 XX XX 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX XX (PHAR-) PHARM PEPTIDES INC.  
 XX PA Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed WJ, Molineaux S;  
 XX PI Kubasek W, Chin J, Lee J, Kelley M;  
 XX XX WPI; 1996-433762/43.  
 XX DR Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
 XX PT protein coupled (indirectly to at least 1 modifying gp., useful in  
 XX PT treatment of Alzheimer's disease.  
 XX XX Claim 16; Page 90; 106pp; English.  
 XX CC AAW02310-W02332 represent the peptide portions of the beta-amyloid  
 XX CC modulator compounds of the invention. Beta-amyloid peptide is a 4  
 XX CC kilodalton peptide that is the major protein component of amyloid  
 XX CC plaques. Amyloid plaques are present both in the brain lesions, and in  
 XX CC the walls of cerebral blood vessels in Alzheimer's disease patients. The  
 XX CC amyloid modulators of the invention comprise an amyloidogenic protein or  
 XX CC peptide (such as this sequence) coupled directly or indirectly to at  
 XX CC least one modifying group. The modifying group is preferably a cyclic,  
 XX CC heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a  
 XX CC biotin containing group, or a fluorescein containing group. These  
 XX CC compounds then modulate the aggregation of these sequences to natural  
 XX CC amyloid proteins or peptides when contacted with the natural  
 XX CC amyloidogenic proteins or peptides. The modulator compounds can be used  
 XX CC in the treatment of disorders associated with amyloidosis, such as  
 XX CC familial amyloid polynuropathy, familial amyloid cardiomyopathy,  
 XX CC isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,  
 XX CC bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
 XX CC diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
 XX CC rephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
 XX CC and other types of amyloidosis. The modulators are also useful for the  
 XX CC treatment of disorders associated with beta-amyloidosis, especially  
 XX CC Alzheimer's disease  
 XX XX Sequence 7 AA;  
 XX SQ  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db 2 QKLVFF 7  
 RESULT 17  
 AAW45940  
 ID AAW45940 standard; peptide; 7 AA.  
 XX AC AAW45940;  
 XX XX 25-MAR-2003 (revised)  
 XX DT 30-JUN-1998 (first entry)  
 XX XX Amyloid beta peptide fragment.  
 XX DE  
 XX XX Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
 KW  
 positron emission tomography; PET; Down's syndrome; amyloidosis.  
 XX OS Homo sapiens.  
 XX XX WO9721728-A1.  
 XX XX 19-JUN-1997.  
 XX XX 09-DEC-1996; 96WO-SE001621.  
 XX XX 12-DEC-1995; 95SE-00004467.  
 XX PR 29-DEC-1995; 95US-0009386P.  
 XX XX (KARO-) KAROLINSKA INNOVATIONS AB.  
 XX XX Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;  
 XX PI WPI; 1997-332723/30.  
 XX DR Use of new and known peptide(s) for inhibition of polymerisation of  
 XX PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
 XX PT Down's syndrome associated with amyloidosis.  
 XX XX Example 1; Fig 2B; 31pp; English.  
 XX CC This sequence represents a fragment of the amyloid beta peptide. The  
 XX CC invention relates to the use of peptide compounds for inhibition of  
 XX CC polymerisation of amyloid beta peptide (ABP), as model substances for  
 XX CC synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a  
 XX CC tool for the identification of other organic compounds with similar  
 XX CC functional properties, or as ligands in positron emission tomography. The  
 XX CC peptides may be used in treatment of amyloidosis, especially in treatment  
 XX CC of Alzheimer's disease associated with amyloidosis, for treatment or  
 XX CC prevention of dementia in patients with Down's syndrome, for treatment or  
 XX CC prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch  
 XX CC type) or for the prevention of fibril formation of human amyloid protein.  
 XX CC They can also be used for identifying other molecules with similar  
 XX CC properties and/or as ligands for detection of amyloid deposits using e.g.  
 XX CC positron emission tomography. (Updated on 25-MAR-2003 to correct PI  
 XX CC field.)  
 XX XX Sequence 7 AA;  
 XX SQ  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db 2 QKLVFF 7  
 RESULT 18  
 AAW89376  
 ID AAW89376 standard; peptide; 7 AA.  
 XX AC AAW89376;  
 XX XX 02-MAR-1999 (first entry)  
 XX DT  
 XX DE Beta-amyloid peptide derivative A-beta-15-21.  
 XX XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 XX KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 XX KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 XX KW Creutzfeldt-Jakob disease; bAP.  
 XX XX Homo sapiens.  
 XX OS Synthetic.  
 XX XX US5854204-A.  
 XX XX 29-DEC-1998.  
 XX PD



XX 14-MAR-1996; 96US-00612785.  
 XX  
 PF 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECS PHARM INC.  
 XX  
 XX Hundal A, Gefter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
 PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
 PI Garnick MB, Kubasek W, Signer ER;  
 XX  
 XX WPI; 1999-094964/08.  
 XX  
 XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.  
 XX  
 XX Example 12; Col 64; 52pp; English.  
 XX  
 XX The present invention describes beta-amyloid peptide (BAP) derivatives.  
 CC The BAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically BAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The BAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of BAP to  
 CC labelled BAP derivatives. Some BAP derivatives inhibit BAP aggregation  
 CC even when BAP is present in molar excess. The present sequence represents  
 CC a BAP derivative  
 XX  
 XX Sequence 7 AA;  
 SQ  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db |||||  
 1 QKLVFF 6  
 RESULT 19  
 AA89375  
 ID AA89375 standard; peptide; 7 AA.  
 AC AA89375;  
 XX  
 XX 02-MAR-1999 (first entry)  
 XX  
 XX Beta-amyloid peptide derivative A-beta-14-20.  
 DE  
 XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; BAP.  
 XX  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 XX US5854204-A.  
 XX  
 XX 29-DEC-1998.  
 PD  
 XX 14-MAR-1996; 96US-00612785.  
 XX  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECS PHARM INC.  
 PA

XX Hundal A, Gefter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
 PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
 PI Garnick MB, Kubasek W, Signer ER;  
 XX  
 XX WPI; 1999-094964/08.  
 XX  
 XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.  
 XX  
 XX Example 12; Col 64; 52pp; English.  
 XX  
 XX The present invention describes beta-amyloid peptide (BAP) derivatives.  
 CC The BAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically BAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The BAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of BAP to  
 CC labelled BAP derivatives. Some BAP derivatives inhibit BAP aggregation  
 CC even when BAP is present in molar excess. The present sequence represents  
 CC a BAP derivative  
 XX  
 XX Sequence 7 AA;  
 SQ  
 Query Match 100.0%; Score 30; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db |||||  
 2 QKLVFF 7  
 RESULT 20  
 ABG71006  
 ID ABG71006 standard; peptide; 7 AA.  
 XX  
 AC ABG71006;  
 XX  
 XX 05-DEC-2002 (first entry)  
 XX  
 XX Long form beta-amyloid protein fragment #3.  
 DE  
 XX Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Strausler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2002098173-A1.  
 XX  
 XX 25-JUL-2002.  
 PD  
 XX 04-OCT-2001; 2001US-00972475.  
 PF  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 PR 14-MAR-1996; 96US-00617267.  
 XX  
 XX (PRAE-) PRAECS PHARM INC.  
 PA  
 XX

PI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2002-697709/75.  
 DR  
 XX Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX  
 XX Example 12; Page 35; 41pp; English.  
 XX The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid polynuropathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),  
 CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Straussler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localised cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polynuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX Sequence 7 AA;  
 SQ  
 Query Match 100.0%; Score 30; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 QKLVFF 6  
 DB 2 QKLVFF 7  
 RESULT 21  
 ABG71007  
 ID ABG71007 standard; peptide; 7 AA.  
 XX  
 AC ABG71007;  
 XX  
 XX 05-DEC-2002 (first entry)  
 DT  
 XX Long form beta-amyloid protein fragment #4.  
 DE  
 XX Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Straussler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002098173-A1.

XX 25-JUL-2002.  
 XX  
 XX 04-OCT-2001; 2001US-00972475.  
 XX  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 PR 14-MAR-1996; 96US-00617267.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX  
 XX Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2002-697709/75.  
 DR  
 XX Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX  
 XX Example 12; Page 35; 41pp; English.  
 XX The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid polynuropathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),  
 CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Straussler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localised cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polynuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX Sequence 7 AA;  
 SQ  
 Query Match 100.0%; Score 30; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 QKLVFF 6  
 DB 1 QKLVFF 6  
 RESULT 22  
 ABB05154  
 ID ABB05154 standard; peptide; 7 AA.  
 XX  
 AC ABB05154;  
 XX  
 XX 02-APR-2002 (first entry)  
 DT  
 XX Beta amyloid peptide (14-20) SEQ ID NO:6.  
 DE  
 XX Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;

KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polynuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US6319498-B1.  
 XX  
 PD 20-NOV-2001.  
 XX  
 PF 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECTIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geftter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-146668/19.  
 XX  
 PT Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Example 11; Col 63; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has nootropic, neuroprotective, immunosuppressive, antimicrobial,  
 CC antidiabetic, antipyretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polynuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db |||||  
 2 QKLVFF 7  
 RESULT 23  
 ABB05155  
 ID ABB05155 standard; peptide; 7 AA.  
 XX  
 AC ABB05155;  
 XX  
 XX 02-APR-2002 (first entry)  
 DT  
 XX Beta amyloid peptide (15-21) SEQ ID NO:7.  
 DE  
 XX Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW nootropic; neuroprotective; immunosuppressive; antimicrobial; auditory;

KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polynuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US6319498-B1.  
 XX  
 PD 20-NOV-2001.  
 XX  
 PF 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECTIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geftter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-146668/19.  
 XX  
 PT Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Disclosure; Col 19; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has nootropic, neuroprotective, immunosuppressive, antimicrobial,  
 CC antidiabetic, antipyretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polynuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 Db |||||  
 1 QKLVFF 6  
 RESULT 24  
 ADA90153  
 ID ADA90153 standard; peptide; 7 AA.  
 XX  
 AC ADA90153;  
 XX  
 XX 20-NOV-2003 (first entry)  
 DT  
 XX Anti-Abeta antibody related amino acid sequence SEQ ID NO:268.  
 DE  
 XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW nootropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;

KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
KW neuronal disorder; aging.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX WO2003070760-A2.  
XX  
XX 28-AUG-2003.  
XX  
XX 20-FEB-2003; 2003WO-EP001759.  
XX  
XX 20-FEB-2002; 2002EP-00003844.  
XX  
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.  
XX (MORP-) MORPHOSYS AG.  
XX  
XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
XX Loehning C, Loetscher H, Nordstedt C, Rothe C;  
XX  
XX WPI; 2003-663848/62.  
XX  
XX New antibody molecule capable of specifically recognizing two regions of  
PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
PT diseases associated with amyloidogenesis or amyloid-plaque formation  
PT (e.g. dementia).  
XX  
XX Disclosure; Page 260; 312pp; English.  
XX  
XX The present invention describes an antibody molecule (I) capable of  
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
CC cell comprising the vector of (2); (4) preparing (1), comprising  
CC culturing the host cell of (3) under conditions that allow synthesis of  
CC (I) and recovering (I) from the culture; (5) a composition comprising (I),  
CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
CC (1); (8) testing the resulting Fab optimisation library by panning  
CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
CC of selected, optimised clones; (11) preparing a pharmaceutical  
CC composition, comprising optimisation of (I), and formulating the  
CC optimised antibody/antibody molecule with a carrier; and (12) a  
CC pharmaceutical composition prepared by method (8). (I) has  
CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
CC vector or host is useful in preparing a pharmaceutical composition for  
CC the prevention and/or treatment of a disease associated with  
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
CC may also be used in preparing a diagnostic composition for the detection  
CC of the disease mentioned above. The antibody is used for the  
CC disintegration of beta-amyloid plaques or for passive immunisation  
CC against beta-amyloid plaque formation. In particular, the disease is  
XX Sequence 7 AA;  
SQ Query Match 100.0%; Score 30; DB 6; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 QKLVFF 6  
| | | | |  
Db 1 QKLVFF 6

RESULT 25  
ADA90936  
ID ADA90936 standard; peptide; 7 AA.  
XX  
XX AC ADA90936;  
XX  
XX DT 20-NOV-2003 (first entry)  
XX  
XX DE Solid-phase synthesis heptapeptide #13.  
XX  
XX KW antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
KW neuronal disorder; aging.  
XX  
XX OS Synthetic.  
OS OS Homo sapiens.  
XX  
XX PN WO2003070760-A2.  
XX  
XX PD 28-AUG-2003.  
XX  
XX PF 20-FEB-2003; 2003WO-EP001759.  
XX  
XX PR 20-FEB-2002; 2002EP-00003844.  
XX  
XX PA (HOFF) HOFFMANN LA ROCHE & CO AG F.  
XX (MORP-) MORPHOSYS AG.  
XX  
XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;  
XX Loehning C, Loetscher H, Nordstedt C, Rothe C;  
XX  
XX WPI; 2003-663848/62.  
XX  
XX New antibody molecule capable of specifically recognizing two regions of  
PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
PT diseases associated with amyloidogenesis or amyloid-plaque formation  
PT (e.g. dementia).  
XX  
XX Example 12; Page 82; 312pp; English.  
XX  
XX The present invention describes an antibody molecule (I) capable of  
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
CC cell comprising the vector of (2); (4) preparing (1), comprising  
CC culturing the host cell of (3) under conditions that allow synthesis of  
CC (I) and recovering (I) from the culture; (5) a composition comprising (I),  
CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
CC (1); (8) testing the resulting Fab optimisation library by panning  
CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
CC of selected, optimised clones; (11) preparing a pharmaceutical  
CC composition, comprising optimisation of (I), and formulating the  
CC optimised antibody/antibody molecule with a carrier; and (12) a  
CC pharmaceutical composition prepared by method (8). (I) has  
CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
CC used in gene therapy. The antibody molecule (I), nucleic acid molecule,  
CC vector or host is useful in preparing a pharmaceutical composition for  
CC the prevention and/or treatment of a disease associated with  
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
CC may also be used in preparing a diagnostic composition for the detection  
CC of the disease mentioned above. The antibody is used for the  
CC disintegration of beta-amyloid plaques or for passive immunisation  
CC against beta-amyloid plaque formation. In particular, the disease is

CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt-Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 30; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 1 QKLVFF 6

RESULT 26  
 ADJ64057  
 ID ADJ64057 standard; peptide; 7 AA.  
 XX AC ADJ64057;  
 XX DT 06-MAY-2004 (first entry)  
 XX DE Human beta-amyloid long form peptide fragment #3.  
 XX KW Amyloidogenic protein; therapy; amyloidosis;  
 KW familial amyloid polynuropathy; cardiomyopathy;  
 KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jacob disease; Gerstmann-Straussler-Scheinker syndrome;  
 KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 KW familial mediterranean fever; urticaria; deafness;  
 KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
 KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 KW beta-amyloid peptide; human.  
 XX OS Homo sapiens.

XX FH Key Location/Qualifiers  
 XX FT Modified-site 1 /note= "Optionally N-terminal choly or N-acetyl  
 FT 7 nuraminyl"  
 FT Modified-site 7 /note= "Optionally C-terminal amide"  
 XX FT  
 XX PN US2004005307-A1.  
 XX PD 08-JAN-2004.  
 XX PF 17-JUN-2003; 2003US-00463729.  
 XX PR 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX PR 14-MAR-1996; 96US-00617267.  
 XX PR 04-OCT-2001; 2001US-00972475.  
 XX PR (PRAE-) PRAECIS PHARM INC.  
 XX PI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX DR WPI; 2004-131767/13.  
 XX PT New amyloidogenic protein aggregation modulators useful for treating  
 PT disorder associated with amyloidosis e.g. familial amyloid  
 PT polynuropathy, Creutzfeldt-Jacob disease and adult onset diabetes.  
 XX PS Example 12; SEQ ID NO 6; 52pp; English.  
 XX CC The invention relates to amyloidogenic proteins or peptide fragments  
 CC aggregation modulators. The invention is used for treating disorder

CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jacob disease,  
 CC Gerstmann-Straussler-Scheinker syndrome, adult onset diabetes,  
 CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
 CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean fever  
 CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 CC polynuropathy III), familial amyloidosis of the thyroid, fibrinogen associated  
 CC associated with medullary carcinoma of the thyroid, hereditary systemic  
 CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 CC in the exemplification of the invention.  
 XX SQ Sequence 7 AA;

Query Match 100.0%; Score 30; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 2 QKLVFF 7

RESULT 27  
 ADJ64058  
 ID ADJ64058 standard; peptide; 7 AA.  
 XX AC ADJ64058;  
 XX DT 06-MAY-2004 (first entry)

XX DE Human beta-amyloid long form peptide fragment #4.  
 XX KW Amyloidogenic protein; therapy; amyloidosis;  
 KW familial amyloid polynuropathy; cardiomyopathy;  
 KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jacob disease; Gerstmann-Straussler-Scheinker syndrome;  
 KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 KW familial mediterranean fever; urticaria; deafness;  
 KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
 KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 KW beta-amyloid peptide; human.  
 XX OS Homo sapiens.

XX PN US2004005307-A1.  
 XX PD 08-JAN-2004.  
 XX PF 17-JUN-2003; 2003US-00463729.  
 XX PR 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX PR 14-MAR-1996; 96US-00617267.  
 XX PR 04-OCT-2001; 2001US-00972475.

XX PR (PRAE-) PRAECIS PHARM INC.  
 XX PI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX DR WPI; 2004-131767/13.

XX PT New amyloidogenic protein aggregation modulators useful for treating  
 PT disorder associated with amyloidosis e.g. familial amyloid

PT polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
 XX Example 12; SEQ ID NO 7; 52pp; English.  
 XX  
 CC The invention relates to amyloidogenic proteins or peptide fragments  
 CC aggregation modulators. The invention is used for treating disorder  
 CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 CC Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
 CC insulidoma, isolated atrial amyloidosis, idiopathic (primary)  
 CC amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary  
 CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
 CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 CC polynuropathy III), familial amyloidosis of Finnish type, amyloidosis  
 CC associated with medullary carcinoma of the thyroid, fibrinogen associated  
 CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 CC in the exemplification of the invention.  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 QKLVFF 6  
 Db 1 QKLVFF 6  
 RESULT 28  
 ADQ37378  
 ID ADQ37378 standard; peptide; 7 AA.  
 XX  
 AC ADQ37378;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Amyloid-beta polymerisation peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 OS Synthetic.  
 XX  
 FN WO2004058239-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 24-DEC-2003; 2003WO-CA002021.  
 XX  
 PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX

PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 PI Gervais F, Bellini F;  
 XX  
 DR WPI; 2004-543342/52.  
 XX  
 PT Composition for treating e.g. Alzheimer's disease comprises first agent  
 CC that prevents or treats amyloid-beta related disease and second agent  
 CC that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 PS Disclosure; Page 95; 143pp; English.  
 XX  
 CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents an amyloid-  
 CC beta polymerisation peptide which is used in the exemplification of the  
 CC present invention.  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 30; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 QKLVFF 6  
 Db 2 QKLVFF 7  
 RESULT 29  
 ADQ37350  
 ID ADQ37350 standard; peptide; 7 AA.  
 XX  
 AC ADQ37350;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Beta-amyloid modulator peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;

amyloid-beta fibril formation; immune response; neurotropic; neuroprotective; cerebroprotective; haemostatic; ophthalmological; antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic; anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic; cardiant; antidepressant; endocrine; hypnotic; amyloid-beta fibril formation modulator; immune system modulator; Alzheimer's disease; mild cognitive impairment; vascular mild-to-moderate cognitive impairment; vascular dementia; cerebral amyloid angiopathy; hereditary cerebral haemorrhage; senile dementia; Down's syndrome; inclusion body myositis; age-related macular degeneration; hypothyroidism; cerebrovascular disease; cardiovascular disease; memory loss; anxiety; behavioural dysfunction; neurovascular condition; psychological condition; vaccine antigen.

Synthetic.

WO2004058239-A1.

15-JUL-2004.

24-DEC-2003; 2003WO-CA002021.

24-DEC-2002; 2002US-0436379P.

23-JUN-2003; 2003US-0482214P.

(NEUR-) NEUROCHEM INT LTD.

Gervais F, Bellini F;

WPI; 2004-543342/52.

Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

Disclosure; Page 87; 143pp; English.

The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have neurotropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, atrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene;

CC having amyloid-beta deposits. The present sequence represents a beta-amyloid modulator peptide which is used in the exemplification of the present invention.

XX Sequence 7 AA;

SQ Query Match 100.0%; Score 30; DB 8; Length 7; Best Local Similarity 100.0%; Pred. No. 1.8e+06; Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 OKLVFF 6  
| | | | |  
Db 2 OKLVFF 7

RESULT 30  
ADQ37351  
ID ADQ37351 standard; peptide; 7 AA.  
XX AC ADQ37351;  
XX DT 07-OCT-2004 (first entry)  
XX DE Beta-amyloid modulator peptide.  
XX KW amyloid-beta; amyloid-beta related disease; amyloid-beta fibril formation; immune response; neurotropic; neuroprotective; cerebroprotective; haemostatic; ophthalmological; antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic; anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic; cardiant; antidepressant; endocrine; hypnotic; amyloid-beta fibril formation modulator; immune system modulator; Alzheimer's disease; mild cognitive impairment; vascular dementia; cerebral amyloid angiopathy; hereditary cerebral haemorrhage; senile dementia; Down's syndrome; inclusion body myositis; age-related macular degeneration; hypothyroidism; cerebrovascular disease; cardiovascular disease; memory loss; anxiety; behavioural dysfunction; neurovascular condition; psychological condition; vaccine antigen.  
XX OS Synthetic.  
XX PN WO2004058239-A1.  
XX PD 15-JUL-2004.  
XX PF 24-DEC-2003; 2003WO-CA002021.  
XX PR 24-DEC-2002; 2002US-0436379P.  
XX PR 23-JUN-2003; 2003US-0482214P.  
XX PA (NEUR-) NEUROCHEM INT LTD.  
XX PI Gervais F, Bellini F;  
XX DR WPI; 2004-543342/52.  
XX PT Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.  
XX PS Disclosure; Page 87; 143pp; English.  
XX CC The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have neurotropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,



CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a beta-  
 CC amyloid modulator peptide which is used in the exemplification of the  
 CC present invention.

XX Sequence 7 AA;

Query Match 100.0%; Score 30; DB 8; Length 7;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6

Db 1 QKLVFF 6

RESULT 31

AAW02310

ID AAW02310 standard; peptide; 8 AA.

AC AAW02310;

DT 02-MAY-1997 (first entry)

DE Beta-amyloid modulator peptide #1.

XX Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;  
 KW cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;  
 KW bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;  
 KW adult-onset diabetes; familial Mediterranean fever; therapy; deafness;  
 KW scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.

OS Synthetic.

PN WO9628471-A1.

PD 19-SEP-1996.

XX 14-MAR-1996; 96WO-US003492.

XX 14-MAR-1995; 95US-00404831.

PR 07-JUN-1995; 95US-00475579.

PR 27-OCT-1995; 95US-00548998.

XX (PHAR-) PHARM PEPTIDES INC.

XX

PI

PI

PI

XX

DR

XX

XX

PT

PT

PT

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;  
 Kubasek W, Chin J, Lee J, Kelley M;  
 WPI; 1996-433762/43.

Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
 protein coupled (in)directly to at least 1 modifying gp., useful in  
 treatment of Alzheimer's disease.

Claim 16; Page 90; 106pp; English.

AAW02310-W02332 represent the peptide portions of the beta-amyloid  
 modulator compounds of the invention. Beta-amyloid peptide is a 4  
 kilodalton peptide that is the major protein component of amyloid  
 plaques. Amyloid plaques are present both in the brain lesions, and in  
 the walls of cerebral blood vessels in Alzheimer's disease patients. The  
 amyloid modulators of the invention comprise an amyloidogenic protein or  
 peptide (such as this sequence) coupled directly or indirectly to at  
 least one modifying group. The modifying group is preferably a cyclic,  
 heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a  
 biotin containing group, or a fluorescein containing group. These  
 compounds then modulate the aggregation of these sequences to natural  
 amyloid proteins or peptides when contacted with the natural  
 amyloidogenic proteins or peptides. The modulator compounds can be used  
 in the treatment of disorders associated with amyloidosis, such as  
 familial amyloid polynuropathy, familial amyloid cardiomyopathy,  
 isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,  
 bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
 diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
 nephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
 and other types of amyloidosis. The modulators are also useful for the  
 treatment of disorders associated with beta-amyloidosis, especially  
 Alzheimer's disease

Sequence 8 AA;

Query Match 100.0%; Score 30; DB 2; Length 8;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6

Db 2 QKLVFF 7

RESULT 32

AAW45937

ID AAW45937 standard; peptide; 8 AA.

AC AAW45937;

XX 25-MAR-2003 (revised)

DT 30-JUN-1998 (first entry)

DE Amyloid beta peptide fragment.

XX Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
 KW positron emission tomography; PET; Down's syndrome; amyloidosis.

OS Homo sapiens.

PN WO9721728-A1.

PD 19-JUN-1997.

XX 09-DEC-1996; 96WO-SE001621.

XX 12-DEC-1995; 95SE-00004467.

PR 29-DEC-1995; 95US-0009386P.

XX (KARO-) KAROLINSKA INNOVATIONS AB.



PI Nordstedt C, Naeislund J, Thyberg J, Tjernberg LO, Terenius L;  
 XX WPI; 1997-332723/30.  
 XX  
 XX Use of new and known peptide(s) for inhibition of polymerisation of  
 PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
 PT Down's syndrome associated with amyloidosis.  
 XX  
 XX Example 1; Fig 2B; 31pp; English.  
 XX  
 CC This sequence represents a fragment of the amyloid beta peptide. The  
 CC invention relates to the use of peptide compounds for inhibition of  
 CC polymerisation of amyloid beta peptide (ABP), as model substances for  
 CC synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a  
 CC tool for the identification of other organic compounds with similar  
 CC functional properties, or as ligands in positron emission tomography. The  
 CC peptides may be used in treatment of amyloidosis, especially in treatment  
 CC of Alzheimer's disease associated with amyloidosis, for treatment or  
 CC prevention of demens in patients with Down's syndrome, for treatment or  
 CC prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch  
 CC type) or for the prevention of fibril formation of human amyloid protein.  
 CC They can also be used for identifying other molecules with similar  
 CC properties and/or as ligands for detection of amyloid deposits using e.g.  
 CC positron emission tomography. (Updated on 25-MAR-2003 to correct PI  
 CC field.)  
 XX  
 SQ Sequence 8 AA;

Query Match 100.0%; Score 30; DB 2; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 3 QKLVFF 8

## RESULT 33

AAW89374  
 ID AAW89374 standard; peptide; 8 AA.

XX  
 AC AAW89374;

XX  
 DT 02-MAR-1999 (first entry)

XX Beta-amyloid peptide derivative A-beta-14-21.

XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; BAP.

XX Homo sapiens.

OS Synthetic.

XX US5854204-A.

XX 29-DEC-1998.

XX 14-MAR-1996; 96US-00612785.

XX 14-MAR-1995; 95US-00404831.

PR 07-JUN-1995; 95US-00475579.

PR 27-OCT-1995; 95US-00548998.

XX (PRAE-) PRAECIS PHARM INC.

PA Hundal A, Geffer ML, Kasman L, Musso G, Molineaux S, Benjamin H;

PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;

PI Garnick MB, Kubasek W, Signer ER;

XX WPI; 1999-094964/08.

XX

PT New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.

XX Example 12; Col 64; 52pp; English.

XX The present invention describes beta-amyloid peptide (BAP) derivatives.  
 CC The BAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically BAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The BAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of BAP to  
 CC labelled BAP derivatives. Some BAP derivatives inhibit BAP aggregation  
 CC even when BAP is present in molar excess. The present sequence represents  
 CC a BAP derivative

XX Sequence 8 AA;

Query Match 100.0%; Score 30; DB 2; Length 8;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 2 QKLVFF 7

## RESULT 34

ABG71005

ID ABG71005 standard; peptide; 8 AA.

XX AC ABG71005;

XX 05-DEC-2002 (first entry)

XX Long form beta-amyloid protein fragment #2.

XX Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Strausler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW familial non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.

XX Homo sapiens.

XX US2002098173-A1.

XX 25-JUL-2002.

XX 04-OCT-2001; 2001US-00972475.

XX 14-MAR-1995; 95US-00404831.

PR 07-JUN-1995; 95US-00475579.

PR 27-OCT-1995; 95US-00548998.

PR 14-MAR-1996; 96US-00612767.

XX (PRAE-) PRAECIS PHARM INC.

XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;

PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;

XX WPI; 2002-697709/75.

XX

PT Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment

coupled to a modifying group.

Example 12; Page 35; 41pp; English.

The invention describes an amyloid modulator comprising an amyloidogenic protein and/or peptide fragment coupled to a modifying group so that the compound modulates the aggregation of natural amyloid proteins or peptides. The modulator is used for treating a disorder associated with amyloidosis e.g. familial amyloid polynuropathy (Danish type), and Swedish types), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset diabetes, Gerstmann-Strausler-Scheinker syndrome, insulinoma, isolated atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary localised cutaneous nodular amyloidosis associated with Sjogren's syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever and familial amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of Icelandic type, amyloidosis associated with long term haemodialysis, hereditary non-neuropathic systemic amyloidosis (familial amyloid polynuropathy III), familial amyloidosis of Finnish type, amyloidosis associated with medullary carcinoma of the thyroid, fibrinogen-associated hereditary renal amyloidosis and lysosome-associated hereditary systemic amyloidosis. The compound is capable of altering and inhibiting beta-amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins or peptides when contacted with a molar excess amount of natural beta-APs relative to the modulator. This sequence represents a fragment of the long form of beta-amyloid used in the creation of an amyloid modulator

Sequence 8 AA;

Query Match 100.0%; Score 30; DB 5; Length 8;

Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
| | | | |  
Db 2 QKLVFF 7

RESULT 35

ID ABB05153  
AC ABB05153 standard; peptide; 8 AA.

XX ABB05153;

XX 02-APR-2002 (first entry)

XX Beta amyloid peptide (14-21) SEQ ID NO:5.

XX Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta; APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease; nontropic; neuroprotective; immunosuppressive; antimicrobial; auditory; antidiabetic; antipruritic; dermatological; cardiovascular; nephrotropic; amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome; amyloidogenic disease; beta amyloid deposition; amyloidosis; hereditary cerebral haemorrhage; familial amyloid polynuropathy.

XX Homo sapiens.

OS Synthetic.

XX US6319498-B1.

XX 20-NOV-2001.

XX 14-MAR-1996; 96US-00617267.

XX 14-MAR-1995; 95US-00404831.

XX 07-JUN-1995; 95US-00475579.

XX 27-OCT-1995; 95US-00548998.

XX (PRAE-) PRACIS PHARM INC.

XX  
PI  
XX

Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
WPI; 2002-146668/19.

Amyloid modulator compound useful for treatment of an amyloidogenic disease such as Alzheimer's disease comprises an aggregation core domain and a modifying group attached to it.

XX Disclosure; Col 18; 54pp; English.

The present invention describes an amyloid modulator compound (I) comprising an aggregation core domain and a modifying group attached to it. (I) has nontropic, neuroprotective, immunosuppressive, antimicrobial, antidiabetic, antipruritic, dermatological, cardiovascular, nephrotropic and auditory activities, and can be used as a natural amyloid aggregation inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide (beta-AP). (I) are used in the manufacture of a medicament for the diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's disease and other clinical occurrences of beta amyloid deposition such as Down's syndrome individuals and in patients with hereditary cerebral haemorrhage with amyloidosis, and for treating a disorder associated with amyloidosis such as familial amyloid polynuropathy. (I) reduces the toxicity of natural beta-AP aggregates to cultured neuronal cells. (I) not only reduces the formation of neurotoxic aggregates but also have the ability to reduce the neurotoxicity of performed A-beta fibrils. The present sequence represents a beta-AP peptide, which is used in the exemplification of the present invention

Sequence 8 AA;

Query Match 100.0%; Score 30; DB 5; Length 8;

Best Local Similarity 100.0%; Pred. NO. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
| | | | |  
Db 2 QKLVFF 7

RESULT 36

ID ADJ64056 standard; peptide; 8 AA.

XX ADJ64056;

XX 06-MAY-2004 (first entry)

XX Human beta-amyloid long form peptide fragment #2.

XX Amyloidogenic protein; therapy; amyloidosis;  
KW familial amyloid polynuropathy; cardiomyopathy;  
KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
KW familial mediterranean fever; urticaria; deafness;  
KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
KW beta-amyloid peptide; human.

XX Homo sapiens.

XX US2004005307-Al.

XX 08-JAN-2004.

XX 17-JUN-2003; 2003US-00463729.

XX 14-MAR-1995; 95US-00404831.

XX 07-JUN-1995; 95US-00475579.

XX 27-OCT-1995; 95US-00548998.

XX 14-MAR-1996; 96US-00617267.

PR 04-OCT-2001; 2001US-00972475.  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX Findeis MA, Benjamin H, Garnick MB, Gafter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2004-131767/13.  
 DR  
 XX New amyloidogenic protein aggregation modulators useful for treating  
 PT disorder associated with amyloidosis e.g. familial amyloid  
 PT polypeuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
 XX  
 XX Example 12; SEQ ID NO 5; 52pp; English.  
 XX  
 CC The invention relates to amyloidogenic proteins or peptide fragments  
 CC aggregation modulators. The invention is used for treating disorder  
 CC associated with amyloidosis, particularly familial amyloid polypeuropathy  
 CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 CC Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
 CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
 CC amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary  
 CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
 CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 CC polypeuropathy III), familial amyloidosis of Finnish type, amyloidosis  
 CC associated with medullary carcinoma of the thyroid, fibrinogen associated  
 CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 CC in the exemplification of the invention.  
 XX  
 SQ Sequence 8 AA;  
 Query Match 100.0%; Score 30; DB 8; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 DB 2 QKLVFF 7  
 RESULT 37  
 ADQ37377  
 ID ADQ37377 standard; peptide; 8 AA.  
 XX  
 AC ADQ37377;  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Amyloid-beta polymerisation peptide.  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiac; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

OS Synthetic.  
 XX WO2004058239-A1.  
 XX 15-JUL-2004.  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX 23-DEC-2002; 2003US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX (NEUR-) NEUROCHEM INT LTD.  
 PA Gervais F, Bellini F;  
 XX WPI; 2004-543342/52.  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX Disclosure; Page 95; 143pp; English.  
 PS The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, muscular,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents an amyloid-  
 CC beta polymerisation peptide which is used in the exemplification of the  
 CC present invention.  
 XX  
 SQ Sequence 8 AA;  
 Query Match 100.0%; Score 30; DB 8; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY . . . 1 QKLVFF 6  
 DB 3 QKLVFF 8

RESULT 38	
ADQ37349	
ADQ37349 standard; peptide; 8 AA.	
XX	
AC	
ADQ37349;	
XX	
DT	07-OCT-2004 (first entry)
XX	
DE	Beta-amyloid modulator peptide.
XX	
KW	amyloid-beta; amyloid-beta related disease;
KW	amyloid-beta fibril formation; immune response; neurotropic;
KW	neuroprotective; cerebroprotective; haemostatic; ophthalmological;
KW	antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;
KW	anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;
KW	cardiant; antidepressant; endocrine; hypnotic;
KW	amyloid-beta fibril formation modulator; immune system modulator;
KW	Alzheimer's disease; mild cognitive impairment;
KW	mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;
KW	cerebral amyloid angiopathy; Down's syndrome; inclusion body myositis;
KW	senile dementia; Down's syndrome; inclusion body myositis;
KW	age-related macular degeneration; hypothyroidism;
KW	cerebrovascular disease; cardiovascular disease; memory loss; anxiety;
KW	behavioural dysfunction; neurological condition; psychological condition;
XX	vaccine antigen.
XX	
OS	Synthetic.
XX	
PN	WO2004059239-A1.
XX	
PD	15-JUL-2004.
XX	
PF	24-DEC-2003; 2003WO-CA002021.
XX	
PR	24-DEC-2002; 2002US-0436379P.
PR	23-JUN-2003; 2003US-0482214P.
XX	
PA	(NEUR-) NEUROCHEM INT LTD.
PI	Gervais F, Bellini F;
XX	
PI	WPI; 2004-543342/52.
XX	
DR	Composition for treating e.g. Alzheimer's disease comprises first agent
PT	that prevents or treats amyloid-beta related disease and second agent
PT	that is either a peptide or peptidomimetic or an immune system modulator.
XX	
PS	Disclosure; Page 87; 143pp; English.
XX	
CC	The present invention describes compositions (C) comprising: (a) a first
CC	agent (a1) that prevents or treats amyloid-beta related disease; and (b)
CC	a second agent (a2) that is: (i) a peptide or peptidomimetic that
CC	modulates amyloid-beta fibril formation or induces a prophylactic or
CC	therapeutic immune response against amyloid-beta fibril formation; or
CC	(ii) an immune system modulator that prevents or inhibits amyloid-beta
CC	fibril formation. Also described is a kit comprising (C). (C) have
CC	neurotropic, neuroprotective, cerebroprotective, haemostatic,
CC	ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser
CC	uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,
CC	neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities
CC	and can be used as amyloid-beta fibril formation modulators, and as
CC	immune system modulators. (C) can be used for preventing or treating an
CC	amyloid-beta related disease e.g. Alzheimer's disease (including sporadic
CC	(non-hereditary) or familial (hereditary)), mild cognitive impairment,
CC	mild-to-moderate cognitive impairment, vascular dementia, cerebral
CC	amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,
CC	Down's syndrome, inclusion body myositis, age-related macular
CC	degeneration or a condition associated with Alzheimer's disease
CC	(including hypothyroidism, cerebrovascular disease, cardiovascular
CC	disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,
CC	aggression, or incontinence), a neurological condition (e.g. Huntington's
CC	disease, amyotrophic lateral sclerosis, acquired immunodeficiency,
CC	Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia

```

XX SQ Sequence 9 AA;
Query Match 100.0%; Score 30; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6
   |||||
DB 1 QKLVFF 6

RESULT 40
AAW45935
ID AAW45935 standard; peptide; 9 AA.
XX AC AAW45935;
XX XX
XX 25-MAR-2003 (revised)
DT 08-JUL-1998 (first entry)
XX XX
XX Amyloid beta peptide fragment.
XX XX
XX Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;
KW positron emission tomography; PET; Down's syndrome; amyloidosis.
XX OS Homo sapiens.
XX XX
XX WO9721728-A1.
PN 19-JUN-1997.
PD 09-DEC-1996; 96WO-SE001621.
PF 12-DEC-1995; 95SE-00004467.
PR 29-DEC-1995; 95US-0009386P.
XX XX
XX (KARO-) KAROLINSKA INNOVATIONS AB.
PA Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;
PI WPI; 1997-332723/30.
DR XX
XX Use of new and known peptide(s) for inhibition of polymerisation of
PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or
PT Down's syndrome associated with amyloidosis.
XX XX
XX Example 1; Fig 2B; 31pp; English.
XX XX
XX This sequence represents a fragment of the amyloid beta peptide. The
CC invention relates to the use of peptide compounds for inhibition of
CC polymerisation of amyloid beta peptide (ABP), as model substances for
CC synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a
CC tool for the identification of other organic compounds with similar
CC functional properties, or as ligands in positron emission tomography. The
CC peptides may be used in treatment of amyloidosis, especially in treatment
CC of Alzheimer's disease associated with amyloidosis, for treatment or
CC prevention of demens in patients with Down's syndrome, for treatment or
CC prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch
CC type) or for the prevention of fibril formation of human amyloid protein.
CC They can also be used for identifying other molecules with similar
CC properties and/or as ligands for detection of amyloid deposits using e.g.
CC positron emission tomography. (Updated on 25-MAR-2003 to correct PI
CC field.)
XX XX
XX Sequence 9 AA;
Query Match 100.0%; Score 30; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6
   |||||
DB 1 QKLVFF 6

RESULT 41
AAB48493
ID AAB48493 standard; peptide; 9 AA.
XX AC AAB48493;
XX XX
XX 02-MAR-2001 (first entry)
DT XX
XX Antifibrillogenic peptide #20.
DE XX
XX Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX Alzheimer's disease.
XX OS Homo sapiens.
XX XX
XX Key Location/Qualifiers
FT Modified-site 9 /note= "C-terminal amide"
FT FT
XX WO200068263-A2.
PN 16-NOV-2000.
PD 04-MAY-2000; 2000WO-CA000515.
PF 05-MAY-1999; 99US-0132592P.
PR (NEUR-) NEUROCHEM INC.
XX PA
XX Chalifour R, Gervais F, Gupta A;
XX WPI; 2001-031852/04.
DR XX
XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for
PT cytoprotection for treating amyloidosis disorders, comprises a peptide,
PT its isomer or peptidomimetic.
XX XX
XX Claim 7; Page 25; 46pp; English.
XX XX
XX Peptides AAB48474-B48496 are antifibrillogenic agents that can be used
CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of
CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore
CC useful for treating amyloidosis disorders such as Alzheimer's disease.
CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan
CC binding region and the prot-prot interaction region of the human amyloid
CC protein
XX SQ Sequence 9 AA;
Query Match 100.0%; Score 30; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6
   |||||
DB 3 QKLVFF 8

RESULT 42
ABB04913
ID ABB04913 standard; peptide; 9 AA.
XX AC ABB04913;
XX XX
XX 14-MAR-2002 (first entry)
DT XX
XX Human amyloid beta protein (beta-A4) peptide 12-20 SEQ ID NO:4.
DE Human; amyloid beta protein; beta-A4; memory enhancement; learning.
KW

```

XX OS Homo sapiens.  
 XX PN US6320024-B1.  
 XX PD 20-NOV-2001.  
 XX PF 09-MAR-1999; 99US-00264709.  
 XX PR 07-FEB-1997; 97US-00797782.  
 XX PA (ROBE/) ROBERTS E.  
 XX PI Roberts E;  
 XX DR WPI; 2002-096566/13.  
 XX PT New peptide compound useful for design of substances that enhance memory.  
 XX PS Disclosure; Col 1; 30pp; English.  
 XX CC The present invention describes a novel peptide compound comprising Lys-His-Tyr-beta-alanine, which has a memory modulating effect. The peptide has nootropic activity. The peptide can be used for the development of topographic models useful to design and synthesize memory-enhancing and life-quality improving substances. The peptide compound restores the balance between excitatory and inhibitory systems in the brain, helps to correct defects in the balance that arise as a result of aging, corrects defects and injury. The substances exert reenergizing effects on nervous system function and has more prolonged desired effects at lower doses than the peptide structures. The substances mimic the action of active peptides without having a peptide structure and do not subject to degradation of peptide-splitting enzymes in the gut or other tissues. The present sequence represents a human amyloid beta protein (beta-A4) peptide, which is used in the exemplification of the present invention

XX SQ Sequence 9 AA;  
 Query Match 100.0%; Score 30; DB 5; Length 9;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 DB 4 QKLVFF 9

RESULT 43  
 AAU11667  
 ID AAU11667 standard; peptide; 9 AA.  
 XX AC AAU11667;  
 XX DT 09-APR-2002 (first entry)  
 XX DE Peptide #20, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy; CAA; nootropic; neuroprotective; cerebroprotective; Alzheimer's disease; cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX OS Synthetic.  
 XX PI Mckeown SC;  
 XX DR WPI; 2003-184066/18.  
 XX FT Analyzing cleavage of polymer, by providing polymer sample, incubating the sample with labeled isotope for cleavage at potential cleavage site, and analyzing the masses of any uncleaved fragments by mass spectrometry.  
 XX PN WO200185093-A2.  
 XX PD 15-NOV-2001.  
 XX PF 22-DEC-2000; 2000WO-IB002078.

XX PR 23-DEC-1999; 99US-0171877P.  
 XX PA (NEUR-) NEUROCHEM INC.  
 XX PI Green AM, Gervais F;  
 XX DR WPI; 2002-075222/10.  
 XX PT Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's disease comprises contacting blood vessel wall cell with amyloid-beta 40 inhibitor.  
 XX PS Disclosure; Page 10; 68pp; English.  
 XX CC The present invention relates to a new method of inhibiting cerebral amyloid angiopathy. The new method of the invention involves contacting a blood vessel wall cell with an amyloid-beta40 inhibitor. The invention can be used for treating disease states characterised by cerebral amyloid angiopathy, particularly Alzheimer's disease, hereditary cerebral haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke. The present sequence represents one of a group of peptides (AAU11648-AAU11669, AAU11910 & AAU11911) that were used in the invention as a carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor was used in the invention to treat a disease state characterised by cerebral amyloid angiopathy (CAA)

XX SQ Sequence 9 AA;  
 Query Match 100.0%; Score 30; DB 5; Length 9;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QKLVFF 6  
 DB 3 QKLVFF 8

RESULT 44  
 ABP57517  
 ID ABP57517 standard; peptide; 9 AA.  
 XX AC ABP57517;  
 XX DT 28-APR-2003 (first entry)  
 XX DE Differentially isotopically labelled (DiMas) peptide #10.  
 XX KW Mass spectrometry; polymer; analysis; cleavage; substrate specificity; isotope; protease.  
 XX OS Synthetic.  
 XX PN WO2003001206-A1.  
 XX PD 03-JAN-2003.  
 XX PF 25-JUN-2002; 2002WO-GB002921.  
 XX PR 26-JUN-2001; 2001GB-00015581.  
 XX PA (GLAX) GLAXO GROUP LTD.  
 XX PI Mckeown SC;  
 XX DR WPI; 2003-184066/18.  
 XX FT Analyzing cleavage of polymer, by providing polymer sample, incubating the sample with labeled isotope for cleavage at potential cleavage site, and analyzing the masses of any uncleaved fragments by mass spectrometry.  
 XX PS Example 3; Page 26; 73pp; English.  
 XX PF

CC The present invention describes a method (M1) for analysing cleavage of a  
 CC polymer. M1 comprises: (a) providing a sample of the polymer, a portion  
 CC of the polymer molecules having been labeled at a position on one side of  
 CC the potential cleavage site with a first isotopic label and a portion of  
 CC the polymer molecules having been labeled at a position on the opposite  
 CC side of the potential cleavage site with a second isotopic label; (b)  
 CC incubating the sample under conditions suitable for cleavage at the  
 CC potential cleavage site; and (c) analysing the mass(es) of any cleaved  
 CC fragments by mass spectrometry and thereby determining whether and/or  
 CC where cleavage has taken place. M1 is useful for analysing cleavage of a  
 CC polymer, where the polymer is a linear polymer, and comprises a peptide  
 CC or protein. Methods from the present invention can be used in discovering  
 CC new or improved synthetic substrates for both known and unknown enzymes,  
 CC e.g. enzymes identified from the human genome. The methods are also  
 CC useful to identify the sequence origin, and in screening methods to  
 CC identify new substrates for enzymes, in positional peptide scanning  
 CC libraries, in vivo/ex vivo/in vitro peptide, and in assaying methods  
 CC for oligonucleotide or peptide sequencing and in measuring differential  
 CC protein expression. The methods are useful for monitoring the cleavage of  
 CC polypeptides or polynucleotides, and for determining optimal polymer  
 CC substrates. ABP57505 to ABP57605 represent peptides used in the  
 CC exemplification of the present invention

SQ Sequence 9 AA;

Query Match 100.0%; Score 30; DB 6; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 3 QKLVFF 8

RESULT 45

ID AAE35436 standard; peptide; 9 AA.

AC AAE35436;

DT 17-JUN-2003 (first entry)

XX Abeta peptide #7.

DE All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX Unidentified.

XX Key Location/Qualifiers

FT Misc-difference 1..9 /note= "D-form residues"

XX WO200296937-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-CA000763.

XX 29-MAY-2001; 2001US-00867847.

XX (NEUR-) NEUROCHEM INC.

XX Gervais F, Hebert L, Chalifour RJ, Kong X;

XX WPI; 2003-201269/19.

PT Prevention and/or treatment of an amyloid-related disease e.g.

PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

XX Claim 1; Page 58; 44pp; English.

XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D-  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention

XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 6; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 3 QKLVFF 8

RESULT 46

ID ADI35874 standard; peptide; 9 AA.

AC ADI35874;

DT 22-APR-2004 (first entry)

XX Amyloid beta peptide SEQ ID NO:28.

XX amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 KW Alzheimer's disease.

XX Synthetic.

XX WO2004006861-A2.

XX 22-JAN-2004.

XX 16-JUL-2003; 2003WO-US022280.

XX 17-JUL-2002; 2002US-0396245P.

XX (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX Chain DG, Fitzer-Attas C;

XX WPI; 2004-122759/12.

PT New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX Example 2; SEQ ID NO 28; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide



CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
 CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QKLVFF 6  
 Db 3 QKLVFF 8

RESULT 47

ADI35981  
 ID ADI35981 standard; peptide; 9 AA.

XX AC ADI35981;

XX DT 22-APR-2004 (first entry)

XX DE Amyloid beta peptide SEQ ID NO:135.

XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
 XX KW Alzheimer's disease.

XX OS Synthetic.

XX PN WO2004006861-A2.

XX PD 22-JAN-2004.

XX PF 16-JUL-2003; 2003WO-US022280.

XX PR 17-JUL-2002; 2002US-0396245P.

XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.

XX PI Chain DG, Fitzer-Attas C;

XX DR WPI; 2004-122759/12.

XX New amyloid beta peptide, useful for preparing a composition for  
 PT preventing the formation or progression of amyloid plaques for preventing  
 PT or treating Alzheimer's disease.

XX Example 6; SEQ ID NO 135; 69pp; English.

XX The present invention describes an isolated amyloid beta peptide or its  
 CC homologue which is selected by a method comprising: (a) determining the  
 CC binding value of each amino acid of a subsequence of amyloid beta peptide  
 CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
 CC determining the resulting score of all amino acids of the subsequence,  
 CC based on the binding value of each amino acid obtained in step (1); and  
 CC (c) comparing the resulting score to a preselected value. Also described:  
 CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier

CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
 CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
 CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
 CC for immunisation of an individual based on the HLA haplotype of the  
 CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
 CC peptide to an individual based on the HLA haplotype of the individual;  
 CC and (6) preventing the formation or progression of amyloid plaques. The  
 CC amyloid beta peptide has neuroprotective activity, and can be used in  
 CC vaccines. The amyloid beta peptide is useful for preparing a composition  
 CC for preventing the formation or progression of amyloid plaques for  
 CC preventing or treating Alzheimer's disease. The present sequence  
 CC represents an amyloid beta (Abeta) peptide, which is used in an example  
 CC from the present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QKLVFF 6  
 Db 4 QKLVFF 9

RESULT 48

ADP44609  
 ID ADP44609 standard; peptide; 9 AA.

XX AC ADP44609;

XX DT 12-AUG-2004 (first entry)

XX DE Radioisotope technetium-related peptide 2.

XX KW radioisotope technetium; Tc complex; aza-diaminedioxime ligand;  
 XX KW radiopharmaceutical; thrombus diagnostic imaging.

XX OS Unidentified.

XX FH Key Location/Qualifiers  
 XX FT Modified-site 1

XX FT /label= OTHER

XX FT /note= "Attached to CO(CH2)2CO2- group"

XX FT Misc-difference 9

XX FT /note= "C-terminal amide"

XX PN WO2004037297-A1.

XX PD 06-MAY-2004.

XX PF 24-OCT-2003; 2003WO-GB004573.

XX PR 25-OCT-2002; 2002GB-00024799.

XX PA (AMSH ) AMERSHAM PLC.

XX PI Brauers G, Farrar G, Barnett DJ, Wadsworth HJ, Lewis JS;

XX DR WPI; 2004-365454/34.

XX Composition useful in radiopharmaceuticals for diagnostic imaging of  
 PT thrombi comprises complex of radioisotope technetium with aza-  
 PT diaminedioxime ligand.

XX Disclosure; Page 28; 50pp; English.

XX The invention relates to a novel composition comprising a complex of  
 CC radioisotope technetium (Tc) with an aza-diaminedioxime ligand. The  
 CC composition of the invention may be useful in radiopharmaceuticals for  
 CC mammalian administration, to be used in diagnostic imaging of thrombi.  
 CC The composition comprises minimised amounts of lipophilic technetium  
 CC complex species, thus improving the overall imaging characteristics. The



CC composition does not form a diastereomeric complex as it does not contain  
 CC a chiral centre and hence does not require purification of the particular  
 CC isomers. The current sequence is that of the radioisotope technetium (Tc)  
 CC -related peptide 2 of the invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6  
 |||||  
 Db 4 QKLVFF 9

RESULT 49

ADQ37260  
 ID ADQ37260 standard; peptide; 9 AA.

XX

AC ADQ37260;

XX 07-OCT-2004 (first entry)

DT Vaccine antigen amyloid-beta related amino acid sequence.

DE amyloid-beta; amyloid-beta related disease;

XX amyloid-beta fibril formation; immune response; nootropic;

KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

KW cardiant; antidepressant; endocrine; hypnotic;

KW amyloid-beta fibril formation modulator; immune system modulator;

KW Alzheimer's disease; mild cognitive impairment;

KW mild-to-moderate cognitive impairment; vascular dementia;

KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

KW senile dementia; Down's syndrome; inclusion body myositis;

KW age-related macular degeneration; hypothyroidism;

KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

KW behavioural dysfunction; neurological condition; psychological condition;

KW vaccine antigen.

XX Synthetic.

OS

XX Key Location/Qualifiers

FT Misc-difference 1..9 /note= "D-form residues"

FT

XX WO2004058239-A1.

XX 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

XX 24-DEC-2002; 2002US-0436379P.

PR 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent

PT that prevents or treats amyloid-beta related disease and second agent

PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 67; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first

XX agent (a1) that prevents or treats amyloid-beta related disease; and (b)

CC a second agent (a2) that is: (1) a peptide or peptidomimetic that

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an Apos gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.

XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 8; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QKLVFF 6

|||||

Db 3 QKLVFF 8

RESULT 50

ADQ37376

ID ADQ37376 standard; peptide; 9 AA.

XX

AC ADQ37376;

XX 07-OCT-2004 (first entry)

XX Amyloid-beta polymerisation peptide.

DE

XX amyloid-beta; amyloid-beta related disease;

KW amyloid-beta fibril formation; immune response; nootropic;

KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

KW cardiant; antidepressant; endocrine; hypnotic;

KW amyloid-beta fibril formation modulator; immune system modulator;

KW Alzheimer's disease; mild cognitive impairment;

KW mild-to-moderate cognitive impairment; vascular dementia;

KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

KW senile dementia; Down's syndrome; inclusion body myositis;

KW age-related macular degeneration; hypothyroidism;

KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

KW behavioural dysfunction; neurological condition; psychological condition;

KW vaccine antigen.

XX Synthetic.

Job time : 63.9452 secs

XX WO2004058239-A1.  
 XX  
 XX PD 15-JUL-2004.  
 XX  
 XX PF 24-DEC-2003; 2003WO-CA002021.  
 XX  
 XX PR 24-DEC-2002; 2002US-0436379P.  
 XX PR 23-JUN-2003; 2003US-0482214P.  
 XX  
 XX PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 XX PI Gervais F, Bellini F;  
 XX  
 XX WPI; 2004-543342/52.  
 XX  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 XX Disclosure; Page 95; 143pp; English.  
 XX  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents an amyloid-  
 CC beta polymerisation peptide which is used in the exemplification of the  
 CC present invention.  
 XX  
 XX Sequence 9 AA;

Query Match 100.0%; Score 30; DB 8; Length 9;  
 Best Local Similarity 100.0%; Freq. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 OKLVFF 6  
 |||||  
 Db 4 OKLVFF 9

Search completed: March 9, 2005, 06:27:40

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 63.9452 Seconds  
(without alignments)  
36.290 Million cell updates/sec

Title: US-10-009-122-1

Perfect score: 29

Sequence: 1 KIVFFA 6

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database : A\_Geneseq\_16Dec04:\*

1: Geneseq1980s:\*

2: Geneseq1990s:\*

3: Geneseq2000s:\*

4: Geneseq2001s:\*

5: Geneseq2002s:\*

6: Geneseq2003as:\*

7: Geneseq2003bs:\*

8: Geneseq2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	100.0	6	4	AAB48483
2	29	100.0	6	4	AAB48474
3	29	100.0	6	4	AAB82623
4	29	100.0	6	4	AAB82631
5	29	100.0	6	5	AAB96819
6	29	100.0	6	5	AAB96811
7	29	100.0	6	5	AAB11657
8	29	100.0	6	5	AAB11648
9	29	100.0	6	6	AAB35446
10	29	100.0	6	6	AAB35438
11	29	100.0	6	8	ADQ37322
12	29	100.0	6	8	ADQ37270
13	29	100.0	6	8	ADQ37313
14	29	100.0	6	8	ADQ37262
15	29	100.0	99	4	ABG26598
16	28	96.6	6	4	AAB48482
17	28	96.6	6	4	AAB48490
18	28	96.6	6	4	AAB82630
19	28	96.6	6	4	AAB82638
20	28	96.6	6	5	AAB96818
21	28	96.6	6	5	AAB96826
22	28	96.6	6	5	AAB11664
23	28	96.6	6	5	AAB11656
24	28	96.6	6	6	AAB35452
25	28	96.6	6	8	ADQ37277

26	28	96.6	6	8	ADQ37321	Adq37321 Antifibri
27	28	96.6	6	8	ADQ37329	Adq37329 Antifibri
28	28	96.6	22	8	ADQ09761	Adq09761 Rice 26kD
29	28	96.6	37	3	AAB05910	Aab05910 Mouse ind
30	28	96.6	37	3	ADK34080	Adk34080 Human nro
31	28	96.6	37	8	ADL70727	Adl70727 Mouse iNo
32	28	96.6	77	3	AAG02840	Aag02840 Human sec
33	28	96.6	175	4	AAO11219	Aao11219 Human pol
34	28	96.6	186	7	ADC07962	Adc07962 Rice prot
35	28	96.6	186	7	ADC07948	Adc07948 Rice prot
36	28	96.6	190	4	AAW83792	Aaw83792 Human imm
37	28	96.6	564	4	ABE61977	AbE61977 Drosophi
38	28	96.6	854	8	ADQ66704	Adq66704 Novel hum
39	28	96.6	922	8	ABM83252	Abm83252 Human dia
40	28	96.6	925	7	ADF76335	Adf76335 Novel hum
41	28	96.6	925	7	ADJ70225	Adj70225 Human hea
42	28	96.6	925	8	ADJ75428	Adj75428 Marker ge
43	28	96.6	925	8	ADJ75495	Adj75495 Marker ge
44	28	96.6	925	8	ADN04860	Adn04860 Antipsori
45	28	96.6	925	8	ADR14233	Adr14233 Human NF-
46	28	96.6	925	8	ADP25011	Adp25011 PRO polyP
47	28	96.6	925	8	ADR97294	Adr97294 Human RIG
48	28	96.6	1144	2	AAW77360	Aaw77360 Inducible
49	28	96.6	1144	2	AAW51246	Aaw51246 Inducible
50	28	96.6	1144	4	AAG64500	Aag64500 Mouse ind
51	28	96.6	1144	6	ABU79138	Abu79138 Inducible
52	28	96.6	1144	7	ADF43404	Adf43404 iNOS poly
53	28	96.6	1144	7	ADF77432	Adf77432 Mouse ind
54	28	96.6	1144	8	ADJ76212	Adj76212 Marker ge
55	28	96.6	1144	8	ADJ76136	Adj76136 Marker ge
56	28	96.6	1443	4	ABB68472	Abb68472 Drosophi
57	27	93.1	6	2	AAW02314	Aaw02314 Beta-amyl
58	27	93.1	6	2	AAW89378	Aaw89378 Beta-amyl
59	27	93.1	6	4	AAB48484	Aab48484 Antifibri
60	27	93.1	6	4	AAB48476	Aab48476 Antifibri
61	27	93.1	6	4	ABM82632	Abm82632 All-D pep
62	27	93.1	6	5	ABG71009	Abg71009 Long form
63	27	93.1	6	5	ABO5157	AbO5157 Beta amyl
64	27	93.1	6	5	AAU96820	Aau96820 Amyloid t
65	27	93.1	6	5	ABB83305	Abb83305 Amyloid-b

ALIGNMENTS

RESULT 1	
AAB48483	
ID	AAB48483 standard; peptide; 6 AA.
XX	
AC	AAB48483;
XX	
DT	02-MAR-2001 (first entry)
XX	
DE	Antifibrillogenic peptide #10.
XX	
KW	Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition; cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX	Alzheimer's disease.
OS	Homo sapiens.
FT	Key
FT	Modified-site 6
XX	Location/Qualifiers
XX	/note: "C-terminal amide"
PN	WO2000068263-A2.
XX	
PD	16-NOV-2000.
XX	
PF	04-MAY-2000; 2000WO-CA000515.
XX	
PR	05-MAY-1999; 99US-0132592P.
XX	

PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Chalifour R, Gervais F, Gupta A;  
 XX  
 XX WPI; 2001-031852/04.  
 XX  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 XX Claim 7; Page 25; 46pp; English.  
 PS  
 XX Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 |||||  
 DB 1 KIVFFA 6

RESULT 2  
 AAB48474  
 ID AAB48474 standard; peptide; 6 AA.  
 XX  
 AC AAB48474;  
 XX  
 DT 02-MAR-2001 (first entry)  
 XX  
 DE Antifibrillogenic peptide #1.  
 XX  
 KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.  
 XX  
 XX Homo sapiens.  
 OS  
 XX WO200068263-A2.  
 PN  
 XX 16-NOV-2000.  
 PD  
 XX 04-MAY-2000; 2000WO-CA000515.  
 PF  
 XX 05-MAY-1999; 99US-0132592P.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 PI Chalifour R, Gervais F, Gupta A;  
 XX  
 XX WPI; 2001-031852/04.  
 DR  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 XX Claim 7; Page 25; 46pp; English.  
 PS  
 XX Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid

CC protein  
 XX  
 SQ Sequence 6 AA;  
 QY 1 KIVFFA 6  
 |||||  
 DB 1 KIVFFA 6

RESULT 3  
 AAB82623  
 ID AAB82623 standard; peptide; 6 AA.  
 XX  
 AC AAB82623;  
 XX  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 XX  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..6  
 FT /note= "all D-form residues"  
 XX  
 XX WO200139796-A2.  
 PN  
 XX 07-JUN-2001.  
 PD  
 XX 29-NOV-2000; 2000WO-CA001413.  
 PF  
 XX 29-NOV-1999; 99US-0168594P.  
 PR  
 XX 28-NOV-2000; 2000US-00724842.  
 XX  
 XX (NEUR-) NEUROCHEM INC.  
 XX  
 XX Chalifour R, Hebert L, Kong X, Gervais F;  
 XX  
 XX WPI; 2001-441458/47.  
 DR  
 XX Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.  
 XX  
 XX Disclosure; Page 10; 31pp; English.  
 PS  
 XX The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 15-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,

CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 |||||  
 DB 1 KIVFFA 6  
 RESULT 4  
 AAB82631  
 ID AAB82631 standard; peptide; 6 AA.  
 XX  
 AC AAB82631;  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 XX  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..6  
 FT Modified-site /note= "all D-form residues"  
 FT /note= "C-terminal amide"  
 XX  
 PN WO200139796-A2.  
 XX  
 PD 07-JUN-2001.  
 XX  
 PF 29-NOV-2000; 2000WO-CA001413.  
 XX  
 PR 29-NOV-1999; 99US-0168594P.  
 PR 28-NOV-2000; 2000US-00724842.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Chalfour R, Hebert L, Kong X, Gervais F;  
 XX  
 DR WPI; 2001-441458/47.  
 XX  
 PT Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.  
 XX  
 PS Disclosure; Page 11; 31pp; English.  
 XX  
 CC The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self',  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic

CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 |||||  
 DB 1 KIVFFA 6  
 RESULT 5  
 AAU96819  
 ID AAU96819 standard; peptide; 6 AA.  
 XX  
 AC AAU96819;  
 XX  
 DT 30-JUL-2002 (first entry)  
 XX  
 DE Amyloid targeting peptide #9.  
 XX  
 KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..6  
 FT Modified-site /note= "Preferably D-form residue"  
 FT /note= "Ala is amidated"  
 XX  
 PN WO200207781-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 25-JUL-2001; 2001WO-CA001071.  
 XX  
 PR 25-JUL-2000; 2000US-0220808P.  
 PR 24-JUL-2001; 2001US-00915092.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Gervais F, Kong X, Chalfour R, Migneault D;  
 XX  
 DR WPI; 2002-371447/40.  
 XX  
 PT New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
 PT plaques and/or for the treatment of amyloidosis disorders.  
 XX  
 PS Claim 49; Page 21; 57pp; English.  
 XX  
 CC The invention relates to an amyloid-targeting imaging agent comprising an

CC amyloid targeting moiety, a linker moiety and a labelling moiety. The  
CC agent is of general formula A-t-(A<sub>1</sub>-n<sub>1</sub>k)-z-A<sub>1</sub>-a<sub>1</sub>b (I) where z = 0 - 1;  
CC A<sub>1</sub>t = an amyloid targeting moiety; A<sub>1</sub>-n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>-a<sub>1</sub>b  
CC = a labelling moiety. Also included are imaging amyloid deposition or  
CC diagnosing an amyloid-related condition in a patient involving  
CC administering (I) to the patient, and ultrasound imaging (I) in the  
CC patient to determine the presence of amyloid or amyloid-related condition  
CC (I), a reducing agent, a buffering agent, a transchelating agent, and  
CC instructions for the preparation and use of the radiopharmaceutical in  
CC the imaging of amyloid or an amyloid-related condition. The agents are  
CC used for imaging amyloid deposition and for diagnosing an amyloid related  
CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
CC cerebral amyloidosis (transmissible virus dementias), familial CJD,  
CC scrapie, transmissible mink encephalopathy, bovine spongiform  
CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
CC barrier and are capable of binding specifically to amyloid plaques. The  
CC present sequence is a peptide forming the amyloid targeting moiety of the  
CC agent of the invention  
XX  
SQ Sequence 6 AA;

Query Match 100.0%; Score 29; DB 5; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFFA 6  
Db 1 KIVFFFA 6

RESULT 6  
AAU96811 standard; peptide; 6 AA.

AAU96811;

30-JUL-2002 (first entry)

Amyloid targeting peptide #1.

XX Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
XX transmissible cerebral amyloidosis; transmissible virus dementias;  
XX scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
XX bovine spongiform encephalopathy; inflammation associated amyloid;  
XX primary amyloidosis; feline spongiform encephalopathy;  
XX Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
XX dialysis-related amyloidosis; light chain-related amyloidosis;  
XX cerebral amyloid angiopathy.

XX Synthetic.

XX Key Location/Qualifiers  
FH Key  
FT Misc-difference 1..6 /note= "Preferably D-form residue"  
XX  
XX  
XX

WO200207781-A2.

31-JAN-2002.

25-JUL-2001; 2001WO-CA001071.

25-JUL-2000; 2000US-0220808P.

24-JUL-2001; 2001US-00915092.

(NEUR-) NEUROCHEM INC.

Gervais F, Kong X, Chalifour R, Migneault D;

XX

WPI; 2002-371447/40.

XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
XX plaques and/or for the treatment of amyloidosis disorders.

XX Claim 49; Page 21; 57pp; English.

XX The invention relates to an amyloid-targeting imaging agent comprising an  
XX amyloid targeting moiety, a linker moiety and a labelling moiety. The  
XX agent is of general formula A-t-(A<sub>1</sub>-n<sub>1</sub>k)-z-A<sub>1</sub>-a<sub>1</sub>b (I) where z = 0 - 1;  
XX A<sub>1</sub>t = an amyloid targeting moiety; A<sub>1</sub>-n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>-a<sub>1</sub>b  
XX = a labelling moiety. Also included are imaging amyloid deposition or  
XX diagnosing an amyloid-related condition in a patient involving  
XX administering (I) to the patient, and ultrasound imaging (I) in the  
XX patient to determine the presence of amyloid or amyloid-related condition  
XX (I), a reducing agent, a buffering agent, a transchelating agent, and  
XX instructions for the preparation and use of the radiopharmaceutical in  
XX the imaging of amyloid or an amyloid-related condition. The agents are  
XX used for imaging amyloid deposition and for diagnosing an amyloid related  
XX condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
XX cerebral amyloidosis (transmissible virus dementias), familial CJD,  
XX scrapie, transmissible mink encephalopathy, bovine spongiform  
XX encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
XX primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
XX cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
XX dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
XX amyloid angiopathy. The agents are capable of crossing the blood-brain  
XX barrier and are capable of binding specifically to amyloid plaques. The  
XX present sequence is a peptide forming the amyloid targeting moiety of the  
XX agent of the invention

XX Sequence 6 AA;

Query Match 100.0%; Score 29; DB 5; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFFA 6  
Db 1 KIVFFFA 6

RESULT 7  
AAU11657 standard; peptide; 6 AA.

AAU11657;

09-APR-2002 (first entry)

Peptide #10, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.

XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
XX CAA; notropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
XX cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX Synthetic.

XX Key Location/Qualifiers  
FH Key  
FT Modified-site 6 /note= "C-terminal amide"  
XX

WO200185093-A2.

15-NOV-2001.

22-DEC-2000; 2000WO-IB002078.

23-DEC-1999; 99US-0171877P.

(NEUR-) NEUROCHEM INC.

XX

PI Green AM, Gervais F;  
 XX WPI; 2002-075222/10.  
 XX  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.  
 XX  
 XX Disclosure; Page 10; 68pp; English.  
 PS  
 XX The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)  
 XX  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 1 KIVFFA 6  
 |||||  
 |||||

RESULT 8  
 AAU11648  
 ID AAU11648 standard; peptide; 6 AA.  
 AC AAU11648;  
 XX  
 XX 09-APR-2002 (first entry)  
 DT  
 XX  
 XX Peptide #1, used as a carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 DE  
 XX  
 XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 XX Synthetic.  
 OS  
 XX WO200185093-A2.  
 PN  
 XX 15-NOV-2001.  
 PD  
 XX 22-DEC-2000; 2000WO-IB002078.  
 PF  
 XX 23-DEC-1999; 99US-0171877P.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Green AM, Gervais F;  
 PI WPI; 2002-075222/10.  
 XX  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.  
 PT  
 XX Disclosure; Page 10; 68pp; English.  
 PS  
 XX The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid

CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)  
 XX  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 1 KIVFFA 6  
 |||||  
 |||||

RESULT 9  
 AAE35446  
 ID AAE35446 standard; peptide; 6 AA.  
 XX  
 XX AAE35446;  
 AC  
 XX 17-JUN-2003 (first entry)  
 DT  
 XX  
 XX Abeta peptide #17.  
 DE  
 XX  
 KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
 XX  
 XX Unidentified.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FH Misc-difference 1..6 /note= "D-form residues"  
 FT Modified-site 6 /note= "C-terminal amide"  
 FT  
 FT WO200296937-A2.  
 PN  
 XX 05-DEC-2002.  
 PD  
 XX 29-MAY-2002; 2002WO-CA000763.  
 PF  
 XX 29-MAY-2001; 2001US-00867847.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
 PI WPI; 2003-201269/19.  
 XX  
 XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
 PT  
 XX Claim 1; Page 59; 44pp; English.  
 PS  
 XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic

CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
CC disease. AA deposits are also produced as a result of chronic microbial  
CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
CC present sequence is an Abeta peptide used to illustrate the method of the  
CC invention  
XX  
XX Sequence 6 AA;  
SQ  
Query Match 100.0%; Score 29; DB 6; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
Db 1 KIVFFA 6  
RESULT 11  
ADQ37322  
ID ADQ37322 standard; peptide; 6 AA.  
XX  
XX  
AC ADQ37322;  
XX  
XX 07-OCT-2004 (first entry)  
XX  
XX Antifibrillogenic amyloidosis inhibiting peptide.  
XX  
XX amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.  
XX  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
FH Modified-site 6  
FT /note= "amidated"  
XX  
XX WO2004058239-A1.  
XX  
XX 15-JUL-2004.  
XX  
XX 24-DEC-2003; 2003WO-CA002021.  
XX  
XX 24-DEC-2002; 2002US-0436379P.  
XX 23-JUN-2003; 2003US-0482214P.  
XX  
XX (NEUR-) NEUROCHEM INT LTD.  
XX  
XX Gervais F, Bellini F;  
XX WPI; 2004-543342/52.  
XX Composition for treating e.g. Alzheimer's disease comprises first agent  
PT that prevents or treats amyloid-beta related disease and second agent  
PT that is either a peptide or peptidomimetic or an immune system modulator.  
PT

CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
CC disease. AA deposits are also produced as a result of chronic microbial  
CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
CC present sequence is an Abeta peptide used to illustrate the method of the  
CC invention  
XX  
XX Sequence 6 AA;  
SQ  
Query Match 100.0%; Score 29; DB 6; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
Db 1 KIVFFA 6  
RESULT 10  
AAE35438  
ID AAE35438 standard; peptide; 6 AA.  
XX  
XX  
AC AAE35438;  
XX  
XX 17-JUN-2003 (first entry)  
XX  
XX Abeta peptide #9.  
XX  
XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic;  
KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
XX  
XX Unidentified.  
XX  
XX Key Location/Qualifiers  
FH Misc-difference 1..6  
FT /note= "D-form residues"  
XX  
XX WO200296937-A2.  
XX  
XX 05-DEC-2002.  
XX  
XX 29-MAY-2002; 2002WO-CA000763.  
XX  
XX 29-MAY-2001; 2001US-00867847.  
XX  
XX (NEUR-) NEUROCHEM INC.  
XX  
XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
XX  
XX WPI; 2003-201269/19.  
XX  
XX Prevention and/or treatment of an amyloid-related disease e.g.  
PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
XX  
XX Claim 1; Page 58; 4app; English.  
XX  
XX The invention relates to a method for prevention and/or treatment of an  
CC amyloid-related disease which comprises administration of an all-D-  
CC amyloid-beta peptide. The method is used for preventing and/or treating  
CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
CC the mammal; and reducing or inhibiting the formation of plaques. It is  
CC also used for treating AA (reactive) amyloid diseases including



XX Disclosure; Page 69; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic, tranquilliser, ophthalmological, antithyroid, vasotropic, cardiovascular, muscular, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; having amyloid-beta deposits. The present sequence represents a peptide that can be used as an antifibrillogenic amyloidosis inhibiting peptide in the exemplification of the present invention.

XX Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|||||

Db 1 KIVFFA 6

RESULT 12

ADQ37270

ID ADQ37270 standard; peptide; 6 AA.

XX ADQ37270;

AC ADQ37270;

XX 07-OCT-2004 (first entry)

XX Vaccine antigen amyloid-beta related amino acid sequence.

XX amyloid-beta; amyloid-beta related disease;

KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

KW cardiant; antidepressant; endocrine; hypnotic;

KW amyloid-beta fibril formation modulator; immune system modulator;

KW Alzheimer's disease; mild cognitive impairment;

KW mild-to-moderate cognitive impairment; vascular dementia;

KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

KW senile dementia; Down's syndrome; inclusion body myositis;

KW age-related macular degeneration; hypothyroidism;

KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

KW behavioural dysfunction; neurological condition; psychological condition; vaccine antigen.

XX Synthetic.

FT Key Location/Qualifiers

FT Misc-difference 1, 6 /note= "D-form residues"

FT Modified-site 6 /note= "amidated"

PN WO2004058239-A1.

PD 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

PF 24-DEC-2002; 2002US-0436379P.

PR 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.

PA Gervais F, Bellini F;

PI WPI; 2004-543342/52.

DR Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 67; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; having amyloid-beta deposits. The present sequence represents a peptide that can be used as a vaccine antigen in the exemplification of the present invention.

CC immune system modulators. (C) can be used for preventing or treating an  
CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
CC Down's syndrome, hereditary cerebral haemorrhage, senile dementia,  
CC amyloid angiopathy, inclusion body myositis, age-related macular  
CC degeneration, or a condition associated with Alzheimer's disease  
CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
CC Parkinson's disease, apraxia, agnosia, Pick disease, dementia  
CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
CC field deficits, incoordination, gait disturbance, transient ischaemic  
CC attack or stroke, transient alertness, attention deficit, frequent falls,  
CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
CC damage), or a psychological condition (e.g. depression, delusions,  
CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
CC amyloid precursor protein gene, an ApoE gene, or a Presenilin gene;  
CC having amyloid-beta deposits. The present sequence represents a peptide  
CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
CC in the exemplification of the present invention.

XX SQ Sequence 6 AA;

Qy 1 KIVFFA 6  
Db 1 KIVFFA 6

Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 13  
ADQ37313  
ID ADQ37313 standard; peptide; 6 AA.  
AC ADQ37313;  
XX 07-OCT-2004 (first entry)  
DE Antifibrillogenic amyloidosis inhibiting peptide.  
XX amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.

OS Synthetic.  
XX WO2004058239-A1.  
XX 15-JUL-2004.

FF 24-DEC-2003; 2003WO-CA002021.  
XX 24-DEC-2002; 2002US-0436379P.  
PR 23-JUN-2003; 2003US-0482214P.  
XX (NEUR-) NEUROCHEM INT LTD.  
XX Gervais F, Bellini F;  
XX WPI; 2004-543342/52.  
XX Composition for treating e.g. Alzheimer's disease comprises first agent  
PT that prevents or treats amyloid-beta related disease and second agent  
PT that is either a peptide or peptidomimetic or an immune system modulator.  
XX Disclosure; Page 69; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
CC modulates amyloid-beta fibril formation or induces a prophylactic or  
CC therapeutic immune response against amyloid-beta fibril formation; or  
CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
CC fibril formation. Also described is a kit comprising (C). (C) have  
CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
CC and can be used as amyloid-beta fibril formation modulators, and as

RESULT 14  
ADQ37262  
ID ADQ37262 standard; peptide; 6 AA.  
XX ADQ37262;  
XX 07-OCT-2004 (first entry)  
XX Vaccine antigen amyloid-beta related amino acid sequence.  
XX amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.

OS Synthetic.  
XX WO2004058239-A1.  
XX 15-JUL-2004.

FF 24-DEC-2003; 2003WO-CA002021.  
XX 24-DEC-2002; 2002US-0436379P.  
PR 23-JUN-2003; 2003US-0482214P.  
XX (NEUR-) NEUROCHEM INT LTD.  
XX Gervais F, Bellini F;  
XX WPI; 2004-543342/52.  
XX Composition for treating e.g. Alzheimer's disease comprises first agent  
PT that prevents or treats amyloid-beta related disease and second agent  
PT that is either a peptide or peptidomimetic or an immune system modulator.  
XX Disclosure; Page 69; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
CC modulates amyloid-beta fibril formation or induces a prophylactic or  
CC therapeutic immune response against amyloid-beta fibril formation; or  
CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
CC fibril formation. Also described is a kit comprising (C). (C) have  
CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
CC and can be used as amyloid-beta fibril formation modulators, and as

XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 XX 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX (NEUR-) NEUROCHEM INT LTD.  
 PA Gervais F, Bellini F;  
 XX WPI; 2004-543342/52.  
 XX  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 XX Disclosure; Page 67; 143pp; English.  
 XX  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nontropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.  
 XX Sequence 6 AA;  
 XX  
 XX Query Match 100.0%; Score 29; DB 8; Length 6;  
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 XX QY 1 KIVFFA 6  
 XX |||||  
 XX Db 1 KIVFFA 6  
 XX  
 XX RESULT 15  
 XX ABG26598  
 XX ID ABG26598 standard; protein; 99 AA.  
 XX  
 XX ABG26598;  
 XX

XX 18-FEB-2002 (first entry)  
 XX  
 XX Novel human diagnostic protein #26589.  
 XX  
 XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO200175067-A2.  
 PN  
 XX 11-OCT-2001.  
 PD  
 XX 30-MAR-2001; 2001WO-US008631.  
 PF  
 XX 31-MAR-2000; 2000US-00540217.  
 PR  
 XX 23-AUG-2000; 2000US-00649167.  
 PR  
 XX (HYSE-) HYSEQ INC.  
 PA Drmanac RT, Liu C, Tang YT;  
 PI WPI; 2001-639362/73.  
 XX N-PSDB; AAS90785.  
 DR  
 XX New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX  
 XX Claim 20; SEQ ID NO 56957; 103pp; English.  
 XX  
 XX The invention relates to isolated polynucleotide (I) and polypeptide (II)  
 CC sequences. (I) is useful as hybridisation probes, polymerase chain  
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
 CC and in recombinant production of (II). The polynucleotides are also used  
 CC in diagnostics as expressed sequence tags for identifying expressed  
 CC genes. (I) is useful in gene therapy techniques to restore normal  
 CC activity of (II) or to treat disease states involving (II). (II) is  
 CC useful for generating antibodies against it, detecting or quantitating a  
 CC polypeptide in tissue, as molecular weight markers and as a food  
 CC supplement. (II) and its binding partners are useful in medical imaging  
 CC of sites expressing (II). (I) and (II) are useful for treating disorders  
 CC involving aberrant protein expression or biological activity. The  
 CC polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
 CC amino acid sequences of the invention. Note: The sequence data for this  
 CC patent did not appear in the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 XX Sequence 99 AA;  
 XX  
 XX Query Match 100.0%; Score 29; DB 4; Length 99;  
 XX Best Local Similarity 100.0%; Pred. No. 44;  
 XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 XX QY 1 KIVFFA 6  
 XX |||||  
 XX Db 63 KIVFFA 68  
 XX  
 XX RESULT 16  
 XX AAB48482  
 XX ID AAB48482 standard; peptide; 6 AA.  
 XX  
 XX AAB48482;  
 AC  
 XX 02-MAR-2001 (first entry)  
 DT

```

XX DE Antifibrillogenic peptide #9.
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
XX KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX KW Alzheimer's disease.
XX OS Homo sapiens.
XX PN WO200068263-A2.
XX PD 16-NOV-2000.
XX PF 04-MAY-2000; 2000WO-CA000515.
XX PR 05-MAY-1999; 99US-0132592P.
XX PA (NEUR-) NEUROCHEM INC.
XX PI Chalifour R, Gervais F, Gupta A;
XX PI WPI; 2001-031852/04.
XX DR Antifibrillogenic agent useful for inhibiting amyloidosis and/or for
XX PT cytoprotection for treating amyloidosis disorders, comprises a peptide,
XX PT its isomer or peptidomimetic.
XX PS Claim 7; Page 25; 46pp; English.
XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used
XX CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of
XX CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore
XX CC useful for treating amyloidosis disorders such as Alzheimer's disease.
XX CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan
XX CC binding region and the prot-prot interaction region of the human amyloid
XX CC protein
XX SQ Sequence 6 AA;
XX Query Match 96.6%; Score 28; DB 4; Length 6;
XX Best Local Similarity 83.3%; Pred. No. 1.8e+06;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 1 KWVFFA 6

RESULT 18
ID AAB82630 standard; peptide; 6 AA.
XX AC AAB82630;
XX DT 02-OCT-2001 (first entry)
XX DE All-D peptide used in Alzheimer's disease vaccine.
XX KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;
XX KW therapy; antigen.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Misc-difference 1..6 /note= "all D-form residues"
XX FT FT
XX PN WO200139796-A2.
XX PD 07-JUN-2001.
XX PF 29-NOV-2000; 2000WO-CA001413.
XX PR 29-NOV-1999; 99US-0168594P.
XX PR 28-NOV-2000; 2000US-00724842.
XX PA (NEUR-) NEUROCHEM INC.
XX PI Chalifour R, Hebert L, Kong X, Gervais F;
XX PI WPI; 2001-441458/47.
XX DR Preventing/treating amyloid-related disease, especially Alzheimer's
XX PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,
XX PT which elicits production of antibodies to prevent fibrillogenesis and
XX PT associated cellular toxicity.
XX

XX DE Antifibrillogenic peptide #9.
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
XX KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX KW Alzheimer's disease.
XX OS Homo sapiens.
XX PN WO200068263-A2.
XX PD 16-NOV-2000.
XX PF 04-MAY-2000; 2000WO-CA000515.
XX PR 05-MAY-1999; 99US-0132592P.
XX PA (NEUR-) NEUROCHEM INC.
XX PI Chalifour R, Gervais F, Gupta A;
XX PI WPI; 2001-031852/04.
XX DR Antifibrillogenic agent useful for inhibiting amyloidosis and/or for
XX PT cytoprotection for treating amyloidosis disorders, comprises a peptide,
XX PT its isomer or peptidomimetic.
XX PS Claim 7; Page 25; 46pp; English.
XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used
XX CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of
XX CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore
XX CC useful for treating amyloidosis disorders such as Alzheimer's disease.
XX CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan
XX CC binding region and the prot-prot interaction region of the human amyloid
XX CC protein
XX SQ Sequence 6 AA;
XX Query Match 96.6%; Score 28; DB 4; Length 6;
XX Best Local Similarity 83.3%; Pred. No. 1.8e+06;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 1 KWVFFA 6

RESULT 17
ID AAB48490 standard; peptide; 6 AA.
XX AC AAB48490;
XX DT 02-MAR-2001 (first entry)
XX DE Antifibrillogenic peptide #17.
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
XX KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX KW Alzheimer's disease.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Modified-site 6 /note= "C-terminal amide"
XX FT FT
XX PN WO200068263-A2.
XX PD 16-NOV-2000.
XX PF 04-MAY-2000; 2000WO-CA000515.

```

PS Disclosure; Page 11; 31pp; English.

XX The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients

XX Sequence 6 AA;

SQ

Query Match 96.6%; Score 28; DB 4; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
 |:|||||  
 Db 1 KVVFFA 6

RESULT 19

AAB82638

ID AAB82638 standard; peptide; 6 AA.

XX

AC AAB82638;

DT

XX

XX 02-OCT-2001 (first entry)

DE All-D peptide used in Alzheimer's disease vaccine.

XX

KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.

XX

OS Synthetic.

XX

FT Key Location/Qualifiers

FT Misc-difference 1..6 /note= "all D-form residues"

FT Modified-site 6 /note= "C-terminal amide"

FT

XX

PN WO200139796-A2.

XX

PD 07-JUN-2001.

XX

XX 29-NOV-2000; 2000WO-CA001413.

XX

PR 29-NOV-1999; 99US-0168594P.

PR 28-NOV-2000; 2000US-00724842.

XX

PA (NEUR-) NEUROCHEM INC.

XX

PI Chalfour R, Hebert L, Kong X, Gervais F;

XX

DR WPI; 2001-441458/47.

XX Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.

XX

XX Disclosure; Page 11; 31pp; English.

XX The present sequence is that of an all-D peptide suitable for use in  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients

XX Sequence 6 AA;

SQ

Query Match 96.6%; Score 28; DB 4; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
 |:|||||  
 Db 1 KVVFFA 6

RESULT 20

AAU96818

ID AAU96818 standard; peptide; 6 AA.

XX

AC AAU96818;

XX

XX 30-JUL-2002 (first entry)

DE Amyloid targeting peptide #8.

XX

KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.

XX

OS Synthetic.

XX

FT Key Location/Qualifiers

FT Misc-difference 1..6 /note= "preferably D-form residue"

FT

XX

PN WO200207781-A2.

```

PD 31-JAN-2002.
XX
XX
XX 25-JUL-2001; 2001WO-CA001071.
XX
XX 25-JUL-2000; 2000US-0220808P.
XX
XX 24-JUL-2001; 2001US-00915092.
XX
XX (NEUR-) NEUROCHEM INC.
XX
XX Gervais F, Kong X, Chalifour R, Migneault D;
XX
XX WPI; 2002-371447/40.
XX
XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid
XX plaques and/or for the treatment of amyloidosis disorders.
XX
XX Claim 49; Page 21; 57pp; English.
XX
XX The invention relates to an amyloid-targeting imaging agent comprising an
XX amyloid targeting moiety, a linker moiety and a labelling moiety. The
XX agent is of general formula A_t-(A_1)_n-k)-z-A_1_a_b (I) where z = 0 - 1;
XX A_t = an amyloid targeting moiety; A_1_n-k) = a linker moiety; and A_1_a_b
XX = a labelling moiety. Also included are imaging amyloid deposition or
XX diagnosing an amyloid-related condition in a patient involving
XX administering (I) to the patient, and ultrasound imaging (I) in the
XX patient to determine the presence of amyloid or amyloid-related condition
XX ; and a kit for preparing a radiopharmaceutical preparation comprising
XX (I), a reducing agent, a buffering agent, a transchelating agent, and
XX instructions for the preparation and use of the radiopharmaceutical in
XX the imaging of amyloid or an amyloid-related condition. The agents are
XX used for imaging amyloid deposition and for diagnosing an amyloid related
XX condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible
XX cerebral amyloidosis (transmissible virus dementias), familial CJD,
XX scrapie, transmissible mink encephalopathy, bovine spongiform
XX encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,
XX primary amyloidosis, Alzheimer's disease, prion-mediated diseases,
XX cerebral amyloidosis, light chain-related amyloidosis, cerebral
XX dialysis-related amyloidosis, the agents are capable of crossing the blood-brain
XX amyloid angiopathy. The agents are capable of binding specifically to amyloid plaques. The
XX present sequence is a peptide forming the amyloid targeting moiety of the
XX agent of the invention
XX
XX Sequence 6 AA;
XX
XX Query Match 96.6%; Score 28; DB 5; Length 6;
XX Best Local Similarity 83.3%; Pred. No. 1.8e+06;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFA 6
XX |:|||||
XX Db 1 KVVFFA 6
XX
XX RESULT 21
XX AAU96826
XX ID AAU96826 standard; peptide; 6 AA.
XX
XX AC AAU96826;
XX
XX 30-JUL-2002 (first entry)
XX
XX Amyloid targeting peptide #16.
XX
XX Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;
XX transmissible cerebral amyloidosis; transmissible virus dementias;
XX scrapie; transmissible mink encephalopathy; BSE; type II diabetes;
XX bovine spongiform encephalopathy; inflammation associated amyloid;
XX primary amyloidosis; feline spongiform encephalopathy;
XX Alzheimer's disease; prion-mediated diseases; blood-brain barrier;
XX dialysis-related amyloidosis; light chain-related amyloidosis;
XX cerebral amyloid angiopathy.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Misc-difference 1..6
XX /note= "Preferably D-form residue"
XX Modified-site 6
XX /note= "Ala is amidated"
XX
XX WO200207781-A2.
XX
XX 31-JAN-2002.
XX
XX 25-JUL-2001; 2001WO-CA001071.
XX
XX 25-JUL-2000; 2000US-0220808P.
XX
XX 24-JUL-2001; 2001US-00915092.
XX
XX (NEUR-) NEUROCHEM INC.
XX
XX Gervais F, Kong X, Chalifour R, Migneault D;
XX
XX WPI; 2002-371447/40.
XX
XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid
XX plaques and/or for the treatment of amyloidosis disorders.
XX
XX Claim 49; Page 21; 57pp; English.
XX
XX The invention relates to an amyloid-targeting imaging agent comprising an
XX amyloid targeting moiety, a linker moiety and a labelling moiety. The
XX agent is of general formula A_t-(A_1)_n-k)-z-A_1_a_b (I) where z = 0 - 1;
XX A_t = an amyloid targeting moiety; A_1_n-k) = a linker moiety; and A_1_a_b
XX = a labelling moiety. Also included are imaging amyloid deposition or
XX diagnosing an amyloid-related condition in a patient involving
XX administering (I) to the patient, and ultrasound imaging (I) in the
XX patient to determine the presence of amyloid or amyloid-related condition
XX ; and a kit for preparing a radiopharmaceutical preparation comprising
XX (I), a reducing agent, a buffering agent, a transchelating agent, and
XX instructions for the preparation and use of the radiopharmaceutical in
XX the imaging of amyloid or an amyloid-related condition. The agents are
XX used for imaging amyloid deposition and for diagnosing an amyloid related
XX condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible
XX cerebral amyloidosis (transmissible virus dementias), familial CJD,
XX scrapie, transmissible mink encephalopathy, bovine spongiform
XX encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,
XX primary amyloidosis, Alzheimer's disease, prion-mediated diseases,
XX cerebral amyloidosis, light chain-related amyloidosis, cerebral
XX dialysis-related amyloidosis, the agents are capable of crossing the blood-brain
XX amyloid angiopathy. The agents are capable of binding specifically to amyloid plaques. The
XX present sequence is a peptide forming the amyloid targeting moiety of the
XX agent of the invention
XX
XX Sequence 6 AA;
XX
XX Query Match 96.6%; Score 28; DB 5; Length 6;
XX Best Local Similarity 83.3%; Pred. No. 1.8e+06;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFA 6
XX |:|||||
XX Db 1 KVVFFA 6
XX
XX RESULT 22
XX AAU11664
XX ID AAU11664 standard; peptide; 6 AA.
XX
XX AC AAU11664;
XX
XX 09-APR-2002 (first entry)
XX
XX Peptide #17, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.

```

XX KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy; CAA; neurotropic; cerebroprotective; Alzheimer's disease; cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 6 /note= "C-terminal amide"

XX PN WO200185093-A2.

XX XX 15-NOV-2001.

XX PF 22-DEC-2000; 2000WO-IB002078.

XX PR 23-DEC-1999; 99US-0171877P.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Green AM, Gervais F;

XX XX WPI; 2002-075222/10.

XX XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's disease comprises contacting blood vessel wall cell with amyloid-beta 40 inhibitor.

XX PS Disclosure; Page 10; 68pp; English.

XX CC The present invention relates to a new method of inhibiting cerebral amyloid angiopathy. The new method of the invention involves contacting a blood vessel wall cell with an amyloid-beta40 inhibitor. The invention can be used for treating disease states characterised by cerebral amyloid angiopathy, particularly Alzheimer's disease, hereditary cerebral haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke. The present sequence represents one of a group of peptides (AAU11648-AAU11669, AAU11910 & AAU11911) that were used in the invention as a carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor was used in the invention to treat a disease state characterised by cerebral amyloid angiopathy (CAA).

XX SQ Sequence 6 AA;

Query Match 96.6%; Score 28; DB 5; Length 6;  
Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIVFFPA 6  
|:||||  
Db 1 KVVFFPA 6

RESULT 23  
AAU11656  
ID AAU11656 standard; peptide; 6 AA.

XX AC AAU11656;

XX XX 09-APR-2002 (first entry)

XX DE Peptide #9, used as a carrier for the amyloid-beta40 (Abeta40) inhibitor.

XX KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy; CAA; neurotropic; cerebroprotective; Alzheimer's disease; cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX OS Synthetic.

XX PN WO200185093-A2.

XX PD 15-NOV-2001.

XX PF 22-DEC-2000; 2000WO-IB002078.

XX PR 23-DEC-1999; 99US-0171877P.

XX PA (NEUR-) NEUROCHEM INC.

XX XX Green AM, Gervais F;

XX XX WPI; 2002-075222/10.

XX XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's disease comprises contacting blood vessel wall cell with amyloid-beta 40 inhibitor.

XX PS Disclosure; Page 10; 68pp; English.

XX CC The present invention relates to a new method of inhibiting cerebral amyloid angiopathy. The new method of the invention involves contacting a blood vessel wall cell with an amyloid-beta40 inhibitor. The invention can be used for treating disease states characterised by cerebral amyloid angiopathy, particularly Alzheimer's disease, hereditary cerebral haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke. The present sequence represents one of a group of peptides (AAU11648-AAU11669, AAU11910 & AAU11911) that were used in the invention as a carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor was used in the invention to treat a disease state characterised by cerebral amyloid angiopathy (CAA).

XX SQ Sequence 6 AA;

Query Match 96.6%; Score 28; DB 5; Length 6;  
Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIVFFPA 6  
|:||||  
Db 1 KVVFFPA 6

RESULT 24  
AAE35452  
ID AAE35452 standard; peptide; 6 AA.

XX AC AAE35452;

XX XX 17-JUN-2003 (first entry)

XX DE Abeta peptide #23.

XX KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis; cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis; psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome; Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic; chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic; Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological; ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX OS Unidentified.

XX FH Key Location/Qualifiers

XX FT Misc-difference 1..6 /note= "D-form residues"

XX FT Modified-site 6 /note= "C-terminal amide"

XX PN WO200296937-A2.

XX PD 05-DEC-2002.

XX XX 29-MAY-2002; 2002WO-CA000763.

XX PR 29-MAY-2001; 2001US-00867847.



XX PA (NEUR-) NEUROCHEM INC.  
 XX PI Gervais F, Hebert L, Chalifour RJ, Kong X;  
 XX DR WPI; 2003-201269/19.  
 XX XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
 XX PS Claim 1; Page 59; 44pp; English.  
 XX CC The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D-  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal, and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (rheumatic) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention.  
 XX SQ Sequence 6 AA;  
 Query Match 96.6%; Score 28; DB 6; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 1 KVVFFA 6  
 RESULT 25  
 ADQ37277  
 ID ADQ37277 standard; peptide; 6 AA.  
 AC ADQ37277;  
 DT 07-OCT-2004 (first entry)  
 DE Vaccine antigen amyloid-beta related amino acid sequence.  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antihypertoid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypochyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX Synthetic.  
 OS  
 XX Key Location/Qualifiers  
 FH Misc-difference 1. .6  
 FT

FT Modified-site /note= "D-form residues"  
 FT 6 /note= "amidated"  
 XX WO2004058239-A1.  
 XX PD 15-JUL-2004.  
 XX XX 24-DEC-2003; 2003WO-CA002021.  
 PF 24-DEC-2002; 2002US-0436379P.  
 XX 23-JUN-2003; 2003US-0482214P.  
 PR (NEUR-) NEUROCHEM INT LTD.  
 XX Gervais F, Bellini F;  
 WPI, 2004-543342/52.  
 PT Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX Disclosure; Page 67; 143pp; English.  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antihypertoid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypochyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.  
 XX SQ Sequence 6 AA;  
 Query Match 96.6%; Score 28; DB 8; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 1 KVVFFA 6

CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
 CC in the exemplification of the present invention.  
 XX  
 SQ Sequence 6 AA;  
 Query Match 96.6%; Score 28; DB 8; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 Db 1 KVVFFA 6  
 :|||  
 1 KVVFFA 6  
 RESULT 27  
 ADQ37329  
 ID ADQ37329 standard; peptide; 6 AA.  
 XX  
 AC ADQ37329;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Antifibrillogenic amyloidosis inhibiting peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 OS Synthetic.  
 XX  
 PN WO2004058239-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 24-DEC-2003; 2003WO-CA002021.  
 XX  
 PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX  
 PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 PI Gervais F, Bellini F;  
 XX  
 XX WPI; 2004-543342/52.  
 XX  
 PT Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 PS Disclosure; Page 69; 143pp; English.  
 XX  
 CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's

DR WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent

PT that prevents or treats amyloid-beta related disease and second agent

PT that is either a peptide or peptidomimetic or an immune system modulator.

XX

PS Disclosure; Page 70; 143pp; English.

XX

CC The present invention describes compositions (C) comprising: (a) a first

CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)

CC a second agent (a2) that is: (i) a peptide or peptidomimetic that

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC therapeutic immune response against amyloid-beta fibril formation; or

CC (ii) an immune system modulator that prevents or inhibits amyloid-beta

CC fibril formation. Also described is a kit comprising (C): (C) have

CC nontropic, neuroprotective, cerebroprotective, haemostatic,

CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,

CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,

CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,

CC and can be used as amyloid-beta fibril formation modulators, and as

CC immune system modulators. (C) can be used for preventing or treating an

CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic

CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,

CC mild-to-moderate cognitive impairment, vascular dementia, cerebral

CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,

CC Down's syndrome, inclusion body myositis, age-related macular

CC degeneration, or a condition associated with Alzheimer's disease

CC (including hypothyroidism, cerebrovascular disease, cardiovascular

CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,

CC aggression, or incontinence), a neurological condition (e.g. Huntington's

CC disease, amytrophic lateral sclerosis, acquired immunodeficiency,

CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia

CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual

CC field deficits, incoordination, gait disturbance, transient ischaemic

CC attack or stroke, transient alertness, attention deficit, frequent falls,

CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural

CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic

CC damage), or a psychological condition (e.g. depression, delusions,

CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep

CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal

CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or

CC excessive guilt)) in a subject e.g. human having a genomic mutation in an

CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;

CC having amyloid-beta deposits. The present sequence represents a peptide

CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide

CC in the exemplification of the present invention.

XX

Sequence 6 AA;

Query Match 96.6%; Score 28; DB 8; Length 6;

Best Local Similarity 83.3%; Pred. No. 1.8e+06;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6

Db :|||||

1 KVVFFA 6

RESULT 28

ADQ09761

ID ADQ09761 standard; peptide; 22 AA.

XX

AC ADQ09761;

XX

DT 23-SEP-2004 (first entry)

XX

DE Rice 26kDa globulin signal sequence SEQ ID NO:117.

XX

XX prolamine; rice; plant; seed; transgenic plant; signal.

XX

OS Oryza sativa.

XX

PN WO2004056993-A1.

XX

08-JUL-2004.

09-DEC-2003; 2003WO-JP015753.

20-DEC-2002; 2002JP-00369700.

(NAAAG-) NAT AGRIC & BIO-ORIENTED RES ORG.

Kuroda M;

WPI; 2004-525439/50.

N-PSDB; ADQ09760.

Novel nucleic acid molecule antisense to nucleic acid sequence encoding

prolamine, useful for reducing expression dose of protein in seed, and

for producing transgenic plant, preferably rice plant having reduced

storage protein.

Example 13; SEQ ID NO 117; 272pp; Japanese.

The present invention describes a nucleic acid molecule (I) comprising a

consecutive nucleic acid sequence (S1) of at least 15 bp in length and

complementary with a nucleic acid sequence encoding a prolamine

polypeptide or a nucleic acid sequence having a homology of at least

about 70% to (S1). Also described: (1) a nucleic acid molecule (N1)

comprising a nucleic acid sequence (A) having about 70% homology to a

nucleic acid sequence encoding a prolamine polypeptide and a nucleic acid

sequence (B) having about 70% homology to the complement of the nucleic

acid sequence encoding a prolamine polypeptide; (2) a factor (II) capable

of causing RNA interference of the gene sequence encoding a prolamine

polypeptide; (3) a nucleic acid cassette (III) containing (I); (4)

producing (III); (5) a vector (IV) comprising (I); (6) a plant cell (V)

comprising (I); (7) a plant tissue (VI) comprising (I); (8) a plant (VII)

containing (I) or (V); (9) a seed (VIII) produced by (VII); (10) starch

preparation produced from (VII) or (VIII); and (11) a composition

containing gene product of foreign gene produced from (VII) or (VIII).

(I) is useful for decreasing the expression level of a protein in the

seed of a plant, for expressing a foreign gene in the seed of a plant and

for decreasing the expression of a natural protein in the seed of a

plant. The method of decreasing the amount of expression level of a

protein in the seed of a plant involves providing (I), introducing (I)

into the cell of the plant, redifferentiating the cell, producing a

transgenic plant, and obtaining the seed from the transgenic plant. The

method after the step of introduction, further involves selecting the

cell introduced with (I), by determining resistance with respect to

antibiotics. The method of expressing a foreign gene in the seed of a

plant, involves providing (I) and the nucleic acid molecule encoding a

foreign gene product, introducing (I) and the nucleic acid molecule

encoding a foreign gene product into cell of the plant, re-

differentiating the cell, producing a transgenic plant, and obtaining the

seed from the transgenic plant. The method further involves isolating the

gene product of the foreign gene from the seed. (I) is useful for

producing transgenic plants having reduced expression of storage proteins

and for reducing the expression dose of a protein in a seed of a plant.

The present sequence represents a rice 26kDa globulin signal sequence,

which is used in the exemplification of the present invention.

Sequence 22 AA;

Query Match 96.6%; Score 28; DB 8; Length 22;

Best Local Similarity 83.3%; Pred. No. 17;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6

Db :|||||

4 KVVFFA 9

RESULT 29

AAB05910

ID AAB05910 standard; peptide; 37 AA.

XX

neuronal nitric oxide; mNOS.

Homo sapiens.

W02004016761-A2.

26-FEB-2004.

15-AUG-2003; 2003WO-US025626.

16-AUG-2002; 2002US-0403637P.

(SCHD ) SCHERING AG.

Dole WP, Kauser K, Qian HS, Rubanyi G;

WPI; 2004-203789/19.

Treating critical limb ischemia (CLI), or angiogenesis comprises administering to a patient a polynucleotide encoding a mammalian endothelial nitric oxide synthase (eNOS) polypeptide.

Example 1; SEQ ID NO 7; 82pp; English.

The invention describes a method of creating critical limb ischaemia (CLI) comprising administering to a patient a polynucleotide encoding a mammalian eNOS (endothelial nitric oxide synthase) polypeptide. Also described are: a method for treating angiogenesis by administering to a patient a polynucleotide encoding eNOS; and ameliorating microvascular dysfunction by administering to the patient the polynucleotide encoding the eNOS polypeptide. The method is useful for treating critical limb ischaemia or angiogenesis, or ameliorating a microvascular dysfunction. This is the amino acid sequence of a human neuronal nitric synthase (nNOS) calmodulin binding domain peptide.

Sequence 37 AA;

Query Match 96.6%; Score 28; DB 8; Length 37;

Best Local Similarity 83.3%; Pred. NO. 28;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0

Qy 1 KIVFFA 6  
|:| | | |

Db 18 KVVFFA 23

RESULT 31

ADL70727

ID ADL70727 standard; peptide; 37 AA.

XX AC ADL70727;

XX 20-MAY-2004 (first entry)

XX Mouse iNOS calmodulin-binding site amino acid sequence SEQ ID NO:7.

XX mouse; endothelial nitric oxide synthase; eNOS; enzyme; mutant;

XX calmodulin-binding domain; vasotropic; antiarteriosclerotic; hypotensive;

XX antidiabetic; vulnerary; antilipaseic; anorectic;

XX reduced calcium dependence; ischaemia; atherosclerosis; hypertension;

XX diabetes; Raynaud's phenomenon; poor wound healing; hyperlipidaemia;

XX obesity; iNOS.

XX Mus musculus.

XX W02004016764-A2.

XX 26-FEB-2004.

XX 15-AUG-2003; 2003WO-US025745.

XX 16-AUG-2002; 2002US-0403638P.

XX

PA (SCHD ) SCHERING AG.  
 XX  
 PI Blasko E, Kauser K, Parkinson J;  
 XX  
 DR WPI; 2004-203792/19.  
 XX  
 PT New isolated endothelial nitric oxide synthase polypeptide mutant, useful  
 PT for diagnosing or treating ischemia, atherosclerosis, hypertension,  
 PT diabetes, Raynaud's phenomenon, poor wound healing, hyperlipidemia or  
 XX obesity.  
 XX  
 PS Example 1; SEQ ID NO 7; 57pp; English.  
 XX  
 CC The present sequence represents the calmodulin-binding site of mouse iNOS  
 CC amino acid sequence. The present invention describes endothelial nitric  
 CC oxide synthase (eNOS) mutants having one or more mutations in an amino  
 CC acid sequence corresponding to a functional domain of a mammalian eNOS.  
 CC At least one of the mutations is at a position corresponding to an amino  
 CC acid residue in a calmodulin-binding domain that is phosphorylated in  
 CC mammalian cells, and not an amino acid substitution to Ala or Asp. Also  
 CC described: (1) an isolated eNOS polypeptide mutant that is substantially  
 CC homologous, or has a 95-99% sequence identity to the amino acid sequence  
 CC of the novel eNOS polypeptide mutant; (2) an isolated polynucleotide  
 CC encoding the polypeptide mutant; (3) a recombinant vector comprising the  
 CC polynucleotide operably linked to at least one regulatory sequence; (4) a  
 CC pharmaceutical composition comprising the polypeptide mutant or the  
 CC polynucleotide; (5) a binding partner of the polypeptide mutant; (6)  
 CC modulating eNOS activity in a cell by administering to the cell the  
 CC polypeptide mutant; (7) modulating eNOS activity in a cell by  
 CC administering the polypeptide mutant or the polynucleotide to the cell,  
 CC such that the polypeptide mutant is expressed in the cell; (8) diagnosing  
 CC a condition associated with aberrant eNOS activity by contacting a cell  
 CC of a patient with the polynucleotide, and detecting a level of eNOS  
 CC activity indicative of the medical condition; and (9) prophylactic and  
 CC therapeutic methods of treating a condition associated with aberrant eNOS  
 CC activity by administering the polypeptide mutant or polynucleotide to the  
 CC patient. The eNOS mutant has vasotropic, antiarteriosclerotic,  
 CC hypotensive, antidiabetic, vulnerary, antilipemic and anorectic  
 CC activities, and has reduced calcium dependence and increased activity.  
 CC The polypeptide mutant, polynucleotide and methods are useful for  
 CC diagnosing or treating a condition associated with aberrant eNOS  
 CC activity, e.g. ischaemia, atherosclerosis, hypertension, diabetes,  
 CC Raynaud's phenomenon, poor wound healing, hyperlipidaemia or obesity.  
 XX  
 SQ Sequence 37 AA;  
 Query Match 96.6%; Score 28; DB 8; Length 37;  
 Best Local Similarity 83.3%; Pred. No. 28;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 18 KVVFFA 23  
 RESULT 32  
 AAG02840  
 ID AAG02840 standard; protein; 77 AA.  
 XX  
 AC AAG02840;  
 XX  
 DT 06-OCT-2000 (first entry)  
 DE Human secreted protein, SEQ ID NO: 6921.  
 XX  
 KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;  
 KW gene therapy; chromosome mapping.  
 XX  
 OS Homo sapiens.  
 XX  
 FN EP1033401-A2.  
 XX  
 PD 06-SEP-2000.

XX 21-FEB-2000; 2000EP-00200610.  
 PF  
 XX 26-FEB-1999; 99US-0122487P.  
 PR  
 XX (GEST ) GENSET.  
 FA  
 XX Dumas Milne Edwards J, Duclert A, Giordano J;  
 PI  
 XX WPI; 2000-500381/45.  
 DR N-PSDB; AAC02846.  
 XX  
 PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for  
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for  
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures.  
 XX  
 PS Claim 13; SEQ ID NO 6921; 71pp + Sequence Listing; English.  
 XX  
 CC The present sequence is a polypeptide encoded by one of a large number of  
 CC 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were  
 CC prepared from total human RNAs or polyA+ RNAs derived from 30 different  
 CC tissues. EST sequences usually correspond mainly to the 3' untranslated  
 CC region (UTR) of the mRNA because they are often obtained from oligo-dT  
 CC primed cDNA libraries. Such ESTs are not well suited for isolating cDNA  
 CC sequences derived from the 5' ends of mRNAs and even in those cases where  
 CC longer cDNA sequences have been obtained, the full 5' UTR is rarely  
 CC included. 5' ESTs are derived from mRNAs with intact 5' ends and can  
 CC therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs  
 CC are also used in diagnostic, forensic, gene therapy and chromosome  
 CC mapping procedures. They are used to obtain upstream regulatory sequences  
 CC and to design expression and secretion vectors  
 XX  
 SQ Sequence 77 AA;  
 Query Match 96.6%; Score 28; DB 3; Length 77;  
 Best Local Similarity 83.3%; Pred. No. 58;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 38 KVVFFA 43  
 RESULT 33  
 AAO11219  
 ID AAO11219 standard; protein; 175 AA.  
 XX  
 AC AAO11219;  
 XX  
 DT 06-NOV-2001 (first entry)  
 DE Human polypeptide SEQ ID NO 25111.  
 XX  
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200164835-A2.  
 XX  
 PD 07-SEP-2001.  
 XX  
 XX 26-FEB-2001; 2001WO-US004927.  
 PF  
 XX 28-FEB-2000; 2000US-00515126.  
 PR  
 XX 18-MAY-2000; 2000US-00577409.  
 PR  
 XX (HYSE-) HYSEQ INC.  
 PA  
 XX Tang YT, Liu C, Drmanac RT;  
 PI  
 XX

DR WPI; 2001-514838/56.  
 XX N-PSDB; AA191150.  
 PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
 PT and treating e.g. leukemia, inflammation and immune disorders.  
 XX  
 PS Claim 20; SEQ ID NO 25111; 1399pp + Sequence Listing; English.  
 XX  
 CC The invention relates to human polynucleotides (AA179941-AA193841) and  
 CC the encoded proteins (AA000010-AA013910) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation. Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic format  
 CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 175 AA;

Query Match 96.6%; Score 28; DB 4; Length 175;  
 Best Local Similarity 83.3%; Pred. No. 1.3e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
 |:|||||  
 Db 128 KVVFFA 133

RESULT 34  
 ADC07962  
 ID ADC07962 standard; protein; 186 AA.  
 XX  
 AC ADC07962;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Rice protein sequence Seq ID228 related to grain filling.  
 XX  
 KW plant biotechnology; carbohydrate synthesis; carbohydrate metabolism;  
 KW carbohydrate degradation; carbohydrate; plant grain; grain filling; corn;  
 KW tomato; banana; canola; cotton; peanut; sorghum; tobacco; sugarbeet;  
 KW wheat; rice; protein; oil; starch; fibre; moisture content; cereal grain;  
 KW gene; ds; plant.  
 XX  
 OS Oryza sativa.  
 XX  
 PN WO2003000905-A2.  
 XX  
 PD 03-JAN-2003.  
 XX  
 PF 21-JUN-2002; 2002WO-IB002450.  
 XX  
 PR 22-JUN-2001; 2001US-0300112P.  
 PR 26-SEP-2001; 2001US-0325277P.  
 PR 20-DEC-2001; 2001US-0342327P.  
 XX  
 PA (SYGN ) SYNGENTA PARTICIPATIONS AG.  
 XX  
 PI Zhu T, Cheng W, Briggs S, Cooper B, Goff SA, Moughamer T;  
 PI Glazebrook J, Katagiri F, Kreps J, Provart N, Ricke D;  
 XX  
 DR WPI; 2003-229341/22.  
 DR N-PSDB; ADC07961.  
 XX  
 PT New plant genes encoding polypeptides having an activity involved in or  
 PT associated with the synthesis, metabolism or degradation of carbohydrates  
 PT in the plant grain useful in generating plants having improved  
 PT nutritional properties.

XX Claim 15; SEQ ID NO 228; 130pp; English.  
 PS  
 XX  
 CC This invention, in the area of plant biotechnology, relates to novel  
 CC polynucleotides comprising a nucleotide sequence encoding a protein which  
 CC is involved in or associated with the synthesis, metabolism or  
 CC degradation of carbohydrates in the plant grain and the expression of  
 CC which is up-regulated during grain filling. The plant is selected from  
 CC corn, tomato, banana, canola, cotton, peanut, sorghum, tobacco,  
 CC sugarbeet, wheat, and rice. The invention may be useful for the  
 CC improvement of protein, oil, starch, fibre and moisture content of the  
 CC cereal grains. In addition, carbohydrate levels may be modified to a more  
 CC desirable level using the present invention. The present sequence is the  
 CC amino acid sequence of a rice protein of the invention. Note: The  
 CC sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences.  
 XX  
 SQ Sequence 186 AA;

Query Match 96.6%; Score 28; DB 7; Length 186;  
 Best Local Similarity 83.3%; Pred. No. 1.4e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
 |:|||||  
 Db 4 KVVFFA 9

RESULT 35  
 ADC07948  
 ID ADC07948 standard; protein; 186 AA.  
 XX  
 AC ADC07948;  
 XX

DT 18-DEC-2003 (first entry)

DE Rice protein sequence Seq ID214 related to grain filling.

XX plant biotechnology; carbohydrate synthesis; carbohydrate metabolism;  
 KW carbohydrate degradation; carbohydrate; plant grain; grain filling; corn;  
 KW tomato; banana; canola; cotton; peanut; sorghum; tobacco; sugarbeet;  
 KW wheat; rice; protein; oil; starch; fibre; moisture content; cereal grain;  
 KW gene; ds; plant.

OS Oryza sativa.

XX WO2003000905-A2.

XX 03-JAN-2003.

XX 21-JUN-2002; 2002WO-IB002450.

XX 22-JUN-2001; 2001US-0300112P.

PR 26-SEP-2001; 2001US-0325277P.

PR 20-DEC-2001; 2001US-0342327P.

XX (SYGN ) SYNGENTA PARTICIPATIONS AG.

XX Zhu T, Cheng W, Briggs S, Cooper B, Goff SA, Moughamer T;  
 PI Glazebrook J, Katagiri F, Kreps J, Provart N, Ricke D;

XX WPI; 2003-229341/22.  
 DR N-PSDB; ADC07947.

XX New plant genes encoding polypeptides having an activity involved in or  
 PT associated with the synthesis, metabolism or degradation of carbohydrates  
 PT in the plant grain useful in generating plants having improved  
 PT nutritional properties.

PS Claim 15; SEQ ID NO 214; 130pp; English.

XX This invention, in the area of plant biotechnology, relates to novel

CC polynucleotides comprising a nucleotide sequence encoding a protein which  
CC is involved in or associated with the synthesis, metabolism or  
CC degradation of carbohydrates in the plant grain and the expression of  
CC which is up-regulated during grain filling. The plant is selected from  
CC corn, tomato, banana, canola, cotton, peanut, sorghum, tobacco,  
CC sugarbeet, wheat, and rice. The invention may be useful for the  
CC improvement of protein, oil, starch, fibre and moisture content of the  
CC cereal grains. In addition, carbohydrate levels may be modified to a more  
CC desirable level using the present invention. The present sequence is the  
CC amino acid sequence of a rice protein of the invention. Note: The  
CC sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences.

XX Sequence 186 AA;

Query Match 96.6%; Score 28; DB 7; Length 186;  
Best Local Similarity 83.3%; Pred. No. 1.4e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
D6 :|||||  
4 KVVFFA 9

#### RESULT 36

AA083792  
ID AA083792 standard; protein; 190 AA.

XX AC AA083792;

DT 07-NOV-2001 (first entry)

XX DE Human immune/haematopoietic antigen SEQ ID NO:11385.

XX KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
XX cytotactic; gene therapy; vaccine; metastasis.

XX OS Homo sapiens.

XX PN WO200157182-A2.

XX PD 09-AUG-2001.

XX PF 17-JAN-2001; 2001WO-US001354.

XX PR 31-JAN-2000; 2000US-0179065P.

XX PR 04-FEB-2000; 2000US-0180628P.

XX PR 24-FEB-2000; 2000US-0184664P.

XX PR 02-MAR-2000; 2000US-0186350P.

XX PR 16-MAR-2000; 2000US-0189874P.

XX PR 17-MAR-2000; 2000US-0190076P.

XX PR 18-APR-2000; 2000US-0198123P.

XX PR 19-MAY-2000; 2000US-0205515P.

XX PR 07-JUN-2000; 2000US-0209467P.

XX PR 28-JUN-2000; 2000US-0214886P.

XX PR 30-JUN-2000; 2000US-0215135P.

XX PR 07-JUL-2000; 2000US-0215647P.

XX PR 07-JUL-2000; 2000US-0215880P.

XX PR 11-JUL-2000; 2000US-0217487P.

XX PR 11-JUL-2000; 2000US-0217496P.

XX PR 14-JUL-2000; 2000US-0218290P.

XX PR 26-JUL-2000; 2000US-0220963P.

XX PR 14-AUG-2000; 2000US-0224518P.

PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226686P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 12-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-024121P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.



PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249264P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 08-DEC-2000; 2000US-0251990P.  
PR 11-DEC-2000; 2000US-0254097P.  
PR 05-JAN-2001; 2001US-02539678P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
PI  
XX WPI; 2001-483426/52.  
DR N-PSDB; AAK56573.  
XX  
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
PT useful for preventing, diagnosing and/or treating cancers and metastasis.  
XX  
XX Claim 11; SEQ ID NO 11385; 3071pp + Sequence Listing; English.

XX  
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)  
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic  
CC activity, and can be used in gene therapy and vaccine production. (I)  
CC proteins, and polynucleotides may be used in the prevention, diagnosis and  
CC treatment of diseases associated with inappropriate (I) expression. For  
CC example, they may be used to treat disorders associated with decreased  
CC expression by rectifying mutations or deletions in a patient's genome  
CC that affect the activity of (I) by expressing inactive proteins or to  
CC supplement the patient's own production of (I). Additionally, (I)  
CC polynucleotides may be used to produce the secreted (I), by inserting the  
CC nucleic acids into a host cell and culturing the cell to express the  
CC protein. (I) proteins and polynucleotides may be used to prevent,  
CC diagnose and treat immune/haematopoietic-related diseases, especially  
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703  
CC to AAK87694 represent human immune/haematopoietic antigen genomic  
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
CC represent sequences used in the exemplification of the present invention.  
XX  
SQ Sequence 190 AA;

Query Match 96.6%; Score 28; DB 4; Length 190;  
Best Local Similarity 83.3%; Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 14 KVVFFA 19

## RESULT 37

ABB61977  
ID ABB61977 standard; protein; 564 AA.

XX ABB61977;

XX 26-MAR-2002 (first entry)

XX Drosophila melanogaster polypeptide SEQ ID NO 12723.

XX Drosophila; developmental biology; cell signalling; insecticide;  
KW pharmaceutical.

XX Drosophila melanogaster.

XX WO200171042-A2.

XX 27-SEP-2001.

XX 23-MAR-2001; 2001WO-US009231.

XX 23-MAR-2000; 2000US-0191637P.

XX 11-JUL-2000; 2000US-00614150.

XX (PEKE) PE CORP NY.

XX Venter JC, Adams M, Li PWD, Myers EW;

XX WPI; 2001-656860/75.

XX N-PSDB; ABL06080.

XX New isolated nucleic acid detection reagent for detecting 1000 or more  
PT genes from Drosophila and for elucidating cell signalling and cell-cell  
PT interactions.

XX Disclosure; SEQ ID NO 12723; 21pp + Sequence Listing; English.

XX The invention relates to an isolated nucleic acid detection reagent  
CC capable of detecting 1000 or more genes from Drosophila. The invention is  
CC useful in developmental biology and in elucidating cell signalling and  
CC cell-cell interactions in higher eukaryotes for the development of  
CC insecticides, therapeutics and pharmaceutical drugs. The invention  
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA  
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-  
CC ABB72072). The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 564 AA;

Query Match 96.6%; Score 28; DB 4; Length 564;  
Best Local Similarity 83.3%; Pred. No. 4.2e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 53 KIIFFA 58

## RESULT 38

ADQ66704  
ID ADQ66704 standard; protein; 854 AA.

XX ADQ66704;

XX 07-OCT-2004 (first entry)

XX Novel human protein sequence #1677.

XX osteopathic; neuroprotective; nootropic; antiparkinsonian; cytostatic;  
 KW gene therapy; diagnostic marker; morbid state; osteoporosis;  
 KW neurological disease; Alzheimer's disease; Parkinson's disease; dementia;  
 KW cancer.  
 XX Homo sapiens.  
 XX EP1440981-A2.  
 XX Xu Y, Kwong M, Policky JL, Hurwitz BL, Ma Y, Jackson JL, Gietzen D;  
 XX Patursky S, Shi X, Suarez CJ;  
 XX WPI; 2004-329368/30.  
 XX N-PSDB; ACN41904.  
 XX New diagnostic and therapeutic polynucleotides and polypeptides, useful  
 XX in diagnosing a condition, disease or disorder associated with human  
 XX molecules, e.g. autoimmune or inflammatory disorders, in gene therapy or  
 XX in gene mapping.  
 XX Claim 27; Page; 190pp; English.  
 XX The invention relates to novel diagnostic and therapeutic polynucleotides  
 XX selected from one of the 2722 sequences defined in the specification. A  
 XX polynucleotide of the invention may have a use in gene therapy. The human  
 XX diagnostic and therapeutic polynucleotides (dithp) or polypeptides may be  
 XX used to diagnose a particular condition, disease or disorder associated  
 XX with human molecules, e.g. cell proliferative disorders,  
 XX autoimmune/inflammatory disorders, developmental disorder, endocrine  
 XX disorder, neurological disorders, gastrointestinal disorders, or  
 XX infections caused by virus, bacteria, fungi or parasite. The dithp  
 XX molecules may also be used in genetic mapping, in identifying individuals  
 XX from minute biological samples, in detecting single nucleotide  
 XX polymorphisms, as molecular weight markers, and for somatic or germline  
 XX gene therapy. The present sequence represents a dithp protein of the  
 XX invention. Note: The sequence data for this patent is not represented in  
 XX the printed specification, but was obtained in electronic format directly  
 XX from WIPO at www.wipo.int/pct/en/sequences/listing.htm  
 XX Sequence 854 AA;  
 XX Query Match 96.6%; Score 28; DB 8; Length 854;  
 XX Best Local Similarity 83.3%; Pred. No. 6.4e+02;  
 XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 221 KVVFFA 226  
 RESULT 39  
 ID ABM83252  
 AC ABM83252 standard; protein; 922 AA.  
 AC ABM83252;  
 XX 18-NOV-2004 (first entry)  
 DE Human diagnostic and therapeutic pprotein SEQ ID NO:3501.  
 KW gene therapy; human diagnostic and therapeutic polynucleotide; dithp.  
 KW Homo sapiens.  
 OS WO2004023973-A2.  
 PN 25-MAR-2004.  
 PD 12-SEP-2003; 2003WO-US028227.  
 XX 12-SEP-2002; 2002US-0410259P.  
 PR 12-SEP-2002; 2002US-0410260P.

XX (INCY-) INCYTE CORP.  
 XX Schmidt JP, Wright RJ, Bruns CM, Marjanovic MM, Shen F;  
 XX Harthorne TA, Suchorolski MT, Altus CM, Pitts SU, Elder LV;  
 XX Mooney EM, Delegeane AM, Panesar IS, Barville SC, Reddy TP;  
 XX Stevens KA, Blanchard JL, Panzer SR, Wang X, Au AP, Gerstin EH;  
 XX Peralta CH, Anderson SB, Rioux P, Shen EJ, Wu MC, Stuve LL;  
 XX Lagace RE, Spiro PA, Stewart EA, Wingrove J, Vitt UA, Kirton ES;  
 XX Xu Y, Kwong M, Policky JL, Hurwitz BL, Ma Y, Jackson JL, Gietzen D;  
 XX Patursky S, Shi X, Suarez CJ;  
 XX WPI; 2004-329368/30.  
 XX N-PSDB; ACN41904.  
 XX New diagnostic and therapeutic polynucleotides and polypeptides, useful  
 XX in diagnosing a condition, disease or disorder associated with human  
 XX molecules, e.g. autoimmune or inflammatory disorders, in gene therapy or  
 XX in gene mapping.  
 XX Claim 27; Page; 190pp; English.  
 XX The invention relates to novel diagnostic and therapeutic polynucleotides  
 XX selected from one of the 2722 sequences defined in the specification. A  
 XX polynucleotide of the invention may have a use in gene therapy. The human  
 XX diagnostic and therapeutic polynucleotides (dithp) or polypeptides may be  
 XX used to diagnose a particular condition, disease or disorder associated  
 XX with human molecules, e.g. cell proliferative disorders,  
 XX autoimmune/inflammatory disorders, developmental disorder, endocrine  
 XX disorder, neurological disorders, gastrointestinal disorders, or  
 XX infections caused by virus, bacteria, fungi or parasite. The dithp  
 XX molecules may also be used in genetic mapping, in identifying individuals  
 XX from minute biological samples, in detecting single nucleotide  
 XX polymorphisms, as molecular weight markers, and for somatic or germline  
 XX gene therapy. The present sequence represents a dithp protein of the  
 XX invention. Note: The sequence data for this patent is not represented in  
 XX the printed specification, but was obtained in electronic format directly  
 XX from WIPO at www.wipo.int/pct/en/sequences/listing.htm  
 XX Sequence 922 AA;  
 XX Query Match 96.6%; Score 28; DB 8; Length 922;  
 XX Best Local Similarity 83.3%; Pred. No. 6.9e+02;  
 XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KIVFFA 6  
 DB 291 KVVFFA 296  
 RESULT 40  
 ID ADF76335  
 AC ADF76335 standard; protein; 925 AA.  
 AC ADF76335;  
 XX 26-FEB-2004 (first entry)  
 DE Novel human secreted and transmembrane protein SeqID 8.  
 KW human; PRO; membrane bound protein; membrane bound receptor;  
 KW cell proliferation; cell migration; cell differentiation;  
 KW mitogenic factor; survival factor; cytotoxic factor;  
 KW differentiation factor; neuroptide; hormone; cell receptor;  
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.  
 XX Homo sapiens.  
 OS WO2003072035-A2.  
 PN 04-SEP-2003.  
 PD 21-FEB-2003; 2003WO-US005241.

22-FEB-2002; 2002US-0359461P.  
(GETH ) GENENTECH INC.  
Bodary SC, Clark H, Hunte B, Jackman JK, Schoenfeld JR;  
Williams PM, Wood WI, Wu TD;  
WPI; 2003-721702/68.  
N-ESDB; ADF76334.  
New PRO polypeptides, useful for diagnosing and treating an immune related disorder, e.g. systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, thyroiditis or diabetes mellitus.  
Claim 10; SEQ ID NO 8; 918pp; English.  
This invention relates to novel nucleic acids encoding human PRO secreted and transmembrane proteins. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides and hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins and receptors may be of use as pharmaceutical and diagnostic agents, such as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel proteins of the invention may have cytostatic activities through the stimulation of chondrocytes. The nucleic acids of the invention may be useful for the manufacture of a medicament for diagnosing or treating a tumour in a mammal. In addition, they may be useful for measuring or detecting the expression of a tumour associated gene. The present sequence is the amino acid sequence of a human PRO protein of the invention.  
Sequence 925 AA;  
SQ

PD	23-OCT-2003.	
XX		
PF	04-APR-2003; 2003WO-US010870.	
XX		
PR	12-APR-2002; 2002US-0372843P.	
PR	17-JUN-2002; 2002US-0389987P.	
PR	20-SEP-2002; 2002US-0412418P.	
XX		
PA	(MITO-) MITOKOR.	
PA	(BUCK-) BUCK INST AGE RES.	
XX		
PI	Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;	
PI	Warnock DE;	
XX		
DR	WPI; 2003-845369/78.	
XX		
PT	Identifying a mitochondrial target for drug screening assays and for	
PT	treating diseases associated with altered mitochondrial function,	
PT	comprises detecting a modified polypeptide in a sample and correlating	
PT	with the disease.	
XX		
PS	Claim 1; SEQ ID NO 2031; 180pp; English.	
XX		
CC	This invention relates to novel mitochondrial targets that can be used	
CC	for therapeutic intervention in treating a disease associated with	
CC	altered mitochondrial function. Specifically, it refers to a method for	
CC	identifying proteins of the human heart mitochondrial proteome that are	
CC	useful for drug screening assays, as well as therapeutic targets. The	
CC	present invention describes a method for identifying such proteins that	
CC	can be used in the treatment of various diseases associated with altered	
CC	mitochondrial function including diabetes mellitus, Huntington's disease,	
CC	osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial	
CC	encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy	
CC	ragged red fibre syndrome (MERRF) or cancer. Accordingly, these	
CC	compositions have neuroprotective, neurotropic, antidiabetic,	
CC	anticonvulsant, antiarthritic, osteopathic, ophthalmological and	
CC	cytostatic activities. This polypeptide sequence is a human heart	
CC	mitochondrial protein of the invention.	
XX		
SQ	Sequence 925 AA;	
	Query Match 96.6%; Score 28; DB 7; Length 925;	
	Best Local Similarity 83.3%; Pred. No. 6.9e+02;	
	Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 KIVFFEA 6	
	:	
Db	292 KVVFFEA 297	
RESULT 42		
ADJ75428		
ID	ADJ75428 standard; protein; 925 AA.	
XX		
AC	ADJ75428;	
XX		
DT	20-MAY-2004 (first entry)	
XX		
DE	Marker gene related amino acid sequence SEQ ID NO:680.	
XX		
KW	bronchial asthma; chronic obstructive pulmonary disease;	
KW	respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;	
KW	gene therapy; marker.	
XX		
OS	Homo sapiens.	
XX		
FN	EP1394274-A2.	
XX		
PD	03-MAR-2004.	
XX		
PF	04-AUG-2003; 2003EP-00254857.	
XX		
PR	06-AUG-2002; 2002JP-00229312.	

```

PR 20-MAR-2003; 2003JP-00077212.
XX (GENO-) GENOX RES INC.
XX Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuahara K;
XX WPI; 2004-193155/19.
XX
XX Testing for bronchial asthma or chronic obstructive pulmonary disease by
XX comparing the expression level of a marker gene in a biological sample
XX from a subject with the expression level of the gene in a sample from a
XX healthy subject.
XX
XX Example 11; SEQ ID NO 680; 241pp; English.
XX
XX The present invention describes a method of testing for bronchial asthma
XX or chronic obstructive pulmonary disease. The method comprises
XX determining the expression level of a marker gene in a biological sample
XX from a subject, comparing the expression level determined with the
XX expression level of the marker gene in a biological sample from a healthy
XX subject, and judging whether the subject has bronchial asthma or chronic
XX obstructive pulmonary disease. The marker gene comprises: (a) a group of
XX genes (S1) whose expression levels increase when respiratory epithelial
XX cells are stimulated with interleukin-13; or (b) a group of genes (S2)
XX whose expression levels decrease when respiratory epithelial cells are
XX stimulated with interleukin-13. Also described: (1) a reagent (I) for
XX testing for bronchial asthma or chronic obstructive pulmonary disease;
XX (2) a kit for screening for a candidate compound for a therapeutic agent
XX to treat bronchial asthma or chronic obstructive pulmonary disease; (3)
XX an animal model for bronchial asthma or chronic obstructive pulmonary
XX disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a
XX method for producing an animal model for bronchial asthma or chronic
XX obstructive pulmonary disease; (6) a therapeutic agent for bronchial
XX asthma or chronic obstructive pulmonary disease, comprising the compound,
XX a marker gene or an antisense nucleic acid corresponding to a portion of
XX the marker gene, a ribozyme, a polynucleotide that suppresses the
XX expression of the gene through an RNAi effect or an antibody recognising
XX a protein encoded by a marker gene; and (7) a DNA chip for testing for
XX bronchial asthma or a chronic obstructive pulmonary disease, on which a
XX probe has been immobilised to assay a marker gene. (I) has respiratory
XX and antiasthmatic activities, and can be used in gene therapy. The method
XX is useful for testing for or screening for a therapeutic agent for
XX bronchial asthma or chronic obstructive pulmonary disease. The present
XX sequence is used in the exemplification of the present invention.
XX
XX Sequence 925 AA;
XX
XX Query Match 96.6%; Score 28; DB 8; Length 925;
XX Best Local Similarity 83.3%; Pred. No. 6.9e+02;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFA 6
XX |:|:|:|
XX 292 KVVFFA 297
XX
XX RESULT 43
XX ADJ75495
XX ID ADJ75495 standard; protein; 925 AA.
XX AC ADJ75495;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Marker gene related amino acid sequence SEQ ID NO:747.
XX
XX KW bronchial asthma; chronic obstructive pulmonary disease;
XX respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;
XX gene therapy; marker.
XX
XX OS Homo sapiens.
XX
XX PN EP1394274-A2.

```

---

```

XX PD 03-MAR-2004.
XX
XX PF 04-AUG-2003; 2003EP-00254857.
XX
XX PR 06-AUG-2002; 2002JP-00229312.
XX PR 20-MAR-2003; 2003JP-00077212.
XX
XX PA (GENO-) GENOX RES INC.
XX
XX PI Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuahara K;
XX WPI; 2004-193155/19.
XX
XX DR Testing for bronchial asthma or chronic obstructive pulmonary disease by
XX comparing the expression level of a marker gene in a biological sample
XX from a subject with the expression level of the gene in a sample from a
XX healthy subject.
XX
XX PS Example 11; SEQ ID NO 747; 241pp; English.
XX
XX CC The present invention describes a method of testing for bronchial asthma
XX or chronic obstructive pulmonary disease. The method comprises
XX determining the expression level of a marker gene in a biological sample
XX from a subject, comparing the expression level determined with the
XX expression level of the marker gene in a biological sample from a healthy
XX subject, and judging whether the subject has bronchial asthma or chronic
XX obstructive pulmonary disease. The marker gene comprises: (a) a group of
XX genes (S1) whose expression levels increase when respiratory epithelial
XX cells are stimulated with interleukin-13; or (b) a group of genes (S2)
XX whose expression levels decrease when respiratory epithelial cells are
XX stimulated with interleukin-13. Also described: (1) a reagent (I) for
XX testing for bronchial asthma or chronic obstructive pulmonary disease;
XX (2) a kit for screening for a candidate compound for a therapeutic agent
XX to treat bronchial asthma or chronic obstructive pulmonary disease; (3)
XX an animal model for bronchial asthma or chronic obstructive pulmonary
XX disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a
XX method for producing an animal model for bronchial asthma or chronic
XX obstructive pulmonary disease; (6) a therapeutic agent for bronchial
XX asthma or chronic obstructive pulmonary disease, comprising the compound,
XX a marker gene or an antisense nucleic acid corresponding to a portion of
XX the marker gene, a ribozyme, a polynucleotide that suppresses the
XX expression of the gene through an RNAi effect or an antibody recognising
XX a protein encoded by a marker gene; and (7) a DNA chip for testing for
XX bronchial asthma or a chronic obstructive pulmonary disease, on which a
XX probe has been immobilised to assay a marker gene. (I) has respiratory
XX and antiasthmatic activities, and can be used in gene therapy. The method
XX is useful for testing for or screening for a therapeutic agent for
XX bronchial asthma or chronic obstructive pulmonary disease. The present
XX sequence is used in the exemplification of the present invention.
XX
XX Sequence 925 AA;
XX
XX Query Match 96.6%; Score 28; DB 8; Length 925;
XX Best Local Similarity 83.3%; Pred. No. 6.9e+02;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFA 6
XX |:|:|:|
XX 292 KVVFFA 297
XX
XX Db
XX
XX RESULT 44
XX ADN04860
XX ID ADN04860 standard; protein; 925 AA.
XX
XX AC ADN04860;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Antipsoriatic protein sequence #610.
XX
XX antipsoriatic; gene therapy; psoriasis; diagnosis.
XX

```

```

XX OS Homo sapiens.
XX PN WO2004028479-A2.
XX PD 08-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030907.
XX PR 25-SEP-2002; 2002US-0414006P.
XX PA (GETH ) GENENTECH INC.
XX PI Bodary S; Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;
XX PU Wu TD;
XX DR WPI; 2004-305105/28.
XX DR N-PSDB; ADN04859.
XX PT New PRO nucleic acid or polypeptide, useful for preparing a
XX PT pharmaceutical composition for diagnosing or treating psoriasis in a
XX PS mammal.
XX PS Claim 9; SEQ ID NO 1254; 3069pp; English.
XX CC The invention relates to novel polynucleotide and polypeptides for
XX CC treating psoriasis or a sequence having at least 80% identity to the
XX CC above sequences. The nucleic acid is useful for preparing a composition
XX CC for diagnosing or treating psoriasis in a mammal. This sequence
XX CC corresponds to one of the polypeptides of the invention.
XX SQ Sequence 925 AA;
XX
XX Query Match 96.6%; Score 28; DB 8; Length 925;
XX Best Local Similarity 83.3%; Pred. No. 6.9e+02;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFPA 6
XX |::|||
XX 292 KVVFFPA 297
XX
XX Db
XX
XX RESULT 45
XX ADRI14233
XX ID ADRI14233 standard; protein; 925 AA.
XX AC ADRI14233;
XX XX
XX DT 21-OCT-2004 (first entry)
XX
XX DE Human NF-kappaB pathway-associated protein SeqID234.
XX
XX KW NF-kappaB pathway; antiinflammatory; cytostatic; hepatotropic; virucide;
XX KW antiarthritic; antirheumatic; gastrointestinal-Gen; antiasthmatic;
XX KW antiarteriosclerotic; immunomodulator; cerebroprotective; vasotropic;
XX KW immunosuppressive; vulnary; gene therapy; immune disorder;
XX KW inflammatory disorder; NF-kappaB regulation; cancer; aberrant apoptosis;
XX KW hepatic disorder; Hodgkin's lymphoma; haematopoietic tumour;
XX KW hyper-IgM syndrome; hypohidrotic ectodermal dysplasia;
XX KW X-linked anhidrotic ectodermal dysplasia; immunodeficiency;
XX KW viral infection; HIV-1; HTLV-1; hepatitis B; hepatitis C; EBV; influenza;
XX KW viral replication; host cell survival; evasion of immune response;
XX KW rheumatoid arthritis; inflammatory bowel disease; colitis; asthma;
XX KW atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAE;
XX KW autoimmune disorder; hyper immune activity;
XX KW aberrant acute phase response; hypercongenital condition; birth defect;
XX KW necrotic lesion; wound; organ transplant rejection;
XX KW aberrant signal transduction; proliferating disorder; cancer;
XX KW HIV propagation; human.
XX
XX OS Homo sapiens.
XX PN WO2004065577-A2.
XX
XX OS 05-AUG-2004.
XX PD 13-JAN-2004; 2004WO-US000798.
XX PF 14-JAN-2003; 2003US-0440068P.
XX PR 12-MAY-2003; 2003US-0469757P.
XX PA (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX XX
XX PI Nadler SG, Neubauer MG, Feder JN, Carman J;
XX DR WPI; 2004-562168/54.
XX DR N-PSDB; ADR14232.
XX XX
XX PT New isolated polynucleotides and polypeptides associated with NF-kappaB
XX PT pathway, useful for diagnosing, treating, or preventing disorders of
XX PT diseases associated with NF-kappaB pathway.
XX PS Claim 6; SEQ ID NO 234; 237pp; English.
XX CC This invention relates to the novel association of protein sequences (and
XX CC the genes which encode them) to the NF-kappaB pathway. The invention may
XX CC be useful for the production of compounds with an antiinflammatory,
XX CC cytostatic, hepatotropic, virucide, antiarthritic, antirheumatic,
XX CC gastromodulator, antiasthmatic, cerebroprotective, vasotropic, immunosuppressive or
XX CC immunomodulator, gene therapy, for gene therapy. The proteins and nucleotides are
XX CC useful for diagnosing, preventing, treating, or ameliorating conditions
XX CC or diseases associated with the NF-kappaB pathway. The condition is an
XX CC immune disorder, an inflammatory disorder, an inflammatory disorder
XX CC related to aberrant NF-kappaB regulation, cancer, aberrant apoptosis,
XX CC hepatic disorders, Hodgkin's lymphomas, haematopoietic tumours, hyper-IgM
XX CC syndromes, hypohidrotic ectodermal dysplasia, X-linked anhidrotic
XX CC ectodermal dysplasia, immunodeficiency, viral infections, HIV-1, HTLV-1,
XX CC hepatitis B, hepatitis C, EBV, influenza, viral replication, host cell
XX CC survival, evasion of immune responses, rheumatoid arthritis, inflammatory
XX CC bowel disease, colitis, asthma, atherosclerosis, cachexia, euthyroid sick
XX CC syndrome, stroke, EAE, autoimmune disorders, disorders related to hyper
XX CC immune activity, disorders related to aberrant acute phase responses,
XX CC hypercongenital conditions, birth defects, necrotic lesions, wounds,
XX CC organ transplant rejection, conditions related to organ transplant
XX CC rejection, disorders related to aberrant signal transduction,
XX CC proliferating disorders, cancers and HIV propagation in cells infected
XX CC with other viruses. The present sequence is that of a human protein which
XX CC is subject to the novel association with the NF-kappaB pathway of the
XX CC invention. Note: This sequence does not appear in the specification but
XX CC was obtained by the indexer from Genbank.
XX SQ Sequence 925 AA;
XX
XX Query Match 96.6%; Score 28; DB 8; Length 925;
XX Best Local Similarity 83.3%; Pred. No. 6.9e+02;
XX Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KIVFFPA 6
XX |::|||
XX 292 KVVFFPA 297
XX
XX Db
XX
XX RESULT 46
XX ADP25011
XX ID ADP25011 standard; protein; 925 AA.
XX AC ADP25011;
XX XX
XX DT 18-NOV-2004 (first entry)
XX DE PRO polypeptide SEQ ID NO:2189.
XX
XX KW PRO; antiinflammatory; antiarthritic; antirheumatic; immunosuppressive;
XX KW osteopathic; antidiabetic; dermatological; antipsoriatic; antiallergic;
XX KW antiasthmatic; hepatotropic; respiratory; gene therapy; immune system.

```

XX	Unidentified.
OS	WO2004041170-A2.
PN	21-MAY-2004.
PD	30-OCT-2003; 2003WO-US034312.
PF	01-NOV-2002; 2002US-0423394P.
PP	(GETH ) GENENTECH INC.
PR	Clark H, Schoenfeld J, Van Lookeren M, Williams PM, Wood WI;
PA	Wu TD;
PB	WPI; 2004-419628/39.
PC	N-PSDB; ADP25010.
DD	New PRO polypeptides and polynucleotides, useful for treating e.g.
DR	erythematosus, rheumatoid arthritis, diabetes mellitus, immune-mediated
DX	renal disease, or demyelinating diseases of the central or peripheral
XX	nervous system.
XX	Claim 7; SEQ ID NO 2189; 2940pp; English.
XX	The invention relates to a novel isolated nucleic acid and the PRO
CC	polypeptide encoded by it. A protein of the invention has
CC	antiinflammatory, antiarthritic, antirheumatic, immunosuppressive,
CC	osteopathic, antidiabetic, dermatological, antipsoriatic, antiallergic,
CC	asthmatic, hepatotropic, and respiratory activity. A polynucleotide
CC	of the invention may have a use in gene therapy. The PRO polypeptide, its
CC	agonist, antagonist, or antibody that specifically binds to the
CC	polypeptide is useful for treating an immune related disorder such as
CC	systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
CC	juvenile chronic arthritis, a spondyloarthritis, systemic sclerosis, an
CC	idiopathic inflammatory myopathy, Sjogren's syndrome, systemic
CC	vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
CC	thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal
CC	disease, a demyelinating disease of the central or peripheral nervous
CC	system, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome,
CC	a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary
CC	disease, infectious or autoimmune chronic active hepatitis, primary
CC	biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis,
CC	inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's
CC	disease, an autoimmune or immune-mediated skin disease, a bullous skin
CC	disease, erythema multiforme, contact dermatitis, psoriasis, an allergic
CC	disease, asthma, allergic rhinitis, atopic dermatitis, food
CC	hypersensitivity, urticaria, an immunologic disease of the lung,
CC	eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity
CC	pneumonitis, a transplantation associated disease, graft rejection or
CC	graft-versus-host disease. The present sequence represents a PRO protein
CC	of the invention.
XX	
SQ	Sequence 925 AA;
XX	
Query Match	96.6%; Score 28; DB 8; Length 925;
Best Local Similarity	83.3%; Pred. No. 6.9e+02;
Matches	5; Conservative 1; Mismatches 0; Indels 0; Gaps 0
QY	1 KIVFFA 6  :     292 KVFFFA 297
Db	
RESULT 47	
ADR97294	
ID	ADR97294 standard; protein; 925 AA.
XX	ADR97294;
AC	
XX	02-DEC-2004 (first entry)
XX	

OS Mus musculus.  
 XX DE4411402-A1.  
 XX  
 XX PD 05-OCT-1995.  
 XX  
 XX PF 31-MAR-1994; 94DE-04411402.  
 XX  
 XX PR 31-MAR-1994; 94DE-04411402.  
 XX  
 XX PA (SCHR/) SCHRADER J.  
 XX  
 XX PI Schrader J, Goedecke A;  
 XX WPI; 1995-345550/45.  
 DR N-PSDB; AAQ94252.  
 XX  
 XX PT Eukaryotic expression vector for nitrogen-monoxide synthase gene -  
 PT useful in the treatment and prevention of diseases of blood vessels by  
 PT gene therapy.  
 XX  
 XX PS Claim 5; Fig 1; 28pp; German.  
 XX  
 XX CC Inducible nitrogen monoxide synthase (iNOS) was isolated from mice, and  
 CC is encoded by AAQ94252. iNOS is homodimer with a mol. wt. of 130 kDa per  
 CC subunit. The activity of iNOS is independent of calmodulin and cellular  
 CC calcium levels. Vectors contg. the DNA are used in the treatment or  
 CC prevention of vascular diseases, high blood pressure, arteriosclerosis,  
 CC stenosis or restenosis of blood vessels, esp. coronary vessels after  
 CC percutane transluminal coronary angioplasty. See AAR77363 and AAR77362  
 CC for endothelial and brain-derived NOS  
 XX  
 XX SQ Sequence 1144 AA;  
 Query Match 96.6%; Score 28; DB 2; Length 1144;  
 Best Local Similarity 83.3%; Pred. No. 8.5e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 KIVFFA 6  
 DB 514 KVVFFA 519  
 : : : : :  
 : : : : :  
 RESULT 49  
 ID AAW51246 standard; protein; 1144 AA.  
 XX  
 XX AC AAW51246;  
 XX  
 XX DT 25-MAR-2003 (revised)  
 XX DT 12-AUG-1998 (first entry)  
 XX  
 XX DE Inducible nitric oxide synthase, long isoform.  
 XX  
 XX KW Inducible nitric oxide synthase; iNOS; recombinant protein; cDNA library;  
 KW isoform.  
 XX  
 XX OS Mus sp.  
 XX  
 XX PN US5766909-A.  
 XX  
 XX PD 16-JUN-1998.  
 XX  
 XX PF 05-NOV-1993; 93US-00147812.  
 XX  
 XX PR 04-FEB-1992; 92US-00841641.  
 XX  
 XX PA (MERI ) MERCK & CO INC.  
 XX  
 XX PI Mumford RA, Calaycay JR, Xie Q, Nathan CF;  
 XX WPI; 1998-361696/31.  
 DR N-PSDB; AAV07247.

XX DNA encoding inducible nitric oxide synthase proteins - useful for  
 PT producing recombinant proteins.  
 XX  
 XX PS Claim 1; Col 25-32; 39pp; English.  
 XX  
 XX CC The invention relates to two DNA molecules encoding inducible nitric  
 CC oxide synthase (iNOS) proteins, where the DNA molecules comprise defined  
 CC sequences of 4041 and 4165 base pairs given in the specification and the  
 CC proteins have 1144 amino acids. Also claimed are expression vectors  
 CC containing the DNA molecules, and recombinant host cells containing the  
 CC vectors. The DNA molecules are useful for producing the recombinant  
 CC proteins. The present sequence represents inducible nitric oxide, long  
 CC isoform. (Updated on 25-MAR-2003 to correct PF field.)  
 XX  
 XX SQ Sequence 1144 AA;  
 Query Match 96.6%; Score 28; DB 2; Length 1144;  
 Best Local Similarity 83.3%; Pred. No. 8.5e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 KIVFFA 6  
 DB 514 KVVFFA 519  
 : : : : :  
 : : : : :  
 RESULT 50  
 ID AAG64500 standard; protein; 1144 AA.  
 XX  
 XX AC AAG64500;  
 XX  
 XX DT 02-OCT-2001 (first entry)  
 XX  
 XX DE Mouse inducible nitric oxide synthase 2.  
 XX  
 XX KW Antisense oligonucleotide; inducible nitric oxide synthase;  
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;  
 KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;  
 KW 2'-O-methoxyethyl; phosphorothioate; mouse.  
 XX  
 XX OS Mus sp.  
 XX  
 XX PN WO200152902-A1.  
 XX  
 XX PD 26-JUL-2001.  
 XX  
 XX PF 15-JAN-2001; 2001WO-US001381.  
 XX  
 XX PR 24-JAN-2000; 2000US-00490208.  
 XX  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX  
 XX PI Bennett CF, Dean NM, Cowseert LM;  
 XX WPI; 2001-465340/50.  
 DR N-PSDB; AAH47974.  
 XX  
 XX PT New antisense oligonucleotides for modulating the expression of inducible  
 PT nitric oxide synthase in cells or tissues, particularly useful for  
 PT treating e.g. immunological, cardiovascular or neurological disorders, or  
 PT ischemia.  
 XX  
 XX PS Example 17; Page 110-114; 144pp; English.  
 XX  
 XX CC The invention relates to antisense compounds, especially  
 CC oligonucleotides, which are targeted to a nucleic acid encoding inducible  
 CC nitric oxide synthase and which specifically hybridise to and modulate  
 CC expression of inducible nitric oxide synthase. The antisense compounds  
 CC have immunomodulator, antidiabetic, cardiovascular, cardiant,  
 CC neuroprotective, disorder and vasotropic activity. The antisense  
 CC oligonucleotides are useful for inhibiting the expression of inducible  
 CC nitric oxide synthase in cells or tissues. In particular, the antisense



CC oligonucleotides are useful for treating diseases or disorders associated  
CC with inducible nitric oxide synthase, e.g. diabetes, immunological  
CC disorder, cardiovascular disorder, neurological disorder or  
CC ischaemia/reperfusion injury. The antisense oligonucleotides are also  
CC useful for research and diagnostics. The present sequence is that of  
CC mouse inducible nitric oxide synthase  
XX

SQ Sequence 1144 AA;

Query Match 96.6%; Score 28; DB 4; Length 1144;

Best Local Similarity 83.3%; Pred. No. 8.5e+02;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIVFFA 6

|:||||

Db 514 KVVFFA 519

Search completed: March 9, 2005, 06:27:25

Job time : 65.9452 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 16.0274 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-1  
Perfect score: 29  
Sequence: 1 KIVFFA 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5A-COMB.pep:\*  
2: /cgn2\_6/ptodata/1/iaa/5B-COMB.pep:\*  
3: /cgn2\_6/ptodata/1/iaa/6A-COMB.pep:\*  
4: /cgn2\_6/ptodata/1/iaa/6B-COMB.pep:\*  
5: /cgn2\_6/ptodata/1/iaa/PTUS-COMB.pep:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	4	US-09-747-408-1
2	29	100.0	6	4	US-09-747-408-10
3	28	96.6	6	4	US-09-747-408-9
4	28	96.6	6	4	US-09-747-408-17
5	28	96.6	77	4	US-09-513-999C-6921
6	28	96.6	1144	1	US-08-147-812-5
7	28	96.6	1144	2	US-08-319-866-12
8	28	96.6	1144	3	US-09-123-708-2
9	28	96.6	1144	3	US-09-123-624-2
10	28	96.6	1144	4	US-09-661-258-5
11	28	96.6	1144	4	US-08-809-917-12
12	27	93.1	6	2	US-08-612-785B-9
13	27	93.1	6	3	US-08-703-675C-32
14	27	93.1	6	3	US-08-617-267C-9
15	27	93.1	6	4	US-09-747-408-3
16	27	93.1	6	4	US-09-747-408-11
17	27	93.1	7	1	US-08-127-904-14
18	27	93.1	7	3	US-08-612-785B-7
19	27	93.1	7	3	US-08-703-675C-30
20	27	93.1	7	3	US-08-617-267C-7
21	27	93.1	7	3	US-09-264-709A-13
22	27	93.1	7	4	US-09-747-408-2
23	27	93.1	7	4	US-09-747-408-18
24	27	93.1	7	4	US-09-747-408-19
25	27	93.1	7	5	PCT-US94-10475-14
26	27	93.1	8	2	US-08-612-785B-5
27	27	93.1	8	2	US-08-630-645-1

28	27	93.1	8	3	US-08-703-675C-28	Sequence 28, Appl
29	27	93.1	8	3	US-08-617-267C-5	Sequence 5, Appl
30	27	93.1	8	3	US-09-095-106A-44	Sequence 44, Appl
31	27	93.1	8	4	US-08-766-596A-1	Sequence 1, Appl
32	27	93.1	8	5	PCT-US96-10220-1	Sequence 1, Appl
33	27	93.1	9	4	US-08-766-596A-64	Sequence 64, Appl
34	27	93.1	9	4	US-09-747-408-20	Sequence 20, Appl
35	27	93.1	10	3	US-08-970-833-3	Sequence 3, Appl
36	27	93.1	10	4	US-09-724-961-20	Sequence 20, Appl
37	27	93.1	10	4	US-09-724-961-21	Sequence 21, Appl
38	27	93.1	10	4	US-09-724-961-22	Sequence 22, Appl
39	27	93.1	10	4	US-09-724-961-23	Sequence 23, Appl
40	27	93.1	10	4	US-09-724-961-24	Sequence 24, Appl
41	27	93.1	10	4	US-09-580-018-20	Sequence 20, Appl
42	27	93.1	10	4	US-09-580-018-21	Sequence 21, Appl
43	27	93.1	10	4	US-09-580-018-22	Sequence 22, Appl
44	27	93.1	10	4	US-09-580-018-23	Sequence 23, Appl
45	27	93.1	10	4	US-09-580-018-24	Sequence 24, Appl
46	27	93.1	10	4	US-09-724-551-20	Sequence 20, Appl
47	27	93.1	10	4	US-09-724-551-21	Sequence 21, Appl
48	27	93.1	10	4	US-09-724-551-22	Sequence 22, Appl
49	27	93.1	10	4	US-09-724-551-23	Sequence 23, Appl
50	27	93.1	10	4	US-09-724-551-24	Sequence 24, Appl
51	27	93.1	11	2	US-08-630-645-14	Sequence 14, Appl
52	27	93.1	11	4	US-08-766-596A-14	Sequence 14, Appl
53	27	93.1	11	4	US-09-988-842-9	Sequence 9, Appl
54	27	93.1	11	4	US-09-988-842-25	Sequence 25, Appl
55	27	93.1	11	5	PCT-US96-10220-14	Sequence 14, Appl
56	27	93.1	14	4	US-09-594-366-5	Sequence 5, Appl
57	27	93.1	15	2	US-08-612-785B-14	Sequence 14, Appl
58	27	93.1	15	2	US-08-612-785B-37	Sequence 37, Appl
59	27	93.1	15	3	US-08-617-267C-14	Sequence 14, Appl
60	27	93.1	15	4	US-08-766-596A-56	Sequence 56, Appl
61	27	93.1	15	4	US-08-766-596A-57	Sequence 57, Appl
62	27	93.1	15	4	US-08-766-596A-58	Sequence 58, Appl
63	27	93.1	15	4	US-08-766-596A-60	Sequence 60, Appl
64	27	93.1	15	4	US-08-766-596A-61	Sequence 61, Appl
65	27	93.1	15	4	US-08-766-596A-63	Sequence 63, Appl

ALIGNMENTS

RESULT 1  
US-09-747-408-1  
; Sequence 1, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 1  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-1

Query Match 100.0%; Score 29; DB 4; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|||||  
DB 1 KIVFFA 6

```

; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PATENT NO. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-10

Query Match 100.0%; Score 29; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6
Db 1 KIVFFA 6

RESULT 3
US-09-747-408-9
; Sequence 9, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-9

Query Match 96.6%; Score 28; DB 4; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6
Db 1 KIVFFA 6

RESULT 4
US-09-747-408-17
; Sequence 17, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-17

Query Match 96.6%; Score 28; DB 4; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6
Db 1 KIVFFA 6

RESULT 5
US-09-513-999C-6921
; Sequence 6921, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 6921
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-513-999C-6921

Query Match 96.6%; Score 28; DB 4; Length 77;
Best Local Similarity 83.3%; Pred. No. 22;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6
Db 38 KIVFFA 43

RESULT 6
US-08-147-812-5
; Sequence 5, Application US/08147812
; Patent No. 5766909
; GENERAL INFORMATION:
; APPLICANT: Xie, Qiao-wen
; APPLICANT: Nathan, Carl F.
; APPLICANT: Mumford, Richard A.
; APPLICANT: Calaycay, Jimmy Ramos
; TITLE OF INVENTION: DNA Encoding Inducible Nitric Oxide Synthase
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 East Lincoln Avenue
; CITY: Rahway
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
```

COMPUTER: Macintosh Centris650  
OPERATING SYSTEM: Macintosh 7.0.1  
SOFTWARE: Microsoft Word 5.1a  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/147,812  
FILING DATE: No. 5766909 Available  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/841,641  
FILING DATE: 02-FEB-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Wallen, John W III  
REGISTRATION NUMBER: 35,403  
REFERENCE/DOCKET NUMBER: 186581A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (908) 594-3905  
TELEFAX: (908) 594-4720  
TELEX: 138825  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1144 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
US-08-147-812-5

Query Match 96.6%; Score 28; DB 1; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

RESULT 7  
US-08-319-866-12  
Sequence 12, Application US/08319866  
Patent No. 5929223  
GENERAL INFORMATION:  
APPLICANT: Tully, Timothy P.  
APPLICANT: Yin, Jerry C.  
APPLICANT: Regulski, Michael  
TITLE OF INVENTION: CLONING AND CHARACTERIZATION OF GENES  
TITLE OF INVENTION: ASSOCIATED WITH LONG-TERM MEMORY  
NUMBER OF SEQUENCES: 24  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: Two Militia Drive  
CITY: Lexington  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02173  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/319,866  
FILING DATE: 7-OCT-1994  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Granahan, Patricia  
REGISTRATION NUMBER: 32,227  
REFERENCE/DOCKET NUMBER: CSHL94-03  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 861-6240  
TELEFAX: (617) 861-9540  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:

LENGTH: 1144 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-319-866-12

Query Match 96.6%; Score 28; DB 2; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

RESULT 8  
US-09-123-708-2  
Sequence 2, Application US/09123708  
Patent No. 6146887  
GENERAL INFORMATION:  
APPLICANT: SCHRADER, Jurgen  
APPLICANT: GOEDECKE, Axel  
TITLE OF INVENTION: DNA EXPRESSION VECTORS FOR USE IN GENE THERAPEUTIC  
TITLE OF INVENTION: TREATMENT OF VASCULAR DISORDERS  
FILE REFERENCE: 511169-2003  
CURRENT APPLICATION NUMBER: US/09/123,708  
CURRENT FILING DATE: 1998-07-28  
EARLIER APPLICATION NUMBER: 08/553,503  
EARLIER FILING DATE: 1996-03-01  
EARLIER APPLICATION NUMBER: P4411402.8  
EARLIER FILING DATE: 1994-03-31  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 2  
LENGTH: 1144  
TYPE: PRT  
ORGANISM: Cytomegalovirus  
US-09-123-708-2

Query Match 96.6%; Score 28; DB 3; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

RESULT 9  
US-09-123-624-2  
Sequence 2, Application US/09123624  
Patent No. 6149936  
GENERAL INFORMATION:  
APPLICANT: SCHRADER, Jurgen  
APPLICANT: GOEDECKE, Axel  
TITLE OF INVENTION: DNA EXPRESSION VECTORS FOR USE IN THE GENE THERAPEUTIC  
TITLE OF INVENTION: TREATMENT OF VASCULAR DISORDERS  
FILE REFERENCE: 511169-2004  
CURRENT APPLICATION NUMBER: US/09/123,624  
CURRENT FILING DATE: 1998-07-28  
PRIOR APPLICATION NUMBER: 08/553,503  
PRIOR FILING DATE: 1996-03-01  
PRIOR APPLICATION NUMBER: 4411402.8  
PRIOR FILING DATE: 1994-03-31  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 1144  
TYPE: PRT  
ORGANISM: Mus musculus  
US-09-123-624-2

Query Match 96.6%; Score 28; DB 3; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

## RESULT 10

US-09-661-258-5  
; Sequence 5, Application US/09661258  
; Patent No. 6620616  
; GENERAL INFORMATION:  
; APPLICANT: Stuehr, Dennis J.  
; APPLICANT: Adak, Subrata  
; TITLE OF INVENTION: Nucleic Acids Encoding Nitric Oxide Synthase Variants  
; FILE REFERENCE: 26473/04028  
; CURRENT APPLICATION NUMBER: US/09/661,258  
; CURRENT FILING DATE: 2000-09-13  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: Patent in version 3.1  
; SEQ ID NO 5  
; LENGTH: 1144  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-09-661-258-5

Query Match 96.6%; Score 28; DB 4; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

## RESULT 11

US-08-809-917-12  
; Sequence 12, Application US/08809917  
; Patent No. 6689557  
; GENERAL INFORMATION:  
; APPLICANT:  
; APPLICANT: APPLICANT  
; TITLE OF INVENTION: CLONING AND CHARACTERIZATION OF GENES  
; TITLE OF INVENTION: ASSOCIATED WITH LONG-TERM MEMORY  
; NUMBER OF SEQUENCES: 25  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/809,917  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US95/13198  
; FILING DATE:  
; APPLICATION NUMBER: US 08/361,063  
; FILING DATE: 21-DEC-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/319,866  
; FILING DATE: 07-OCT-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia

; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: CSHL94-03A2 PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1144 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-809-917-12

Query Match 96.6%; Score 28; DB 4; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 3e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

## RESULT 12

US-08-612-785B-9  
; Sequence 9, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: AB Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PEI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 227-7400  
; TELEFAX: (617) 742-4214  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-9

Query Match 93.1%; Score 27; DB 2; Length 6;

```
Best Local Similarity 83.3%; Pred. No. 4.1e+05; Indels 0; Gaps 0;
Matches 5; Conservative 1; Mismatches 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 13
US-08-703-675C-32
; Sequence 32, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703.675C
; FILING DATE: 27-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-32

Query Match 93.1%; Score 27; DB 3; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 14
US-08-617-267C-9
; Sequence 9, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-617-267C-9

Query Match 93.1%; Score 27; DB 3; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 15
US-09-747-408-3
; Sequence 3, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 3
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-3
```

Wed Mar 9 08:15:43 2005

Query Match 93.1%; Score 27; DB 4; Length 6;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 16

US-09-747-408-11  
; Sequence 11, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NEI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 11  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-11

Query Match 93.1%; Score 27; DB 4; Length 6;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 17

US-08-127-904-14  
; Sequence 14, Application US/08127904  
; Patent No. 5470951  
; GENERAL INFORMATION:  
; APPLICANT: Eugene Roberts  
; TITLE OF INVENTION: Method For Antagonizing  
; TITLE OF INVENTION: Amesic Effects of Amyloid n  
; TITLE OF INVENTION: Protein and Improving the  
; TITLE OF INVENTION: Quality of Life in Individuals  
; TITLE OF INVENTION: With Alzheimer Disease  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: City of Hope  
; STREET: 1500 East Duarte Road  
; CITY: Duarte  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 91010-0269  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3M Double Density 5 1/4" diskette  
; OPERATING SYSTEM: MS DOS Version 3.20  
; SOFTWARE: Microsoft  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/127,904  
; FILING DATE: 29 September 1993  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA: No. 5470951e  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Irons, Edward S.  
; REGISTRATION NUMBER: 16,541  
; REFERENCE/DOCKET NUMBER: No. 5470951e

; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 783-6040  
; TELEFAX: (202) 783-6031  
; TELEX: NO. 5470951e  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7  
; TYPE: Amino Acid  
; STRANDEDNESS:  
; TOPOLOGY: Unknown  
; US-08-127-904-14

Query Match 93.1%; Score 27; DB 1; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 18

US-08-612-785B-7  
; Sequence 7, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-7

Query Match 93.1%; Score 27; DB 2; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;



```

QY      1 KIVFFA 6
      1:|||||
Db      2 KLVFFA 7

RESULT 19
US-08-703-675C-30
; Sequence 30, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findis, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-30

Query Match      93.1%; Score 27; DB 3; Length 7;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
      1:|||||
Db      2 KLVFFA 7

RESULT 20
US-08-617-267C-7
; Sequence 7, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findis, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation

```

```

; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-617-267C-7

Query Match      93.1%; Score 27; DB 3; Length 7;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
      1:|||||
Db      2 KLVFFA 7

RESULT 21
US-09-264-709A-13
; Sequence 13, Application US/09264709A
; Patent No. 6320824
; GENERAL INFORMATION:
; APPLICANT: Roberts, Eugene
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and
; TITLE OF INVENTION: Improve the Quality of Life
; FILE REFERENCE: 2124-310
; CURRENT APPLICATION NUMBER: US/09/264,709A
; CURRENT FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: 08/797,782
; PRIOR FILING DATE: 1997-02-07
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 13
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-264-709A-13

Query Match      93.1%; Score 27; DB 3; Length 7;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

Oy 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 22

US-09-747-408-2  
; Sequence 2, Application US/09747408  
; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-2

Query Match 93.1%; Score 27; DB 4; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 1 KIVFFA 6  
|:||||  
Db 2 KLVFFA 7

## RESULT 23

US-09-747-408-18  
; Sequence 18, Application US/09747408  
; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 18

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-18

Query Match 93.1%; Score 27; DB 4; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 24

US-09-747-408-19

; Sequence 19, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 19

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-19

Query Match 93.1%; Score 27; DB 4; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 25

PCT-US94-10475-14

; Sequence 14, Application PC/TUS9410475

; GENERAL INFORMATION:

; APPLICANT: Eugene Roberts  
; TITLE OF INVENTION: Method For  
; TITLE OF INVENTION: Antagonizing Amnestic  
; TITLE OF INVENTION: Effects of Amyloid n  
; TITLE OF INVENTION: Protein and Improving  
; TITLE OF INVENTION: the Quality of Life  
; TITLE OF INVENTION: in Individuals  
; TITLE OF INVENTION: With Alzheimer Disease

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: City of Hope

; STREET: 1500 East Duarte Road

; CITY: Duarte

; STATE: California

; COUNTRY: United States of America

; ZIP: 91010-0269

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3M Double Density 5 1/4"

; COMPUTER: Wang PC

; OPERATING SYSTEM: MS DOS Version 3.20

; SOFTWARE: Microsoft

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US94/10475

; FILING DATE: 16 September 1994

; CLASSIFICATION:

; PRIOR APPLICATION DATA: U. S. Application

; PRIOR APPLICATION DATA: Serial No.

; PRIOR APPLICATION DATA: 08/127,904; filed

; PRIOR APPLICATION DATA: 29 September 1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Irons, Edward S.

; REGISTRATION NUMBER: 16,541

; REFERENCE/DOCKET NUMBER: None

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 626-3564 or 783-6030

; TELEFAX: (202) 783-6031

; TELEX: None

; INFORMATION FOR SEQ ID NO: 14:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 7

; TYPE: Amino Acid

; STRANDEDNESS:

TOPOLOGY: Unknown  
PCT-US94-10475-14

Query Match 93.1%; Score 27; DB 5; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:|||||  
Db 1 KLVFFA 6

## RESULT 26

US-08-612-785B-5  
; Sequence 5, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; OPERATING SYSTEM: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; APPLICATION DATA: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Decont, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-5

Query Match 93.1%; Score 27; DB 2; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:|||||  
Db 3 KLVFFA 8

## RESULT 27

US-08-630-645-1  
; Sequence 1, Application US/08630645

; Patent No. 5948763  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/630,645  
; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-630-645-1

Query Match 93.1%; Score 27; DB 2; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:|||||  
Db 1 KLVFFA 6

## RESULT 28

US-08-703-675C-28  
; Sequence 28, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25

Aggregation Comprising D-

us-10-009-122-1.ra1

Wed Mar 9 08:15:43 2005

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703.675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-703-675C-28

Query Match 93.1%; Score 27; DB 3; Length 8;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 3 KLVFFA 8

RESULT 29
US-08-617-267C-5
; Sequence 5, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-617-267C-5

Query Match 93.1%; Score 27; DB 3; Length 8;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 3 KLVFFA 8

RESULT 30
US-09-095-106A-44
; Sequence 44, Application US/09095106A
; Patent No. 6331440
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; APPLICANT: NASLUND, Jan
; APPLICANT: THYBERG, Johan
; APPLICANT: TJERNBERG, Lars O.
; APPLICANT: TERNIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 000500-124
; CURRENT APPLICATION NUMBER: US/09/095,106A
; CURRENT FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 44
; LENGTH: 8
; TYPE: PPT
; ORGANISM: Amyloidosis
; US-09-095-106A-44

Query Match 93.1%; Score 27; DB 3; Length 8;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 31
US-08-766-596A-1
; Sequence 1, Application US/08766596A
; Patent No. 6462171
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; TITLE OF INVENTION: DEPOSITS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; US-08-766-596A-1
```

STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-1

Query Match 93.1%; Score 27; DB 4; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 32  
PCT-US96-10220-1  
Sequence 1, Application PC/TUS9610220  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/10220  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1 PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
PCT-US96-10220-1

Query Match 93.1%; Score 27; DB 5; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 33  
US-08-766-596A-64  
Sequence 64, Application US/08766596A  
Patent No. 6462171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 64:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid

```
;
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-766-596A-64

Query Match          93.1%; Score 27; DB 4; Length 9;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
Db      2 KLVFFA 7

RESULT 34
US-09-747-408-20
; Sequence 20, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-20

Query Match          93.1%; Score 27; DB 4; Length 9;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
Db      4 KLVFFA 9

RESULT 35
US-08-970-833-3
; Sequence 3, Application US/08970833
; Patent No. 6022859
; GENERAL INFORMATION:
; APPLICANT: Kiessling, Laura L.
; APPLICANT: Murphy, Regina M.
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Quarles & Brady
; STREET: 411 East Wisconsin Avenue
; CITY: Milwaukee
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53202-4497
; COMPUTER READABLE FORM:
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,833
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Baker, Jean C.
; REGISTRATION NUMBER: 35,433
```

```
;
; REFERENCE/DOCKET NUMBER: 960296.94291
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (414) 277-5709
; TELEFAX: (414) 271-3552
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-970-833-3

Query Match          93.1%; Score 27; DB 3; Length 10;
Best Local Similarity 83.3%; Pred. No. 5.1;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
Db      1 KLVFFA 6

RESULT 36
US-09-724-961-20
; Sequence 20, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 03/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-20

Query Match          93.1%; Score 27; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 5.1;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
Db      5 KLVFFA 10

RESULT 37
US-09-724-961-21
; Sequence 21, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
```

; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US 09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-21

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 4 KLVFFA 9

RESULT 38  
US-09-724-961-22  
; Sequence 22, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US 09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-21

; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-22

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 39  
US-09-724-961-23  
; Sequence 23, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US 09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-23

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 40  
US-09-724-961-24  
; Sequence 24, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US 09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; OTHER INFORMATION: peptide)  
US-09-724-961-23





; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-23

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 45  
US-09-580-018-24  
; Sequence 24, Application US/095800018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-24

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 46  
US-09-724-551-20  
; Sequence 20, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551

; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-20

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 5 KLVFFA 10

RESULT 47  
US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-21

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:||||  
Db 4 KLVFFA 9

RESULT 48  
US-09-724-551-22  
; Sequence 22, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US

; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-22

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KIVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 49  
US-09-724-551-23  
; Sequence 23, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-23

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KIVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 50  
US-09-724-551-24  
; Sequence 24, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease

; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-24

Query Match 93.1%; Score 27; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 5.1;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

Search completed: March 9, 2005, 06:42:58  
Job time : 17.0274 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 74.6027 Seconds  
(without alignments)  
36.290 Million cell updates/sec

Title: US-10-009-122-2

Perfect score: 34

Sequence: 1 KKLVPFA 7

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-Processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database :

A\_Geneseq\_16Dec04:\*

1: Geneseqp1980s:\*

2: Geneseqp1990s:\*

3: Geneseqp2000s:\*

4: Geneseqp2001s:\*

5: Geneseqp2002s:\*

6: Geneseqp2003as:\*

7: Geneseqp2003bs:\*

8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	34	100.0	7	4	AAB48475 Antifibri
2	34	100.0	7	4	AAB82624 All-D pep
3	34	100.0	7	5	Aau96812 Amyloid t
4	34	100.0	7	5	Aau11649 Peptide #
5	34	100.0	7	6	Aae35439 Abeta pep
6	34	100.0	7	8	ADQ37314 Antifibri
7	34	100.0	7	8	ADQ37263 Vaccine a
8	34	100.0	7	6	ABU79063 Aggregati
9	34	100.0	9	7	ABW00197 Peptide #
10	31	91.2	277	7	ADK82706 Beta-amyl
11	30	88.2	7	2	Aaw02312 Beta-amyl
12	30	88.2	7	2	Aaw89376 Beta-amyl
13	30	88.2	7	5	ABG71007 Long form
14	30	88.2	7	5	ABG71005 Long form
15	30	88.2	7	8	ADJ64058 Human bet
16	30	88.2	7	8	ADQ37351 Beta-amyl
17	30	88.2	8	2	Aaw02310 Beta-amyl
18	30	88.2	8	2	Aaw89374 Beta-amyl
19	30	88.2	8	5	ABG71005 Long form
20	30	88.2	8	5	ABG05153 Beta amyl
21	30	88.2	8	8	ADJ64056 Human bet
22	30	88.2	8	8	ADQ37349 Beta-amyl
23	30	88.2	9	2	AAR45239 Mutant am
24	30	88.2	9	4	AAB48493 Antifibri
25	30	88.2	9	5	Aau11667 Peptide #

26	30	88.2	9	6	ABP57517 Different
27	30	88.2	9	6	ABU79053 Aggregati
28	30	88.2	9	6	AAE35436 Abeta pep
29	30	88.2	9	7	ABW00187 Peptide #
30	30	88.2	9	8	ADI35874 Amyloid b
31	30	88.2	9	8	ADQ37260 Vaccine a
32	30	88.2	9	8	ADQ37332 Antifibri
33	30	88.2	10	4	AAE46226 Human APP
34	30	88.2	10	4	AAE46225 Human APP
35	30	88.2	10	4	AAE46224 Human APP
36	30	88.2	10	4	AAE46227 Human APP
37	30	88.2	10	4	AAE46241 All-D pep
38	30	88.2	10	5	AAU96829 Amyloid t
39	30	88.2	10	6	ABP57511 Different
40	30	88.2	10	6	AAE35455 Abeta pep
41	30	88.2	10	8	ADQ37280 Vaccine a
42	30	88.2	10	8	ADQ37371 Amyloid-b
43	30	88.2	10	8	ADQ37374 Amyloid-b
44	30	88.2	11	2	AAW32560 Anti-amyl
45	30	88.2	11	5	AAU99431 Human amy
46	30	88.2	11	5	AAE29504 Amyloid b
47	30	88.2	11	6	ABU79013 Amyloidog
48	30	88.2	11	7	ABR84683 Aggreca
49	30	88.2	11	7	ABW00147 Amyloid-b
50	30	88.2	12	6	AAE35464 Abeta pep
51	30	88.2	12	6	AAE35435 Abeta pep
52	30	88.2	12	6	AAE35466 Abeta pep
53	30	88.2	12	7	ADD20745 Human bet
54	30	88.2	12	7	ADD20744 Human bet
55	30	88.2	12	8	ADJ71476 N-termina
56	30	88.2	12	8	ADQ37407 Amyloid-b
57	30	88.2	12	8	ADQ37289 Vaccine a
58	30	88.2	12	8	ADQ37259 Vaccine a
59	30	88.2	13	6	ADA37467 Human amy
60	30	88.2	13	8	ADJ71477 N-termina
61	30	88.2	13	8	ADJ71464 N-termina
62	30	88.2	14	6	ADA89887 Beta-A4 s
63	30	88.2	14	8	ADJ71452 N-termina
64	30	88.2	14	8	ADJ71465 N-termina
65	30	88.2	14	8	ADJ71478 N-termina

## ALIGNMENTS

RESULT 1	
AAB48475	
ID	AAB48475 standard; peptide; 7 AA.
XX	
AC	AAB48475;
XX	
DT	02-MAR-2001 (first entry)
XX	
DE	Antifibrillogenic peptide #2.
XX	
XX	Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
KW	cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX	Alzheimer's disease.
XX	
OS	Homo sapiens.
XX	
XX	WO200068263-A2.
XX	
XX	16-NOV-2000.
XX	
PF	04-MAY-2000; 2000WO-CA000515.
XX	
PR	05-MAY-1999; 99US-0132592P.
XX	
PA	(NEUR-) NEUROCHEM INC.
XX	
PI	Chalifour R, Gervais F, Gupta A;
XX	

DR WPI; 2001-031852/04.  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 PS Claim 7; Page 25; 46pp; English.  
 XX  
 CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 34; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVEFFA 7  
 Db 1 KKLVEFFA 7  
 RESULT 2  
 ID AAB82624 standard; peptide; 7 AA.  
 XX  
 AC AAB82624;  
 XX  
 DT 02-OCT-2001 (first entry)  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..7 /note= "all D-form residues"  
 XX  
 PN WO200139796-A2.  
 XX  
 PD 07-JUN-2001.  
 XX  
 PF 29-NOV-2000; 2000WO-CA001413.  
 XX  
 PR 29-NOV-1999; 99US-0168594P.  
 PR 28-NOV-2000; 2000US-00724842.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Chalifour R, Hebert L, Kong X, Gervais F;  
 XX  
 XX WPI; 2001-441458/47.  
 DR  
 XX Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 XX associated cellular toxicity.  
 PS Disclosure; Page 10; 31pp; English.  
 XX  
 CC The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more

CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self',  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-17, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis, and  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 34; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVEFFA 7  
 Db 1 KKLVEFFA 7  
 RESULT 3  
 ID AAU96812 standard; peptide; 7 AA.  
 XX  
 AC AAU96812;  
 XX  
 DT 30-JUL-2002 (first entry)  
 DE Amyloid targeting peptide #2.  
 XX  
 KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..7 /note= "Preferably D-form residue"  
 FT  
 XX WO200207781-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 25-JUL-2001; 2001WO-CA001071.  
 XX  
 PR 25-JUL-2000; 2000US-0220808P.  
 PR 24-JUL-2001; 2001US-00915092.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Gervais F, Kong X, Chalifour R, Migneault D;  
 XX  
 DR WPI; 2002-371447/40.  
 XX  
 XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid

PT plaques and/or for the treatment of amyloidosis disorders.

PS Claim 49; Page 21; 57pp; English.

XX The invention relates to an amyloid-targeting imaging agent comprising an  
 CC amyloid targeting moiety, a linker moiety and a labelling moiety. The  
 CC agent is of general formula A<sub>t</sub>-(A<sub>1</sub>)<sub>n</sub>-(A<sub>2</sub>)<sub>m</sub>-(A<sub>3</sub>)<sub>k</sub>-(A<sub>4</sub>)<sub>p</sub> where z = 0 - 1;  
 CC A<sub>t</sub> = an amyloid targeting moiety; A<sub>1</sub> = a linker moiety; and A<sub>1</sub>-a<sub>b</sub>  
 CC = a labelling moiety. Also included are imaging amyloid deposition or  
 CC diagnosing an amyloid-related condition in a patient involving  
 CC administering (i) to the patient, and ultrasound imaging (i) in the  
 CC patient to determine the presence of amyloid or amyloid-related condition  
 CC ; and a kit for preparing a radiopharmaceutical preparation comprising  
 CC (i), a reducing agent, a buffering agent, a transchelating agent, and  
 CC instructions for the preparation and use of the radiopharmaceutical in  
 CC the imaging of amyloid or an amyloid-related condition. The agents are  
 CC used for imaging amyloid deposition and for diagnosing an amyloid related  
 CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
 CC cerebral amyloidosis (transmissible virus dementia), familial CJD,  
 CC scrapie, transmissible mink encephalopathy, bovine spongiform  
 CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
 CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
 CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
 CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
 CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
 CC barrier and are capable of binding specifically to amyloid plaques. The  
 CC present sequence is a peptide forming the amyloid targeting moiety of the  
 CC agent of the invention

XX Sequence 7 AA;

Query Match 100.0%; Score 34; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7

Db 1 KKLVEFFA 7

RESULT 4

AAU11649  
 ID AAU11649 standard; peptide; 7 AA.

AC AAU11649;

DT 09-APR-2002 (first entry)

XX Peptide #2, used as a carrier for the amyloid-beta40 (Abeta40) inhibitor.

XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; neurotropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX Synthetic.

XX WO200185093-A2.

XX 15-NOV-2001.

PF 22-DEC-2000; 2000WO-IB002078.

PR 23-DEC-1999; 99US-0171877P.

PA (NEUR-) NEUROCHEM INC.

PI Green AM, Gervais F;

XX WPI; 2002-075222/10.

XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.

XX

PS Disclosure; Page 10; 68pp; English.

XX The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)

SQ Sequence 7 AA;

Query Match 100.0%; Score 34; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7

Db 1 KKLVEFFA 7

RESULT 5

AAE35439  
 ID AAE35439 standard; peptide; 7 AA.

XX AAE35439;

DT 17-JUN-2003 (first entry)

XX Abeta peptide #10.

XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX Unidentified.

XX Key Location/Qualifiers

FT Misc-difference 1..7 /note= "D-form residues"

XX WO200296937-A2.

XX 05-DEC-2002.

PF 29-MAY-2002; 2002WO-CA000763.

PR 29-MAY-2001; 2001US-00867847.

XX (NEUR-) NEUROCHEM INC.

PI Gervais F, Hebert L, Chalifour RJ, Kong X;

XX WPI; 2003-201269/19.

XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

PS Claim 1; Page 59; 44pp; English.

XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid

CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (rheumatoid arthritis, juvenile chronic  
 CC inflammatory diseases e.g. rheumatoid arthritis, psoriatic arthropathy,  
 CC arthritis, ankylosing spondylitis, psoriasis, Bechet's syndrome and Crohn's  
 CC Reiter's syndrome, Adult Still's disease, a result of chronic microbial  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention

XX Sequence 7 AA;  
 SQ Query Match 100.0%; Score 34; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVPFA 7  
 DB 1 KKLVPFA 7

RESULT 6  
 ADQ37314  
 ID ADQ37314 standard; peptide; 7 AA.

XX AC ADQ37314;  
 DT 07-OCT-2004 (first entry)  
 XX DE Antifibrillogenic amyloidosis inhibiting peptide.

XX amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nototropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment; vascular dementia;  
 KW mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

XX OS Synthetic.

XX FN WO2004058239-A1.

XX PD 15-JUL-2004.

XX PF 24-DEC-2003; 2003WO-CA002021.

XX PR 24-DEC-2002; 2002US-0436379P.

XX PR 23-JUN-2003; 2003US-0482214P.

XX PA (NEUR-) NEUROCHEM INT LTD.

XX PI Gervais F, Bellini F;

XX DR WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 69; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic, tranquiliser,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, muscular,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a neurological condition (e.g. Huntington's  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
 CC in the exemplification of the present invention.

XX Sequence 7 AA;

Query Match 100.0%; Score 34; DB 8; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVPFA 7  
 DB 1 KKLVPFA 7

RESULT 7  
 ADQ37263  
 ID ADQ37263 standard; peptide; 7 AA.

XX AC ADQ37263;

XX DT 07-OCT-2004 (first entry)

XX Vaccine antigen amyloid-beta related amino acid sequence.

DE amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nototropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment; vascular dementia;  
 KW mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;



senile dementia; Down's syndrome; inclusion body myositis;  
age-related macular degeneration; hypothyroidism;  
cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
behavioural dysfunction; neurological condition; psychological condition;  
vaccine antigen.

Synthetic.

Key Location/Qualifiers

Misc-difference 1..7

/note= "D-form residues"

WO2004058239-A1.

15-JUL-2004.

24-DEC-2003; 2003WO-CA002021.

24-DEC-2002; 2002US-0436379P.

23-JUN-2003; 2003US-0482214P.

(NEUR-) NEUROCHEM INT LTD.

Gervais F, Bellini F;

WPI; 2004-543342/52.

Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

Disclosure; Page 67; 143pp; English.

The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have neurotropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, cerebral mild-to-moderate cognitive impairment, vascular dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; having amyloid-beta deposits. The present sequence represents a peptide that can be used as a vaccine antigen in the exemplification of the present invention.

Sequence 7 AA;

Query Match 100.0%; Score 34; DB 8; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

RESULT 8  
ABU79063  
ID ABU79063 standard; peptide; 9 AA.  
XX  
AC ABU79063;  
XX  
DT 17-JUN-2003 (first entry)  
XX  
DE Aggregation blocking peptide #15.  
XX  
KW Amyloid formation; amyloid-like deposit; Alzheimer's disease;  
KW pathological beta-sheet-rich conformation; Down's syndrome;  
KW amyloidosis disorder; human prion disease; kuru; CJD;  
KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome; GSS;  
KW prion associated human neurodegenerative disease; animal prion disease;  
KW scrapie; spongiform encephalopathy; transmissible mink encephalopathy;  
KW chronic wasting disease.  
XX  
OS Unidentified.  
XX  
PN US6462171-B1.  
XX  
PD 08-OCT-2002.  
XX  
PP 12-DEC-1996; 96US-00766596.  
XX  
PR 07-JUN-1995; 95US-00478326.  
PR 10-APR-1996; 96US-00630645.  
XX  
PA (UUNY ) UNIV NEW YORK STATE.  
XX  
PI Soto-Jara C, Baumann MH, Frangione B;  
WPI; 2003-379012/36.  
XX  
PT Novel inhibitory peptides which inhibit and structurally block abnormal folding of protein into amyloid or amyloid-like deposit and into pathological beta-sheet rich conformation, useful for treating Alzheimer's disease.  
XX  
PS Disclosure; Col 51-52; 51pp; English.  
XX  
CC The invention describes an isolated inhibitory peptide (I) which interacts with a hydrophobic beta-sheet forming cluster of amino acid residues on a protein or peptide for amyloid or amyloid-like deposit formation, and inhibits or structurally blocks the abnormal folding of proteins and peptides into amyloid or amyloid-like deposits and into pathological beta-sheet-rich conformation. (I) is useful for disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits or into pathological beta-sheet-rich precursors of such deposits, such as Alzheimer's disease, Down's syndrome, other amyloidosis disorders, human prion diseases, such as kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Strausler-Scheinker syndrome (GSS), prion associated human neurodegenerative diseases as well as animal prion diseases such as scrapie, spongiform encephalopathy, transmissible mink encephalopathy and chronic wasting disease of mule deer and elk. (I) is also useful for detecting and diagnosing the presence or absence of amyloid or amyloid-like deposits in vivo and its precursors. This is the amino acid sequence of peptide associated with the inhibition of amyloid or amyloid like deposits

Sequence 9 AA;

Wed Mar 9 08:15:51 2005

us-10-009-122-2.rag

```

Query Match      100.0%; Score 34; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
DB      1 KKLVEFFA 7

RESULT 9
ABW00197
ID ABW00197 standard; peptide; 9 AA.
XX
AC ABW00197;
XX
DT 15-JAN-2004 (first entry)
XX
DE Peptide #15 used in the invention.
XX
KW Amyloid-like fibril deposit; prion related encephalopathy; gene therapy;
KW Alzheimer's disease.
XX
OS Unidentified.
XX
PN US2003087407-A1.
XX
PD 08-MAY-2003.
XX
PF 06-SEP-2002; 2002US-00235483.
XX
PR 07-JUN-1995; 95US-00478326.
PR 10-APR-1996; 96US-00630645.
PR 12-DEC-1996; 96US-00766596.
XX
FA (UUNY ) UNIV NEW YORK STATE.
XX
XX Soto-Jara C, Baumann MH, Frangione B;
XX WPI; 2003-616149/58.
XX
XX New inhibitory peptide, useful for preparing a composition for
XX diagnosing, preventing or treating disorders associated with amyloid-like
XX fibril deposits, e.g. Alzheimer's disease, or prion related
XX encephalopathies.
XX
PS Claim 1; Page 28; 52pp; English.
XX
XX The invention relates to inhibitory peptide comprising a portion of at
XX least three amino acid residues and a sequence predicted not to adopt a
XX beta-sheet structure that associates with a hydrophobic beta-sheet
XX cluster on a protein or peptide involved in the abnormal folding of the
XX beta-sheet structure, to structurally block the abnormal folding of the
XX protein or peptide. The inhibitory peptide is useful for preparing a
XX composition for preventing, treating or detecting disorders or diseases
XX associated with amyloid-like fibril deposits e.g. Alzheimer's disease and
XX prion related encephalopathies. The invention is also useful in gene
XX therapy. The present sequence is a peptide used in the invention
XX
XX Sequence 9 AA;
Query Match      100.0%; Score 34; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
DB      1 KKLVEFFA 7

RESULT 10
ADK82706
ID ADK82706 standard; protein; 277 AA.
XX
XX

```

```

ADK82706;
XX
DT 06-MAY-2004 (first entry)
XX
DE Beta-amyloid peptide antibody sequence #2.
XX
KW fusion antibody; senile dementia; beta-amyloid peptide; fibre;
KW immunocell.
XX
OS Unidentified.
XX
PN CN1396183-A.
XX
PD 12-FEB-2003.
XX
PF 13-JUL-2001; 2001CN-00120278.
XX
PR 13-JUL-2001; 2001CN-00120278.
XX
PA (ZHAN/) ZHANG X.
XX
PI Zhang X, Zhang J;
XX
DR WPI; 2003-442233/42.
XX
XX Human fusion antibody for reducing cerebral amyloid fibers associated
XX with senile dementia.
XX
PS Disclosure; Page 8; 26pp; Chinese.
XX
XX The invention relates to a human fusion antibody for preventing and
XX treating senile dementia. The antibody recognises and binds the beta-
XX amyloid peptide and the fibres generated by it. The human antibody PC
XX segment recognized by human immunocells are sequentially contained by its
XX terminals from N to C. The fusion gene coding for the antibody is also
XX disclosed. This sequence represents the sequence of a anti-beta-amyloid
XX peptide antibody.
XX
SQ Sequence 277 AA;
Query Match      91.2%; Score 31; DB 7; Length 277;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
DB      32 KKLVEFFA 38

RESULT 11
AAW02312
ID AAW02312 standard; peptide; 7 AA.
XX
AC AAW02312;
XX
DT 02-MAY-1997 (first entry)
XX
DE Beta-amyloid modulator peptide #3.
XX
XX Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;
XX cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;
XX familial amyloid polyneuropathy; familial amyloid cardiomyopathy;
XX isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;
XX bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;
XX adult-onset diabetes; familial Mediterranean fever; therapy; deafness;
XX scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.
XX
OS Synthetic.
XX
PN WO9628471-A1.
XX
PD 19-SEP-1996.
XX

```

```

PF 14-MAR-1996; 96WO-US003492.
XX
XX 14-MAR-1995; 95US-00404831.
PR 07-JUN-1995; 95US-00475579.
PR 27-OCT-1995; 95US-00548998.
XX
XX (PHAR-) PHARM PEPTIDES INC.
XX
XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;
PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;
PI Kubasek W, Chin J, Lee J, Kelley M;
XX
XX WPI; 1996-433762/43.
XX
XX Modulators of amyloid aggregation - comprising, e.g. amyloidogenic
PT protein coupled (in)directly to at least 1 modifying gp., useful in
PT treatment of Alzheimer's disease.
XX
XX Claim 16; Page 91; 106pp; English.
XX
XX AAW02310-W02332 represent the peptide portions of the beta-amyloid
CC modulator compounds of the invention. Beta-amyloid peptide is a 4
CC kilodalton peptide that is the major protein component of amyloid
CC plaques. Amyloid plaques are present both in the brain lesions, and in
CC the walls of cerebral blood vessels in Alzheimer's disease patients. The
CC amyloid modulators of the invention comprise an amyloidogenic protein or
CC peptide (such as this sequence) coupled directly or indirectly to at
CC least one modifying group. The modifying group is preferably a cyclic,
CC heterocyclic, or polycyclic group, such as deca-, a cholanyl group, a
CC biotin containing group, or a fluorescein containing group. These
CC compounds then modulate the aggregation of these sequences to natural
CC amyloid proteins or peptides when contacted with the natural
CC amyloidogenic proteins or peptides. The modulator compounds can be used
CC in the treatment of disorders associated with amyloidosis, such as
CC familial amyloid polynuropathy, familial amyloid cardiomyopathy,
CC isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,
CC bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset
CC diabetes, insulinoma, familial Mediterranean fever, familial amyloid
CC nephropathy with urticaria and deafness, hereditary cerebral haemorrhage
CC and other types of amyloidosis. The modulators are also useful for the
CC treatment of disorders associated with beta-amyloidosis, especially
CC Alzheimer's disease
XX
XX Sequence 7 AA;
SQ
Query Match 88.2%; Score 30; DB 2; Length 7;
Best Local Similarity 85.7%; Pred. No. 1.8e+06;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVPFFA 7
Db 1 QKLVPFFA 7
:|||||
:|||||

RESULT 12
AAW89376
ID AAW89376 standard; peptide; 7 AA.
XX
XX AAW89376;
AC
XX
XX 02-MAR-1999 (first entry)
DT
XX
XX Beta-amyloid peptide derivative A-beta-15-21.
DE
XX
XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;
KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;
KW familial amyloid polynuropathy; bovine spongiform encephalopathy;
KW Creutzfeldt-Jakob disease; BAP.
XX
XX Homo sapiens.
OS
XX Synthetic.
PN
XX US5854204-A.
PD

XX 29-DEC-1998.
XX
XX 14-MAR-1996; 96US-00612785.
XX
XX 14-MAR-1995; 95US-00404831.
PR 07-JUN-1995; 95US-00475579.
PR 27-OCT-1995; 95US-00548998.
XX
XX (PRAE-) PRAECIS PHARM INC.
XX
XX Hundal A, Geffer ML, Kasman L, Musso G, Molineaux S, Benjamin H;
PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;
PI Garnick MB, Kubasek W, Signer ER;
XX
XX WPI; 1999-094964/08.
XX
XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid
PT aggregation - and neurotoxicity, specifically for treatment and
PT prevention of Alzheimer's disease.
XX
XX Example 12; Col 64; 52pp; English.
XX
XX The present invention describes beta-amyloid peptide (BAP) derivatives.
CC The BAP derivatives inhibit aggregation of amyloidogenic proteins and
CC peptides, specifically BAP, and their neurotoxicity, so are useful for
CC treating and preventing any disease involving amyloidosis, specifically
CC Alzheimer's disease but also Down's syndrome, familial amyloid
CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and
CC Creutzfeldt-Jakob disease. The BAP derivatives are also used to diagnose
CC these diseases, in vitro or in vivo, by detecting binding of BAP to
CC labelled BAP derivatives. Some BAP derivatives inhibit BAP aggregation
CC even when BAP is present in molar excess. The present sequence represents
CC a BAP derivative
XX
XX Sequence 7 AA;
SQ
Query Match 88.2%; Score 30; DB 2; Length 7;
Best Local Similarity 85.7%; Pred. No. 1.8e+06;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVPFFA 7
Db 1 QKLVPFFA 7
:|||||
:|||||

RESULT 13
ABG71007
ID ABG71007 standard; peptide; 7 AA.
XX
XX ABG71007;
AC
XX
XX 05-DEC-2002 (first entry)
DT
XX
XX Long form beta-amyloid protein fragment #4.
DE
XX
XX Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;
KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;
KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;
KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;
KW adult onset diabetes; Gerstmann-Strausser-Scheinker syndrome;
KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;
KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;
KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;
KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;
KW hereditary non-neuropathic systemic amyloidosis;
KW familial Mediterranean fever.
XX
XX Homo sapiens.
OS
XX
XX US2002098173-A1.
PN
XX
XX 25-JUL-2002.
PD

```

Wed Mar 9 08:15:51 2005

XX 04-OCT-2001; 2001US-00972475.  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 PR 14-MAR-1996; 96US-00617267.  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2002-697709/75.  
 XX Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX Example 12; Page 35; 41pp; English.  
 XX The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid cardiomyopathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),  
 CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Strausler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localized cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polynuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysozyme-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX Sequence 7 AA;  
 SQ  
 Query Match 88.2%; Score 30; DB 5; Length 7;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVEFFA 7  
 Db 1 QKLVEFFA 7  
 :|||||  
 :|||||  
 RESULT 14  
 ABB05155  
 ID ABB05155 standard; peptide; 7 AA.  
 XX ABB05155;  
 AC ABB05155;  
 XX 02-APR-2002 (first entry)  
 DT Beta amyloid peptide (15-21) SEQ ID NO:7.  
 XX Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW nontropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyrretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polynuropathy.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX US6319498-B1.  
 XX 20-NOV-2001.  
 PD 14-MAR-1996; 96US-00617267.  
 XX 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2002-146668/19.  
 DR Amyloid modulator compound useful for treatment of an amyloidogenic  
 XX disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 PT Disclosure; Col 19; 54pp; English.  
 PS The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has nontropic, neuroprotective, immunosuppressive, antimicrobial,  
 CC antidiabetic, antipyrretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polynuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention  
 XX Sequence 7 AA;  
 SQ  
 Query Match 88.2%; Score 30; DB 5; Length 7;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVEFFA 7  
 Db 1 QKLVEFFA 7  
 :|||||  
 :|||||  
 RESULT 15  
 ADJ64058  
 ID ADJ64058 standard; peptide; 7 AA.  
 XX ADJ64058;  
 AC ADJ64058;  
 XX 06-MAY-2004 (first entry)  
 DT Human beta-amyloid long form peptide fragment #4.  
 XX Amyloidogenic protein; therapy; amyloidosis;  
 KW familial amyloid polynuropathy; cardiomyopathy;  
 KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
 KW diabetes; insulinoma; myeloma; Sjogren's syndrome;

KW familial mediterranean fever; urticaria; deafness;  
KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
KW renal amyloidosis; lysozyme-associated hereditary systemic amyloidosis;  
KW beta-amyloid peptide; human.  
XX Homo sapiens.  
OS  
XX US2004005307-A1.  
XX  
XX PD 08-JAN-2004.  
XX  
XX PD 17-JUN-2003; 2003US-00463729.  
XX  
XX PR 14-MAR-1995; 95US-00404831.  
XX PR 07-JUN-1995; 95US-00475579.  
XX PR 27-OCT-1995; 95US-00548998.  
XX PR 14-MAR-1996; 96US-00617267.  
XX PR 04-OCT-2001; 2001US-00972475.  
XX  
XX (PRAE-) PRAECIS PHARM INC.  
XX  
XX PI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
XX  
XX DR WPI; 2004-131767/13.  
XX  
XX PT New amyloidogenic protein aggregation modulators useful for treating  
XX disorder associated with amyloidosis e.g. familial amyloid  
XX polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
XX  
XX PS Example 12; SEQ ID NO 7; 52pp; English.  
XX  
XX CC The invention relates to amyloidogenic proteins or peptide fragments  
XX aggregation modulators. The invention is used for treating disorder  
XX associated with amyloidosis, particularly familial amyloid polynuropathy  
XX (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
XX (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
XX scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
XX Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
XX insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
XX amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary  
XX localized cutaneous nodular amyloidosis associated with Sjogren's  
XX syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
XX and familial amyloid nephropathy with urticaria and deafness (Muckle-  
XX Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
XX Icelandic type, amyloidosis associated with long term haemodialysis,  
XX hereditary non-neuropathic systemic amyloidosis (familial amyloid  
XX polynuropathy III), familial amyloidosis of Finnish type, amyloidosis  
XX associated with medullary carcinoma of the thyroid, fibrinogen associated  
XX hereditary renal amyloidosis and lysozyme-associated hereditary systemic  
XX amyloidosis. The present sequence is beta-amyloid peptide fragment used  
XX in the exemplification of the invention.  
XX  
XX SQ Sequence 7 AA;  
  
XX Query Match 88.2%; Score 30; DB 8; Length 7;  
XX Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
XX Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
XX QY 1 KKLVPFA 7  
XX :|||||  
XX Db 1 OKLVFPFA 7  
  
XX RESULT 16  
XX ADQ37351  
XX ID ADQ37351 standard; peptide; 7 AA.  
XX AC  
XX ADQ37351;  
XX  
XX DT 07-OCT-2004 (first entry)  
XX  
XX DE Beta-amyloid modulator peptide.

XX amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; nootropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; uroepileptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
vaccine antigen.  
XX Synthetic.  
XX OS  
XX WO2004058239-A1.  
XX  
XX PD 15-JUL-2004.  
XX  
XX PF 24-DEC-2003; 2003WO-CA002021.  
XX  
XX PR 24-DEC-2002; 2002US-0436379P.  
XX PR 23-JUN-2003; 2003US-0482214P.  
XX  
XX (NEUR-) NEUROCHEM INT LTD.  
XX  
XX Gervais F, Bellini F;  
XX  
XX WPI; 2004-543342/52.  
XX  
XX PT Composition for treating e.g. Alzheimer's disease comprises first agent  
XX that prevents or treats amyloid-beta related disease and second agent  
XX that is either a peptide or peptidomimetic or an immune system modulator.  
XX  
XX PS Disclosure; Page 87; 143pp; English.  
XX  
XX CC The present invention describes compositions (C) comprising: (a) a first  
XX agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
XX a second agent (a2) that is: (i) a peptide or peptidomimetic that  
XX modulates amyloid-beta fibril formation or induces a prophylactic or  
XX therapeutic immune response against amyloid-beta fibril formation; or  
XX (ii) an immune system modulator that prevents or inhibits amyloid-beta  
XX fibril formation. Also described is a kit comprising (C). (C) have  
XX nootropic, neuroprotective, cerebroprotective, haemostatic,  
XX ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,  
XX uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
XX neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
XX and can be used as amyloid-beta fibril formation modulators, and as  
XX immune system modulators. (C) can be used for preventing or treating an  
XX amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
XX (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
XX mild-to-moderate cognitive impairment, vascular dementia, cerebral  
XX Down's syndrome, hereditary cerebral haemorrhage, senile dementia,  
XX degeneration, or a condition associated with Alzheimer's disease  
XX (including hypothyroidism, cerebrovascular disease, cardiovascular  
XX disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
XX aggression, or incontinence), a neurological condition (e.g. Huntington's  
XX disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
XX Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
XX with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
XX field deficits, incoordination, gait disturbance, transient ischaemic  
XX attack or stroke, transient alertness, attention deficit, frequent falls,  
XX syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
XX haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
XX damage), or a psychological condition (e.g. depression, delusions,  
XX illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
XX disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
XX ideation, depressed mood, irritability, anhedonia, social withdrawal, or

CC amyloidogenic proteins or peptides. The modulator compounds can be used in the treatment of disorders associated with amyloidosis, such as familial amyloid polyneuropathy, familial amyloid cardiomyopathy, isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset diabetes, insulinoma, familial Mediterranean fever, familial amyloid nephropathy with urticaria and deafness, hereditary cerebral haemorrhage and other types of amyloidosis. The modulators are also useful for the treatment of disorders associated with beta-amyloidosis, especially Alzheimer's disease

XX Sequence 7 AA;

Query Match 88.2%; Score 30; DB 8; Length 7;  
Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
Db 1 QKLVFPA 7

RESULT 17  
AAW02310  
ID AAW02310 standard; peptide; 8 AA.  
XX  
AC AAW02310;  
XX  
DT 02-MAY-1997 (first entry)  
XX  
DE Beta-amyloid modulator peptide #1.  
XX  
KW Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis; cerebral blood vessel; Alzheimer's disease; amyloidogenic protein; familial amyloid polyneuropathy; systemic senile amyloidosis; insulinoma; isolated cardiac amyloidosis; Creutzfeldt-Jakob disease; urticaria; bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; adult-onset diabetes; familial Mediterranean fever; therapy; deafness; scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.

XX Synthetic.  
XX  
XX WO9628471-A1.  
XX  
XX 19-SEP-1996.  
XX  
XX 14-MAR-1996; 96WO-US003492.  
XX  
XX 14-MAR-1995; 95US-00404831.  
XX  
XX 07-JUN-1995; 95US-00475579.  
XX  
XX 27-OCT-1995; 95US-00548998.  
XX  
XX (PHAR-) PHARM PEPTIDES INC.  
XX  
XX Findeis MA, Benjamin H, Garnick MB, Gelter ML, Hundal A, Kaaman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S, Kubasek W, Chin J, Lee J, Kelley M;  
XX  
XX WPI; 1996-433762/43.  
XX  
XX Modulators of amyloid aggregation - comprising, e.g. amyloidogenic protein coupled (indirectly) to at least 1 modifying gp., useful in treatment of Alzheimer's disease.  
XX  
XX Claim 16; Page 90; 106pp; English.

CC AAW02310-W02332 represent the peptide portions of the beta-amyloid modulator compounds of the invention. Beta-amyloid peptide is a 4 kilodalton peptide that is the major protein component of amyloid plaques. Amyloid plaques are present both in the brain lesions, and in the walls of cerebral blood vessels in Alzheimer's disease patients. The amyloid modulators of the invention comprise an amyloidogenic protein or peptide (such as this sequence) coupled directly or indirectly to at least one modifying group. The modifying group is preferably a cyclic, heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a biotin containing group, or a fluorescein containing group. These compounds then modulate the aggregation of these sequences to natural amyloid proteins or peptides when contacted with the natural

CC amyloidogenic proteins or peptides. The modulator compounds can be used in the treatment of disorders associated with amyloidosis, such as familial amyloid polyneuropathy, familial amyloid cardiomyopathy, isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset diabetes, insulinoma, familial Mediterranean fever, familial amyloid nephropathy with urticaria and deafness, hereditary cerebral haemorrhage and other types of amyloidosis. The modulators are also useful for the treatment of disorders associated with beta-amyloidosis, especially Alzheimer's disease

XX Sequence 8 AA;

Query Match 88.2%; Score 30; DB 2; Length 8;  
Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
Db 2 QKLVFPA 8

RESULT 18  
AAW89374  
ID AAW89374 standard; peptide; 8 AA.  
XX  
AC AAW89374;  
XX  
DT 02-MAR-1999 (first entry)  
XX  
DE Beta-amyloid peptide derivative A-beta-14-21.  
XX  
KW Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein; aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy; familial amyloid polyneuropathy; bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; BAP.

XX Homo sapiens.  
XX Synthetic.  
XX  
XX US5854204-A.  
XX  
XX 29-DEC-1998.  
XX  
XX 14-MAR-1996; 96US-00612785.  
XX  
XX 14-MAR-1995; 95US-00404831.  
XX  
XX 07-JUN-1995; 95US-00475579.  
XX  
XX 27-OCT-1995; 95US-00548998.  
XX  
XX (PRAE-) PRAECIS PHARM INC.  
XX  
XX Hundal A, Gelter ML, Kasman L, Musso G, Molineaux S, Benjamin H; Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J; Garnick MB, Kubasek W, Signer ER;  
XX  
XX WPI; 1999-094964/08.  
XX  
XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid aggregation - and neurotoxicity, specifically for treatment and prevention of Alzheimer's disease.  
XX  
XX Example 12; Col 64; 52pp; English.

CC The present invention describes beta-amyloid peptide (bap) derivatives. The bap derivatives inhibit aggregation of amyloidogenic proteins and peptides, specifically bap, and their neurotoxicity, so are useful for treating and preventing any disease involving amyloidosis, specifically Alzheimer's disease but also Down's syndrome, familial amyloid polyneuropathy or cardiomyopathy, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. The bap derivatives are also used to diagnose these diseases, in vitro or in vivo, by detecting binding of bap to labelled bap derivatives. Some bap derivatives inhibit bap aggregation

CC even when bAP is present in molar excess. The present sequence represents  
 CC a bAP derivative  
 XX  
 SQ Sequence 8 AA;

Query Match 88.2%; Score 30; DB 2; Length 8;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
 Db 2 QKLVFPA 8  
 :|||||

RESULT 19  
 ABG71005  
 ID ABG71005 standard; peptide; 8 AA.  
 XX  
 AC ABG71005;  
 XX  
 DT 05-DEC-2002 (first entry)  
 XX  
 DE Long form beta-amyloid protein fragment #2.  
 XX  
 KW Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polyneuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Strausler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2002098173-A1.  
 XX  
 XX 25-JUL-2002.  
 XX  
 XX 04-OCT-2001; 2001US-00972475.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 PR 14-MAR-1996; 96US-00617267.  
 XX  
 PA (PRAE-) PRAECIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 XX WPI; 2002-697709/75.  
 XX  
 PT Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX  
 PS Example 12; Page 35; 41pp; English.  
 XX  
 CC The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid polyneuropathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),  
 CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Strausler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localised cutaneous

CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polyneuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysozyme-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX  
 SQ Sequence 8 AA;

Query Match 88.2%; Score 30; DB 5; Length 8;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
 Db 2 QKLVFPA 8  
 :|||||

RESULT 20  
 ABB05153  
 ID ABB05153 standard; peptide; 8 AA.  
 XX  
 AC ABB05153;  
 XX  
 DT 02-APR-2002 (first entry)  
 XX  
 DE Beta amyloid peptide (14-21) SEQ ID NO:5.  
 XX  
 KW Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polyneuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX US6319498-B1.  
 XX  
 XX 20-NOV-2001.  
 XX  
 XX 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 XX WPI; 2002-146668/19.  
 XX  
 XX Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Disclosure; Col 18; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has neurotropic, neuroprotective, immunosuppressive, antimicrobial,



CC antidiabetic, antipyrretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences in patients with hereditary cerebral  
 CC Down's syndrome individuals and for treating a disorder associated with  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polynuropathy. (II) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention

XX Sequence 8 AA;  
 SQ Query Match 88.2%; Score 30; DB 5; Length 8;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 7  
 :|||||  
 Db 2 QKLVFFFA 8

RESULT 21  
 ADJ64056  
 ID ADJ64056 standard; peptide; 8 AA.  
 AC ADJ64056;  
 DT 06-MAY-2004 (first entry)  
 DE Human beta-amyloid long form peptide fragment #2.  
 XX  
 XX Amyloidogenic protein; therapy; amyloidosis;  
 KW familial amyloid polynuropathy; cardiomyopathy;  
 KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; Gerstmann-Straussler-Scheinker syndrome;  
 KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 KW familial mediterranean fever; urticaria; deafness;  
 KW hereditary cerebral hemorrhage; haemodialysis; thyroid;  
 KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 KW beta-amyloid peptide; human.

OS Homo sapiens.  
 XX US2004005307-A1.  
 XX 08-JAN-2004.  
 XX 17-JUN-2003; 2003US-00463729.  
 XX 14-MAR-1995; 95US-00404831.  
 XX 07-JUN-1995; 95US-00475379.  
 XX 27-OCT-1995; 95US-00548998.  
 XX 14-MAR-1996; 96US-00617267.  
 XX 04-OCT-2001; 2001US-00972475.  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX Findels MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kaeman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX WPI; 2004-131767/13.  
 XX New amyloidogenic protein aggregation modulators useful for treating  
 PT disorder associated with amyloidosis e.g. familial amyloid  
 PT polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
 XX Example 12; SEQ ID NO 5; 52pp; English.

CC The invention relates to amyloidogenic proteins or peptide fragments  
 CC aggregation modulators. The invention is used for treating disorder  
 CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 CC Gerstmann-Straussler-Scheinker syndrome, adult onset diabetes,  
 CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
 CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
 CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 CC polynuropathy III), familial amyloidosis of Finnish type, amyloidosis  
 CC associated with medullary carcinoma of the thyroid, fibrinogen associated  
 CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 CC in the exemplification of the invention.

XX Sequence 8 AA;

Query Match 88.2%; Score 30; DB 8; Length 8;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 7  
 :|||||  
 Db 2 QKLVFFFA 8

RESULT 22  
 ADQ37349  
 ID ADQ37349 standard; peptide; 8 AA.

AC ADQ37349;  
 XX 07-OCT-2004 (first entry)  
 DE Beta-amyloid modulator peptide.  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nootropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment; vascular dementia;  
 KW mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 XX vaccine antigen.

OS Synthetic.  
 XX WO2004058239-A1.  
 XX 15-JUL-2004.  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX 24-DEC-2002; 2002US-0436379P.  
 XX 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.  
 XX Gervais F, Bellini F;

DR WPI; 2004-543342/52.  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 XX that prevents or treats amyloid-beta related disease and second agent  
 XX that is either a peptide or peptidomimetic or an immune system modulator.  
 PT  
 PT  
 PT  
 XX  
 XX Disclosure; Page 87; 143pp; English.  
 XX  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiac, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a beta-  
 CC amyloid modulator peptide which is used in the exemplification of the  
 CC present invention.  
 XX  
 XX Sequence 8 AA;  
 SQ  
 Query Match 88.2%; Score 30; DB 8; Length 8;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVPFA 7  
 :|||||  
 Db 2 QKLVPFA 8  
 RESULT 23  
 AAR45239  
 ID AAR45239 standard; peptide; 9 AA.  
 XX  
 XX AAR45239;  
 XX  
 XX 20-JUN-1994 (first entry)  
 DT  
 XX Mutant amyloid precursor protein fragment.  
 DE  
 XX Amyloid precursor protein; APP; beta amyloid protein; BAP; detection;  
 KW Alzheimer's disease; Down's syndrome.  
 XX  
 XX Homo sapiens.  
 OS

PN AU9338358-A.  
 XX  
 XX 04-NOV-1993.  
 XX  
 XX 03-MAY-1993; 93AU-00038358.  
 XX  
 XX 01-MAY-1992; 92US-00877675.  
 XX  
 XX (AMCY ) AMERICAN CYANAMID CO.  
 PA  
 XX Vitek MP, Jacobsen JS;  
 PI  
 XX WPI; 1993-406194/51.  
 XX  
 XX N-PSDB; AAQ54267.  
 DR  
 XX New mutant forms of amyloid precursor protein - for detecting cpds. that  
 PT modify activity of enzymes involved in precursor cleavage, also new  
 PT nucleic acid encoding them.  
 PT  
 XX Disclosure; Page 35; 66pp; English.  
 PS  
 XX Recombinant polypeptides produced using the coding sequences of mutant  
 CC forms of amyloid precursor proteins comprising from the 5' to the 3' end  
 CC a sequence encoding a marker and either (1) a sequence encoding the N-  
 CC terminus of an amyloid precursor protein (APP) up to, but not including,  
 CC the nucleotides encoding the beta amyloid protein (BAP) domain or (2) the  
 CC BAP domain; or the two ligated together, can be used to detect drugs or  
 CC compounds that inhibit/augment the activity of proteolytic enzymes which  
 CC cleave APP to generate BAP fragments (deposition of which occurs in  
 CC patients with Alzheimers disease and Down's syndrome). This is a fragment  
 CC of amyloid precursor protein containing a mutation which is associated  
 CC with diseases involving BAP deposition  
 XX  
 XX Sequence 9 AA;  
 SQ  
 Query Match 88.2%; Score 30; DB 2; Length 9;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVPFA 7  
 :|||||  
 Db 1 QKLVPFA 7  
 RESULT 24  
 AAB48493  
 ID AAB48493 standard; peptide; 9 AA.  
 XX  
 XX AAB48493;  
 XX  
 XX 02-MAR-2001 (first entry)  
 DT  
 XX Antifibrillogenic peptide #20.  
 DE  
 XX Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.  
 XX  
 XX Homo sapiens.  
 OS  
 XX Key Location/Qualifiers  
 FH Modified-site 9  
 FT /note= "C-terminal amide"  
 XX  
 XX WO2000068263-A2.  
 PN  
 XX 16-NOV-2000.  
 PD  
 XX 04-MAY-2000; 2000WO-CA000515.  
 XX  
 XX 05-MAY-1999; 99US-0132592P.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA

CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)  
 XX  
 SQ Sequence 9 AA;  
 Query Match 88.2%; Score 30; DB 5; Length 9;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVFFA 7  
 :|||||  
 Db 3 QKLVFFA 9

RESULT 26  
 ABP57517  
 ID ABP57517 standard; peptide; 9 AA.  
 XX AC  
 XX ABP57517;  
 XX DT 28-APR-2003 (first entry)  
 XX DE Differentially isotopically labelled (DiMas) peptide #10.  
 XX KW Mass spectrometry; polymer; analysis; cleavage; substrate specificity;  
 XX KW isotope; protease.  
 XX OS Synthetic.  
 XX PN WO2003001206-A1.  
 XX PD 03-JAN-2003.  
 XX PF 25-JUN-2002; 2002WO-GB002921.  
 XX PR 26-JUN-2001; 2001GB-00015581.  
 XX PA (GLAX ) GLAXO GROUP LTD.  
 XX PI Mckeown SC;  
 XX WPI; 2003-184066/18.  
 XX Analyzing cleavage of polymer, by providing polymer sample, incubating  
 XX the sample with labeled isotope for cleavage at potential cleavage site,  
 XX and analyzing the masses of any uncleaved fragments by mass spectrometry.  
 XX Example 3; Page 26; 73pp; English.

CC The present invention describes a method (M1) for analysing cleavage of a  
 CC polymer. M1 comprises: (a) providing a sample of the polymer, a portion  
 CC of the polymer molecules having been labeled at a position on one side of  
 CC the potential cleavage site with a first isotopic label and a portion of  
 CC the polymer molecules having been labeled at a position on the opposite  
 CC side of the potential cleavage site with a second isotopic label; (b)  
 CC incubating the sample under conditions suitable for cleavage at the  
 CC potential cleavage site; and (c) analysing the mass(es) of any cleaved  
 CC fragments by mass spectrometry and thereby determining whether and/or  
 CC where cleavage has taken place. M1 is useful for analysing cleavage of a  
 CC polymer, where the polymer is a linear polymer, and comprises a peptide  
 CC or protein. Methods from the present invention can be used in discovering  
 CC new or improved synthetic substrates for both known and unknown enzymes,  
 CC e.g. enzymes identified from the human genome. The methods are also  
 CC useful to identify the sequence origin, and in screening methods to  
 CC identify new substrates for enzymes, in positional peptide scanning  
 CC libraries, in vivo/ex vivo/in vitro peptide, and in assaying methods  
 CC for oligonucleotide or peptide sequencing and in measuring differential

CC Chalifour R, Gervais F, Gupta A;  
 XX WPI; 2001-031852/04.  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 XX cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 XX its isomer or peptidomimetic.  
 XX Claim 7; Page 25; 46pp; English.  
 XX Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 XX for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 XX AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 XX useful for treating amyloidosis disorders such as Alzheimer's disease.  
 XX Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 XX binding region and the prot-prot interaction region of the human amyloid  
 XX protein  
 XX Sequence 9 AA;  
 Query Match 88.2%; Score 30; DB 4; Length 9;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVFFA 7  
 :|||||  
 Db 3 QKLVFFA 9

RESULT 25  
 AAU11667  
 ID AAU11667 standard; peptide; 9 AA.  
 XX AC  
 XX AAU11667;  
 XX DT 09-APR-2002 (first entry)  
 XX DE Peptide #20, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 XX CAA; neurotropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 XX KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX OS Synthetic.  
 XX Key Location/Qualifiers  
 XX Modified-site 9 /note= "C-terminal amide"  
 XX WO200185093-A2.  
 XX 15-NOV-2001.  
 XX 22-DEC-2000; 2000WO-IB002078.  
 XX 23-DEC-1999; 99US-0171877P.  
 XX (NEUR-) NEUROCHEM INC.  
 XX Green AM, Gervais F;  
 XX WPI; 2002-075222/10.  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 XX disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 XX inhibitor.  
 XX Disclosure; Page 10; 68pp; English.  
 XX The present invention relates to a new method of inhibiting cerebral  
 XX amyloid angiopathy. The new method of the invention involves contacting a  
 XX blood vessel wall cell with an amyloid-beta40 inhibitor. The invention

CC protein expression. The methods are useful for monitoring the cleavage of  
 CC polypeptides or polynucleotides, and for determining optimal polymer  
 CC substrates. ABP57505 to ABP57605 represent peptides used in the  
 CC exemplification of the present invention

XX Sequence 9 AA;

Query Match 88.2%; Score 30; DB 6; Length 9;  
 Best Local Similarity 85.7%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVPFA 7  
 :|||||  
 Db 3 QKLVPFA 9

RESULT 27

ABU79053  
 ID ABU79053 standard; peptide; 9 AA.

XX AC ABU79053;

XX DT 17-JUN-2003 (first entry)

XX DE Aggregation blocking peptide #5.

XX KW Amyloid formation; amyloid-like deposit; Alzheimer's disease;

XX KW pathological beta-sheet-rich conformation; Down's syndrome;

XX KW amyloidosis disorder; human prion disease; kuru; CJD;

XX KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome; GSS;

XX KW prion associated human neurodegenerative disease; animal prion disease;

XX KW scrapie; spongiform encephalopathy; transmissible mink encephalopathy;

XX KW chronic wasting disease.

XX OS Unidentified.

XX XX

XX FH US6462171-B1.

XX PN

XX FT 08-OCT-2002.

XX XX

XX PF 12-DEC-1996; 96US-00766596.

XX XX

XX PR 07-JUN-1995; 95US-00478326.

XX PR 10-APR-1996; 96US-00630645.

XX XX

XX PA (UUNY ) UNIV NEW YORK STATE.

XX XX

XX PI Soto-Jara C, Baumann MH, Frangione B;

XX XX

XX DR WPI; 2003-379012/36.

XX XX

XX PT Novel inhibitory peptides which inhibit and structurally block abnormal

XX PT folding of protein into amyloid or amyloid-like deposit and into

XX PT pathological beta-sheet rich conformation, useful for treating

XX PT Alzheimer's disease.

XX XX

XX PS Disclosure; Col 47-48; Sipp; English.

XX XX

CC The invention describes an isolated inhibitory peptide (I) which  
 CC interacts with a hydrophobic beta-sheet forming cluster of amino acid  
 CC residues on a protein or peptide for amyloid or amyloid-like deposit  
 CC formation, and inhibits or structurally blocks the abnormal folding of  
 CC proteins and peptides into amyloid or amyloid-like deposits and into  
 CC pathological beta-sheet-rich conformation. (I) is useful for disorders or  
 CC diseases associated with abnormal protein folding into amyloid or such  
 CC -like deposits or into pathological beta-sheet-rich precursors of amyloid  
 CC deposits, such as Alzheimer's disease, Down's syndrome, other amyloidosis  
 CC disorders, human prion diseases, such as kuru, Creutzfeldt-Jakob disease  
 CC (CJD), Gerstmann-Strausler-Scheinker syndrome (GSS), prion associated  
 CC human neurodegenerative diseases as well as animal prion diseases such as  
 CC scrapie, spongiform encephalopathy, transmissible mink encephalopathy and  
 CC chronic wasting disease of mule deer and elk. (I) is also useful for  
 CC detecting and diagnosing the presence or absence of amyloid or amyloid-

CC like deposits in vivo and its precursors. This is the amino acid sequence  
 CC of peptide associated with the inhibition of amyloid or amyloid like  
 CC deposits

XX SQ Sequence 9 AA;

Query Match 88.2%; Score 30; DB 6; Length 9;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFF 6  
 :|||||  
 Db 1 KKLVEFF 6

RESULT 28

AAE35436

ID AAE35436 standard; peptide; 9 AA.

XX AC AAE35436;

XX DT 17-JUN-2003 (first entry)

XX DE Abeta peptide #7.

XX KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;

XX KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;

XX KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;

XX KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neutropenic;

XX KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;

XX KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;

XX KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX OS Unidentified.

XX XX

XX FH Key Location/Qualifiers

XX FT Misc-difference 1. .9

XX FT /note= "D-form residues"

XX XX

XX PN WO200296937-A2.

XX XX

XX PD 05-DEC-2002.

XX XX

XX PF 29-MAY-2002; 2002WO-CA000763.

XX PR

XX PR 29-MAY-2001; 2001US-00867847.

XX XX

XX PA (NEUR-) NEUROCHEM INC.

XX XX

XX PI Gervais F, Hebert L, Chalifour RJ, Kong X;

XX XX

XX DR WPI; 2003-201269/19.

XX XX

XX PT Prevention and/or treatment of an amyloid-related disease e.g.

XX PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

XX XX

XX PS Claim 1; Page 58; 44pp; English.

XX XX

CC The invention relates to a method for prevention and/or treatment of an

CC amyloid-related disease which comprises administration of an all-D -

CC amyloid-beta peptide. The method is used for preventing and/or treating

CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid

CC angiopathy; for altering serum levels of amyloid-beta in a mammal and

CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from

CC the mammal; and reducing or inhibiting the formation of plaques. It is

CC also used for treating AA (reactive) amyloid diseases including

CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic

CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,

CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's

CC disease. AA deposits are also produced as a result of chronic microbial

CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus

CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).

CC Certain malignant neoplasms can also result in AA fibril amyloid deposits

CC

CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
CC present sequence is an Abeta peptide used to illustrate the method of the  
CC invention

XX SQ Sequence 9 AA;  
Query Match 88.2%; Score 30; DB 6; Length 9;  
Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
:|||||  
Db 3 QKLVEFA 9

RESULT 29  
ABW00187  
ID ABW00187 standard; peptide; 9 AA.  
XX AC ABW00187;  
XX DT 15-JAN-2004 (first entry)  
XX DE Peptide #5 used in the invention.  
XX KW Amyloid-like fibril deposit; prion related encephalopathy; gene therapy;  
XX KW Alzheimer's disease.  
XX OS Unidentified.  
XX PN US2003087407-A1.  
XX PD 08-MAY-2003.  
XX PF 06-SEP-2002; 2002US-00235483.  
XX PR 07-JUN-1995; 95US-00478326.  
XX PR 10-APR-1996; 96US-00630645.  
XX PR 12-DEC-1996; 96US-00766596.  
XX PA (UUNY ) UNIV NEW YORK STATE.  
XX PI Soto-Jara C, Baumann MH, Frangione B;  
XX DR WPI; 2003-616149/58.  
XX PT New inhibitory peptide, useful for preparing a composition for  
XX PT diagnosing, preventing or treating disorders associated with amyloid-like  
XX PT fibril deposits, e.g. Alzheimer's disease, or prion related  
XX PT encephalopathies.

XX PS Claim 1; Page 25; 52pp; English.  
XX SQ The invention relates to inhibitory peptide comprising a portion of at  
CC least three amino acid residues and a sequence predicted not to adopt a  
CC beta-sheet structure that associates with a hydrophobic beta-sheet  
CC cluster on a protein or peptide involved in the abnormal folding of the  
CC beta-sheet structure, to structurally block the abnormal folding of the  
CC protein or peptide. The inhibitory peptide is useful for preparing a  
CC composition for preventing, treating or detecting disorders or diseases  
CC associated with amyloid-like fibril deposits e.g. Alzheimer's disease and  
CC prion related encephalopathies. The invention is also useful in gene  
CC therapy. The present sequence is a peptide used in the invention

XX SQ Sequence 9 AA;  
Query Match 88.2%; Score 30; DB 7; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 6  
:|||||

Db 1 KKLVEFA 6  
RESULT 30  
ADI35874  
ID ADI35874 standard; peptide; 9 AA.  
XX AC ADI35874;  
XX DT 22-APR-2004 (first entry)  
XX DE Amyloid beta peptide SEQ ID NO:28.  
XX KW amyloid beta peptide; vaccine; immunisation; neuroprotective;  
XX KW Alzheimer's disease.  
XX OS Synthetic.  
XX PN WO2004006861-A2.  
XX PD 22-JAN-2004.  
XX PF 16-JUL-2003; 2003WO-US022280.  
XX PR 17-JUL-2002; 2002US-0396245P.  
XX PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.  
XX PI Chain DG, Fitzer-Attas C;  
XX DR WPI; 2004-122759/12.

XX PT New amyloid beta peptide, useful for preparing a composition for  
XX PT preventing the formation or progression of amyloid plaques for preventing  
XX PT or treating Alzheimer's disease.

XX PS Example 2; SEQ ID NO 28; 69pp; English.  
XX SQ The present invention describes an isolated amyloid beta peptide or its  
CC homologue which is selected by a method comprising: (a) determining the  
CC binding value of each amino acid of a subsequence of amyloid beta peptide  
CC upon binding to a HLA class I and/or class II molecule of interest; (b)  
CC determining the resulting score of all amino acids obtained in step (1); and  
CC based on the binding value of each amino acid to a preselected value. Also described:  
CC (c) comparing the resulting score to a preselected value. Also described:  
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier  
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;  
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a  
CC vaccine comprising a beta amyloid or homologue peptide to an individual,  
CC for immunisation of an individual based on the HLA haplotype of the  
CC individual; (5) a kit for matching a vaccine comprising amyloid beta  
CC peptide to an individual based on the HLA haplotype of the individual;  
CC and (6) preventing the formation or progression of amyloid plaques. The  
CC amyloid beta peptide has neuroprotective activity, and can be used in  
CC vaccines. The amyloid beta peptide is useful for preparing a composition  
CC for preventing the formation or progression of amyloid plaques for  
CC preventing or treating Alzheimer's disease. The present sequence  
CC represents an amyloid beta (Abeta) peptide, which is used in an example  
CC from the present invention.

XX SQ Sequence 9 AA;  
Query Match 88.2%; Score 30; DB 8; Length 9;  
Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
:|||||

Db 3 QKLVEFA 9

RESULT 31  
ADQ37260

ID ADQ37260 standard; peptide; 9 AA.  
 AC ADQ37260;  
 XX  
 DT 07-OCT-2004 (first entry)  
 DE Vaccine antigen amyloid-beta related amino acid sequence.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW anticholinergic; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..9 /note= "D-form residues"  
 FT  
 XX  
 PN WO2004058239-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX  
 PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 PI Gervais F, Bellini F;  
 XX  
 DR WPI; 2004-543342/52.  
 XX  
 PT Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 PS Disclosure; Page 67; 143pp; English.  
 XX  
 CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic, tranquilliser,  
 CC ophthalmological, anticholinergic, vasotropic, cardiovascular, muscular,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's

CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, anhedonia, social withdrawal, or  
 CC ideation, depressed mood, irritability, anhedonia, a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.  
 XX  
 SQ Sequence 9 AA;  
 Query Match 88.2%; Score 30; DB 8; Length 9;  
 Best Local Similarity 85.7%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KKLVFPA 7  
 DB 3 QKLVFPA 9  
 :|||||  
 RESULT 32  
 ADQ37332  
 ID ADQ37332 standard; peptide; 9 AA.  
 XX  
 AC ADQ37332;  
 XX  
 DT 07-OCT-2004 (first entry)  
 DE Antifibrillogenic amyloidosis inhibiting peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW anticholinergic; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 9 /note= "amidated"  
 FT  
 FT WO2004058239-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX  
 PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 PI Gervais F, Bellini F;  
 XX

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent

PI that prevents or treats amyloid-beta related disease and second agent

PT that is either a peptide or peptidomimetic or an immune system modulator.

XX

PS Disclosure; Page 70; 143pp; English.

XX

XX The present invention describes compositions (C) comprising: (a) a first

CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)

CC a second agent (a2) that is: (i) a peptide or peptidomimetic that

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC therapeutic immune response against amyloid-beta fibril formation; or

CC (ii) an immune system modulator that prevents or inhibits amyloid-beta

CC fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic,

CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,

CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, and

CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,

CC and can be used as amyloid-beta fibril formation modulators, and as

CC immune system modulators. (C) can be used for preventing or treating an

CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic

CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,

CC mild-to-moderate cognitive impairment, vascular dementia, senile dementia,

CC amyloid angiopathy, hereditary cerebral myelitis, age-related macular

CC Down's syndrome, inclusion body myositis, age-related macular

CC degeneration, or a condition associated with Alzheimer's disease

CC (including hypothyroidism, cerebrovascular disease, cardiovascular

CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,

CC aggression, or incontinence), a neurological condition (e.g. Huntington's

CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,

CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia

CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual

CC field deficits, incoordination, gait disturbance, transient ischaemic

CC attack or stroke, transient alertness, attention deficit, frequent falls,

CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural

CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic

CC damage), or a psychological condition (e.g. depression, delusions,

CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep

CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal

CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or

CC excessive guilt) in a subject e.g. human having a genomic mutation in an

CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;

CC having amyloid-beta deposits. The present sequence represents a peptide

CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide

CC in the exemplification of the present invention.

XX

SQ Sequence 9 AA;

Query Match 88.2%; Score 30; DB 8; Length 9;

Best Local Similarity 85.7%; Pred. No. 1.8e+06;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVFFA 7

Db 3 QKLVFFA 9

RESULT 33

AAB46226

ID AAB46226 standard; peptide; 10 AA.

XX AAB46226;

XX

XX 04-APR-2001 (first entry)

XX Human APP derived immunogenic peptide #22.

XX Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;

XX Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;

XX amyloid precursor protein; Alzheimer's disease.

XX Homo sapiens.

OS

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent

PI that prevents or treats amyloid-beta related disease and second agent

PT that is either a peptide or peptidomimetic or an immune system modulator.

XX

PS Disclosure; Page 70; 143pp; English.

XX

XX The present invention describes compositions (C) comprising: (a) a first

CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)

CC a second agent (a2) that is: (i) a peptide or peptidomimetic that

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC modulates amyloid-beta fibril formation or induces a prophylactic or

CC therapeutic immune response against amyloid-beta fibril formation; or

CC (ii) an immune system modulator that prevents or inhibits amyloid-beta

CC fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic,

CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,

CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, and

CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,

CC and can be used as amyloid-beta fibril formation modulators, and as

CC immune system modulators. (C) can be used for preventing or treating an

CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic

CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,

CC mild-to-moderate cognitive impairment, vascular dementia, senile dementia,

CC amyloid angiopathy, hereditary cerebral myelitis, age-related macular

CC Down's syndrome, inclusion body myositis, age-related macular

CC degeneration, or a condition associated with Alzheimer's disease

CC (including hypothyroidism, cerebrovascular disease, cardiovascular

CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,

CC aggression, or incontinence), a neurological condition (e.g. Huntington's

CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,

CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia

CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual

CC field deficits, incoordination, gait disturbance, transient ischaemic

CC attack or stroke, transient alertness, attention deficit, frequent falls,

CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural

CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic

CC damage), or a psychological condition (e.g. depression, delusions,

CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep

CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal

CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or

CC excessive guilt) in a subject e.g. human having a genomic mutation in an

CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;

CC having amyloid-beta deposits. The present sequence represents a peptide

CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide

CC in the exemplification of the present invention.

XX

SQ Sequence 10 AA;

Query Match 88.2%; Score 30; DB 4; Length 10;

Best Local Similarity 85.7%; Pred. No. 12;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVFFA 7

Db 2 QKLVFFA 8

RESULT 34

AAB46225

ID AAB46225 standard; peptide; 10 AA.

XX AAB46225;

XX

XX 04-APR-2001 (first entry)

XX Human APP derived immunogenic peptide #21.

XX Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;

XX Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;

XX amyloid precursor protein; Alzheimer's disease.

XX Homo sapiens.

XX WO200072880-A2.

XX 07-DEC-2000.

XX 26-MAY-2000; 2000WO-US014810.

XX 28-MAY-1999; 99US-00322289.

XX (NEUR-) NEURALAB LTD.

XX Schenk DB, Bard F, Vasquez NJ, Yednock T;

XX WPI; 2001-032104/04.

XX Preventing or treating a disease associated with amyloid deposits,

PT especially Alzheimer's disease, comprises administering amyloid specific

PT antibody.

XX Disclosure; Fig 19; 143pp; English.

XX This invention describes a novel method of preventing or treating a

CC disease associated with amyloid deposits of amyloid precursor protein

CC (APP) Abeta fragments in the brain of a patient, which comprises

CC administering to the patient: (a) an antibody that binds to Abeta, the

CC antibody binds to an amyloid deposit and induces a clearing response (Fc

CC receptor mediated phagocytosis) against it (b) a polypeptide containing

CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent

CC that induces an immunogenic response against residues 1-3 to 7-11 of

CC Abeta. The products of the invention have nootropic and neuroprotective

CC activity. The method is also useful for monitoring a course of treatment

CC being administered to a patient e.g. active and passive immunization. The

CC methods are useful for prophylactic and therapeutic treatment of

CC Alzheimer's disease

XX



XX WPI; 2001-032104/04.  
XX Preventing or treating a disease associated with amyloid deposits,  
PT especially Alzheimer's disease, comprises administering amyloid specific  
PT antibody.  
XX Disclosure; Fig 19; 143pp; English.  
XX This invention describes a novel method of preventing or treating a  
CC disease associated with amyloid deposits of amyloid precursor protein  
CC (APP) Abeta fragments in the brain of a patient, which comprises  
CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of  
CC Abeta. The products of the invention have neurotropic and neuroprotective  
CC activity. The method is also useful for monitoring a course of treatment  
CC being administered to a patient e.g. active and passive immunization. The  
CC methods are useful for prophylactic and therapeutic treatment of  
CC Alzheimer's disease  
XX  
SQ Sequence 10 AA;  
Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVPFA 7  
DB 3 OKLVPFA 9  
RESULT 35  
AAB46224  
ID AAB46224 standard; peptide; 10 AA.  
XX AC AAB46224;  
XX 04-APR-2001 (first entry)  
XX Human APP derived immunogenic peptide #20.  
XX Amyloid deposit; APP; Abeta; brain; human; clearing response; neurotropic;  
KW Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;  
KW amyloid precursor protein; Alzheimer's disease.  
XX Homo sapiens.  
XX WO200072880-A2.  
XX 07-DEC-2000.  
XX 26-MAY-2000; 2000WO-US014810.  
XX 28-MAY-1999; 99US-00322289.  
XX (NEUR-) NEURALAB LTD.  
XX Schenk DB, Bard F, Vasquez NJ, Yednock T;  
XX WPI; 2001-032104/04.  
XX Preventing or treating a disease associated with amyloid deposits,  
PT especially Alzheimer's disease, comprises administering amyloid specific  
PT antibody.  
XX Disclosure; Fig 19; 143pp; English.  
XX This invention describes a novel method of preventing or treating a  
CC disease associated with amyloid deposits of amyloid precursor protein  
CC (APP) Abeta fragments in the brain of a patient, which comprises  
CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of  
CC Abeta. The products of the invention have neurotropic and neuroprotective  
CC activity. The method is also useful for monitoring a course of treatment  
CC being administered to a patient e.g. active and passive immunization. The  
CC methods are useful for prophylactic and therapeutic treatment of  
CC Alzheimer's disease  
XX  
SQ Sequence 10 AA;  
Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVPFA 7  
DB 3 OKLVPFA 9

CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of  
CC Abeta. The products of the invention have neurotropic and neuroprotective  
CC activity. The method is also useful for monitoring a course of treatment  
CC being administered to a patient e.g. active and passive immunization. The  
CC methods are useful for prophylactic and therapeutic treatment of  
CC Alzheimer's disease  
XX  
SQ Sequence 10 AA;  
Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVPFA 7  
DB 4 OKLVPFA 10  
RESULT 36  
AAB46227  
ID AAB46227 standard; peptide; 10 AA.  
XX AC AAB46227;  
XX 04-APR-2001 (first entry)  
XX Human APP derived immunogenic peptide #23.  
XX Amyloid deposit; APP; Abeta; brain; human; clearing response; neurotropic;  
KW Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;  
KW amyloid precursor protein; Alzheimer's disease.  
XX Homo sapiens.  
XX WO200072880-A2.  
XX 07-DEC-2000.  
XX 26-MAY-2000; 2000WO-US014810.  
XX 28-MAY-1999; 99US-00322289.  
XX (NEUR-) NEURALAB LTD.  
XX Schenk DB, Bard F, Vasquez NJ, Yednock T;  
XX WPI; 2001-032104/04.  
XX Preventing or treating a disease associated with amyloid deposits,  
PT especially Alzheimer's disease, comprises administering amyloid specific  
PT antibody.  
XX Disclosure; Fig 19; 143pp; English.  
XX This invention describes a novel method of preventing or treating a  
CC disease associated with amyloid deposits of amyloid precursor protein  
CC (APP) Abeta fragments in the brain of a patient, which comprises  
CC administering to the patient: (a) an antibody that binds to Abeta, the  
CC antibody binds to an amyloid deposit and induces a clearing response (Fc  
CC receptor mediated phagocytosis) against it (b) a polypeptide containing  
CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent  
CC that induces an immunogenic response against residues 1-3 to 7-11 of  
CC Abeta. The products of the invention have neurotropic and neuroprotective  
CC activity. The method is also useful for monitoring a course of treatment  
CC being administered to a patient e.g. active and passive immunization. The  
CC methods are useful for prophylactic and therapeutic treatment of  
CC Alzheimer's disease  
XX  
SQ Sequence 10 AA;

us-10-009-122-2-rag

Wed Mar 9 08:15:51 2005

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

CC Chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
CC amyloidosis found in long-term haemodialysis patients  
XX  
SQ Sequence 10 AA;

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 3 QKLVEFA 9

RESULT 38  
AAU96829  
ID AAU96829 standard; peptide; 10 AA.  
XX  
AC AAU96829;  
XX  
DT 30-JUL-2002 (first entry)  
XX  
DE Amyloid targeting peptide #19.  
XX  
KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
KW transmissible cerebral amyloidosis; transmissible virus dementia;  
KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
KW bovine spongiform encephalopathy; inflammation associated amyloid;  
KW primary amyloidosis; feline spongiform encephalopathy;  
KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
KW dialysis-related amyloidosis; light chain-related amyloidosis;  
KW cerebral amyloid angiopathy.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1.10  
FT /note= "Preferably D-form residue"  
XX  
XX WO200207781-A2.  
XX  
XX 31-JAN-2002.  
XX  
XX 25-JUL-2001; 2001WO-CA001071.  
XX  
XX 25-JUL-2000; 2000US-0220808P.  
XX  
XX 24-JUL-2001; 2001US-00915092.  
XX  
XX (NEUR-) NEUROCHEM INC.  
XX  
XX Gervais F, Kong X, Chalifour R, Migneault D;  
XX  
XX WPI; 2002-371447/40.  
XX  
XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
XX plaques and/or for the treatment of amyloidosis disorders.  
XX  
XX Claim 49; Page 22; 57pp; English.  
XX  
XX The invention relates to an amyloid-targeting imaging agent comprising an  
XX amyloid targeting moiety, a linker moiety and a labelling moiety. The  
XX agent is of general formula A\_t-(A\_1)\_n-k-2-A\_1-a\_b (I) where z = 0 - 1;  
XX A\_t = an amyloid targeting moiety; A\_1)\_n-k = a linker moiety; and A\_1-a\_b  
XX = a labelling moiety. Also included are imaging amyloid deposition or  
XX diagnosing an amyloid-related condition in a patient involving  
XX administering (I) to the patient, and ultrasound imaging (I) in the  
XX patient to determine the presence of amyloid or amyloid-related condition  
XX ; and a kit for preparing a radiopharmaceutical preparation comprising  
XX (I), a reducing agent, a buffering agent, a transchelating agent, and  
XX instructions for the preparation and use of the radiopharmaceutical in  
XX the imaging of amyloid or an amyloid-related condition. The agents are  
XX used for imaging amyloid deposition and for diagnosing an amyloid related  
XX

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 3 QKLVEFA 9

RESULT 37  
AAB82641  
ID AAB82641 standard; peptide; 10 AA.  
XX  
AC AAB82641;  
XX  
DT 02-OCT-2001 (first entry)  
XX  
DE All-D peptide used in Alzheimer's disease vaccine.  
XX  
XX Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
XX therapy; antigen.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1.10  
FT /note= "all D-form residues"  
XX  
XX WO200139796-A2.  
XX  
XX 07-JUN-2001.  
XX  
XX 29-NOV-2000; 2000WO-CA001413.  
XX  
XX 29-NOV-1999; 99US-0168594P.  
XX  
XX 28-NOV-2000; 2000US-00724842.  
XX  
XX (NEUR-) NEUROCHEM INC.  
XX  
XX Chalifour R, Hebert L, Kong X, Gervais F;  
XX  
XX WPI; 2001-441458/47.  
XX  
XX Preventing/treating amyloid-related disease, especially Alzheimer's  
XX disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
XX which elicits production of antibodies to prevent fibrillogenesis and  
XX associated cellular toxicity.  
XX  
XX Disclosure; Page 11; 31pp; English.  
XX  
XX The present sequence is that of an all-D peptide suitable for use in  
XX preparing vaccines for preventing or treating Alzheimer's disease and  
XX other amyloid related disorders in humans. It is based on a portion of  
XX amyloid-beta peptide (see AAB82642), and may be modified by removing or  
XX inserting 1 or more amino acid residues, or by substituting 1 or more  
XX amino acid residues with other amino acid residues or non-amino acid  
XX fragments. Vaccines of the invention are produced using 'non-self'  
XX peptides synthesised from the unnatural D-configuration amino acids to  
XX avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
XX aggregated to be operative or immunogenic. They preferably interact with  
XX at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
XX GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
XX fragments, protein conjugates, immunogenic derivative peptides and  
XX immunogenic peptidomimetics. Examples include all-D peptides  
XX corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
XX 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
XX in AAB82643-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
XX preventing fibrillogenesis and associated cellular toxicity. The amyloid  
XX related diseases may be localised amyloidosis, e.g. diabetes type II,  
XX neurodegenerative diseases, e.g. bovine spongiform encephalitis, and  
XX Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
XX prion protein related disorders, or systemic amyloidosis associated with

CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
 CC cerebral amyloidosis (transmissible virus dementia), familial CJD,  
 CC scrapie, transmissible mink encephalopathy, bovine spongiform  
 CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
 CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
 CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
 CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
 CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
 CC barrier and are capable of binding specifically to amyloid plaques. The  
 CC present sequence is a peptide forming the amyloid targeting moiety of the  
 CC agent of the invention  
 XX Sequence 10 AA;  
 SQ

Query Match 88.2%; Score 30; DB 5; Length 10;  
 Best Local Similarity 85.7%; Pred. No. 12;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
 :|||||  
 Db 3 QKLVEFFA 9

RESULT 39  
 ABP57511  
 ID ABP57511 standard; peptide; 10 AA.  
 XX  
 AC ABP57511;

DT 28-APR-2003 (first entry)

XX Differentially isotopically labelled (DiMas) peptide #4.

XX Mass spectrometry; polymer; analysis; cleavage; substrate specificity;  
 KW isotope; protease.

XX Synthetic.

XX WO2003001206-A1.

XX 03-JAN-2003.

XX 25-JUN-2002; 2002WO-GB002921.

XX 26-JUN-2001; 2001GB-00015581.

XX (GLAXO) GLAXO GROUP LTD.

XX Mckewn SC;

XX WPI; 2003-184066/18.

XX Analyzing cleavage of polymer, by providing polymer sample, incubating  
 PT the sample with labeled isotope for cleavage at potential cleavage site,  
 PT and analyzing the masses of any uncleaved fragments by mass spectrometry.

PS Example 3; Page 22; 73pp; English.

XX The present invention describes a method (M1) for analysing cleavage of a  
 CC polymer. M1 comprises: (a) providing a sample of the polymer, a portion  
 CC of the polymer molecules having been labeled at a position on one side of  
 CC the potential cleavage site with a first isotopic label and a portion of  
 CC the polymer molecules having been labeled at a position on the opposite  
 CC side of the potential cleavage site with a second isotopic label; (b)  
 CC incubating the sample under conditions suitable for cleavage at the  
 CC potential cleavage site; and (c) analysing the mass(es) of any cleaved  
 CC fragments by mass spectrometry and thereby determining whether and/or  
 CC where cleavage has taken place. M1 is useful for analysing cleavage of a  
 CC polymer, where the polymer is a linear polymer, and comprises a peptide  
 CC or protein. Methods from the present invention can be used in discovering  
 CC new or improved synthetic substrates for both known and unknown enzymes,  
 CC e.g. enzymes identified from the human genome. The methods are also  
 CC useful to identify the sequence origin, and in screening methods to

CC identify new substrates for enzymes, in positional peptide scanning  
 CC libraries, in vivo/ex vivo/in vitro peptide, and in assaying methods  
 CC for oligonucleotide or peptide sequencing and in measuring differential  
 CC protein expression. The methods are useful for monitoring the cleavage of  
 CC polypeptides or polynucleotides, and for determining optimal polymer  
 CC substrates. ABP57505 to ABP57605 represent peptides used in the  
 CC exemplification of the present invention  
 XX Sequence 10 AA;  
 SQ

Query Match 88.2%; Score 30; DB 6; Length 10;  
 Best Local Similarity 85.7%; Pred. No. 12;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
 :|||||  
 Db 3 QKLVEFFA 9

RESULT 40

AAE35455

ID AAE35455 standard; peptide; 10 AA.

XX AAE35455;

DT 17-JUN-2003 (first entry)

XX Abeta peptide #26.

XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotrophic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX Unidentified.

XX Key Location/Qualifiers

FT Misc-difference 1..10 /note= "D-form residues"

XX WO200296937-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-CA000763.

XX 29-MAY-2001; 2001US-00867847.

XX (NEUR-) NEUROCHEM INC.

XX Gervais F, Hebert L, Chalifour RJ, Kong X;

XX WPI; 2003-201269/19.

XX Prevention and/or treatment of an amyloid-related disease e.g.

XX Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

XX Claim 1; Page 59; 44pp; English.

XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, Bechet's syndrome and Crohn's  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's

CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention  
 CC  
 CC Sequence 10 AA;  
 CC  
 CC Query Match 88.2%; Score 30; DB 6; Length 10;  
 CC Best Local Similarity 85.7%; Pred. NO. 12;  
 CC Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 CC  
 CC QY 1 KKLVEFFA 7  
 CC :|||||  
 CC Db 3 QKLVEFFA 9  
 CC  
 CC RESULT 41  
 CC ADQ37280  
 CC ID ADQ37280 standard; peptide; 10 AA.  
 CC AC  
 CC ADQ37280;  
 CC DT 07-OCT-2004 (first entry)  
 CC DE Vaccine antigen amyloid-beta related amino acid sequence.  
 CC  
 CC amyloid-beta; amyloid-beta related disease;  
 CC amyloid-beta fibril formation; immune response; neurotropic;  
 CC neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 CC antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 CC anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 CC cardiant; antidepressant; endocrine; hypnotic;  
 CC amyloid-beta fibril formation modulator; immune system modulator;  
 CC Alzheimer's disease; mild cognitive impairment;  
 CC mild-to-moderate cognitive impairment; vascular dementia;  
 CC cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 CC senile dementia; Down's syndrome; inclusion body myositis;  
 CC age-related macular degeneration; hypothyroidism;  
 CC cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 CC behavioural dysfunction; neurological condition; psychological condition;  
 CC vaccine antigen.  
 CC  
 CC Synthetic.  
 CC  
 CC Key Location/Qualifiers  
 CC Misc-difference 1..10 /note= "D-form residues"  
 CC  
 CC WO2004058239-A1.  
 CC  
 CC 15-JUL-2004.  
 CC  
 CC 24-DEC-2003; 2003WO-CA002021.  
 CC  
 CC 24-DEC-2002; 2002US-0436379P.  
 CC  
 CC 23-JUN-2003; 2003US-0482214P.  
 CC  
 CC (NEUR-) NEUROCHEM INT LTD.  
 CC  
 CC Gervais F, Bellini F;  
 CC  
 CC WPI; 2004-543342/52.  
 CC  
 CC Composition for treating e.g. Alzheimer's disease comprises first agent  
 CC that prevents or treats amyloid-beta related disease and second agent  
 CC that is either a peptide or peptidomimetic or an immune system modulator.  
 CC  
 CC Disclosure; Page 67; 143pp; English.

CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.

CC Sequence 10 AA;  
 CC  
 CC Query Match 88.2%; Score 30; DB 8; Length 10;  
 CC Best Local Similarity 85.7%; Pred. No. 12;  
 CC Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 CC  
 CC QY 1 KKLVEFFA 7  
 CC :|||||  
 CC Db 3 QKLVEFFA 9  
 CC  
 CC RESULT 42  
 CC ADQ37371  
 CC ID ADQ37371 standard; peptide; 10 AA.  
 CC AC  
 CC ADQ37371;  
 CC DT 07-OCT-2004 (first entry)  
 CC DE Amyloid-beta polymerisation peptide.  
 CC  
 CC amyloid-beta; amyloid-beta related disease;  
 CC amyloid-beta fibril formation; immune response; neurotropic;  
 CC neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 CC antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 CC anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 CC cardiant; antidepressant; endocrine; hypnotic;  
 CC amyloid-beta fibril formation modulator; immune system modulator;  
 CC Alzheimer's disease; mild cognitive impairment;  
 CC mild-to-moderate cognitive impairment; vascular dementia;  
 CC cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 CC senile dementia; Down's syndrome; inclusion body myositis;  
 CC age-related macular degeneration; hypothyroidism;  
 CC cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 CC behavioural dysfunction; neurological condition; psychological condition;  
 CC vaccine antigen.



aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; CC having amyloid-beta deposits. The present sequence represents an amyloid-beta polymersation peptide which is used in the exemplification of the present invention.

Sequence 10 AA;

Query Match 88.2%; Score 30; DB 8; Length 10;  
Best Local Similarity 85.7%; Pred. No. 12;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
Db 4 QKLVEFA 10

RESULT 44  
AAW32560  
ID AAW32560 standard; peptide; 11 AA.  
AC AAW32560;  
XX 21-JAN-1998 (first entry)  
XX Anti-amyloid peptide Abeta inhibiting abnormal protein folding.  
XX Anti-amyloid peptide; iAbeta; abnormal protein folding inhibitor;  
KW Alzheimer's disease; dementia; Down's syndrome; amyloidosis disorder;  
KW human prion disease; Kuru; Creutzfeldt-Jakob disease;  
KW Gerstmann-Strausler-Scheinker Syndrome; animal prion disease;  
KW prion associated human neurodegenerative disease; scrapie;  
KW spongiform encephalopathy; transmissible mink encephalopathy;  
KW chronic wasting disease; mule; deer; elk; human.  
XX Homo sapiens.  
OS Synthetic.  
XX WO9639834-A1.  
XX 19-DEC-1996.  
XX 06-JUN-1996; 96WO-US010220.  
XX 07-JUN-1995; 95US-00478326.  
XX 10-APR-1996; 96US-00630645.  
XX (UJNY ) UNIV NEW YORK STATE.  
XX Soto-Jara C, Baumann MH, Frangione B;  
XX WPI; 1997-051637/05.  
XX New inhibitors of fibrillogenesis proteins or peptides - used for  
XX preventing, treating or detecting amyloidosis disorders such as  
XX Alzheimer's disease.  
XX Example 1; Fig 9; 63pp; English.  
XX A method has been developed for the prevention or treatment of a disorder  
XX or disease associated with the formation of amyloid or amyloid-like

deposits, involving the abnormal folding of a protein or peptide. The method involves administering an inhibitory peptide which prevents the abnormal folding or which dissolves existing amyloid or amyloid-like deposits, where the peptide comprises a sequence of 3-15 amino acid residues and has a hydrophobic cluster of at least 3 amino acids, where at least one of the 3 amino acids is a beta-sheet blocking amino acid residue selected from Pro, Gly, Asn and His. The present sequence represents an anti-amyloid peptide, Abeta, which inhibits abnormal protein folding. The inhibitory peptide is capable of associating with a structural determinant on the protein or peptide to structurally block CC and inhibit the abnormal folding into amyloid or amyloid-like deposits. CC The method can be used for preventing, treating or detecting e.g. CC Alzheimer's dementia or disease, Down's syndrome, other amyloidosis disorders, human prion diseases such as Kuru, Creutzfeldt-Jakob disease, CC Gerstmann-Strausler-Scheinker Syndrome, prion associated human CC neurodegenerative diseases or animal prion diseases such as scrapie, CC spongiform encephalopathy, transmissible mink encephalopathy and chronic CC wasting disease of mule deer and elk

Sequence 11 AA;

Query Match 88.2%; Score 30; DB 2; Length 11;  
Best Local Similarity 85.7%; Pred. No. 13;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
Db 1 QKLVEFA 7

RESULT 45  
AAU99431  
ID AAU99431 standard; peptide; 11 AA.  
AC AAU99431;  
XX 07-OCT-2002 (first entry)  
XX Human amyloid beta-peptide (Iba6) helical segment.  
XX I-helical conformation; discordant helix; amyloid beta-peptide; I-helix;  
KW theta-strand structure; amyloidogenic disorder; Abeta; amyloidosis;  
KW Alzheimer's disease; prion disease; scrapie; BSE;  
KW bovine spongiform encephalopathy; Creutzfeld-Jacob disease; CJD;  
KW fibrillation; aggregation; neurotropic; neuroprotective; PDB;  
KW protein databank code; Iba6; human.  
XX Homo sapiens.  
OS WO200241002-A2.  
XX 23-MAY-2002.  
XX 20-NOV-2001; 2001WO-GB005117.  
XX 20-NOV-2000; 2000US-0253695P.  
XX 06-DEC-2000; 2000US-0251662P.  
XX (ALPH-) ALPHABETA AB.  
XX (WHIT/) WHITE M P.  
XX White MP, Johansson J;  
XX WPI; 2002-519389/55.  
XX Identifying compounds that stabilize I-helix of discordant helix in  
XX polypeptide, by measuring amount of I-helix in sample containing  
XX discordant helix-containing polypeptide in presence and absence of  
XX compound.  
XX Example 1; Fig 2A; 55pp; English.  
XX The present invention relates to a method of identifying a compound that

CC stabilises an I-helical conformation of a discordant helix in a  
 CC polypeptide, particularly amyloid beta-peptide (Abeta). The method  
 CC comprises providing a test sample comprising a polypeptide that contains  
 CC a discordant helix in the form of an I-helix, contacting the test sample  
 CC with a test compound and determining the rate of decrease in the amount  
 CC of I-helix or the amount of I-helix present in the test sample. The  
 CC method is useful for identifying a compound that stabilises an I-helical  
 CC conformation of a discordant helix in a polypeptide. Such compounds are  
 CC useful for decreasing the rate of formation of the beta-strand structures  
 CC between at least two discordant helix-containing polypeptides, and for  
 CC treating amyloidogenic disorders such as amyloidosis in Alzheimer's  
 CC disease, and prion diseases (e.g. scrapie, bovine spongiform  
 CC encephalopathy (BSE), Creutzfeldt-Jacob disease (CJD)). AAU99426-AAU99446  
 CC represent >9-residue discordant helical segments from various proteins  
 XX  
 SQ Sequence 11 AA;

Query Match 88.2%; Score 30; DB 5; Length 11;  
 Best Local Similarity 85.7%; Pred. No. 13;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
 :|||||  
 Db 1 QKLVFPA 7

RESULT 46  
 AA29504  
 ID AA29504 standard; peptide; 11 AA.  
 XX  
 AC AA29504;  
 XX  
 DT 27-JAN-2003 (first entry)  
 XX  
 DE Amyloid beta-protein related peptide #1.  
 XX  
 KW Metallopeptide; nontropic; amyloid beta-protein; Alzheimer's disease; AD;  
 KW Prion's disease; oxytocin; angiotensin; vasopressin; neuroprotective;  
 KW therapy; amyloid beta-protein related peptide.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200264734-A2.  
 XX  
 PD 22-AUG-2002.  
 XX  
 PF 19-DEC-2001; 2001WO-US050075.  
 XX  
 PR 19-DEC-2000; 2000US-0256842P.  
 PR 11-JUL-2001; 2001US-0304835P.  
 PR 04-OCT-2001; 2001US-0327835P.  
 XX  
 PA (PALA-) PALATIN TECHNOLOGIES INC.  
 XX  
 PI Sharma SD, Shi Y;  
 XX  
 DR WPI; 2002-740699/80.  
 XX  
 PT Determining secondary structure binding to desired targets within parent  
 PT polypeptides that bind to targets, by constructing and complexing  
 PT peptides to metal ions to form metallopeptides and screening the  
 PT metallopeptides.  
 XX  
 PS Claim 194; Page 98; 165pp; English.  
 XX  
 CC The invention relates to a method for identification and determination of  
 CC target-specific folding sites in peptides and proteins. The invention  
 CC also relates to a method for determining a secondary structure binding to  
 CC desired targets within parent polypeptides that bind to targets, by  
 CC constructing and complexing peptides to metal ions to form  
 CC metallopeptides and screening the metallopeptides. The method is useful  
 CC for determining secondary structure binding to desired target within  
 CC parent polypeptide with primary structure that binds to the target, where

CC the target of interest is a receptor, antibody, toxin, enzyme, hormone,  
 CC nucleic acid, intracellular protein domain of biological relevance or  
 CC extracellular protein domain of biological relevance. A library of  
 CC amyloid beta-protein related peptides is useful for the treatment of  
 CC Alzheimer's disease (AD). A library of peptides targeting vasopressin,  
 CC oxytocin or angiotensin receptor is useful for treating Prion's disease.  
 CC The present sequence is an amyloid beta-protein related peptide  
 XX  
 SQ Sequence 11 AA;

Query Match 88.2%; Score 30; DB 5; Length 11;  
 Best Local Similarity 85.7%; Pred. No. 13;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
 :|||||  
 Db 2 EKLVFPA 8

RESULT 47  
 ABU79013  
 ID ABU79013 standard; peptide; 11 AA.  
 XX  
 AC ABU79013;  
 XX  
 DT 17-JUN-2003 (first entry)  
 XX  
 DE Amyloidogenic Amyloid A peptide #3.  
 XX  
 KW Amyloid formation; amyloid-like deposit; Alzheimer's disease;  
 KW pathological beta-sheet-rich conformation; Down's syndrome;  
 KW amyloidosis disorder; human prion disease; kuru; CJD;  
 KW Creutzfeldt-Jacob disease; Gerstmann-Strausler-Scheinker syndrome; GSS;  
 KW prion associated human neurodegenerative disease; animal prion disease;  
 KW scrapie; spongiform encephalopathy; transmissible mink encephalopathy;  
 KW chronic wasting disease.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6462171-B1.  
 XX  
 PD 08-OCT-2002.  
 XX  
 PF 12-DEC-1996; 96US-00766596.  
 XX  
 PR 07-JUN-1995; 95US-00478326.  
 PR 10-APR-1996; 96US-00630645.  
 XX  
 PA (UANY ) UNIV NEW YORK STATE.  
 XX  
 PI Soto-Jara C, Baumann MH, Frangione B;  
 XX  
 DR WPI; 2003-379012/36.  
 XX  
 PT Novel inhibitory peptides which inhibit and structurally block abnormal  
 PT folding of protein into amyloid or amyloid-like deposit and into  
 PT pathological beta-sheet rich conformation, useful for treating  
 PT Alzheimer's disease.  
 XX  
 PS Disclosure; Fig 9; 51pp; English.  
 XX  
 CC The invention describes an isolated inhibitory peptide (I) which  
 CC interacts with a hydrophobic beta-sheet forming cluster of amino acid  
 CC residues on a protein or peptide for amyloid or amyloid-like deposit  
 CC formation, and inhibits or structurally blocks the abnormal folding of  
 CC proteins and peptides into amyloid or amyloid-like deposits and into  
 CC pathological beta-sheet-rich conformation. (I) is useful for disorders or  
 CC diseases associated with abnormal protein folding into amyloid or amyloid  
 CC -like deposits or into pathological beta-sheet-rich precursors of such  
 CC deposits, such as Alzheimer's disease, Down's syndrome, other amyloidosis  
 CC disorders, human prion diseases, such as kuru, Creutzfeldt-Jacob disease  
 CC (CJD), Gerstmann-Strausler-Scheinker syndrome (GSS), prion associated  
 CC human neurodegenerative diseases as well as animal prion diseases such as



CC scrapie, spongiform encephalopathy, transmissible mink encephalopathy and  
CC chronic wasting disease of mule deer and elk. (1) is also useful for  
CC detecting and diagnosing the presence or absence of amyloid or amyloid-  
CC like deposits in vivo and its precursors. This is the amino acid sequence  
CC of peptide associated with the inhibition of amyloid or amyloid like  
CC deposits  
XX  
SQ Sequence 11 AA;

Query Match 88.2%; Score 30; DB 6; Length 11;  
Best Local Similarity 85.7%; Pred. No. 13;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVSFA 7  
Db 1 QKLVSFA 7

RESULT 48  
ABR84683  
ID ABR84683 standard; peptide; 11 AA.  
XX  
AC ABR84683;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Aggrcanase-1 and -2 peptide substrate SEQ ID NO: 33.  
XX  
DE Human; truncated aggrcanase-1; aggrcanase-1; aggrcanase-2;  
XX  
KW metalloprotease; enzyme; substrate.  
XX  
OS Synthetic.

Key Location/Qualifiers  
FH modified\_site 1  
FT /note= "modified by Aedans"  
FT modified\_site 11  
FT /note= "modified by (Dabcy1)K-amide"  
XX WO2003062263-A2.  
XX  
XX 31-JUL-2003.

XX 15-JAN-2003; 2003WO-US001327.  
XX 16-JAN-2002; 2002US-00050200.  
XX (ORTH-) ORTHO MC NEIL PHARM INC.  
XX  
XX Fourie A, Karlsson L, Coles F;  
XX WPI; 2003-748002/70.  
XX

New peptides useful as aggrcanase substrates in assays for aggrcanase  
inhibitors comprise an aggrcanase cleavage site between a glutamic acid  
residue and a nonpolar or uncharged residue.

Example 2; Page 52; Opp; English.  
The present invention relates to peptides having an aggrcanase cleavage  
site between a glutamic acid residue on the N-terminal side and a  
nonpolar or uncharged residue on the C-terminal side, and capable of  
being cleavable by aggrcanase-1 and/or aggrcanase-2. The peptides are  
useful as aggrcanase substrates in high-throughput screening assays for  
aggrcanase inhibitors as potential therapeutic compounds. The present  
sequence is a peptide substrate of human aggrcanase-1 and -2 proteins  
SQ Sequence 11 AA;

Query Match 88.2%; Score 30; DB 7; Length 11;  
Best Local Similarity 85.7%; Pred. No. 13;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVSFA 7  
Db 5-QKLVSFA 11

RESULT 49  
ABW00147  
ID ABW00147 standard; peptide; 11 AA.  
XX  
AC ABW00147;  
XX  
DT 15-JAN-2004 (first entry)  
XX  
DE Amyloid-beta (Abeta) peptide.

XX Amyloid-like fibril deposit; prion related encephalopathy; gene therapy;  
XX Alzheimer's disease; amyloid-beta; Abeta.  
XX  
OS Unidentified.

XX US2003087407-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 06-SEP-2002; 2002US-00235483.  
XX  
PR 07-JUN-1995; 95US-00478326.  
PR 10-APR-1996; 96US-00630645.  
PR 12-DEC-1996; 96US-00766596.  
XX  
PA (UJNY) UNIV NEW YORK STATE.

XX Soto-Jara C, Baumann MH, Frangione B;  
XX WPI; 2003-616149/58.

XX New inhibitory peptide, useful for preparing a composition for  
diagnosing, preventing or treating disorders associated with amyloid-like  
fibril deposits, e.g. Alzheimer's disease, or prion related  
encephalopathies.  
XX  
PS Disclosure; Fig 9; 52pp; English.

The invention relates to inhibitory peptide comprising a portion of at  
least three amino acid residues and a sequence predicted not to adopt a  
beta-sheet structure that associates with a hydrophobic beta-sheet  
cluster on a protein or peptide involved in the abnormal folding of the  
beta-sheet structure, to structurally block the abnormal folding of the  
protein or peptide. The inhibitory peptide is useful for preparing a  
composition for preventing, treating or detecting disorders or diseases  
associated with amyloid-like fibril deposits e.g. Alzheimer's disease and  
prion related encephalopathies. The invention is also useful in gene  
therapy. The present sequence is amyloid-beta (Abeta) peptide. This  
peptide is used in the invention

Sequence 11 AA;

Query Match 88.2%; Score 30; DB 7; Length 11;  
Best Local Similarity 85.7%; Pred. No. 13;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVSFA 7  
Db 1 QKLVSFA 7

RESULT 50  
AAE35464  
ID AAE35464 standard; peptide; 12 AA.  
XX  
AC AAE35464;  
XX  
DT 17-JUN-2003 (first entry)



XX Abeta peptide #35.  
DE  
XX  
KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic;  
KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
XX  
OS Unidentified.  
XX  
XX  
XX Key Location/Qualifiers  
FH Misc-difference 7.12  
FT  
FT  
XX  
XX  
XX WO200296937-A2.  
PN  
XX  
XX 05-DEC-2002.  
PD  
XX  
XX 29-MAY-2002; 2002WO-CA000763.  
PF  
XX  
XX 29-MAY-2001; 2001US-00867847.  
PR  
XX  
XX (NEUR-) NEUROCHEM INC.  
PA  
XX  
XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
PI  
XX  
XX WPI; 2003-201269/19.  
DR  
XX  
XX Prevention and/or treatment of an amyloid-related disease e.g.  
PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
XX  
XX  
PS Claim 1; Page 61; 44pp; English.  
XX  
XX The invention relates to a method for prevention and/or treatment of an  
CC amyloid-related disease which comprises administration of an all-D -  
CC amyloid-beta peptide. The method is used for preventing and/or treating  
CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
CC the mammal; and reducing or inhibiting the formation of plaques. It is  
CC also used for treating AA (reactive) amyloid diseases including  
CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
CC disease. AA deposits are also produced as a result of chronic microbial  
CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
CC present sequence is an Abeta peptide used to illustrate the method of the  
CC invention  
XX  
SQ Sequence 12 AA;

Query Match 88.2%; Score 30; DB 6; Length 12;  
Best Local Similarity 85.7%; Pred. No. 14;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVPFA 7  
Db :|||||  
6 QKLVPFA 12

Search completed: March 9, 2005, 06:27:27  
Job time : 76.6027 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 18.6986 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-2  
Perfect score: 34  
Sequence: 1 KKLVEFFA 7

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/aaa/5A COMB.pep:\*  
2: /cgn2\_6/ptodata/1/aaa/5B COMB.pep:\*  
3: /cgn2\_6/ptodata/1/aaa/6A COMB.pep:\*  
4: /cgn2\_6/ptodata/1/aaa/6B COMB.pep:\*  
5: /cgn2\_6/ptodata/1/aaa/PTUS COMB.pep:\*  
6: /cgn2\_6/ptodata/1/aaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	34	100.0	7	4	US-09-747-408-2
2	34	100.0	9	4	US-08-766-596A-64
3	34	100.0	34	2	US-08-475-579A-4
4	30	88.2	6	3	US-09-242-724-33
5	30	88.2	7	2	US-08-612-785B-7
6	30	88.2	7	3	US-08-703-675C-30
7	30	88.2	7	3	US-08-617-267C-7
8	30	88.2	8	2	US-08-612-785B-5
9	30	88.2	8	3	US-08-703-675C-28
10	30	88.2	8	3	US-08-617-267C-5
11	30	88.2	9	4	US-08-766-596A-54
12	30	88.2	9	4	US-09-747-408-20
13	30	88.2	10	4	US-09-724-961-20
14	30	88.2	10	4	US-09-724-961-21
15	30	88.2	10	4	US-09-724-961-22
16	30	88.2	10	4	US-09-724-961-23
17	30	88.2	10	4	US-09-580-018-20
18	30	88.2	10	4	US-09-580-018-21
19	30	88.2	10	4	US-09-580-018-22
20	30	88.2	10	4	US-09-580-018-23
21	30	88.2	10	4	US-09-724-551-20
22	30	88.2	10	4	US-09-724-551-21
23	30	88.2	10	4	US-09-724-551-22
24	30	88.2	10	4	US-09-724-551-23
25	30	88.2	11	2	US-08-630-645-14
26	30	88.2	11	4	US-08-766-596A-14
27	30	88.2	11	4	US-09-988-842-9

28	30	88.2	11	4	US-09-988-842-25
29	30	88.2	11	5	PCT-US96-10220-14
30	30	88.2	14	4	US-09-594-366-5
31	30	88.2	15	2	US-08-612-785B-37
32	30	88.2	15	4	US-08-766-596A-56
33	30	88.2	15	4	US-08-766-596A-57
34	30	88.2	15	4	US-08-766-596A-60
35	30	88.2	15	4	US-08-766-596A-61
36	30	88.2	15	4	US-08-766-596A-63
37	30	88.2	15	4	US-08-766-596A-65
38	30	88.2	17	3	US-09-264-709A-2
39	30	88.2	17	4	US-09-594-366-3
40	30	88.2	19	3	US-08-970-833-11
41	30	88.2	19	4	US-09-723-384-5
42	30	88.2	19	4	US-09-724-551-75
43	30	88.2	19	4	US-09-724-552-5
44	30	88.2	19	4	US-09-580-018-75
45	30	88.2	19	4	US-09-723-927-5
46	30	88.2	19	4	US-09-724-489-5
47	30	88.2	19	4	US-09-724-477-5
48	30	88.2	19	4	US-09-723-762-5
49	30	88.2	19	4	US-09-201-430-5
50	30	88.2	19	4	US-09-724-551-75
51	30	88.2	19	4	US-10-815-353-5
52	30	88.2	19	4	US-10-816-529-5
53	30	88.2	20	3	US-08-970-833-10
54	30	88.2	26	1	US-08-304-585-7
55	30	88.2	26	1	US-08-346-849-4
56	30	88.2	28	1	US-08-302-808-7
57	30	88.2	28	2	US-08-609-090-2
58	30	88.2	28	2	US-08-986-948-7
59	30	88.2	28	2	US-08-293-284A-4
60	30	88.2	28	2	US-08-461-216-2
61	30	88.2	28	3	US-09-388-890-2
62	30	88.2	28	3	US-09-388-890-3
63	30	88.2	28	3	US-09-388-890-4
64	30	88.2	28	3	US-09-388-890-5
65	30	88.2	28	3	US-09-388-890-6

ALIGNMENTS

RESULT 1  
US-09-747-408-2  
; Sequence 2, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-2

Query Match 100.0%; Score 34; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

Wed Mar 9 08:15:52 2005

us-10-009-122-2-rai

```

RESULT 2
US-08-766-596A-64
; Sequence 64, Application US/08766596A
; Patent No. 6462171
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMILOID OR AMYLOID-LIKE
; TITLE OF INVENTION: DEPOSITS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766,596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-766-596A-64

Query Match 100.0%; Score 34; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
DB 1 KKLVEFA 7

RESULT 3
US-08-475-579A-4
; Sequence 4, Application US/08475579A
; Patent No. 5854215
; GENERAL INFORMATION:
; APPLICANT: Mark A. Findeis et al.
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "symbol"}-Amyloid Peptide Aggrega
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street
; CITY: Boston

```

```

STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,579A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/404,831
FILING DATE: 14-MAR-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kara, Catherine J.
REGISTRATION NUMBER: P41,106
REFERENCE/DOCKET NUMBER: PPI-002CP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)742-4214
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 34 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
US-08-475-579A-4

Query Match 100.0%; Score 34; DB 2; Length 34;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
DB 9 KKLVEFA 15

RESULT 4
US-09-242-724-33
; Sequence 33, Application US/09242724
; Patent No. 6316405
; GENERAL INFORMATION:
; APPLICANT: Solomon, Michael E.
; APPLICANT: Rich, Daniel H.
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor
; FILE REFERENCE: Cyclosporin Analogs
; CURRENT APPLICATION NUMBER: US/09/242,724
; CURRENT FILING DATE: 1999-02-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 33
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: polypeptide
US-09-242-724-33

Query Match 88.2%; Score 30; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEF 6
DB 1 KKLVEF 6

RESULT 5

```

```
US-08-612-785B-7
; Sequence 7, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid
; TITLE OF INVENTION: Aggregation
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,785B
; FILING DATE: Herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-612-785B-7

Query Match 88.2%; Score 30; DB 2; Length 7;
Best Local Similarity: 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7
Db 1 QKLVFPA 7

RESULT 6
US-08-703-675C-30
; Sequence 30, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 14-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-30

Query Match 88.2%; Score 30; DB 3; Length 7;
Best Local Similarity: 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7
Db 1 QKLVFPA 7

RESULT 7
US-08-617-267C-7
; Sequence 7, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-30
```

```
US-08-612-785B-7
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-30

Query Match 88.2%; Score 30; DB 3; Length 7;
Best Local Similarity: 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7
Db 1 QKLVFPA 7

RESULT 7
US-08-617-267C-7
; Sequence 7, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-30
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-617-267C-7

Query Match      88.2%; Score 30; DB 3; Length 7;
Best Local Similarity 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVEFFA 7
        :|||||
Db      1 QKLVEFFA 7

RESULT 8
US-08-612-785B-5
; Sequence 5, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,785B
; FILING DATE: Herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

US-08-612-785B-5
; Sequence 5, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Aggregation
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,785B
; FILING DATE: Herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

US-08-612-785B-5
; Sequence 5, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-28

Query Match      88.2%; Score 30; DB 3; Length 8;
Best Local Similarity 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVEFFA 7
        :|||||
Db      2 QKLVEFFA 8

RESULT 9
US-08-703-675C-28
; Sequence 28, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-28

Query Match      88.2%; Score 30; DB 3; Length 8;
Best Local Similarity 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVEFFA 7
        :|||||
Db      2 QKLVEFFA 8

RESULT 10
```

```

? COUNTRY: USA
? ZIP: 20004
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC-DOS/MS-DOS
? SOFTWARE: PatentIn Release #1.0, Version #1.30
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/766,596A
? FILING DATE:
? CLASSIFICATION: 435
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/630,645
? FILING DATE: 10-APR-1996
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/478,326
? FILING DATE: 06-JUN-1995
? ATTORNEY/AGENT INFORMATION:
? NAME: YUN, Allen C.
? REGISTRATION NUMBER: 37,971
? REFERENCE/DOCKET NUMBER: SOTO-JARA=1A
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 202-628-5197
? TELEFAX: 202-737-3528
? INFORMATION FOR SEQ ID NO: 54:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 9 amino acids
? TYPE: amino acid
? STRANDEDNESS: single
? TOPOLOGY: linear
? MOLECULE TYPE: peptide
? US-08-766-596A-54
?
? Query Match 88.2%; Score 30; DB 4; Length 9;
? Best Local Similarity 100.0%; Pred. No. 4.1e+05;
? Matches 6; Conservative 0; Mismatches 0; Indels
?
Qy 1 KKLVEFF 6
Db 1 KKLVEFF 6
?
RESULT 12
US-09-747-408-20
? Sequence 20, Application US/09747408
? Patent No. 6670399
? GENERAL INFORMATION:
? APPLICANT: Green, Allan M.
? APPLICATOR: Gervais, Francine
? TITLE OF INVENTION: Compounds And Methods For Modulating
? TITLE OF INVENTION: Cerebral Amyloid Angiopathy
? FILE REFERENCE: NEI-088
? CURRENT APPLICATION NUMBER: US/09/747,408
? CURRENT FILING DATE: 2000-12-22
? PRIOR APPLICATION NUMBER: 60/171,877
? PRIOR FILING DATE: 1999-12-23
? NUMBER OF SEQ ID NOS: 24
? SOFTWARE: FASTSEQ for Windows Version 4.0
? SEQ ID NO 20
? LENGTH: 9
? TYPE: PRT
? ORGANISM: Homo sapiens
? US-09-747-408-20
?
? Query Match 88.2%; Score 30; DB 4; Length 9;
? Best Local Similarity 85.7%; Pred. No. 4.1e+05;
? Matches 6; Conservative 1; Mismatches 0; Indels
?
Qy 1 KKLVEFF 7
Db 3 QKLVEFF 9

```

us-10-009-122-2.ra1

Wed Mar 9 08:15:52 2005

```
RESULT 13
US-09-724-961-20
; Sequence 20, Application US/09724961
; Patent No. 6743427
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; OTHER INFORMATION: peptide)
US-09-724-961-20
Query Match 88.2%; Score 30; DB 4; Length 10;
Best Local Similarity 85.7%; Pred. No. 4.6;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVEFFA 7
Db 3 QKLVEFFA 9
RESULT 14
US-09-724-961-21
; Sequence 21, Application US/09724961
; Patent No. 6743427
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; OTHER INFORMATION: peptide)
US-09-724-961-21
Query Match 88.2%; Score 30; DB 4; Length 10;
Best Local Similarity 85.7%; Pred. No. 4.6;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVEFFA 7
Db 4 QKLVEFFA 10
RESULT 15
US-09-724-961-22
; Sequence 22, Application US/09724961
; Patent No. 6743427
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; OTHER INFORMATION: peptide)
US-09-724-961-22
Query Match 88.2%; Score 30; DB 4; Length 10;
Best Local Similarity 85.7%; Pred. No. 4.6;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVEFFA 7
Db 2 QKLVEFFA 8
RESULT 16
US-09-724-961-23
; Sequence 23, Application US/09724961
; Patent No. 6743427
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
; OTHER INFORMATION: peptide)
US-09-724-961-23
Query Match 88.2%; Score 30; DB 4; Length 10;
Best Local Similarity 85.7%; Pred. No. 4.6;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 KKLVEFFA 7
Db 2 QKLVEFFA 8
```



; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
US-09-724-961-23

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
:|||||  
Db 1 QKLVFPA 7

RESULT 17  
US-09-580-018-20  
; Sequence 20, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-20

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
:|||||  
Db 4 QKLVFPA 10

RESULT 18  
US-09-580-018-21  
; Sequence 21, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-21

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
:|||||  
Db 3 QKLVFPA 9

RESULT 19  
US-09-580-018-22  
; Sequence 22, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-22

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
:|||||  
Db 2 QKLVFPA 8

RESULT 20  
US-09-580-018-23  
; Sequence 23, Application US/09580018

Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-23

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
:|||||  
Db 1 QKLVEFFA 7

RESULT 21  
US-09-724-551-20  
; Sequence 20, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-20

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
:|||||  
Db 4 QKLVEFFA 10

RESULT 22  
US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637

GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-21

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
:|||||  
Db 3 QKLVEFFA 9

RESULT 23  
US-09-724-551-22  
; Sequence 22, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-22

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
:|||||  
Db 2 QKLVEFFA 8

RESULT 24  
US-09-724-551-23  
; Sequence 23, Application US/09724551

Patent No. 6787637  
GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Yednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004760US  
CURRENT APPLICATION NUMBER: US/09/724,551  
CURRENT FILING DATE: 2000-11-28  
PRIOR APPLICATION NUMBER: US/09/580,018  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: Patent in Ver. 2.1  
SEQ ID NO 23  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: 10-mer peptide  
OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
OTHER INFORMATION: peptide)  
US-09-724-551-23

Query Match 88.2%; Score 30; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 4.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 QKLVEFA 7

RESULT 25  
US-08-630-645-14  
Sequence 14, Application US/08630645  
Patent No. 5948763  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-630-645-14

Query Match 88.2%; Score 30; DB 2; Length 11;  
Best Local Similarity 85.7%; Pred. No. 5;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 QKLVEFA 7

RESULT 26  
US-08-766-596A-14  
Sequence 14, Application US/08766596A  
Patent No. 6462171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
TITLE OF INVENTION: DEPOSITS  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-14

Query Match 88.2%; Score 30; DB 4; Length 11;  
Best Local Similarity 85.7%; Pred. No. 5;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7

```

PCT-US96-10220-14
; Sequence 14, Application PC/TUS9610220
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10220
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US96-10220-14

Query Match 88.2%; Score 30; DB 5; Length 11;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 1 QKLVEFA 7

RESULT 30
US-09-594-366-5
; Sequence 5, Application US/09594366
; Patent No. 6582945
; GENERAL INFORMATION:
; APPLICANT: Raso, Victor
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO
; FILE REFERENCE: BBRI-2004
; CURRENT APPLICATION NUMBER: US/09/594,366
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/139,408
; PRIOR FILING DATE: 1999-08-16
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 5
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-594-366-5

US-09-988-842-9
; Sequence 9, Application US/09988842
; Patent No. 6716589
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT APPLICATION NUMBER: US/09/988,842
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
; US-09-988-842-9

Query Match 88.2%; Score 30; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 1 QKLVEFA 7

RESULT 28
US-09-988-842-25
; Sequence 25, Application US/09988842
; Patent No. 6716589
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT APPLICATION NUMBER: US/09/988,842
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
; US-09-988-842-25

Query Match 88.2%; Score 30; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 1 QKLVEFA 7

RESULT 29

```

Query Match 88.2%; Score 30; DB 4; Length 14;  
Best Local Similarity 85.7%; Pred. No. 6.2;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVPFA 7  
Db 3 QKLVPFA 9

## RESULT 31

US-08-612-785B-37  
Sequence 37, Application US/08612785B  
Patent No. 5854204

GENERAL INFORMATION:  
APPLICANT: FINDELS, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith

CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995

ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503

REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELEPHONE: (617) 227-7400  
TELEFAX: (617) 742-4214

INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid

TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal

US-08-612-785B-37

Query Match 88.2%; Score 30; DB 2; Length 15;  
Best Local Similarity 85.7%; Pred. No. 6.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVPFA 7  
Db 5 QKLVPFA 11

## RESULT 32

US-08-766-596A-56  
Sequence 56, Application US/08766596A  
Patent No. 6462171

GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995

ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A

TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 56:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid

STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-56

Query Match 88.2%; Score 30; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 6.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVPFA 7  
Db 4 QKLVPFA 10

RESULT 33  
US-08-766-596A-57  
Sequence 57, Application US/08766596A  
Patent No. 6462171

GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas

TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington

us-10-009-122-2-rai

Wed Mar 9 08:15:52 2005

```

; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766.596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 60:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-766-596A-60

Query Match 88.2%; Score 30; DB 4; Length 15;
Best Local Similarity 85.7%; Pred. No. 6.6;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVFFA 7
Db 4 QKLVFFA 10

US-08-766-596A-61
; Sequence 61, Application US/08766596A
; Patent No. 6462171
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; TITLE OF INVENTION: DEPOSITS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766.596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 61:

```

SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-61

Query Match 88.2%; Score 30; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 6.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 4 QKLVEFA 10

RESULT 36  
US-08-766-596A-63  
; Sequence 63, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-63

Query Match 88.2%; Score 30; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 6.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7

DB 4 QKLVEFA 10

RESULT 37  
US-08-766-596A-65  
; Sequence 65, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 65:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-65

Query Match 88.2%; Score 30; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 6.6;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 4 QKLVEFA 10

RESULT 38  
US-09-264-709A-2  
; Sequence 2, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; TITLE OF INVENTION: Improve the Quality of Life  
; FILE REFERENCE: 2124-310

us-10-009-122-2-rai

Wed Mar 9 08:15:52 2005

```

; CURRENT APPLICATION NUMBER: US/09/264.709A
; CURRENT FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: 08/797,782
; PRIOR FILING DATE: 1997-02-07
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-264-709A-2

Query Match      88.2%; Score 30; DB 3; Length 17;
Best Local Similarity 85.7%; Pred. No. 7.4;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      4 QKLVFPA 10

RESULT 39
US-09-594-366-3
; Sequence 3, Application US/09594366
; Patent No. 6582945
; GENERAL INFORMATION:
; APPLICANT: Raso, Victor
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO
; FILE REFERENCE: BBRI-2004
; CURRENT APPLICATION NUMBER: US/09/594,366
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/139,408
; PRIOR FILING DATE: 1999-06-16
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-594-366-3

Query Match      88.2%; Score 30; DB 4; Length 17;
Best Local Similarity 85.7%; Pred. No. 7.4;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      7 QKLVFPA 13

RESULT 40
US-08-970-833-11
; Sequence 11, Application US/08970833
; Patent No. 6022859
; GENERAL INFORMATION:
; APPLICANT: Kiesel, Laura L.
; APPLICANT: Murphy, Regina M.
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Charles & Brady
; STREET: 411 East Wisconsin Avenue
; CITY: Milwaukee
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53202-4497
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,833

```

```

; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Baker, Jean C.
; REGISTRATION NUMBER: 35,433
; REFERENCE/DOCKET NUMBER: 960296.94291
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (414) 277-5709
; TELEFAX: (414) 271-3552
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-970-833-11

Query Match      88.2%; Score 30; DB 3; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      9 QKLVFPA 15

RESULT 41
US-09-723-384-5
; Sequence 5, Application US/09723384
; Patent No. 6710226
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004740US
; CURRENT APPLICATION NUMBER: US/09/723,384
; CURRENT FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Abeta13-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; NAME/KEY: MOD RES
; LOCATION: (1)
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-723-384-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      3 QKLVFPA 9

RESULT 42
US-09-724-961-75
; Sequence 75, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted

```



```
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta 13-28
; OTHER INFORMATION: peptide with two Gly residues added and inserted
; OTHER INFORMATION: Cys residue
; NAME/KEY: MOD_RES
; LOCATION: (1)
; OTHER INFORMATION: Xaa = N-acetyl His
US-09-724-961-75

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
        :|||||
Db      3 QKLVEFFA 9

RESULT 43
US-09-724-552-5
; Sequence 5, Application US/09724552
; Patent No. 6750324
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004740US
; CURRENT APPLICATION NUMBER: US/09/724,552
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,019A
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (1)
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-724-552-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
        :|||||
Db      3 QKLVEFFA 9

RESULT 44
US-09-580-018-75
; Sequence 75, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta 13-28
; OTHER INFORMATION: peptide with two Gly residues added and inserted
; OTHER INFORMATION: Cys residue
; NAME/KEY: MOD_RES
; LOCATION: (1)
; OTHER INFORMATION: Xaa = N-acetyl His
US-09-580-018-75

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVEFFA 7
        :|||||
Db      3 QKLVEFFA 9

RESULT 45
US-09-723-927-5
; Sequence 5, Application US/09723927
; Patent No. 6787138
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004720US
; CURRENT APPLICATION NUMBER: US/09/723,927
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; FEATURE:
```

```
; NAME/KEY: MOD_RES
; LOCATION: (1)_
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-723-927-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 3 QKLVEFA 9

RESULT 46
US-09-724-489-5
; Sequence 5, Application US/09724489
; Patent No. 6787140
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004720US
; CURRENT APPLICATION NUMBER: US/09/724,489
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abetal3-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; NAME/KEY: MOD_RES
; LOCATION: (1)_
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-724-489-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 3 QKLVEFA 9

RESULT 47
US-09-724-477-5
; Sequence 5, Application US/09724477
; Patent No. 6787143
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004720US
; CURRENT APPLICATION NUMBER: US/09/724,477
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abetal3-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; NAME/KEY: MOD_RES
; LOCATION: (1)_
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-724-477-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 3 QKLVEFA 9

RESULT 48
US-09-723-762-5
; Sequence 5, Application US/09723762
; Patent No. 6787144
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004720US
; CURRENT APPLICATION NUMBER: US/09/723,762
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abetal3-28
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue
; OTHER INFORMATION: inserted and two added Gly residues
; NAME/KEY: MOD_RES
; LOCATION: (1)_
; OTHER INFORMATION: Xaa = acetyl histidine
US-09-723-762-5

Query Match      88.2%; Score 30; DB 4; Length 19;
Best Local Similarity 85.7%; Pred. No. 8.2;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7
Db 3 QKLVEFA 9

RESULT 49
US-09-201-430-5
; Sequence 5, Application US/09201430
; Patent No. 6787523
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Neuralab Limited
```

; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease

; FILE REFERENCE: 15270J-004720US  
; CURRENT APPLICATION NUMBER: US/09/201,430  
; CURRENT FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 19  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28  
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue  
; OTHER INFORMATION: inserted and two added Gly residues  
; NAME/KEY: MOD\_RES  
; LOCATION: (1)  
; OTHER INFORMATION: Xaa = acetyl histidine  
; OTHER INFORMATION:  
US-09-201-430-5

Query Match 88.2%; Score 30; DB 4; Length 19;  
Best Local Similarity 85.7%; Pred. No. 8.2;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFFA 7  
:|||||  
Db 3 QKLVEFFA 9

RESULT 50  
US-09-724-551-75  
; Sequence 75, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 75  
; LENGTH: 19  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:Abeta 13-28  
; OTHER INFORMATION: peptide with two Gly residues added and inserted  
; OTHER INFORMATION: Cys residue  
; FEATURE:  
; NAME/KEY: MOD\_RES  
; LOCATION: (1)  
; OTHER INFORMATION: Xaa = N-acetyl His  
US-09-724-551-75

Query Match 88.2%; Score 30; DB 4; Length 19;  
Best Local Similarity 85.7%; Pred. No. 8.2;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFFA 7  
:|||||  
Db 3 QKLVEFFA 9

Search completed: March 9, 2005, 06:42:59  
Job time : 19.6986 secs

**THIS PAGE BLANK (USP10)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 63.9452 Seconds  
(without alignments)  
36.290 Million cell updates/sec

Title: US-10-009-122-3

Perfect score: 29

Sequence: 1 KLVFFA 6

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database : A\_Geneseq\_16Dec04:\*

1: Geneseqp1980s:\*

2: Geneseqp1990s:\*

3: Geneseqp2000s:\*

4: Geneseqp2001s:\*

5: Geneseqp2002s:\*

6: Geneseqp2003as:\*

7: Geneseqp2003bs:\*

8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	100.0	6	2 AAW02314	Aaw02314 Beta-amyl
2	29	100.0	6	2 AAW89378	Aaw89378 Beta-amyl
3	29	100.0	6	4 AAB48484	Aab48484 Antifibri
4	29	100.0	6	4 AAB48476	Aab48476 Antifibri
5	29	100.0	6	4 AAB82632	Aab82632 All-D pep
6	29	100.0	6	5 ABG71009	Abg71009 Long form
7	29	100.0	6	5 ABB05157	Aau56820 Amyloid t
8	29	100.0	6	5 AAW96820	Aau96820 Amyloid t
9	29	100.0	6	5 ABB83305	Aau11658 Peptide #
10	29	100.0	6	5 AAW11658	Aau11658 Peptide #
11	29	100.0	6	5 AAW11650	Aau11650 Peptide #
12	29	100.0	6	6 AAE35445	Aae35445 Abeta pep
13	29	100.0	6	6 AAE35434	Aae35434 Abeta pep
14	29	100.0	6	8 ADJ64060	Adj64060 Human bet
15	29	100.0	6	8 ADQ37271	Adq37271 Vaccine a
16	29	100.0	6	8 ADQ37315	Adq37315 Antifibri
17	29	100.0	6	8 ADQ37368	Adq37368 Beta-amyl
18	29	100.0	6	8 ADQ37269	Adq37269 Vaccine a
19	29	100.0	6	8 ADQ37292	Adq37292 Vaccine a
20	29	100.0	6	8 ADQ37258	Adq37258 Vaccine a
21	29	100.0	6	8 ADQ37353	Adq37353 Beta-amyl
22	29	100.0	6	8 ADQ37323	Adq37323 Antifibri
23	29	100.0	7	2 AAR88300	Aar88300 Non-amnes
24	29	100.0	7	2 AAR87921	Aar87921 Test pept
25	29	100.0	7	2 AAW02312	Aaw02312 Beta-amyl

26	29	100.0	7	2 AAW89376	Aaw89376 Beta-amyl
27	29	100.0	7	4 AAB67281	Aab67281 Residues
28	29	100.0	7	4 AAB48475	Aab48475 Antifibri
29	29	100.0	7	4 AAB48492	Aab48492 Antifibri
30	29	100.0	7	4 AAB48491	Aab48491 Antifibri
31	29	100.0	7	4 AAB82624	Aab82624 All-D pep
32	29	100.0	7	4 AAB82640	Aab82640 All-D pep
33	29	100.0	7	4 AAB82639	Aab82639 All-D pep
34	29	100.0	7	5 ABG71007	Abg71007 Long form
35	29	100.0	7	5 ABB05155	Abb05155 Beta amyl
36	29	100.0	7	5 AAW96827	Aau96827 Amyloid t
37	29	100.0	7	5 AAW96812	Aau96812 Amyloid t
38	29	100.0	7	5 AAW96828	Aau96828 Amyloid t
39	29	100.0	7	5 ABB04920	Abb04920 Human amyl
40	29	100.0	7	5 AAW11665	Aau11665 Peptide #
41	29	100.0	7	5 AAW11649	Aau11649 Peptide #
42	29	100.0	7	5 AAW11666	Aau11666 Peptide #
43	29	100.0	7	6 ABB82630	Abb82630 Abeta fib
44	29	100.0	7	6 AAE35439	Aae35439 Abeta pep
45	29	100.0	7	6 AAE35454	Aae35454 Abeta pep
46	29	100.0	7	6 AAE35453	Aae35453 Abeta pep
47	29	100.0	7	6 ADA90937	Ada90937 Solid-pha
48	29	100.0	7	6 ADA90154	Ada90154 Anti-Abet
49	29	100.0	7	7 ADD20746	Add20746 Human bet
50	29	100.0	7	7 ADF50855	Adf50855 Human cal
51	29	100.0	7	8 ADJ64058	Adj64058 Human bet
52	29	100.0	7	8 ADP64922	Adp64922 Beta-amyl
53	29	100.0	7	8 ADQ37278	Adq37278 Vaccine a
54	29	100.0	7	8 ADQ37314	Adq37314 Antifibri
55	29	100.0	7	8 ADQ37263	Adq37263 Vaccine a
56	29	100.0	7	8 ADQ37279	Adq37279 Vaccine a
57	29	100.0	7	8 ADQ37330	Adq37330 Antifibri
58	29	100.0	7	8 ADQ37331	Adq37331 Antifibri
59	29	100.0	7	8 ADQ37351	Adq37351 Beta-amyl
60	29	100.0	8	2 AAW02310	Aaw02310 Beta-amyl
61	29	100.0	8	2 AAW45967	Aaw45967 Peptide d
62	29	100.0	8	2 AAW32551	Aaw32551 Amyloidog
63	29	100.0	8	2 AAW89374	Aaw89374 Beta-amyl
64	29	100.0	8	4 AAE10663	Aae10663 Human amyl
65	29	100.0	8	4 AAE02615	Aae02615 Human amyl

ALIGNMENTS

RESULT 1	
AAW02314	AAW02314 standard; peptide; 6 AA.
ID	AAW02314
XX	AAW02314;
AC	AAW02314;
XX	02-MAY-1997 (first entry)
DT	02-MAY-1997 (first entry)
XX	Beta-amyl modulator peptide #5.
DE	Beta-amyl modulator peptide #5.
XX	Beta-amyl modulator; amyloid plaque; brain lesion; amyloidosis;
KW	cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;
KW	familial amyloid polyneuropathy; familial amyloid cardiomyopathy;
KW	isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;
KW	bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; uricaria;
KW	adult-onset diabetes; familial Mediterranean fever; therapy; deafness;
XX	scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.
OS	Synthetic.
XX	WO9628471-A1.
FN	19-SEP-1996.
XX	14-MAR-1996; 96WO-US003492.
PD	14-MAR-1995; 95US-00404831.
XX	07-JUN-1995; 95US-00475579.
PR	07-JUN-1995; 95US-00475579.

27-OCT-1995; 95US-00548998.  
(PHAR-) PHARM PEPTIDES INC.  
Findeis MA, Benjamin H, Garnick MB, Gafter ML, Hundal A;  
Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;  
Kubasek W, Chin J, Lee J, Kelley M;  
WPI; 1996-433762/43.  
Modulators of amyloid aggregation - comprising, e.g. amyloidogenic protein coupled (indirectly) to at least 1 modifying gp., useful in treatment of Alzheimer's disease.  
Claim 16; Page 91; 106pp; English.  
AAW02310-W02332 represent the peptide portions of the beta-amyloid modulator compounds of the invention. Beta-amyloid peptide is a 4 kilodalton peptide that is the major protein component of amyloid plaques. Amyloid plaques are present both in the brain lesions, and in the walls of cerebral blood vessels in Alzheimer's disease patients. The amyloid modulators of the invention comprise an amyloidogenic protein or peptide (such as this sequence) coupled directly or indirectly to at least one modifying group. The modifying group is preferably a cyclic, heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a biotin containing group, or a fluorescein containing group. These compounds then modulate the aggregation of these sequences to natural amyloid proteins or peptides when contacted with the natural amyloidogenic proteins or peptides. The modulator compounds can be used in the treatment of disorders associated with amyloidosis, such as familial amyloid polynuropathy, familial amyloid cardiomyopathy, isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset diabetes, insulinoma, familial Mediterranean fever, familial amyloid nephropathy with urticaria and deafness, hereditary cerebral haemorrhage and other types of amyloidosis. The modulators are also useful for the treatment of disorders associated with beta-amyloidosis, especially Alzheimer's disease  
Sequence 6 AA;  
Query Match 100.0%; Score 29; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
| | | | |  
Db 1 KLVFFA 6  
RESULT 2  
AAW89378  
ID AAW89378 standard; peptide; 6 AA.  
XX AC AAW89378;  
XX DT 02-MAR-1999 (first entry)  
XX DE Beta-amyloid peptide derivative A-beta-16-21.  
XX KW Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein; aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy; familial amyloid polynuropathy; bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; BAP.  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX PN US5854204-A.  
XX PD 29-DEC-1998.  
XX PF 14-MAR-1996; 96US-00612785.

14-MAR-1995; 95US-00404831.  
27-JUN-1995; 95US-00475579.  
27-OCT-1995; 95US-00548998.  
(PRAE-) PRACIS PHARM INC.  
Hundal A, Gafter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
Garnick MB, Kubasek W, Signer ER;  
WPI; 1999-094964/08.  
New peptide(s) derived from beta-amyloid peptide that inhibit amyloid aggregation - and neurotoxicity, specifically for treatment and prevention of Alzheimer's disease.  
Example 12; Col 64; 52pp; English.  
The present invention describes beta-amyloid peptide (BAP) derivatives. The BAP derivatives inhibit aggregation of amyloidogenic proteins and peptides, specifically BAP, and their neurotoxicity, so are useful for treating and preventing any disease involving amyloidosis, specifically Alzheimer's disease but also Down's syndrome, familial amyloid polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. The BAP derivatives are also used to diagnose these diseases, in vitro or in vivo, by detecting binding of BAP to labelled BAP derivatives. Some BAP derivatives inhibit BAP aggregation even when BAP is present in molar excess. The present sequence represents a BAP derivative  
Sequence 6 AA;  
Query Match 100.0%; Score 29; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
| | | | |  
Db 1 KLVFFA 6  
RESULT 3  
AAB48484  
ID AAB48484 standard; peptide; 6 AA.  
XX AC AAB48484;  
XX DT 02-MAR-2001 (first entry)  
XX DE Antifibrillogenic peptide #11.  
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition; cytoprotection; amyloid deposit degradation; amyloidosis disorder; Alzheimer's disease.  
XX OS Homo sapiens.  
XX FH Key Location/Qualifiers  
XX FT Modified-site 6 /note="C-terminal amide"  
XX PN WO200068263-A2.  
XX PD 16-NOV-2000.  
XX PF 04-MAY-2000; 2000WO-CA000515.  
XX PR 05-MAY-1999; 99US-0132592P.  
XX PA (NEUR-) NEUROCHEM INC.  
XX PI Chalifour R, Gervais F, Gupta A;

XX WPI; 2001-031852/04.  
 XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 XX Claim 7; Page 25; 46pp; English.  
 XX  
 CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 DB 1 KLVFFA 6

RESULT 4  
 AAB48476  
 ID AAB48476 standard; peptide; 6 AA.  
 AC AAB48476;  
 XX  
 DT 02-MAR-2001 (first entry)  
 XX  
 DE Antifibrillogenic peptide #3.  
 KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.  
 XX Homo sapiens.  
 OS  
 XX WO200068263-A2.  
 PN 16-NOV-2000.  
 XX  
 PD 04-MAY-2000; 2000WO-CA000515.  
 PF 05-MAY-1999; 99US-0132592P.  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Chalifour R, Gervais F, Gupta A;  
 PI WPI; 2001-031852/04.  
 DR Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 XX Claim 7; Page 25; 46pp; English.  
 XX  
 CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 DB 1 KLVFFA 6

RESULT 5  
 AAB82632  
 ID AAB82632 standard; peptide; 6 AA.  
 XX  
 AC AAB82632;  
 XX  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 XX Key Location/Qualifiers  
 FT Misc-difference 1..6 /note= "all D-form residues"  
 FT Modified-site 6 /note= "C-terminal amide"  
 FT  
 XX WO200139796-A2.  
 PN 07-JUN-2001.  
 XX  
 PD 29-NOV-2000; 2000WO-CA001413.  
 PF 29-NOV-1999; 99US-0168594P.  
 PR 28-NOV-2000; 2000US-00724842.  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Chalifour R, Hebert L, Kong X, Gervais F;  
 PI WPI; 2001-441458/47.  
 DR Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.  
 XX  
 PS Disclosure; Page 11; 31pp; English.  
 XX  
 CC The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42' of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC

CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients. The present all-D  
 CC peptide was demonstrated to elicit antibody production in rabbits, and  
 CC provided greater anti-fibrillogenic activity than its all-L equivalent  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
 Matches 6; Conservative 0; Mismatches 0;  
 QY 1 KLVFFA 6  
 DB 1 KLVFFA 6  
 RESULT 6  
 ID ABG71009 standard; peptide; 6 AA.  
 AC ABG71009;  
 DT 05-DEC-2002 (first entry)  
 XX  
 DE Long form beta-amyloid protein fragment #6.  
 XX  
 KW Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polyneuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Strausler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localized cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2002098173-A1.  
 XX  
 XX 25-JUL-2002.  
 XX  
 XX 04-OCT-2001; 2001US-00972475.  
 XX  
 XX 14-MAR-1995; 95US-00404831.  
 XX 07-JUN-1995; 95US-00475579.  
 XX 27-OCT-1995; 95US-00548998.  
 XX 14-MAR-1996; 96US-00617267.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX  
 XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 XX Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 XX WPI; 2002-697709/75.  
 XX  
 XX Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX  
 XX Example 12; Page 35; 41pp; English.  
 XX  
 XX The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid polyneuropathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),

CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Strausler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localized cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polyneuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysozyme-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
 Matches 6; Conservative 0; Mismatches 0;  
 QY 1 KLVFFA 6  
 DB 1 KLVFFA 6  
 RESULT 7  
 ID ABB05157 standard; peptide; 6 AA.  
 XX  
 AC ABB05157;  
 DT 02-APR-2002 (first entry)  
 XX  
 DE Beta amyloid peptide (16-21) SEQ ID NO:9.  
 XX  
 KW Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polyneuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX US6319498-B1.  
 XX  
 XX 20-NOV-2001.  
 XX  
 XX 14-MAR-1996; 96US-00617267.  
 XX  
 XX 14-MAR-1995; 95US-00404831.  
 XX 07-JUN-1995; 95US-00475579.  
 XX 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 XX  
 XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 XX Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 XX WPI; 2002-146668/19.  
 XX  
 XX Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX





PS Disclosure; Page 10; 68pp; English.

XX The present invention relates to a new method of inhibiting cerebral

CC amyloid angiopathy. The new method of the invention involves contacting a

CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention

CC can be used for treating disease states characterised by cerebral amyloid

CC angiopathy, particularly Alzheimer's disease, hereditary cerebral

CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.

CC The present sequence represents one of a group of peptides (AAU11648-

CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a

CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor

CC was used in the invention to treat a disease state characterised by

CC cerebral amyloid angiopathy (CAA)

XX Sequence 6 AA;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

Best Match 100.0%; Score 29; DB 5; Length 6;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 11

AAU11650

ID AAU11650 standard; peptide; 6 AA.

XX AAU11650;

AC AAU11650;

DT 09-APR-2002 (first entry)

XX Peptide #3, used as a carrier for amyloid-beta40 (Abeta40) inhibitor.

XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;

XX CAA; nontropic; neuroprotective; cerebroprotective; Alzheimer's disease;

XX cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX Synthetic.

XX WO200185093-A2.

PN 15-NOV-2001.

PD 22-DEC-2000; 2000WO-IB002078.

PF 23-DEC-1999; 99US-0171877P.

XX (NEUR-) NEUROCHEM INC.

XX Green AM, Gervais F;

XX WPI; 2002-075222/10.

XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's

XX disease comprises contacting blood vessel wall cell with amyloid-beta 40

XX inhibitor.

XX Disclosure; Page 10; 68pp; English.

XX The present invention relates to a new method of inhibiting cerebral

XX amyloid angiopathy. The new method of the invention involves contacting a

XX blood vessel wall cell with an amyloid-beta40 inhibitor. The invention

XX can be used for treating disease states characterised by cerebral amyloid

XX angiopathy, particularly Alzheimer's disease, hereditary cerebral

XX haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.

XX The present sequence represents one of a group of peptides (AAU11648-

XX AAU11669, AAU11910 & AAU11911) that were used in the invention as a

XX carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor

XX was used in the invention to treat a disease state characterised by

XX cerebral amyloid angiopathy (CAA)

DR WPI; 2002-519078/55.

XX New antifibrillogenic peptide useful for inhibiting amyloidosis and/or

PT for cytoprotection in the treatment of amyloidosis disorders e.g. type I

PT or type II.

XX Disclosure; Page 5; 77pp; English.

PS The present invention relates to antifibrillogenic agents (ABB83281-

XX ABB83298), derived from human islet amyloid polypeptide (IAPP, ABB83307).

CC The present sequence is a peptide fragment of the amyloid-beta (Abeta)

CC peptide. Aggregation of IAPP, also known as amylin, or Abeta results in

CC fibrillar accumulations, leading to amyloidosis. The antifibrillogenic

CC peptides prevent fibril formation and amyloidosis and hence control

CC folding or deposition of amyloid proteins. The antifibrillogenic peptides

CC of the invention are useful in the manufacture of a medicament for

CC inhibiting or treating amyloidosis or amyloid deposits e.g. Type I and

CC Type II diabetes and/or for cytoprotection. They are also useful for

CC treating secondary amyloidosis associated with chronic infection e.g.

CC tuberculosis and chronic inflammation e.g. rheumatoid arthritis, and

CC familial inflammation, fever, neurodegenerative diseases e.g. scrapie,

CC bovine spongy form encephalitis, Creutzfeldt-Jacob disease, Alzheimer's

CC disease, cerebral amyloid angiopathy

XX Sequence 6 AA;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

Best Match 100.0%; Score 29; DB 5; Length 6;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 10

AAU11658

ID AAU11658 standard; peptide; 6 AA.

XX AAU11658;

AC AAU11658;

DT 09-APR-2002 (first entry)

XX Peptide #11, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.

XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;

XX CAA; nontropic; neuroprotective; cerebroprotective; Alzheimer's disease;

XX cerebral haemorrhage; amyloidosis; haemorrhagic stroke.

XX Synthetic.

XX Key Location/Qualifiers

XX Modified-site 6

XX /note= "C-terminal amide"

XX WO200185093-A2.

PN 15-NOV-2001.

PD 22-DEC-2000; 2000WO-IB002078.

PF 23-DEC-1999; 99US-0171877P.

XX (NEUR-) NEUROCHEM INC.

XX Green AM, Gervais F;

XX WPI; 2002-075222/10.

XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's

XX disease comprises contacting blood vessel wall cell with amyloid-beta 40

XX inhibitor.

SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 5; Length 6;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 |||||  
 Db 1 KLVFFA 6

RESULT 12  
 AAE35445  
 ID AAE35445 standard; peptide; 6 AA.  
 XX AAE35445;  
 AC AAE35445;  
 DT 17-JUN-2003 (first entry)  
 XX Abeta peptide #16.  
 DE XX  
 KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
 XX Unidentified.  
 OS  
 XX Key Location/Qualifiers  
 FH Misc-difference 1. .6  
 FT Modified-site 6 /note= "D-form residues"  
 FT Modified-site 6 /note= "C-terminal amide"  
 FT  
 XX WO200296937-A2.  
 PN  
 XX 05-DEC-2002.  
 PD  
 XX 29-MAY-2002; 2002WO-CA000763.  
 PF  
 XX 29-MAY-2001; 2001US-00867847.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
 PI WPI; 2003-201269/19.  
 DR  
 XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
 PT  
 XX Claim 1; Page 59; 44pp; English.  
 PS  
 XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The

CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention  
 XX  
 SQ Sequence 6 AA;  
 Query Match 100.0%; Score 29; DB 6; Length 6;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 |||||  
 Db 1 KLVFFA 6

RESULT 13  
 AAE35434  
 ID AAE35434 standard; peptide; 6 AA.  
 XX AAE35434;  
 AC AAE35434;  
 DT 17-JUN-2003 (first entry)  
 XX Abeta peptide #5.  
 DE XX  
 KW All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
 XX Unidentified.  
 OS  
 XX Key Location/Qualifiers  
 FH Misc-difference 1. .6  
 FT Modified-site 6 /note= "D-form residues"  
 FT  
 XX WO200296937-A2.  
 PN  
 XX 05-DEC-2002.  
 PD  
 XX 29-MAY-2002; 2002WO-CA000763.  
 PF  
 XX 29-MAY-2001; 2001US-00867847.  
 PR  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
 PI WPI; 2003-201269/19.  
 DR  
 XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
 PT  
 XX Claim 1; Page 58; 44pp; English.  
 PS  
 XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The

CC and familial amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of Icelandic type, amyloidosis associated with long term haemodialysis, hereditary non-neuropathic systemic amyloidosis (familial amyloid polynuropathy III), familial amyloidosis of Finnish type, amyloidosis associated with medullary carcinoma of the thyroid, fibrinogen associated hereditary renal amyloidosis and lysosome-associated hereditary systemic amyloidosis. The present sequence is beta-amyloid peptide fragment used in the exemplification of the invention.

XX  
SQ Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 14  
ADJ64060  
ID ADJ64060 standard; peptide; 6 AA.  
XX  
AC ADJ64060;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Human beta-amyloid long form peptide fragment #6.  
XX  
KW Amyloidogenic protein; therapy; amyloidosis;  
KW familial amyloid polynuropathy; cardiomyopathy;  
KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
KW familial mediterranean fever; urticaria; deafness;  
KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
KW beta-amyloid peptide; human.  
XX  
OS Homo sapiens.  
XX  
FN US2004005307-A1.  
XX  
PD 08-JAN-2004.  
XX  
PF 17-JUN-2003; 2003US-00463729.  
XX  
PR 14-MAR-1995; 95US-00404831.  
PR 07-JUN-1995; 95US-00475579.  
PR 27-OCT-1995; 95US-00548998.  
PR 14-MAR-1996; 96US-00617267.  
PR 04-OCT-2001; 2001US-00972475.  
XX  
PA (PRAE-) PRAECIS PHARM INC.  
XX  
FI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
XX  
XX WPI; 2004-131767/13.  
XX  
DR New amyloidogenic protein aggregation modulators useful for treating disorder associated with amyloidosis e.g. familial amyloid polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
XX  
PS Example 12; SEQ ID NO 9; 52pp; English.  
XX  
CC The invention relates to amyloidogenic proteins or peptide fragments aggregation modulators. The invention is used for treating disorder associated with amyloidosis, particularly familial amyloid polynuropathy (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes, amyloidosis, isolated atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary localized cutaneous nodular amyloidosis associated with Sjogren's syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever

CC and familial amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of Icelandic type, amyloidosis associated with long term haemodialysis, hereditary non-neuropathic systemic amyloidosis (familial amyloid polynuropathy III), familial amyloidosis of Finnish type, amyloidosis associated with medullary carcinoma of the thyroid, fibrinogen associated hereditary renal amyloidosis and lysosome-associated hereditary systemic amyloidosis. The present sequence is beta-amyloid peptide fragment used in the exemplification of the invention.

XX  
SQ Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 15  
ADQ37271  
ID ADQ37271 standard; peptide; 6 AA.  
XX  
AC ADQ37271;  
XX  
DT 07-OCT-2004 (first entry)  
XX  
DE Vaccine antigen amyloid-beta related amino acid sequence.  
XX  
KW amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1..6 /note= "D-form residues"  
FT Modified-site 6 /note= "amidated"  
XX  
XX WO2004058239-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 24-DEC-2003; 2003WO-CA002021.  
XX  
XX 24-DEC-2002; 2002US-0436379P.  
PR 23-JUN-2003; 2003US-0482214P.  
XX  
XX (NEUR-) NEUROCHEM INT LTD.  
XX  
XX Gervais F, Bellini F;  
XX WPI; 2004-543342/52.  
XX  
XX Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 67; 143pp; English.

PS The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic, tranquiliser, ophthalmological, anticonvulsant, anti-HIV, antiparkinsonian, muscular, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; CC having amyloid-beta deposits. The present sequence represents a peptide that can be used as a vaccine antigen in the exemplification of the present invention.

XX Sequence 6 AA;

SQ Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLWFFA 6  
|||||

DB 1 KLWFFA 6

RESULT 16

ADQ37315

ID ADQ37315 standard; peptide; 6 AA.

XX ADQ37315;

AC ADQ37315;

XX 07-OCT-2004 (first entry)

XX Antifibrillogenic amyloidosis inhibiting peptide.

XX amyloid-beta; amyloid-beta related disease;

KW amyloid-beta fibril formation; immune response; nootropic;

KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;

KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

KW cardiant; antidepressant; endocrine; hypnotic;

KW amyloid-beta fibril formation modulator; immune system modulator;

KW Alzheimer's disease; mild cognitive impairment;

KW mild-to-moderate cognitive impairment; vascular dementia;

KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

KW senile dementia; Down's syndrome; inclusion body myositis;

KW age-related macular degeneration; hypothyroidism;

KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

KW behavioural dysfunction; neurological condition; psychological condition; vaccine antigen.

XX Synthetic.

PN WO2004058239-A1.

XX 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

XX 24-DEC-2002; 2002US-0436379P.

XX 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent that prevents or treats amyloid-beta related disease and second agent that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 69; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first agent (a1) that prevents or treats amyloid-beta related disease; and (b) a second agent (a2) that is: (i) a peptide or peptidomimetic that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation; or (ii) an immune system modulator that prevents or inhibits amyloid-beta fibril formation. Also described is a kit comprising (C). (C) have

CC nootropic, neuroprotective, cerebroprotective, haemostatic, ophthalmological, anticonvulsant, anti-HIV, antiparkinsonian, muscular, uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular, neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities, and can be used as amyloid-beta fibril formation modulators, and as immune system modulators. (C) can be used for preventing or treating an amyloid-beta related disease e.g. Alzheimer's disease (including sporadic (non-hereditary) or familial (hereditary)), mild cognitive impairment, mild-to-moderate cognitive impairment, vascular dementia, cerebral amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia, Down's syndrome, inclusion body myositis, age-related macular degeneration, or a condition associated with Alzheimer's disease (including hypothyroidism, cerebrovascular disease, cardiovascular disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy, aggression, or incontinence), a neurological condition (e.g. Huntington's disease, amyotrophic lateral sclerosis, acquired immunodeficiency, Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia with Lewy bodies, altered muscle tone, seizures, sensory loss, visual field deficits, incoordination, gait disturbance, transient ischaemic attack or stroke, transient alertness, attention deficit, frequent falls, syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural haematoma, brain tumour, posttraumatic brain injury, or posthypoxic damage), or a psychological condition (e.g. depression, delusions, disturbance, insomnia, behavioural disinhibition, poor insight, suicidal ideation, depressed mood, irritability, anhedonia, social withdrawal, or excessive guilt)) in a subject e.g. human having a genomic mutation in an amyloid precursor protein gene, an ApoE gene, or a presenilin gene; CC having amyloid-beta deposits. The present sequence represents a peptide that can be used as an antifibrillogenic amyloidosis inhibiting peptide in the exemplification of the present invention.

XX Sequence 6 AA;

SQ Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
| | | | |  
Db 1 KLVFFA 6

RESULT 17  
ADQ37368  
ID ADQ37368 standard; peptide; 6 AA.  
XX  
AC ADQ37368;  
XX  
DT 07-OCT-2004 (first entry)  
XX  
DE Beta-amyloid modulator peptide.  
XX  
KW amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Modified-site 6 /label= bala  
FT /note= "beta-alanine"

WO2004058239-A1.  
XX  
XX 15-JUL-2004.  
XX  
XX 24-DEC-2003; 2003WO-CA002021.  
XX  
XX 24-DEC-2002; 2002US-0436379P.  
XX  
XX 23-JUN-2003; 2003US-0482214P.  
XX  
XX (NEUR-) NEUROCHEM INT LTD.  
XX  
XX Gervais F, Bellini F;  
XX  
XX WPI; 2004-543342/52.  
XX  
XX Composition for treating e.g. Alzheimer's disease comprises first agent  
XX that prevents or treats amyloid-beta related disease and second agent  
XX that is either a peptide or peptidomimetic or an immune system modulator.  
XX  
XX Disclosure; Page 87; 143pp; English.  
XX  
XX The present invention describes compositions (C) comprising: (a) a first  
XX agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
XX a second agent (a2) that is: (i) a peptide or peptidomimetic that  
XX modulates amyloid-beta fibril formation or induces a prophylactic or  
XX therapeutic immune response against amyloid-beta fibril formation; or  
XX (ii) an immune system modulator that prevents or inhibits amyloid-beta  
XX fibril formation. Also described is a kit comprising (C). (C) have  
XX neurotropic, neuroprotective, cerebroprotective, haemostatic,  
XX ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
XX uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
XX neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
XX and can be used as amyloid-beta fibril formation modulators, and as  
XX immune system modulators. (C) can be used for preventing or treating an

Query Match 100.0%; Score 29; DB 8; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVFFA 6  
Db 1 KLVFFA 6  
RESULT 18  
ADQ37269  
ID ADQ37269 standard; peptide; 6 AA.  
XX  
AC ADQ37269;  
XX  
DT 07-OCT-2004 (first entry)  
XX  
DE Vaccine antigen amyloid-beta related amino acid sequence.  
XX  
KW amyloid-beta; amyloid-beta related disease;  
KW amyloid-beta fibril formation; immune response; neurotropic;  
KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
KW cardiant; antidepressant; endocrine; hypnotic;  
KW amyloid-beta fibril formation modulator; immune system modulator;  
KW Alzheimer's disease; mild cognitive impairment;  
KW mild-to-moderate cognitive impairment; vascular dementia;  
KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
KW senile dementia; Down's syndrome; inclusion body myositis;  
KW age-related macular degeneration; hypothyroidism;  
KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
KW behavioural dysfunction; neurological condition; psychological condition;  
KW vaccine antigen.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1, 6 /note= "D-form residues"  
FT Modified-site 6 /note= "amidated"  
XX  
XX WO2004058239-A1.





CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.  
 XX Sequence 6 AA;  
 SQ

Query Match 100.0%; Score 29; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 DB 1 KLVFFA 6

RESULT 20  
 ADQ37258  
 ID ADQ37258 standard; peptide; 6 AA.  
 XX AC  
 XX ADQ37258;  
 XX DT  
 XX 07-OCT-2004 (first entry)  
 XX Vaccine antigen amyloid-beta related amino acid sequence.  
 XX amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX OS  
 XX Synthetic.  
 XX FH  
 XX Key Location/Qualifiers  
 FT Misc-difference 1. .6 /note= "D-form residues"  
 FT FT  
 XX XX  
 XX WO2004058239-A1.  
 XX PN  
 XX 15-JUL-2004.  
 XX DD  
 XX 24-DEC-2003; 2003WO-CR002021.  
 XX PF  
 XX 24-DEC-2002; 2002US-0436379P.  
 XX PR  
 XX 23-JUN-2003; 2003US-0482214P.  
 XX PA  
 XX (NEUR-) NEUROCHEM INT LTD.  
 XX Gervais F, Bellini F;

WPI; 2004-543342/52.

DR Composition for treating e.g. Alzheimer's disease comprises first agent  
 XX that prevents or treats amyloid-beta related disease and second agent  
 FT that is either a peptide or peptidomimetic or an immune system modulator.  
 PT  
 XX Disclosure; Page 67; 143pp; English.

PS The present invention describes compositions (C) comprising: (a) a first  
 XX agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uteropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.

Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6

DB 1 KLVFFA 6

RESULT 21

ADQ37353  
 ID ADQ37353 standard; peptide; 6 AA.

XX AC

XX ADQ37353;

XX 07-OCT-2004 (first entry)

XX Beta-amyloid modulator peptide.

DE amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;



KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

XX Synthetic.

XX WO2004058239-A1.

XX 15-JUL-2004.

XX 24-DEC-2003; 2003WO-CA002021.

XX 24-DEC-2002; 2002US-0436379P.

XX 23-JUN-2003; 2003US-0482214P.

XX (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 87; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic, and  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a beta-  
 CC amyloid modulator peptide which is used in the exemplification of the  
 CC present invention.

SQ Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 KLVFFFA 6

Db 1 KLVFFFA 6

RESULT 22

ADQ37323

ID ADQ37323 standard; peptide; 6 AA.

XX AC ADQ37323;

XX DT 07-OCT-2004 (first entry)

XX DE Antifibrillogenic amyloidosis inhibiting peptide.

XX KW amyloid-beta; amyloid-beta related disease;

KW amyloid-beta fibril formation; immune response; nootropic;

KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;

KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;

KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;

KW cardiant; antidepressant; endocrine; hypnotic;

KW amyloid-beta fibril formation modulator; immune system modulator;

KW Alzheimer's disease; mild cognitive impairment;

KW mild-to-moderate cognitive impairment; vascular dementia;

KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;

KW senile dementia; Down's syndrome; inclusion body myositis;

KW age-related macular degeneration; hypothyroidism;

KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;

KW behavioural dysfunction; neurological condition; psychological condition;

KW vaccine antigen.

XX Synthetic.

Key Location/Qualifiers

Modified-site 6 /note="amidated"

WO2004058239-A1..

15-JUL-2004.

24-DEC-2003; 2003WO-CA002021.

24-DEC-2002; 2002US-0436379P.

23-JUN-2003; 2003US-0482214P.

(NEUR-) NEUROCHEM INT LTD.

Gervais F, Bellini F;

WPI; 2004-543342/52.

Composition for treating e.g. Alzheimer's disease comprises first agent  
 that prevents or treats amyloid-beta related disease and second agent  
 that is either a peptide or peptidomimetic or an immune system modulator.

Disclosure; Page 69-70; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nootropic, neuroprotective, cerebroprotective, haemostatic, and  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,

CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
 CC in the exemplification of the present invention.

XX Sequence 6 AA;

Query Match 100.0%; Score 29; DB 8; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
 |||||  
 Db 1 KLVFFFA 6

RESULT 23

AAR88300  
 ID AAR88300 standard; peptide; 7 AA.

XX AC AAR88300;

XX 23-FEB-1996 (first entry)

XX Non-amnestic peptide Beta-A4 (16-22).

XX memory; enhancer; topographic model; amnestic peptide binding site;  
 KW beta-A4.

XX Synthetic.

XX WO9507093-A1.

XX 16-MAR-1995.

XX 08-SEP-1994; 94WO-US010083.

XX 08-SEP-1993; 93US-00117927.

XX (CITY ) CITY OF HOPE.

XX Roberts E;

XX WPI; 1995-123235/16.

XX Topographic model for amnestic peptide binding - used to design cpds.  
 PT which enhance memory; and new peptide(s) so designed.

XX

PS Disclosure; Page 28; Sipp; English.

XX The peptide AAR88300 corresponds to residues 16-22 of beta-A4 was  
 CC designed as a potential memory enhancing peptide but was found not to be  
 CC amnestic. (Amnestic peptides are memory-enhancing at lower concentrations  
 CC than those at which they cause amnesia)

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
 |||||  
 Db 1 KLVFFFA 6

RESULT 24

AAR87921  
 ID AAR87921 standard; peptide; 7 AA.

XX AC AAR87921;

XX 01-MAR-1996 (first entry)

XX Test peptide used in study of antagonism of amyloid beta protein.

XX amnesia; amyloid beta; Alzheimer's disease.

XX Synthetic.

XX WO9508999-A1.

XX 06-APR-1995.

XX 16-SEP-1994; 94WO-US010475.

XX 29-SEP-1993; 93US-00127904.

XX (CITY ) CITY OF HOPE.

XX Roberts E;

XX WPI; 1995-147244/19.

XX New peptide(s) which block binding of amyloid beta protein - used for  
 PT antagonising the amnestic effects of amyloid beta protein, partic. in  
 PT Alzheimer's disease.

PS Disclosure; Page 9; 27pp; English.

XX The invention relates to three new peptides which block the amnestic  
 CC effects of amyloid beta protein and which can be used to ameliorate  
 CC amnesia and other neurotoxicity in Alzheimer's disease caused by  
 CC deposition of this protein. The peptides themselves are not amnestic or  
 CC memory-enhancing. The new peptides are described in AAR87912, AAR87913  
 CC and AAR87914. The present sequence is an additional peptide tested in the  
 CC process but found not to be active

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
 |||||  
 Db 1 KLVFFFA 6

RESULT 25

AAW02312

ID AAW02312 standard; peptide; 7 AA.  
 AC AAW02312;  
 XX  
 DT 02-MAY-1997 (first entry)  
 XX  
 DE Beta-amyloid modulator peptide #3.  
 XX  
 KW Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;  
 KW cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;  
 KW familial amyloid polynuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;  
 KW bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;  
 KW adult-onset diabetes; familial Mediterranean fever; therapy; deafness;  
 KW scurvy; familial amyloid nephropathy; hereditary cerebral haemorrhage.  
 XX  
 OS Synthetic.  
 XX  
 XX WO9628471-A1.  
 PN  
 XX  
 PD 19-SEP-1996.  
 XX  
 PP 14-MAR-1996; 96WO-US003492.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PHAR-) PHARM PEPTIDES INC.  
 PA  
 XX Findeis MA, Benjamin H, Garnick MB, Geftter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ, Molineaux S;  
 PI Kubasek W, Chin J, Lee J, Kelley M;  
 XX  
 DR WPI; 1996-433762/43.  
 XX  
 PT Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
 PT protein coupled (in)directly to at least 1 modifying gp., useful in  
 PT treatment of Alzheimer's disease.  
 XX  
 PS Claim 16; Page 91; 106pp; English.  
 XX  
 CC AAW02310-W02332 represent the peptide portions of the beta-amyloid  
 CC modulator compounds of the invention. Beta-amyloid peptide is a 4  
 CC kilodalton peptide that is the major protein component of amyloid  
 CC plaques. Amyloid plaques are present both in the brain lesions, and in  
 CC the walls of cerebral blood vessels in Alzheimer's disease patients. The  
 CC amyloid modulators of the invention comprise an amyloidogenic protein or  
 CC peptide (such as this sequence) coupled directly or indirectly to at  
 CC least one modifying group. The modifying group is preferably a cyclic,  
 CC heterocyclic, or polycyclic group, such as declain, a cholanyl group, a  
 CC biotin containing group, or a fluorescein containing group. These  
 CC compounds then modulate the aggregation of these sequences to natural  
 CC amyloid proteins or peptides when contacted with the natural  
 CC amyloidogenic proteins or peptides. The modulator compounds can be used  
 CC in the treatment of disorders associated with amyloidosis, such as  
 CC familial amyloid polynuropathy, familial amyloid cardiomyopathy,  
 CC isolated cardiac amyloidosis, systemic senile amyloidosis, scurvy,  
 CC bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
 CC diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
 CC nephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
 CC and other types of amyloidosis. The modulators are also useful for the  
 CC treatment of disorders associated with beta-amyloidosis, especially  
 CC Alzheimer's disease  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 |||||  
 DB 2 KLVFFA 7  
 RESULT 27  
 AAB67281  
 ID AAB67281 standard; peptide; 7 AA.  
 XX  
 AC AAB67281;

Db 2 KLVFFA 7  
 RESULT 26  
 AAW89376  
 ID AAW89376 standard; peptide; 7 AA.  
 XX  
 AC AAW89376;  
 XX  
 DT 02-MAR-1999 (first entry)  
 XX  
 DE Beta-amyloid peptide derivative A-beta-15-21.  
 XX  
 KW Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; bAP.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US5854204-A.  
 XX  
 PD 29-DEC-1998.  
 XX  
 PP 14-MAR-1996; 96US-00612785.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 XX (PRAE-) PRAECIS PHARM INC.  
 PA  
 XX Hundal A, Geftter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
 PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
 PI Garnick MB, Kubasek W, Signer ER;  
 XX  
 DR WPI; 1999-094964/08.  
 XX  
 PT New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.  
 XX  
 PS Example 12; Col 64; 52pp; English.  
 XX  
 CC The present invention describes beta-amyloid peptide (bAP) derivatives.  
 CC The bAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically bAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The bAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of bAP to  
 CC labelled bAP derivatives. Some bAP derivatives inhibit bAP aggregation  
 CC even when bAP is present in molar excess. The present sequence represents  
 CC a bAP derivative  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 |||||  
 DB 2 KLVFFA 7  
 RESULT 27  
 AAB67281  
 ID AAB67281 standard; peptide; 7 AA.  
 XX  
 AC AAB67281;

XX DT 20-APR-2001 (first entry)  
XX DE Residues 16-22 of Alzheimer's Abeta peptide.  
XX KW Alzheimer's; Abeta; beta-strand.  
XX OS Homo sapiens.  
XX PN WO200107473-A1.  
XX PD 01-FEB-2001.  
XX PF 28-JUL-2000; 2000WO-CB002901.  
XX PR 28-JUL-1999; 99GB-00017724.  
XX PA (STOT/) STOTT K.  
XX PI Stott K;  
XX DR WPI; 2001-182777/18.  
XX PT Novel chemical compound or composition useful for preventing beta-strand  
PT association, comprises peptides containing N-alpha substituted L-amino  
PT acids.  
XX PS Claim 17; Page 46; 77pp; English.  
XX CC The present invention relates to a chemical compound or composition  
CC comprising a peptide with a beta strand forming section and associates  
CC with a target beta-strand formed by a separate peptide-containing  
CC molecule. The invention is useful for inhibiting or reversing the  
CC association of target beta-strand, formed by Alzheimer's Abeta peptide  
CC into a beta-sheet or beta-fibre and the aggregation of proteins or  
CC peptides  
XX CC  
SQ Sequence 7 AA;  
Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
DB 1 KLVFFA 6  
RESULT 28  
AAB48475  
ID AAB48475 standard; peptide; 7 AA.  
XX AC AAB48475;  
XX DT 02-MAR-2001 (first entry)  
XX DE Antifibrillogenic peptide #2.  
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
KW Alzheimer's disease.  
XX OS Homo sapiens.  
XX PN WO200068263-A2.  
XX PD 16-NOV-2000.  
XX PF 04-MAY-2000; 2000WO-CA000515.  
XX PR 05-MAY-1999; 99US-0132592P.  
XX PA (NEUR-) NEUROCHEM INC.  
XX PI Chalifour R, Gervais F, Gupta A;  
XX DR WPI; 2001-031852/04.  
XX PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
PT its isomer or peptidomimetic.  
XX PS Claim 7; Page 25; 46pp; English.  
XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
CC binding region and the prot-prot interaction region of the human amyloid  
CC protein  
XX CC  
SQ Sequence 7 AA;  
Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
DB 2 KLVFFA 7  
RESULT 29  
AAB48492  
ID AAB48492 standard; peptide; 7 AA.  
XX AC AAB48492;  
XX DT 02-MAR-2001 (first entry)  
XX DE Antifibrillogenic peptide #19.  
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
KW Alzheimer's disease.  
XX OS Homo sapiens.  
XX PN WO200068263-A2.  
XX PD 16-NOV-2000.  
XX PF 04-MAY-2000; 2000WO-CA000515.  
XX PR 05-MAY-1999; 99US-0132592P.  
XX PA (NEUR-) NEUROCHEM INC.  
XX PI Chalifour R, Gervais F, Gupta A;  
XX DR WPI; 2001-031852/04.  
XX PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
PT its isomer or peptidomimetic.  
XX PS Claim 7; Page 25; 46pp; English.  
XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
CC

CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 |||||  
 Db 1 KLVFFA 6

## RESULT 30

AAB48491  
 ID AAB48491 standard; peptide; 7 AA.

XX AC AAB48491;

XX DT 02-MAR-2001 (first entry)

XX DE Antifibrillogenic peptide #18.

XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.

XX OS Homo sapiens.

XX PN WO200068263-A2.

XX PD 16-NOV-2000.

XX PF 04-MAY-2000; 2000WO-CA000515.

XX PR 05-MAY-1999; 99US-0132592P.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Chalifour R, Gervais F, Gupta A;

XX WPI; 2001-031852/04.

XX PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.

XX PS Claim 7; Page 25; 46pp; English.

XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 |||||  
 Db 1 KLVFFA 6

## RESULT 31

AAB82624

ID AAB82624 standard; peptide; 7 AA.

XX AC AAB82624;

XX DT 02-OCT-2001 (first entry)

XX DE All-D peptide used in Alzheimer's disease vaccine.

XX KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Misc-difference 1..7

XX FT /note= "all D-form residues"

XX PN WO200139796-A2.

XX PD 07-JUN-2001.

XX PF 29-NOV-2000; 2000WO-CA001413.

XX PR 29-NOV-1999; 99US-0168594P.

XX PR 28-NOV-2000; 2000US-00724842.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Chalifour R, Hebert L, Kong X, Gervais F;

XX WPI; 2001-441458/47.

XX PT Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.

XX PS Disclosure; Page 10; 31pp; English.

XX CC The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 |||||

Db	2	KLFFFA 7	Query Match	100.0%;	Score 29;	DB 4;	Length 7;
			Best Local Similarity	100.0%;	Pred. NO. 1.8e+06;		
			Matches	6;	Conservative 0;	Mismatches 0;	Indels 0;
							Gaps 0;
Db	1	KLFFFA 6	QY	1	KLFFFA 6		
Db	1	KLFFFA 6	Db	1	KLFFFA 6		
RESULT 33							
AAB82639							
ID	AAB82639	standard; peptide; 7 AA.					
XX							
AC	AAB82639;						
XX							
DT	02-OCT-2001	(first entry)					
XX							
DE	All-D peptide used in Alzheimer's disease vaccine.						
XX							
KW	Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;						
KW	therapy; antigen.						
XX							
OS	Synthetic.						
XX							
FH	Key	Location/Qualifiers					
FT	Misc-difference 1..7	/note= "all D-form residues"					
FT	Modified-site 6	/note= "C-terminal amide"					
FT							
XX	WO200139796-A2.						
XX							
XX	07-JUN-2001.						
XX							
PF	29-NOV-2000;	2000WO-CA001413.					
XX							
PR	29-NOV-1999;	99US-0168594P.					
PR	28-NOV-2000;	2000US-00724842.					
XX							
PA	(NEUR-) NEUROCHEM INC.						
XX							
PI	Chalifour R, Hebert L, Kong X, Gervais F;						
XX							
DR	WPI; 2001-441458/47.						
XX							
XX	Preventing/treating amyloid-related disease, especially Alzheimer's						
PT	disease, comprises administering antigenic all-D peptide, eg. as vaccine,						
PT	which elicits production of antibodies to prevent fibrillogenesis and						
PT	associated cellular toxicity.						
XX							
PS	Disclosure; Page 11; 31pp; English.						
XX							
CC	The present sequence is that of an all-D peptide suitable for use in						
CC	preparing vaccines for preventing or treating Alzheimer's disease and						
CC	other amyloid related disorders in humans. It is based on a portion of						
CC	amyloid-beta peptide (see AAB82622), and may be modified by removing or						
CC	inserting 1 or more amino acid residues, or by substituting 1 or more						
CC	amino acid residues with other amino acid residues or non-amino acid						
CC	fragments. Vaccines of the invention are produced using 'non-self'						
CC	peptides synthesised from the unnatural D-configuration amino acids to						
CC	avoid the drawbacks of 'self' proteins. The all-D peptides need not be						
CC	aggregated to be operative or immunogenic. They preferably interact with						
CC	at least 1 region of an amyloid protein, e.g. the beta-sheet region or						
CC	GAG-binding site region, the amyloid-beta peptide, or their immunogenic						
CC	immunogenic peptidomimetics. Examples include all-D peptides						
CC	corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and						
CC	36-42 of the amyloid-beta peptide and the all-D derivative peptides given						
CC	in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,						
CC	preventing fibrillogenesis and associated cellular toxicity. The amyloid						
CC	related diseases may be localised amyloidosis, e.g. diabetes type II,						
CC	neurodegenerative diseases, e.g. bovine spongiform encephalitis,						
CC	Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and						
CC	prion protein related disorders, or systemic amyloidosis associated with						
CC	chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.						
CC	rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic						
CC	amyloidosis found in long-term haemodialysis patients						
XX	Sequence 7 AA;						

CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 4; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 |||||  
 Db 1 KLVFFA 6  
 RESULT 34  
 ABG71007  
 ID ABG71007 standard; peptide; 7 AA.  
 XX  
 AC ABG71007;  
 XX  
 DT 05-DEC-2002 (first entry)  
 XX  
 DE Long form beta-amyloid protein fragment #4.  
 XX  
 KW Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polyneuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Strausler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002098173-A1.  
 XX  
 PD 25-JUL-2002.  
 XX  
 PF 04-OCT-2001; 2001US-00972475.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 PR 14-MAR-1996; 96US-00617267.  
 XX  
 PA (PRAE-) PRAECIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geftter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-697709/75.  
 XX  
 PT Amyloid modulator useful for treating a disorder associated with  
 PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment  
 PT coupled to a modifying group.  
 XX  
 PS Example 12; Page 35; 41pp; English.  
 XX  
 CC The invention describes an amyloid modulator comprising an amyloidogenic  
 CC protein and/or peptide fragment coupled to a modifying group so that the  
 CC compound modulates the aggregation of natural amyloid proteins or  
 CC peptides. The modulator is used for treating a disorder associated with  
 CC amyloidosis e.g. familial amyloid polyneuropathy (Portuguese, Japanese  
 CC and Swedish types), familial amyloid cardiomyopathy (Danish type),  
 CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine  
 CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Strausler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or

CC macroglobulinaemia-associated amyloidosis, primary localised cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polyneuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysozyme-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-AP) aggregation of natural amyloidogenic proteins  
 CC or peptides when contacted with a molar excess amount of natural beta-APs  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 |||||  
 Db 2 KLVFFA 7  
 RESULT 35  
 AB05155  
 ID AB05155 standard; peptide; 7 AA.  
 XX  
 AC AB05155;  
 XX  
 DT 02-APR-2002 (first entry)  
 XX  
 DE Beta amyloid peptide (15-21) SEQ ID NO:7.  
 XX  
 KW Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polyneuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US6319498-B1.  
 XX  
 PD 20-NOV-2001.  
 XX  
 PF 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 PA (PRAE-) PRAECIS PHARM INC.  
 XX  
 PI Findeis MA, Benjamin H, Garnick MB, Geftter ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-146668/19.  
 XX  
 PT Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Disclosure; Col 19; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to

it. (1) has neurotropic, neuroprotective, immunosuppressive, antimicrobial, antidiabetic, antipruritic, dermatological, cardiovascular, nephrotoxic and auditory activities, and can be used as a natural amyloid aggregation inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide (beta-AP). (1) are used in the manufacture of a medicament for the diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's disease and other clinical occurrences of beta amyloid deposition such as Down's syndrome individuals and in patients with hereditary cerebral haemorrhage with amyloidosis, and for treating a disorder associated with amyloidosis such as familial amyloid polynuropathy. (1) reduces the toxicity of natural beta-AP aggregates to cultured neuronal cells. (1) not only reduces the formation of neurotoxic aggregates but also have the ability to reduce the neurotoxicity of performed A-beta fibrils. The present sequence represents a beta-AP peptide, which is used in the exemplification of the present invention

Sequence 7 AA;  
Query Match 100.0%; Score 29; DB 5; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
DB 2 KLVFFA 7  
|||||

RESULT 36  
AAU96827  
ID AAU96827 standard; peptide; 7 AA.  
AC AAU96827;  
XX  
XX  
30-JUL-2002 (first entry)  
Amyloid targeting peptide #17.  
Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
transmissible cerebral amyloidosis; transmissible virus dementias;  
scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
bovine spongiform encephalopathy; inflammation associated amyloid;  
primary amyloidosis; feline spongiform encephalopathy;  
Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
dialysis-related amyloidosis; light chain-related amyloidosis;  
cerebral amyloid angiopathy.

Synthetic.  
Key Location/Qualifiers  
Misc-difference 1..7 /note= "Preferably D-form residue"  
WO200207781-A2.  
31-JAN-2002.  
25-JUL-2001; 2001WO-CA001071.  
25-JUL-2000; 2000US-0220808P.  
24-JUL-2001; 2001US-00915092.  
(NEUR-) NEUROCHEM INC.  
Gervais F, Kong X, Chalfour R, Migneault D;  
WPI; 2002-371447/40.  
New amyloid-targeting imaging agents useful for in vivo imaging amyloid plaques and/or for the treatment of amyloidosis disorders.

Claim 49; Page 22; 57pp; English.  
The invention relates to an amyloid-targeting imaging agent comprising an

amyloid targeting moiety, a linker moiety and a labelling moiety. The agent is of general formula A-t-(A<sub>1</sub>n<sub>1</sub>k)z-A<sub>1</sub>l a b (1) where z = 0 - 1; A<sub>1</sub>t = an amyloid targeting moiety; A<sub>1</sub>n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>l a b = a labelling moiety. Also included are imaging amyloid deposition or diagnosing an amyloid-related condition in a patient involving administering (1) to the patient, and ultrasound imaging (1) in the patient to determine the presence of amyloid or amyloid-related condition (1), a reducing agent, a buffering agent, a transchelating agent, and instructions for the preparation and use of the radiopharmaceutical in the imaging of amyloid or an amyloid-related condition. The agents are used for imaging amyloid deposition and for diagnosing an amyloid related condition e.g. Creutzfeldt-Jakob disease (CJD), Kuru, transmissible cerebral amyloidosis (transmissible virus dementias), familial CJD, scrapie, transmissible mink encephalopathy, bovine spongiform encephalopathy (BSE), inflammation-associated amyloid, type II diabetes, primary amyloidosis, feline spongiform encephalopathy, non-transmissible cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases, dialysis-related amyloidosis, light chain-related amyloidosis, cerebral amyloid angiopathy. The agents are capable of crossing the blood-brain barrier and are capable of binding specifically to amyloid plaques. The present sequence is a peptide forming the amyloid targeting moiety of the agent of the invention

Sequence 7 AA;  
Query Match 100.0%; Score 29; DB 5; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
DB 1 KLVFFA 6  
|||||

RESULT 37  
AAU96812  
ID AAU96812 standard; peptide; 7 AA.  
XX  
AC AAU96812;  
XX  
30-JUL-2002 (first entry)  
Amyloid targeting peptide #2.  
Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
transmissible cerebral amyloidosis; transmissible virus dementias;  
scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
bovine spongiform encephalopathy; inflammation associated amyloid;  
primary amyloidosis; feline spongiform encephalopathy;  
Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
dialysis-related amyloidosis; light chain-related amyloidosis;  
cerebral amyloid angiopathy.

Synthetic.  
Key Location/Qualifiers  
Misc-difference 1..7 /note= "Preferably D-form residue"  
WO200207781-A2.  
31-JAN-2002.  
25-JUL-2001; 2001WO-CA001071.  
25-JUL-2000; 2000US-0220808P.  
24-JUL-2001; 2001US-00915092.  
(NEUR-) NEUROCHEM INC.  
Gervais F, Kong X, Chalfour R, Migneault D;  
XX



DR WPI; 2002-371447/40.

XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid

PT plaques and/or for the treatment of amyloidosis disorders.

XX

XX Claim 49; Page 21; 57pp; English.

XX

CC The invention relates to an amyloid-targeting imaging agent comprising an

CC amyloid targeting moiety, a linker moiety and a labelling moiety. The

CC agent is of general formula A-t-(A<sub>1</sub>n<sub>1</sub>k) z-A<sub>1</sub>a<sub>1</sub>b (I) where z = 0 - 1;

CC A<sub>1</sub>t = an amyloid targeting moiety; A<sub>1</sub>n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>a<sub>1</sub>b

CC = a labelling moiety. Also included are imaging amyloid deposition or

CC diagnosing an amyloid-related condition in a patient involving

CC administering (I) to the patient, and ultrasound imaging (I) in the

CC patient to determine the presence of amyloid or amyloid-related condition

CC ; and a kit for preparing a radiopharmaceutical preparation comprising

CC (I), a reducing agent, a buffering agent, a transchelating agent, and

CC instructions for the preparation and use of the radiopharmaceutical in

CC the imaging of amyloid or an amyloid-related condition. The agents are

CC used for imaging amyloid deposition and for diagnosing an amyloid related

CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible

CC cerebral amyloidosis (transmissible virus dementias), familial CJD,

CC scrapie, transmissible mink encephalopathy, bovine spongiform

CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,

CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible

CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,

CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral

CC amyloid angiopathy. The agents are capable of crossing the blood-brain

CC barrier and are capable of binding specifically to amyloid plaques. The

CC present sequence is a peptide forming the amyloid targeting moiety of the

CC agent of the invention

XX

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 5; Length 7;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6

Db 2 KLVFFFA 7

|||||

RESULT 38

AAU96828

ID AAU96828 standard; peptide; 7 AA.

XX

XX AAU96828;

XX

XX 30-JUL-2002 (first entry)

XX

XX Amyloid targeting peptide #18.

XX

KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;

KW transmissible cerebral amyloidosis; transmissible virus dementia;

KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;

KW bovine spongiform encephalopathy; inflammation associated amyloid;

KW primary amyloidosis; feline spongiform encephalopathy;

KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;

KW dialysis-related amyloidosis; light chain-related amyloidosis;

KW cerebral amyloid angiopathy.

XX

OS Synthetic.

XX

XX Key Location/Qualifiers

PH

FT Misc-difference 1.7

FT /note= "Preferably D-form residue"

FT Modified-site 7

FT /note= "Gln is amidated"

XX

XX WO200207781-A2.

XX

XX 31-JAN-2002.

XX

PF 25-JUL-2001; 2001WO-CA001071.

XX

XX 25-JUL-2000; 2000US-0220808P.

PR

XX 24-JUL-2001; 2001US-00915092.

XX

PA (NEUR-) NEUROCHEM INC.

XX

XX Gervais F, Kong X, Chalifour R, Migneault D;

PI

XX WPI; 2002-371447/40.

DR

XX New amyloid-targeting imaging agents useful for in vivo imaging amyloid

PT plaques and/or for the treatment of amyloidosis disorders.

XX

XX Claim 49; Page 22; 57pp; English.

XX

CC The invention relates to an amyloid-targeting imaging agent comprising an

CC amyloid targeting moiety, a linker moiety and a labelling moiety. The

CC agent is of general formula A-t-(A<sub>1</sub>n<sub>1</sub>k) z-A<sub>1</sub>a<sub>1</sub>b (I) where z = 0 - 1;

CC A<sub>1</sub>t = an amyloid targeting moiety; A<sub>1</sub>n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>a<sub>1</sub>b

CC = a labelling moiety. Also included are imaging amyloid deposition or

CC diagnosing an amyloid-related condition in a patient involving

CC administering (I) to the patient, and ultrasound imaging (I) in the

CC patient to determine the presence of amyloid or amyloid-related condition

CC ; and a kit for preparing a radiopharmaceutical preparation comprising

CC (I), a reducing agent, a buffering agent, a transchelating agent, and

CC instructions for the preparation and use of the radiopharmaceutical in

CC the imaging of amyloid or an amyloid-related condition. The agents are

CC used for imaging amyloid deposition and for diagnosing an amyloid related

CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible

CC cerebral amyloidosis (transmissible virus dementias), familial CJD,

CC scrapie, transmissible mink encephalopathy, bovine spongiform

CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,

CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible

CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,

CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral

CC amyloid angiopathy. The agents are capable of crossing the blood-brain

CC barrier and are capable of binding specifically to amyloid plaques. The

CC present sequence is a peptide forming the amyloid targeting moiety of the

CC agent of the invention

XX

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 5; Length 7;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6

Db 1 KLVFFFA 6

|||||

RESULT 39

ABB04920

ID ABB04920 standard; peptide; 7 AA.

XX

XX ABB04920;

XX

XX 14-MAR-2002 (first entry)

XX

XX Human amyloid beta protein (beta-A4) peptide 16-22 SEQ ID NO:13.

XX

XX Human; amyloid beta protein; beta-A4; memory enhancement; learning.

XX

XX Homo sapiens.

XX

XX US6320024-B1.

XX

XX 20-NOV-2001.

XX

XX 09-MAR-1999; 99US-00264709.

XX

PR 07-FEB-1997; 97US-00797782.  
 XX (ROBE/) ROBERTS E.  
 PA Roberts E;  
 XX  
 PI  
 XX  
 XX WPI; 2002-096566/13.  
 DR  
 XX  
 PT New peptide compound useful for design of substances that enhance memory.  
 XX  
 XX Disclosure; Col 6; 30pp; English.  
 XX  
 XX The present invention describes a novel peptide compound comprising Lys-  
 CC His-Tyr-beta-alanine, which has a memory modulating effect. The peptide  
 CC has nootropic activity. The peptide can be used for the development of  
 CC topographic models useful to design and synthesize memory-enhancing and  
 CC life-quality improving substances. The peptide compound restores the  
 CC balance between excitatory and inhibitory systems in the brain, which is  
 CC required for optimal acquisition and retention of learning and helps to  
 CC correct defects in the balance that arise as a result of aging,  
 CC infections and injury. The substances exert reynerneticising effects on  
 CC nervous system function and has more prolonged desired effects at lower  
 CC doses than the peptide structures. The substances mimic the action of  
 CC active peptides without having a peptide structure and do not subject to  
 CC degradation of peptide-splitting enzymes in the gut or other tissues. The  
 CC present sequence represents a human amyloid beta protein (beta-A4)  
 CC peptide which is not amnesiac, and is used in the exemplification of the  
 CC present invention  
 XX  
 XX SQ Sequence 7 AA;  
 XX  
 XX Query Match 100.0%; Score 29; DB 5; Length 7;  
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 QY 1 KLVFFFA 6  
 DB |||||  
 1 KLVFFFA 6  
 RESULT 40  
 AAU11665  
 ID AAU11665 standard; peptide; 7 AA.  
 XX  
 XX AC AAU11665;  
 XX  
 XX 09-APR-2002 (first entry)  
 XX  
 XX Peptide #18, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX  
 XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 XX CAA; nootropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 XX cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 XX Synthetic.  
 XX  
 XX WO200185093-A2.  
 XX  
 XX 15-NOV-2001.  
 XX  
 XX 22-DEC-2000; 2000WO-IB002078.  
 XX  
 XX 23-DEC-1999; 99US-0171877P.  
 XX  
 XX (NEUR-) NEUROCHEM INC.  
 XX  
 XX Green AM, Gervais F;  
 XX  
 XX WPI; 2002-075222/10.  
 XX  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 XX disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 XX inhibitor.  
 XX  
 XX Disclosure; Page 10; 68pp; English.  
 XX  
 XX The present invention relates to a new method of inhibiting cerebral  
 XX amyloid angiopathy. The new method of the invention involves contacting a  
 XX blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 XX can be used for treating disease states characterised by cerebral amyloid  
 XX angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 XX haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 XX The present sequence represents one of a group of peptides (AAU11648-  
 XX AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 XX carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 XX was used in the invention to treat a disease state characterised by  
 XX cerebral amyloid angiopathy (CAA)  
 XX  
 XX SQ Sequence 7 AA;  
 XX  
 XX Query Match 100.0%; Score 29; DB 5; Length 7;  
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 QY 1 KLVFFFA 6  
 DB |||||  
 1 KLVFFFA 6  
 RESULT 41  
 AAU11649  
 ID AAU11649 standard; peptide; 7 AA.  
 XX  
 XX AC AAU11649;  
 XX  
 XX 09-APR-2002 (first entry)  
 XX  
 XX Peptide #2, used as a carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX  
 XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 XX CAA; nootropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 XX cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 XX Synthetic.  
 XX  
 XX WO200185093-A2.  
 XX  
 XX 15-NOV-2001.  
 XX  
 XX 22-DEC-2000; 2000WO-IB002078.  
 XX  
 XX 23-DEC-1999; 99US-0171877P.  
 XX  
 XX (NEUR-) NEUROCHEM INC.  
 XX  
 XX Green AM, Gervais F;  
 XX  
 XX WPI; 2002-075222/10.  
 XX  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 XX disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 XX inhibitor.  
 XX  
 XX Disclosure; Page 10; 68pp; English.  
 XX  
 XX The present invention relates to a new method of inhibiting cerebral  
 XX amyloid angiopathy. The new method of the invention involves contacting a  
 XX blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 XX can be used for treating disease states characterised by cerebral amyloid  
 XX angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 XX haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 XX The present sequence represents one of a group of peptides (AAU11648-  
 XX AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 XX carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 XX was used in the invention to treat a disease state characterised by  
 XX cerebral amyloid angiopathy (CAA)

XX SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 5; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 Db 2 KLVFFA 7

RESULT 42  
 AAU11666  
 ID AAU11666 standard; peptide; 7 AA.  
 XX AC AAU11666;  
 XX OS Homo sapiens.  
 XX FH Key Location/Qualifiers  
 XX FT Modified-site 7 /note= "C-terminal amide"  
 XX PN WO200185093-A2.  
 XX PD 15-NOV-2001.  
 XX PF 22-DEC-2000; 2000WO-IB002078.  
 XX PR 23-DEC-1999; 99US-0171877P.  
 XX PA (NEUR-) NEUROCHEM INC.  
 XX PI Green AM, Gervais F;  
 XX DR WPI; 2002-075222/10.  
 XX PT Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 XX PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 XX PS Inhibitor.  
 XX PS Disclosure; Page 10; 68pp; English.  
 XX CC The present invention relates to a new method of inhibiting cerebral  
 XX CC amyloid angiopathy. The new method of the invention involves contacting a  
 XX CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 XX CC can be used for treating disease states characterised by cerebral amyloid  
 XX CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 XX CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 XX CC The present sequence represents one of a group of peptides (AAU1648-  
 XX CC AAU1669, AAU1910 & AAU1911) that were used in the invention as a  
 XX CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 XX CC was used in the invention to treat a disease state characterised by  
 XX CC cerebral amyloid angiopathy (CAA)

QY 1 KLVFFA 6  
 Db 1 KLVFFA 6

RESULT 43  
 ABB82630  
 ID ABB82630 standard; peptide; 7 AA.  
 XX AC ABB82630;  
 XX DT 04-FEB-2003 (first entry)  
 XX DE Abeta fibrillogenesis inhibitor peptide Abeta16-22.  
 XX KW Abeta; beta-amyloid; fibrillogenesis; fibril; nootropic; neuroprotective;  
 XX KW cerebroprotective; haemostatic; antipyretic; nephrotropic; vasotropic;  
 XX KW dermatological; auditory; antidiabetic; cytostatic; antiinflammatory;  
 XX KW antimicrobial; anticonvulsant; antidiabetic.  
 XX OS Homo sapiens.  
 XX FH Key Location/Qualifiers  
 XX FT Modified-site 3, 6  
 XX FT /note= "can be methylated; both the methylated and non-  
 XX FT methylated versions of this peptide are poor  
 XX FT fibrillogenesis inhibitor"  
 XX FT Modified-site 7  
 XX FT /note= "C-terminal CONH2"  
 XX PN WO200274931-A2.  
 XX PD 26-SEP-2002.  
 XX PF 20-MAR-2002; 2002WO-US008803.  
 XX PR 20-MAR-2001; 2001US-0277477P.  
 XX PA (UYCH-) UNIV CHICAGO.  
 XX PI Gordon DJ, Meredith SC;  
 XX DR WPI; 2003-040553/03.  
 XX PT Novel peptide for inhibiting fibrillogenesis, and for screening  
 XX PT fibrillogenesis inhibitors, has beta-strand with one face having hydrogen  
 XX PT bonds and other face blocking propagation of hydrogen bonding between  
 XX PT beta-strands.  
 XX PS Disclosure; Page 7; 151pp; English.  
 XX CC The invention relates to a peptide (I) inhibiting fibrillogenesis, that  
 XX CC comprises a beta-strand with two faces, where the first face has hydrogen  
 XX CC bonds, and the second face blocks or disrupts propagation of hydrogen  
 XX CC bonding between beta-strands needed to form fibrils. (I) is useful for  
 XX CC inhibiting fibrillogenesis, for detecting fibrils in a subject and for  
 XX CC screening candidate fibrillogenesis inhibitors. A pharmaceutical  
 XX CC composition comprising (I) is useful for inhibiting or disassembling  
 XX CC fibrils associated with pathological states such as Alzheimer's disease,  
 XX CC Down's syndrome, Dutch-Type hereditary cerebral haemorrhage amyloidosis,  
 XX CC reactive amyloidosis, familial Mediterranean fever, familial amyloid  
 XX CC nephropathy with utricaria and deafness, Muckle-Wells syndrome,  
 XX CC idiopathic myeloma, macroglobulinemia-associated myeloma, familial  
 XX CC amyloid polynuropathy, familial amyloid cardiomyopathy, isolated cardiac  
 XX CC amyloid, systemic senile amyloidosis, adult onset diabetes, insulinoma,  
 XX CC isolated atrial amyloid, medullary carcinoma of the thyroid, familial  
 XX CC amyloidosis, hereditary cerebral haemorrhage with amyloidosis, familial  
 XX CC amyloidotic polynuropathy, scrapie, Creutzfeldt-Jakob disease, Gerstmann  
 XX CC -Straussler-Scheinker syndrome, bovine spongiform encephalitis, prion-  
 XX CC mediated diseases, or Huntington's disease. (I) is useful for treating  
 XX CC disease associated with fibrillogenesis or for treating and/or diagnosing  
 XX CC a subject which is a mammal, preferably human, having protein aggregation  
 XX CC disease or protein misfolding disease. The composition is useful in both  
 XX CC preventive and curative therapies of fibril based pathologies mentioned  
 XX CC above. The present sequence represents a peptide which can comprise  
 XX CC consecutive N-methylation, but is a weak inhibitor of Abeta

: fibrillogenesis  
Sequence 7 AA;      100.0%; Score 29; DB 6; Length 7;  
Query Match Similarity 100.0%; Pred. No. 1.8e+06; Gaps 0;  
Best Local Similarity 100.0%; Mismatches 0; Indels 0;  
Matches 6; Conservative 0;

/ 1 KLVFFA 6  
| | | |  
D 1 KLVFFA 6

RESULT 44  
AAE35439 standard; peptide; 7 AA.  
AAE35439;  
17-JUN-2003 (first entry)  
Beta peptide #10.

All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
psoriasis; Reiter's syndrome; Adult Still's disease; Behcet's syndrome;  
Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
ulcer; antiinflammatory; cytostatic; uropathic; therapy.

Unidentified.

Key Location/Qualifiers  
Misc-difference 1..7 /note= "D-form residues"  
WO200296937-A2.  
05-DEC-2002.  
29-MAY-2002; 2002WO-CA000763.  
29-MAY-2001; 2001US-00867847.  
(NEUR-) NEUROCHEM INC.  
Gervais F, Hebert L, Chalifour RJ, Kong X;  
WPI; 2003-201269/19.

Prevention and/or treatment of an amyloid-related disease e.g.  
Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

Claim 1; Page 59; 44pp; English.

The invention relates to a method for prevention and/or treatment of an amyloid-related disease which comprises administration of an all-D-amyloid-beta peptide. The method is used for preventing and/or treating Alzheimer's and other amyloid related disease e.g. cerebral amyloid angiopathy; for altering serum levels of amyloid-beta in a mammal and favours the clearance of soluble amyloid-beta or fibril amyloid-beta from the mammal; and reducing or inhibiting the formation of plaques. It is also used for treating AA (reactive) amyloid diseases including inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy, Reiter's syndrome, Adult Still's disease, Behcet's syndrome and Crohn's disease. AA deposits are also produced as a result of chronic microbial infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease). Certain malignant neoplasms can also result in AA fibril amyloid deposits including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung and bladder, melanocarcinoma and hairy cell leukaemia. The

CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 |||||  
 DB 1 KLVFFA 6

RESULT 46  
 AAE35453  
 ID AAE35453 standard; peptide; 7 AA.

AC AAE35453;

DT 17-JUN-2003 (first entry)

XX Abeta peptide #24.

XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
 KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
 KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; neurotropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.

XX Unidentified.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 1.7 /note= "D-form residues"

XX WO200296937-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-CA000763.

XX 29-MAY-2001; 2001US-00867847.

XX (NEUR-) NEUROCHEM INC.

XX Gervais F, Hebert L, Chalifour RJ, Kong X;

XX WPI; 2003-201269/19.

XX Prevention and/or treatment of an amyloid-related disease e.g.

XX Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.

XX Claim 1; Page 59; 44pp; English.

XX The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus

CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention  
 XX

SQ Sequence 7 AA;

Query Match 100.0%; Score 29; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
 |||||  
 DB 1 KLVFFA 6

RESULT 47  
 ADA90937  
 ID ADA90937 standard; peptide; 7 AA.

XX ADA90937;

XX 20-NOV-2003 (first entry)

XX Solid-phase synthesis heptapeptide #14.

XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.

OS Synthetic.

OS Homo sapiens.

XX WO2003070760-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-EP001759.

XX 20-FEB-2002; 2002EP-00003844.

XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.

XX (MORP-) MORPHOSYS AG.

XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;

XX Loehning C, Loetscher H, Nordstedt C, Rothe C;

XX WPI; 2003-663848/62.

XX New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 PT diseases associated with amyloidogenesis or amyloid-plaque formation  
 PT (e.g. dementia).

XX Example 12; Page 82; 312pp; English.

XX The present invention describes an antibody molecule (I) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (1), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (I) and recovering (I) from the culture; (5) a composition comprising (I)  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (I),

CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (1) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (1), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 Db 1 KLVFFA 6  
 RESULT 48  
 ADA90154  
 ID ADA90154 standard; peptide; 7 AA.  
 AC ADA90154;  
 XX  
 XX 20-NOV-2003 (first entry)  
 DT  
 DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:269.  
 XX  
 XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;  
 KW neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;  
 KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;  
 KW Alzheimer's disease; motor neuropathy; Down's syndrome;  
 KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage;  
 KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;  
 KW neuronal disorder; aging.  
 XX  
 XX Synthetic.  
 OS Homo sapiens.  
 OS  
 XX WO2003070760-A2.  
 PN  
 XX 28-AUG-2003.  
 PD  
 XX 20-FEB-2003; 2003WO-EP001759.  
 PF  
 XX 20-FEB-2002; 2002EP-00003844.  
 PR  
 XX (HOFF) HOFFMANN LA ROCHE & CO AG F.  
 PA (MORP-) MORPHOSYS AG.  
 XX  
 XX Bardroff M, Bohrmann B, Brookhaus M, Huber W, Kretzschmar T;  
 PI Loehning C, Loetscher H, Nordstedt C, Rothe C;  
 PI WPI; 2003-663848/62.  
 DR  
 XX New antibody molecule capable of specifically recognizing two regions of  
 PT the beta-A4 peptide, useful for diagnosing, preventing or treating  
 PT diseases associated with amyloidogenesis or amyloid-plaque formation

PT (e.g. dementia).  
 XX  
 PS Disclosure; Page 260; 312pp; English.  
 XX  
 CC The present invention describes an antibody molecule (1) capable of  
 CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The  
 CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-  
 CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the  
 CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-  
 CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule  
 CC encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host  
 CC cell comprising the vector of (2); (4) preparing (1), comprising  
 CC culturing the host cell of (3) under conditions that allow synthesis of  
 CC (1) and recovering (1) from the culture; (5) a composition comprising (1),  
 CC or an antibody molecule produced by method (4); (6) a kit comprising (1),  
 CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising  
 CC (1); (8) testing the resulting Fab optimisation library by panning  
 CC against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing  
 CC of selected, optimised clones; (11) preparing a pharmaceutical  
 CC composition, comprising optimisation of (1), and formulating the  
 CC optimised antibody/antibody molecule with a carrier; and (12) a  
 CC pharmaceutical composition prepared by method (8). (1) has  
 CC neuroprotective, neurotropic and antiparkinsonian activities, and can be  
 CC used in gene therapy. The antibody molecule (1), nucleic acid molecule,  
 CC vector or host is useful in preparing a pharmaceutical composition for  
 CC the prevention and/or treatment of a disease associated with  
 CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule  
 CC may also be used in preparing a diagnostic composition for the detection  
 CC of the disease mentioned above. The antibody is used for the  
 CC disintegration of beta-amyloid plaques or for passive immunisation  
 CC against beta-amyloid plaque formation. In particular, the disease is  
 CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,  
 CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with  
 CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,  
 CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The  
 CC present sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 7 AA;  
 Query Match 100.0%; Score 29; DB 6; Length 7;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVFFA 6  
 Db 1 KLVFFA 6  
 RESULT 49  
 ADD20746  
 ID ADD20746 standard; peptide; 7 AA.  
 XX  
 XX ADD20746;  
 AC  
 XX 15-JAN-2004 (first entry)  
 DT  
 XX Human beta-amyloid 16-22 amino acid sequence.  
 DE  
 XX self-assembly; peptide-based structure; beta-amyloid;  
 KW self-assembling structure; molecular-level probing; human.  
 KW  
 XX Homo sapiens.  
 OS  
 XX Key Location/Qualifiers  
 FH Modified-site 1  
 FT /note= "N-terminally modified with CH3CO-"  
 FT Modified-site 6  
 FT /label= amidated  
 FT  
 XX WO2003082900-A2.  
 PN  
 XX 09-OCT-2003.  
 PD  
 XX



**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 16.0274 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-3  
Perfect score: 29  
Sequence: 1 KLVFFA 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649084 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA: \*  
1: /cgn2\_6/ptodata/1/1aa/5A-COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/5B-COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/6A-COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/6B-COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/PCTUS-COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	2	US-08-612-785B-9
2	29	100.0	6	3	US-08-703-675C-32
3	29	100.0	6	3	US-08-617-267C-9
4	29	100.0	6	4	US-09-747-408-3
5	29	100.0	6	4	US-09-747-408-11
6	29	100.0	7	1	US-08-127-904-14
7	29	100.0	7	2	US-08-612-785B-7
8	29	100.0	7	3	US-08-703-675C-30
9	29	100.0	7	3	US-08-617-267C-7
10	29	100.0	7	3	US-09-264-709A-13
11	29	100.0	7	4	US-09-747-408-2
12	29	100.0	7	4	US-09-747-408-18
13	29	100.0	7	4	US-09-747-408-19
14	29	100.0	7	5	PCT-US94-10475-14
15	29	100.0	8	2	US-08-612-785B-5
16	29	100.0	8	2	US-08-630-645-1
17	29	100.0	8	3	US-08-703-675C-28
18	29	100.0	8	3	US-08-617-267C-5
19	29	100.0	8	3	US-09-095-106A-44
20	29	100.0	8	4	US-08-766-596A-1
21	29	100.0	8	5	PCT-US96-10220-1
22	29	100.0	9	4	US-08-766-596A-64
23	29	100.0	9	4	US-09-747-408-20
24	29	100.0	10	3	US-08-970-833-3
25	29	100.0	10	4	US-09-724-961-20
26	29	100.0	10	4	US-09-724-961-21
27	29	100.0	10	4	US-09-724-961-22

28	29	100.0	10	4	US-09-724-961-23	Sequence 23, Appl
29	29	100.0	10	4	US-09-724-961-24	Sequence 24, Appl
30	29	100.0	10	4	US-09-580-018-20	Sequence 20, Appl
31	29	100.0	10	4	US-09-580-018-21	Sequence 21, Appl
32	29	100.0	10	4	US-09-580-018-22	Sequence 22, Appl
33	29	100.0	10	4	US-09-580-018-23	Sequence 23, Appl
34	29	100.0	10	4	US-09-580-018-24	Sequence 24, Appl
35	29	100.0	10	4	US-09-724-551-20	Sequence 20, Appl
36	29	100.0	10	4	US-09-724-551-21	Sequence 21, Appl
37	29	100.0	10	4	US-09-724-551-22	Sequence 22, Appl
38	29	100.0	10	4	US-09-724-551-23	Sequence 23, Appl
39	29	100.0	10	4	US-09-724-551-24	Sequence 24, Appl
40	29	100.0	11	2	US-08-630-645-14	Sequence 14, Appl
41	29	100.0	11	4	US-08-766-596A-14	Sequence 14, Appl
42	29	100.0	11	4	US-09-988-842-9	Sequence 9, Appl
43	29	100.0	11	4	US-09-988-842-25	Sequence 25, Appl
44	29	100.0	11	5	PCT-US96-10220-14	Sequence 14, Appl
45	29	100.0	14	4	US-09-594-366-5	Sequence 5, Appl
46	29	100.0	15	2	US-08-612-785B-14	Sequence 14, Appl
47	29	100.0	15	2	US-08-612-785B-37	Sequence 37, Appl
48	29	100.0	15	3	US-08-617-267C-14	Sequence 14, Appl
49	29	100.0	15	4	US-08-766-596A-56	Sequence 56, Appl
50	29	100.0	15	4	US-08-766-596A-57	Sequence 57, Appl
51	29	100.0	15	4	US-08-766-596A-58	Sequence 58, Appl
52	29	100.0	15	4	US-08-766-596A-60	Sequence 60, Appl
53	29	100.0	15	4	US-08-766-596A-61	Sequence 61, Appl
54	29	100.0	15	4	US-08-766-596A-63	Sequence 63, Appl
55	29	100.0	15	4	US-08-766-596A-65	Sequence 65, Appl
56	29	100.0	17	3	US-09-264-709A-2	Sequence 2, Appl
57	29	100.0	17	4	US-09-594-366-3	Sequence 3, Appl
58	29	100.0	19	3	US-08-970-833-11	Sequence 11, Appl
59	29	100.0	19	4	US-09-723-384-5	Sequence 5, Appl
60	29	100.0	19	4	US-09-724-961-75	Sequence 75, Appl
61	29	100.0	19	4	US-09-724-552-5	Sequence 5, Appl
62	29	100.0	19	4	US-09-580-018-75	Sequence 75, Appl
63	29	100.0	19	4	US-09-723-927-5	Sequence 5, Appl
64	29	100.0	19	4	US-09-724-489-5	Sequence 5, Appl
65	29	100.0	19	4	US-09-724-477-5	Sequence 5, Appl

ALIGNMENTS

RESULT 1  
US-08-612-785B-9  
; Sequence 9, Application US/08612785B  
; Patent No. 5954204  
; GENERAL INFORMATION:  
; APPLICANT: Eladels, Mark A. et al.  
; TITLE OF INVENTION: Ab peptides that modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579

; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; INFORMATION FOR SEQ ID NO: 9  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-9

Query Match 100.0%; Score 29; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 2  
US-08-703-675C-32  
; Sequence 32, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Fintelis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; FILING DATE: 27-AUG-1996  
; APPLICATION NUMBER: USSN 08/703,675C  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 32:  
; SEQUENCE CHARACTERISTICS:

; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; INFORMATION FOR SEQ ID NO: 9  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-9

Query Match 100.0%; Score 29; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 2  
US-08-703-675C-32  
; Sequence 32, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Fintelis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; FILING DATE: 27-AUG-1996  
; APPLICATION NUMBER: USSN 08/703,675C  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081  
; FILING DATE: 14-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 32:  
; SEQUENCE CHARACTERISTICS:

; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-7400  
; INFORMATION FOR SEQ ID NO: 9  
; SEQUENCE CHARACTERISTICS:

; Sequence 3, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Gervais, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 6

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-747-408-3

Query Match

Best Local Similarity 100.0%; Score 29; DB 4; Length 6;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 5

US-09-747-408-11

; Sequence 11, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 11

; LENGTH: 6

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-747-408-11

Query Match

Best Local Similarity 100.0%; Score 29; DB 4; Length 6;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 6

US-08-127-904-14

; Sequence 14, Application US/08127904

; Patent No. 5470951

; GENERAL INFORMATION:

; APPLICANT: Eugene Roberts

; TITLE OF INVENTION: Method For Antagonizing

; TITLE OF INVENTION: Amnestic Effects Of Amyloid n

; TITLE OF INVENTION: Protein And Improving the

; TITLE OF INVENTION: Quality of Life in Individuals

; TITLE OF INVENTION: With Alzheimer Disease

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: City of Hope

; STREET: 1500 East Duarte Road

; CITY: Duarte

; STATE: California

; COUNTRY: United States of America

; ZIP: 91010-0289

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3M Double Density 5 1/4" diskette

; OPERATING SYSTEM: MS DOS Version 3.20

; SOFTWARE: Microsoft

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/127,904

; FILING DATE: 29 September 1993

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA: No. 5470951e

; ATTORNEY/AGENT INFORMATION:

; NAME: Irons, Edward S.

; REGISTRATION NUMBER: 16,541

; REFERENCE/DOCKET NUMBER: No. 5470951e

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 783-6040

; TELEFAX: (202) 783-6031

; TELEX: No. 5470951e

; INFORMATION FOR SEQ ID NO: 14:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 7

; TYPE: Amino Acid

; STRANDEDNESS:

; TOPOLOGY: Unknown

; US-08-127-904-14

Query Match

Best Local Similarity 100.0%; Score 29; DB 1; Length 7;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 7

US-08-612-785B-7

; Sequence 7, Application US/08612785B

; Patent No. 5854204

; GENERAL INFORMATION:

; APPLICANT: Findeis, Mark A. et al.

; TITLE OF INVENTION: AB Peptides that Modulate b-Amyloid

; NUMBER OF SEQUENCES: 40

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD

; STREET: 28 State Street, Suite 510

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02109-1875

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/612,785B

; FILING DATE: Herewith

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/404,831

; FILING DATE: 14-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/475,579

; FILING DATE: 07-JUN-1995

; PRIOR APPLICATION DATA:

us-10-009-122-3-rai

Wed Mar 9 08:15:54 2005

```

; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-612-785B-7

Query Match 100.0%; Score 29; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
DB 2 KLVFFA 7

RESULT 8
US-08-703-675C-30
; Sequence 30, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: USSN/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; Aggregation Comprising D-

```

```

; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-703-675C-30

Query Match 100.0%; Score 29; DB 3; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
DB 2 KLVFFA 7

RESULT 9
US-08-617-267C-7
; Sequence 7, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-617-267C-7

Query Match 100.0%; Score 29; DB 3; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
DB 2 KLVFFA 7

RESULT 10
US-09-264-709A-13
; Sequence 13, Application US/09264709A
; Patent No. 6320024

```

; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; FILE REFERENCE: 2124-310  
; CURRENT APPLICATION NUMBER: US/09/264,709A  
; PRIOR FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 13  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-13

Query Match 100.0%; Score 29; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||  
Db 1 KLVFFA 6

## RESULT 11

US-09-747-408-2  
; Sequence 2, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-2

Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||  
Db 2 KLVFFA 7

## RESULT 12

US-09-747-408-18  
; Sequence 18, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0

Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; SEQ ID NO 18  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-18

Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||  
Db 1 KLVFFA 6

## RESULT 13

US-09-747-408-19  
; Sequence 19, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 19  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-19

Query Match 100.0%; Score 29; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||  
Db 1 KLVFFA 6

## RESULT 14

PCT-US94-10475-14  
; Sequence 14, Application PC/TUS9410475  
; GENERAL INFORMATION:  
; APPLICANT: Eugene Roberts  
; TITLE OF INVENTION: Method For  
; TITLE OF INVENTION: Antagonizing Amnestic  
; TITLE OF INVENTION: Effects of Amyloid n  
; TITLE OF INVENTION: Protein and Improving  
; TITLE OF INVENTION: the Quality of Life  
; TITLE OF INVENTION: in Individuals  
; TITLE OF INVENTION: With Alzheimer Disease  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: City of Hope  
; STREET: 1500 East Duarte Road  
; CITY: Duarte  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 91010-0269  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3M Double Density 5 1/4"  
; MEDIUM TYPE: diskette  
; COMPUTER: Wang PC  
; OPERATING SYSTEM: MS DOS Version 3.20  
; SOFTWARE: Microsoft  
; CURRENT APPLICATION DATA:

Wed Mar 9 08:15:54 2005

```

; APPLICATION NUMBER: PCT/US94/10475
; FILING DATE: 16 September 1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA: U. S. Application
; PRIOR APPLICATION DATA: Serial No.
; PRIOR APPLICATION DATA: 08/127,904; filed
; PRIOR APPLICATION DATA: 29 September 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Irons, Edward S.
; REGISTRATION NUMBER: 16,541
; REFERENCE/DOCKET NUMBER: None
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 626-3584 or 783-6030
; TELEFAX: (202) 783-6031
; TELEX: None
; LENGTH: 7
; TYPE: Amino Acid
; STRANDEDNESS:
; TOPOLOGY: Unknown
; PCT-US94-10475-14

Query Match 100.0%; Score 29; DB 5; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 15
US-08-612-785B-5
; Sequence 5, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid
; TITLE OF INVENTION: Aggregation
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,785B
; FILING DATE: Herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214

; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-612-785B-5

Query Match 100.0%; Score 29; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 3 KLVFFA 8

RESULT 16
US-08-630-645-1
; Sequence 1, Application US/08630645
; Patent No. 5948763
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEROF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,645
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-630-645-1

Query Match 100.0%; Score 29; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6
```

## RESULT 17

US-08-703-675C-28  
; Sequence 28, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide Aggregation Comprising D-  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/703,675C  
; FILING DATE: 27-AUG-1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081  
; FILING DATE: 14-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 28:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-703-675C-28

Query Match 100.0%; Score 29; DB 3; Length 8;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 3 KLVFFA 8

RESULT 18  
US-08-617-267C-5  
; Sequence 5, Application US/08617267C  
; Patent No. 6319498  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts

COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/617,267C  
FILING DATE: 14-MAR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-617-267C-5

Query Match 100.0%; Score 29; DB 3; Length 8;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 3 KLVFFA 8

RESULT 19  
US-09-095-106A-44  
; Sequence 44, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERENIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 44  
; LENGTH: 8  
; TYPE: PPT  
; ORGANISM: Amyloidosis  
US-09-095-106A-44

Query Match 100.0%; Score 29; DB 3; Length 8;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

us-10-009-122-3.ra1

Wed Mar 9 08:15:54 2005

```

; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10220
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US96-10220-1

Query Match 100.0%; Score 29; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. NO. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 22
US-08-766-596A-64
; Sequence 64, Application US/08766596A
; Patent No. 6462171
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10220
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US96-10220-1

Query Match 100.0%; Score 29; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. NO. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 21
PCT-US96-10220-1
; Sequence 1, Application PC/TUS9610220
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS

```



APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 64:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-64

Query Match 100.0%; Score 29; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
DB 2 KLVFFA 7

## RESULT 23

US-09-747-408-20  
Sequence 20, Application US/09747408  
Patent No. 6670399  
GENERAL INFORMATION:  
APPLICANT: Green, Allan M.  
TITLE OF INVENTION: Compounds And Methods For Modulating  
TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
FILE REFERENCE: NBI-088  
CURRENT APPLICATION NUMBER: US/09/747,408  
CURRENT FILING DATE: 2000-12-22  
PRIOR APPLICATION NUMBER: 60/171,877  
PRIOR FILING DATE: 1999-12-23  
NUMBER OF SEQ ID NOS: 24  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 20  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-747-408-20

Query Match 100.0%; Score 29; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
DB 4 KLVFFA 9

## RESULT 24

US-08-970-833-3  
Sequence 3, Application US/08970833  
Patent No. 6022859  
GENERAL INFORMATION:  
APPLICANT: Kissling, Laura L.  
APPLICANT: Murphy, Regina M.  
TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY

NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Quarles & Brady  
STREET: 411 East Wisconsin Avenue  
CITY: Milwaukee  
STATE: Wisconsin  
COUNTRY: U.S.A.  
ZIP: 53202-4497  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/970,833  
FILING DATE:  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Baker, Jean C.  
REGISTRATION NUMBER: 35,433  
REFERENCE/DOCKET NUMBER: 960296.94291  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (414) 277-5709  
TELEFAX: (414) 271-3552  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-970-833-3

Query Match 100.0%; Score 29; DB 3; Length 10;  
Best Local Similarity 100.0%; Pred. No. 1.9;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
DB 1 KLVFFA 6

## RESULT 25

US-09-724-961-20  
Sequence 20, Application US/09724961  
Patent No. 6743427  
GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vasquez, Nicki  
APPLICANT: Vednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 152703-004750UC  
CURRENT APPLICATION NUMBER: US/09/724,961  
CURRENT FILING DATE: 2000-11-28  
PRIOR APPLICATION NUMBER: US 09/580,015  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
PRIOR APPLICATION NUMBER: US 09/201,430  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: US 60/080,970  
PRIOR FILING DATE: 1998-04-07  
PRIOR APPLICATION NUMBER: US 60/067,740  
PRIOR FILING DATE: 1997-12-02  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 20  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence



```
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 29
US-09-724-961-24
; Sequence 24, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-24

Query Match 100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 30
US-09-580-018-20
; Sequence 20, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-20

Query Match 100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 31
US-09-580-018-21
; Sequence 21, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-21

Query Match 100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 32
US-09-580-018-22
; Sequence 22, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-22
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-20

Query Match 100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 5 KLVFFA 10

RESULT 31
US-09-580-018-21
; Sequence 21, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-21

Query Match 100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 32
US-09-580-018-22
; Sequence 22, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-22
```

us-10-009-122-3-rai

Wed Mar 9 08:15:54 2005

```

; OTHER INFORMATION: peptide)
US-09-580-018-22

Query Match      100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 3 KLVFFA 8

RESULT 33
US-09-580-018-23
; Sequence 23, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-23

Query Match      100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 34
US-09-580-018-24
; Sequence 24, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-24

Query Match      100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 5 KLVFFA 10

RESULT 35
US-09-724-551-20
; Sequence 20, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-20

Query Match      100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 5 KLVFFA 10

RESULT 36
US-09-724-551-21
; Sequence 21, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-21
```

```
Query Match          100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
   |||||
Db 4 KLVFFA 9

RESULT 37
US-09-724-551-22
; Sequence 22, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-22

Query Match          100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
   |||||
Db 3 KLVFFA 8

RESULT 38
US-09-724-551-23
; Sequence 23, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
```

```
US-09-724-551-23

Query Match          100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
   |||||
Db 2 KLVFFA 7

RESULT 39
US-09-724-551-24
; Sequence 24, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-24

Query Match          100.0%; Score 29; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
   |||||
Db 1 KLVFFA 6

RESULT 40
US-08-630-645-14
; Sequence 14, Application US/08630645
; Patent No. 5948763
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/08/630,645  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-630-645-14

Query Match 100.0%; Score 29; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 41  
US-08-766-596A-14  
Sequence 14, Application US/08766596A  
Patent No. 6462171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
TITLE OF INVENTION: DEPOSITS  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-14

Query Match 100.0%; Score 29; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 42  
US-09-988-842-9  
Sequence 9, Application US/09988842  
Patent No. 6716589  
GENERAL INFORMATION:  
APPLICANT: Johansson, Jan  
TITLE OF INVENTION: DISORDANT HELIX STABILIZATION FOR PREVENTION  
TITLE OF INVENTION: OF AMYLOID FORMATION  
FILE REFERENCE: 12125-002001  
CURRENT APPLICATION NUMBER: US/09/988,842  
CURRENT FILING DATE: 2001-11-19  
PRIOR APPLICATION NUMBER: US 60/251,662  
PRIOR FILING DATE: 2000-12-06  
PRIOR APPLICATION NUMBER: US 60/253,695  
PRIOR FILING DATE: 2000-11-20  
NUMBER OF SEQ ID NOS: 26  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 9  
LENGTH: 11  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-9

Query Match 100.0%; Score 29; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 43  
US-09-988-842-25  
Sequence 25, Application US/09988842  
Patent No. 6716589  
GENERAL INFORMATION:  
APPLICANT: Johansson, Jan  
TITLE OF INVENTION: DISORDANT HELIX STABILIZATION FOR PREVENTION  
TITLE OF INVENTION: OF AMYLOID FORMATION  
FILE REFERENCE: 12125-002001  
CURRENT APPLICATION NUMBER: US/09/988,842  
CURRENT FILING DATE: 2001-11-19  
PRIOR APPLICATION NUMBER: US 60/251,662  
PRIOR FILING DATE: 2000-12-06  
PRIOR APPLICATION NUMBER: US 60/253,695  
PRIOR FILING DATE: 2000-11-20  
NUMBER OF SEQ ID NOS: 26  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 25  
LENGTH: 11  
TYPE: PRT  
ORGANISM: Artificial Sequence

; FEATURE:  
; OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-25

Query Match 100.0%; Score 29; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
|||  
DB 2 KLVFFFA 7

RESULT 44  
PCT-US96-10220-14  
; Sequence 14, Application PC/TUS9610220  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEWMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/10220  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995

PRIOR APPLICATION DATA: US 08/630,645  
FILING DATE: 10-APR-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1 PCT  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
PCT-US96-10220-14

Query Match 100.0%; Score 29; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
|||  
DB 2 KLVFFFA 7

RESULT 45  
US-09-594-366-5  
; Sequence 5, Application US/09594366  
; Patent No. 6582945  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/09/594,366  
; CURRENT FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 14  
; TYPE: PPT  
; ORGANISM: Homo sapiens  
US-09-594-366-5

Query Match 100.0%; Score 29; DB 4; Length 14;  
Best Local Similarity 100.0%; Pred. No. 2.6;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFFA 6  
|||  
DB 4 KLVFFFA 9

RESULT 46  
US-08-612-785B-14  
; Sequence 14, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Deconti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal  
US-08-612-785B-14

Query Match 100.0%; Score 29; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 47  
US-08-612-785B-37  
; Sequence 37, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 37:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
; US-08-612-785B-37

Query Match 100.0%; Score 29; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 6 KLVFFA 11

RESULT 48  
US-08-617-267C-14  
; Sequence 14, Application US/08617267C  
; Patent No. 6319498

GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
; US-08-617-267C-14

Query Match 100.0%; Score 29; DB 3; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 49  
US-08-766-596A-56  
; Sequence 56, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004



COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A

FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:

NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 56:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-56

Query Match 100.0%; Score 29; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
Db 5 KLVFFA 10

## RESULT 50

US-08-766-596A-57  
Sequence 57, Application US/08766596A  
Patent No. 6462171

## GENERAL INFORMATION:

APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Bias

TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL

TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES

TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE

TITLE OF INVENTION: DEPOSITS

NUMBER OF SEQUENCES: 69

CORRESPONDENCE ADDRESS:

ADDRESSEE: BROWDY AND NEIMARK

STREET: 419 Seventh Street, N.W., Suite 400

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20004

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/766,596A

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/630,645

FILING DATE: 10-APR-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 57:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-57

Query Match 100.0%; Score 29; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
Db 5 KLVFFA 10

Search completed: March 9, 2005, 06:42:59  
Job time : 16.0274 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 16.0274 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-4

Perfect score: 31

Sequence: 1 KVFVFA 6

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database :

Issued Patents AA:\*  
1: /cgn2\_6/prodata/1/1aa/5A-COMB.pep:\*  
2: /cgn2\_6/prodata/1/1aa/5B-COMB.pep:\*  
3: /cgn2\_6/prodata/1/1aa/6A-COMB.pep:\*  
4: /cgn2\_6/prodata/1/1aa/6B-COMB.pep:\*  
5: /cgn2\_6/prodata/1/1aa/PCTUS-COMB.pep:\*  
6: /cgn2\_6/prodata/1/1aa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	31	100.0	6	4	US-09-747-408-4
2	31	100.0	6	4	US-09-747-408-12
3	30	96.8	1283	4	US-09-248-796A-18091
4	28	90.3	506	3	US-08-888-998-2
5	28	90.3	506	3	US-09-362-633-2
6	28	90.3	506	4	US-09-877-476-2
7	28	90.3	506	4	US-09-877-476-28
8	28	90.3	506	4	US-09-877-476-30
9	28	90.3	506	4	US-09-877-476-36
10	27	87.1	67	4	US-09-248-796A-26311
11	27	87.1	82	4	US-09-513-999C-4859
12	27	87.1	98	4	US-09-270-767-40694
13	27	87.1	98	4	US-09-270-767-55910
14	27	87.1	104	4	US-09-823-153-4
15	27	87.1	116	4	US-09-270-767-57813
16	27	87.1	238	4	US-09-902-540-10859
17	27	87.1	240	3	US-09-134-001C-5445
18	27	87.1	266	4	US-09-270-767-42516
19	27	87.1	320	4	US-09-248-796A-19539
20	27	87.1	340	4	US-09-270-767-40453
21	27	87.1	340	4	US-09-270-767-50569
22	27	87.1	475	4	US-09-270-767-45548
23	27	87.1	525	4	US-09-270-767-34763
24	27	87.1	525	4	US-09-270-767-49980
25	27	87.1	579	3	US-08-704-711A-1
26	27	87.1	579	3	US-09-521-220-1
27	27	87.1	582	3	US-08-704-711A-2

28	87.1	582	3	US-08-448-489-1	Sequence 1, Appli
29	87.1	582	3	US-09-211-704A-9	Sequence 9, Appli
30	87.1	582	3	US-09-521-220-2	Sequence 2, Appli
31	87.1	582	3	US-09-391-104-28	Sequence 84, Appli
32	87.1	582	4	US-09-919-497-84	Sequence 28, Appli
33	87.1	582	4	US-09-689-730-1	Sequence 1, Appli
34	87.1	582	4	US-09-270-767-37091	Sequence 37091, A
35	83.9	45	4	US-09-270-767-52308	Sequence 52308, A
36	83.9	61	4	US-09-583-110-4885	Sequence 4885, Ap
37	83.9	84	4	US-09-270-767-60733	Sequence 60733, A
38	83.9	104	4	US-09-621-976-6739	Sequence 6739, Ap
39	83.9	111	4	US-09-205-258-303	Sequence 303, App
40	83.9	118	3	US-09-627-376-17	Sequence 17, Appli
41	83.9	118	4	US-10-047-676B-17	Sequence 45241, A
42	83.9	156	4	US-09-270-767-45241	Sequence 35390, A
43	83.9	177	4	US-09-270-767-35390	Sequence 35390, A
44	83.9	177	4	US-09-270-767-50607	Sequence 50607, A
45	83.9	186	3	US-09-251-645-4	Sequence 4, Appli
46	83.9	201	4	US-09-270-767-33463	Sequence 33463, A
47	83.9	201	4	US-09-270-767-48680	Sequence 48680, A
48	83.9	249	4	US-09-270-767-38186	Sequence 38186, A
49	83.9	249	4	US-09-270-767-53403	Sequence 53403, A
50	83.9	249	4	US-09-248-796A-27128	Sequence 27128, A
51	83.9	310	4	US-09-830-910-2	Sequence 2, Appli
52	83.9	328	4	US-09-248-796A-15301	Sequence 15301, A
53	83.9	394	4	US-09-270-767-41366	Sequence 41366, A
54	83.9	394	4	US-09-270-767-56582	Sequence 56582, A
55	83.9	402	4	US-09-252-991A-25289	Sequence 25289, A
56	83.9	414	4	US-09-902-540-11308	Sequence 11308, A
57	83.9	426	4	US-09-602-787A-424	Sequence 424, App
58	83.9	437	4	US-09-489-039A-8958	Sequence 8958, Ap
59	83.9	446	4	US-09-252-991A-17185	Sequence 17185, A
60	83.9	453	4	US-09-489-039A-8303	Sequence 8303, Ap
61	83.9	493	4	US-09-252-991A-28992	Sequence 28992, A
62	83.9	557	4	US-09-540-236-2206	Sequence 2206, Ap
63	83.9	573	4	US-09-483-039A-11884	Sequence 11884, A
64	83.9	597	4	US-09-252-991A-22560	Sequence 22560, A
65	83.9	745	4	US-09-902-540-10275	Sequence 10275, A

# ALIGNMENTS

RESULT 1  
US-09-747-408-4  
; Sequence 4, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: PsetSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-4

Query Match 100.0%; Score 31; DB 4; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVFA 6

Db 1 KVFVFA 6

<hr/>					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release #1.0, Version #1.30					
CURRENT APPLICATION DATA:					
APPLICATION NUMBER: US/08/888,998					
FILING DATE: 07-JUL-1997					
CLASSIFICATION: 800					
PRIOR APPLICATION DATA:					
APPLICATION NUMBER: US 08/329,603					
FILING DATE: 26-OCT-1994					
ATTORNEY/AGENT INFORMATION:					
NAME: Bastian, Kevin L.					
REGISTRATION NUMBER: 34,774					
REFERENCE/DOCKET NUMBER: 12176-004300					
TELECOMMUNICATION INFORMATION:					
TELEPHONE: (415) 543-9600					
TELEFAX: (415) 543-5043					
INFORMATION FOR SEQ ID NO: 2:					
SEQUENCE CHARACTERISTICS:					
LENGTH: 506 amino acids					
TYPE: amino acid					
STRANDEDNESS: not relevant					
TOPOLOGY: not relevant					
MOLECULE TYPE: peptide					
FEATURE:					
NAME/KEY: Protein					
LOCATION: 1..506					
OTHER INFORMATION: /note= "Amino acid sequence of FAEL protein."					
US-08-888-998-2					
Query Match 90.3%; Score 28; DB 3; Length 506;					
Best Local Similarity 83.3%; Pred. No. 4.6e+02;					
Matches 5; Conservative 1; Mismatches 0; Indels					
QY 1 KFVFFFA 6					
:					
Db 356 KFLFFFA 361					
RESULT 5					
US-09-362-633-2					
Sequence 2, Application US/09362633					
Patent No. 6184355					
GENERAL INFORMATION:					
APPLICANT: JAMES, Douglas W.					
APPLICANT: LIM, Eda					
APPLICANT: KELLER, Janis					
APPLICANT: DOONER, Hugo K.					
TITLE OF INVENTION: FAEL GENES AND THEIR USES					
NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30					
; NUMBER OF SEQUENCES: 8					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Townsend and Townsend Kourie and Crew					
STREET: Steuart Street Tower, One Market Plaza					
CITY: San Francisco					
STATE: California					
COUNTRY: US					
ZIP: 94105-1493					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: PatentIn Release#1.0, Version #1.30</					

;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/09/362,633  
;; FILING DATE:  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/888,998  
;; FILING DATE:  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Bastian, Kevin L.  
;; REGISTRATION NUMBER: 34,774  
;; REFERENCE/DOCKET NUMBER: 12176-004300  
;; TELEPHONE: (415) 543-9600  
;; TELEFAX: (415) 543-5043  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 506 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: not relevant  
;; TOPOLOGY: not relevant  
;; MOLECULE TYPE: peptide  
;; FEATURE:  
;; NAME/KEY: Protein  
;; LOCATION: 1..506  
;; OTHER INFORMATION: /note= "Amino acid sequence of FAEL  
;; OTHER INFORMATION: protein."  
US-09-362-633-2

Query Match 90.3%; Score 28; DB 3; Length 506;  
Best Local Similarity 83.3%; Pred. No. 4.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFA 6  
||:||||  
DB 356 KFLFFA 361

RESULT 6  
US-09-877-476-2  
; Sequence 2, Application US/09877476  
; Patent No. 6713664  
; GENERAL INFORMATION:  
; APPLICANT: Jaworski, Jan G.  
; TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA  
; FILE REFERENCE: 07148-108001  
; CURRENT APPLICATION NUMBER: US/09/877,476  
; CURRENT FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/210,326  
; PRIOR FILING DATE: 2000-06-08  
; NUMBER OF SEQ ID NOS: 56  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 506  
; TYPE: PRT  
; ORGANISM: Arabidopsis thaliana  
US-09-877-476-2

Query Match 90.3%; Score 28; DB 4; Length 506;  
Best Local Similarity 83.3%; Pred. No. 4.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFA 6  
||:||||  
DB 356 KFLFFA 361

RESULT 7  
US-09-877-476-28  
; Sequence 28, Application US/09877476  
; Patent No. 6713664  
; GENERAL INFORMATION:

;; APPLICANT: Jaworski, Jan G.  
;; APPLICANT: Blacklock, Brenda J.  
;; TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA  
;; FILE REFERENCE: 07148-108001  
;; CURRENT APPLICATION NUMBER: US/09/877,476  
;; CURRENT FILING DATE: 2001-06-08  
;; PRIOR APPLICATION NUMBER: US 60/210,326  
;; PRIOR FILING DATE: 2000-06-08  
;; NUMBER OF SEQ ID NOS: 56  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 28  
;; LENGTH: 506  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: 5' 176 amino acids from B. napus elongase KCS (SEQ  
;; OTHER INFORMATION: ID NO:4) and 3' 330 amino acids from A. thaliana  
;; OTHER INFORMATION: FAEL (SEQ ID NO:2); designated Bn176  
US-09-877-476-28

Query Match 90.3%; Score 28; DB 4; Length 506;  
Best Local Similarity 83.3%; Pred. No. 4.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFA 6  
||:||||  
DB 356 KFLFFA 361

RESULT 8  
US-09-877-476-30  
; Sequence 30, Application US/09877476  
; Patent No. 6713664  
; GENERAL INFORMATION:  
; APPLICANT: Jaworski, Jan G.  
; TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA  
; FILE REFERENCE: 07148-108001  
; CURRENT APPLICATION NUMBER: US/09/877,476  
; CURRENT FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/210,326  
; PRIOR FILING DATE: 2000-06-08  
; NUMBER OF SEQ ID NOS: 56  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 30  
; LENGTH: 506  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: 5' 399 amino acids from A. thaliana FAEL (SEQ ID  
; OTHER INFORMATION: NO:2) and 3' 107 amino acids from B. napus  
; OTHER INFORMATION: elongase KCS (SEQ ID NO:4); designated At399  
; NAME/KEY: VARIANT  
; LOCATION: (1)....(0)  
; OTHER INFORMATION: Xaa = Pro or Gln  
US-09-877-476-30

Query Match 90.3%; Score 28; DB 4; Length 506;  
Best Local Similarity 83.3%; Pred. No. 4.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFA 6  
||:||||  
DB 356 KFLFFA 361

RESULT 9  
US-09-877-476-36  
; Sequence 36, Application US/09877476  
; Patent No. 6713664  
; GENERAL INFORMATION:

```
; APPLICANT: Jaworski, Jan G.
; APPLICANT: Blacklock, Brenda J.
; TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA
; TITLE OF INVENTION: SYNTHASE POLYPEPTIDES
; FILE REFERENCE: 07148-108001
; CURRENT APPLICATION NUMBER: US/09/877,476
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,326
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 506
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 506 amino acids from A. thaliana FAE1 (SEQ ID
; OTHER INFORMATION: NO:2) having a mutation at residue 92; designated
; OTHER INFORMATION: At K92R; hypothetical
US-09-877-476-36

Query Match          90.3%; Score 28; DB 4; Length 506;
Best Local Similarity 83.3%; Pred. No. 4.6e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVFA 6
DB      356 KLFVFA 361

RESULT 10
US-09-248-796A-26311
; Sequence 26311, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 26311
; LENGTH: 67
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-26311

Query Match          87.1%; Score 27; DB 4; Length 67;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVFA 6
DB      16 KFIYA 21

RESULT 11
US-09-513-999C-4859
; Sequence 4859, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
```

```
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 4859
; LENGTH: 82
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-513-999C-4859
```

```
Query Match          87.1%; Score 27; DB 4; Length 82;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 KVFVFF 5
DB      32 KVFVFF 36
```

## RESULT 12

```
US-09-270-767-40694
; Sequence 40694, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 40694
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-40694
```

```
Query Match          87.1%; Score 27; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 KVFVFF 5
DB      84 KVFVFF 89
```

## RESULT 13

```
US-09-270-767-55910
; Sequence 55910, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55910
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-55910
```

```
Query Match          87.1%; Score 27; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 KVFVF 5  
Db 84 KVFVF 88

## RESULT 14

US-09-823-153-4  
; Sequence 4, Application US/09823153  
; Patent No. 6713248  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Company  
; APPLICANT: Roberts, Susan  
; APPLICANT: Pak, Roger  
; APPLICANT: Lewis, Martin  
; APPLICANT: Smith, David  
; APPLICANT: Hendrick, Joseph  
; APPLICANT: Vinitsky, Alexander  
; TITLE OF INVENTION: ISOLATION OF FUNCTIONALLY ACTIVE GAMMA-SECRETASE PROTEIN COMPLEX  
; TITLE OF INVENTION: METHODS FOR DETECTION OF ACTIVITY AND INHIBITORS THEREOF  
; FILE REFERENCE: D0004  
; CURRENT APPLICATION NUMBER: US/09/823,153  
; CURRENT FILING DATE: 2001-07-02  
; NUMBER OF SEQ ID NOS: 11  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4  
; LENGTH: 104  
; TYPE: PRT  
; ORGANISM: Human Beta App  
US-09-823-153-4

Query Match 87.1%; Score 27; DB 4; Length 104;  
Best Local Similarity 83.3%; Pred. No. 1.8e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 6  
Db 21 EFVFFA 26

## RESULT 15

US-09-270-767-57813  
; Sequence 57813, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:  
; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17  
; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 57813  
; LENGTH: 116  
; TYPE: PRT  
; ORGANISM: Drosophila melanogaster  
; FEATURE:  
; OTHER INFORMATION: Xaa means any amino acid  
US-09-270-767-57813

Query Match 87.1%; Score 27; DB 4; Length 116;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5  
Db 62 KVFVF 66

## RESULT 16

US-09-540-10859  
; Sequence 10859, Application US/09902540  
; Patent No. 6833447  
; GENERAL INFORMATION:

; APPLICANT: Goldman, Barry S.  
; APPLICANT: Hinkle, Gregory J.  
; APPLICANT: Slater, Steven C.  
; APPLICANT: Wiegand, Roger C.  
; TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof  
; FILE REFERENCE: 38-10(15849)B  
; CURRENT APPLICATION NUMBER: US/09/902,540  
; CURRENT FILING DATE: 2001-07-10  
; PRIOR APPLICATION NUMBER: 60/217,883  
; PRIOR FILING DATE: 2000-07-10  
; NUMBER OF SEQ ID NOS: 16825  
; SEQ ID NO 10859  
; LENGTH: 238  
; TYPE: PRT  
; ORGANISM: Myxococcus xanthus  
US-09-902-540-10859

Query Match 87.1%; Score 27; DB 4; Length 238;  
Best Local Similarity 100.0%; Pred. No. 3.7e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5  
Db 132 KVFVF 136

## RESULT 17

US-09-134-001C-5445  
; Sequence 5445, Application US/09134001C  
; Patent No. 6380370  
; GENERAL INFORMATION:  
; APPLICANT: Lynn Doucette-Stamm et al  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS  
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS  
; FILE REFERENCE: GTC-007  
; CURRENT APPLICATION NUMBER: US/09/134,001C  
; CURRENT FILING DATE: 1998-08-13  
; PRIOR APPLICATION NUMBER: US 60/064,964  
; PRIOR FILING DATE: 1997-11-08  
; PRIOR APPLICATION NUMBER: US 60/055,779  
; PRIOR FILING DATE: 1997-08-14  
; NUMBER OF SEQ ID NOS: 5674  
; SEQ ID NO 5445  
; LENGTH: 240  
; TYPE: PRT  
; ORGANISM: Staphylococcus epidermidis  
US-09-134-001C-5445

Query Match 87.1%; Score 27; DB 3; Length 240;  
Best Local Similarity 83.3%; Pred. No. 3.7e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFA 6  
Db 168 QVFVFA 173

## RESULT 18

US-09-270-767-42516  
; Sequence 42516, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:  
; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17  
; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 42516  
; LENGTH: 266  
; TYPE: PRT  
; ORGANISM: Drosophila melanogaster

```

;
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-42516

Query Match      87.1%; Score 27; DB 4; Length 266;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVF 5
Db 62 KVFVF 66

RESULT 19
US-09-248-796A-19539
; Sequence 19539, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICANS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 19539
; LENGTH: 320
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-19539

Query Match      87.1%; Score 27; DB 4; Length 320;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVF 5
Db 23 KVFVF 27

RESULT 20
US-09-270-767-40453
; Sequence 40453, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 40453
; LENGTH: 340
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-40453

Query Match      87.1%; Score 27; DB 4; Length 340;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVFA 6
Db 310 KYIIFFA 315

RESULT 21
US-09-270-767-55669
; Sequence 55669, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55669
; LENGTH: 340
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-55669

Query Match      87.1%; Score 27; DB 4; Length 340;
Best Local Similarity 66.7%; Pred. No. 5.1e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVFA 6
Db 310 KYIIFFA 315

RESULT 22
US-09-270-767-45548
; Sequence 45548, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 45548
; LENGTH: 475
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-45548

Query Match      87.1%; Score 27; DB 4; Length 475;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVFVF 5
Db 49 KVFVF 53

RESULT 23
US-09-270-767-34763
; Sequence 34763, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34763
; LENGTH: 525
; TYPE: PRT

```



```
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-34763

Query Match      87.1%; Score 27; DB 4; Length 525;
Best Local Similarity 66.7%; Pred. No. 7.4e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVFA 6
      |:|:|
Db      446 KYIFFA 451

RESULT 24
US-09-270-767-49980
; Sequence 49980, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 49980
; LENGTH: 525
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-49980

Query Match      87.1%; Score 27; DB 4; Length 525;
Best Local Similarity 66.7%; Pred. No. 7.4e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVFA 6
      |:|:|
Db      446 KYIFFA 451

RESULT 25
US-08-704-711A-1
; Sequence 1, Application US/08704711A
; Patent No. 6114159
; GENERAL INFORMATION:
; APPLICANT: WILL, Horst
; APPLICANT: HINZMANN, Bernd
; TITLE OF INVENTION: DNA SEQUENCES FOR MATRIX
; TITLE OF INVENTION: METALLOPROTEASES, THEIR PRODUCTION AND USE
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/704,711A
; FILING DATE: 20-NOV-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/DE95/00357
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: DE 4438838.1
; FILING DATE: 21-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 4409663.1
; FILING DATE: 17-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: GRANADOS, Patricia D.
; REGISTRATION NUMBER: 33,683
; REFERENCE/DOCKET NUMBER: 26083/124
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 579 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-704-711A-1

Query Match      87.1%; Score 27; DB 3; Length 579;
Best Local Similarity 100.0%; Pred. No. 8.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVF 5
      |:|:|
Db      375 KVFVF 379

RESULT 26
US-09-521-220-1
; Sequence 1, Application US/09521220
; Patent No. 639348
; GENERAL INFORMATION:
; APPLICANT: WILL, Horst
; APPLICANT: HINZMANN, Bernd
; TITLE OF INVENTION: DNA SEQUENCES FOR MATRIX
; TITLE OF INVENTION: METALLOPROTEASES, THEIR PRODUCTION AND USE
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/521,220
; FILING DATE: 08-Mar-2000
; CLASSIFICATION: <Unknown>
; 21-OCT-1994
; 17-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/704,711
; FILING DATE: <Unknown>
; APPLICATION NUMBER: DE 4438838.1
; FILING DATE: 21-OCT-1994
; APPLICATION NUMBER: DE 4409663.1
; FILING DATE: 17-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: GRANADOS, Patricia D.
; REGISTRATION NUMBER: 33,683
; REFERENCE/DOCKET NUMBER: 26083/124
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
```

; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 579 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:

US-09-521-220-1

Query Match 87.1%; Score 27; DB 3; Length 579;  
Best Local Similarity 100.0%; Pred. No. 8.1e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5

DB 375 KVFVF 379

RESULT 27

US-08-704-711A-2  
; Sequence 2, Application US/08704711A

; Patent No. 6114159

; GENERAL INFORMATION:

; APPLICANT: WILL, Horst

; APPLICANT: HINZMANN, Bernd

; TITLE OF INVENTION: DNA SEQUENCES FOR MATRIX

; TITLE OF INVENTION: METALLOPROTEASES, THEIR PRODUCTION AND USE

; NUMBER OF SEQUENCES: 22

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Foley & Lardner

; STREET: 3000 K Street, N.W., Suite 500

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20007-5109

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/704,711A

; FILING DATE: 20-NOV-1996

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: WO PCT/DE95/00357

; FILING DATE: 17-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: DE 4438838.1

; FILING DATE: 21-OCT-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: DE 4409663.1

; FILING DATE: 17-MAR-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: GRANADOS, Patricia D.

; REGISTRATION NUMBER: 33,683

; REFERENCE/DOCKET NUMBER: 26083/124

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202)672-5300

; TELEFAX: (202)672-5399

; TELEX: 904136

; INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 582 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-704-711A-2

Query Match 87.1%; Score 27; DB 3; Length 582;  
Best Local Similarity 100.0%; Pred. No. 8.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5

DB 378 KVFVF 382

RESULT 28

US-08-448-489-1

; Sequence 1, Application US/08448489

; Patent No. 6184022

; GENERAL INFORMATION:

; APPLICANT: SEIKI, Motoharu

; APPLICANT: SATO, Hiroshi

; APPLICANT: SHINAGAWA, Akira

; TITLE OF INVENTION: NOVEL METALLOPROTEINASE AND ENCODING DNA THEREFOR

; FILE REFERENCE: 55-290P

; CURRENT APPLICATION NUMBER: US/08/448,489

; CURRENT FILING DATE: 1995-06-07

; NUMBER OF SEQ ID NOS: 19

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1

; LENGTH: 582

; TYPE: PRT

; ORGANISM: Homo sapiens

US-08-448-489-1

Query Match

87.1%; Score 27; DB 3; Length 582;

Best Local Similarity 100.0%; Pred. No. 8.2e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5

DB 378 KVFVF 382

RESULT 29

US-09-211-704A-9

; Sequence 9, Application US/09211704A

; Patent No. 6271014

; GENERAL INFORMATION:

; APPLICANT: de Saint-Vis, Blandine Marie

; APPLICANT: Fossiez, Francois

; APPLICANT: Caux, Christophe

; APPLICANT: Lebecque, Serge J.E.

; TITLE OF INVENTION: Mammalian Proteinases; Related Reagents

; TITLE OF INVENTION: and Methods

; NUMBER OF SEQUENCES: 10

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DNAX Research Institute

; STREET: 901 California Avenue

; CITY: Palo Alto

; STATE: California

; COUNTRY: USA

; ZIP: 94304-1104

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/211,704A

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 09/005,263

; FILING DATE: 09-JAN-1998

; ATTORNEY/AGENT INFORMATION:

; NAME: Ching, Edwin P.

; REGISTRATION NUMBER: 34,090

; REFERENCE/DOCKET NUMBER: SF0781K

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (650)852-9196

; TELEFAX: (650)496-1200

; INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:  
LENGTH: 582 amino acids  
TYPE: amino acid  
STRANDEDNESS: not relevant  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-211-704A-9

Query Match 87.1%; Score 27; DB 3; Length 582;  
Best Local Similarity 100.0%; Pred. No. 8.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KPVFF 5  
DB 378 KPVFF 382

## RESULT 30

US-09-521-220-2  
Sequence 2, Application US/09521220  
Patent No. 6399348  
GENERAL INFORMATION:

APPLICANT: WILL, Horst  
TITLE OF INVENTION: DNA SEQUENCES FOR MATRIX  
METALLOPROTEASES, THEIR PRODUCTION AND USE  
NUMBER OF SEQUENCES: 22  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/521,220  
FILING DATE: 08-Mar-2000  
CLASSIFICATION: <Unknown>  
21-OCT-1994  
17-MAR-1994

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/704,711  
FILING DATE: <Unknown>  
APPLICATION NUMBER: DE 4438838.1  
FILING DATE: 21-OCT-1994  
APPLICATION NUMBER: DE 4409663.1  
FILING DATE: 17-MAR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: GRANADOS, Patricia D.  
REGISTRATION NUMBER: 33,683  
REFERENCE/DOCKET NUMBER: 26083/124  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136

## INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:  
LENGTH: 582 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

## SEQUENCE DESCRIPTION: SEQ ID NO: 2:

US-09-521-220-2

Query Match 87.1%; Score 27; DB 3; Length 582;  
Best Local Similarity 100.0%; Pred. No. 8.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KPVFF 5  
DB 378 KPVFF 382

## RESULT 31

US-09-391-104-28  
Sequence 28, Application US/09391104  
Patent No. 6399371  
GENERAL INFORMATION:  
APPLICANT: Abbott Laboratories  
APPLICANT: Falduto, Michael T.  
APPLICANT: Magnuson, Scott R.  
APPLICANT: Morgan, Douglas W.  
TITLE OF INVENTION: HUMAN MATRIX METALLOPROTEASE GENE,  
PROTEINS ENCODED THEREFROM AND METHODS  
TITLE OF INVENTION: OF USING SAME  
FILE REFERENCE: 6073.US.F1  
CURRENT APPLICATION NUMBER: US/09/391,104  
CURRENT FILING DATE: 1999-09-07  
PRIOR FILING DATE: US 08/814,394  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 28  
LENGTH: 582  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-391-104-28

Query Match 87.1%; Score 27; DB 3; Length 582;  
Best Local Similarity 100.0%; Pred. No. 8.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KPVFF 5  
DB 378 KPVFF 382

## RESULT 32

US-09-919-497-84  
Sequence 84, Application US/09919497  
Patent No. 6773883  
GENERAL INFORMATION:  
APPLICANT: Mutter, George L.  
TITLE OF INVENTION: PROGNOSTIC CLASSIFICATION OF ENDOMETRIAL CANCER  
FILE REFERENCE: B0801/7225  
CURRENT APPLICATION NUMBER: US/09/919,497  
CURRENT FILING DATE: 2001-07-31  
PRIOR APPLICATION NUMBER: US 60/221,735  
PRIOR FILING DATE: 2000-07-31  
NUMBER OF SEQ ID NOS: 100  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 84  
LENGTH: 582  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-919-497-84

Query Match 87.1%; Score 27; DB 4; Length 582;  
Best Local Similarity 100.0%; Pred. No. 8.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KPVFF 5  
DB 378 KPVFF 382

## RESULT 33

US-09-689-730-1  
Sequence 1, Application US/09689730  
Patent No. 6825024  
GENERAL INFORMATION:

```
; APPLICANT: SEIKI, Motoharu
; APPLICANT: SATO, Hiroshi
; APPLICANT: SHINAGAWA, Akira
; TITLE OF INVENTION: NOVEL METALLOPROTEINASE AND ENCODING DNA THEREFOR
; FILE REFERENCE: 55-290P
; CURRENT APPLICATION NUMBER: US/09/689,730
; CURRENT FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US/08/448,489
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 582
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-689-730-1

Query Match      87.1%; Score 27; DB 4; Length 582;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5
   |||||
Db 378 KVFVF 382

RESULT 34
US-09-270-767-37091
; Sequence 37091, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 37091
; LENGTH: 45
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-37091

Query Match      83.9%; Score 26; DB 4; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFFA 6
   |||||
Db 16 FVFFA 20

RESULT 35
US-09-270-767-52308
; Sequence 52308, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 52308
; LENGTH: 45
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-52308

Query Match      83.9%; Score 26; DB 4; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
```

```
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFFA 6
   |||||
Db 16 FVFFA 20

RESULT 36
US-09-583-110-4885
; Sequence 4885, Application US/09583110
; Patent No. 669703
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al.
; TITLE OF INVENTION: Nucleic Acid and Amino Acid Sequences Relating to Streptococcus
; TITLE OF INVENTION: Pneumoniae for Diagnostics and Therapeutics
; FILE REFERENCE: PATH00-07A
; CURRENT APPLICATION NUMBER: US/09/583,110
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/107,433
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/085,131
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: US 60/051,553
; PRIOR FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 5322
; SEQ ID NO 4885
; LENGTH: 61
; TYPE: PRT
; ORGANISM: Streptococcus pneumoniae
US-09-583-110-4885
```

```
Query Match      83.9%; Score 26; DB 4; Length 61;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5
   |||||
Db 44 KFIFF 48
```

```
RESULT 37
US-09-270-767-60733
; Sequence 60733, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60733
; LENGTH: 84
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-60733
```

```
Query Match      83.9%; Score 26; DB 4; Length 84;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVF 5
   |||||
Db 48 KFIFF 52
```

```
RESULT 38
US-09-621-976-6739
; Sequence 6739, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
```

APPLICANT: Jobert, S.  
APPLICANT: Giordano, J.Y.  
TITLE OF INVENTION: ESTs and Encoded Human Proteins.  
FILE REFERENCE: GENSET.054PR2

CURRENT APPLICATION NUMBER: US/09/621,976  
CURRENT FILING DATE: 2000-07-21

NUMBER OF SEQ ID NOS: 19335

SOFTWARE: Patent.pm  
SEQ ID NO 6739

LENGTH: 104

TYPE: PRT

ORGANISM: Homo sapiens

US-09-621-976-6739

Query Match 83.9%; Score 26; DB 4; Length 104;

Best Local Similarity 100.0%; Pred. No. 2.7e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFFA 6

DB 31 FVFFA 35

RESULT 39

US-09-205-258-303

Sequence 303, Application US/09205258

Patent No. 6525174

GENERAL INFORMATION:

APPLICANT: Young et al.

TITLE OF INVENTION: 207 Human Secreted Proteins

FILE REFERENCE: P2007P1

CURRENT APPLICATION NUMBER: US/09/205,258

CURRENT FILING DATE: 1998-12-04

EARLIER APPLICATION NUMBER: PCT/US98/11422

EARLIER FILING DATE: 1998-06-04

EARLIER APPLICATION NUMBER: 60/048,885

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/049,375

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,881

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,880

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,896

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/049,020

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,876

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,895

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,884

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,894

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,971

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,964

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,882

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,899

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,893

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,900

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,901

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,892

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,915

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/049,019  
EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,970

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,972

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,916

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/049,373

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,875

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/049,374

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,917

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,949

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,974

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,883

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,897

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,898

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,962

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,963

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,877

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/048,878

EARLIER FILING DATE: 1997-06-06

EARLIER APPLICATION NUMBER: 60/070,923

EARLIER FILING DATE: 1997-12-18

EARLIER APPLICATION NUMBER: 60/092,921

EARLIER FILING DATE: 1998-07-15

EARLIER APPLICATION NUMBER: 60/094,657

EARLIER FILING DATE: 1998-07-30

NUMBER OF SEQ ID NOS: 1227

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 303

LENGTH: 111

TYPE: PRT

ORGANISM: Homo sapiens

FEATURE:

NAME/KEY: SITE

LOCATION: (9)

OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids

US-09-205-258-303

Query Match 83.9%; Score 26; DB 4; Length 111;

Best Local Similarity 100.0%; Pred. No. 2.9e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFFA 6

DB 79 FVFFA 83

RESULT 40

US-09-627-376-17

Sequence 17, Application US/09627376

Patent No. 6342385

GENERAL INFORMATION:

APPLICANT: Qi, Fengxia

TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS

FILE REFERENCE: UAB-17402/22

CURRENT APPLICATION NUMBER: US/09/627,376

CURRENT FILING DATE: 2001-05-30

NUMBER OF SEQ ID NOS: 17

SOFTWARE: Patentin version 3.0

Caufield, Page

Chen, Ping

```
; SEQ ID NO 17
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-09-627-376-17

Query Match      83.9%; Score 26; DB 3; Length 118;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FVFFA 6
Db      39 FVFFA 43

RESULT 41
US-10-047-676B-17
; Sequence 17, Application US/10047676B
; Patent No. 669970
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia
; APPLICANT: Caulfield, Page W.
; APPLICANT: Chen, Ping
; TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: UAB-17403/22
; CURRENT APPLICATION NUMBER: US/10/047,676B
; PRIOR FILING DATE: 2002-01-14
; PRIOR APPLICATION NUMBER: US 09/627,376
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-10-047-676B-17

Query Match      83.9%; Score 26; DB 4; Length 118;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FVFFA 6
Db      39 FVFFA 43

RESULT 42
US-09-270-767-45241
; Sequence 45241, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 45241
; LENGTH: 156
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-45241

Query Match      83.9%; Score 26; DB 4; Length 156;
Best Local Similarity 80.0%; Pred. No. 3.9e+02;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVFVF 5
Db      120 KPIFF 124

RESULT 43
US-09-270-767-35390
; Sequence 35390, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35390
; LENGTH: 177
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-35390

Query Match      83.9%; Score 26; DB 4; Length 177;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FVFFA 6
Db      122 FVFFA 126

RESULT 44
US-09-270-767-50607
; Sequence 50607, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 50607
; LENGTH: 177
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-50607

Query Match      83.9%; Score 26; DB 4; Length 177;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FVFFA 6
Db      122 FVFFA 126

RESULT 45
US-09-251-645-4
; Sequence 4, Application US/09251645
; Patent No. 6281413
; GENERAL INFORMATION:
; APPLICANT: Kramer, Vance C.
; APPLICANT: Morgan, Michael K.
; APPLICANT: Anderson, Arne R.
; APPLICANT: Hart, Hope
; APPLICANT: Warren, Gregory W.
; APPLICANT: Dunn, Martha
; APPLICANT: Chen, Jeng S.
; TITLE OF INVENTION: NOVEL INSECTICIDAL TOXINS FROM PHOTORHABDUS LUMINESCENS
; TITLE OF INVENTION: AND NUCLEIC ACID SEQUENCES CODING THEREFOR
; FILE REFERENCE: CGC1963/A
```

; CURRENT APPLICATION NUMBER: US/09/251,645  
; CURRENT FILING DATE: 1999-02-17  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 4  
; LENGTH: 186  
; TYPE: PRT  
; ORGANISM: Photorhabdus luminescens  
US-09-251-645-4

Query Match 83.9%; Score 26; DB 3; Length 186;  
Best Local Similarity 66.7%; Pred. No. 4.6e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFFFA 6  
:|||||  
DB 134 QFIFFA 139

## RESULT 46

US-09-270-767-33463  
; Sequence 33463, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17

; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 33463  
; LENGTH: 201  
; TYPE: PRT

; ORGANISM: Drosophila melanogaster  
US-09-270-767-33463

Query Match 83.9%; Score 26; DB 4; Length 201;  
Best Local Similarity 100.0%; Pred. No. 4.9e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFPPA 6  
:|||||  
DB 80 FVFPPA 84

## RESULT 47

US-09-270-767-48680  
; Sequence 48680, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17

; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 48680  
; LENGTH: 201  
; TYPE: PRT

; ORGANISM: Drosophila melanogaster  
US-09-270-767-48680

Query Match 83.9%; Score 26; DB 4; Length 201;  
Best Local Similarity 100.0%; Pred. No. 4.9e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FVFPPA-6  
:|||||  
DB 80 FVFPPA 84

RESULT 48  
US-09-270-767-38186  
; Sequence 38186, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17

; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 38186  
; LENGTH: 249  
; TYPE: PRT

; ORGANISM: Drosophila melanogaster  
; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid  
US-09-270-767-38186

Query Match 83.9%; Score 26; DB 4; Length 249;  
Best Local Similarity 80.0%; Pred. No. 6e+02;  
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFF 5  
:|||||  
DB 196 KFIFF 200

## RESULT 49

US-09-270-767-53403  
; Sequence 53403, Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17

; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 53403  
; LENGTH: 249  
; TYPE: PRT

; ORGANISM: Drosophila melanogaster  
; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid  
US-09-270-767-53403

Query Match 83.9%; Score 26; DB 4; Length 249;  
Best Local Similarity 80.0%; Pred. No. 6e+02;  
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KVFVFF 5  
:|||||  
DB 196 KFIFF 200

## RESULT 50

US-09-248-796A-27128  
; Sequence 27128, Application US/09248796A  
; Patent No. 6747137  
; GENERAL INFORMATION:

; APPLICANT: Keith Weinstock et al  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICA  
; FILE REFERENCE: FOR DIAGNOSTICS AND THERAPEUTICS  
; FILE REFERENCE: 107196.132

; CURRENT APPLICATION NUMBER: US/09/248,796A  
; CURRENT FILING DATE: 1999-02-12  
; PRIOR APPLICATION NUMBER: US 60/074,725  
; PRIOR FILING DATE: 1998-02-13

; PRIOR APPLICATION NUMBER: US 60/096,409  
; PRIOR FILING DATE: 1998-08-13

```
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 27128
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-27128

Query Match      83.9%; Score 26; DB 4; Length 249;
Best Local Similarity 80.0%; Pred. No. 6e+02;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KEVFP 5
      ||:|
Db      108 KPFP 112

Search completed: March 9, 2005, 06:43:00
Job time : 17.0274 secs
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 16.0274 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-5

Perfect score: 29  
Sequence: 1 AFFVLK 6

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database : Issued Patents.AA.\*

1: /cgn2\_6/prodata/1/iaa/5A COMB.pep.\*

2: /cgn2\_6/prodata/1/iaa/5B COMB.pep.\*

3: /cgn2\_6/prodata/1/iaa/6A COMB.pep.\*

4: /cgn2\_6/prodata/1/iaa/6B COMB.pep.\*

5: /cgn2\_6/prodata/1/iaa/PCTUS COMB.pep.\*

6: /cgn2\_6/prodata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	4	US-09-747-408-5
2	29	100.0	6	4	US-09-747-408-13
3	29	100.0	73	4	US-09-583-110-3676
4	28	96.6	85	4	US-09-621-976-4521
5	28	96.6	107	4	US-09-489-039A-13627
6	28	96.6	392	4	US-09-248-796A-26952
7	26	89.7	58	4	US-09-621-976-6455
8	26	89.7	63	4	US-09-107-532A-4668
9	26	89.7	206	3	US-08-506-296B-64
10	26	89.7	243	3	US-09-134-001C-4114
11	26	89.7	307	3	US-08-506-296B-63
12	26	89.7	393	3	US-09-489-039A-7842
13	26	89.7	394	3	US-08-506-296B-62
14	26	89.7	399	4	US-09-134-000C-5712
15	26	89.7	434	4	US-09-540-236-2853
16	26	89.7	443	3	US-08-506-296B-76
17	26	89.7	545	3	US-08-506-296B-75
18	26	89.7	632	3	US-08-506-296B-74
19	26	89.7	844	4	US-09-341-505-2
20	26	89.7	911	4	US-08-461-562B-2
21	26	89.7	1268	3	US-08-506-296B-28
22	25	86.2	20	1	US-07-670-296-20
23	25	86.2	20	1	US-08-093-781-17
24	25	86.2	22	1	US-07-670-296-24
25	25	86.2	41	4	US-09-673-395A-467
26	25	86.2	62	4	US-09-248-796A-24335
27	25	86.2	80	4	US-09-134-000C-6793

ALIGNMENTS

RESULT 1  
US-09-747-408-5  
; Sequence 5, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-5

Query Match 100.0%; Score 29; DB 4; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
|||||

Db 1 AFFVLK 6

28 25 86.2 102 4 US-09-270-767-32277 Sequence 32277, A  
29 25 86.2 102 4 US-09-270-767-47494 Sequence 47494, A  
30 25 86.2 111 4 US-09-543-681A-7876 Sequence 7876, Ap  
31 25 86.2 117 4 US-09-270-767-57477 Sequence 57477, A  
32 25 86.2 158 4 US-09-270-767-32960 Sequence 32960, A  
33 25 86.2 158 4 US-09-270-767-48177 Sequence 48177, A  
34 25 86.2 166 4 US-09-621-976-4638 Sequence 4638, Ap  
35 25 86.2 183 4 US-09-107-532A-5068 Sequence 5068, Ap  
36 25 86.2 185 4 US-09-529-157-6 Sequence 6, Appli  
37 25 86.2 185 4 US-09-529-157-7 Sequence 7, Appli  
38 25 86.2 188 4 US-09-489-039A-13866 Sequence 13866, A  
39 25 86.2 189 4 US-09-252-991A-28289 Sequence 28289, A  
40 25 86.2 197 4 US-09-134-000C-5350 Sequence 5350, Ap  
41 25 86.2 204 4 US-09-949-016-9489 Sequence 9489, Ap  
42 25 86.2 205 4 US-09-673-395A-205 Sequence 205, App  
43 25 86.2 219 4 US-09-489-039A-7731 Sequence 7731, Ap  
44 25 86.2 229 4 US-09-270-767-42203 Sequence 42203, A  
45 25 86.2 229 4 US-10-101-464A-759 Sequence 759, App  
46 25 86.2 247 1 US-07-648-796A-2 Sequence 2, Appli  
47 25 86.2 269 3 US-09-724-864-47 Sequence 47, Appli  
48 25 86.2 282 4 US-09-134-000C-4468 Sequence 4468, Ap  
49 25 86.2 296 4 US-09-543-681A-4672 Sequence 4672, Ap  
50 25 86.2 339 2 US-08-855-714-3 Sequence 3, Appli  
51 25 86.2 340 4 US-09-252-991A-20826 Sequence 20826, A  
52 25 86.2 344 4 US-09-134-000C-4671 Sequence 4671, Ap  
53 25 86.2 376 1 US-07-648-796A-6 Sequence 6, Appli  
54 25 86.2 392 3 US-09-147-926-2 Sequence 2, Appli  
55 25 86.2 445 4 US-08-887-534A-61 Sequence 61, Appli  
56 25 86.2 445 4 US-09-527-431-61 Sequence 61, Appli  
57 25 86.2 445 4 US-09-446-861-61 Sequence 61, Appli  
58 25 86.2 471 4 US-09-902-540-10808 Sequence 10808, A  
59 25 86.2 585 4 US-09-134-000C-5945 Sequence 5945, Ap  
60 25 86.2 661 4 US-09-575-081B-23 Sequence 23, Appli  
61 25 86.2 770 1 US-07-648-796A-8 Sequence 8, Appli  
62 25 86.2 799 1 US-07-648-796A-7 Sequence 7, Appli  
63 25 86.2 905 4 US-09-538-092-1079 Sequence 1079, Ap  
64 25 86.2 906 1 US-08-190-802A-31 Sequence 31, Appli  
65 25 86.2 906 3 US-08-477-346-31 Sequence 31, Appli

us-10-009-122-5.ra1

Wed Mar 9 08:15:58 2005

; TITLE OF INVENTION: ESTs and Encoded Human Proteins.

; FILE REFERENCE: GENSET.054PR2

; CURRENT APPLICATION NUMBER: US/09/621,976

; CURRENT FILING DATE: 2000-07-21

; NUMBER OF SEQ ID NOS: 19335

; SOFTWARE: Patent.pm

; SEQ ID NO 4521

; LENGTH: 85

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-621-976-4521

Query Match 96.6%; Score 28; DB 4; Length 85;

Best Local Similarity 83.3%; Pred. No. 62;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6

Db 25 AFFILK 30

RESULT 5

US-09-489-039A-13627

; Sequence 13627, Application US/09489039A

; Patent No. 6610836

; GENERAL INFORMATION:

; APPLICANT: Gary Breton et. al

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA

; FILE REFERENCE: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS

; FILE REFERENCE: 2709.2004001

; CURRENT APPLICATION NUMBER: US/09/489,039A

; CURRENT FILING DATE: 2000-01-27

; PRIOR APPLICATION NUMBER: US 60/117,747

; PRIOR FILING DATE: 1999-01-29

; NUMBER OF SEQ ID NOS: 14342

; SEQ ID NO 13627

; LENGTH: 107

; TYPE: PRT

; ORGANISM: Klebsiella pneumoniae

; US-09-489-039A-13627

Query Match 96.6%; Score 28; DB 4; Length 107;

Best Local Similarity 83.3%; Pred. No. 76;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6

Db 19 AFFILK 24

RESULT 6

US-09-248-796A-26952

; Sequence 26952, Application US/09248796A

; Patent No. 6747137

; GENERAL INFORMATION:

; APPLICANT: Keith Weinstock et al

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN.

; FILE REFERENCE: FOR DIAGNOSTICS AND THERAPEUTICS

; FILE REFERENCE: 107196.132

; CURRENT APPLICATION NUMBER: US/09/248,796A

; CURRENT FILING DATE: 1999-02-12

; PRIOR APPLICATION NUMBER: US 60/074,725

; PRIOR FILING DATE: 1998-02-13

; PRIOR APPLICATION NUMBER: US 60/096,409

; PRIOR FILING DATE: 1998-08-13

; NUMBER OF SEQ ID NOS: 28208

; SEQ ID NO 26952

; LENGTH: 392

; TYPE: PRT

; ORGANISM: Candida albicans

; US-09-248-796A-26952

Query Match 96.6%; Score 28; DB 4; Length 392;

RESULT 2

US-09-747-408-13

; Sequence 13, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; TITLE OF INVENTION: Cerebral Amyloid Angiopathy

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 13

; LENGTH: 6

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-747-408-13

Query Match 100.0%; Score 29; DB 4; Length 6;

Best Local Similarity 100.0%; Pred. No. 4.1e+05;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6

Db 1 AFFVLK 6

RESULT 3

US-09-583-110-3676

; Sequence 3676, Application US/09583110

; Patent No. 6689703

; GENERAL INFORMATION:

; APPLICANT: Lynn Doucette-Stamm et al.

; TITLE OF INVENTION: Nucleic Acid and Amino Acid Sequences Relating to Streptococcus

; TITLE OF INVENTION: Pneumoniae for Diagnostics and Therapeutics

; FILE REFERENCE: PATH00-07A

; CURRENT APPLICATION NUMBER: US/09/583,110

; CURRENT FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: US 09/107,433

; PRIOR FILING DATE: 1998-06-30

; PRIOR APPLICATION NUMBER: US 60/085,131

; PRIOR FILING DATE: 1998-05-12

; PRIOR APPLICATION NUMBER: US 60/051,553

; PRIOR FILING DATE: 1997-07-02

; NUMBER OF SEQ ID NOS: 5322

; SEQ ID NO 3676

; LENGTH: 73

; TYPE: PRT

; ORGANISM: Streptococcus pneumoniae

; US-09-583-110-3676

Query Match 100.0%; Score 29; DB 4; Length 73;

Best Local Similarity 100.0%; Pred. No. 34;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6

Db 68 AFFVLK 73

RESULT 4

US-09-621-976-4521

; Sequence 4521, Application US/09621976

; Patent No. 6639063

; GENERAL INFORMATION:

; APPLICANT: Dumas Milne Edwards, J.B.

; APPLICANT: Jobert, S.

; APPLICANT: Giordano, J.Y.

```

; INFORMATION FOR SEQ ID NO: 4668:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 63 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Enterococcus faecium
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1...63
; SEQUENCE DESCRIPTION: SEQ ID NO: 4668:
US-09-107-532A-4668

Query Match      89.7%; Score 26; DB 4; Length 63;
Best Local Similarity 83.3%; Pred No. 1.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
Db 53 SPFFVLK 58

RESULT 9
US-08-506-296B-64
; Sequence 64, Application US/08506296B
; Patent No. 6313265
; GENERAL INFORMATION:
; APPLICANT: Phillips, Greg
; APPLICANT: Cunningham, Bruce A.
; APPLICANT: Crossin, Kathryn L.
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: U.S.
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/506.296B
; FILING DATE: 24-JUL-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: TSRI 488.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 206 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-506-296B-64

Query Match      89.7%; Score 26; DB 3; Length 206;
Best Local Similarity 83.3%; Pred No. 3.4e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
; :|||||

```

```

; INFORMATION FOR SEQ ID NO: 4668:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 63 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Enterococcus faecium
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1...63
; SEQUENCE DESCRIPTION: SEQ ID NO: 4668:
US-09-107-532A-4668

Query Match      89.7%; Score 26; DB 4; Length 63;
Best Local Similarity 83.3%; Pred No. 1.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
Db 53 SPFFVLK 58

RESULT 9
US-08-506-296B-64
; Sequence 64, Application US/08506296B
; Patent No. 6313265
; GENERAL INFORMATION:
; APPLICANT: Phillips, Greg
; APPLICANT: Cunningham, Bruce A.
; APPLICANT: Crossin, Kathryn L.
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: U.S.
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/506.296B
; FILING DATE: 24-JUL-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: TSRI 488.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 206 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-506-296B-64

Query Match      89.7%; Score 26; DB 3; Length 206;
Best Local Similarity 83.3%; Pred No. 3.4e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
; :|||||

```

```

; INFORMATION FOR SEQ ID NO: 4668:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 63 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Enterococcus faecium
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1...63
; SEQUENCE DESCRIPTION: SEQ ID NO: 4668:
US-09-107-532A-4668

Query Match      89.7%; Score 26; DB 4; Length 63;
Best Local Similarity 83.3%; Pred No. 1.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
Db 53 SPFFVLK 58

RESULT 9
US-08-506-296B-64
; Sequence 64, Application US/08506296B
; Patent No. 6313265
; GENERAL INFORMATION:
; APPLICANT: Phillips, Greg
; APPLICANT: Cunningham, Bruce A.
; APPLICANT: Crossin, Kathryn L.
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: U.S.
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/506.296B
; FILING DATE: 24-JUL-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: TSRI 488.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 206 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-506-296B-64

Query Match      89.7%; Score 26; DB 3; Length 206;
Best Local Similarity 83.3%; Pred No. 3.4e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
; :|||||

```

```
Db      156 SFFVLK 161

RESULT 10
US-09-134-001C-4114
; Sequence 4114, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; FILE REFERENCE: GTC-007
; CURRENT APPLICATION NUMBER: US/09/134,001C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 4114
; LENGTH: 243
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4114

Query Match      89.7%; Score 26; DB 3; Length 243;
Best Local Similarity 66.7%; Pred. No. 3.9e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFFVLK 6
      :|||||
Db      127 AFFLIK 132

RESULT 11
US-08-506-296B-63
; Sequence 63, Application US/08506296B
; Patent No. 6313265
; GENERAL INFORMATION:
; APPLICANT: Phillips, Greg
; APPLICANT: Cunningham, Bruce A.
; APPLICANT: Crossin, Kathryn L.
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: U.S.
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/506,296B
; FILING DATE: 24-JUL-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: TSRI 488.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 63:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 307 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-506-296B-63

Query Match      89.7%; Score 26; DB 3; Length 307;
Best Local Similarity 83.3%; Pred. No. 4.8e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFFVLK 6
      :|||||
Db      257 SFFVLK 262

RESULT 12
US-09-489-039A-7842
; Sequence 7842, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 7842
; LENGTH: 393
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-7842

Query Match      89.7%; Score 26; DB 4; Length 393;
Best Local Similarity 66.7%; Pred. No. 6e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFFVLK 6
      :|||||
Db      16 AFFLIK 21

RESULT 13
US-08-506-296B-62
; Sequence 62, Application US/08506296B
; Patent No. 6313265
; GENERAL INFORMATION:
; APPLICANT: Phillips, Greg
; APPLICANT: Cunningham, Bruce A.
; APPLICANT: Crossin, Kathryn L.
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: U.S.
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/506,296B
; FILING DATE: 24-JUL-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: TSRI 488.0
```

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 554-2937  
TELEFAX: (619) 554-6312  
INFORMATION FOR SEQ ID NO: 62:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 394 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: C-terminal  
US-08-506-296B-62

Query Match 89.7%; Score 26; DB 3; Length 394;  
Best Local Similarity 83.3%; Pred. No. 6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
DB 209 SFFVLK 214

RESULT 14  
US-09-134-000C-5712  
Sequence 5712, Application US/09134000C  
Patent No. 6617156  
GENERAL INFORMATION:  
APPLICANT: Lynn Doucette-Stamm et al  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO  
TITLE OF INVENTION: ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS  
FILE REFERENCE: 032796-032  
CURRENT APPLICATION NUMBER: US/09/134,000C  
CURRENT FILING DATE: 1998-08-13  
PRIOR APPLICATION NUMBER: US 60/055,778  
PRIOR FILING DATE: 1997-08-15  
NUMBER OF SEQ ID NOS: 6812  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 5712  
LENGTH: 399  
TYPE: PRT  
ORGANISM: Enterococcus faecalis  
US-09-134-000C-5712

Query Match 89.7%; Score 26; DB 4; Length 399;  
Best Local Similarity 83.3%; Pred. No. 6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
DB 198 AFFLKK 203

RESULT 15  
US-09-540-236-2853  
Sequence 2853, Application US/09540236  
Patent No. 6673910  
GENERAL INFORMATION:  
APPLICANT: Gary L. Breton et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO MORAXELLA CATAR  
TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS  
FILE REFERENCE: 2709 2005-001  
CURRENT APPLICATION NUMBER: US/09/540,236  
CURRENT FILING DATE: 2000-04-04  
NUMBER OF SEQ ID NOS: 3840  
SEQ ID NO 2853  
LENGTH: 434  
TYPE: PRT  
ORGANISM: M.catarrhalis  
US-09-540-236-2853

Query Match 89.7%; Score 26; DB 4; Length 434;  
Best Local Similarity 83.3%; Pred. No. 6.5e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
DB 322 AFYVLK 327

RESULT 16  
US-08-506-296B-76  
Sequence 76, Application US/08506296B  
Patent No. 6313265  
GENERAL INFORMATION:  
APPLICANT: Phillips, Greg  
APPLICANT: Cunningham, Bruce A.  
APPLICANT: Crossin, Kathryn L.  
TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES  
TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE  
NUMBER OF SEQUENCES: 77  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: The Scripps Research Institute  
STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8  
CITY: La Jolla  
STATE: California  
COUNTRY: U.S.  
ZIP: 92037

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/506,296B  
FILING DATE: 24-JUL-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Fitting, Thomas  
REGISTRATION NUMBER: 34,163  
REFERENCE/DOCKET NUMBER: TSRI 488.0  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 554-2937  
TELEFAX: (619) 554-6312  
INFORMATION FOR SEQ ID NO: 76:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 443 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: internal  
US-08-506-296B-76

Query Match 89.7%; Score 26; DB 3; Length 443;  
Best Local Similarity 83.3%; Pred. No. 6.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
DB 382 SFFVLK 387

RESULT 17  
US-08-506-296B-75  
Sequence 75, Application US/08506296B  
Patent No. 6313265  
GENERAL INFORMATION:  
APPLICANT: Phillips, Greg  
APPLICANT: Cunningham, Bruce A.  
APPLICANT: Crossin, Kathryn L.  
TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES  
TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE  
NUMBER OF SEQUENCES: 77  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: The Scripps Research Institute  
STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8  
CITY: La Jolla  
STATE: California

Query Match 89.7%; Score 26; DB 3; Length 443;  
Best Local Similarity 83.3%; Pred. No. 6.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

COUNTRY: U.S.  
ZIP: 92037  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/506,296B  
FILING DATE: 24-JUL-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Fitting, Thomas  
REGISTRATION NUMBER: 34,163  
REFERENCE/DOCKET NUMBER: TSRI 488.0  
TELEPHONE: (619) 554-2937  
TELEFAX: (619) 554-6312  
INFORMATION FOR SEQ ID NO: 75:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 545 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: Internal  
US-08-506-296B-75

Query Match 89.7%; Score 26; DB 3; Length 545;  
Best Local Similarity 83.3%; Pred. No. 7.9e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
:|||||  
Db 483 SPFVLK 488

RESULT 18  
US-08-506-296B-74  
; Sequence 74, Application US/08506296B  
; Patent No. 6313265  
; GENERAL INFORMATION:  
; APPLICANT: Phillips, Greg  
; APPLICANT: Cunningham, Bruce A.  
; APPLICANT: Crossin, Kathryn L.  
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES  
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE  
; NUMBER OF SEQUENCES: 77  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: The Scripps Research Institute  
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8  
; CITY: La Jolla  
; STATE: California  
; COUNTRY: U.S.  
; ZIP: 92037  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/506,296B  
FILING DATE: 24-JUL-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Fitting, Thomas  
REGISTRATION NUMBER: 34,163  
REFERENCE/DOCKET NUMBER: TSRI 488.0  
TELEPHONE: (619) 554-2937  
TELEFAX: (619) 554-6312  
INFORMATION FOR SEQ ID NO: 74:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 632 amino acids

TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: C-terminal  
US-08-506-296B-74

Query Match 89.7%; Score 26; DB 3; Length 632;  
Best Local Similarity 83.3%; Pred. No. 9e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
:|||||  
Db 435 SPFVLK 440

RESULT 19  
US-09-341-505-2  
; Sequence 2, Application US/09341505  
; Patent No. 6753158  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, Stephen P  
; APPLICANT: Critchlow, Susan E  
; TITLE OF INVENTION: Assays, agents, therapy and diagnosis relating to  
; TITLE OF INVENTION: modulation of cellular DNA repair activity  
; FILE REFERENCE: MEWE-005  
; CURRENT APPLICATION NUMBER: US/09/341,505  
; CURRENT FILING DATE: 1999-07-12  
; EARLIER APPLICATION NUMBER: PCT/GB98/00095  
; EARLIER FILING DATE: 1998-01-13  
; EARLIER APPLICATION NUMBER: GB 9700574.8  
; EARLIER FILING DATE: 1997-01-13  
; EARLIER APPLICATION NUMBER: GB 9713131.2  
; EARLIER FILING DATE: 1997-06-20  
; NUMBER OF SEQ ID NOS: 18  
; SOFTWARE: Patent in Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 844  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-341-505-2

Query Match 89.7%; Score 26; DB 4; Length 844;  
Best Local Similarity 83.3%; Pred. No. 1.2e+03;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
:|||||  
Db 62 AYFVLK 67

RESULT 20  
US-08-461-562B-2  
; Sequence 2, Application US/08461562B  
; Patent No. 6455274  
; GENERAL INFORMATION:  
; APPLICANT: WEI, YING-FEI  
; APPLICANT: HASELTINE, WILLIAM H  
; TITLE OF INVENTION: HUMAN DNA LIGASE IV  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HUMAN GENOME SCIENCES, INC.  
; STREET: 9410 KEY WEST AVE  
; CITY: ROCKVILLE  
; STATE: MD  
; COUNTRY: US  
; ZIP: 20850  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/461,562B

;; FILING DATE: 05-JUN-1995  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/US94/12922  
;; FILING DATE: 08-NOV-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: A. ANDERS BROOKES  
;; REGISTRATION NUMBER: 36,373  
;; REFERENCE/DOCKET NUMBER: PF142P1  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 301-309-8504  
;; TELEFAX: 301-309-8439  
;; INFORMATION FOR SEQ ID NO: 2:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 911 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-08-461-562B-2

Query Match 89.7%; Score 26; DB 4; Length 911;  
Best Local Similarity 83.3%; Pred. No. 1.2e+03;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
Db 129 AYFVLK 134

RESULT 21  
US-08-506-296B-28  
; Sequence 28, Application US/08506296B  
; Patent No. 6313265  
; GENERAL INFORMATION:  
; APPLICANT: Phillips, Greg  
; APPLICANT: Cunningham, Bruce A.  
; TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES  
; TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE  
; NUMBER OF SEQUENCES: 77  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: The Scripps Research Institute  
; STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8  
; CITY: La Jolla  
; STATE: California  
; COUNTRY: U.S.  
; ZIP: 92037

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/506,296B  
FILING DATE: 24-JUL-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Fitting, Thomas

REGISTRATION NUMBER: 34,163  
REFERENCE/DOCKET NUMBER: TSRI 488.0  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 554-2937  
TELEFAX: (619) 554-6312  
INFORMATION FOR SEQ ID NO: 28:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1268 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein

US-08-506-296B-28  
Query Match 89.7%; Score 26; DB 3; Length 1268;  
Best Local Similarity 83.3%; Pred. No. 1.6e+03;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AFFVLK 6  
Db 1083 SFVLK 1088

RESULT 22  
US-07-670-296-20  
; Sequence 20, Application US/07670296  
; Patent No. 5229364  
; GENERAL INFORMATION:  
; APPLICANT: Chiodi, Francesca  
; TITLE OF INVENTION: POLYPEPTIDES DERIVED FROM THE HUMAN  
; TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Dressler, Goldsmith, Shore, Suker & Milnamow  
; STREET: 11300 Sorrento Valley Road, Suite 200  
; CITY: San Diego  
; STATE: CA  
; COUNTRY: U.S.A.  
; ZIP: 92121

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/670,296  
FILING DATE: 19910607  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Bingham, Douglas A.

REGISTRATION NUMBER: 32,457  
REFERENCE/DOCKET NUMBER: BCI-0009P  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 619-546-1555  
INFORMATION FOR SEQ ID NO: 20:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 amino acids  
TYPE: AMINO ACID  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal

US-07-670-296-20  
Query Match 86.2%; Score 25; DB 1; Length 20;  
Best Local Similarity 66.7%; Pred. No. 73;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
Db 7 AYFVLK 12

RESULT 23  
US-08-093-781-17  
; Sequence 17, Application US/08093781  
; Patent No. 5401628  
; GENERAL INFORMATION:  
; APPLICANT: Chiodi, Francesca  
; TITLE OF INVENTION: POLYPEPTIDES DERIVED FROM THE HUMAN  
; TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN  
; NUMBER OF SEQUENCES: 24  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Dressler, Goldsmith, Shore & Milnamow, Ltd.  
; STREET: 180 No. 5401628th Stetson, Suite 4700  
; CITY: Chicago  
; STATE: IL

COUNTRY: USA  
ZIP: 60601  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/093,781  
FILING DATE: 19-JUL-1993  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Gamson, Edward P.  
REGISTRATION NUMBER: 29,381  
TELEPHONE: (312)616-5400  
TELEFAX: (312)616-5460  
INFORMATION FOR SEQ ID NO: 17:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FEATURE:  
NAME/KEY: Peptide  
LOCATION: 1..20  
OTHER INFORMATION: /note= "This peptide represents a repeating subunit of a homoblock polypeptide in which the number of subunits is limited to that of the number of subunits in the homoblock polypeptide."  
US-08-093-781-17

Query Match 86.2%; Score 25; DB 1; Length 20;  
Best Local Similarity 66.7%; Pred. No. 73;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
|:|:|  
Db 7 AYFILK 12

RESULT 24  
US-07-670-296-24  
Sequence 24, Application US/07670296  
Patent No. 5229364  
GENERAL INFORMATION:  
APPLICANT: Chiodi, Francesca  
TITLE OF INVENTION: POLYPEPTIDES DERIVED FROM THE HUMAN  
TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS ENDONUCLEASE PROTEIN  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dressler, Goldsmith, Shore, Suter & Milnamow  
STREET: 11300 Sorrento Valley Road, Suite 200  
CITY: San Diego  
STATE: CA  
COUNTRY: U.S.A.  
ZIP: 92121  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/670,296  
FILING DATE: 19910607  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Bingham, Douglas A.  
REGISTRATION NUMBER: 32,457  
REFERENCE/DOCKET NUMBER: BCI-0009P  
TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-546-1555  
INFORMATION FOR SEQ ID NO: 24:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 22 amino acids  
TYPE: AMINO ACID  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal  
FEATURE:  
NAME/KEY: Region  
LOCATION: 1  
OTHER INFORMATION: /note= "Wherein 'Xaa' at position #1 corresponds to 'x' in the specification, and is a chain of from 1 to 20 amino acid residues or an amino-terminal group."  
OTHER INFORMATION:  
FEATURE:  
NAME/KEY: Region  
LOCATION: 22  
OTHER INFORMATION: /note= "Wherein 'Xaa' at position #22 corresponds to 'z' in the specification, and is a chain of from 1 to 20 amino acid residues or a carboxy-terminal group."  
US-07-670-296-24

Query Match 86.2%; Score 25; DB 1; Length 22;  
Best Local Similarity 66.7%; Pred. No. 80;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
|:|:|  
Db 8 AYFILK 13

RESULT 25  
US-09-673-395A-467  
Sequence 467, Application US/09673395A  
Patent No. 6620923  
GENERAL INFORMATION:  
APPLICANT: SPECHT, THOMAS  
APPLICANT: HINZMANN, BERND  
APPLICANT: SCHMITT, ARMIN  
APPLICANT: PILARSKY, CHRISTIAN  
APPLICANT: DAHL, EDGAR  
APPLICANT: ROSENTHAL, ANDRE  
TITLE OF INVENTION: HUMAN NUCLEIC ACID SEQUENCES FROM UTERUS TUMOR TISSUE  
FILE REFERENCE: ALBRE-12  
CURRENT APPLICATION NUMBER: US/09/673,395A  
CURRENT FILING DATE: 2000-10-17  
NUMBER OF SEQ ID NOS: 637  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 467  
LENGTH: 41  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-673-395A-467

Query Match 86.2%; Score 25; DB 4; Length 41;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|:|:|  
Db 13 FFVLK 17

RESULT 26  
US-09-248-796A-24335  
Sequence 24335, Application US/09248796A  
Patent No. 6747137  
GENERAL INFORMATION:  
APPLICANT: Keith Weinstein et al  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICANS  
TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS



; FILE REFERENCE: 107196.132  
 ; CURRENT APPLICATION NUMBER: US/09/248,796A  
 ; PRIOR FILING DATE: 1999-02-12  
 ; PRIOR APPLICATION NUMBER: US 60/074,725  
 ; PRIOR FILING DATE: 1998-02-13  
 ; PRIOR APPLICATION NUMBER: US 60/096,409  
 ; PRIOR FILING DATE: 1998-08-13  
 ; NUMBER OF SEQ ID NOS: 28208  
 ; SEQ ID NO 24335  
 ; LENGTH: 62  
 ; TYPE: PRT  
 ; ORGANISM: Candida albicans  
 US-09-248-796A-24335

Query Match 86.2%; Score 25; DB 4; Length 62;  
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
 Db 47 FFVLK 51

## RESULT 27

US-09-134-000C-6793  
 ; Sequence 6793, Application US/09134000C  
 ; Patent No. 6617156  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Lynn Doucette-Stamm et al  
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO  
 ; ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS  
 ; FILE REFERENCE: 032796-032  
 ; CURRENT APPLICATION NUMBER: US/09/134,000C  
 ; CURRENT FILING DATE: 1998-08-13  
 ; PRIOR APPLICATION NUMBER: US 60/055,778  
 ; PRIOR FILING DATE: 1997-08-15  
 ; NUMBER OF SEQ ID NOS: 6812  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 6793  
 ; LENGTH: 80  
 ; TYPE: PRT  
 ; ORGANISM: Enterococcus faecalis  
 US-09-134-000C-6793

Query Match 86.2%; Score 25; DB 4; Length 80;  
 Best Local Similarity 66.7%; Pred. No. 2.4e+02;  
 Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 Db 46 SPFVLK 51

## RESULT 28

US-09-270-767-32277  
 ; Sequence 32277, Application US/09270767  
 ; Patent No. 6703491  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Homburger et al.

; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
 ; FILE REFERENCE: File Reference: 7326-094  
 ; CURRENT APPLICATION NUMBER: US/09/270,767  
 ; CURRENT FILING DATE: 1999-03-17  
 ; NUMBER OF SEQ ID NOS: 62517  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 32277  
 ; LENGTH: 102  
 ; TYPE: PRT

; ORGANISM: Drosophila melanogaster

; FEATURE:  
 ; OTHER INFORMATION: Xaa means any amino acid  
 US-09-270-767-32277

Query Match 86.2%; Score 25; DB 4; Length 102;  
 Best Local Similarity 100.0%; Pred. No. 3e+02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
 Db 9 FFVLK 13

## RESULT 29

US-09-270-767-47494  
 ; Sequence 47494, Application US/09270767  
 ; Patent No. 6703491  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Homburger et al.

; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
 ; FILE REFERENCE: File Reference: 7326-094  
 ; CURRENT APPLICATION NUMBER: US/09/270,767  
 ; CURRENT FILING DATE: 1999-03-17  
 ; NUMBER OF SEQ ID NOS: 62517  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 47494  
 ; LENGTH: 102  
 ; TYPE: PRT

; ORGANISM: Drosophila melanogaster  
 ; FEATURE:  
 ; OTHER INFORMATION: Xaa means any amino acid  
 US-09-270-767-47494

Query Match 86.2%; Score 25; DB 4; Length 102;  
 Best Local Similarity 100.0%; Pred. No. 3e+02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
 Db 9 FFVLK 13

## RESULT 30

US-09-543-681A-7876  
 ; Sequence 7876, Application US/09543681A  
 ; Patent No. 6805709  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GARY BRETON

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PROTEUS MIRABILIS  
 ; FILE REFERENCE: 2709.1002-001  
 ; CURRENT APPLICATION NUMBER: US/09/543,681A  
 ; CURRENT FILING DATE: 2000-04-05  
 ; PRIOR APPLICATION NUMBER: US 60/128,706  
 ; PRIOR FILING DATE: 1999-04-09  
 ; NUMBER OF SEQ ID NOS: 8344  
 ; SEQ ID NO 7876  
 ; LENGTH: 111  
 ; TYPE: PRT

; ORGANISM: Proteus mirabilis  
 US-09-543-681A-7876

Query Match 86.2%; Score 25; DB 4; Length 111;  
 Best Local Similarity 66.7%; Pred. No. 3.2e+02;  
 Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 Db 29 AFFILR 34

## RESULT 31

US-09-270-767-57477  
 ; Sequence 57477, Application US/09270767  
 ; Patent No. 6703491  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Homburger et al.

```

; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 57477
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-57477

Query Match      86.2%; Score 25; DB 4; Length 117;
Best Local Similarity 83.3%; Pred. No. 3.4e+02;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 101 AFFALK 106

RESULT 32
US-09-270-767-32960
; Sequence 32960, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32960
; LENGTH: 158
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-32960

Query Match      86.2%; Score 25; DB 4; Length 158;
Best Local Similarity 66.7%; Pred. No. 4.4e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 112 AFFILR 117

RESULT 33
US-09-270-767-48177
; Sequence 48177, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 48177
; LENGTH: 158
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-48177

Query Match      86.2%; Score 25; DB 4; Length 158;
Best Local Similarity 66.7%; Pred. No. 4.4e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
```

```

Db 112 AFFILR 117
||||:
RESULT 34
US-09-621-976-4638
; Sequence 4638, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Jobert, S.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: ESTs and Encoded Human Proteins.
; FILE REFERENCE: GENSET.054PR2
; CURRENT APPLICATION NUMBER: US/09/621,976
; CURRENT FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 19335
; SOFTWARE: Patent.pm
; SEQ ID NO 4638
; LENGTH: 166
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-621-976-4638

Query Match      86.2%; Score 25; DB 4; Length 166;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 153 SFFILK 158

RESULT 35
US-09-107-532A-5068
; Sequence 5068, Application US/09107532A
; Patent No. 6583275
; GENERAL INFORMATION:
; APPLICANT: Lynn A Doucette-Stamm and David Bush
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
; ENTEROCOCCUS FAECIUM FOR DIAGNOSTICS AND THERAPEUTICS
; NUMBER OF SEQUENCES: 7310
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENOME THERAPEUTICS CORPORATION
; STREET: 100 Beaver Street
; CITY: Waltham
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02354
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-ROM ISO9660
; COMPUTER: PC
; OPERATING SYSTEM: <Unknown>
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/107,532A
; FILING DATE: 30-Jun-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/085,598
; FILING DATE: 14 May 1998
; APPLICATION NUMBER: 60/051571
; FILING DATE: July 2, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Ariniello, Pamela Deneke
; REGISTRATION NUMBER: 40,489
; REFERENCE/DOCKET NUMBER: GTC-012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (781)893-5007
; TELEFAX: (781)893-8277
; INFORMATION FOR SEQ ID NO: 5068:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 183 amino acids
; TYPE: amino acid
```

```
;
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Enterococcus faecium
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (B) LOCATION 1...183
; SEQUENCE DESCRIPTION: SEQ ID NO: 5068:
US-09-107-532A-5068

Query Match      86.2%; Score 25; DB 4; Length 183;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FFVLK 6
      |||||
Db      107 FFVLK 111

RESULT 36
US-09-529-157-6
; Sequence 6, Application US/09529157
; Patent No. 6500939
; GENERAL INFORMATION:
; APPLICANT: Kato, Seishi
; TITLE OF INVENTION: cDNAs Coding For Human Proteins Having Transmembrane
; FILE REFERENCE: GIN-6711CPUS
; CURRENT APPLICATION NUMBER: US/09/529,157
; PRIOR FILING DATE: 2000-08-21
; PRIOR APPLICATION NUMBER: PCT/JP98/04447
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: JP 9-276270
; PRIOR FILING DATE: 1997-10-08
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 185
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-529-157-6

Query Match      86.2%; Score 25; DB 4; Length 185;
Best Local Similarity 66.7%; Pred. No. 5e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      :|||:|
Db      153 SFFILK 158

RESULT 37
US-09-529-157-7
; Sequence 7, Application US/09529157
; Patent No. 6500939
; GENERAL INFORMATION:
; APPLICANT: Kato, Seishi
; TITLE OF INVENTION: cDNAs Coding For Human Proteins Having Transmembrane
; FILE REFERENCE: GIN-6711CPUS
; CURRENT APPLICATION NUMBER: US/09/529,157
; PRIOR FILING DATE: 2000-08-21
; PRIOR APPLICATION NUMBER: PCT/JP98/04447
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: JP 9-276270
; PRIOR FILING DATE: 1997-10-08
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 185

; TYPE: PRT
; ORGANISM: Rattus sp.
US-09-529-157-7

Query Match      86.2%; Score 25; DB 4; Length 185;
Best Local Similarity 66.7%; Pred. No. 5e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      :|||:|
Db      153 SFFILK 158

RESULT 38
US-09-489-039A-13866
; Sequence 13866, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 13866
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-13866

Query Match      86.2%; Score 25; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FFVLK 6
      |||||
Db      35 FFVLK 39

RESULT 39
US-09-252-991A-28289
; Sequence 28289, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 28289
; LENGTH: 189
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-28289

Query Match      86.2%; Score 25; DB 4; Length 189;
Best Local Similarity 66.7%; Pred. No. 5.1e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      ||||:|
Db      140 AFFVLK 145
```

```
RESULT 40
US-09-134-000C-5350
; Sequence 5350, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
; TITLE OF INVENTION: ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 032796-032
; CURRENT APPLICATION NUMBER: US/09/134,000C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/055,778
; PRIOR FILING DATE: 1997-08-15
; NUMBER OF SEQ ID NOS: 6812
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5350
; LENGTH: 197
; TYPE: PRT
; ORGANISM: Enterococcus faecalis
US-09-134-000C-5350

Query Match      86.2%; Score 25; DB 4; Length 197;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FFVLK 6
Db      103 FFVLK 107
      |||||

RESULT 41
US-09-949-016-9489
; Sequence 9489, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9489
; LENGTH: 204
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-9489

Query Match      86.2%; Score 25; DB 4; Length 204;
Best Local Similarity 66.7%; Pred. No. 5.4e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      :|||:
Db      172 SFPLK 177

RESULT 42
US-09-673-395A-205
; Sequence 205, Application US/09673395A
; Patent No. 6620923
; GENERAL INFORMATION:
; APPLICANT: SPECHT, THOMAS
; APPLICANT: HINZMANN, BERND
; APPLICANT: SCHMITT, ARMIN
; APPLICANT: PILARSKY, CHRISTIAN

Query Match      86.2%; Score 25; DB 4; Length 229;
Best Local Similarity 66.7%; Pred. No. 5.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FFVLK 6
      :|||:
Db      36 FFVLK 40

RESULT 43
US-09-489-039A-7731
; Sequence 7731, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; TITLE OF INVENTION: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709,2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 7731
; LENGTH: 219
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-7731

Query Match      86.2%; Score 25; DB 4; Length 219;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 FFVLK 6
      :|||:
Db      36 FFVLK 40

RESULT 44
US-09-270-767-42203
; Sequence 42203, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42203
; LENGTH: 229
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-42203

Query Match      86.2%; Score 25; DB 4; Length 229;
```



```
; LENGTH: 282
; TYPE: PRT
; ORGANISM: Enterococcus faecalis
US-09-134-000C-4488

Query Match      86.2%; Score 25; DB 4; Length 282;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 FFVLK 6
Db      167 FFVLK 171
      |||||

RESULT 49
US-09-543-681A-4672
; Sequence 4672, Application US/09543681A
; Patent No. 6605709
; GENERAL INFORMATION:
; APPLICANT: GARY BRETON
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PROTEUS MIRABILIS
; TITLE OF INVENTION: DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.1002-001
; CURRENT APPLICATION NUMBER: US/09/543,681A
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/128,706
; PRIOR FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 8344
; SEQ ID NO 4672
; LENGTH: 296
; TYPE: PRT
; ORGANISM: Proteus mirabilis
US-09-543-681A-4672

Query Match      86.2%; Score 25; DB 4; Length 296;
Best Local Similarity 66.7%; Pred. No. 7.5e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFFVLK 6
Db      291 AFFVK 296
      |||||

RESULT 50
US-08-855-714-3
; Sequence 3, Application US/08855714
; Patent No. 5939075
; GENERAL INFORMATION:
; APPLICANT: Houng, Huo-Shu H.
; APPLICANT: Warren, Richard L.
; TITLE OF INVENTION: MUTANTS OF BRUCELLA MELITENSIS
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John Moran, Esq.
; STREET: HQ USAMRDC, Dept. of Army, Fort Detrick
; CITY: Frederick
; STATE: MD
; COUNTRY: US
; ZIP: 21702-5012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/855,714
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/334,129
; FILING DATE: 04-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hendricks, Glenna
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 42.6301 Seconds  
(without alignments)  
36.290 Million cell updates/sec

Title: US-10-009-122-6

Perfect score: 19

Sequence: 1 KLVF 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

- Database : A\_Geneseq\_16Dec04:\*
- 1: Geneseqp1980s:\*
  - 2: Geneseqp1990s:\*
  - 3: Geneseqp2000s:\*
  - 4: Geneseqp2001s:\*
  - 5: Geneseqp2002s:\*
  - 6: Geneseqp2003as:\*
  - 7: Geneseqp2003bs:\*
  - 8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	4	2	Aaw45956 Amyloid b
2	19	100.0	4	3	Aay79936 Beta-amyl
3	19	100.0	4	4	Aab48487 Antifibr
4	19	100.0	4	4	Aab48479 Antifibr
5	19	100.0	4	4	Aab82635 All-D pep
6	19	100.0	4	4	Aab82627 All-D pep
7	19	100.0	4	5	Aau96815 Amyloid t
8	19	100.0	4	5	Aau96823 Amyloid t
9	19	100.0	4	5	Aau11661 Peptide #
10	19	100.0	4	5	Aau11653 Peptide #
11	19	100.0	4	6	Aae35442 Abeta pep
12	19	100.0	4	6	Aae35449 Abeta pep
13	19	100.0	4	8	Adq37266 Vaccine a
14	19	100.0	4	8	Adq37384 Amyloid-b
15	19	100.0	4	8	Adq37326 Antifibr
16	19	100.0	4	8	Adq37318 Antifibr
17	19	100.0	4	8	Adq37274 Vaccine a
18	19	100.0	5	2	Aar87922 Test pep
19	19	100.0	5	2	Aaw02315 Beta-amyl
20	19	100.0	5	2	Aaw45933 Partial s
21	19	100.0	5	2	Aaw45966 Peptide d
22	19	100.0	5	2	Aaw45950 Amyloid b
23	19	100.0	5	2	Aaw29089 A-beta-bi
24	19	100.0	5	2	Aaw89367 Beta-amyl
25	19	100.0	5	3	Aay79937 Beta-amyl

26	19	100.0	5	4	AAB67279 Residues
27	19	100.0	5	4	AAB48489 Antifibr
28	19	100.0	5	4	AAB48481 Antifibr
29	19	100.0	5	4	AAB82637 All-D pep
30	19	100.0	5	4	AAB82629 All-D pep
31	19	100.0	5	4	AAB82803 Residues
32	19	100.0	5	5	ABG71010 Long form
33	19	100.0	5	5	ABO15847 Beta-amyl
34	19	100.0	5	5	ABO5183 Beta amyl
35	19	100.0	5	5	ABO5158 Beta amyl
36	19	100.0	5	5	Aau96825 Amyloid t
37	19	100.0	5	5	Aau96817 Amyloid t
38	19	100.0	5	5	ABB84001 Transglut
39	19	100.0	5	5	Aau11655 Peptide #
40	19	100.0	5	5	Aau11663 Peptide #
41	19	100.0	5	6	AB882632 Abeta fib
42	19	100.0	5	6	Aae35444 Abeta pep
43	19	100.0	5	6	Aae35451 Abeta pep
44	19	100.0	5	6	ABR43903 Beta-amyl
45	19	100.0	5	7	ADF60931 C-termina
46	19	100.0	5	8	ADJ71329 Pathologi
47	19	100.0	5	8	ADJ64061 Human bet
48	19	100.0	5	8	ADJ64088 Human bet
49	19	100.0	5	8	ADM97741 Amyloid b
50	19	100.0	5	8	ADP64923 Beta-amyl
51	19	100.0	5	8	ADQ37328 Antifibr
52	19	100.0	5	8	ADQ37276 Vaccine a
53	19	100.0	5	8	ADQ37354 Beta-amyl
54	19	100.0	5	8	ADQ37268 Vaccine a
55	19	100.0	5	8	ADQ37320 Antifibr
56	19	100.0	5	8	ADQ37342 Amyloid-b
57	19	100.0	5	8	ADQ37382 Amyloid-b
58	19	100.0	6	2	Aaw02331 Beta-amyl
59	19	100.0	6	2	Aaw02313 Beta-amyl
60	19	100.0	6	2	Aaw02314 Beta-amyl
61	19	100.0	6	2	Aaw45945 Amyloid b
62	19	100.0	6	2	Aaw45944 Amyloid b
63	19	100.0	6	2	Aaw29092 A-beta-bi
64	19	100.0	6	2	Aaw29091 A-beta-bi
65	19	100.0	6	2	Aaw29090 A-beta-bi

ALIGNMENTS

RESULT 1	
AAW45956	
ID	AAW45956 standard; peptide; 4 AA.
XX	AAW45956;
AC	25-MAR-2003 (revised)
DT	30-JUN-1998 (first entry)
XX	Amyloid beta peptide fragment.
DE	Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;
KW	positron emission tomography; PET; Down's syndrome; amyloidosis.
XX	Homo sapiens.
OS	WO9721728-A1.
XX	19-JUN-1997.
XX	09-DEC-1996; 96WO-SE001621.
PR	12-DEC-1995; 95SE-00004467.
PR	29-DEC-1995; 95US-0009386P.
XX	(KARO-) KAROLINSKA INNOVATIONS AB.
PA	Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;
PI	

Wed Mar 9 08:15:59 2005

us-10-009-122-6.rag

```
XX DR WPI; 1997-332723/30.
XX
XX Use of new and known peptide(s) for inhibition of polymerisation of
PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or
PT Down's syndrome associated with amyloidosis.
XX
XX Example 1; Fig 2B; 31pp; English.
XX
XX This sequence represents a fragment of the amyloid beta peptide. The
XX invention relates to the use of peptide compounds for inhibition of
XX polymerisation of amyloid beta peptide (ABP), as model substances for
XX synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a
XX tool for the identification of other organic compounds with similar
XX functional properties, or as ligands in positron emission tomography. The
XX peptides may be used in treatment of amyloidosis, especially in treatment
XX of Alzheimer's disease associated with Down's syndrome, for treatment or
XX prevention of demens in patients with Down's syndrome, for treatment or
XX prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch
XX type) or for the prevention of fibril formation of human amyloid protein.
XX They can also be used for identifying other molecules with similar
XX properties and/or as ligands for detection of amyloid deposits using e.g.
XX positron emission tomography. (Updated on 25-MAR-2003 to correct PI
XX field.)
XX
XX Sequence 4 AA;
XX
XX Query Match 100.0%; Score 19; DB 2; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KLVF 4
XX Db 1 KLVF 4
XX
XX RESULT 2
XX ID AAY79936 standard; peptide; 4 AA.
XX AC AAY79936;
XX
XX DT 11-MAY-2000 (first entry)
XX
XX DE Beta-amyloid recognition peptide SEQ ID NO:1.
XX
XX KW Beta-amyloid; inhibitor; recognition element; hybrid; aggregation;
XX Alzheimer's disease; neuroprotective; nootropic.
XX
XX OS Homo sapiens.
XX
XX FN US6022859-A.
XX
XX PD 08-FEB-2000.
XX
XX PF 14-NOV-1997; 97US-00970833.
XX
XX PR 15-NOV-1996; 96US-0030840P.
XX
XX PA (WISC) WISCONSIN ALUMNI RES FOUND.
XX
XX PI Murphy RM, Kieselring LL;
XX
XX DR WPI; 2000-160387/14.
XX
XX PT Beta-amyloid inhibitor useful for treating Alzheimer's disease.
XX
XX PS Example; Col 7; 15pp; English.
XX
XX The present invention describes a beta-amyloid inhibitor peptide. Beta-
XX amyloid inhibitors have neuroprotective and nootropic properties. The
XX inhibitor peptides are useful for the treatment of Alzheimer's disease.
XX The present sequence represents a beta-amyloid recognition peptide used
XX
XX CC in the exemplification of present invention
XX
XX SQ Sequence 4 AA;
XX
XX Query Match 100.0%; Score 19; DB 3; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KLVF 4
XX Db 1 KLVF 4
XX
XX RESULT 3
XX ID AAB48487 standard; peptide; 4 AA.
XX AC AAB48487;
XX
XX DT 02-MAR-2001 (first entry)
XX
XX DE Antifibrillogenic peptide #14.
XX
XX KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;
XX cytoprotection; amyloid deposit degradation; amyloidosis disorder;
XX Alzheimer's disease.
XX
XX OS Homo sapiens.
XX
XX FN WO200068263-A2.
XX
XX PD 16-NOV-2000.
XX
XX PF 04-MAY-2000; 2000WO-CA000515.
XX
XX PR 05-MAY-1999; 99US-0132592P.
XX
XX PA (NEUR-) NEUROCHEM INC.
XX
XX PI Chalifour R, Gervais F, Gupta A;
XX
XX DR WPI; 2001-031852/04.
XX
XX PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for
XX cytoprotection for treating amyloidosis disorders, comprises a peptide,
XX its isomer or peptidomimetic.
XX
XX PS Claim 7; Page 25; 46pp; English.
XX
XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used
XX for inhibiting amyloidosis and/or for cytoprotection. The peptides of
XX AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore
XX useful for treating amyloidosis disorders such as Alzheimer's disease.
XX Peptides AAB48474-B48496 were identified from the glycosaminoglycan
XX CC binding region and the prot-prot interaction region of the human amyloid
XX protein
XX
XX SQ Sequence 4 AA;
XX
XX Query Match 100.0%; Score 19; DB 4; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;
XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 KLVF 4
XX Db 1 KLVF 4
XX
XX RESULT 4
```



AAB48479  
 ID AAB48479 standard; peptide; 4 AA.  
 XX  
 AC AAB48479;  
 XX  
 DT 02-MAR-2001 (first entry)  
 XX  
 DE Antifibrillogenic peptide #6.  
 XX  
 KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition;  
 KW cytoprotection; amyloid deposit degradation; amyloidosis disorder;  
 KW Alzheimer's disease.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200068263-A2.  
 XX  
 PD 16-NOV-2000.  
 XX  
 PF 04-MAY-2000; 2000WO-CA000515.  
 XX  
 PR 05-MAY-1999; 99US-0132592P.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Chalifour R, Gervais F, Gupta A;  
 XX  
 DR WPI; 2001-031852/04.  
 XX  
 PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for  
 PT cytoprotection for treating amyloidosis disorders, comprises a peptide,  
 PT its isomer or peptidomimetic.  
 XX  
 PS Claim 7; Page 25; 46pp; English.  
 XX  
 CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used  
 CC for inhibiting amyloidosis and/or for cytoprotection. The peptides of  
 CC AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore  
 CC useful for treating amyloidosis disorders such as Alzheimer's disease.  
 CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan  
 CC binding region and the prot-prot interaction region of the human amyloid  
 CC protein  
 XX  
 SQ Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 4; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 RESULT 5  
 ID AAB82635  
 XX AAB82635 standard; peptide; 4 AA.  
 AC AAB82635;  
 XX  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 XX  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 PH Key Location/Qualifiers  
 FT Misc-difference 1..4  
 FT /note= "all D-form residues"  
 FT Modified-site 6

/note= "C-terminal amide"  
 WO200139796-A2.  
 07-JUN-2001.  
 29-NOV-2000; 2000WO-CA001413.  
 28-NOV-1999; 99US-0168594P.  
 28-NOV-2000; 2000US-00724842.  
 (NEUR-) NEUROCHEM INC.  
 Chalifour R, Hebert L, Kong X, Gervais F;  
 WPI; 2001-441458/47.  
 Preventing/treating amyloid-related disease, especially Alzheimer's  
 disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 which elicits production of antibodies to prevent fibrillogenesis and  
 associated cellular toxicity.  
 Disclosure; Page 11; 31pp; English.  
 The present sequence is that of an all-D peptide suitable for use in  
 preparing vaccines for preventing or treating Alzheimer's disease and  
 other amyloid related disorders in humans. It is based on a portion of  
 amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 inserting 1 or more amino acid residues, or by substituting 1 or more  
 amino acid residues with other amino acid residues or non-amino acid  
 fragments. Vaccines of the invention are produced using 'non-self',  
 peptides synthesised from the unnatural D-configuration amino acids to  
 avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 aggregated to be operative or immunogenic. They preferably interact with  
 at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 fragments, protein conjugates, immunogenic derivative peptides and  
 immunogenic peptidomimetics. Examples include all-D peptides  
 corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 related diseases may be localised amyloidosis, e.g. diabetes type II,  
 neurodegenerative diseases, e.g. bovine spongiform encephalitis,  
 Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 prion protein related disorders, or systemic amyloidosis associated with  
 chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 amyloidosis found in long-term haemodialysis patients  
 Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 4; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 RESULT 6  
 ID AAB82627  
 XX AAB82627 standard; peptide; 4 AA.  
 AC AAB82627;  
 XX  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 XX  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Misc-difference 1..4

XX FT /note= "all D-form residues"

XX PN WO200139796-A2.

XX PD 07-JUN-2001.

XX PF 29-NOV-2000; 2000WO-CA001413.

XX PR 29-NOV-1999; 95US-0168594P.

XX PR 28-NOV-2000; 2000US-00724842.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Chalifour R, Hebert L, Kong X, Gervais F;

XX PD WPI; 2001-441458/47.

XX PT Preventing/treating amyloid-related disease, especially Alzheimer's

XX PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,

XX PT which elicits production of antibodies to prevent fibrillogenesis and

XX PT associated cellular toxicity.

XX PS Disclosure; Page 11; 31pp; English.

XX CC The present sequence is that of an all-D peptide suitable for use for

XX CC preparing vaccines for preventing or treating Alzheimer's disease and

XX CC other amyloid related disorders in humans. It is based on a portion of

XX CC amyloid-beta peptide (see AAB2622), and may be modified by removing or

XX CC inserting 1 or more amino acid residues, or by substituting 1 or more

XX CC amino acid residues with other amino acid residues or non-amino acid

XX CC fragments. Vaccines of the invention are produced using 'non-self'

XX CC peptides synthesised from the unnatural D-configuration amino acids to

XX CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be

XX CC aggregated to be operative or immunogenic. They preferably interact with

XX CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or

XX CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic

XX CC fragments, protein conjugates, immunogenic derivative peptides and

XX CC immunogenic peptidomimetics. Examples include all-D peptides

XX CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and

XX CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given

XX CC in AAB2623-64. The vaccine elicits a preferential TH-2 or TH-1 response,

XX CC preventing fibrillogenesis and associated cellular toxicity. The amyloid

XX CC related diseases may be localised amyloidosis, e.g. diabetes type II,

XX CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,

XX CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and

XX CC prion protein related disorders, or systemic amyloidosis associated with

XX CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.

XX CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic

XX CC amyloidosis found in long-term haemodialysis patients

XX SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 4; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0;

Matches 4; Conservative 0; Mismatches 0; Gaps 0;

OY 1 KLVF 4

Db 1 KLVF 4

RESULT 7

AAU96815

ID AAU96815 standard; peptide; 4 AA.

XX AC AAU96815;

XX DT 30-JUL-2002 (first entry)

XX DE Amyloid targeting peptide #5.

XX KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;

XX KW transmissible cerebral amyloidosis; transmissible virus dementia;

XX KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;

XX KW bovine spongiform encephalopathy; inflammation associated amyloid;

XX KW primary amyloidosis; feline spongiform encephalopathy;

XX KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;

XX KW dialysis-related amyloidosis; light chain-related amyloidosis;

XX KW cerebral amyloid angiopathy.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Misc-difference 1..4

XX FT /note= "Preferably D-form residue"

XX PN WO200207781-A2.

XX PD 31-JAN-2002.

XX PF 25-JUL-2001; 2001WO-CA001071.

XX PR 25-JUL-2000; 2000US-0220808P.

XX PR 24-JUL-2001; 2001US-00915092.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Gervais F, Kong X, Chalifour R, Migneault D;

XX PD WPI; 2002-371447/40.

XX PT New amyloid-targeting imaging agents useful for in vivo imaging amyloid

XX PT plaques and/or for the treatment of amyloidosis disorders.

XX PS Claim 49; Page 21; 57pp; English.

XX CC The invention relates to an amyloid-targeting imaging agent comprising an

XX CC amyloid targeting moiety, a linker moiety and a labelling moiety. The

XX CC agent is of general formula A t-(A 1 n k) z-A 1 a b (i) where z = 0 - 1;

XX CC A t = an amyloid targeting moiety; A 1 n k = a linker moiety; and A 1 a b

XX CC = a labelling moiety. Also included are imaging amyloid deposition or

XX CC diagnosing an amyloid-related condition in a patient involving

XX CC administering (i) to the patient, and ultrasound imaging (i) in the

XX CC patient to determine the presence of amyloid or amyloid-related condition

XX CC ; and a kit for preparing a radiopharmaceutical preparation comprising

XX CC (i), a reducing agent, a buffering agent, a transchelating agent, and

XX CC instructions for the preparation and use of the radiopharmaceutical in

XX CC the imaging of amyloid or an amyloid-related condition. The agents are

XX CC used for imaging amyloid deposition and for diagnosing an amyloid related

XX CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible

XX CC cerebral amyloidosis (transmissible virus dementia), familial CJD,

XX CC scrapie, transmissible mink encephalopathy, bovine spongiform

XX CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,

XX CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible

XX CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,

XX CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral

XX CC amyloid angiopathy. The agents are capable of crossing the blood-brain

XX CC barrier and are capable of binding specifically to amyloid plaques. The

XX CC present sequence is a peptide forming the amyloid targeting moiety of the

XX CC agent of the invention

XX SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 5; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 KLVF 4

Db 1 KLVF 4

RESULT 8  
 AAU96823  
 ID AAU96823 standard; peptide; 4 AA.  
 XX Query Match 100.0%; Score 19; DB 5; Length 4;  
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 AC Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 AAU96823;  
 DT 30-JUL-2002 (first entry)  
 XX  
 DE Amyloid targeting peptide #13.  
 XX  
 KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..4 /note= "Preferably D-form residue"  
 FT Modified-site 4  
 FT /note= "Phe is amidated"  
 XX  
 PN WO200207781-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 25-JUL-2001; 2001WO-CA001071.  
 XX  
 PR 25-JUL-2000; 2000US-0220808P.  
 PR 24-JUL-2001; 2001US-00915092.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Gervais F, Kong X, Chalifour R, Migneault D;  
 XX  
 DR WPI; 2002-371447/40.  
 XX  
 PT New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
 PT plaques and/or for the treatment of amyloidosis disorders.  
 XX  
 PS Claim 49; Page 21; 57pp; English.  
 XX  
 CC The invention relates to an amyloid-targeting imaging agent comprising an  
 CC amyloid targeting moiety, a linker moiety and a labelling moiety. The  
 CC agent is of general formula A-t-(A<sub>1</sub>n<sub>1</sub>k) z-A<sub>1</sub>l<sub>1</sub>a<sub>1</sub>b<sub>1</sub>(i) where z = 0 - 1;  
 CC A-t = an amyloid targeting moiety; A<sub>1</sub>n<sub>1</sub>k = a linker moiety; and A<sub>1</sub>l<sub>1</sub>a<sub>1</sub>b<sub>1</sub>  
 CC = a labelling moiety. Also included are imaging amyloid deposition or  
 CC diagnosing an amyloid-related condition in a patient involving  
 CC administering (i) to the patient, and ultrasound imaging (i) in the  
 CC patient to determine the presence of amyloid or amyloid-related condition  
 CC ; and a kit for preparing a radiopharmaceutical preparation comprising  
 CC instructions for the preparation and use of the radiopharmaceutical in  
 CC the imaging of amyloid or an amyloid-related condition. The agents are  
 CC used for imaging amyloid deposition and for diagnosing an amyloid related  
 CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
 CC cerebral amyloidosis (transmissible virus dementia), familial CJD,  
 CC scrapie, transmissible mink encephalopathy, bovine spongiform  
 CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
 CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
 CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
 CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
 CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
 CC barrier and are capable of binding specifically to amyloid plaques. The  
 CC present sequence is a peptide forming the amyloid targeting moiety of the  
 CC agent of the invention  
 XX

SQ Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 ||||  
 RESULT 9  
 AAU11661  
 ID AAU11661 standard; peptide; 4 AA.  
 XX  
 AC AAU11661;  
 XX  
 DT 09-APR-2002 (first entry)  
 XX  
 DE Peptide #14, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX  
 KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; neurotropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 4 /note= "C-terminal amide"  
 FT  
 XX  
 PN WO200185093-A2.  
 XX  
 PD 15-NOV-2001.  
 XX  
 PF 22-DEC-2000; 2000WO-IB002078.  
 XX  
 PR 23-DEC-1999; 99US-0171877P.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Green AM, Gervais F;  
 XX  
 DR WPI; 2002-075222/10.  
 XX  
 PT Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.  
 XX  
 PS Disclosure; Page 10; 68pp; English.  
 XX  
 CC The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11669, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)  
 XX  
 SQ Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 ||||



KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
 KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
 KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
 KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
 KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
 OS Unidentified.  
 XX  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..4  
 FT Modified-site 4 /note= "D-form residues"  
 FT /note= "C-terminal amide"  
 XX WO200296937-A2.  
 XX  
 XX 05-DEC-2002.  
 XX  
 XX 29-MAY-2002; 2002WO-CA000763.  
 XX  
 XX 29-MAY-2001; 2001US-00867847.  
 XX (NEUR-) NEUROCHEM INC.  
 XX  
 XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
 XX WPI; 2003-201269/19.  
 DR  
 XX Prevention and/or treatment of an amyloid-related disease e.g.  
 PT Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
 XX  
 PS Claim 1; Page 59; 44pp; English.  
 XX  
 CC The invention relates to a method for prevention and/or treatment of an  
 CC amyloid-related disease which comprises administration of an all-D -  
 CC amyloid-beta peptide. The method is used for preventing and/or treating  
 CC Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
 CC angiopathy; for altering serum levels of amyloid-beta in a mammal and  
 CC favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
 CC the mammal; and reducing or inhibiting the formation of plaques. It is  
 CC also used for treating AA (reactive) amyloid diseases including  
 CC inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
 CC arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
 CC Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
 CC disease. AA deposits are also produced as a result of chronic microbial  
 CC infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
 CC ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
 CC Certain malignant neoplasms can also result in AA fibril amyloid deposits  
 CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention  
 XX Sequence 4 AA;  
 SQ  
 Query Match 100.0%; Score 19; DB 6; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 RESULT 13  
 ADQ37266  
 ID ADQ37266 standard; peptide; 4 AA.  
 XX  
 AC ADQ37266;  
 XX  
 DT 07-OCT-2004 (first entry)  
 XX  
 DE Vaccine antigen amyloid-beta related amino acid sequence.

XX amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nontropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment; vascular dementia;  
 KW mild-to-moderate cognitive impairment; hereditary cerebral haemorrhage;  
 KW cerebral amyloid angiopathy; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX Synthetic.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..4  
 FT /note= "D-form residues"  
 FT  
 XX WO2004058239-A1.  
 XX  
 XX 15-JUL-2004.  
 XX  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 XX 24-DEC-2002; 2002US-0436379P.  
 XX 23-JUN-2003; 2003US-0482214P.  
 XX (NEUR-) NEUROCHEM INT LTD.  
 XX  
 XX Gervais F, Bellini F;  
 XX WPI; 2004-543342/52.  
 DR  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 PS Disclosure; Page 67; 143pp; English.  
 XX  
 CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC nontropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, ischaemic  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic

CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.  
 XX  
 SQ Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 8; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 KLVF 4  
 Db 1 KLVF 4  
 RESULT 14  
 ADQ37384  
 ID ADQ37384 standard; peptide; 4 AA.  
 XX  
 AC ADQ37384;  
 XX  
 DT 07-OCT-2004 (first entry)  
 DE  
 DE Amyloid-beta polymerisation peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 OS Synthetic.  
 XX  
 PN WO2004058239-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 24-DEC-2003; 2003WO-CA002021.  
 XX  
 PR 24-DEC-2002; 2002US-0436379P.  
 PR 23-JUN-2003; 2003US-0482214P.  
 XX  
 PA (NEUR-) NEUROCHEM INT LTD.  
 XX  
 FI Gervais F, Bellini F;  
 XX  
 XX WPI, 2004-543342/52.  
 DR  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 PS Disclosure; Page 95; 143pp; English.  
 XX  
 CC The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that

CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC Down's syndrome, hereditary cerebral haemorrhage, senile dementia,  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents an amyloid-  
 CC beta polymerisation peptide which is used in the exemplification of the  
 CC present invention.  
 XX  
 SQ Sequence 4 AA;  
 Query Match 100.0%; Score 19; DB 8; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 KLVF 4  
 Db 1 KLVF 4  
 RESULT 15  
 ADQ37326  
 ID ADQ37326 standard; peptide; 4 AA.  
 XX  
 AC ADQ37326;  
 XX  
 DT 07-OCT-2004 (first entry)  
 DE  
 DE Antifibrillogenic amyloidosis inhibiting peptide.  
 XX  
 KW amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX

OS Synthetic.  
 XX Key Location/Qualifiers  
 FH Modified-site 4  
 FT /note= "amidated"  
 FT  
 XX WO2004058239-A1.  
 XX 15-JUL-2004.  
 XX  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 XX 24-DEC-2002; 2002US-0436379P.  
 XX 23-JUN-2003; 2003US-0482214P.  
 XX  
 XX (NEUR-) NEUROCHEM INT LTD.  
 XX  
 XX Gervais F, Bellini F;  
 XX WPI; 2004-543342/52.  
 XX  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 XX Disclosure; Page 70; 143pp; English.  
 XX  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC a nontropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC in the exemplification of the present invention.  
 XX  
 XX Sequence 4 AA;  
 XX Query Match 100.0%; Score 19; DB 8; Length 4;  
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX 1 KLVF 4

Db 1 KLVF 4

RESULT 16  
 ADQ37318  
 ID ADQ37318 standard; peptide; 4 AA.  
 XX  
 XX ADQ37318;  
 XX  
 XX 07-OCT-2004 (first entry)  
 XX  
 XX Antifibrillogenic amyloidosis inhibiting peptide.  
 XX  
 XX amyloid-beta; amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; nontropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.  
 XX  
 XX Synthetic.  
 OS  
 XX WO2004058239-A1.  
 XX  
 XX 15-JUL-2004.  
 XX  
 XX 24-DEC-2003; 2003WO-CA002021.  
 XX  
 XX 24-DEC-2002; 2002US-0436379P.  
 XX 23-JUN-2003; 2003US-0482214P.  
 XX  
 XX (NEUR-) NEUROCHEM INT LTD.  
 XX  
 XX Gervais F, Bellini F;  
 XX WPI; 2004-543342/52.  
 XX  
 XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.  
 XX  
 XX Disclosure; Page 69; 143pp; English.  
 XX  
 XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC a nontropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC in the exemplification of the present invention.



CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as an antifibrillogenic amyloidosis inhibiting peptide  
 CC in the exemplification of the present invention.

XX Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4

DB 1 KLVF 4

RESULT 17

ADQ37274

ID ADQ37274 standard; peptide; 4 AA.

XX AC ADQ37274;

XX DT 07-OCT-2004 (first entry)

XX DE Vaccine antigen amyloid-beta related amino acid sequence.

XX amyloid-beta, amyloid-beta related disease;  
 KW amyloid-beta fibril formation; immune response; neurotropic;  
 KW neuroprotective; cerebroprotective; haemostatic; ophthalmological;  
 KW antithyroid; vasotropic; cardiovascular; tranquiliser; uropathic;  
 KW anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;  
 KW cardiant; antidepressant; endocrine; hypnotic;  
 KW amyloid-beta fibril formation modulator; immune system modulator;  
 KW Alzheimer's disease; mild cognitive impairment;  
 KW mild-to-moderate cognitive impairment; vascular dementia;  
 KW cerebral amyloid angiopathy; hereditary cerebral haemorrhage;  
 KW senile dementia; Down's syndrome; inclusion body myositis;  
 KW age-related macular degeneration; hypothyroidism;  
 KW cerebrovascular disease; cardiovascular disease; memory loss; anxiety;  
 KW behavioural dysfunction; neurological condition; psychological condition;  
 KW vaccine antigen.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Misc-difference 1..4

FT /note= "D-form residues"

FT Modified-site 4

FT /note= "amidated"

XX PN WO2004058239-A1.

XX PD 15-JUL-2004.

XX PF 24-DEC-2003; 2003WO-CA002021.

XX PR 24-DEC-2002; 2002US-0436379P.

XX PR 23-JUN-2003; 2003US-0482214P.

XX

PA (NEUR-) NEUROCHEM INT LTD.

XX Gervais F, Bellini F;

XX WPI; 2004-543342/52.

XX Composition for treating e.g. Alzheimer's disease comprises first agent  
 PT that prevents or treats amyloid-beta related disease and second agent  
 PT that is either a peptide or peptidomimetic or an immune system modulator.

XX Disclosure; Page 67; 143pp; English.

XX The present invention describes compositions (C) comprising: (a) a first  
 CC agent (a1) that prevents or treats amyloid-beta related disease; and (b)  
 CC a second agent (a2) that is: (i) a peptide or peptidomimetic that  
 CC modulates amyloid-beta fibril formation or induces a prophylactic or  
 CC therapeutic immune response against amyloid-beta fibril formation; or  
 CC (ii) an immune system modulator that prevents or inhibits amyloid-beta  
 CC fibril formation. Also described is a kit comprising (C). (C) have  
 CC neurotropic, neuroprotective, cerebroprotective, haemostatic,  
 CC ophthalmological, antithyroid, vasotropic, cardiovascular, tranquiliser,  
 CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,  
 CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,  
 CC and can be used as amyloid-beta fibril formation modulators, and as  
 CC immune system modulators. (C) can be used for preventing or treating an  
 CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic  
 CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,  
 CC mild-to-moderate cognitive impairment, vascular dementia, cerebral  
 CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,  
 CC Down's syndrome, inclusion body myositis, age-related macular  
 CC degeneration, or a condition associated with Alzheimer's disease  
 CC (including hypothyroidism, cerebrovascular disease, cardiovascular  
 CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,  
 CC aggression, or incontinence), a neurological condition (e.g. Huntington's  
 CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,  
 CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia  
 CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual  
 CC field deficits, incoordination, gait disturbance, transient ischaemic  
 CC attack or stroke, transient alertness, attention deficit, frequent falls,  
 CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural  
 CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic  
 CC damage), or a psychological condition (e.g. depression, delusions,  
 CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep  
 CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal  
 CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or  
 CC excessive guilt)) in a subject e.g. human having a genomic mutation in an  
 CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;  
 CC having amyloid-beta deposits. The present sequence represents a peptide  
 CC that can be used as a vaccine antigen in the exemplification of the  
 CC present invention.

XX Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4

DB 1 KLVF 4

RESULT 18

AA887922

ID AA887922 standard; peptide; 5 AA.

XX AC AA887922;

XX DT 01-MAR-1996 (first entry)

XX DE Test peptide used in study of antagonism of amyloid beta protein.

XX amnesia, amyloid beta; Alzheimer's disease.

XX



XX OS Synthetic.  
 XX PN W09508999-A1.  
 XX XX  
 XX PD 06-APR-1995.  
 XX PF 16-SEP-1994; 94WO-US010475.  
 XX PR 29-SEP-1993; 93US-00127904.  
 XX PA (CITY ) CITY OF HOPE.  
 XX PI Roberts E;  
 XX DR WPI; 1995-147244/19.  
 XX XX  
 XX PT New peptide(s) which block binding of amyloid beta protein - used for  
 XX PT antagonising the amnestic effects of amyloid beta protein, partic. in  
 XX PT Alzheimer's disease.  
 XX PS Disclosure; Page 9; 27pp; English.  
 XX CC The invention relates to three new peptides which block the amnestic  
 XX CC effects of amyloid beta protein and which can be used to ameliorate  
 XX CC amnesia and other neurotoxicity in Alzheimer's disease caused by  
 XX CC deposition of this protein. The peptides themselves are not amnestic or  
 XX CC memory-enhancing. The new peptides are described in AAR87912, AAR87913  
 XX CC and AAR87914. The present sequence is an additional peptide tested in the  
 XX CC process but found not to be active  
 XX SQ  
 Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 2; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 Db 1 KLVF 4  
 RESULT 19  
 AAW02315  
 ID AAW02315 standard; peptide; 5 AA.  
 XX AC AAW02315;  
 XX DT 02-MAY-1997 (first entry)  
 XX DE Beta-amyloid modulator peptide #6.  
 XX KW Beta-amyloid; modulator; amyloid plaque; brain lesion; amyloidosis;  
 KW Cerebral blood vessel; Alzheimer's disease; amyloidogenic protein;  
 KW familial amyloid polyneuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloidosis; systemic senile amyloidosis; insulinoma;  
 KW bovine spongiform encephalopathy; Creutzfeldt-Jakob disease; urticaria;  
 KW adult-onset diabetes; familial Mediterranean fever; therapy; deafness;  
 KW scrapie; familial amyloid nephropathy; hereditary cerebral haemorrhage.  
 XX OS Synthetic.  
 XX PN W09628471-A1.  
 XX PD 19-SEP-1996.  
 XX PF 14-MAR-1996; 96WO-US003492.  
 XX PR 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX PA (PHAR-) PHARM PEPTIDES INC.

XX PI Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed WJ, Molineaux S;  
 XX PI Kubasek W, Chin J, Lee J, Kelley M;  
 XX DR WPI; 1996-433762/43.  
 XX XX  
 XX PT Modulators of amyloid aggregation - comprising, e.g. amyloidogenic  
 XX PT protein coupled (in)directly to at least 1 modifying gp., useful in  
 XX PT treatment of Alzheimer's disease.  
 XX PS Claim 16; Page 91; 106pp; English.  
 XX XX  
 XX CC AAW02310-W02332 represent the peptide portions of the beta-amyloid  
 XX CC modulator compounds of the invention. Beta-amyloid peptide is a 4  
 XX CC kilodalton peptide that is the major protein component of amyloid  
 XX CC plaques. Amyloid plaques are present both in the brain lesions, and in  
 XX CC the walls of cerebral blood vessels in Alzheimer's disease patients. The  
 XX CC amyloid modulators of the invention comprise an amyloidogenic protein or  
 XX CC peptide (such as this sequence) coupled directly or indirectly to at  
 XX CC least one modifying group. The modifying group is preferably a cyclic,  
 XX CC heterocyclic, or polycyclic group, such as decalin, a cholanyl group, a  
 XX CC biotin containing group, or a fluorescein containing group. These  
 XX CC compounds then modulate the aggregation of these sequences to natural  
 XX CC amyloid proteins or peptides when contacted with the natural  
 XX CC amyloidogenic proteins or peptides. The modulator compounds can be used  
 XX CC in the treatment of disorders associated with amyloidosis, such as  
 XX CC familial amyloid polyneuropathy, familial amyloid cardiomyopathy,  
 XX CC isolated cardiac amyloidosis, systemic senile amyloidosis, scrapie,  
 XX CC bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, adult-onset  
 XX CC diabetes, insulinoma, familial Mediterranean fever, familial amyloid  
 XX CC nephropathy with urticaria and deafness, hereditary cerebral haemorrhage  
 XX CC and other types of amyloidosis. The modulators are also useful for the  
 XX CC treatment of disorders associated with beta-amyloidosis, especially  
 XX CC Alzheimer's disease  
 XX SQ  
 Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 2; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Mismatches 0; Indels 0; Gaps 0;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 Db 1 KLVF 4  
 RESULT 20  
 AAW45933  
 ID AAW45933 standard; peptide; 5 AA.  
 XX AC AAW45933;  
 XX DT 25-MAR-2003 (revised)  
 XX DT 08-JUL-1998 (first entry)  
 XX DE Partial sequence of amyloid beta peptide critical for its polymerisation.  
 XX KW Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
 KW positron emission tomography; PET; Down's syndrome; amyloidosis.  
 XX OS Homo sapiens.  
 XX PN W09721728-A1.  
 XX PD 19-JUN-1997.  
 XX PF 09-DEC-1996; 96WO-SE001621.  
 XX PR 12-DEC-1995; 95SE-00004467.  
 XX PR 29-DEC-1995; 95US-0009386P.  
 XX PA (KARO-) KAROLINSKA INNOVATIONS AB.

XX Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;  
 XX WPI; 1997-332723/30.  
 XX Use of new and known peptide(s) for inhibition of polymerisation of  
 PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
 PT Down's syndrome associated with amyloidosis.  
 XX Example 5; Page 14; 31pp; English.  
 XX This is a partial sequence of the amyloid beta peptide which is critical  
 CC for its polymerisation. The invention relates to the use of peptide  
 CC compounds for inhibition of polymerisation of amyloid beta peptide (ABP),  
 CC as model substances for synthesis of ABP-ligands for inhibition of  
 CC polymerisation of ABP, as a tool for the identification of other organic  
 CC compounds with similar functional properties, or as ligands in positron  
 CC emission tomography. The peptides may be used in treatment of  
 CC amyloidosis, especially in treatment of Alzheimer's disease associated  
 CC with amyloidosis, for treatment or prevention of demens in patients with  
 CC Down's syndrome, for treatment or prevention of hereditary cerebral  
 CC haemorrhage with amyloidosis (Dutch type) or for the prevention of fibril  
 CC formation of human amyloid protein. They can also be used for identifying  
 CC other molecules with similar properties and/or as ligands for detection  
 CC of amyloid deposits using e.g. positron emission tomography. (Updated on  
 CC 25-MAR-2003 to correct PI field.)  
 XX Sequence 5 AA;  
 SQ Query Match 100.0%; Score 19; DB 2; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVP 4  
 DB 1 KLVP 4  
 RESULT 21  
 AAW45966  
 ID AAW45966 standard; peptide; 5 AA.  
 XX AC AAW45966;  
 XX 25-MAR-2003 (revised)  
 DT 30-JUN-1998 (first entry)  
 XX Peptide derived from amyloid beta peptide fragment.  
 XX Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
 KW positron emission tomography; PET; Down's syndrome; amyloidosis.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX WO9721728-A1.  
 PN 19-JUN-1997.  
 XX 09-DEC-1996; 96WO-SE001621.  
 XX 12-DEC-1995; 95SE-00004467.  
 PR 29-DEC-1995; 95US-0009386P.  
 XX (KARO-) KAROLINSKA INNOVATIONS AB.  
 XX Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;  
 XX WPI; 1997-332723/30.  
 XX Use of new and known peptide(s) for inhibition of polymerisation of  
 PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
 PT Down's syndrome associated with amyloidosis.

XX Example 1; Fig 2C; 31pp; English.  
 XX Sequences AAW45962-6 represent a fragment of the amyloid beta peptide  
 CC KLVPF with an amino acid residue replaced with alanine. The invention  
 CC relates to the use of peptide compounds for inhibition of polymerisation  
 CC of amyloid beta peptide (ABP), as model substances for synthesis of ABP-  
 CC ligands for inhibition of polymerisation of ABP, as a tool for the  
 CC identification of other organic compounds with similar functional  
 CC properties, or as ligands in positron emission tomography. The peptides  
 CC may be used in treatment of amyloidosis, especially in treatment of  
 CC Alzheimer's disease associated with amyloidosis, for treatment or  
 CC prevention of demens in patients with Down's syndrome, for treatment or  
 CC prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch  
 CC type) or for the prevention of fibril formation of human amyloid protein.  
 CC They can also be used for identifying other molecules with similar  
 CC properties and/or as ligands for detection of amyloid deposits using e.g.  
 CC positron emission tomography. (Updated on 25-MAR-2003 to correct PI  
 CC field.)  
 XX Sequence 5 AA;  
 SQ Query Match 100.0%; Score 19; DB 2; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVP 4  
 DB 1 KLVP 4  
 RESULT 22  
 AAW45950  
 ID AAW45950 standard; peptide; 5 AA.  
 XX AC AAW45950;  
 XX 25-MAR-2003 (revised)  
 DT 30-JUN-1998 (first entry)  
 XX Amyloid beta peptide fragment.  
 XX Amyloid beta peptide; Alzheimer's disease; polymerisation; aggregation;  
 KW positron emission tomography; PET; Down's syndrome; amyloidosis.  
 XX Homo sapiens.  
 OS WO9721728-A1.  
 PN 19-JUN-1997.  
 XX 09-DEC-1996; 96WO-SE001621.  
 XX 12-DEC-1995; 95SE-00004467.  
 PR 29-DEC-1995; 95US-0009386P.  
 XX (KARO-) KAROLINSKA INNOVATIONS AB.  
 XX Nordstedt C, Naeslund J, Thyberg J, Tjernberg LO, Terenius L;  
 XX WPI; 1997-332723/30.  
 XX Use of new and known peptide(s) for inhibition of polymerisation of  
 PT amyloid beta peptide - e.g. for treatment of Alzheimer's disease or  
 PT Down's syndrome associated with amyloidosis.  
 XX Example 1; Fig 2B; 31pp; English.  
 XX This sequence represents a fragment of the amyloid beta peptide. The  
 CC invention relates to the use of peptide compounds for inhibition of  
 CC polymerisation of amyloid beta peptide (ABP), as model substances for  
 CC synthesis of ABP-ligands for inhibition of polymerisation of ABP, as a  
 CC tool for the identification of other organic compounds with similar

CC functional properties, or as ligands in positron emission tomography. The  
 CC peptides may be used in treatment of amyloidosis, especially in treatment  
 CC of Alzheimer's disease associated with amyloidosis, for treatment or  
 CC prevention of demens in patients with Down's syndrome, for treatment or  
 CC prevention of hereditary cerebral haemorrhage with amyloidosis (Dutch  
 CC type) or for the prevention of fibril formation of human amyloid protein.  
 CC They can also be used for identifying other molecules with similar  
 CC properties and/or as ligands for detection of amyloid deposits using e.g.  
 CC positron emission tomography. (Updated on 25-MAR-2003 to correct PI  
 CC field.)

XX Sequence 5 AA;

SQ Query Match 100.0%; Score 19; DB 2; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4

DB 2 KLVP 5

RESULT 23

AAW29089

ID AAW29089 standard; peptide; 5 AA.

XX AAW29089;

XX 20-JUL-1999 (first entry)

DE A-beta-binding peptide fragment conjugated to cyclosporin.

XX Cyclosporin; A-beta peptide; conjugate; neurological disease; Alzheimer;  
 KW multiple sclerosis; amyotrophic lateral sclerosis; ALS;  
 KW non-immunosuppressive; amyloid plaque formation.

XX Homo sapiens.

XX Key Location/Qualifiers

PH Modified-site 5

FT /note= "The C-terminal is condensed onto the side chain  
 FT of Lys(7) of the cyclosporin analog described in  
 FT AAW29087, AAW29088, AAW29095 and AAW29097"

XX WO9910374-A1.

XX 04-MAR-1999.

XX 25-AUG-1998; 98WO-US017544.

XX 26-AUG-1997; 97US-0057751P.

XX (WISC ) WISCONSIN ALUMNI RES FOUND.

XX Rich DH, Solomon ME;

XX WPI; 1999-276928/23.

XX New A-b-binding peptide conjugates and Csa analogs - useful in treatment  
 PT of neurological diseases e.g. Alzheimer's disease, Multiple Sclerosis  
 PT etc.

PS Claim 5; Page 98; 129pp; English.

XX New conjugates are disclosed which are of formula A-Z, in which: A is (1)  
 CC a cyclosporin A analogue described in AAW29087 or (2) an FK506 binding  
 CC peptide inhibitor; and Z is a polypeptide comprising 5 or more contiguous  
 CC residues of A-beta peptide. The compounds are novel chemical inducers of  
 CC dimerization which are non-immunosuppressive and which are inhibitors of  
 CC A-beta peptide aggregation and deposition in amyloid plaques. The adverse  
 CC consequences of amyloid plaque formation can be prevented or ameliorated  
 CC by sequestering the A-beta peptide in monomeric form with a conjugate  
 CC which links the A-beta to cyclophilin or FKBP, therefore providing a

CC mechanism to minimize the amount of free A-beta available for fibril  
 CC formation and deposition. The compounds can be used for the treatment of  
 CC Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis  
 XX SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 2; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4

DB 1 KLVP 4

RESULT 24

AAW89367

ID AAW89367 standard; peptide; 5 AA.

XX AAW89367;

XX 02-MAR-1999 (first entry)

DE Beta-amyloid peptide derivative A-beta-16-20.

XX Human; beta-amyloid peptide; Alzheimer's disease; amyloidogenic protein;  
 KW aggregation; neurotoxicity; amyloidosis; Down's syndrome; cardiomyopathy;  
 KW familial amyloid polynuropathy; bovine spongiform encephalopathy;  
 KW Creutzfeldt-Jakob disease; BAP.

XX Homo sapiens.

OS Synthetic.

PN US5854204-A.

XX 29-DEC-1998.

XX 14-MAR-1996; 96US-00612785.

XX 14-MAR-1995; 95US-00404831.

XX 07-JUN-1995; 95US-00475579.

XX 27-OCT-1995; 95US-00548998.

XX (PRAE-) PRAECIS PHARM INC.

XX Hundal A, Gefter ML, Kasman L, Musso G, Molineaux S, Benjamin H;  
 PI Findeis MA, Chin J, Lee J, Kelley M, Reed M, Wakefield J;  
 PI Garnick MB, Kubasek W, Signer ER;

XX WPI; 1999-094964/08.

XX New peptide(s) derived from beta-amyloid peptide that inhibit amyloid  
 PT aggregation - and neurotoxicity, specifically for treatment and  
 PT prevention of Alzheimer's disease.

XX Example 11; Col 63; 52pp; English.

XX The present invention describes beta-amyloid peptide (bAP) derivatives.  
 CC The bAP derivatives inhibit aggregation of amyloidogenic proteins and  
 CC peptides, specifically bAP, and their neurotoxicity, so are useful for  
 CC treating and preventing any disease involving amyloidosis, specifically  
 CC Alzheimer's disease but also Down's syndrome, familial amyloid  
 CC polynuropathy or cardiomyopathy, bovine spongiform encephalopathy and  
 CC Creutzfeldt-Jakob disease. The bAP derivatives are also used to diagnose  
 CC these diseases, in vitro or in vivo, by detecting binding of bAP to  
 CC labelled bAP derivatives. Some bAP derivatives inhibit bAP aggregation  
 CC even when bAP is present in molar excess. The present sequence represents  
 CC a bAP derivative

XX Sequence 5 AA;

Query Match 100.0%; Score 19; DB 2; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|  
|  
|  
|  
Db 1 KLVP 4

## RESULT 25

AA79937  
ID AA79937 standard; peptide; 5 AA.

XX

AC AA79937;

XX 11-MAY-2000 (first entry)

DT

DE Beta-amyloid recognition peptide SEQ ID NO:2.

XX Beta-amyloid; inhibitor; recognition element; hybrid; aggregation;  
KW Alzheimer's disease; neuroprotective; nontropic.

XX Homo sapiens.

OS

XX US6022859-A.

PN

XX 08-FEB-2000.

PD

XX 14-NOV-1997; 97US-00970833.

XX

XX 15-NOV-1996; 96US-0030840P.

PR

XX (WISC) WISCONSIN ALUMNI RES FOUND.

PA

XX Murphy RM, Kiessling LL;

PI

XX WPI; 2000-160387/14.

DR

XX Beta-amyloid inhibitor useful for treating Alzheimer's disease.

PT

XX Example; Col 7; 15pp; English.

PS

XX The present invention describes a beta-amyloid inhibitor peptide. Beta-amyloid inhibitors have neuroprotective and nontropic properties. The inhibitor peptides are useful for the treatment of Alzheimer's disease. The present sequence represents a beta-amyloid recognition peptide used in the exemplification of present invention

XX

SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 3; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|  
|  
|  
|  
Db 1 KLVP 4

## RESULT 26

AA67279

ID AA67279 standard; peptide; 5 AA.

XX

AC AA67279;

XX 20-APR-2001 (first entry)

DT

XX Residues 16-20 of Alzheimer's Abeta peptide.

DE

XX Alzheimer's; Abeta; beta-strand.

XX

XX Homo sapiens.

OS

XX WO200107473-A1.

PN

XX

PD 01-FEB-2001.

XX

PF 28-JUL-2000; 2000WO-GB002901.

XX

PR 28-JUL-1999; 99GE-00017724.

XX

PA (STOT/) STOTT K.

XX

PI Stott K;

XX

XX WPI; 2001-182777/18.

DR

XX Novel chemical compound or composition useful for preventing beta-strand association, comprises peptides containing N-alpha substituted L-amino acids.

PT

XX

XX Example 1; Page 42; 77pp; English.

PS

XX The present invention relates to a chemical compound or composition comprising a peptide with a beta strand forming section and associates with a target beta-strand formed by a separate peptide-containing molecule. The invention is useful for inhibiting or reversing the association of target beta-strand, formed by Alzheimer's Abeta peptide into a beta-sheet or beta-fibre and the aggregation of proteins or peptides

CC

XX Sequence 5 AA;

SQ

Query Match 100.0%; Score 19; DB 4; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|  
|  
|  
|  
Db 1 KLVP 4

## RESULT 27

AA48489

ID AA48489 standard; peptide; 5 AA.

XX

AC AA48489;

XX

DT 02-MAR-2001 (first entry)

XX

XX Antifibrillogenic peptide #16.

DR

XX Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition; cytoprotection; amyloid deposit degradation; amyloidosis disorder; Alzheimer's disease.

KW

XX Homo sapiens.

OS

XX Key Location/Qualifiers

PH Modified-site 5

FT /note= "C-terminal amide"

XX

XX WO200068263-A2.

PN

XX 16-NOV-2000.

PD

XX 04-MAY-2000; 2000WO-CA000515.

XX

XX 05-MAY-1999; 99US-0132592P.

XX

XX (NEUR-) NEUROCHEM INC.

PA

XX Chalifour R, Gervais F, Gupta A;

PI

XX WPI; 2001-031852/04.

DR

XX Antifibrillogenic agent useful for inhibiting amyloidosis and/or for cytoprotection for treating amyloidosis disorders, comprises a peptide,

PT

PT its isomer or peptidomimetic.

XX PS Claim 7; Page 25; 46pp; English.

XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used for inhibiting amyloidosis and/or for cytoprotection. The peptides of AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore useful for treating amyloidosis disorders such as Alzheimer's disease.

XX CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan binding region and the prot-prot interaction region of the human amyloid protein

XX SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 4; Length 5;

Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Mismatches 0; Conservative 0; Indels 0; Gaps 0;

OY 1 KLVP 4

DB 1 KLVP 4

RESULT 28

ID AAB48481 standard; peptide; 5 AA.

XX AC AAB48481;

DT 02-MAR-2001 (first entry)

DE Antifibrillogenic peptide #8.

KW Nootropic; neuroprotective; antifibrillogenic; amyloidosis inhibition; cytoprotection; amyloid deposit degradation; amyloidosis disorder; Alzheimer's disease.

XX OS Homo sapiens.

XX PN WO200068263-A2.

XX PD 16-NOV-2000.

XX PF 04-MAY-2000; 2000WO-CA000515.

XX PR 05-MAY-1999; 99US-0132592P.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Chalfour R, Gervais F, Gupta A;

XX DR WPI; 2001-031852/04.

XX PT Antifibrillogenic agent useful for inhibiting amyloidosis and/or for cytoprotection for treating amyloidosis disorders, comprises a peptide, its isomer or peptidomimetic.

XX PS Claim 7; Page 25; 46pp; English.

XX CC Peptides AAB48474-B48496 are antifibrillogenic agents that can be used for inhibiting amyloidosis and/or for cytoprotection. The peptides of AAB48474-B48496 cause the breakdown of amyloid deposits and are therefore useful for treating amyloidosis disorders such as Alzheimer's disease.

XX CC Peptides AAB48474-B48496 were identified from the glycosaminoglycan binding region and the prot-prot interaction region of the human amyloid protein

XX SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 4; Length 5;

Best Local Similarity 100.0%; Pred. NO. 1.8e+06; Mismatches 0; Conservative 0; Indels 0; Gaps 0;

OY 1 KLVP 4

DB 1 KLVP 4

RESULT 29

AAB82637

ID AAB82637 standard; peptide; 5 AA.

XX AC AAB82637;

DT 02-OCT-2001 (first entry)

DE All-D peptide used in Alzheimer's disease vaccine.

KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine; therapy; antigen.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Misc-difference 1..5 /note= "all D-form residues"

FT Modified-site 6 /note= "C-terminal amide"

XX WO200139796-A2.

XX PD 07-JUN-2001.

XX PF 29-NOV-2000; 2000WO-CA001413.

XX PR 28-NOV-1999; 99US-0168594P.

XX PA (NEUR-) NEUROCHEM INC.

XX PI Chalfour R, Hebert L, Kong X, Gervais F;

XX DR WPI; 2001-441458/47.

XX PT Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, eg. as vaccine, which elicits production of antibodies to prevent fibrillogenesis and associated cellular toxicity.

XX PS Disclosure; Page 11; 31pp; English.

XX CC The present sequence is that of an all-D peptide suitable for use in preparing vaccines for preventing or treating Alzheimer's disease and other amyloid related disorders in humans. It is based on a portion of amyloid-beta peptide (see AAB82622), and may be modified by removing or inserting 1 or more amino acid residues, or by substituting 1 or more amino acid residues with other amino acid residues or non-amino acid fragments. Vaccines of the invention are produced using 'non-self' peptides synthesised from the unnatural D-configuration amino acids to avoid the drawbacks of 'self' proteins. The all-D peptides need not be aggregated to be operative or immunogenic. They preferably interact with at least 1 region of an amyloid protein, e.g. the beta-sheet region or GAG-binding site region, the amyloid-beta peptide, or their immunogenic fragments, protein conjugates, immunogenic derivative peptides and immunogenic peptidomimetics. Examples include all-D peptides corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and 36-42 of the amyloid-beta peptide and the all-D derivative peptides given in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response, preventing fibrillogenesis and associated cellular toxicity. The amyloid related diseases may be localised amyloidosis, e.g. diabetes type II, neurodegenerative diseases, e.g. bovine spongiform encephalitis, Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and prion protein related disorders, or systemic amyloidosis associated with chronic infection (e.g. tuberculosis) or chronic inflammation (e.g. rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic amyloidosis found in long-term haemodialysis patients

CC Creutzfeldt-Jakob disease, scrapie, cerebral amyloid angiopathy, and  
 CC prion protein related disorders, or systemic amyloidosis associated with  
 CC chronic infection (e.g. tuberculosis) or chronic inflammation (e.g.  
 CC rheumatoid arthritis), familial Mediterranean fever (FMF) and systemic  
 CC amyloidosis found in long-term haemodialysis patients  
 XX Sequence 5 AA;  
 SQ

Query Match 100.0%; Score 19; DB 4; Length 5;  
 Best Local Similarity 100.0%; Pred. NO. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 Db 1 KLVF 4

RESULT 30  
 AAB82629  
 ID AAB82629 standard; peptide; 5 AA.  
 XX  
 AC AAB82629;  
 XX  
 DT 02-OCT-2001 (first entry)  
 XX  
 DE All-D peptide used in Alzheimer's disease vaccine.  
 XX  
 KW Alzheimer's disease; amyloidosis; amyloid-related disease; vaccine;  
 KW therapy; antigen.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1..5 "all D-form residues"  
 FT  
 XX WO200139796-A2.  
 PN  
 XX 07-JUN-2001.  
 PD  
 XX 29-NOV-2000; 2000WO-CA001413.  
 PF  
 XX 29-NOV-1999; 99US-0168594P.  
 PR  
 XX 28-NOV-2000; 2000US-00724842.  
 XX  
 XX (NEUR-) NEUROCHEM INC.  
 PA  
 XX Chalfour R, Hebert L, Kong X, Gervais F;  
 PI  
 XX WPI; 2001-441458/47.  
 DR  
 XX Preventing/treating amyloid-related disease, especially Alzheimer's  
 PT disease, comprises administering antigenic all-D peptide, eg. as vaccine,  
 PT which elicits production of antibodies to prevent fibrillogenesis and  
 PT associated cellular toxicity.  
 XX  
 XX Disclosure; Page 11; 31pp; English.  
 PS  
 XX The present sequence is that of an all-D peptide suitable for use for  
 CC preparing vaccines for preventing or treating Alzheimer's disease and  
 CC other amyloid related disorders in humans. It is based on a portion of  
 CC amyloid-beta peptide (see AAB82622), and may be modified by removing or  
 CC inserting 1 or more amino acid residues, or by substituting 1 or more  
 CC amino acid residues with other amino acid residues or non-amino acid  
 CC fragments. Vaccines of the invention are produced using 'non-self'  
 CC peptides synthesised from the unnatural D-configuration amino acids to  
 CC avoid the drawbacks of 'self' proteins. The all-D peptides need not be  
 CC aggregated to be operative or immunogenic. They preferably interact with  
 CC at least 1 region of an amyloid protein, e.g. the beta-sheet region or  
 CC GAG-binding site region, the amyloid-beta peptide, or their immunogenic  
 CC fragments, protein conjugates, immunogenic derivative peptides and  
 CC immunogenic peptidomimetics. Examples include all-D peptides  
 CC corresponding to residues 1-42, 1-40, 1-35, 1-28, 1-7, 10-16, 16-21 and  
 CC 36-42 of the amyloid-beta peptide and the all-D derivative peptides given  
 CC in AAB82623-64. The vaccine elicits a preferential TH-2 or TH-1 response,  
 CC preventing fibrillogenesis and associated cellular toxicity. The amyloid  
 CC related diseases may be localised amyloidosis, e.g. diabetes type II,  
 CC neurodegenerative diseases, e.g. bovine spongiform encephalitis,

CC dentatorubral-pallidoluysian atrophy, and at least 5'genetically distinct  
 CC forms of spinocerebellar ataxia; Non-neurodegenerative diseases such as  
 CC type II diabetes mellitus, familial amyloidosis and dialysis-related  
 CC amyloidosis. The present sequence represents a fragment of the  
 CC Alzheimer's disease related beta-amyloid peptide. The peptide is used in  
 CC an example illustrating the use of a peptide of the invention

XX Sequence 5 AA;

Query Match 100.0%; Score 19; DB 4; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06; Indels 0; Gaps 0;  
 Matches 4; Conservative 0; Mismatches 0;

Qy 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 32

ABG71010  
 ID ABG71010 standard; peptide; 5 AA.

AC ABG71010;

DT 05-DEC-2002 (first entry)

DE Long form beta-amyloid protein fragment #7.

KW Beta-amyloid; amyloid modulator; amyloidogenic protein; amyloidosis;  
 KW familial amyloid polyneuropathy; familial amyloid cardiomyopathy;  
 KW isolated cardiac amyloid; systemic senile amyloidosis; scrapie; myeloma;  
 KW bovine spongiform encephalopathy; BSE; Creutzfeldt-Jakob disease;  
 KW adult onset diabetes; Gerstmann-Straussler-Scheinker syndrome;  
 KW insulinoma; atrial amyloidosis; idiopathic amyloidosis; haemodialysis;  
 KW macroglobulinaemia-associated amyloidosis; reactive amyloidosis;  
 KW primary localised cutaneous nodular amyloidosis; Sjogren's syndrome;  
 KW hereditary cerebral haemorrhage with amyloidosis; Muckle-Wells syndrome;  
 KW hereditary non-neuropathic systemic amyloidosis;  
 KW familial Mediterranean Fever.

XX Homo sapiens.

XX US2002098173-A1.

FN 25-JUL-2002.

XX 04-OCT-2001; 2001US-00972475.

PF 14-MAR-1995; 95US-00404831.

PR 07-JUN-1995; 95US-00475579.

PR 27-OCT-1995; 95US-00548998.

PR 14-MAR-1996; 96US-00617267.

XX (PRAE-) PRAECIS PHARM INC.

XX Findeis MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;

PI Kasman L, Musso G, Signer ER, Wakefield J, Reed WJ;

XX WPI; 2002-697709/75.

DR Amyloid modulator useful for treating a disorder associated with

PT amyloidosis, comprises an amyloidogenic protein and/or a peptide fragment

PT coupled to a modifying group.

XX Example 12; Page 35; 41pp; English.

XX The invention describes an amyloid modulator comprising an amyloidogenic

CC protein and/or peptide fragment coupled to a modifying group so that the

CC compound modulates the aggregation of natural amyloid proteins or

CC peptides. The modulator is used for treating a disorder associated with

CC amyloidosis e.g. familial amyloid polyneuropathy (Portuguese, Japanese

CC and Swedish types), familial amyloid cardiomyopathy (Danish type),

CC isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine

CC

XX Sequence 5 AA;

SQ

XX

XX

XX

XX

XX

XX

XX

XX

CC spongiform encephalopathy, Creutzfeldt-Jakob disease, adult onset  
 CC diabetes, Gerstmann-Straussler-Scheinker syndrome, insulinoma, isolated  
 CC atrial amyloidosis, idiopathic (primary) amyloidosis, myeloma or  
 CC macroglobulinaemia-associated amyloidosis, primary localised cutaneous  
 CC nodular amyloidosis associated with Sjogren's syndrome, reactive  
 CC (secondary) amyloidosis, familial Mediterranean Fever and familial  
 CC amyloid nephropathy with urticaria and deafness (Muckle-Wells syndrome),  
 CC hereditary cerebral haemorrhage with amyloidosis of Icelandic type,  
 CC amyloidosis associated with long term haemodialysis, hereditary non-  
 CC neuropathic systemic amyloidosis (familial amyloid polyneuropathy III),  
 CC familial amyloidosis of Finnish type, amyloidosis associated with  
 CC medullary carcinoma of the thyroid, fibrinogen-associated hereditary  
 CC renal amyloidosis and lysosome-associated hereditary systemic  
 CC amyloidosis. The compound is capable of altering and inhibiting beta-  
 CC amyloid protein (beta-Ap) aggregation of natural amyloidogenic prote-  
 CC or peptides when contacted with a molar excess amount of natural beta-Aps  
 CC relative to the modulator. This sequence represents a fragment of the  
 CC long form of beta-amyloid used in the creation of an amyloid modulator  
 XX Sequence 5 AA;

Query Match 100.0%; Score 19; DB 5; Length 5;

Best Local Similarity 100.0%; Pred. No. 1.8e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 33

AAO15847

ID AAO15847 standard; peptide; 5 AA.

AC AAO15847;

DT 19-DEC-2002 (first entry)

DE Beta-amyloid protein (Abeta) aggregation inhibitor peptide.

XX Abeta; beta-amyloid protein aggregation inhibitor; Alzheimer's disease;

KW C-terminal aspartyl-aspartyl (aminoethoxy) ethoxyacetic acid.

XX Unidentified.

XX JP2002241302-A.

XX 28-AUG-2002.

PF 19-FEB-2001; 2001JP-00041170.

PR 19-FEB-2001; 2001JP-00041170.

XX (DOKU-) DOKURITSU GYOSHI HOJIN SANGYO GIJUTSU SO.

XX WPI; 2002-744799/81.

XX An aggregation inhibitor of beta-amyloid protein of sequence Lys-Leu-Val-

PT Phe-Phe with modified C-terminal of aspartyl-aspartyl-

PT (aminoethoxy)ethoxyacetic acid, for prevention, diagnosis and treatment

XX of Alzheimer's.

PS Claim 1; Page 2; 4pp; Japanese.

XX The invention comprises an aggregation inhibitor of beta-amyloid protein

CC (Abeta). The aggregation inhibitor of the invention has the sequence Lys-

CC Leu-Val-Phe-Phe with a modified C-terminal of aspartyl-aspartyl

CC (aminoethoxy) ethoxyacetic acid. The Abeta aggregation inhibitor of the

CC invention is useful for the prevention, diagnosis and treatment of

CC Alzheimer's disease. The present amino acid sequence represents the Abeta

CC aggregation inhibitor peptide of the invention

XX

XX Sequence 5 AA;

SQ

XX

XX

XX

XX

XX

XX

XX

XX

Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 Db 1 KLVF 4

RESULT 34  
 ABB05183  
 ID ABB05183 standard; peptide; 5 AA.  
 XX  
 AC ABB05183;  
 XX  
 DT 02-APR-2002 (first entry)  
 XX  
 DE Beta amyloid peptide related peptide PPI-366 SEQ ID NO:37.  
 XX  
 KW Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polyneuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US6319498-B1.  
 XX  
 PD 20-NOV-2001.  
 XX  
 PF 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 PA (PRAE-) PRACIS PHARM INC.  
 XX  
 PI Findex MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-146668/19.  
 XX  
 PT Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Example 11; Col 63; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has neurotropic, neuroprotective, immunosuppressive, antimicrobial,  
 CC antidiabetic, antipyretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polyneuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a peptide which is used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 Db 1 KLVF 4

RESULT 35  
 ABB05158  
 ID ABB05158 standard; peptide; 5 AA.  
 XX  
 AC ABB05158;  
 XX  
 DT 02-APR-2002 (first entry)  
 XX  
 DE Beta amyloid peptide (16-20) SEQ ID NO:10.  
 XX  
 KW Beta amyloid peptide; beta-AP; beta amyloid precursor protein; A-beta;  
 KW APP-770; amyloid aggregation; amyloidogenic; Alzheimer's disease;  
 KW neurotropic; neuroprotective; immunosuppressive; antimicrobial; auditory;  
 KW antidiabetic; antipyretic; dermatological; cardiovascular; nephrotropic;  
 KW amyloid aggregation inhibitor; neurotoxicity inhibitor; Down's syndrome;  
 KW amyloidogenic disease; beta amyloid deposition; amyloidosis;  
 KW hereditary cerebral haemorrhage; familial amyloid polyneuropathy.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN US6319498-B1.  
 XX  
 PD 20-NOV-2001.  
 XX  
 PF 14-MAR-1996; 96US-00617267.  
 XX  
 PR 14-MAR-1995; 95US-00404831.  
 PR 07-JUN-1995; 95US-00475579.  
 PR 27-OCT-1995; 95US-00548998.  
 XX  
 PA (PRAE-) PRACIS PHARM INC.  
 XX  
 PI Findex MA, Benjamin H, Garnick MB, Geffer ML, Hundal A;  
 PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 DR WPI; 2002-146668/19.  
 XX  
 PT Amyloid modulator compound useful for treatment of an amyloidogenic  
 PT disease such as Alzheimer's disease comprises an aggregation core domain  
 PT and a modifying group attached to it.  
 XX  
 PS Example 11; Col 63; 54pp; English.  
 XX  
 CC The present invention describes an amyloid modulator compound (I)  
 CC comprising an aggregation core domain and a modifying group attached to  
 CC it. (I) has neurotropic, neuroprotective, immunosuppressive, antimicrobial,  
 CC antidiabetic, antipyretic, dermatological, cardiovascular, nephrotropic  
 CC and auditory activities, and can be used as a natural amyloid aggregation  
 CC inhibitor and a neurotoxicity inhibitor of natural beta amyloid peptide  
 CC (beta-AP). (I) are used in the manufacture of a medicament for the  
 CC diagnosis or treatment of an amyloidogenic disease e.g. Alzheimer's  
 CC disease and other clinical occurrences of beta amyloid deposition such as  
 CC Down's syndrome individuals and in patients with hereditary cerebral  
 CC haemorrhage with amyloidosis, and for treating a disorder associated with  
 CC amyloidosis such as familial amyloid polyneuropathy. (I) reduces the  
 CC toxicity of natural beta-AP aggregates to cultured neuronal cells. (I)  
 CC not only reduces the formation of neurotoxic aggregates but also have the  
 CC ability to reduce the neurotoxicity of performed A-beta fibrils. The  
 CC present sequence represents a beta-AP peptide, which is used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 5 AA;



Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 DB 1 KLVF 4

RESULT 36  
 AAU96825  
 ID AAU96825 standard; peptide; 5 AA.  
 AC AAU96825;  
 DT 30-JUL-2002 (first entry)  
 DE Amyloid targeting peptide #15.  
 KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.  
 XX Synthetic.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1. .5  
 FT Modified-site 5 /note= "Preferably D-form residue"  
 FT /note= "phe is amidated"  
 XX  
 PN WO200207781-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 25-JUL-2001; 2001WO-CA001071.  
 XX  
 PR 25-JUL-2000; 2000US-0220808P.  
 PR 24-JUL-2001; 2001US-00915092.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Gervais F, Kong X, Chalifour R, Migneault D;  
 XX  
 DR WPI; 2002-371447/40.  
 XX  
 PT New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
 PT plaques and/or for the treatment of amyloidosis disorders.  
 XX  
 PS Claim 49; Page 21; 57pp; English.  
 XX  
 CC The invention relates to an amyloid-targeting imaging agent comprising an  
 CC amyloid targeting moiety, a linker moiety and a labelling moiety. The  
 CC agent is of general formula A\_t-(A\_l)\_n\_k)-z-A\_l\_a\_b (I) where z = 0 - 1;  
 CC A\_t = an amyloid targeting moiety; A\_l\_n\_k = a linker moiety; and A\_l\_a\_b  
 CC = a labelling moiety. Also included are imaging amyloid deposition or  
 CC diagnosing an amyloid-related condition in a patient involving  
 CC administering (I) to the patient, and ultrasound imaging (I) in the  
 CC patient to determine the presence of amyloid or amyloid-related condition  
 CC ; and a kit for preparing a radiopharmaceutical preparation comprising  
 CC (I), a reducing agent, a buffering agent, a transchelating agent, and  
 CC instructions for the preparation and use of the radiopharmaceutical in  
 CC the imaging of amyloid or an amyloid-related condition. The agents are  
 CC used for imaging amyloid deposition and for diagnosing an amyloid related  
 CC condition e.g. Creutzfeldt-Jakob disease (CJD), Kuru, transmissible  
 CC cerebral amyloidosis (transmissible virus dementia), familial CJD,  
 CC scrapie, transmissible mink encephalopathy, bovine spongiform

CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
 CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
 CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
 CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
 CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
 CC barrier and are capable of binding specifically to amyloid plaques. The  
 CC present sequence is a peptide forming the amyloid targeting moiety of the  
 CC agent of the invention  
 XX  
 SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 DB 1 KLVF 4

RESULT 37  
 AAU96817  
 ID AAU96817 standard; peptide; 5 AA.  
 AC AAU96817;  
 DT 30-JUL-2002 (first entry)  
 DE Amyloid targeting peptide #7.  
 XX  
 KW Amyloid; imaging agent; Creutzfeldt-Jakob disease; Kuru; CJD;  
 KW transmissible cerebral amyloidosis; transmissible virus dementia;  
 KW scrapie; transmissible mink encephalopathy; BSE; type II diabetes;  
 KW bovine spongiform encephalopathy; inflammation associated amyloid;  
 KW primary amyloidosis; feline spongiform encephalopathy;  
 KW Alzheimer's disease; prion-mediated disease; blood-brain barrier;  
 KW dialysis-related amyloidosis; light chain-related amyloidosis;  
 KW cerebral amyloid angiopathy.  
 XX Synthetic.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1. .5  
 FT /note= "Preferably D-form residue"  
 XX  
 PN WO200207781-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 25-JUL-2001; 2001WO-CA001071.  
 XX  
 PR 25-JUL-2000; 2000US-0220808P.  
 PR 24-JUL-2001; 2001US-00915092.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Gervais F, Kong X, Chalifour R, Migneault D;  
 XX  
 DR WPI; 2002-371447/40.  
 XX  
 PT New amyloid-targeting imaging agents useful for in vivo imaging amyloid  
 PT plaques and/or for the treatment of amyloidosis disorders.  
 XX  
 PS Claim 49; Page 21; 57pp; English.  
 XX  
 CC The invention relates to an amyloid-targeting imaging agent comprising an  
 CC amyloid targeting moiety, a linker moiety and a labelling moiety. The  
 CC agent is of general formula A\_t-(A\_l)\_n\_k)-z-A\_l\_a\_b (I) where z = 0 - 1;  
 CC A\_t = an amyloid targeting moiety; A\_l\_n\_k = a linker moiety; and A\_l\_a\_b  
 CC = a labelling moiety. Also included are imaging amyloid deposition or  
 CC diagnosing an amyloid-related condition in a patient involving  
 CC administering (I) to the patient, and ultrasound imaging (I) in the  
 CC patient to determine the presence of amyloid or amyloid-related condition

CC ; and a kit for preparing a radiopharmaceutical preparation comprising  
 CC (1), a reducing agent, a buffering agent, a transchelating agent, and  
 CC instructions for the preparation and use of the radiopharmaceutical in  
 CC the imaging of amyloid or an amyloid-related condition. The agents are  
 CC used for imaging amyloid deposition and for diagnosing an amyloid related  
 CC condition e.g. Creutzfeldt-Jakob disease (CJD), kuru, transmissible  
 CC cerebral amyloidosis (transmissible virus dementias), familial CJD,  
 CC scrapie, transmissible mink encephalopathy, bovine spongiform  
 CC encephalopathy (BSE), inflammation-associated amyloid, type II diabetes,  
 CC primary amyloidosis, feline spongiform encephalopathy, non-transmissible  
 CC cerebral amyloidosis, Alzheimer's disease, prion-mediated diseases,  
 CC dialysis-related amyloidosis, light chain-related amyloidosis, cerebral  
 CC amyloid angiopathy. The agents are capable of crossing the blood-brain  
 CC barrier and are capable of binding specifically to amyloid plaques. The  
 CC present sequence is a peptide forming the amyloid targeting moiety of the  
 CC agent of the invention  
 XX  
 SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 RESULT 38  
 ABB84001  
 ID ABB84001 standard; peptide; 5 AA.  
 XX  
 AC ABB84001;  
 XX  
 DT 21-AUG-2002 (first entry)  
 DE  
 DE Transglutaminase inhibitory peptide ap type #1.  
 XX  
 XX Transglutaminase inhibitor; Factor XIII inhibitor; XIIIa inhibitor;  
 KW ophthalmological; antiinflammatory; antirheumatic; antiarthritic;  
 KW thrombolytic; neuroprotective; nootropic; antiseborrheic; dermatological;  
 KW cytostatic; anti-HIV; antipsoriatic; cataract; inflammatory disease;  
 KW arthritis; thrombosis; Alzheimer's disease; Huntington's chorea; acne;  
 KW cancer; HIV infection; psoriasis.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200236799-A2.  
 XX  
 PD 10-MAY-2002.  
 XX  
 PF 02-NOV-2001; 2001WO-EP012727.  
 XX  
 PR 03-NOV-2000; 2000DE-01054687.  
 XX  
 PA (NZYM-) N ZYME BIOTEC GMBH.  
 XX  
 PI Fuchsbaauer H, Pasternack R, Zotzel J;  
 XX WPI; 2002-444364/47.  
 XX  
 DR New amino acid or peptide derivatives or analogs, are selective  
 PT transglutaminase inhibitors useful e.g. for treating cataract,  
 PT inflammatory diseases, rheumatoid arthritis, thrombosis, Alzheimer's  
 PT disease and cancer.  
 XX  
 PS Disclosure; Page 13; 44pp; German.  
 XX  
 CC This invention describes novel amino acid or peptide derivatives or  
 CC analogues (I), containing a modified side-chain (e.g. containing a formyl  
 CC group) which are transglutaminase inhibitors and Factor XIII/XIIa  
 CC inhibitors. The products of the invention have ophthalmological,  
 CC antiinflammatory, antirheumatic, antiarthritic, thrombolytic,

CC neuroprotective, nootropic, antiseborrheic, dermatological, cytostatic,  
 CC anti-HIV and antipsoriatic activity. (I) are transglutaminase inhibitors,  
 CC especially inhibitors of crosslinking of proteins or peptides  
 CC (specifically fibrin and/or alpha<sub>2</sub>-plasmin inhibitor), incorporation of  
 CC primary amines in proteins and peptides, hydrolysis of the gamma-  
 CC carboxamido group of glutamine residues bound in proteins or peptides,  
 CC blood factor XIII/XIIa and mammalian, human, tissue, liver, brain, eye  
 CC lens, keratinocyte, epidermal, prostate, plant, parasitic and/or  
 CC bacterial transglutaminases. The products of the invention can be used  
 CC for treating cataract, inflammatory diseases, rheumatoid arthritis,  
 CC chronic arthritis, thrombosis, Alzheimer's disease, Huntington's chorea,  
 CC acne, cancer (by induction of apoptosis), HIV infections and psoriasis.  
 CC (I) are targeted and specific transglutaminase inhibitors, which can  
 CC inhibit a specific type of transglutaminase in the human or animal body  
 CC without affecting other transglutaminases. ABB84001-ABB84049 represent  
 CC transglutaminase inhibitors described in the method of the invention  
 XX  
 SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 DB 1 KLVF 4  
 RESULT 39  
 AAU11655  
 ID AAU11655 standard; peptide; 5 AA.  
 XX  
 AC AAU11655;  
 XX  
 DT 09-APR-2002 (first entry)  
 DE  
 DE Peptide #8, used as a carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX  
 XX Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; nootropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200185093-A2.  
 XX  
 PD 15-NOV-2001.  
 XX  
 PF 22-DEC-2000; 2000WO-IB002078.  
 XX  
 PR 23-DEC-1999; 99US-0171877P.  
 XX  
 PA (NEUR-) NEUROCHEM INC.  
 XX  
 PI Green AM, Gervais F;  
 XX WPI; 2002-075222/10.  
 XX  
 DR Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.  
 XX  
 PS Disclosure; Page 10; 68pp; English.  
 XX  
 CC The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11659, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor

CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)  
 XX  
 SQ Sequence 5 AA;

Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 40  
 AAU11663  
 ID AAU11663 standard; peptide; 5 AA.  
 XX  
 AC AAU11663;  
 XX  
 DT 09-APR-2002 (first entry)  
 XX  
 DE Peptide #16, used as carrier for the amyloid-beta40 (Abeta40) inhibitor.  
 XX  
 KW Amyloid-beta40 inhibitor; Abeta40 inhibitor; cerebral amyloid angiopathy;  
 KW CAA; neurotropic; neuroprotective; cerebroprotective; Alzheimer's disease;  
 KW cerebral haemorrhage; amyloidosis; haemorrhagic stroke.  
 XX  
 OS Synthetic.

Key Location/Qualifiers  
 FH Modified-site 5 /note= "C-terminal amide"  
 FT  
 FT  
 XX WO200185093-A2.  
 XX  
 XX 15-NOV-2001.

XX 22-DEC-2000; 2000WO-IB002078.  
 XX 23-DEC-1999; 99US-0171877P.  
 XX (NEUR-) NEUROCHEM INC.  
 XX Green AM, Gervais F;  
 XX WPI; 2002-075222/10.  
 XX  
 XX Inhibiting cerebral amyloid angiopathy used for treating e.g. Alzheimer's  
 PT disease comprises contacting blood vessel wall cell with amyloid-beta 40  
 PT inhibitor.  
 XX  
 XX Disclosure; Page 10; 68pp; English.

XX The present invention relates to a new method of inhibiting cerebral  
 CC amyloid angiopathy. The new method of the invention involves contacting a  
 CC blood vessel wall cell with an amyloid-beta40 inhibitor. The invention  
 CC can be used for treating disease states characterised by cerebral amyloid  
 CC angiopathy, particularly Alzheimer's disease, hereditary cerebral  
 CC haemorrhage with amyloidosis of the Dutch type and haemorrhagic stroke.  
 CC The present sequence represents one of a group of peptides (AAU11648-  
 CC AAU11663, AAU11910 & AAU11911) that were used in the invention as a  
 CC carrier for the amyloid-beta40 (Abeta40) inhibitor. The Abeta40 inhibitor  
 CC was used in the invention to treat a disease state characterised by  
 CC cerebral amyloid angiopathy (CAA)

XX  
 SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 5; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4

Db ||||  
 1 KLVF 4

RESULT 41  
 ABB82632  
 ID ABB82632 standard; peptide; 5 AA.  
 XX  
 AC ABB82632;  
 XX  
 DT 04-FEB-2003 (first entry)  
 XX  
 DE Abeta fibrillogenesis inhibitor peptide Ac Abeta16-22.

XX Abeta; beta-amyloid; fibrillogenesis; fibril; neurotropic; neuroprotective;  
 KW cerebroprotective; haemostatic; antipyretic; nephrotropic; vasotropic;  
 KW dermatological; auditory; antidiabetic; cytostatic; antiinflammatory;  
 KW antimicrobial; anticonvulsant; antidiabetic.

XX Homo sapiens.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 1 /note= "N-terminal ACNH"  
 FT Modified-site 5 /note= "C-terminal CONH2"  
 FT  
 XX WO200274931-A2.  
 XX  
 XX 26-SEP-2002.

XX 20-MAR-2002; 2002WO-US008803.  
 XX 20-MAR-2001; 2001US-0277477P.  
 XX (UYCH-) UNIV CHICAGO.

XX Gordon DJ, Meredith SC;  
 XX WPI; 2003-040553/03.

XX Novel peptide for inhibiting fibrillogenesis, and for screening  
 PT fibrillogenesis inhibitors, has beta-strand with one face having hydrogen  
 PT bonds and other face blocking propagation of hydrogen bonding between  
 PT beta-strands.

XX Disclosure; Page 25; 151pp; English.

XX The invention relates to a peptide (I) inhibiting fibrillogenesis, that  
 CC comprises a beta-strand with two faces, where the first face has hydrogen  
 CC bonds, and the second face blocks or disrupts propagation of hydrogen  
 CC bonding between beta-strands needed to form fibrils. (I) is useful for  
 CC inhibiting fibrillogenesis, for detecting fibrils in a subject and for  
 CC screening candidate fibrillogenesis inhibitors. A pharmaceutical  
 CC composition comprising (I) is useful for inhibiting or disassembling  
 CC fibrils associated with pathological states such as Alzheimer's disease,  
 CC Down's syndrome, Dutch-Type hereditary cerebral haemorrhage amyloidosis,  
 CC reactive amyloidosis, familial Mediterranean fever, familial amyloid  
 CC nephropathy with utricaria and deafness, Muckle-Wells syndrome,  
 CC idiopathic myeloma, macroglobulinemia-associated myeloma, familial  
 CC amyloid polynuropathy, familial amyloid cardiomyopathy, isolated cardiac  
 CC amyloid, systemic senile amyloidosis, adult onset diabetes, insulinoma,  
 CC isolated atrial amyloid, medullary carcinoma of the thyroid, familial  
 CC amyloidosis, hereditary cerebral haemorrhage with amyloidosis, familial  
 CC amyloidotic polynuropathy, scrapie, Creutzfeldt-Jakob disease, Gerstmann  
 CC -Straussler-Scheinker syndrome, bovine spongiform encephalitis, prion-  
 CC mediated diseases, or Huntington's disease. (I) is useful for treating  
 CC disease associated with fibrillogenesis or for treating and/or diagnosing  
 CC a subject which is a mammal, preferably human, having protein aggregation  
 CC disease or protein misfolding disease. The composition is useful in both  
 CC preventive and curative therapies of fibril based pathologies mentioned  
 CC above. The present sequence represents a peptide from the core domain of  
 CC beta-amyloid, and can inhibit Abeta fibrillogenesis

XX SQ Sequence 5 AA;  
Query Match 100.0%; Score 19; DB 6; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVF 4  
Db 1 KLVF 4

RESULT 42  
AAE35444  
ID AAE35444 standard; peptide; 5 AA.  
XX  
AC AAE35444;  
DT 17-JUN-2003 (first entry)  
DE Abeta peptide #15.  
XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
XX Unidentified.  
OS  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1..5 /note= "D-form residues"  
FT  
FT Modified-site 5 /note= "C-terminal amide"  
FT  
XX WO200296937-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 29-MAY-2002; 2002WO-CA000763.  
XX  
PR 29-MAY-2001; 2001US-00867847.  
XX (NEUR-) NEUROCHEM INC.  
XX  
XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
XX WPI; 2003-201269/19.  
XX Prevention and/or treatment of an amyloid-related disease e.g.  
XX Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
XX Claim 1; Page 59; 44pp; English.  
XX The invention relates to a method for prevention and/or treatment of an  
XX amyloid-related disease which comprises administration of an all-D -  
XX amyloid-beta peptide. The method is used for preventing and/or treating  
XX Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
XX angiopathy; for altering serum levels of amyloid-beta in a mammal and  
XX favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
XX the mammal; and reducing or inhibiting the formation of plaques. It is  
XX also used for treating AA (reactive) amyloid diseases including  
XX inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
XX arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
XX Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
XX disease. AA deposits are also produced as a result of chronic microbial  
XX infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
XX ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
XX Certain malignant neoplasms can also result in AA fibril amyloid deposits  
XX including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
XX and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
XX present sequence is an Abeta peptide used to illustrate the method of the

CC invention  
XX Sequence 5 AA;  
SQ Query Match 100.0%; Score 19; DB 6; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVF 4  
Db 1 KLVF 4

RESULT 43  
AAE35451  
ID AAE35451 standard; peptide; 5 AA.  
XX  
AC AAE35451;  
DT 17-JUN-2003 (first entry)  
DE Abeta peptide #22.  
XX All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;  
KW cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;  
KW psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;  
KW Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nontropic;  
KW chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;  
KW Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;  
KW ulcer; antiinflammatory; cytostatic; uropathic; therapy.  
XX Unidentified.  
OS  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 1..5 /note= "D-form residues"  
FT  
FT Modified-site 5 /note= "C-terminal amide"  
FT  
XX WO200296937-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 29-MAY-2002; 2002WO-CA000763.  
XX  
PR 29-MAY-2001; 2001US-00867847.  
XX (NEUR-) NEUROCHEM INC.  
XX  
XX Gervais F, Hebert L, Chalifour RJ, Kong X;  
XX WPI; 2003-201269/19.  
XX Prevention and/or treatment of an amyloid-related disease e.g.  
XX Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.  
XX Claim 1; Page 59; 44pp; English.  
XX The invention relates to a method for prevention and/or treatment of an  
XX amyloid-related disease which comprises administration of an all-D -  
XX amyloid-beta peptide. The method is used for preventing and/or treating  
XX Alzheimer's and other amyloid related disease e.g. cerebral amyloid  
XX angiopathy; for altering serum levels of amyloid-beta in a mammal and  
XX favours the clearance of soluble amyloid-beta or fibril amyloid-beta from  
XX the mammal; and reducing or inhibiting the formation of plaques. It is  
XX also used for treating AA (reactive) amyloid diseases including  
XX inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic  
XX arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,  
XX Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's  
XX disease. AA deposits are also produced as a result of chronic microbial  
XX infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus  
XX ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).  
XX Certain malignant neoplasms can also result in AA fibril amyloid deposits  
XX including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
XX and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
XX present sequence is an Abeta peptide used to illustrate the method of the

CC including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung  
 CC and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The  
 CC present sequence is an Abeta peptide used to illustrate the method of the  
 CC invention

XX Sequence 5 AA;  
 SQ

Query Match 100.0%; Score 19; DB 6; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 44

ABR43903  
 ID ABR43903 standard; protein; 5 AA.

AC ABR43903;

XX 11-AUG-2003 (first entry)

DE Beta-amyloid binding peptide fragment.

XX APP770; Alzheimer's disease; plaque-recognition peptide; neurotropic;  
 KW neuroprotective; fibril formation; beta-amyloid peptide; human.

XX Synthetic.

XX WO2003018609-A2.

XX 06-MAR-2003.

XX 23-AUG-2002; 2002WO-US026889.

XX 23-AUG-2001; 2001US-0314382P.

XX (STEI/) STEIN S.

XX Stein S;

XX WPI; 2003-342445/32.

XX Chemical compound for use in diagnosing or treating Alzheimer's disease,  
 PT comprises multiple copies of a plaque-recognition peptide and is capable  
 PT of crossing blood brain-barrier.

XX Disclosure; Page 6; 37pp; English.

XX The invention relates to a chemical compound for use in diagnosing or  
 CC treating patients with Alzheimer's disease, comprising multiple copies of  
 CC a plaque-recognition peptide (Phe-Phe-Val-Leu-Lys), where all amino acids  
 CC are the D-isomer. The compound interferes with formation of fibril from  
 CC beta-amyloid peptide effecting an inhibition of disease process. It is  
 CC useful for diagnosing and treating Alzheimer's disease in mammals,  
 CC especially a human. The present sequence represents a beta-amyloid  
 CC binding peptide

XX Sequence 5 AA;

Query Match 100.0%; Score 19; DB 6; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 45

ADF60931

ID ADF60931 standard; peptide; 5 AA.

AC ADF60931;

XX 12-FEB-2004 (first entry)

DE C-terminally modified peptide inhibitor of beta-amyloid aggregation.

XX Beta-amyloid protein; aggregation inhibitor; fibril formation inhibitor;  
 KW peptide inhibitor; C-terminal modification; hydrophilic ether group;  
 KW poly(aminoethoxy)ethoxyacetic acid; neural cell; Alzheimer's disease;  
 KW neurotropic; neuroprotective.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 5  
 FT /note= "Linked to hydrophilic ether group such as a  
 FT poly(aminoethoxy)ethoxyacetic acid group"

XX JP2002265382-A.

XX 18-SEP-2002.

XX 08-MAR-2001; 2001JP-00065451.

XX 08-MAR-2001; 2001JP-00065451.

XX (DOKU-) DOKURITSU GYOSEI HOJIN SANGYO GIJUTSU SO.

XX WPI; 2003-620628/59.

XX Peptides whose carboxyl terminal is modified with hydrophilic groups, are  
 PT useful as inhibitors for aggregation of beta-amyloid protein and are used  
 PT in the treatment of Alzheimer's.

XX Claim 1; SEQ ID NO 1; 4pp; Japanese.

XX The invention relates to a peptide inhibitor (ADF60931) of the  
 CC aggregation of beta-amyloid protein (ADF60932). The peptide inhibitor has  
 CC a C-terminus which is modified with hydrophilic ether groups having an  
 CC amino group and a carboxyl group at the ends of the molecule (e.g.,  
 CC poly(aminoethoxy)ethoxyacetic acids). The C-terminally modified peptide  
 CC inhibitor inhibits the aggregation of beta-amyloid protein (fibril  
 CC formation), thereby preventing the death of neural cells. The inhibitor  
 CC is useful in the prevention, treatment, and diagnosis of Alzheimer's  
 CC disease. The present sequence represents the amino acid sequence of the C  
 CC -terminally modified inhibitor of the invention.

XX Sequence 5 AA;

Query Match 100.0%; Score 19; DB 7; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 46

ADJ71329

ID ADJ71329 standard; peptide; 5 AA.

AC ADJ71329;

XX 06-MAY-2004 (first entry)

DE Pathologic modified prions-proteins PrPSC peptide #2.

XX Prion; PrPSC; prions protein; transmissible spongiform encephalopathy.

XX Synthetic.

XX FN WO2004005920-A2.  
 XX PD 15-JAN-2004.  
 XX XX 04-JUL-2003; 2003WO-DE002249.  
 XX PF 04-JUL-2002; 2002DE-01030141.  
 XX PR (PRIO-) PRIONTYPE GMBH.  
 XX PA (SCHL/) SCHLEUSSNER C.  
 XX PI Engemann C, Hoeschler K, Lehmann J, Gabert J, Krummrei U;  
 XX XX WPI; 2004-108912/11.  
 XX XX Detecting pathological prions in live animals, useful for diagnosis of  
 XX PT transmissible spongiform encephalopathy, using immobilized agent that  
 XX PT binds to beta-sheets.  
 XX PS Claim 5; Page 10; 24pp; German.  
 XX CC The present invention relates to a method for detecting pathologically  
 XX CC altered prion proteins (PrP<sup>Sc</sup>), which comprises incubating a test sample  
 XX CC with a solid carrier to which an agent is able to bind, removing unbound  
 XX CC proteins, and detecting proteins bound to the agent. The method is used  
 XX CC to diagnose transmissible spongiform encephalopathies in live animals,  
 XX CC even shortly after infection. The present sequence is a PrP<sup>Sc</sup> peptide  
 XX CC used to demonstrate the method of the invention.  
 XX SQ Sequence 5 AA;  
 XX CC Query Match 100.0%; Score 19; DB 8; Length 5;  
 XX CC Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX CC Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX QY 1 KLVP 4  
 XX DB 1 KLVP 4  
 XX RESULT 47  
 XX ID ADJ64061 standard; peptide; 5 AA.  
 XX AC ADJ64061;  
 XX XX 06-MAY-2004 (first entry)  
 XX DT Human beta-amyloid long form peptide fragment #7.  
 XX DE  
 XX XX Amyloidogenic protein; therapy; amyloidosis;  
 XX KW familial amyloid polynuropathy; cardiomyopathy;  
 XX KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 XX KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
 XX KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 XX KW familial mediterranean fever; urticaria; deafness;  
 XX KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
 XX KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 XX KW beta-amyloid peptide; human.  
 XX OS Homo sapiens.  
 XX XX  
 XX XX Location/Qualifiers  
 XX FH Modified-site 1 /note= "Optionally N-terminal choly or N-acetyl  
 XX FT neuraminyl or iminobiotinyl"  
 XX FT Modified-site 5 /note= "Optionally C-terminal amide"  
 XX FT  
 XX XX US2004005307-A1.  
 XX FN 08-JAN-2004.  
 XX PD

XX PF 17-JUN-2003; 2003US-00463729.  
 XX XX 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX PR 14-MAR-1996; 96US-00617267.  
 XX PR 04-OCT-2001; 2001US-00972475.  
 XX XX (PRAE-) PRAECIS PHARM INC.  
 XX XX Findeis MA, Benjamin H, Garnick MB, Gefter ML, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX XX WPI; 2004-131767/13.  
 XX XX New amyloidogenic protein aggregation modulators useful for treating  
 XX PT disorder associated with amyloidosis e.g. familial amyloid  
 XX PT polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
 XX PS Example 12; SEQ ID NO 10; 52pp; English.  
 XX CC The invention relates to amyloidogenic proteins or peptide fragments  
 XX CC aggregation modulators. The invention is used for treating disorder  
 XX CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 XX CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 XX CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 XX CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 XX CC Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
 XX CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
 XX CC amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary  
 XX CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 XX CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
 XX CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 XX CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 XX CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 XX CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 XX CC polynuropathy III), familial amyloidosis of Finnish type, amyloidosis  
 XX CC associated with medullary carcinoma of the thyroid, fibrinogen associated  
 XX CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 XX CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 XX CC in the exemplification of the invention.  
 XX SQ Sequence 5 AA;  
 XX CC Query Match 100.0%; Score 19; DB 8; Length 5;  
 XX CC Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 XX CC Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX QY 1 KLVP 4  
 XX DB 1 KLVP 4  
 XX RESULT 48  
 XX ID ADJ64088 standard; peptide; 5 AA.  
 XX AC ADJ64088;  
 XX XX 06-MAY-2004 (first entry)  
 XX DT Human beta-amyloid long form peptide fragment #32.  
 XX DE  
 XX XX Amyloidogenic protein; therapy; amyloidosis;  
 XX KW familial amyloid polynuropathy; cardiomyopathy;  
 XX KW systemic senile amyloidosis; bovine spongiform encephalopathy;  
 XX KW Creutzfeldt-Jakob disease; Gerstmann-Strausler-Scheinker syndrome;  
 XX KW diabetes; insulinoma; myeloma; Sjogren's syndrome;  
 XX KW familial mediterranean fever; urticaria; deafness;  
 XX KW hereditary cerebral haemorrhage; haemodialysis; thyroid;  
 XX KW renal amyloidosis; lysosome-associated hereditary systemic amyloidosis;  
 XX KW beta-amyloid peptide; human.

XX OS Homo sapiens.  
 XX Key Location/Qualifiers  
 FH Modified-site 1  
 FT /note= "N-terminal cholyl"  
 FT  
 XX US2004005307-A1.  
 XX  
 XX PD 08-JAN-2004.  
 XX  
 XX PF 17-JUN-2003; 2003US-00463729.  
 XX  
 XX PR 14-MAR-1995; 95US-00404831.  
 XX PR 07-JUN-1995; 95US-00475579.  
 XX PR 27-OCT-1995; 95US-00548998.  
 XX PR 14-MAR-1996; 96US-00617267.  
 XX PR 04-OCT-2001; 2001US-00972475.  
 XX  
 XX PA (PRAE-) PRAECIS PHARM INC.  
 XX  
 XX PI Findeis MA, Benjamin H, Garnick MB, Geffer MB, Hundal A;  
 XX PI Kasman L, Musso G, Signer ER, Wakefield J, Reed MJ;  
 XX  
 XX DR WPI; 2004-131767/13.  
 XX  
 XX PT New amyloidogenic protein aggregation modulators useful for treating  
 XX PT disorder associated with amyloidosis e.g. familial amyloid  
 XX PT polynuropathy, Creutzfeldt-Jakob disease and adult onset diabetes.  
 XX  
 XX PS Example 11; SEQ ID NO 37; 52pp; English.  
 XX  
 XX CC The invention relates to amyloidogenic proteins or peptide fragments  
 XX CC aggregation modulators. The invention is used for treating disorder  
 XX CC associated with amyloidosis, particularly familial amyloid polynuropathy  
 XX CC (Portuguese, Japanese and Swedish types), familial amyloid cardiomyopathy  
 XX CC (Danish type), isolated cardiac amyloid, systemic senile amyloidosis,  
 XX CC scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease,  
 XX CC Gerstmann-Strausler-Scheinker syndrome, adult onset diabetes,  
 XX CC insulinoma, isolated atrial amyloidosis, idiopathic (primary)  
 XX CC amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary  
 XX CC localized cutaneous nodular amyloidosis associated with Sjogren's  
 XX CC syndrome, reactive (secondary) amyloidosis, familial Mediterranean Fever  
 XX CC and familial amyloid nephropathy with urticaria and deafness (Muckle-  
 XX CC Wells syndrome), hereditary cerebral haemorrhage with amyloidosis of  
 XX CC Icelandic type, amyloidosis associated with long term haemodialysis,  
 XX CC hereditary non-neuropathic systemic amyloidosis (familial amyloid  
 XX CC polynuropathy III), familial amyloidosis of Finnish type, amyloidosis  
 XX CC associated with medullary carcinoma of the thyroid, fibrinogen associated  
 XX CC hereditary renal amyloidosis and lysosome-associated hereditary systemic  
 XX CC amyloidosis. The present sequence is beta-amyloid peptide fragment used  
 XX CC in the exemplification of the invention.  
 XX  
 XX SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 8; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 Db ||||  
 1 KLVF 5  
 RESULT 49  
 ADM97741  
 ID ADM97741 standard; peptide; 5 AA.  
 XX  
 XX AC ADM97741;  
 XX  
 XX DT 01-JUL-2004 (first entry)  
 XX  
 XX DE Amyloid beta protein fragment #1.

XX immunostimulant; neuroprotective; nootropic; Alzheimer's disease;  
 KW Down's syndrome; vaccine; amyloid beta; ADDL;  
 KW amyloid beta-derived diffusible ligand.  
 XX  
 OS Unidentified.  
 XX  
 XX PN WO2004031400-A2.  
 XX  
 XX PD 15-APR-2004.  
 XX  
 XX PF 01-OCT-2003; 2003WO-US030930.  
 XX  
 XX PR 01-OCT-2002; 2002US-0415074P.  
 XX  
 XX PA (NOUN ) UNIV NORTHWESTERN.  
 XX  
 XX PI Klein W, Krafft GA, Chang L, Gong Y, Viola K, Lambert M;  
 XX PI Chromy B, Summa D;  
 XX  
 XX DR WPI; 2004-330196/30.  
 XX  
 XX PT New amyloid beta-derived diffusible ligands, useful in generating an  
 XX PT immune response and in preventing, ameliorating or treating Alzheimer's  
 XX PT disease, memory and learning deficits, degeneration or malfunction of  
 XX PT neurons or Down's syndrome.  
 XX  
 XX PS Disclosure; Page 41; 176pp; English.  
 XX  
 XX CC The present invention relates to a new pharmaceutical composition  
 XX CC comprising amyloid beta-derived diffusible ligands (ADDLs) capable of  
 XX CC generating an immune response in a host organism, where the composition  
 XX CC is a vaccine or a component of a vaccine and where the ADDLs are  
 XX CC antigenic, immunogenic or act as a binding molecule when the composition  
 XX CC is administered to a host organism. The composition, vaccine or  
 XX CC antibodies are useful in inducing an immune response. The composition,  
 XX CC peptides, molecules and antibodies are useful in preventing or  
 XX CC ameliorating Alzheimer's disease, memory and learning deficits,  
 XX CC degeneration or malfunction of neurons and in preventing or treating  
 XX CC Down's syndrome. The present sequence is a polypeptide shown in the  
 XX CC exemplification of the invention.  
 XX  
 XX SQ Sequence 5 AA;  
 Query Match 100.0%; Score 19; DB 8; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KLVF 4  
 Db ||||  
 1 KLVF 4  
 RESULT 50  
 ADP64923  
 ID ADP64923 standard; protein; 5 AA.  
 XX  
 XX AC ADP64923;  
 XX  
 XX DT 09-SEP-2004 (first entry)  
 XX  
 XX DE Beta-amyloid central core structure amino acid sequence.  
 XX  
 XX KW spherical nanostructure; tubular nanostructure; field emitter device;  
 KW nanoscale environment; electron emission lithography; memory cell;  
 KW mechanical transmission device; electronic inverter;  
 KW heat transfer device; electron emission; beta-amyloid;  
 KW central aromatic core structure; nanotube self-assembly;  
 KW Alzheimer's disease; beta-amyloid core recognition element.  
 XX  
 XX OS Synthetic.  
 XX  
 XX PN WO2004052773-A2.

XX 24-JUN-2004.  
XX 09-DEC-2003; 2003WO-IL001045.  
XX 09-DEC-2002; 2002US-0431709P.  
PR 31-MAR-2003; 2003US-0458378P.  
XX (UVR-) UNIV RAMOT AT TEL AVIV LTD.  
XX Reches M, Gazit E;  
PI WPI; 2004-480855/45.  
XX  
XX Tubular of spherical nanostructure for e.g. use in obtaining information  
PT from nanoscale environment, is composed of peptides including aromatic or  
PT polyaromatic amino acids.  
XX  
XX Example 1; Fig 9a; 94pp; English.  
XX  
XX The present invention describes a tubular of spherical nanostructure  
CC composed of peptides including no more than 4 aromatic or polyaromatic  
CC amino acids. Also described: (1) a method of generating a tubular or  
CC spherical nanostructure; (2) a field emitter device; (3) a device for  
CC obtaining information from a nanoscale environment; (4) an apparatus for  
CC electron emission lithography; (5) a memory cell; (6) a mechanical  
CC transmission device; (7) an electronic inverter having a first switching  
CC device and a second switching device; (8) a composition; (9) a heat  
CC transfer device; (10) a method of emitting electrons; and (11) a method  
CC of obtaining information from a nanoscale environment. The nanostructure  
CC can be used in a field emitter device, a device for obtaining information  
CC from a nanoscale environment, an apparatus for electron emission  
CC lithography, a memory cell, a mechanical transmission device, an  
CC electronic inverter, and a matrix-containing composition. It is used in  
CC emitting electrons, in obtaining information from a nanoscale  
CC environment, in recording binary information, in transmitting mechanical  
CC motion, grabbing and/or in manipulating nanoscale objects, and  
CC transferring heat. The nanostructure is highly robust under extreme pH  
CC and temperatures. It enhances electromagnetic fields near ultra small  
CC metal objects. The use of nanostructure as gates in electronic device  
CC allows operation at low gate voltage and enables the switching of several  
CC individual devices on the same substrates. The present sequence  
CC represents a beta-amyloid central aromatic core structure amino acid  
CC sequence, which is used in an example from the present invention for the  
CC nanotube self-assembly of Alzheimer's beta-amyloid core recognition  
CC element.  
XX  
XX Sequence 5 AA;  
SQ  
Query Match 100.0%; Score 19; DB 8; Length 5;  
Best Local Similarity 100.0%; Pred. No. 1.8e+06;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVF 4  
|||  
Db 1 KLVF 4  
Search completed: March 9, 2005, 06:27:34  
Job time : 43.6301 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 10.6849 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-6

Perfect score: 19

Sequence: 1 KLVP 4

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

.Listing first 65 summaries

Database :

Issued Patents AA.\*  
1: /cgn2\_6/ptodata/1/1aa/5A-COMB.pep.\*  
2: /cgn2\_6/ptodata/1/1aa/5B-COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/6A-COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/6B-COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/PTCUS-COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19	100.0	4	3 US-08-970-833-1	Sequence 1, Appli
2	19	100.0	4	3 US-08-664-379B-17	Sequence 17, Appl
3	19	100.0	4	3 US-09-095-106A-25	Sequence 25, Appl
4	19	100.0	4	4 US-09-747-408-6	Sequence 6, Appli
5	19	100.0	4	4 US-09-747-408-14	Sequence 14, Appl
6	19	100.0	5	1 US-08-127-904-15	Sequence 15, Appl
7	19	100.0	5	2 US-08-612-785B-10	Sequence 10, Appl
8	19	100.0	5	3 US-08-970-833-2	Sequence 2, Appli
9	19	100.0	5	3 US-08-703-675C-46	Sequence 46, Appl
10	19	100.0	5	3 US-09-242-724-25	Sequence 25, Appl
11	19	100.0	5	3 US-09-242-724-26	Sequence 26, Appl
12	19	100.0	5	3 US-08-617-267C-10	Sequence 10, Appl
13	19	100.0	5	3 US-08-617-267C-37	Sequence 37, Appl
14	19	100.0	5	3 US-09-095-106A-19	Sequence 19, Appl
15	19	100.0	5	3 US-09-095-106A-19	Sequence 19, Appl
16	19	100.0	5	3 US-09-095-106A-43	Sequence 43, Appl
17	19	100.0	5	4 US-09-747-408-8	Sequence 8, Appli
18	19	100.0	5	4 US-09-747-408-15	Sequence 15, Appl
19	19	100.0	5	5 PCT-US94-10475-15	Sequence 15, Appl
20	19	100.0	6	2 US-08-612-785B-8	Sequence 8, Appli
21	19	100.0	6	2 US-08-612-785B-9	Sequence 9, Appli
22	19	100.0	6	2 US-08-612-785B-31	Sequence 31, Appl
23	19	100.0	6	3 US-08-664-379B-19	Sequence 19, Appl
24	19	100.0	6	3 US-08-703-675C-31	Sequence 31, Appl
25	19	100.0	6	3 US-08-703-675C-32	Sequence 32, Appl
26	19	100.0	6	3 US-08-703-675C-44	Sequence 44, Appl
27	19	100.0	6	3 US-09-242-724-24	Sequence 24, Appl

28	19	100.0	6	3 US-09-242-724-27	Sequence 27, Appl
29	19	100.0	6	3 US-09-242-724-30	Sequence 30, Appl
30	19	100.0	6	3 US-09-242-724-31	Sequence 31, Appl
31	19	100.0	6	3 US-09-242-724-33	Sequence 33, Appl
32	19	100.0	6	3 US-08-617-267C-8	Sequence 8, Appli
33	19	100.0	6	3 US-08-617-267C-9	Sequence 9, Appli
34	19	100.0	6	3 US-08-617-267C-31	Sequence 31, Appl
35	19	100.0	6	3 US-08-617-267C-43	Sequence 43, Appl
36	19	100.0	6	3 US-09-095-106A-5	Sequence 5, Appli
37	19	100.0	6	3 US-09-095-106A-15	Sequence 15, Appl
38	19	100.0	6	4 US-09-747-408-3	Sequence 3, Appli
39	19	100.0	6	4 US-09-747-408-11	Sequence 11, Appl
40	19	100.0	6	4 US-09-747-408-24	Sequence 24, Appl
41	19	100.0	7	1 US-08-127-904-14	Sequence 14, Appl
42	19	100.0	7	2 US-08-612-785B-6	Sequence 6, Appli
43	19	100.0	7	2 US-08-612-785B-7	Sequence 7, Appli
44	19	100.0	7	3 US-08-703-675C-29	Sequence 29, Appl
45	19	100.0	7	3 US-08-703-675C-30	Sequence 30, Appl
46	19	100.0	7	3 US-08-617-267C-6	Sequence 6, Appli
47	19	100.0	7	3 US-08-617-267C-7	Sequence 7, Appli
48	19	100.0	7	3 US-09-264-709A-13	Sequence 13, Appl
49	19	100.0	7	3 US-09-095-106A-11	Sequence 11, Appl
50	19	100.0	7	3 US-09-095-106A-12	Sequence 12, Appl
51	19	100.0	7	4 US-09-747-408-2	Sequence 2, Appli
52	19	100.0	7	4 US-09-747-408-18	Sequence 18, Appl
53	19	100.0	7	4 US-09-747-408-19	Sequence 19, Appl
54	19	100.0	7	5 PCT-US94-10475-14	Sequence 14, Appl
55	19	100.0	8	1 US-08-457-804-1	Sequence 1, Appli
56	19	100.0	8	1 US-08-457-804-6	Sequence 6, Appli
57	19	100.0	8	1 US-08-457-804-7	Sequence 7, Appli
58	19	100.0	8	2 US-08-612-785B-5	Sequence 5, Appli
59	19	100.0	8	2 US-08-630-645-1	Sequence 1, Appli
60	19	100.0	8	3 US-08-703-675C-28	Sequence 28, Appl
61	19	100.0	8	3 US-08-617-267C-5	Sequence 5, Appli
62	19	100.0	8	3 US-09-095-106A-8	Sequence 8, Appli
63	19	100.0	8	3 US-09-095-106A-9	Sequence 9, Appli
64	19	100.0	8	3 US-09-095-106A-44	Sequence 44, Appl
65	19	100.0	8	4 US-08-766-596A-1	Sequence 1, Appli

## ALIGNMENTS

RESULT 1  
US-08-970-833-1  
; Sequence 1, Application US/08970833  
; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kiesel, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESSES:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA: US/08/970.833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/POCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:

Wed Mar 9 08:16:00 2005

TELEPHONE: (414) 277-5709  
TELEFAX: (414) 271-3552  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 4 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-970-833-1

Query Match 100.0%; Score 19; DB 3; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

## RESULT 2

US-08-664-379B-17  
Sequence 17, Application US/08664379B  
Patent No. 6034211  
GENERAL INFORMATION:  
APPLICANT: Kelly, Jeffery W.  
TITLE OF INVENTION: BETA-SHEET NUCLEATING PEPTIDOMIMETICS  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: U.S.A.  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FASTSEQ Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/664,379B  
FILING DATE: 14-JUN-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/019,925  
FILING DATE: 03-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Freeman, John W.  
REGISTRATION NUMBER: 29,066  
REFERENCE/DOCKET NUMBER: 08435/003001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 17:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 4 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-664-379B-17

Query Match 100.0%; Score 19; DB 3; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

## RESULT 3

US-09-095-106A-25

Sequence 25, Application US/09095106A  
Patent No. 6331440  
GENERAL INFORMATION:  
APPLICANT: NORDSTEDT, Christer  
APPLICANT: NASLUND, Jan  
APPLICANT: THYBERG, Johan  
APPLICANT: TJERNBERG, Lars O.  
APPLICANT: TERENIUS, Lars  
TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
FILE REFERENCE: 000500-124  
CURRENT APPLICATION NUMBER: US/09/095,106A  
CURRENT FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: US 60/009,386  
PRIOR FILING DATE: 1995-12-29  
PRIOR APPLICATION NUMBER: PCT/SE96/01621  
PRIOR FILING DATE: 1996-12-09  
NUMBER OF SEQ ID NOS: 44  
SOFTWARE: RatentIn Ver. 2.0  
SEQ ID NO 25  
LENGTH: 4  
TYPE: PPT  
ORGANISM: Amyloidosis  
US-09-095-106A-25

Query Match 100.0%; Score 19; DB 3; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

## RESULT 4

US-09-747-408-6  
Sequence 6, Application US/09747408  
Patent No. 6670399  
GENERAL INFORMATION:  
APPLICANT: Green, Allan M.  
APPLICANT: Gervais, Francine  
TITLE OF INVENTION: Compounds And Methods For Modulating  
TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
FILE REFERENCE: NBI-088  
CURRENT APPLICATION NUMBER: US/09/747,408  
CURRENT FILING DATE: 2000-12-22  
PRIOR APPLICATION NUMBER: 60/171,877  
PRIOR FILING DATE: 1999-12-23  
NUMBER OF SEQ ID NOS: 24  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 6  
LENGTH: 4  
TYPE: PPT  
ORGANISM: Homo sapiens  
US-09-747-408-6

Query Match 100.0%; Score 19; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

## RESULT 5

US-09-747-408-14  
Sequence 14, Application US/09747408  
Patent No. 6670399  
GENERAL INFORMATION:  
APPLICANT: Green, Allan M.  
APPLICANT: Gervais, Francine  
TITLE OF INVENTION: Compounds And Methods For Modulating  
TITLE OF INVENTION: Cerebral Amyloid Angiopathy

FILE REFERENCE: NBI-088  
CURRENT APPLICATION NUMBER: US/09/747,408  
CURRENT FILING DATE: 2000-12-22  
PRIOR APPLICATION NUMBER: 60/171,877  
PRIOR FILING DATE: 1999-12-23  
NUMBER OF SEQ ID NOS: 24  
SOFTWARE: FASTSEQ for Windows Version 4.0  
SEQ ID NO: 14  
LENGTH: 4  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-747-408-14

Query Match 100.0%; Score 19; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4

Db 1 KLVF 4

## RESULT 6

US-08-127-904-15  
Sequence 15, Application US/08127904  
Patent No. 5470951  
GENERAL INFORMATION:

APPLICANT: Eugene Roberts  
TITLE OF INVENTION: Method For Antagonizing  
TITLE OF INVENTION: Amnestic Effects of Amyloid n  
TITLE OF INVENTION: Protein and Improving the  
TITLE OF INVENTION: Quality of Life in Individuals  
TITLE OF INVENTION: With Alzheimer Disease  
NUMBER OF SEQUENCES: 15  
CORRESPONDENCE ADDRESS:

ADDRESSEE: City of Hope  
STREET: 1500 East Duarte Road  
CITY: Duarte  
STATE: California

COUNTRY: United States of America  
ZIP: 91010-0269

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3M Double Density 5 1/4" diskette  
COMPUTER: Wang PC

OPERATING SYSTEM: MS DOS Version 3.20  
SOFTWARE: Microsoft

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/127,904  
FILING DATE: 29 September 1993

CLASSIFICATION: 424

PRIOR APPLICATION DATA: No. 5470951e  
ATTORNEY/AGENT INFORMATION:

NAME: Irons, Edward S.

REGISTRATION NUMBER: 16,541

REFERENCE/DOCKET NUMBER: No. 5470951e

TELEPHONE: (202) 783-6040

TELEFAX: (202) 783-6031

TELEX: No. 5470951e

INFORMATION FOR SEQ ID NO: 15:

SEQUENCE CHARACTERISTICS:

LENGTH: 5

TYPE: Amino Acid

STRANDEDNESS:

TOPOLOGY: Unknown

US-08-127-904-15

Query Match 100.0%; Score 19; DB 1; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4

Db 1 KLVF 4

Db 1 KLVF 4

## RESULT 7

US-08-612-785B-10  
Sequence 10, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:

APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:

ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02109-1875

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/612,785B

FILING DATE: Herewith

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/404,831

FILING DATE: 14-MAR-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/475,579

FILING DATE: 07-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/548,998

FILING DATE: 27-OCT-1995

ATTORNEY/AGENT INFORMATION:

NAME: DeConti, Giulio A.

REGISTRATION NUMBER: 31,503

REFERENCE/DOCKET NUMBER: PFI-002CF3

TELEPHONE: (617) 227-7400

TELEFAX: (617) 742-4214

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 5 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-612-785B-10

Query Match 100.0%; Score 19; DB 2; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4

Db 1 KLVF 4

## RESULT 8

US-08-970-833-2  
Sequence 2, Application US/08970833  
Patent No. 6022859  
GENERAL INFORMATION:

APPLICANT: Kiesel, Laura L.

APPLICANT: Murphy, Regina M.

TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY

NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:

ADDRESSEE: Quarles & Brady

STREET: 411 East Wisconsin Avenue

;  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C. 35.433  
; REGISTRATION NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-970-833-2

Query Match 100.0%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

RESULT 9  
US-08-703-675C-46  
; Sequence 46, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/703,675C  
; FILING DATE: 27-AUG-1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081

Aggregation Comprising D-

;  
; FILING DATE: 14-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 46:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-703-675C-46

Query Match 100.0%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

RESULT 10  
US-09-242-724-25  
; Sequence 25, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.  
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
; FILE REFERENCE: Cyclosporin Analogs  
; CURRENT APPLICATION NUMBER: US/09/242,724  
; CURRENT FILING DATE: 1999-02-22  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 25  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: :  
US-09-242-724-25

Query Match 100.0%; Score 19; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
Db 1 KLVF 4

RESULT 11  
US-09-242-724-26  
; Sequence 26, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.  
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
; FILE REFERENCE: Cyclosporin Analogs  
; CURRENT APPLICATION NUMBER: US/09/242,724  
; CURRENT FILING DATE: 1999-02-22  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 26  
; LENGTH: 5  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:

NAME/KEY: MOD\_RES  
 LOCATION: (1)  
 OTHER INFORMATION: ACETYLATION; K(2Cl-Cbz) =  
 OTHER INFORMATION: 2-chlorobenzyloxycarbonyl-protected lysine  
 US-09-242-724-26

Query Match 100.0%; Score 19; DB 3; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 12  
 US-08-617-267C-10  
 Sequence 10, Application US/08617267C  
 Patent No. 6319498  
 GENERAL INFORMATION:  
 APPLICANT: Findeis, Mark A. et al.  
 TITLE OF INVENTION: Modulators of Amyloid Aggregation  
 NUMBER OF SEQUENCES: 45  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: LAHIVE & COCKFIELD, LLP  
 STREET: 28 State Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: USA  
 ZIP: 02109-1875

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/617,267C  
 FILING DATE: 14-MAR-1996  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/404,831  
 FILING DATE: 14-MAR-1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/475,579  
 FILING DATE: 07-JUN-1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/548,998  
 FILING DATE: 27-OCT-1995  
 ATTORNEY/AGENT INFORMATION:  
 NAME: DeConti, Giulio A.  
 REGISTRATION NUMBER: 31,503  
 REFERENCE/DOCKET NUMBER: PPI-002CP2  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617)227-7400  
 TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 10:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 5 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-617-267C-10

Query Match 100.0%; Score 19; DB 3; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

RESULT 13  
 US-08-617-267C-37

Sequence 37, Application US/08617267C  
 Patent No. 6319498  
 GENERAL INFORMATION:  
 APPLICANT: Findeis, Mark A. et al.  
 TITLE OF INVENTION: Modulators of Amyloid Aggregation  
 NUMBER OF SEQUENCES: 45  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: LAHIVE & COCKFIELD, LLP  
 STREET: 28 State Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: USA  
 ZIP: 02109-1875

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/617,267C  
 FILING DATE: 14-MAR-1996  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/404,831  
 FILING DATE: 14-MAR-1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/475,579  
 FILING DATE: 07-JUN-1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: USSN 08/548,998  
 FILING DATE: 27-OCT-1995  
 ATTORNEY/AGENT INFORMATION:  
 NAME: DeConti, Giulio A.  
 REGISTRATION NUMBER: 31,503  
 REFERENCE/DOCKET NUMBER: PPI-002CP2  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617)227-7400  
 TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 37:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 5 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 FRAGMENT TYPE: internal  
 US-08-617-267C-37

Query Match 100.0%; Score 19; DB 3; Length 5;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
 ||||  
 Db 2 KLVF 5

RESULT 14  
 US-09-095-106A-1  
 Sequence 1, Application US/09095106A  
 Patent No. 6331440  
 GENERAL INFORMATION:  
 APPLICANT: NORDSTEDT, Christer  
 APPLICANT: NASLUND, Jan  
 APPLICANT: THYBERG, Johan  
 APPLICANT: TJERNBERG, Lars O.  
 APPLICANT: TERNIUS, Lars  
 TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
 FILE REFERENCE: 000500-124  
 CURRENT APPLICATION NUMBER: US/09/095,106A  
 CURRENT FILING DATE: 1998-06-10  
 PRIOR APPLICATION NUMBER: US 60/009,386  
 PRIOR FILING DATE: 1995-12-29  
 PRIOR APPLICATION NUMBER: PCT/SE96/01621  
 PRIOR FILING DATE: 1996-12-09

```
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-1

Query Match      100.0%; Score 19; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      1 KLVF 4

RESULT 15
US-09-095-106A-19
; Sequence 19, Application US/09095106A
; Patent No. 6331440
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; APPLICANT: NASLUND, Jan
; APPLICANT: THYBERG, Johan
; APPLICANT: TJERNBERG, Lars O.
; APPLICANT: TERENIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 000500-124
; CURRENT APPLICATION NUMBER: US/09/095,106A
; CURRENT FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 19
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-19

Query Match      100.0%; Score 19; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      2 KLVF 5

RESULT 16
US-09-095-106A-43
; Sequence 43, Application US/09095106A
; Patent No. 6331440
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; APPLICANT: NASLUND, Jan
; APPLICANT: THYBERG, Johan
; APPLICANT: TJERNBERG, Lars O.
; APPLICANT: TERENIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 000500-124
; CURRENT APPLICATION NUMBER: US/09/095,106A
; CURRENT FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43

; LENGTH: 5
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-43

Query Match      100.0%; Score 19; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      2 KLVF 5

; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-43

Query Match      100.0%; Score 19; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      1 KLVF 4

RESULT 17
US-09-747-408-8
; Sequence 8, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NEI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-8

Query Match      100.0%; Score 19; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      1 KLVF 4

RESULT 18
US-09-747-408-16
; Sequence 16, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NEI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-16

Query Match      100.0%; Score 19; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVF 4
Db      1 KLVF 4
```

Db 1 KLVP 4

## RESULT 19

PCT-US94-10475-15  
; Sequence 15, Application PC/TUS9410475  
; GENERAL INFORMATION:  
; APPLICANT: Eugene Roberts  
; TITLE OF INVENTION: Method For  
; TITLE OF INVENTION: Antagonizing Amyloid n  
; TITLE OF INVENTION: Effects of Amyloid n  
; TITLE OF INVENTION: Protein and Improving  
; TITLE OF INVENTION: the Quality of Life  
; TITLE OF INVENTION: in Individuals  
; TITLE OF INVENTION: With Alzheimer Disease  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: City of Hope  
; STREET: 1500 East Duarte Road  
; CITY: Duarte  
; STATE: California  
; COUNTRY: United States of America  
; Zip: 91010-0269  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3M Double Density 5 1/4"  
; MEDIUM TYPE: diskette  
; COMPUTER: Wang PC  
; OPERATING SYSTEM: MS DOS Version 3.20  
; SOFTWARE: Microsoft  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US94/10475  
; FILING DATE: 16 September 1994  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA: U. S. Application  
; PRIOR APPLICATION DATA: Serial No.  
; PRIOR APPLICATION DATA: 08/127,904; filed  
; PRIOR APPLICATION DATA: 29 September 1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Irons, Edward S.  
; REGISTRATION NUMBER: 16,541  
; REFERENCE/DOCKET NUMBER: None  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 626-3564 or 783-6030  
; TELEFAX: (202) 783-6031  
; TELEX: None  
; INFORMATION FOR SEQ ID NO: 15:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 5  
; TYPE: Amino Acid  
; STRANDEDNESS:  
; TOPOLOGY: Unknown  
PCT-US94-10475-15

Query Match 100.0%; Score 19; DB 5; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4

Db 1 KLVP 4

## RESULT 20

US-08-612-785B-8  
; Sequence 8, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: AB Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD

; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Gaudio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CF3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 227-7400  
; TELEFAX: (617) 742-4214  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-8

Query Match 100.0%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4

Db 2 KLVP 5

## RESULT 21

US-08-612-785B-9  
; Sequence 9, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: AB Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:

Wed Mar 9 08:16:00 2005

APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-612-785B-9

Query Match 100.0%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|||  
Db 1 KLVP 4

RESULT 22  
US-08-612-785B-31  
Sequence 31, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:  
APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214

INFORMATION FOR SEQ ID NO: 31:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FEATURE:  
NAME/KEY: Modified site  
LOCATION: 6  
OTHER INFORMATION: /note= Xaa is beta-alanyl  
US-08-612-785B-31

Query Match 100.0%; Score 19; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|||  
Db 1 KLVP 4

RESULT 23  
US-08-664-379B-19  
Sequence 19, Application US/08664379B  
Patent No. 6034211  
GENERAL INFORMATION:  
APPLICANT: Kelly, Jeffery W.  
TITLE OF INVENTION: BETA-SHEET NUCLEATING PEPTIDOMIMETICS  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: U.S.A.  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/664,379B  
FILING DATE: 14-JUN-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/018,925  
FILING DATE: 03-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Freeman, John W.  
REGISTRATION NUMBER: 29,066  
REFERENCE/DOCKET NUMBER: 08435/003001  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154

INFORMATION FOR SEQ ID NO: 19:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FEATURE:  
LOCATION: 1...1  
OTHER INFORMATION: wherein Xaa at position 1 is Ornithine  
US-08-664-379B-19

Query Match 100.0%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
|||  
Db 2 KLVP 5



```
RESULT 24
US-08-703-675C-31
; Sequence 31, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-31

Query Match 100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 2 KLVF 5

RESULT 25
US-08-703-675C-32
; Sequence 32, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-31

Query Match 100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 2 KLVF 5

RESULT 26
US-08-703-675C-44
; Sequence 44, Application US/08703675C
; Patent No. 6303567
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of -Amyloid Peptide
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/703,675C
; FILING DATE: 27-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/616,081
; FILING DATE: 14-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kara, Catherine J.
; REGISTRATION NUMBER: 41,106
; REFERENCE/DOCKET NUMBER: PPI-016CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-703-675C-32

Query Match 100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 1 KLVF 4
```

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/404,831  
;; FILING DATE: 14-MAR-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/475,579  
;; FILING DATE: 07-JUN-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/548,998  
;; FILING DATE: 27-OCT-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/616,081  
;; FILING DATE: 14-MAR-1996  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Kara, Catherine J.  
;; REGISTRATION NUMBER: 41,106  
;; REFERENCE/DOCKET NUMBER: PPT-016CP2  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617)227-7400  
;; TELEFAX: (617)742-4214  
;; INFORMATION FOR SEQ ID NO: 44:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 6 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
;; FEATURE:  
;; NAME/KEY: Modified site  
;; LOCATION: 6  
;; OTHER INFORMATION: /note= Xaa is beta-alanyl  
US-08-703-675C-44

Query Match 100.0%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 1 KLVF 4

RESULT 27  
US-09-242-724-24  
; Sequence 24, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.  
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
; FILE REFERENCE: Cyclosporin Analogs  
; CURRENT APPLICATION NUMBER: US/09/242,724  
; CURRENT FILING DATE: 1999-02-22  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 24  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: ;  
US-09-242-724-24

Query Match 100.0%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5

RESULT 28  
US-09-242-724-27  
; Sequence 27, Application US/09242724

;; Patent No. 6316405  
;; GENERAL INFORMATION:  
;; APPLICANT: Solomon, Michael E.  
;; APPLICANT: Rich, Daniel H.  
;; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
;; FILE REFERENCE: Cyclosporin Analogs  
;; CURRENT APPLICATION NUMBER: US/09/242,724  
;; CURRENT FILING DATE: 1999-02-22  
;; NUMBER OF SEQ ID NOS: 33  
;; SOFTWARE: Patentin Ver. 2.0  
;; SEQ ID NO 27  
;; LENGTH: 6  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
;; NAME/KEY: MOD RES  
;; LOCATION: (1)  
;; OTHER INFORMATION: ACETYLATION  
;; NAME/KEY: MOD RES  
;; LOCATION: (2)  
;; OTHER INFORMATION: K(2Cl-Cbz) = 2-chlorobenzoyloxycarbonyl-protected  
;; OTHER INFORMATION: lysine  
US-09-242-724-27

Query Match 100.0%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5

RESULT 29  
US-09-242-724-30  
; Sequence 30, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.  
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
; FILE REFERENCE: Cyclosporin Analogs  
; CURRENT APPLICATION NUMBER: US/09/242,724  
; CURRENT FILING DATE: 1999-02-22  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 30  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
; OTHER INFORMATION: polypeptide  
US-09-242-724-30

Query Match 100.0%; Score 19; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0; Gaps 0;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5

RESULT 30  
US-09-242-724-31  
; Sequence 31, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.

```
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor
; FILE REFERENCE: Cyclosporin Analogs
; CURRENT APPLICATION NUMBER: US/09/242,724
; CURRENT FILING DATE: 1999-02-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 31
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: polypeptide
US-09-242-724-31

Query Match          100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 1 KLVF 4

RESULT 31
US-09-242-724-33
; Sequence 33, Application US/09242724
; Patent No. 6316405
; GENERAL INFORMATION:
; APPLICANT: Solomon, Michael E.
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor
; FILE REFERENCE: Cyclosporin Analogs
; CURRENT APPLICATION NUMBER: US/09/242,724
; CURRENT FILING DATE: 1999-02-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: polypeptide
US-09-242-724-33

Query Match          100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 2 KLVF 5

RESULT 32
US-09-617-267C-8
; Sequence 8, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: USN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-617-267C-8

Query Match          100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4
Db 2 KLVF 5

RESULT 33
US-08-617-267C-9
; Sequence 9, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
```

```

; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-617-267C-9

Query Match 100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4
Db 1 KLVF 4

RESULT 34
US-08-617-267C-31
; Sequence 31, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
; APPLICANT: Fintel, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION NUMBER: US/08/617,267C
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION NUMBER: USSN 08/475,579
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
US-08-617-267C-43

Query Match 100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4
Db 2 KLVF 5

RESULT 36
US-09-095-106A-5
; Sequence 5, Application US/09095106A
; Patent No. 6331440
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; OTHER INFORMATION: /note= xaa is beta-alanyl
US-08-617-267C-31

Query Match 100.0%; Score 19; DB 3; Length 6;
```

```
; APPLICANT: TUERNBERG, Lars O.
; APPLICANT: TERENIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVPF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 000500-124
; CURRENT APPLICATION NUMBER: US/09/095,106A
; CURRENT FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-5

Query Match      100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVPF 4
DB      2 KLVPF 5

RESULT 37
US-09-095-106A-15
; Sequence 15, Application US/09095106A
; Patent No. 6331440
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; APPLICANT: NASLUND, Jan
; APPLICANT: THYBERG, Johan
; APPLICANT: TUERNBERG, Lars O.
; APPLICANT: TERENIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVPF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 000500-124
; CURRENT APPLICATION NUMBER: US/09/095,106A
; CURRENT FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Amyloidosis
US-09-095-106A-15

Query Match      100.0%; Score 19; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVPF 4
DB      3 KLVPF 6

RESULT 38
US-09-747-408-3
; Sequence 3, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-24

Query Match      100.0%; Score 19; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVPF 4
DB      1 KLVPF 4

RESULT 39
US-09-747-408-11
; Sequence 11, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-11

Query Match      100.0%; Score 19; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVPF 4
DB      1 KLVPF 4

RESULT 40
US-09-747-408-24
; Sequence 24, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-24
```

Query Match 100.0%; Score 19; DB 4; Length 6;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05; Indels 0;  
 Matches 4; Conservative 0; Mismatches 0; Gaps 0;

Qy 1 KLVF 4  
 ||||  
 Db 2 KLVF 5

## RESULT 41

US-08-127-904-14  
 ; Sequence 14, Application US/08127904

; Patent No. 5470951

; GENERAL INFORMATION:

; APPLICANT: Eugene Roberts

; TITLE OF INVENTION: Method For Antagonizing

; TITLE OF INVENTION: Amniotic Effects Of Amyloid n

; TITLE OF INVENTION: Protein and Improving the

; TITLE OF INVENTION: Quality of Life in Individuals

; TITLE OF INVENTION: With Alzheimer Disease

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: City of Hope

; STREET: 1500 East Duarte Road

; CITY: Duarte

; STATE: California

; COUNTRY: United States of America

; ZIP: 91010-0269

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3M Double Density 5 1/4" diskette

; COMPUTER: Wang PC

; OPERATING SYSTEM: MS DOS Version 3.20

; SOFTWARE: Microsoft

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/127,904

; FILING DATE: 29 September 1993

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA: No. 5470951e

; ATTORNEY/AGENT INFORMATION:

; NAME: Irons, Edward S.

; REGISTRATION NUMBER: 16,541

; REFERENCE/DOCKET NUMBER: No. 5470951e

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 783-6040

; TELEFAX: (202) 783-6031

; TELEX: No. 5470951e

; INFORMATION FOR SEQ ID NO: 14:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 7

; TYPE: Amino Acid

; STRANDEDNESS:

; TOPOLOGY: Unknown

US-08-127-904-14

Query Match 100.0%; Score 19; DB 1; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0;

Qy 1 KLVF 4  
 ||||  
 Db 1 KLVF 4

## RESULT 42

US-08-612-785B-6

; Sequence 6, Application US/08612785B

; Patent No. 5854204

; GENERAL INFORMATION:

; APPLICANT: Findels, Mark A. et al.

; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid

; TITLE OF INVENTION: Aggregation

; NUMBER OF SEQUENCES: 40

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD  
 ; STREET: 28 State Street, Suite 510  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: USA  
 ; ZIP: 02109-1875  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: Patent In Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/612,785B  
 ; FILING DATE: Herewith  
 ; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USN 08/404,831

; FILING DATE: 14-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USN 08/475,579

; FILING DATE: 07-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USN 08/548,998

; FILING DATE: 27-OCT-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: DeConti, Giulio A.

; REGISTRATION NUMBER: 31,503

; REFERENCE/DOCKET NUMBER: PPI-002CP3

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617)227-7400

; TELEFAX: (617)742-4214

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 7 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-612-785B-6

Query Match 100.0%; Score 19; DB 2; Length 7;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0;

Qy 1 KLVF 4  
 ||||  
 Db 3 KLVF 6

## RESULT 43

US-08-612-785B-7

; Sequence 7, Application US/08612785B

; Patent No. 5854204

; GENERAL INFORMATION:

; APPLICANT: Findels, Mark A. et al.

; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid

; TITLE OF INVENTION: Aggregation

; NUMBER OF SEQUENCES: 40

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD

; STREET: 28 State Street, Suite 510

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02109-1875

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/612,785B

; FILING DATE: Herewith

; CLASSIFICATION: 514

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/404,831  
;; FILING DATE: 14-MAR-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/475,579  
;; FILING DATE: 07-JUN-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/548,998  
;; FILING DATE: 27-OCT-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: DeConti, Giulio A.  
;; REGISTRATION NUMBER: 31,503  
;; REFERENCE/DOCKET NUMBER: PPI-002CP3  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617)227-7400  
;; TELEFAX: (617)742-4214  
;; INFORMATION FOR SEQ ID NO: 7:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 7 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-612-785B-7

Query Match 100.0%; Score 19; DB 2; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
Db 2 KLVP 5

RESULT 44  
US-08-703-675C-29  
; Sequence 29, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/703,675C  
; FILING DATE: 27-AUG-1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081  
; FILING DATE: 14-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2

;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617)227-7400  
;; TELEFAX: (617)742-4214  
;; INFORMATION FOR SEQ ID NO: 29:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 7 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-703-675C-29

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVP 4  
Db 3 KLVP 6

RESULT 45  
US-08-703-675C-30  
; Sequence 30, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/703,675C  
; FILING DATE: 27-AUG-1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081  
; FILING DATE: 14-MAR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: 41,106  
; REFERENCE/DOCKET NUMBER: PPI-016CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 30:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-703-675C-30

Aggregation Comprising D-

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5

## RESULT 46

US-08-617-267C-6  
; Sequence 6, Application US/08617267C  
; Patent No. 6319498  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-617-267C-6  
Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 3 KLVF 6

## RESULT 47

US-08-617-267C-7  
; Sequence 7, Application US/08617267C  
; Patent No. 6319498  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-617-267C-6  
Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 3 KLVF 6

## RESULT 48

US-09-264-709A-13  
; Sequence 13, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; FILE REFERENCE: 2124-310  
; CURRENT APPLICATION NUMBER: US/09/264,709A  
; CURRENT FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 13  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-13

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||

STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-617-267C-7  
Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5

US-09-264-709A-13  
; Sequence 13, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; FILE REFERENCE: 2124-310  
; CURRENT APPLICATION NUMBER: US/09/264,709A  
; CURRENT FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 13  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-13

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVF 4  
|||  
Db 2 KLVF 5



Search completed: March 9, 2005, 06:43:02  
Job time : 10.6849 secs

Db 1 KLVF 4

RESULT 49  
US-09-095-106A-11  
; Sequence 11, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERENIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 11  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-11

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
|||  
Db 3 KLVF 6

RESULT 50  
US-09-095-106A-12  
; Sequence 12, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERENIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 12  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-12

Query Match 100.0%; Score 19; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVF 4  
|||  
Db 4 KLVF 7



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 16.0274 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-9  
Perfect score: 29  
Sequence: 1 KVVFFA 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents, AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep:\*  
2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep:\*  
3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep:\*  
4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep:\*  
5: /cgn2\_6/ptodata/1/iaa/PCTUS\_COMB.pep:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	4	US-09-747-408-9
2	29	100.0	6	4	US-09-747-408-17
3	29	100.0	77	4	US-09-513-999C-6921
4	29	100.0	1144	1	US-08-147-812-5
5	29	100.0	1144	2	US-08-319-866-12
6	29	100.0	1144	3	US-09-123-708-2
7	29	100.0	1144	3	US-09-123-624-2
8	29	100.0	1144	4	US-09-661-258-5
9	29	100.0	1144	4	US-08-809-917-12
10	28	96.6	6	4	US-09-747-408-1
11	28	96.6	6	4	US-09-747-408-10
12	28	96.6	123	4	US-09-902-540-13513
13	26	89.7	6	2	US-08-612-785B-9
14	26	89.7	6	3	US-08-703-675C-32
15	26	89.7	6	3	US-08-617-267C-9
16	26	89.7	6	4	US-09-747-408-3
17	26	89.7	6	4	US-09-747-408-11
18	26	89.7	7	1	US-08-127-904-14
19	26	89.7	7	2	US-08-612-785B-7
20	26	89.7	7	3	US-08-703-675C-30
21	26	89.7	7	3	US-08-617-267C-7
22	26	89.7	7	3	US-09-264-709A-13
23	26	89.7	7	4	US-09-747-408-2
24	26	89.7	7	4	US-09-747-408-18
25	26	89.7	7	4	US-09-747-408-19
26	26	89.7	7	5	PCT-US94-10475-14
27	26	89.7	8	2	US-08-612-785B-5

RESULT 1  
US-09-747-408-9  
; Sequence 9, Application US/09747408  
; Patent No. 6870399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 9  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-9

Query Match 100.0%; Score 29; DB 4; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 KVVFFA 6  
Db 1 KVVFFA 6

ALIGNMENTS

28	26	89.7	8	2	US-08-630-645-1	Sequence 1, Appli
29	26	89.7	8	3	US-08-703-675C-28	Sequence 28, Appl
30	26	89.7	8	3	US-08-617-267C-5	Sequence 5, Appli
31	26	89.7	8	3	US-09-095-106A-44	Sequence 44, Appl
32	26	89.7	8	4	US-08-766-596A-1	Sequence 1, Appli
33	26	89.7	8	5	PCT-US96-10220-1	Sequence 1, Appli
34	26	89.7	9	4	US-08-766-596A-64	Sequence 64, Appl
35	26	89.7	9	4	US-09-747-408-20	Sequence 20, Appl
36	26	89.7	10	3	US-08-970-833-3	Sequence 3, Appli
37	26	89.7	10	4	US-09-724-961-20	Sequence 20, Appl
38	26	89.7	10	4	US-09-724-961-21	Sequence 21, Appl
39	26	89.7	10	4	US-09-724-961-22	Sequence 22, Appl
40	26	89.7	10	4	US-09-724-961-23	Sequence 23, Appl
41	26	89.7	10	4	US-09-724-961-24	Sequence 24, Appl
42	26	89.7	10	4	US-09-580-018-20	Sequence 20, Appl
43	26	89.7	10	4	US-09-580-018-21	Sequence 21, Appl
44	26	89.7	10	4	US-09-580-018-22	Sequence 22, Appl
45	26	89.7	10	4	US-09-580-018-23	Sequence 23, Appl
46	26	89.7	10	4	US-09-580-018-24	Sequence 24, Appl
47	26	89.7	10	4	US-09-724-551-20	Sequence 20, Appl
48	26	89.7	10	4	US-09-724-551-21	Sequence 21, Appl
49	26	89.7	10	4	US-09-724-551-22	Sequence 22, Appl
50	26	89.7	10	4	US-09-724-551-23	Sequence 23, Appl
51	26	89.7	10	4	US-09-724-551-24	Sequence 24, Appl
52	26	89.7	11	2	US-08-630-645-14	Sequence 14, Appl
53	26	89.7	11	4	US-08-766-596A-14	Sequence 14, Appl
54	26	89.7	11	4	US-09-988-842-9	Sequence 9, Appli
55	26	89.7	11	4	US-09-988-842-25	Sequence 25, Appl
56	26	89.7	11	5	PCT-US96-10220-14	Sequence 14, Appl
57	26	89.7	14	4	US-09-594-366-5	Sequence 5, Appli
58	26	89.7	15	2	US-08-612-785B-14	Sequence 14, Appl
59	26	89.7	15	2	US-08-612-785B-37	Sequence 37, Appl
60	26	89.7	15	3	US-08-617-267C-14	Sequence 14, Appl
61	26	89.7	15	4	US-08-766-596A-56	Sequence 56, Appl
62	26	89.7	15	4	US-08-766-596A-57	Sequence 57, Appl
63	26	89.7	15	4	US-08-766-596A-58	Sequence 58, Appl
64	26	89.7	15	4	US-08-766-596A-60	Sequence 60, Appl
65	26	89.7	15	4	US-08-766-596A-61	Sequence 61, Appl

```
RESULT 2
US-09-747-408-17
; Sequence 17, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-17

Query Match      100.0%; Score 29; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVFFFA 6
Db      1 KVFFFA 6

RESULT 3
US-09-513-999C-6921
; Sequence 6921, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 6921
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-513-999C-6921

Query Match      100.0%; Score 29; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVFFFA 6
Db      38 KVFFFA 43

RESULT 4
US-08-147-812-5
; Sequence 5, Application US/08147812
; Patent No. 5766909
; GENERAL INFORMATION:
; APPLICANT: Xie, Qiao-wen
; APPLICANT: Nathan, Carl F.
; APPLICANT: Mumford, Richard A.
; APPLICANT: Calaycay, Jimmy Ramos
```

```
; TITLE OF INVENTION: DNA Encoding Inducible Nitric Oxide Synthase
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 East Lincoln Avenue
; CITY: Rahway
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: Macintosh Centris650
; OPERATING SYSTEM: Macintosh 7.0.1
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/147,812
; FILING DATE: No. 5766909 Available
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/841,641
; FILING DATE: 02-FEB-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wallen, John W III
; REGISTRATION NUMBER: 35,403
; REFERENCE/DOCKET NUMBER: 186581A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 594-3905
; TELEFAX: (908) 594-4720
; TELEX: 138825
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1144 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-147-812-5

Query Match      100.0%; Score 29; DB 1; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVFFFA 6
Db      514 KVFFFA 519

RESULT 5
US-08-319-866-12
; Sequence 12, Application US/08319866
; Patent No. 5929223
; GENERAL INFORMATION:
; APPLICANT: Tully, Timothy P.
; APPLICANT: Yin, Jerry C.
; APPLICANT: Regulski, Michael
; TITLE OF INVENTION: CLONING AND CHARACTERIZATION OF GENES
; TITLE OF INVENTION: ASSOCIATED WITH LONG-TERM MEMORY
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,866
; FILING DATE: 7-OCT-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: CSHL94-03
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1144 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-319-866-12

Query Match      100.0%; Score 29; DB 2; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVVFPA 6
Db      514 KVVFPA 519

RESULT 6
US-09-123-708-2
; Sequence 2, Application US/09123708
; Patent No. 6146887
; GENERAL INFORMATION:
; APPLICANT: SCHRAEDER, Juergen
; APPLICANT: GOEDECKE, Axel
; TITLE OF INVENTION: DNA EXPRESSION VECTORS FOR USE IN GENE THERAPEUTIC
; TITLE OF INVENTION: TREATMENT OF VASCULAR DISORDERS
; FILE REFERENCE: 511169-2003
; CURRENT APPLICATION NUMBER: US/09/123,708
; CURRENT FILING DATE: 1998-07-28
; EARLIER APPLICATION NUMBER: 08/553,503
; EARLIER FILING DATE: 1996-03-01
; EARLIER APPLICATION NUMBER: P4411402.8
; EARLIER FILING DATE: 1994-03-31
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 1144
; TYPE: PRT
; ORGANISM: Cytomegalovirus
US-09-123-708-2

Query Match      100.0%; Score 29; DB 3; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVVFPA 6
Db      514 KVVFPA 519

RESULT 7
US-09-123-624-2
; Sequence 2, Application US/09123624
; Patent No. 6149936
; GENERAL INFORMATION:
; APPLICANT: SCHRAEDER, Juergen
; APPLICANT: GOEDECKE, Axel
; TITLE OF INVENTION: DNA EXPRESSION VECTORS FOR USE IN THE GENE THERAPEUTIC
; TITLE OF INVENTION: TREATMENT OF VASCULAR DISORDERS
; FILE REFERENCE: 511169-2004
; CURRENT APPLICATION NUMBER: US/09/123,624
; CURRENT FILING DATE: 1998-07-28
; PRIOR APPLICATION NUMBER: 08/553,503
```

```
; PRIOR FILING DATE: 1996-03-01
; PRIOR APPLICATION NUMBER: 4411402.8
; PRIOR FILING DATE: 1994-03-31
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1144
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-123-624-2

Query Match      100.0%; Score 29; DB 3; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVVFPA 6
Db      514 KVVFPA 519

RESULT 8
US-09-661-258-5
; Sequence 5, Application US/09661258
; Patent No. 6620616
; GENERAL INFORMATION:
; APPLICANT: Stuehr, Dennis J.
; APPLICANT: Adak, Subrata
; TITLE OF INVENTION: Nucleic Acids Encoding Nitric Oxide Synthase Variants
; FILE REFERENCE: 26473/04028
; CURRENT APPLICATION NUMBER: US/09/661,258
; CURRENT FILING DATE: 2000-09-13
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 1144
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-661-258-5

Query Match      100.0%; Score 29; DB 4; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KVVFPA 6
Db      514 KVVFPA 519

RESULT 9
US-08-809-917-12
; Sequence 12, Application US/08809917
; Patent No. 6689557
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT: APPLICANT
; TITLE OF INVENTION: CLONING AND CHARACTERIZATION OF GENES
; TITLE OF INVENTION: ASSOCIATED WITH LONG-TERM MEMORY
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/809,917
; FILING DATE:
```

```
;
; CLASSIFICATION:
; PRIOR APPLICATION DATA: PCT/US95/13198
; FILING DATE: 2000-12-22
; APPLICATION NUMBER: US 08/361,063
; FILING DATE: 21-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/319,866
; FILING DATE: 07-OCT-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: CSHL94-03A2 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1144 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-809-917-12

Query Match 100.0%; Score 29; DB 4; Length 1144;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6
Db 514 KVVFFA 519

RESULT 10
US-09-747-408-1
; Sequence 1, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-1

Query Match 96.6%; Score 28; DB 4; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6
Db 1 KVVFFA 6

RESULT 11
US-09-747-408-10
; Sequence 10, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
```

```
;
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-10

Query Match 96.6%; Score 28; DB 4; Length 6;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6
Db 1 KVVFFA 6

RESULT 12
US-09-902-540-13513
; Sequence 13513, Application US/09902540
; Patent No. 6833447
; GENERAL INFORMATION:
; APPLICANT: Goldman, Barry S.
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Wiegand, Roger C.
; TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15849)B
; CURRENT APPLICATION NUMBER: US/09/902,540
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: 60/217,883
; PRIOR FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 16825
; SEQ ID NO 13513
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Myxococcus xanthus
US-09-902-540-13513

Query Match 96.6%; Score 28; DB 4; Length 123;
Best Local Similarity 83.3%; Pred. No. 34;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6
Db 52 KVVFFA 57

RESULT 13
US-08-612-785B-9
; Sequence 9, Application US/08612785B
; Patent No. 5854204
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid
; TITLE OF INVENTION: Aggregation
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-612-785B-9

Query Match 89.7%; Score 26; DB 2; Length 6;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
DB 1 KLVFFA 6

RESULT 14  
US-08-703-675C-32  
Sequence 32, Application US/08703675C  
Patent No. 6303567  
GENERAL INFORMATION:  
APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Modulators of -Amyloid Peptide  
NUMBER OF SEQUENCES: 46  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/703,675C  
FILING DATE: 27-AUG-1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/616,081  
FILING DATE: 14-MAR-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Kara, Catherine J.  
REGISTRATION NUMBER: 41,106  
REFERENCE/DOCKET NUMBER: PPI-016CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 32:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-703-675C-32

Query Match 89.7%; Score 26; DB 3; Length 6;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
DB 1 KLVFFA 6

RESULT 15  
US-08-617-267C-9  
Sequence 9, Application US/08617267C  
Patent No. 6319498  
GENERAL INFORMATION:  
APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/617,267C  
FILING DATE: 14-MAR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-617-267C-9

Query Match 89.7%; Score 26; DB 3; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 Db 1 KLVFFA 6

## RESULT 16

US-09-747-408-3

; Sequence 3, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; FILE OF INVENTION: Cerebral Amyloid Angiopathy

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 6

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-3

Query Match 89.7%; Score 26; DB 4; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 Db 1 KLVFFA 6

## RESULT 17

US-09-747-408-11

; Sequence 11, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; FILE OF INVENTION: Cerebral Amyloid Angiopathy

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747,408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 11

; LENGTH: 6

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-11

Query Match 89.7%; Score 26; DB 4; Length 6;  
 Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 Db 1 KLVFFA 6

## RESULT 18

US-08-127-904-14

; Sequence 14, Application US/08127904  
 ; Patent No. 5470951  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Eugene Roberts  
 ; TITLE OF INVENTION: Method For Antagonizing  
 ; TITLE OF INVENTION: Amnestic Effects of Amyloid n  
 ; TITLE OF INVENTION: Protein and Improving the  
 ; TITLE OF INVENTION: Quality of Life in Individuals  
 ; TITLE OF INVENTION: With Alzheimer Disease  
 ; NUMBER OF SEQUENCES: 15  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: City of Hope  
 ; STREET: 1500 East Duarte Road  
 ; CITY: Duarte  
 ; STATE: California  
 ; COUNTRY: United States of America  
 ; ZIP: 91010-0269  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3M Double Density 5 1/4" diskette  
 ; COMPUTER: Wang PC  
 ; OPERATING SYSTEM: MS DOS Version 3.20  
 ; SOFTWARE: Microsoft  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/127,904  
 ; FILING DATE: 29 September 1993  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA: No. 5470951e  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Irons, Edward S.  
 ; REGISTRATION NUMBER: 16,541  
 ; REFERENCE/DOCKET NUMBER: No. 5470951e  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (202) 783-6040  
 ; TELEFAX: (202) 783-6031  
 ; TELEX: No. 5470951e  
 ; INFORMATION FOR SEQ ID NO: 14:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 7  
 ; TYPE: Amino Acid  
 ; STRANDEDNESS:  
 ; TOPOLOGY: Unknown  
 ; US-08-127-904-14

Query Match 89.7%; Score 26; DB 1; Length 7;  
 Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
 Db 1 KLVFFA 6

## RESULT 19

US-08-612-785B-7

; Sequence 7, Application US/08612785B

; Patent No. 5854204

; GENERAL INFORMATION:

; APPLICANT: Findeis, Mark A. et al.

; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid

; TITLE OF INVENTION: Aggregation

; NUMBER OF SEQUENCES: 40

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD

; STREET: 28 State Street, Suite 510

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02109-1875

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25



;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/612,785B  
;; FILING DATE: Herewith  
;; CLASSIFICATION: 514  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/404,831  
;; FILING DATE: 14-MAR-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/475,579  
;; FILING DATE: 07-JUN-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: USSN 08/548,998  
;; FILING DATE: 27-OCT-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: DeConti, Giulio A.  
;; REGISTRATION NUMBER: 31,503  
;; REFERENCE/DOCKET NUMBER: PPI-002CP3  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617)227-7400  
;; TELEFAX: (617)742-4214  
;; INFORMATION FOR SEQ ID NO: 7:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 7 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-612-785B-7

Query Match 89.7%; Score 26; DB 2; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 20  
US-08-703-675C-30  
; Sequence 30, Application US/08703675C  
; Patent No. 6303567  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of -Amyloid Peptide Aggregation Comprising D-  
; NUMBER OF SEQUENCES: 46  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/703,675C  
; FILING DATE: 27-AUG-1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/616,081  
; FILING DATE: 14-MAR-1996

;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Kara, Catherine J.  
;; REGISTRATION NUMBER: 41,106  
;; REFERENCE/DOCKET NUMBER: PPI-016CP2  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617)227-7400  
;; TELEFAX: (617)742-4214  
;; INFORMATION FOR SEQ ID NO: 30:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 7 amino acids  
;; TYPE: amino acid  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-703-675C-30

Query Match 89.7%; Score 26; DB 3; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 21  
US-08-617-267C-7  
; Sequence 7, Application US/08617267C  
; Patent No. 6319498  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-617-267C-7

Query Match 89.7%; Score 26; DB 3; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 2 KLVFFA 7

## RESULT 22

US-09-264-709A-13

; Sequence 13, Application US/09264709A

; Patent No. 6320024

; GENERAL INFORMATION:

; APPLICANT: Roberts, Eugene

; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and

; TITLE OF INVENTION: Improve the Quality of Life

; FILE REFERENCE: 2124-310

; CURRENT APPLICATION NUMBER: US/09/264.709A

; CURRENT FILING DATE: 1999-03-09

; PRIOR APPLICATION NUMBER: 08/797,782

; PRIOR FILING DATE: 1997-02-07

; NUMBER OF SEQ ID NOS: 39

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 13

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-264-709A-13

Query Match 89.7%; Score 26; DB 3; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 23

US-09-747-408-2

; Sequence 2, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; TITLE OF INVENTION: Compounds And Methods For Modulating

; TITLE OF INVENTION: Cerebral Amyloid Angiopathy

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747.408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-2

Query Match 89.7%; Score 26; DB 4; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 2 KLVFFA 7

## RESULT 24

US-09-747-408-18

; Sequence 18, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747.408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 18  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-18

Query Match 89.7%; Score 26; DB 4; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 25

US-09-747-408-19

; Sequence 19, Application US/09747408

; Patent No. 6670399

; GENERAL INFORMATION:

; APPLICANT: Green, Allan M.

; APPLICANT: Gervais, Francine

; TITLE OF INVENTION: Compounds And Methods For Modulating

; TITLE OF INVENTION: Cerebral Amyloid Angiopathy

; FILE REFERENCE: NBI-088

; CURRENT APPLICATION NUMBER: US/09/747.408

; CURRENT FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/171,877

; PRIOR FILING DATE: 1999-12-23

; NUMBER OF SEQ ID NOS: 24

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 19

; LENGTH: 7

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-747-408-19

Query Match 89.7%; Score 26; DB 4; Length 7;

Best Local Similarity 83.3%; Pred. No. 4.1e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 26

PCT-US94-10475-14

; Sequence 14, Application PC/TUS9410475

; GENERAL INFORMATION:

; APPLICANT: Eugene Roberts

; TITLE OF INVENTION: Method For

; TITLE OF INVENTION: Antagonizing Anesthetic

; TITLE OF INVENTION: Effects of Amyloid n

; TITLE OF INVENTION: Protein and Improving

; TITLE OF INVENTION: the Quality of Life

; TITLE OF INVENTION: in Individuals

; TITLE OF INVENTION: With Alzheimer Disease

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: City of Hope

; STREET: 1500 East Duarte Road

CITY: Duarte  
STATE: California  
COUNTRY: United States of America  
ZIP: 91010-0269  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3M Double Density 5 1/4"  
MEDIUM TYPE: diskette  
COMPUTER: Wang PC  
OPERATING SYSTEM: MS DOS Version 3.20  
SOFTWARE: Microsoft  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US94/10475  
FILING DATE: 16 September 1994  
CLASSIFICATION:  
PRIOR APPLICATION DATA: U. S. Application  
PRIOR APPLICATION DATA: Serial No.  
PRIOR APPLICATION DATA: 08/127,904; filed  
PRIOR APPLICATION DATA: 29 September 1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Irons, Edward S.  
REGISTRATION NUMBER: 16,541  
REFERENCE/DOCKET NUMBER: None  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 626-3564 or 783-6030  
TELEFAX: (202) 783-6031  
TELEX: None  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7  
TYPE: Amino Acid  
STRANDEDNESS:  
TOPOLOGY: Unknown  
PCT-US94-10475-14

Query Match 89.7%; Score 26; DB 5; Length 7;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 27  
US-08-612-785B-5  
Sequence 5, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:  
APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579

FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-612-785B-5

Query Match 89.7%; Score 26; DB 2; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 28  
US-08-630-645-1  
Sequence 1, Application US/08630645  
Patent No. 5948763  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
TITLE OF INVENTION: THEROF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/630,645  
FILING DATE:  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

US-08-630-645-1

Query Match 89.7%; Score 26; DB 2; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 29

US-08-703-675C-28

; Sequence 28, Application US/08703675C  
; Patent No. 6303567

; GENERAL INFORMATION:

; APPLICANT: Findeis, Mark A. et al.

; TITLE OF INVENTION: Modulators of -Amyloid Peptide

Aggregation Comprising D-

; NUMBER OF SEQUENCES: 46

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD, LLP

; STREET: 28 State Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02109-1875

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/703.675C

; FILING DATE: 27-AUG-1996

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/404,831

; FILING DATE: 14-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/475,579

; FILING DATE: 07-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/548,998

; FILING DATE: 27-OCT-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/616,081

; FILING DATE: 14-MAR-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Kara, Catherine J.

; REGISTRATION NUMBER: 41,106

; REFERENCE/DOCKET NUMBER: PPI-016CP2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 227-7400

; TELEFAX: (617) 742-4214

; INFORMATION FOR SEQ ID NO: 28:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 8 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-703-675C-28

Query Match 89.7%; Score 26; DB 3; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 30

US-08-617-267C-5

; Sequence 5, Application US/08617267C  
; Patent No. 6319498

; GENERAL INFORMATION:

; APPLICANT: Findeis, Mark A. et al.

; TITLE OF INVENTION: Modulators of Amyloid Aggregation

; NUMBER OF SEQUENCES: 45

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LAHIVE & COCKFIELD, LLP

; STREET: 28 State Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02109-1875

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/617,267C

; FILING DATE: 14-MAR-1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/404,831

; FILING DATE: 14-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/475,579

; FILING DATE: 07-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/548,998

; FILING DATE: 27-OCT-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: DeConti, Giulio A.

; REGISTRATION NUMBER: 31,503

; REFERENCE/DOCKET NUMBER: PPI-002CP2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 227-7400

; TELEFAX: (617) 227-5941

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 8 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-617-267C-5

Query Match 89.7%; Score 26; DB 3; Length 8;  
Best Local Similarity 83.3%; Pred. No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 31

US-09-095-106A-44

; Sequence 44, Application US/09095106A

; Patent No. 6331440

; GENERAL INFORMATION:

; APPLICANT: NORDSTEDT, Christer

; APPLICANT: NASLUND, Jan

; APPLICANT: THYBERG, Johan

; APPLICANT: TUERNBERG, Lars O.

; APPLICANT: TERENTUS, Lars

; TITLE OF INVENTION: PEPTIDE BINDING THE KLKFF-SEQUENCE OF AMYLOID-BETA

; FILE REFERENCE: 000500-124

; CURRENT APPLICATION NUMBER: US/09/095,106A

; CURRENT FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: US 60/009,386

; PRIOR FILING DATE: 1995-12-29

; PRIOR APPLICATION NUMBER: PCT/SE96/01621

; PRIOR FILING DATE: 1996-12-09

; NUMBER OF SEQ ID NOS: 44

; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 44  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-44

Query Match 89.7%; Score 26; DB 3; Length 8;  
Best Local Similarity 83.3%; Pred.No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:|||||  
Db 1 KLVFFA 6

RESULT 32  
US-08-766-596A-1  
; Sequence 1, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-1

Query Match 89.7%; Score 26; DB 4; Length 8;  
Best Local Similarity 83.3%; Pred.No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:|||||

Db 1 KLVFFA 6

RESULT 33  
PCT-US96-10220-1  
; Sequence 1, Application PC/TUS9610220  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/10220  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
PCT-US96-10220-1

Query Match 89.7%; Score 26; DB 5; Length 8;  
Best Local Similarity 83.3%; Pred.No. 4.1e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|:|||||  
Db 1 KLVFFA 6

RESULT 34  
US-08-766-596A-64  
; Sequence 64, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK

```
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766.596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630.645
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478.326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-766-596A-64

Query Match      89.7%; Score 26; DB 4; Length 9;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 35
US-09-747-408-20
; Sequence 20, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-747-408-20

Query Match      89.7%; Score 26; DB 4; Length 9;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

STREET: 419 Seventh Street, N.W., Suite 400
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/766.596A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630.645
FILING DATE: 10-APR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/478.326
FILING DATE: 06-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: YUN, Allen C.
REGISTRATION NUMBER: 37,971
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-766-596A-64

Query Match      89.7%; Score 26; DB 4; Length 9;
Best Local Similarity 83.3%; Pred. No. 4.1e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 36
US-08-970-833-3
; Sequence 3, Application US/08970833
; Patent No. 6022859
; GENERAL INFORMATION:
; APPLICANT: Kiesel, Laura L.
; APPLICANT: Murphy, Regina M.
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Quarles & Brady
; STREET: 411 East Wisconsin Avenue
; CITY: Milwaukee
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53202-4497
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,833
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Baker, Jean C.
; REGISTRATION NUMBER: 35,433
; REFERENCE/DOCKET NUMBER: 960296.94291
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (414) 277-5709
; TELEFAX: (414) 271-3552
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-970-833-3

Query Match      89.7%; Score 26; DB 3; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 37
US-09-724-961-20
; Sequence 20, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 152703-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
```

; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
US-09-724-961-20

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6  
|:||||  
Db 5 KLVFFA 10

## RESULT 38

US-09-724-961-21  
; Sequence 21, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
US-09-724-961-21

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6  
|:||||  
Db 4 KLVFFA 9

## RESULT 39

US-09-724-961-22  
; Sequence 22, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
US-09-724-961-22

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KVVFFA 6  
|:||||  
Db 3 KLVFFA 8

## RESULT 40

US-09-724-961-23  
; Sequence 23, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23

```

; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-23

Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVVFFA 6
       |:||||
Db      2 KLVFFA 7

RESULT 41
US-09-724-961-24
; Sequence 24, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-24

Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVVFFA 6
       |:||||
Db      1 KLVFFA 6

RESULT 42
US-09-580-018-20
; Sequence 20, Application US/095800018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-21

Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVVFFA 6
       |:||||
Db      4 KLVFFA 9

RESULT 44
US-09-580-018-22
; Sequence 22, Application US/095800018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
```

```

; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-20

Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVVFFA 6
       |:||||
Db      5 KLVFFA 10

RESULT 43
US-09-580-018-21
; Sequence 21, Application US/095800018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-21

Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KVVFFA 6
       |:||||
Db      4 KLVFFA 9

RESULT 44
US-09-580-018-22
; Sequence 22, Application US/095800018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
```



; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: Peptide)  
US-09-580-018-22

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 45  
US-09-580-018-23  
; Sequence 23, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: Peptide)  
US-09-580-018-23

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 2 KLVFFA 7

RESULT 46  
US-09-580-018-24  
; Sequence 24, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77

; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-24

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 47  
US-09-724-551-20  
; Sequence 20, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-20

Query Match 89.7%; Score 26; DB 4; Length 10;  
Best Local Similarity 83.3%; Pred. No. 7.6;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|:||||  
Db 5 KLVFFA 10

RESULT 48  
US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28

```
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-21
```

```
Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6; Indels 0; Gaps 0;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9
```

```
RESULT 49
US-09-724-551-22
; Sequence 22, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-22
```

```
Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6; Indels 0; Gaps 0;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 3 KLVFFA 8
```

```
RESULT 50
US-09-724-551-23
; Sequence 23, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
```

```
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-23
```

```
Query Match      89.7%; Score 26; DB 4; Length 10;
Best Local Similarity 83.3%; Pred. No. 7.6; Indels 0; Gaps 0;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 2 KLVFFA 7
```

```
Search completed: March 9, 2005, 06:43:04
Job time : 17.0274 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 18.6986 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-18  
Perfect score: 34  
Sequence: 1 KLVFFAQ 7

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep:\*  
2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep:\*  
3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep:\*  
4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep:\*  
5: /cgn2\_6/ptodata/1/iaa/PTUS\_COMB.pep:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	34	100.0	7	4	US-09-747-408-18
2	34	100.0	7	4	US-09-747-408-19
3	34	100.0	28	3	US-09-388-890-12
4	34	100.0	28	4	US-09-660-954-12
5	34	100.0	40	1	US-08-304-585-8
6	34	100.0	43	4	US-09-573-789-1
7	34	100.0	63	1	US-08-462-859A-3
8	34	100.0	63	1	US-08-123-659A-3
9	34	100.0	63	1	US-08-464-247A-3
10	34	100.0	63	1	US-08-464-248A-3
11	34	100.0	99	3	US-08-339-708A-6
12	31	91.2	7	1	US-08-127-904-14
13	31	91.2	7	3	US-09-264-709A-13
14	31	91.2	7	5	PCT-US94-10475-14
15	31	91.2	8	2	US-08-630-645-1
16	31	91.2	8	4	US-08-766-596A-1
17	31	91.2	8	5	PCT-US96-10220-1
18	31	91.2	9	4	US-08-766-596A-64
19	31	91.2	10	3	US-08-970-833-3
20	31	91.2	10	4	US-09-724-961-21
21	31	91.2	10	4	US-09-724-961-22
22	31	91.2	10	4	US-09-724-961-23
23	31	91.2	10	4	US-09-724-961-24
24	31	91.2	10	4	US-09-580-018-21
25	31	91.2	10	4	US-09-580-018-22
26	31	91.2	10	4	US-09-580-018-23
27	31	91.2	10	4	US-09-580-018-24

28	31	91.2	10	4	US-09-724-551-21	Sequence 21, Appl
29	31	91.2	10	4	US-09-724-551-22	Sequence 22, Appl
30	31	91.2	10	4	US-09-724-551-23	Sequence 23, Appl
31	31	91.2	10	4	US-09-724-551-24	Sequence 24, Appl
32	31	91.2	11	2	US-08-630-645-14	Sequence 14, Appl
33	31	91.2	11	4	US-08-766-596A-14	Sequence 14, Appl
34	31	91.2	11	4	US-09-988-842-9	Sequence 9, Appl
35	31	91.2	11	4	US-09-988-842-25	Sequence 25, Appl
36	31	91.2	11	5	PCT-US96-10220-14	Sequence 14, Appl
37	31	91.2	14	4	US-09-594-366-5	Sequence 5, Appl
38	31	91.2	15	2	US-08-612-785B-14	Sequence 14, Appl
39	31	91.2	15	2	US-08-612-785B-37	Sequence 37, Appl
40	31	91.2	15	3	US-08-617-267C-14	Sequence 14, Appl
41	31	91.2	15	4	US-08-766-596A-56	Sequence 56, Appl
42	31	91.2	15	4	US-08-766-596A-57	Sequence 57, Appl
43	31	91.2	15	4	US-08-766-596A-58	Sequence 58, Appl
44	31	91.2	15	4	US-08-766-596A-61	Sequence 61, Appl
45	31	91.2	15	4	US-08-766-596A-63	Sequence 63, Appl
46	31	91.2	15	4	US-08-766-596A-65	Sequence 65, Appl
47	31	91.2	17	3	US-09-264-709A-2	Sequence 2, Appl
48	31	91.2	17	4	US-09-594-366-3	Sequence 3, Appl
49	31	91.2	19	3	US-08-970-833-11	Sequence 11, Appl
50	31	91.2	19	4	US-09-723-384-5	Sequence 5, Appl
51	31	91.2	19	4	US-09-724-961-75	Sequence 75, Appl
52	31	91.2	19	4	US-09-724-552-5	Sequence 5, Appl
53	31	91.2	19	4	US-09-580-018-75	Sequence 75, Appl
54	31	91.2	19	4	US-09-723-927-5	Sequence 5, Appl
55	31	91.2	19	4	US-09-724-479-5	Sequence 5, Appl
56	31	91.2	19	4	US-09-724-477-5	Sequence 5, Appl
57	31	91.2	19	4	US-09-723-762-5	Sequence 5, Appl
58	31	91.2	19	4	US-09-201-430-5	Sequence 5, Appl
59	31	91.2	19	4	US-09-724-551-75	Sequence 75, Appl
60	31	91.2	19	4	US-10-815-353-5	Sequence 5, Appl
61	31	91.2	19	4	US-10-815-329-5	Sequence 5, Appl
62	31	91.2	20	3	US-08-970-833-10	Sequence 10, Appl
63	31	91.2	26	1	US-08-304-585-7	Sequence 7, Appl
64	31	91.2	28	1	US-08-346-849-4	Sequence 4, Appl
65	31	91.2	28	1	US-08-302-808-7	Sequence 7, Appl

ALIGNMENTS

RESULT 1  
US-09-747-408-18  
; Sequence 18, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 18  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-18

Query Match 100.0%; Score 34; DB 4; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches .7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFAQ 7  
DB 1 KLVFFAQ 7

```
RESULT 2
US-09-747-408-19
; Sequence 19, Application US/09747408
; Patent No. 6670399
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-19

Query Match      100.0%; Score 34; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      1 KLVFFAQ 7
      |||||

RESULT 3
US-09-388-890-12
; Sequence 12, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/09/388,890
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,959
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Query Match      100.0%; Score 34; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.44;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      1 KLVFFAQ 7
      |||||
```

```
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
US-09-388-890-12

Query Match      100.0%; Score 34; DB 3; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.44;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      16 KLVFFAQ 22
      |||||

RESULT 4
US-09-660-954-12
; Sequence 12, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:

US-09-660-954-12

Query Match      100.0%; Score 34; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.44;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      16 KLVFFAQ 22
      |||||
```

Db 16 KLVFFAQ 22

## RESULT 5

US-08-304-585-8  
; Sequence 8, Application US/08304585  
; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: Mueeting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; FILING DATE: 12-SEP-1994  
; APPLICATION NUMBER: US/08/304,585  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mueeting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide  
US-08-304-585-8

Query Match 100.0%; Score 34; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.64; Mismatches 0; Indels 0; Gaps 0;  
Matches 7; Conservative 0;

Qy 1 KLVFFAQ 7

Db 16 KLVFFAQ 22

## RESULT 6

US-08-573-789-1  
; Sequence 1, Application US/09573789  
; Patent No. 6737038  
; GENERAL INFORMATION:  
; APPLICANT: Bristol-Myers Squibb Pharma Company (formerly DuPont Pharmaceuticals  
; APPLICANT: Company)  
; APPLICANT: Zacsek, Robert  
; APPLICANT: Olson, Richard E.  
; APPLICANT: Seiffert, Dietmar A.  
; APPLICANT: Thompson, Lorin A.  
; TITLE OF INVENTION: USE OF SMALL MOLECULE RADIOLIGANDS TO DISCOVER INHIBITORS OF AMYL  
; FILE REFERENCE: PH-7048-A  
; CURRENT APPLICATION NUMBER: US/09/573,789  
; CURRENT FILING DATE: 2000-05-17  
; PRIOR APPLICATION NUMBER: US 09/438,901  
; PRIOR FILING DATE: 1999-11-12  
; PRIOR APPLICATION NUMBER: US 60/108,147

; PRIOR FILING DATE: 1998-11-12  
; PRIOR APPLICATION NUMBER: US 60/131,284  
; PRIOR FILING DATE: 1999-04-27  
; NUMBER OF SEQ ID NOS: 1  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 43  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-573-789-1

Query Match 100.0%; Score 34; DB 4; Length 43;  
Best Local Similarity 100.0%; Pred. No. 0.69;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7

Db 16 KLVFFAQ 22

## RESULT 7

US-08-462-859A-3  
; Sequence 3, Application US/08462859A  
; Patent No. 5652092  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vittek, M. P.  
; TITLE OF INVENTION: No. 5652092el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: American Cyanamid Company  
; STREET: One Cyanamid Plaza  
; CITY: Wayne  
; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07470-8426  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/462,859A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-04  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (201)831-3246  
; TELEFAX: (201)831-3305  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 63 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-462-859A-3

Query Match 100.0%; Score 34; DB 1; Length 63;  
Best Local Similarity 100.0%; Pred. No. 1;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7

Db 25 KLVFFAQ 31

## RESULT 8

US-08-123-659A-3  
; Sequence 3, Application US/08123659A  
; Patent No. 5656477  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5656477el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Anne Rosenblum  
; STREET: 163 Delaware Avenue, Suite 212  
; CITY: Delmar  
; STATE: New York  
; COUNTRY: U.S.A.  
; ZIP: 12054  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/123.659A  
; FILING DATE: 20-SEP-1993  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Rosenblum, Anne M.  
; REGISTRATION NUMBER: 30,419  
; REFERENCE/DOCKET NUMBER: 31,844-01  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (518)475-0611  
; TELEFAX: (518)475-0619  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 63 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-123-659A-3  
Query Match 100.0%; Score 34; DB 1; Length 63;  
Best Local Similarity 100.0%; Pred. No. 1;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVFFAQ 7  
Db 25 KLVFFAQ 31  
RESULT 9  
US-08-464-247A-3  
; Sequence 3, Application US/08464247A  
; Patent No. 5693478  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5693478el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: One Campus Drive  
; CITY: Parsippany  
; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07054  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/464,247A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-03  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-683-2158  
; TELEFAX: 201-683-4117  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 63 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-464-247A-3  
Query Match 100.0%; Score 34; DB 1; Length 63;  
Best Local Similarity 100.0%; Pred. No. 1;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVFFAQ 7  
Db 25 KLVFFAQ 31  
RESULT 10  
US-08-464-248A-3  
; Sequence 3, Application US/08464248A  
; Patent No. 5703209  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5703209el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: One Cyanamid Plaza  
; CITY: Wayne  
; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07470-8426  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/464,248A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-02  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (201)831-3246  
; TELEFAX: (201)831-3305  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 63 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-464-248A-3  
Query Match 100.0%; Score 34; DB 1; Length 63;

```
Best Local Similarity 100.0%; Pred. No. 1;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7
Db 25 KLVFFAQ 31

RESULT 11
US-08-339-708A-6
; Sequence 6, Application US/08339708A
; Patent No. 6037521
; GENERAL INFORMATION:
; APPLICANT: Sato, Masahiro
; APPLICANT: Takashi, Kobayashi
; APPLICANT: Tada, No. 6037521hiro
; APPLICANT: Shoji, Mikio
; APPLICANT: Kawarabayashi, Takeshi
; TITLE OF INVENTION: TRANSGENIC ANIMAL MODEL FOR ALZHEIMER'S
; DISEASE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/339,708A
; FILING DATE: 14-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 306026/93
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, COLIN G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 02e083/0159
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 99 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-339-708A-6

Query Match 100.0%; Score 34; DB 3; Length 99;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7
Db 16 KLVFFAQ 22

RESULT 12
US-08-127-904-14
; Sequence 14, Application US/08127904
; Patent No. 5470951
; GENERAL INFORMATION:
; APPLICANT: Eugene Roberts
; TITLE OF INVENTION: Method For Antagonizing
; TITLE OF INVENTION: Amnestic Effects of Amyloid n
; TITLE OF INVENTION: Protein and Improving the

Best Local Similarity 100.0%; Pred. No. 1;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7
Db 25 KLVFFAQ 31

TITLE OF INVENTION: Quality of Life in Individuals
TITLE OF INVENTION: With Alzheimer Disease
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: City of Hope
STREET: 1500 East Duarte Road
CITY: Duarte
STATE: California
COUNTRY: United States of America
ZIP: 91010-0269
COMPUTER READABLE FORM:
MEDIUM TYPE: 3M Double Density 5 1/4" diskette
COMPUTER: Wang PC
OPERATING SYSTEM: MS DOS Version 3.20
SOFTWARE: Microsoft
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/127,904
FILING DATE: 29 September 1993
CLASSIFICATION: 424
PRIOR APPLICATION DATA: No. 5470951e
ATTORNEY/AGENT INFORMATION:
NAME: Irons, Edward S.
REGISTRATION NUMBER: 16,541
REFERENCE/DOCKET NUMBER: No. 5470951e
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 783-6040
TELEFAX: (202) 783-6031
TELEX: No. 5470951e
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 7
TYPE: Amino Acid
STRANDEDNESS:
TOPOLOGY: Unknown
US-08-127-904-14

Query Match 91.2%; Score 31; DB 1; Length 7;
Best Local Similarity 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7
Db 1 KLVFFAQ 7

RESULT 13
US-09-264-709A-13
; Sequence 13, Application US/09264709A
; Patent No. 6320024
; GENERAL INFORMATION:
; APPLICANT: Roberts, Eugene
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and
; FILE REFERENCE: 2124-310
; CURRENT APPLICATION NUMBER: US/09/264,709A
; CURRENT FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: 08/797,782
; PRIOR FILING DATE: 1997-02-07
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-264-709A-13

Query Match 91.2%; Score 31; DB 3; Length 7;
Best Local Similarity 85.7%; Pred. No. 4.1e+05;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7
Db 1 KLVFFAQ 7
```

RESULT 14  
PCT-US94-10475-14  
; Sequence 14, Application PC/TUS9410475  
; GENERAL INFORMATION:  
; APPLICANT: Eugene Roberts  
; TITLE OF INVENTION: Method For  
; TITLE OF INVENTION: Antagonizing Amnestic  
; TITLE OF INVENTION: Effects of Amyloid n  
; TITLE OF INVENTION: Protein and Improving  
; TITLE OF INVENTION: the Quality of Life  
; TITLE OF INVENTION: in Individuals  
; TITLE OF INVENTION: With Alzheimer Disease  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: City of Hope  
; STREET: 1500 East Duarte Road  
; CITY: Duarte  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 91010-0269  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3M Double Density 5 1/4"  
; MEDIUM TYPE: diskette  
; COMPUTER: Wang PC  
; OPERATING SYSTEM: MS DOS Version 3.20  
; SOFTWARE: Microsoft  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US94/10475  
; FILING DATE: 16 September 1994  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA: U. S. Application  
; PRIOR APPLICATION DATA: Serial No.  
; PRIOR APPLICATION DATA: 08/127,904; filed  
; PRIOR APPLICATION DATA: 29 September 1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Irons, Edward S.  
; REGISTRATION NUMBER: 16,541  
; REFERENCE/DOCKET NUMBER: None  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 626-3564 or 783-6030  
; TELEFAX: (202) 783-6031  
; TELEX: None  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7  
; TYPE: Amino Acid  
; STRANDEDNESS:  
; TOPOLOGY: Unknown  
PCT-US94-10475-14

Query Match 91.2%; Score 31; DB 5; Length 7;  
Best Local Similarity 85.7%; Pred. No. 4.1e+05;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVFFAQ 7  
Db 1 KLVFFAE 7  
RESULT 15  
US-08-630-645-1  
; Sequence 1, Application US/08630645  
; Patent No. 5948763  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/630,645  
; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-630-645-1

Query Match 91.2%; Score 31; DB 2; Length 8;  
Best Local Similarity 85.7%; Pred. No. 4.1e+05;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVFFAQ 7  
Db 1 KLVFFAE 7

RESULT 16  
US-08-766-596A-1  
; Sequence 1, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435



;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/630,645  
;; FILING DATE: 10-APR-1996  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/478,326  
;; FILING DATE: 06-JUN-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: YUN, Allen C.  
;; REGISTRATION NUMBER: 37,971  
;; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 202-628-5197  
;; TELEFAX: 202-737-3528  
;; INFORMATION FOR SEQ ID NO: 1:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 8 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-766-596A-1

Query Match 91.2%; Score 31; DB 4; Length 8;  
Best Local Similarity 85.7%; Pred. No. 4.1e+05;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 1 KLVFFAE 7

RESULT 17  
PCT-US96-10220-1  
;; Sequence 1, Application PC/TUS9610220  
;; GENERAL INFORMATION:  
;; APPLICANT:  
;; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
;; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
;; WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
;; NUMBER OF SEQUENCES: 26  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: BROWDY AND NEIMARK  
;; STREET: 419 Seventh Street, N.W., Suite 400  
;; CITY: Washington  
;; STATE: D.C.  
;; COUNTRY: USA  
;; ZIP: 20004  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/US96/10220  
;; FILING DATE:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/478,326  
;; FILING DATE: 06-JUN-1995  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/630,645  
;; FILING DATE: 10-APR-1996  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: BROWDY, Roger L.  
;; REGISTRATION NUMBER: 25,618  
;; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 202-628-5197  
;; TELEFAX: 202-737-3528  
;; INFORMATION FOR SEQ ID NO: 1:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 8 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single

;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
PCT-US96-10220-1

Query Match 91.2%; Score 31; DB 5; Length 8;  
Best Local Similarity 85.7%; Pred. No. 4.1e+05;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 1 KLVFFAE 7

RESULT 18  
US-08-766-596A-64  
;; Sequence 64, Application US/08766596A  
;; Patent No. 6462171  
;; GENERAL INFORMATION:  
;; APPLICANT: SOTO-JARA, Claudio  
;; APPLICANT: BAUMANN, Marc  
;; APPLICANT: FRANGIONE, Blas  
;; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
;; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
;; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
;; TITLE OF INVENTION: DEPOSITS  
;; NUMBER OF SEQUENCES: 69  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: BROWDY AND NEIMARK  
;; STREET: 419 Seventh Street, N.W., Suite 400  
;; CITY: Washington  
;; STATE: D.C.  
;; COUNTRY: USA  
;; ZIP: 20004  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/766,596A  
;; FILING DATE:  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/630,645  
;; FILING DATE: 10-APR-1996  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/478,326  
;; FILING DATE: 06-JUN-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: YUN, Allen C.  
;; REGISTRATION NUMBER: 37,971  
;; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 202-628-5197  
;; TELEFAX: 202-737-3528  
;; INFORMATION FOR SEQ ID NO: 64:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 9 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
US-08-766-596A-64

Query Match 91.2%; Score 31; DB 4; Length 9;  
Best Local Similarity 85.7%; Pred. No. 4.1e+05;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 2 KLVFFAE 8

RESULT 19  
US-08-970-833-3  
; Sequence 3, Application US/08970833  
; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kiessling, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC Compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/DOCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-970-833-3  
Query Match 91.2%; Score 31; DB 3; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVEFFAQ 7  
| | | | |  
Db 1 KLVEFFAE 7  
| | | | |  
RESULT 20  
US-09-724-961-21  
; Sequence 21, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-21  
Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVEFFAQ 7  
| | | | |  
Db 3 KLVEFFAE 9  
| | | | |  
RESULT 22  
US-09-724-961-23  
; Sequence 23, Application US/09724961  
; Patent No. 6743427

; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-21  
Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVEFFAQ 7  
| | | | |  
Db 4 KLVEFFAE 10  
| | | | |  
RESULT 21  
US-09-724-961-22  
; Sequence 22, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-22  
Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 KLVEFFAQ 7  
| | | | |  
Db 3 KLVEFFAE 9  
| | | | |  
RESULT 22  
US-09-724-961-23  
; Sequence 23, Application US/09724961  
; Patent No. 6743427

GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vasquez, Nicki  
APPLICANT: Vednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004750UC  
CURRENT APPLICATION NUMBER: US/09/724,961  
CURRENT FILING DATE: 2000-11-28  
PRIOR APPLICATION NUMBER: US 09/580,015  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
PRIOR APPLICATION NUMBER: US 09/201,430  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: US 60/080,970  
PRIOR FILING DATE: 1998-04-07  
PRIOR APPLICATION NUMBER: US 60/067,740  
PRIOR FILING DATE: 1997-12-02  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 23  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
OTHER INFORMATION: peptide)  
US-09-724-961-23

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
| | | | |  
Db 2 KLVFFAE 8

RESULT 23  
US-09-724-961-24  
Sequence 24, Application US/09724961  
Patent No. 6743427  
GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vasquez, Nicki  
APPLICANT: Vednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004750UC  
CURRENT APPLICATION NUMBER: US/09/724,961  
CURRENT FILING DATE: 2000-11-28  
PRIOR APPLICATION NUMBER: US 09/580,015  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
PRIOR APPLICATION NUMBER: US 09/201,430  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
PRIOR FILING DATE: 1998-11-30  
PRIOR APPLICATION NUMBER: US 60/080,970  
PRIOR FILING DATE: 1998-04-07  
PRIOR APPLICATION NUMBER: US 60/067,740  
PRIOR FILING DATE: 1997-12-02  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 24  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence

FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
OTHER INFORMATION: peptide)  
US-09-724-961-24

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
| | | | |  
Db 1 KLVFFAE 7

RESULT 24  
US-09-580-018-21  
Sequence 21, Application US/09580018  
Patent No. 6761888  
GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004760US  
CURRENT APPLICATION NUMBER: US/09/580,018  
CURRENT FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 21  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
OTHER INFORMATION: peptide)  
US-09-580-018-21

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
| | | | |  
Db 4 KLVFFAE 10

RESULT 25  
US-09-580-018-22  
Sequence 22, Application US/09580018  
Patent No. 6761888  
GENERAL INFORMATION:  
APPLICANT: Schenk, Dale B.  
APPLICANT: Bard, Frederique  
APPLICANT: Vednock, Ted  
TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
FILE REFERENCE: 15270J-004760US  
CURRENT APPLICATION NUMBER: US/09/580,018  
CURRENT FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 09/322,289  
PRIOR FILING DATE: 1999-05-28  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 22  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
OTHER INFORMATION: peptide)

; OTHER INFORMATION: peptide)  
US-09-580-018-22

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73; Mismatches 1; Indels 0; Gaps 0;  
Matches 6; Conservative 1;

Qy 1 KLVFFAQ 7  
Db 3 KLVFFAE 9

## RESULT 26

US-09-580-018-23  
; Sequence 23, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-23

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73; Mismatches 1; Indels 0; Gaps 0;  
Matches 6; Conservative 1;

Qy 1 KLVFFAQ 7  
Db 2 KLVFFAE 8

## RESULT 27

US-09-580-018-24  
; Sequence 24, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-24

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73; Mismatches 0; Indels 0; Gaps 0;  
Matches 6; Conservative 1;

Qy 1 KLVFFAQ 7

Db 1 KLVFFAE 7

## RESULT 28

US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-21

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73; Mismatches 1; Indels 0; Gaps 0;  
Matches 6; Conservative 1;

Qy 1 KLVFFAQ 7  
Db 4 KLVFFAE 10

## RESULT 29

US-09-724-551-22  
; Sequence 22, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-22

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7  
| | | | |  
DB 3 KLVFFAE 9

RESULT 30  
US-09-724-551-23  
; Sequence 23, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-23

Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7  
| | | | |  
DB 2 KLVFFAE 8

RESULT 31  
US-09-724-551-24  
; Sequence 24, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)

US-09-724-551-24  
Query Match 91.2%; Score 31; DB 4; Length 10;  
Best Local Similarity 85.7%; Pred. No. 0.73;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7  
| | | | |  
DB 1 KLVFFAE 7

RESULT 32  
US-08-630-645-14  
; Sequence 14, Application US/08630645  
; Patent No. 5948763  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/630,645  
; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-630-645-14

Query Match 91.2%; Score 31; DB 2; Length 11;  
Best Local Similarity 85.7%; Pred. No. 0.81;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7  
| | | | |  
DB 2 KLVFFAE 8

RESULT 33  
US-08-766-596A-14  
; Sequence 14, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio

```
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Blas
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; TITLE OF INVENTION: ASSOCIATION WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; TITLE OF INVENTION: DEPOSITS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766,596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; APPLICATION DATA: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-766-596A-14

Query Match          91.2%; Score 31; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      2 KLVFFAE 8

RESULT 34
US-09-988-842-9
; Sequence 9, Application US/09988842
; Patent No. 6716589
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-09-988-842-25

Query Match          91.2%; Score 31; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      2 KLVFFAE 8

RESULT 35
US-09-988-842-25
; Sequence 25, Application US/09988842
; Patent No. 6716589
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT APPLICATION NUMBER: US/09/988,842
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-09-988-842-25

Query Match          91.2%; Score 31; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      2 KLVFFAE 8

RESULT 36
PCT-US96-10220-14
; Sequence 14, Application PC/TUS9610220
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10220
; FILING DATE:
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-09-988-842-9

Query Match          91.2%; Score 31; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      2 KLVFFAE 8

RESULT 35
US-09-988-842-25
; Sequence 25, Application US/09988842
; Patent No. 6716589
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT APPLICATION NUMBER: US/09/988,842
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-09-988-842-25

Query Match          91.2%; Score 31; DB 4; Length 11;
Best Local Similarity 85.7%; Pred. No. 0.81;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KLVFFAQ 7
Db      2 KLVFFAE 8

RESULT 36
PCT-US96-10220-14
; Sequence 14, Application PC/TUS9610220
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10220
; FILING DATE:
```

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 11 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
PCT-US96-10220-14

Query Match 91.2%; Score 31; DB 5; Length 11;  
Best Local Similarity 85.7%; Pred. No. 0.81;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 2 KLVFPAE 8

## RESULT 37

US-09-594-366-5  
Sequence 5, Application US/09594366  
Patent No. 6582945  
GENERAL INFORMATION:  
APPLICANT: Rasco, Victor  
TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
FILE REFERENCE: BBRI-2004  
CURRENT APPLICATION NUMBER: US/09/594,366  
CURRENT FILING DATE: 2000-05-15  
PRIOR APPLICATION NUMBER: 60/139,408  
PRIOR FILING DATE: 1999-06-16  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 5  
LENGTH: 14  
TYPE: PPT  
ORGANISM: Homo sapiens  
US-09-594-366-5

Query Match 91.2%; Score 31; DB 4; Length 14;  
Best Local Similarity 85.7%; Pred. No. 1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 4 KLVFPAE 10

## RESULT 38

US-08-612-785B-14  
Sequence 14, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston

STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal  
US-08-612-785B-14

Query Match 91.2%; Score 31; DB 2; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1.1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFPAQ 7  
Db 1 KLVFPAE 7

## RESULT 39

US-08-612-785B-37  
Sequence 37, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612,785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831

```

; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; US-08-612-785B-37

Query Match 91.2%; Score 31; DB 2; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7
Db 6 KLVFFAE 12

RESULT 40
US-08-617-267C-14
; Sequence 14, Application US/08617267C
; Patent No. 631949
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
; FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; US-08-612-785B-37

; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; US-08-617-267C-14

Query Match 91.2%; Score 31; DB 3; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7
Db 1 KLVFFAE 7

RESULT 41
US-08-766-596A-56
; Sequence 56, Application US/08766596A
; Patent No. 6462171
; GENERAL INFORMATION:
; APPLICANT: SOTO-JARA, Claudio
; APPLICANT: BAUMANN, Marc
; APPLICANT: FRANGIONE, Bias
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; DEPOSITS
; TITLE OF INVENTION: ASSOCIATIONS WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE
; DEPOSITS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 400
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766,596A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,645
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,326
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: YUN, Allen C.
; REGISTRATION NUMBER: 37,971
; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-766-596A-56

Query Match 91.2%; Score 31; DB 4; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7
Db 1 KLVFFAE 7
```



Db 5 KLVFFAE 11

RESULT 42  
US-08-766-596A-57  
; Sequence 57, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 57:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-57

Query Match 91.2%; Score 31; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1.1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAQ 7  
Db 5 KLVFFAE 11

RESULT 44  
US-08-766-596A-61  
; Sequence 61, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible

Db 5 KLVFFAE 11

RESULT 43  
US-08-766-596A-58  
; Sequence 58, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES

OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA: US/08/766,596A  
FILING DATE:  
PRIOR APPLICATION DATA:  
CLASSIFICATION: 435  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 61:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-61

Query Match 91.2%; Score 31; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1.1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVEFAQ 7  
DB 5 KLVEFAE 11

RESULT 45  
US-08-766-596A-63  
Sequence 63, Application US/08766596A  
Patent No. 6462171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
TITLE OF INVENTION: DEPOSITS  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 63:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-63

Query Match 91.2%; Score 31; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1.1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVEFAQ 7  
DB 5 KLVEFAE 11

RESULT 46  
US-08-766-596A-65  
Sequence 65, Application US/08766596A  
Patent No. 6462171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
TITLE OF INVENTION: DEPOSITS  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

## US-08-766-596A-65

Query Match 91.2%; Score 31; DB 4; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1.1;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVPFAQ 7  
Db 5 KLVPFAE 11

## RESULT 47

US-09-264-709A-2  
; Sequence 2, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; FILE REFERENCE: 2124-310  
; CURRENT FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-2

Query Match 91.2%; Score 31; DB 3; Length 17;  
Best Local Similarity 85.7%; Pred. No. 1.3;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVPFAQ 7  
Db 5 KLVPFAE 11

## RESULT 48

US-09-594-366-3  
; Sequence 3, Application US/09594366  
; Patent No. 6582945  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/09/594,366  
; CURRENT FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-594-366-3

Query Match 91.2%; Score 31; DB 4; Length 17;  
Best Local Similarity 85.7%; Pred. No. 1.3;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVPFAQ 7  
Db 8 KLVPFAE 14

## RESULT 49

US-08-970-833-11  
; Sequence 11, Application US/08970833

; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kieselring, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/DOCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-970-833-11

Query Match 91.2%; Score 31; DB 3; Length 19;  
Best Local Similarity 85.7%; Pred. No. 1.4;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVPFAQ 7  
Db 10 KLVPFAE 16

## RESULT 50

US-09-723-384-5  
; Sequence 5, Application US/09723384  
; Patent No. 6710226  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: NeurLab Limited  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004740US  
; CURRENT APPLICATION NUMBER: US/09/723,384  
; CURRENT FILING DATE: 2000-11-27  
; PRIOR APPLICATION NUMBER: 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 19  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Abeta13-28  
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue  
; OTHER INFORMATION: inserted and two added Gly residues  
; NAME/KEY: MOD\_RES  
; LOCATION: (1)  
; OTHER INFORMATION: Xaa = acetyl histidine

US-09-723-384-5

Query Match 91.2%; Score 31; DB 4; Length 19;  
Best Local Similarity 85.7%; Fred. No. 1.4;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAQ 7  
      |||||:  
Db 4 KLVFFAE 10

Search completed: March 9, 2005, 06:43:04  
Job time : 18.6986 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 24.0411 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-20  
Perfect score: 50  
Sequence: 1 HHQKLVFFA 9

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/protdata/1/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/protdata/1/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/protdata/1/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/protdata/1/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/protdata/1/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/protdata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	100.0	9	4 US-09-747-408-20	Sequence 20, Appl
2	50	100.0	10	4 US-09-724-961-20	Sequence 20, Appl
3	50	100.0	10	4 US-09-724-961-21	Sequence 21, Appl
4	50	100.0	10	4 US-09-580-018-20	Sequence 20, Appl
5	50	100.0	10	4 US-09-580-018-21	Sequence 21, Appl
6	50	100.0	10	4 US-09-724-551-20	Sequence 20, Appl
7	50	100.0	10	4 US-09-724-551-21	Sequence 21, Appl
8	50	100.0	15	2 US-08-612-785B-37	Sequence 37, Appl
9	50	100.0	15	4 US-08-766-596A-60	Sequence 60, Appl
10	50	100.0	15	4 US-08-766-596A-61	Sequence 61, Appl
11	50	100.0	15	4 US-08-766-596A-63	Sequence 63, Appl
12	50	100.0	15	4 US-08-766-596A-65	Sequence 65, Appl
13	50	100.0	17	3 US-09-264-709A-2	Sequence 2, Appli
14	50	100.0	17	3 US-09-594-366-3	Sequence 3, Appli
15	50	100.0	26	1 US-08-304-585-7	Sequence 7, Appli
16	50	100.0	28	1 US-08-346-849-4	Sequence 4, Appli
17	50	100.0	28	1 US-08-302-808-7	Sequence 7, Appli
18	50	100.0	28	2 US-08-609-090-2	Sequence 2, Appli
19	50	100.0	28	2 US-08-986-948-7	Sequence 7, Appli
20	50	100.0	28	2 US-08-293-284A-4	Sequence 4, Appli
21	50	100.0	28	2 US-08-461-216-2	Sequence 2, Appli
22	50	100.0	28	3 US-09-388-890-2	Sequence 2, Appli
23	50	100.0	28	3 US-09-388-890-3	Sequence 3, Appli
24	50	100.0	28	3 US-09-388-890-4	Sequence 4, Appli
25	50	100.0	28	3 US-09-388-890-5	Sequence 5, Appli
26	50	100.0	28	3 US-09-388-890-6	Sequence 6, Appli
27	50	100.0	28	3 US-09-388-890-7	Sequence 7, Appli

28	50	100.0	28	3 US-09-388-890-8	Sequence 8, Appli
29	50	100.0	28	3 US-09-388-890-12	Sequence 12, Appl
30	50	100.0	28	3 US-09-388-890-13	Sequence 13, Appl
31	50	100.0	28	3 US-09-388-890-14	Sequence 14, Appl
32	50	100.0	28	3 US-09-264-709A-1	Sequence 1, Appli
33	50	100.0	28	3 US-08-723-661B-2	Sequence 2, Appli
34	50	100.0	28	4 US-09-660-954-2	Sequence 2, Appli
35	50	100.0	28	4 US-09-660-954-3	Sequence 3, Appli
36	50	100.0	28	4 US-09-660-954-4	Sequence 4, Appli
37	50	100.0	28	4 US-09-660-954-5	Sequence 5, Appli
38	50	100.0	28	4 US-09-660-954-6	Sequence 6, Appli
39	50	100.0	28	4 US-09-660-954-7	Sequence 7, Appli
40	50	100.0	28	4 US-09-660-954-8	Sequence 8, Appli
41	50	100.0	28	4 US-09-660-954-12	Sequence 12, Appl
42	50	100.0	28	4 US-09-660-954-13	Sequence 13, Appl
43	50	100.0	28	4 US-09-660-954-14	Sequence 14, Appl
44	50	100.0	28	4 US-08-988-300-4	Sequence 4, Appli
45	50	100.0	28	4 US-08-824-513-4	Sequence 4, Appli
46	50	100.0	30	2 US-08-609-090-3	Sequence 3, Appli
47	50	100.0	30	4 US-09-861-847A-1	Sequence 1, Appli
48	50	100.0	33	2 US-08-609-090-4	Sequence 4, Appli
49	50	100.0	35	1 US-08-304-585-6	Sequence 6, Appli
50	50	100.0	35	2 US-08-612-785B-36	Sequence 36, Appl
51	50	100.0	35	2 US-08-612-785B-38	Sequence 38, Appl
52	50	100.0	35	2 US-08-612-785B-40	Sequence 40, Appl
53	50	100.0	36	2 US-08-609-090-6	Sequence 6, Appli
54	50	100.0	36	4 US-09-861-847A-6	Sequence 6, Appli
55	50	100.0	36	4 US-09-861-847A-11	Sequence 11, Appl
56	50	100.0	38	1 US-08-302-808-1	Sequence 1, Appli
57	50	100.0	38	2 US-07-737-371B-68	Sequence 68, Appl
58	50	100.0	38	2 US-08-986-948-1	Sequence 1, Appli
59	50	100.0	39	1 US-08-304-585-5	Sequence 5, Appli
60	50	100.0	39	1 US-08-302-808-2	Sequence 2, Appli
61	50	100.0	39	2 US-08-609-090-7	Sequence 7, Appli
62	50	100.0	39	2 US-08-682-245A-1	Sequence 1, Appli
63	50	100.0	39	2 US-08-986-948-2	Sequence 2, Appli
64	50	100.0	40	1 US-07-744-767A-1	Sequence 1, Appli
65	50	100.0	40	1 US-08-235-400-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1  
US-09-747-408-20  
; Sequence 20, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 20  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-20

Query Match 100.0%; Score 50; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 HHQKLVFFA 9  
Db 1 HHQKLVFFA 9

```
RESULT 2
US-09-724-961-20
; Sequence 20, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-20

Query Match 100.0%; Score 50; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9
Db 2 HHQKLVFFA 10

RESULT 3
US-09-724-961-21
; Sequence 21, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77

Query Match 100.0%; Score 50; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9
Db 2 HHQKLVFFA 10

RESULT 4
US-09-580-018-20
; Sequence 20, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-20

Query Match 100.0%; Score 50; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9
Db 2 HHQKLVFFA 10

RESULT 5
US-09-580-018-21
; Sequence 21, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-21

Query Match 100.0%; Score 50; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9
Db 1 HHQKLVFFA 9

RESULT 4
US-09-580-018-20
; Sequence 20, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-20

Query Match 100.0%; Score 50; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9
Db 2 HHQKLVFFA 10

RESULT 5
US-09-580-018-21
; Sequence 21, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
```

; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-21

Query Match 100.0%; Score 50; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.0021;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 1 HHQKLVFFA 9

## RESULT 6

US-09-724-551-20  
; Sequence 20, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-20

Query Match 100.0%; Score 50; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.0021;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 2 HHQKLVFFA 10

## RESULT 7

US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21

; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-21

Query Match 100.0%; Score 50; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.0021;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 1 HHQKLVFFA 9

## RESULT 8

US-08-612-785B-37  
; Sequence 37, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; FILE REFERENCE: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Deconti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 227-7400  
; TELEFAX: (617) 742-4214  
; INFORMATION FOR SEQ ID NO: 37:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-612-785B-37

Query Match 100.0%; Score 50; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.0031;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9





COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 08-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION/DOCKET NUMBER: 37,971  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 63:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-63

Query Match 100.0%; Score 50; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.0031;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 2 HHQKLVFFA 10  
|||

RESULT 12  
US-08-766-596A-65  
Sequence 65, Application US/08766596A  
Patent No. 642171  
GENERAL INFORMATION:  
APPLICANT: SOTO-JARA, Claudio  
APPLICANT: BAUMANN, Marc  
APPLICANT: FRANGIONE, Blas  
TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
TITLE OF INVENTION: DEPOSITS  
NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSER: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596A  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995

ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION/DOCKET NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-766-596A-65

Query Match 100.0%; Score 50; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.0031;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 2 HHQKLVFFA 10  
|||

RESULT 13  
US-09-264-709A-2  
Sequence 2, Application US/09264709A  
Patent No. 632024  
GENERAL INFORMATION:  
APPLICANT: Roberts, Eugene  
TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
TITLE OF INVENTION: Improve the Quality of Life  
FILE REFERENCE: 2124-310  
CURRENT APPLICATION NUMBER: US/09/264,709A  
CURRENT FILING DATE: 1999-03-09  
PRIOR APPLICATION NUMBER: 08/797,782  
PRIOR FILING DATE: 1997-02-07  
NUMBER OF SEQ ID NOS: 39  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 17  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-264-709A-2

Query Match 100.0%; Score 50; DB 3; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.0036;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
Db 2 HHQKLVFFA 10  
|||

RESULT 14  
US-09-594-366-3  
Sequence 3, Application US/09594366  
Patent No. 6582945  
GENERAL INFORMATION:  
APPLICANT: Raso, Victor  
TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
FILE REFERENCE: BBRI-2004  
CURRENT APPLICATION NUMBER: US/09/594,366  
CURRENT FILING DATE: 2000-06-15  
PRIOR APPLICATION NUMBER: 60/139,408  
PRIOR FILING DATE: 1999-06-16  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 3  
LENGTH: 17  
TYPE: PRT  
ORGANISM: Homo sapiens

us-10-009-122-20.ra1

Wed Mar 9 08:15:45 2005

US-09-594-366-3

Query Match 100.0%; Score 50; DB 4; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.0036;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 5 HHQKLVFFA 13

RESULT 15

US-08-304-585-7 Application US/08304585

Sequence 7, Application US/08304585  
Patent No. 5721106  
GENERAL INFORMATION:  
APPLICANT: Magglio, John E.  
APPLICANT: Mantyh, Patrick W.  
TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
NUMBER OF SEQUENCES: 12  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Mueeting, Raasch, Gebhardt & Schwappach, P.A.  
STREET: P.O. Box 581415  
CITY: Minneapolis  
STATE: MN  
COUNTRY: USA  
ZIP: 55458-1415

COMPUTER READABLE FORM: disk  
MEDIUM TYPE: IBM PC compatible  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/304,585  
FILING DATE: 12-SEP-1994

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Mueeting, Ann M.

REGISTRATION NUMBER: 33,977

REFERENCE/DOCKET NUMBER: 110.00010120

TELEPHONE: 612-305-1217

TELEFAX: 612-305-1228

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 26 amino acids

TYPE: amino acid

STRANDEDNESS: not relevant

TOPOLOGY: not relevant

MOLECULE TYPE: peptide

US-08-304-585-7

Query Match 100.0%; Score 50; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 0.0055;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 4 HHQKLVFFA 12

RESULT 16

US-08-346-849-4

Sequence 4, Application US/08346849

Patent No. 5670483

GENERAL INFORMATION:

APPLICANT: Zhang, Shuangang

APPLICANT: Lockshin, Curtis

APPLICANT: Rich, Alexander

APPLICANT: Holmes, Todd

TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY

SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES

TITLE OF INVENTION: THEREFOR  
NUMBER OF SEQUENCES: 64  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

STREET: Two Militia Drive

CITY: Lexington

STATE: Massachusetts

COUNTRY: U.S.A.

ZIP: 02173-4799

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/346,849

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/973,326

FILING DATE: 28 DECEMBER 1992

ATTORNEY/AGENT INFORMATION:

NAME: Brook, David E.

REGISTRATION NUMBER: 22,592

REFERENCE/DOCKET NUMBER: MIT-6008

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 861-6240

TELEFAX: (617) 861-9540

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 28 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-346-849-4

Query Match 100.0%; Score 50; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 13 HHQKLVFFA 21

RESULT 17

US-08-302-808-7

Sequence 7, Application US/08302808

Patent No. 5750349

GENERAL INFORMATION:

APPLICANT: SUZUKI, No. 5750349uhiro

APPLICANT: ODAKA, Asano

APPLICANT: KITADA, Chieko

TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR

DERIVATIVES AND USE THEREOF

NUMBER OF SEQUENCES: 14

CORRESPONDENCE ADDRESS:

ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN

STREET: 130 WATER STREET

CITY: BOSTON

STATE: MA

COUNTRY: USA

ZIP: 02019

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/302,808

FILING DATE: 15-SEP-1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/JP94/00089  
FILING DATE: 24-JAN-1994  
APPLICATION NUMBER: 010132/1993  
FILING DATE: 25-JAN-1993  
APPLICATION NUMBER: 019035/1993  
FILING DATE: 05-FEB-1993  
APPLICATION NUMBER: 286985/1993  
FILING DATE: 16-NOV-1993  
APPLICATION NUMBER: 334773/1993  
FILING DATE: 28-DEC-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: DAVID, RESNICK S  
REGISTRATION NUMBER: 34,235  
REFERENCE/DOCKET NUMBER: 44631  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-523-3400  
TELEFAX: 617-523-6440  
TELEX: 200291 STRE  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE: N-terminal  
ORIGINAL SOURCE:  
US-08-302-808-7

Query Match 100.0%; Score 50; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 13 HHQKLVFFA 21

RESULT 18  
US-08-609-090-2  
Sequence 2, Application US/08609090  
Patent No. 5840838  
GENERAL INFORMATION:  
APPLICANT: HENSLEY, Kenneth  
APPLICANT: BUTTERFIELD, D. A.  
APPLICANT: CARNEY, John M.  
APPLICANT: AKSENOV, Michael  
TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
AN OLIGOPEPTIDE OR POLYPEPTIDES  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
STREET: 99 Canal Center Plaza, Suite 300  
CITY: Alexandria  
STATE: Virginia  
COUNTRY: USA  
ZIP: 22314  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/609,090  
FILING DATE: 29-FEB-1996  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Kraus, Eric J.  
REGISTRATION NUMBER: 36,190  
REFERENCE/DOCKET NUMBER: 434-059  
TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-684-1111  
TELEFAX: 703-684-1124  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-609-090-2

Query Match 100.0%; Score 50; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 13 HHQKLVFFA 21

RESULT 19  
US-08-986-948-7  
Sequence 7, Application US/08986948  
Patent No. 5955317  
GENERAL INFORMATION:  
APPLICANT: SUZUKI, No. 5955317uhiro  
APPLICANT: OZAKA, Asano  
APPLICANT: KITADA, Chieko  
TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
STREET: 130 WATER STREET  
CITY: BOSTON  
STATE: MA  
COUNTRY: USA  
ZIP: 02019  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/986,948  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/302,808  
FILING DATE: 15-SEP-1994  
APPLICATION NUMBER: PCT/JP94/00089  
FILING DATE: 24-JAN-1994  
APPLICATION NUMBER: 010132/1993  
FILING DATE: 25-JAN-1993  
APPLICATION NUMBER: 019035/1993  
FILING DATE: 05-FEB-1993  
APPLICATION NUMBER: 286985/1993  
FILING DATE: 16-NOV-1993  
APPLICATION NUMBER: 334773/1993  
FILING DATE: 28-DEC-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: DAVID, RESNICK S  
REGISTRATION NUMBER: 34,235  
REFERENCE/DOCKET NUMBER: 44631  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-523-3400  
TELEFAX: 617-523-6440  
TELEX: 200291 STRE  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
STRANDEDNESS: single

us-10-009-122-20.ra1

Wed Mar 9 08:15:45 2005

```

; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
US-08-986-948-7

Query Match 100.0%; Score 50; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

```

```

RESULT 20
US-08-293-284A-4
; Sequence 4, Application US/08293284A
; Patent No. 5955343
; GENERAL INFORMATION:
; APPLICANT: Holmes, Todd
; APPLICANT: Zhang, Shuguang
; APPLICANT: Rich, Alexander
; APPLICANT: Dipersio, C. Michael
; APPLICANT: Lockshin, Curtis
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES
; TITLE OF INVENTION: THEREFOR
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02173-4799
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,284A
; FILING DATE: 22-AUG-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/973,326
; FILING DATE: 28-DEC-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: MIT-6008A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-293-284A-4

Query Match 100.0%; Score 50; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

```

```

RESULT 21
US-08-461-216-2
; Sequence 2, Application US/08461216
; Patent No. 5958883
; GENERAL INFORMATION:
; APPLICANT: Snow, A.D.
; TITLE OF INVENTION: ANIMAL MODELS OF HUMAN AMYLOIDOSES
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen, O'Connor, Johnson and Kindness
; STREET: 1420 Fifth Avenue, Suite 2800
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette-5.25 inch, 1.2Mb storage
; COMPUTER: IBM PC/386 Compatible
; OPERATING SYSTEM: MS-DOS 4.01
; SOFTWARE: Word for Windows-t
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/461,216
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/969,734
; FILING DATE: October 23, 1992
; APPLICATION NUMBER: 07/950,417
; FILING DATE: September 23, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Broderick, Thomas F.
; REGISTRATION NUMBER: 31,332
; REFERENCE/DOCKET NUMBER: UOFW-1-6707
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 1-206-682-8100; 1-206-224-0709 (direct)
; TELEFAX: 1-206-224-0779
; TELEX: 4938023
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; DESCRIPTION: {SYMBOL 98 \f "Symbol"}A4(1-28);
; DESCRIPTION: page 83, line 31
US-08-461-216-2

Query Match 100.0%; Score 50; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 22
US-09-388-890-2
; Sequence 2, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US

```

```

;
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,959
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: B(1-28) peptide of amyloid B protein
;
; US-09-388-890-2
;
; Query Match 100.0%; Score 50; DB 3; Length 28;
; Best Local Similarity 100.0%; Pred. No. 0.006;
; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HHQKLVFFA 9
; Db 13 HHQKLVFFA 21
;
; RESULT 23
; US-09-388-890-3
; Sequence 3, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,959
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E3Q B(1-28) peptide of amyloid B protein
;
; US-09-388-890-4

```

```

;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: D1N B(1-28) peptide of amyloid B protein
;
; US-09-388-890-3
;
; Query Match 100.0%; Score 50; DB 3; Length 28;
; Best Local Similarity 100.0%; Pred. No. 0.006;
; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HHQKLVFFA 9
; Db 13 HHQKLVFFA 21
;
; RESULT 24
; US-09-388-890-4
; Sequence 4, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,959
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E3Q B(1-28) peptide of amyloid B protein
;
; US-09-388-890-4

```

Query Match 100.0%; Score 50; DB 3; Length 28;  
 Best Local Similarity 100.0%; Pred. No. 0.006;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9  
 |||||  
 Db 13 HHQKLVFFA 21

## RESULT 25

US-09-388-890-5  
 ; Sequence 5, Application US/09388890  
 ; Patent No. 6136548  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ANDERSON, STEPHEN  
 ; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
 ; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
 ; NUMBER OF SEQUENCES: 14  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: HOWREY & SIMON  
 ; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
 ; CITY: WASHINGTON  
 ; STATE: D.C.  
 ; COUNTRY: US  
 ; ZIP: 20004  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/388,890  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/686,959  
 ; FILING DATE:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: AUERBACH, JEFFREY I.  
 ; REGISTRATION NUMBER: 32,680  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (202) 383-7451  
 ; TELEFAX: (202) 383-6610  
 ; INFORMATION FOR SEQ ID NO: 5:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 28 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; HYPOTHETICAL: YES  
 ; FRAGMENT TYPE: N-terminal  
 ; ORIGINAL SOURCE:  
 ; ORGANISM: HOMO SAPIENS  
 ; IMMEDIATE SOURCE:  
 ; CLONE: R5Q B(1-28) peptide of amyloid B protein  
 ; US-09-388-890-5

Query Match 100.0%; Score 50; DB 3; Length 28;  
 Best Local Similarity 100.0%; Pred. No. 0.006;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9  
 |||||  
 Db 13 HHQKLVFFA 21

## RESULT 26

US-09-388-890-6  
 ; Sequence 6, Application US/09388890  
 ; Patent No. 6136548  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ANDERSON, STEPHEN

; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
 ; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
 ; NUMBER OF SEQUENCES: 14  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: HOWREY & SIMON  
 ; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
 ; CITY: WASHINGTON  
 ; STATE: D.C.  
 ; COUNTRY: US  
 ; ZIP: 20004  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/388,890  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/686,959  
 ; FILING DATE:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: AUERBACH, JEFFREY I.  
 ; REGISTRATION NUMBER: 32,680  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (202) 383-7451  
 ; TELEFAX: (202) 383-6610  
 ; INFORMATION FOR SEQ ID NO: 6:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 28 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; HYPOTHETICAL: YES  
 ; FRAGMENT TYPE: N-terminal  
 ; ORIGINAL SOURCE:  
 ; ORGANISM: HOMO SAPIENS  
 ; IMMEDIATE SOURCE:  
 ; CLONE: H6Q B(1-28) peptide of amyloid B protein  
 ; US-09-388-890-6

Query Match 100.0%; Score 50; DB 3; Length 28;  
 Best Local Similarity 100.0%; Pred. No. 0.006;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9  
 |||||  
 Db 13 HHQKLVFFA 21

## RESULT 27

US-09-388-890-7  
 ; Sequence 7, Application US/09388890  
 ; Patent No. 6136548  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ANDERSON, STEPHEN  
 ; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
 ; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
 ; NUMBER OF SEQUENCES: 14  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: HOWREY & SIMON  
 ; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
 ; CITY: WASHINGTON  
 ; STATE: D.C.  
 ; COUNTRY: US  
 ; ZIP: 20004  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/388,890  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/686,959  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: AUERBACH, JEFFREY I.  
REGISTRATION NUMBER: 32,680  
TELEPHONE: (202) 383-7451  
TELEFAX: (202) 383-6610  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
HYPOTHETICAL: YES  
FRAGMENT TYPE: N-terminal  
ORIGINAL SOURCE:  
ORGANISM: HOMO SAPIENS  
IMMEDIATE SOURCE:  
CLONE: D7Q B(1-28) peptide of amyloid B protein  
US-09-388-890-7

Query Match 100.0%; Score 50; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
DB 13 HHQKLVFFA 21

RESULT 28  
US-09-388-890-8  
Sequence 8, Application US/09388890  
Patent No. 6136548  
GENERAL INFORMATION:  
APPLICANT: ANDERSON, STEPHEN  
TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HOWREY & SIMON  
STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
CITY: WASHINGTON  
STATE: D.C.  
COUNTRY: US  
ZIP: 20004  
COMPUTER READABLE FORM:  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/388,890  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/686,959  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: AUERBACH, JEFFREY I.  
REGISTRATION NUMBER: 32,680  
TELEPHONE: (202) 383-7451  
TELEFAX: (202) 383-6610  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid

TOPOLOGY: linear  
MOLECULE TYPE: peptide  
HYPOTHETICAL: YES  
FRAGMENT TYPE: N-terminal  
ORIGINAL SOURCE:  
ORGANISM: HOMO SAPIENS  
IMMEDIATE SOURCE:  
CLONE: E11Q B(1-28) peptide of amyloid B protein  
US-09-388-890-8

Query Match 100.0%; Score 50; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||  
DB 13 HHQKLVFFA 21

RESULT 29  
US-09-388-890-12  
Sequence 12, Application US/09388890  
Patent No. 6136548  
GENERAL INFORMATION:  
APPLICANT: ANDERSON, STEPHEN  
TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HOWREY & SIMON  
STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
CITY: WASHINGTON  
STATE: D.C.  
COUNTRY: US  
ZIP: 20004  
COMPUTER READABLE FORM:  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/388,890  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/686,959  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: AUERBACH, JEFFREY I.  
REGISTRATION NUMBER: 32,680  
TELEPHONE: (202) 383-7451  
TELEFAX: (202) 383-6610  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
HYPOTHETICAL: YES  
FRAGMENT TYPE: N-terminal  
ORIGINAL SOURCE:  
ORGANISM: HOMO SAPIENS  
IMMEDIATE SOURCE:  
CLONE: E22Q B(1-28) peptide of amyloid B protein  
US-09-388-890-12

Query Match 100.0%; Score 50; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
|||

```
Db      13 HHQKLVFFA 21

RESULT 30
US-09-388-890-13
; Sequence 13, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,959
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-7451
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: D23Q B(1-28) peptide of amyloid B protein
US-09-388-890-13
Query Match      100.0%; Score 50; DB 3; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

RESULT 32
US-09-264-709A-1
; Sequence 1, Application US/09264709A
; Patent No. 6320024
; GENERAL INFORMATION:
; APPLICANT: Roberts, Eugene
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and
; FILE REFERENCE: 2124-310
; TITLE OF INVENTION: Improve the Quality of Life
; CURRENT APPLICATION NUMBER: US/09/264,709A
; CURRENT FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: 08/797,782
; PRIOR FILING DATE: 1997-02-07
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 28
; TYPE: PNT
; ORGANISM: Homo sapiens
US-09-264-709A-1
Query Match      100.0%; Score 50; DB 3; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

RESULT 31
US-09-388-890-14
; Sequence 14, Application US/09388890
; Patent No. 6136548
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
```



```
RESULT 33
US-08-723-661B-2
; Sequence 2, Application US/08723661B
; Patent No. 6340783
; GENERAL INFORMATION:
; APPLICANT: Alan D Snow
; TITLE OF INVENTION: Animal Models of Human Amyloidoses
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrick M. Dwyer
; STREET: 1818 Westlake Avenue N, Suite 114
; CITY: Seattle
; STATE: WA (Washington)
; COUNTRY: United States of America
; ZIP: 98109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC
; OPERATING SYSTEM: PC-DOS (Windows 98)
; SOFTWARE: WordPerfect 5.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/723,661B
; FILING DATE: 31-Oct-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/461,216
; FILING DATE: 05-Jun-1995
; APPLICATION NUMBER: 07/969,734
; FILING DATE: 23-Oct-1992
; APPLICATION NUMBER: 07/950,417
; FILING DATE: 23-Sep-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Dwyer, Patrick M.
; REGISTRATION NUMBER: 32,411
; REFERENCE/DOCKET NUMBER: PROTO.P00C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 343-7074
; TELEFAX: (206) 343-7085
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 AMINO ACIDS
; TYPE: AMINO ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; MOLECULE TYPE: PEPTIDE
; DESCRIPTION: /A4 (1-28); page 83, line 31
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-08-723-661B-2

Query Match 100.0%; Score 50; DB 3; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 34
US-09-660-954-2
; Sequence 2, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; CLASSIFICATION: <Unknown>
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
```

```
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: D1N B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-660-954-3

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 36
US-09-660-954-4
; Sequence 4, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: R5Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-660-954-5

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E3Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-660-954-4

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 37
US-09-660-954-5
; Sequence 5, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: R5Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-660-954-5

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 38	
US-09-660-954-6	
; Sequence 6, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 7:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: D70 B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:	
US-09-660-954-7	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 40	
US-09-660-954-8	
; Sequence 8, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 6:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: HQ B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:	
US-09-660-954-6	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 39	
US-09-660-954-7	
; Sequence 7, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	

Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 38	
US-09-660-954-6	
; Sequence 6, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 7:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: D70 B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:	
US-09-660-954-7	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 40	
US-09-660-954-8	
; Sequence 8, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 6:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: HQ B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:	
US-09-660-954-6	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 39	
US-09-660-954-7	
; Sequence 7, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	

Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 38	
US-09-660-954-6	
; Sequence 6, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 7:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: D70 B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:	
US-09-660-954-7	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 40	
US-09-660-954-8	
; Sequence 8, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	
; NUMBER OF SEQUENCES: 14	
; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: HOWREY & SIMON	
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.	
; CITY: WASHINGTON	
; STATE: D.C.	
; COUNTRY: US	
; ZIP: 20004	
; COMPUTER READABLE FORM:	
; MEDIUM TYPE: Floppy disk	
; COMPUTER: IBM PC compatible	
; OPERATING SYSTEM: PC-DOS/MS-DOS	
; SOFTWARE: Patentin Release #1.0, Version #1.25	
; CURRENT APPLICATION DATA:	
; FILING DATE: 13-Sep-2000	
; APPLICATION NUMBER: US/09/660,954	
; CLASSIFICATION: <Unknown>	
; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: US/09/388,890	
; FILING DATE: <Unknown>	
; APPLICATION NUMBER: 08/686,959	
; FILING DATE: <Unknown>	
; ATTORNEY/AGENT INFORMATION:	
; NAME: AUERBACH, JEFFREY I.	
; REGISTRATION NUMBER: 32,680	
; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (202) 383-7451	
; TELEFAX: (202) 383-6610	
; INFORMATION FOR SEQ ID NO: 6:	
; SEQUENCE CHARACTERISTICS:	
; LENGTH: 28 amino acids	
; TYPE: amino acid	
; TOPOLOGY: linear	
; MOLECULE TYPE: peptide	
; HYPOTHETICAL: YES	
; FRAGMENT TYPE: N-terminal	
; ORIGINAL SOURCE:	
; ORGANISM: HOMO SAPIENS	
; IMMEDIATE SOURCE:	
; CLONE: HQ B(1-28) peptide of amyloid B protein	
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:	
US-09-660-954-6	
Query Match 100.0%; Score 50; DB 4; Length 28;	
Best Local Similarity 100.0%; Pred. No. 0.006;	
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 HHOKLVFFA 9 
Db	13 HHOKLVFFA 21
 RESULT 39	
US-09-660-954-7	
; Sequence 7, Application US/09660954	
; Patent No. 6471960	
; GENERAL INFORMATION:	
; APPLICANT: ANDERSON, STEPHEN	
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT	
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE	

```
;
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E11Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-660-954-8

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 41
US-09-660-954-12
; Sequence 12, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E11Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-660-954-12

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 42
US-09-660-954-13
; Sequence 13, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-660-954-12

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21
```

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-660-954-12

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21

RESULT 42
US-09-660-954-13
; Sequence 13, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: E22Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-660-954-12

Query Match 100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQKLVFFA 9
Db 13 HHQKLVFFA 21
```

```
; IMMEDIATE SOURCE:
; CLONE: D23Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-660-954-13

Query Match      100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

RESULT 43
US-09-660-954-14
; Sequence 14, Application US/09660954
; Patent No. 6471960
; GENERAL INFORMATION:
; APPLICANT: ANDERSON, STEPHEN
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/660,954
; FILING DATE: 13-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/388,890
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/686,959
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I.
; REGISTRATION NUMBER: 32,680
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: YES
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: HOMO SAPIENS
; IMMEDIATE SOURCE:
; CLONE: K28Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-660-954-14

Query Match      100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

; IMMEDIATE SOURCE:
; CLONE: D23Q B(1-28) peptide of amyloid B protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-660-954-13

Query Match      100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

RESULT 44
US-08-898-300-4
; Sequence 4, Application US/08898300
; Patent No. 6548630
; GENERAL INFORMATION:
; APPLICANT: Zhang, Shuguang
; APPLICANT: Lockshin, Curtis
; APPLICANT: Rich, Alexander
; APPLICANT: Holmes, Todd
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY
; SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02173-4799
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/898,300
; FILING DATE: 22 JULY 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/346,849
; FILING DATE: 30 NOVEMBER 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/973,326
; FILING DATE: 28 DECEMBER 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: MIT-6008FB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (781) 861-6240
; TELEFAX: (781) 861-9540
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-898-300-4

Query Match      100.0%; Score 50; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.006; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

Qy      1 HHQKLVFFA 9
      |||||
Db      13 HHQKLVFFA 21

RESULT 45
US-08-824-513-4
; Sequence 4, Application US/08824513
; Patent No. 6800481
; GENERAL INFORMATION:
; APPLICANT: Holmes, Todd
; APPLICANT: Zhang, Shuguang
; APPLICANT: Rich, Alexander
; APPLICANT: Dipersio, C. Michael
; APPLICANT: Lockshin, Curtis
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY
; SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES
```

NUMBER OF SEQUENCES: 64  
CORRESPONDENCE ADDRESS:  
ADDRESSES: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
STREET: Two Militia Drive  
CITY: Lexington  
STATE: Massachusetts  
COUNTRY: U.S.A.  
ZIP: 02173-4799  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/824,513  
FILING DATE: March 26, 1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/293,284  
FILING DATE: August 22, 1998  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/973,326  
FILING DATE: 28 DECEMBER 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Brook, David E.  
REGISTRATION NUMBER: 22,592  
REFERENCE/DOCKET NUMBER: MIT-6008A2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (781) 861-6240  
TELEFAX: (781) 861-9540  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 28 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-824-513-4

Query Match 100.0%; Score 50; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.006; 0; Mismatches 0; Indels 0; Gaps 0;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
Db 13 HHQKLVFFA 21

RESULT 46  
US-08-609-090-3  
Sequence 3, Application US/08609090  
Patent No. 5840838  
GENERAL INFORMATION:  
APPLICANT: HENSLEY, Kenneth  
APPLICANT: BUTTERFIELD, D. A.  
APPLICANT: CARNEY, John M.  
APPLICANT: AKSENOV, Michael  
TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
STREET: 99 Canal Center Plaza, Suite 300  
CITY: Alexandria  
STATE: Virginia  
COUNTRY: USA  
ZIP: 22314  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/609,090

FILING DATE: 29-FEB-1996  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Kraus, Eric J.  
REGISTRATION NUMBER: 36,190  
REFERENCE/DOCKET NUMBER: 434-059  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 703-684-1111  
TELEFAX: 703-684-1124  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 30 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-609-090-3

Query Match 100.0%; Score 50; DB 2; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.0064;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
Db 13 HHQKLVFFA 21

RESULT 47  
US-09-861-847A-1  
Sequence 1, Application US/09861847A  
Patent No. 6713450  
GENERAL INFORMATION:  
APPLICANT: FRANGIONE, Blas  
APPLICANT: WISNIEWSKI, Thomas  
APPLICANT: SIGURDSSON, Einar  
TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDGENIC PEPTIDES  
TITLE OF INVENTION: HOMOLOGOUS TO AMYLOID BETA FOR INDUCTION OF AN IMMUNE  
TITLE OF INVENTION: RESPONSE TO AMYLOID BETA AND AMYLOID DEPOSITS  
FILE REFERENCE: 5986/1K433-US1  
CURRENT APPLICATION NUMBER: US/09/861,847A  
CURRENT FILING DATE: 2001-05-22  
PRIOR APPLICATION NUMBER: 60/016,233  
PRIOR FILING DATE: 2000-05-22  
NUMBER OF SEQ ID NOS: 15  
SOFTWARE: Patent In version 3.0  
SEQ ID NO 1  
LENGTH: 30  
TYPE: PRT  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-09-861-847A-1

Query Match 100.0%; Score 50; DB 4; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.0064;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
Db 13 HHQKLVFFA 21

RESULT 48  
US-08-609-090-4  
Sequence 4, Application US/08609090  
Patent No. 5840838  
GENERAL INFORMATION:  
APPLICANT: HENSLEY, Kenneth  
APPLICANT: BUTTERFIELD, D. A.  
APPLICANT: CARNEY, John M.  
APPLICANT: AKSENOV, Michael  
TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES

NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
STREET: 99 Canal Center Plaza, Suite 300  
CITY: Alexandria  
STATE: Virginia  
COUNTRY: USA  
ZIP: 22314  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/609,090  
FILING DATE: 29-FEB-1996  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Kraus, Eric J.  
REGISTRATION NUMBER: 36,190  
REFERENCE/DOCKET NUMBER: 434-059  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 703-684-1111  
TELEFAX: 703-684-1124  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 33 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-609-090-4

Query Match 100.0%; Score 50; DB 2; Length 33;  
Best Local Similarity 100.0%; Pred. No. 0.007; 0; Indels 0; Gaps 0;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 13 HHQKLVFFA 21

RESULT 49  
US-08-304-585-6  
Sequence 6, Application US/08304585  
Patent No. 5721106  
GENERAL INFORMATION:  
APPLICANT: Maggio, John E.  
APPLICANT: Mantyh, Patrick W.  
TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
NUMBER OF SEQUENCES: 12  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Mueeting, Raasch, Gebhardt & Schwappach, P.A.  
STREET: P.O. Box 581415  
CITY: Minneapolis  
STATE: MN  
COUNTRY: USA  
ZIP: 55458-1415  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/304,585  
FILING DATE: 12-SEP-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Mueeting, Ann M.  
REGISTRATION NUMBER: 33,977  
REFERENCE/DOCKET NUMBER: 110.00010120  
TELECOMMUNICATION INFORMATION:

TELEPHONE: 612-305-1217  
TELEFAX: 612-305-1228  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 amino acids  
TYPE: amino acid  
STRANDEDNESS: not relevant  
TOPOLOGY: not relevant  
MOLECULE TYPE: peptide  
US-08-304-585-6

Query Match 100.0%; Score 50; DB 1; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.0075;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQKLVFFA 9  
DB 13 HHQKLVFFA 21

RESULT 50  
US-08-612-785B-36  
Sequence 36, Application US/08612785B  
Patent No. 5854204  
GENERAL INFORMATION:  
APPLICANT: Findels, Mark A. et al.  
TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
TITLE OF INVENTION: Aggregation  
NUMBER OF SEQUENCES: 40  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD  
STREET: 28 State Street, Suite 510  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/612.785B  
FILING DATE: Herewith  
CLASSIFICATION: 514  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 227-7400  
TELEFAX: (617) 742-4214  
INFORMATION FOR SEQ ID NO: 36:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FRAGMENT TYPE: internal  
US-08-612-785B-36

Query Match 100.0%; Score 50; DB 2; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.0075;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHOKLVFFA 9  
| | | | |  
Db 8 HHOKLVFFA 16

Search completed: March 9, 2005, 06:43:05  
Job time : 25.0411 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:36 ; Search time 10.6849 Seconds  
(without alignments)  
27.946 Million cell updates/sec

Title: US-10-009-122-23  
Perfect score: 26  
Sequence: 1 HHQK 4

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/1aa/5A\_COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/5B\_COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/6A\_COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/6B\_COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/6CTUS\_COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	100.0	4	3 US-08-717-551A-1	Sequence 1, Appli
2	26	100.0	4	3 US-09-095-106A-28	Sequence 28, Appl
3	26	100.0	4	4 US-08-922-930-1	Sequence 1, Appli
4	26	100.0	4	4 US-08-923-055-1	Sequence 1, Appli
5	26	100.0	4	4 US-08-922-889-1	Sequence 1, Appli
6	26	100.0	4	4 US-09-747-408-23	Sequence 23, Appl
7	26	100.0	5	3 US-09-095-106A-21	Sequence 21, Appl
8	26	100.0	5	3 US-09-095-106A-22	Sequence 22, Appl
9	26	100.0	6	2 US-08-461-216-3	Sequence 3, Appli
10	26	100.0	6	3 US-09-095-106A-16	Sequence 16, Appl
11	26	100.0	6	3 US-09-095-106A-17	Sequence 17, Appl
12	26	100.0	6	3 US-09-095-106A-18	Sequence 18, Appl
13	26	100.0	6	3 US-08-723-661B-3	Sequence 3, Appli
14	26	100.0	7	1 US-08-397-633A-105	Sequence 105, App
15	26	100.0	7	3 US-09-095-106A-12	Sequence 12, Appl
16	26	100.0	7	3 US-09-095-106A-13	Sequence 13, Appl
17	26	100.0	7	3 US-09-095-106A-14	Sequence 14, Appl
18	26	100.0	8	3 US-09-095-106A-8	Sequence 8, Appli
19	26	100.0	8	3 US-09-095-106A-9	Sequence 9, Appli
20	26	100.0	8	3 US-09-095-106A-10	Sequence 10, Appl
21	26	100.0	9	3 US-09-264-709A-4	Sequence 4, Appli
22	26	100.0	9	3 US-09-095-106A-6	Sequence 6, Appli
23	26	100.0	9	3 US-09-095-106A-7	Sequence 7, Appli
24	26	100.0	9	4 US-09-747-408-20	Sequence 20, Appl
25	26	100.0	10	3 US-09-095-106A-2	Sequence 2, Appli
26	26	100.0	10	4 US-09-724-961-15	Sequence 15, Appl
27	26	100.0	10	4 US-09-724-961-16	Sequence 16, Appl

RESULT 1  
US-08-717-551A-1  
; Sequence 1, Application US/08717551A  
; Patent No. 6071493  
; GENERAL INFORMATION:  
; APPLICANT: Dana-Gilman  
; TITLE OR INVENTION: Identification of Agents that Protect  
; TITLE OF INVENTION: Against Inflammatory Injury to Neurons  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
; ADDRESSEE: & No. 6071493ris LLP  
; STREET: One Liberty Place - 46th Floor  
; CITY: Philadelphia  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS  
; SOFTWARE: WORDPERFECT for WINDOWS 6.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/717,551A  
; FILING DATE: Sept-20-96  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:

ALIGNMENTS

28	26	100.0	10	4	US-09-724-961-17	Sequence 17, Appl
29	26	100.0	10	4	US-09-724-961-18	Sequence 18, Appl
30	26	100.0	10	4	US-09-724-961-19	Sequence 19, Appl
31	26	100.0	10	4	US-09-724-961-20	Sequence 20, Appl
32	26	100.0	10	4	US-09-724-961-21	Sequence 21, Appl
33	26	100.0	10	4	US-09-580-018-15	Sequence 15, Appl
34	26	100.0	10	4	US-09-580-018-16	Sequence 16, Appl
35	26	100.0	10	4	US-09-580-018-17	Sequence 17, Appl
36	26	100.0	10	4	US-09-580-018-18	Sequence 18, Appl
37	26	100.0	10	4	US-09-580-018-19	Sequence 19, Appl
38	26	100.0	10	4	US-09-580-018-20	Sequence 20, Appl
39	26	100.0	10	4	US-09-580-018-21	Sequence 21, Appl
40	26	100.0	10	4	US-09-724-551-15	Sequence 15, Appl
41	26	100.0	10	4	US-09-724-551-16	Sequence 16, Appl
42	26	100.0	10	4	US-09-724-551-17	Sequence 17, Appl
43	26	100.0	10	4	US-09-724-551-18	Sequence 18, Appl
44	26	100.0	10	4	US-09-724-551-19	Sequence 19, Appl
45	26	100.0	10	4	US-09-724-551-20	Sequence 20, Appl
46	26	100.0	10	4	US-09-724-551-21	Sequence 21, Appl
47	26	100.0	11	4	US-08-766-596A-68	Sequence 68, Appl
48	26	100.0	15	2	US-08-612-785B-4	Sequence 4, Appli
49	26	100.0	15	2	US-08-612-785B-37	Sequence 37, Appli
50	26	100.0	15	3	US-08-617-287C-4	Sequence 4, Appli
51	26	100.0	15	4	US-08-766-596A-55	Sequence 55, Appl
52	26	100.0	15	4	US-08-766-596A-60	Sequence 60, Appl
53	26	100.0	15	4	US-08-766-596A-61	Sequence 61, Appl
54	26	100.0	15	4	US-08-766-596A-62	Sequence 62, Appl
55	26	100.0	15	4	US-08-766-596A-63	Sequence 63, Appl
56	26	100.0	15	4	US-08-766-596A-65	Sequence 65, Appl
57	26	100.0	16	1	US-08-303-808-10	Sequence 10, Appl
58	26	100.0	16	2	US-08-659-984A-20	Sequence 20, Appl
59	26	100.0	16	2	US-08-986-948-10	Sequence 10, Appl
60	26	100.0	16	3	US-08-660-531-20	Sequence 20, Appl
61	26	100.0	17	3	US-09-102-451-2	Sequence 2, Appli
62	26	100.0	17	3	US-09-264-709A-2	Sequence 2, Appli
63	26	100.0	17	4	US-09-594-366-2	Sequence 3, Appli
64	26	100.0	17	4	US-09-594-366-3	Sequence 3, Appli
65	26	100.0	21	2	US-08-659-984A-18	Sequence 18, Appl

NAME: Lori Y. Beardell  
REGISTRATION NUMBER: 34,293  
REFERENCE/DOCKET NUMBER: BYLR-0031  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (215) 568-3100  
TELEFAX: (215) 568-3439  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 4 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-717-551A-1

Query Match 100.0%; Score 26; DB 3; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

## RESULT 2

US-09-095-106A-28  
Sequence 28, Application US/09095106A  
Patent No. 6331440

## GENERAL INFORMATION:

APPLICANT: NORDSTEDT, Christer  
APPLICANT: NASLUND, Jan  
APPLICANT: THYBERG, Johan  
APPLICANT: TJERNBERG, Lars O.  
APPLICANT: TERENIUS, Lars  
TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
FILE REFERENCE: 000500-124  
CURRENT APPLICATION NUMBER: US/09/095,106A  
CURRENT FILING DATE: 1998-06-10  
PRIOR APPLICATION NUMBER: US 60/009,386  
PRIOR FILING DATE: 1995-12-29  
PRIOR APPLICATION NUMBER: PCT/SE96/01621  
PRIOR FILING DATE: 1996-12-09  
SOFTWARE: PatentIn Ver. 2.0  
NUMBER OF SEQ ID NOS: 44  
SEQ ID NO 28  
LENGTH: 4  
TYPE: PPT  
ORGANISM: Amyloidosis  
US-09-095-106A-28

Query Match 100.0%; Score 26; DB 3; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

## RESULT 3

US-08-922-930-1  
Sequence 1, Application US/08922930  
Patent No. 6451544

## GENERAL INFORMATION:

APPLICANT: Dana Giulian  
TITLE OF INVENTION: Identification of Agents that Protect  
TITLE OF INVENTION: Against Inflammatory Injury to Neurons  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
ADDRESSEE: & No. 6451544ris LLP  
STREET: One Liberty Place - 46th Floor  
CITY: Philadelphia  
STATE: PA

COUNTRY: USA  
ZIP: 19103  
COMPUTER READABLE FORM:  
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE  
COMPUTER: IBM PS/2  
OPERATING SYSTEM: PC-DOS  
SOFTWARE: WORDPERFECT for WINDOWS 6.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/922,930  
FILING DATE: Sept-03-97  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Lori Y. Beardell  
REGISTRATION NUMBER: 34,293  
REFERENCE/DOCKET NUMBER: BYLR-0039  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (215) 568-3100  
TELEFAX: (215) 568-3439  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 4 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-922-930-1

Query Match 100.0%; Score 26; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

## RESULT 4

US-08-923-055-1  
Sequence 1, Application US/08923055  
Patent No. 6475742

## GENERAL INFORMATION:

APPLICANT: Dana Giulian  
TITLE OF INVENTION: Identification of Agents that Protect  
TITLE OF INVENTION: Against Inflammatory Injury to Neurons  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
ADDRESSEE: & No. 6475742ris LLP  
STREET: One Liberty Place - 46th Floor  
CITY: Philadelphia  
STATE: PA  
COUNTRY: USA  
ZIP: 19103

COMPUTER READABLE FORM:  
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE  
COMPUTER: IBM PS/2  
OPERATING SYSTEM: PC-DOS  
SOFTWARE: WORDPERFECT for WINDOWS 6.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/923,055  
FILING DATE: Sept-03-97  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Lori Y. Beardell  
REGISTRATION NUMBER: 34,293  
REFERENCE/DOCKET NUMBER: BYLR-0038  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (215) 568-3100

; TELEFAX: (215) 568-3439  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-923-055-1

Query Match 100.0%; Score 26; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 5  
US-08-922-989-1  
; Sequence 1, Application US/08922889  
; Patent No. 6475745  
; GENERAL INFORMATION:  
; APPLICANT: Dora Giulian  
; TITLE OF INVENTION: Identification of Agents that Protect  
; TITLE OF INVENTION: Against Inflammatory Injury to Neurons  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
; ADDRESSEE: & No. 6475745rib LLP  
; STREET: One Liberty Place - 46th Floor  
; CITY: Philadelphia  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19103

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: PC-DOS

; SOFTWARE: WORDPERFECT FOR WINDOWS 6.0

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/922,889

; FILING DATE: Sept-03-97

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Lori Y. Beardell

; REGISTRATION NUMBER: 34,293

; REFERENCE/DOCKET NUMBER: BYLR-0040

; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (215) 568-3100

; TELEFAX: (215) 568-3439

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 4 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-922-889-1

Query Match 100.0%; Score 26; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 6  
US-09-747-408-23

; Sequence 23, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FASTSEQ for Windows Version 4.0  
; SEQ ID NO: 23  
; LENGTH: 4  
; TYPE: PPT  
; ORGANISM: Homo sapiens  
US-09-747-408-23

Query Match 100.0%; Score 26; DB 4; Length 4;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 7

US-09-095-106A-21

; Sequence 21, Application US/09095106A

; Patent No. 6331440

; GENERAL INFORMATION:

; APPLICANT: NORSTEDT, Christer

; APPLICANT: NASLUND, Johan

; APPLICANT: THYBERG, Johan

; APPLICANT: TJERNBERG, Lars O.

; APPLICANT: TERNIUS, Lars

; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA

; FILE REFERENCE: 000500-124

; CURRENT APPLICATION NUMBER: US/09/095,106A

; CURRENT FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: US 60/009,386

; PRIOR FILING DATE: 1995-12-29

; PRIOR APPLICATION NUMBER: PCT/SE96/01621

; PRIOR FILING DATE: 1996-12-09

; NUMBER OF SEQ ID NOS: 44

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 21

; LENGTH: 5

; TYPE: PPT

; ORGANISM: Amyloidosis

US-09-095-106A-21

Query Match 100.0%; Score 26; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 8

US-09-095-106A-22

; Sequence 22, Application US/09095106A

; Patent No. 6331440

; GENERAL INFORMATION:

; APPLICANT: NORSTEDT, Christer

; APPLICANT: NASLUND, Johan

; APPLICANT: THYBERG, Johan

; APPLICANT: TJERNBERG, Lars O.

;; APPLICANT: TERNIUS, Lars  
;; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
;; FILE REFERENCE: 000500-124  
;; CURRENT APPLICATION NUMBER: US/09/095,106A  
;; CURRENT FILING DATE: 1998-06-10  
;; PRIOR APPLICATION NUMBER: US 60/009,386  
;; PRIOR FILING DATE: 1995-12-29  
;; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
;; PRIOR FILING DATE: 1996-12-09  
;; NUMBER OF SEQ ID NOS: 44  
;; SOFTWARE: PatentIn Ver. 2.0  
;; SEQ ID NO 22  
;; LENGTH: 5  
;; TYPE: PRT  
;; ORGANISM: Amyloidosis  
US-09-095-106A-22

Query Match 100.0%; Score 26; DB 3; Length 5;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 2 HHQK 5

RESULT 9  
US-08-461-216-3  
; Sequence 3, Application US/08461216  
; Patent No. 5958883  
; GENERAL INFORMATION:  
; APPLICANT: SNOW, A.D.  
; TITLE OF INVENTION: ANIMAL MODELS OF HUMAN AMYLOIDOSES  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Christensen, O'Connor, Johnson and Kindness  
; STREET: 1420 Fifth Avenue, Suite 2800  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: USA  
; ZIP: 98101-2347  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette-5.25 inch, 1.2Mb storage  
; COMPUTER: IBM PC/386 Compatible  
; OPERATING SYSTEM: MS-DOS 4.01  
; SOFTWARE: Word for Windows-t  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/461,216  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: October 23, 1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: September 23, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Broderick, Thomas F.  
; REGISTRATION NUMBER: 31,332  
; REFERENCE/DOCKET NUMBER: UOFW-1-6707  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 1-206-682-8100; 1-206-224-0709 (direct)  
; TELEFAX: 1-206-224-0779  
; TELEX: 4938023  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; DESCRIPTION: {SYMBOL 98 \f "Symbol"}A4(12-17);  
; DESCRIPTION: page 60, line 4-5; page 83, line 33 and 27-28  
US-08-461-216-3

Query Match 100.0%; Score 26; DB 2; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 2 HHQK 5

RESULT 10  
US-09-095-106A-16  
; Sequence 16, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 16  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-16

Query Match 100.0%; Score 26; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 11  
US-09-095-106A-17  
; Sequence 17, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 17  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-17

Query Match 100.0%; Score 26; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
Db 2 HHQK 5

RESULT 12  
US-09-095-106A-18  
; Sequence 18, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERENIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 18  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-18

Query Match 100.0%; Score 26; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
Db 3 HHQK 6

RESULT 13  
US-08-723-661B-3  
; Sequence 3, Application US/08723661B.  
; Patent No. 6340783  
; GENERAL INFORMATION:  
; APPLICANT: Alan D Snow  
; TITLE OF INVENTION: Animal Models of Human Amyloidosis  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrick M. Dwyer  
; STREET: 1818 Westlake Avenue N, Suite 114  
; City: Seattle  
; STATE: WA (Washington)  
; COUNTRY: United States of America  
; ZIP: 98109  
; MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage  
; COMPUTER: IBM PC  
; OPERATING SYSTEM: PC-DOS (Windows 98)  
; SOFTWARE: WordPerfect 5.2  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/723,661B  
; FILING DATE: 31-Oct-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/461,216  
; FILING DATE: 05-Jun-1995  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: 23-Oct-1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: 23-Sep-1992  
; ATTORNEY/AGENT INFORMATION:

NAME: Dwyer, Patrick M.  
REGISTRATION NUMBER: 32,411  
REFERENCE/DOCKET NUMBER: PROTEO.P00C1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 343-7074  
TELEFAX: (206) 343-7085  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 AMINO ACIDS  
TYPE: AMINO ACID  
STRANDEDNESS: SINGLE  
TOPOLOGY: LINEAR  
MOLECULE TYPE: PEPTIDE  
DESCRIPTION: /A4 (12-17); page 60, lines 4-5; page 83,  
SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
US-08-723-661B-3

Query Match 100.0%; Score 26; DB 3; Length 6;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
Db 2 HHQK 5

RESULT 14  
US-08-397-633A-105  
; Sequence 105, Application US/08397633A  
; Patent No. 5773577  
; GENERAL INFORMATION:  
; APPLICANT: Cappello, Joseph  
; TITLE OF INVENTION: PRODUCTS COMPRISING SUBSTRATESCAPABLE  
; OF ENZYMIC CROSS-LINKING  
; NUMBER OF SEQUENCES: 105  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: FLHR, HOHBACH, TEST, ALBRITTON & HERBERT  
; STREET: 4 Embarcadero Center, Suite 3400  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-4187  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC Compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/397,633A  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Rowland, Bertram I  
; REGISTRATION NUMBER: 20,015  
; REFERENCE/DOCKET NUMBER: A-58848-1/BIR PROP-011-1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 781-1989  
; TELEFAX: (415) 398-3249  
; TELEX: 910 277299  
; INFORMATION FOR SEQ ID NO: 105:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-397-633A-105

Query Match 100.0%; Score 26; DB 1; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4

Db 2 HHQK 5  
||||

## RESULT 15

US-09-095-106A-12  
; Sequence 12, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095.106A  
; PRIOR FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 12  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-12

Query Match 100.0%; Score 26; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 1 HHQK 4

## RESULT 16

US-09-095-106A-13  
; Sequence 13, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095.106A  
; PRIOR FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 13  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-13

Query Match 100.0%; Score 26; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 2 HHQK 5

## RESULT 17

US-09-095-106A-14  
; Sequence 14, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095.106A  
; PRIOR FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 14  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-14

Query Match 100.0%; Score 26; DB 3; Length 7;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 3 HHQK 6

## RESULT 18

US-09-095-106A-8  
; Sequence 8, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERNIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095.106A  
; PRIOR FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 8  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-8

Query Match 100.0%; Score 26; DB 3; Length 8;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 1 HHQK 4

## RESULT 19

US-09-095-106A-9

; Sequence 9, Application US/09095106A  
 ; Patent No. 6331440  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NORDSTEDT, Christer  
 ; APPLICANT: NASLUND, Jan  
 ; APPLICANT: THYBERG, Johan  
 ; APPLICANT: TJERNBERG, Lars O.  
 ; APPLICANT: TERENIUS, Lars  
 ; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
 ; FILE REFERENCE: 000500-124  
 ; CURRENT APPLICATION NUMBER: US/09/095,106A  
 ; CURRENT FILING DATE: 1998-06-10  
 ; PRIOR APPLICATION NUMBER: US 60/009,386  
 ; PRIOR FILING DATE: 1995-12-29  
 ; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
 ; PRIOR FILING DATE: 1996-12-09  
 ; NUMBER OF SEQ ID NOS: 44  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 9  
 ; LENGTH: 8  
 ; TYPE: PRT  
 ; ORGANISM: Amyloidosis  
 US-09-095-106A-9

Query Match 100.0%; Score 26; DB 3; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
 ||||  
 Db 2 HHQK 5

## RESULT 20

US-09-095-106A-10  
 ; Sequence 10, Application US/09095106A  
 ; Patent No. 6331440  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NORDSTEDT, Christer  
 ; APPLICANT: NASLUND, Jan  
 ; APPLICANT: THYBERG, Johan  
 ; APPLICANT: TJERNBERG, Lars O.  
 ; APPLICANT: TERENIUS, Lars  
 ; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
 ; FILE REFERENCE: 000500-124  
 ; CURRENT APPLICATION NUMBER: US/09/095,106A  
 ; CURRENT FILING DATE: 1998-06-10  
 ; PRIOR APPLICATION NUMBER: US 60/009,386  
 ; PRIOR FILING DATE: 1995-12-29  
 ; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
 ; PRIOR FILING DATE: 1996-12-09  
 ; NUMBER OF SEQ ID NOS: 44  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 10  
 ; LENGTH: 8  
 ; TYPE: PRT  
 ; ORGANISM: Amyloidosis  
 US-09-095-106A-10

Query Match 100.0%; Score 26; DB 3; Length 8;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
 ||||  
 Db 3 HHQK 6

## RESULT 21

US-09-264-709A-4  
 ; Sequence 4, Application US/09264709A  
 ; Patent No. 6320024  
 ; GENERAL INFORMATION:

; APPLICANT: Roberts, Eugene  
 ; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
 ; FILE REFERENCE: 2124-310  
 ; CURRENT APPLICATION NUMBER: US/09/264,709A  
 ; CURRENT FILING DATE: 1999-03-09  
 ; PRIOR APPLICATION NUMBER: 08/797,782  
 ; PRIOR FILING DATE: 1997-02-07  
 ; NUMBER OF SEQ ID NOS: 39  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 4  
 ; LENGTH: 9  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-09-264-709A-4

Query Match 100.0%; Score 26; DB 3; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
 ||||  
 Db 2 HHQK 5

## RESULT 22

US-09-095-106A-6  
 ; Sequence 6, Application US/09095106A  
 ; Patent No. 6331440  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NORDSTEDT, Christer  
 ; APPLICANT: NASLUND, Jan  
 ; APPLICANT: THYBERG, Johan  
 ; APPLICANT: TJERNBERG, Lars O.  
 ; APPLICANT: TERENIUS, Lars  
 ; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
 ; FILE REFERENCE: 000500-124  
 ; CURRENT APPLICATION NUMBER: US/09/095,106A  
 ; CURRENT FILING DATE: 1998-06-10  
 ; PRIOR APPLICATION NUMBER: US 60/009,386  
 ; PRIOR FILING DATE: 1995-12-29  
 ; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
 ; PRIOR FILING DATE: 1996-12-09  
 ; NUMBER OF SEQ ID NOS: 44  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 6  
 ; LENGTH: 9  
 ; TYPE: PRT  
 ; ORGANISM: Amyloidosis  
 US-09-095-106A-6

Query Match 100.0%; Score 26; DB 3; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
 ||||  
 Db 2 HHQK 5

## RESULT 23

US-09-095-106A-7  
 ; Sequence 7, Application US/09095106A  
 ; Patent No. 6331440  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NORDSTEDT, Christer  
 ; APPLICANT: NASLUND, Jan  
 ; APPLICANT: THYBERG, Johan  
 ; APPLICANT: TJERNBERG, Lars O.  
 ; APPLICANT: TERENIUS, Lars  
 ; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
 ; FILE REFERENCE: 000500-124  
 ; CURRENT APPLICATION NUMBER: US/09/095,106A

; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 7  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-7

Query Match 100.0%; Score 26; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 3 HHQK 6

RESULT 24  
US-09-747-408-20  
; Sequence 20, Application US/09747408  
; Patent No. 6670399  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 20  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-20

Query Match 100.0%; Score 26; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 4.1e+05;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 1 HHQK 4

RESULT 25  
US-09-095-106A-2  
; Sequence 2, Application US/09095106A  
; Patent No. 6331440  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TERENIUS, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 000500-124  
; CURRENT APPLICATION NUMBER: US/09/095,106A  
; CURRENT FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 2  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Amyloidosis  
US-09-095-106A-2

Query Match 100.0%; Score 26; DB 3; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 3 HHQK 6

RESULT 26  
US-09-724-961-15  
; Sequence 15, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 15  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from ANI792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-15

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
Db 7 HHQK 10

RESULT 27  
US-09-724-961-16  
; Sequence 16, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961



;; CURRENT FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: US 09/580,015  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: US 09/322,289  
;; PRIOR FILING DATE: 1999-05-28  
;; PRIOR APPLICATION NUMBER: US 09/201,430  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: US 60/080,970  
;; PRIOR FILING DATE: 1998-04-07  
;; PRIOR APPLICATION NUMBER: US 60/067,740  
;; PRIOR FILING DATE: 1997-12-02  
;; NUMBER OF SEQ ID NOS: 77  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 16  
;; LENGTH: 10  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
;; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
;; OTHER INFORMATION: peptide)  
US-09-724-961-16

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 6 HHQK 9

RESULT 28  
US-09-724-961-17  
;; Sequence 17, Application US/09724961  
;; Patent No. 6743427  
;; GENERAL INFORMATION:  
;; APPLICANT: Schenk, Dale B.  
;; APPLICANT: Bard, Frederique  
;; APPLICANT: Vasquez, Nicki  
;; APPLICANT: Vednock, Ted  
;; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
;; FILE REFERENCE: 15270J-004750UC  
;; CURRENT APPLICATION NUMBER: US/09/724,961  
;; CURRENT FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: US 09/580,015  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: US 09/322,289  
;; PRIOR FILING DATE: 1999-05-28  
;; PRIOR APPLICATION NUMBER: US 09/201,430  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: US 60/080,970  
;; PRIOR FILING DATE: 1998-04-07  
;; PRIOR APPLICATION NUMBER: US 60/067,740  
;; PRIOR FILING DATE: 1997-12-02  
;; NUMBER OF SEQ ID NOS: 77  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 17  
;; LENGTH: 10  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
;; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
;; OTHER INFORMATION: peptide)  
US-09-724-961-17

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 HHQK 4  
|||  
Db 5 HHQK 8

RESULT 29  
US-09-724-961-18  
;; Sequence 18, Application US/09724961  
;; Patent No. 6743427  
;; GENERAL INFORMATION:  
;; APPLICANT: Schenk, Dale B.  
;; APPLICANT: Bard, Frederique  
;; APPLICANT: Vasquez, Nicki  
;; APPLICANT: Vednock, Ted  
;; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
;; FILE REFERENCE: 15270J-004750UC  
;; CURRENT APPLICATION NUMBER: US/09/724,961  
;; CURRENT FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: US 09/580,015  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: US 09/322,289  
;; PRIOR FILING DATE: 1999-05-28  
;; PRIOR APPLICATION NUMBER: US 09/201,430  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: US 60/080,970  
;; PRIOR FILING DATE: 1998-04-07  
;; PRIOR APPLICATION NUMBER: US 60/067,740  
;; PRIOR FILING DATE: 1997-12-02  
;; NUMBER OF SEQ ID NOS: 77  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 18  
;; LENGTH: 10  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
;; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
;; OTHER INFORMATION: peptide)  
US-09-724-961-18

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 4 HHQK 7

RESULT 30  
US-09-724-961-19  
;; Sequence 19, Application US/09724961  
;; Patent No. 6743427  
;; GENERAL INFORMATION:  
;; APPLICANT: Schenk, Dale B.  
;; APPLICANT: Bard, Frederique  
;; APPLICANT: Vasquez, Nicki  
;; APPLICANT: Vednock, Ted  
;; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
;; FILE REFERENCE: 15270J-004750UC  
;; CURRENT APPLICATION NUMBER: US/09/724,961  
;; CURRENT FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: US 09/580,015  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: US 09/322,289  
;; PRIOR FILING DATE: 1999-05-28  
;; PRIOR APPLICATION NUMBER: US 09/201,430  
;; PRIOR FILING DATE: 1998-11-30  
;; PRIOR APPLICATION NUMBER: WO PCT/US00/14810

; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 19  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-19

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 3 HHQK 6

RESULT 31  
US-09-724-961-20  
; Sequence 20, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-20

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 2 HHQK 5

RESULT 32

US-09-724-961-21  
; Sequence 21, Application US/09724961  
; Patent No. 6743427  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/09/724,961  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US 09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-961-21

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 1 HHQK 4

RESULT 33  
US-09-580-018-15  
; Sequence 15, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 15  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-15

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 7 HHQK 10

RESULT 34  
US-09-580-018-16  
; Sequence 16, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 16  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-16

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 6 HHQK 9

RESULT 35  
US-09-580-018-17  
; Sequence 17, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 17  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-17

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4

Db ||||  
5 HHQK 8

RESULT 36  
US-09-580-018-18  
; Sequence 18, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 18  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-18

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 4 HHQK 7

RESULT 37  
US-09-580-018-19  
; Sequence 19, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; CURRENT FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 19  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-19

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
||||  
Db 3 HHQK 6

RESULT 38  
US-09-580-018-20  
; Sequence 20, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-20

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 2 HHQK 5

RESULT 39  
US-09-580-018-21  
; Sequence 21, Application US/09580018  
; Patent No. 6761888  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-580-018-21

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 1 HHQK 4

RESULT 40  
US-09-724-551-15

; Sequence 15, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 15  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-15

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 7 HHQK 10

RESULT 41  
US-09-724-551-16  
; Sequence 16, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 16  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-16

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HHQK 4  
|||  
Db 6 HHQK 9

RESULT 42

US-09-724-551-17  
; Sequence 17, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 17  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-17

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 5 HHQK 8

RESULT 43  
US-09-724-551-18  
; Sequence 18, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 18  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-18

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 4 HHQK 7

RESULT 44  
US-09-724-551-19  
; Sequence 19, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 19  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-19

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 3 HHQK 6

RESULT 45  
US-09-724-551-20  
; Sequence 20, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-20

Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
|||  
DB 2 HHQK 5

RESULT 46  
US-09-724-551-21  
; Sequence 21, Application US/09724551  
; Patent No. 6787637  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Yednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 152703-004760US  
; CURRENT APPLICATION NUMBER: US/09/724,551  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AML192 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-724-551-21  
  
Query Match 100.0%; Score 26; DB 4; Length 10;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 HHQK 4  
DB 1 HHQK 4  
  
RESULT 47  
US-08-766-596A-68  
; Sequence 68, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995

; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 68:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-68  
  
Query Match 100.0%; Score 26; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 27;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 HHQK 4  
DB 4 HHQK 7  
  
RESULT 48  
US-08-612-785B-4  
; Sequence 4, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785B-4

Query Match 100.0%; Score 26; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
DB 8 HHQK 11

## RESULT 49

US-08-612-785B-37  
; Sequence 37, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 37:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-612-785B-37

Query Match 100.0%; Score 26; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
DB 3 HHQK 6

## RESULT 50

US-08-617-267C-4  
; Sequence 4, Application US/08617267C  
; Patent No. 6319498

; GENERAL INFORMATION:  
; APPLICANT: Findels, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-617-267C-4

Query Match 100.0%; Score 26; DB 3; Length 15;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HHQK 4  
DB 8 HHQK 11

Search completed: March 9, 2005, 06:43:05  
Job time : 10.6849 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:14:45 ; Search time 8.30137 Seconds  
(without alignments)  
34.070 Million cell updates/sec

Title: US-10-009-122-1  
Perfect score: 29  
Sequence: 1 KIVFFA 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 189387 seqs, 47137929 residues

Total number of hits satisfying chosen parameters: 189387

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Pending Patents\_AA\_New:\*  
1: /cgn2\_6/prodata/1/paa/PCT\_NEW\_COMB.pep.\*  
2: /cgn2\_6/prodata/1/paa/US06\_NEW\_COMB.pep.\*  
3: /cgn2\_6/prodata/1/paa/US07\_NEW\_COMB.pep.\*  
4: /cgn2\_6/prodata/1/paa/US08\_NEW\_COMB.pep.\*  
5: /cgn2\_6/prodata/1/paa/US09\_NEW\_COMB.pep.\*  
6: /cgn2\_6/prodata/1/paa/US10\_NEW\_COMB.pep.\*  
7: /cgn2\_6/prodata/1/paa/US11\_NEW\_COMB.pep.\*  
8: /cgn2\_6/prodata/1/paa/US60\_NEW\_COMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	6 US-10-705-028-1	Sequence 1, Appl
2	29	100.0	6	6 US-10-705-028-10	Sequence 10, Appl
3	29	100.0	99	6 US-10-450-763-56957	Sequence 56957, A
4	28	96.6	6	6 US-10-705-028-9	Sequence 9, Appl
5	28	96.6	6	6 US-10-705-028-17	Sequence 17, Appl
6	28	96.6	416	7 US-11-042-922-14	Sequence 14, Appl
7	28	96.6	514	7 US-11-042-922-13	Sequence 13, Appl
8	28	96.6	1144	6 US-10-937-758A-101	Sequence 101, App
9	27	93.1	6	6 US-10-705-028-3	Sequence 3, Appl
10	27	93.1	6	6 US-10-705-028-11	Sequence 11, Appl
11	27	93.1	7	6 US-10-705-028-2	Sequence 2, Appl
12	27	93.1	7	6 US-10-705-028-18	Sequence 18, Appl
13	27	93.1	7	6 US-10-705-028-19	Sequence 19, Appl
14	27	93.1	8	1 PCT-US04-44093-51	Sequence 51, Appl
15	27	93.1	8	1 PCT-US04-44093-54	Sequence 54, Appl
16	27	93.1	9	1 PCT-US04-44093-45	Sequence 45, Appl
17	27	93.1	9	1 PCT-US04-44093-48	Sequence 48, Appl
18	27	93.1	9	6 US-10-705-028-20	Sequence 20, Appl
19	27	93.1	10	5 US-09-979-701-20	Sequence 20, Appl
20	27	93.1	10	5 US-09-979-701-21	Sequence 21, Appl
21	27	93.1	10	5 US-09-979-701-22	Sequence 22, Appl
22	27	93.1	10	5 US-09-979-701-23	Sequence 23, Appl
23	27	93.1	10	5 US-09-979-701-24	Sequence 24, Appl
24	27	93.1	10	7 US-11-058-757-20	Sequence 20, Appl
25	27	93.1	10	7 US-11-058-757-21	Sequence 21, Appl

26	27	93.1	10	7	US-11-058-757-22	Sequence 22, Appl
27	27	93.1	10	7	US-11-058-757-23	Sequence 23, Appl
28	27	93.1	10	7	US-11-058-757-24	Sequence 24, Appl
29	27	93.1	19	5	US-09-979-701-75	Sequence 75, Appl
30	27	93.1	19	7	US-11-058-757-75	Sequence 75, Appl
31	27	93.1	20	5	US-09-908-943B-25	Sequence 25, Appl
32	27	93.1	28	6	US-10-250-581A-20	Sequence 20, Appl
33	27	93.1	42	1	PCT-US04-44093-21	Sequence 21, Appl
34	27	93.1	42	1	PCT-US04-44093-42	Sequence 42, Appl
35	27	93.1	42	5	US-09-979-701-42	Sequence 42, Appl
36	27	93.1	42	6	US-10-903-279-1	Sequence 1, Appl
37	27	93.1	42	7	US-11-021-951-130	Sequence 190, App
38	27	93.1	42	7	US-11-058-757-42	Sequence 42, Appl
39	27	93.1	42	8	US-60-647-493-7	Sequence 7, Appl
40	27	93.1	43	6	US-10-250-581A-1	Sequence 1, Appl
41	27	93.1	93	6	US-10-450-763-49442	Sequence 49442, A
42	27	93.1	123	7	US-11-031-175-13513	Sequence 13513, A
43	27	93.1	695	8	US-60-647-493-3	Sequence 3, Appl
44	27	93.1	695	8	US-60-651-509-336	Sequence 336, App
45	27	93.1	695	8	US-60-651-509-340	Sequence 340, App
46	27	93.1	751	8	US-60-651-509-332	Sequence 332, App
47	27	93.1	751	8	US-60-651-509-339	Sequence 339, App
48	27	93.1	770	6	US-10-287-436A-471	Sequence 471, App
49	27	93.1	770	6	US-10-287-436A-1168	Sequence 1168, App
50	27	93.1	770	6	US-10-903-279-2	Sequence 2, Appl
51	27	93.1	770	8	US-60-651-509-333	Sequence 333, App
52	27	93.1	770	8	US-60-651-509-334	Sequence 334, App
53	27	93.1	770	8	US-60-651-509-341	Sequence 341, App
54	27	93.1	772	6	US-10-450-763-49445	Sequence 49445, A
55	27	93.1	777	6	US-10-450-763-49448	Sequence 49448, A
56	26	89.7	352	8	US-60-643-717-17472	Sequence 17472, A
57	26	89.7	356	8	US-60-643-717-3819	Sequence 3819, App
58	26	89.7	360	8	US-60-643-717-2133	Sequence 2133, App
59	26	89.7	366	8	US-60-643-717-5408	Sequence 5408, App
60	26	89.7	368	8	US-60-643-717-15881	Sequence 15881, A
61	25	86.2	6	6	US-10-705-028-4	Sequence 4, Appl
62	25	86.2	6	6	US-10-705-028-12	Sequence 12, Appl
63	25	86.2	126	7	US-11-031-175-12962	Sequence 12962, A
64	25	86.2	269	6	US-10-467-657-330	Sequence 330, App
65	25	86.2	466	7	US-11-027-399-3345	Sequence 3345, App

ALIGNMENTS

RESULT 1  
US-10-705-028-1  
; Sequence 1, Application US/10705028  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088CN  
; CURRENT APPLICATION NUMBER: US/10705,028  
; CURRENT FILING DATE: 2003-11-11  
; PRIOR APPLICATION NUMBER: 09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ IDS NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 1  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-705-028-1

Query Match 100.0%; Score 29; DB 6; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.7e+05;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6

```
Db      1 KIVFFA 6
|||||
Query Match      100.0%; Score 29; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 2
US-10-705-028-10
; Sequence 10, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-10

Query Match      100.0%; Score 29; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      1 KIVFFA 6
|||||
Query Match      100.0%; Score 29; DB 6; Length 99;
Best Local Similarity 100.0%; Pred. No. 2.4;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-450-763-56957
; Sequence 56957, Application US/10450763
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 56957
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: DOMAIN
; LOCATION: (13)..(62)
; OTHER INFORMATION: kw TRANSCRIPTASE REVERSE II ORF2 domain identified by
; OTHER INFORMATION: eMATRIX, accession number DM01354Z, p-value=2.452e-13, raw score
; OTHER INFORMATION: 9.06
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(99)
; OTHER INFORMATION: xaa = X or * as defined in Table 2
US-10-450-763-56957
```

```
QY      1 KIVFFA 6
|||||
Db      63 KIVFFA 68
|||||

RESULT 4
US-10-705-028-9
; Sequence 9, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-9

Query Match      96.6%; Score 28; DB 6; Length 6;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
|||||
Db      1 KIVFFA 6
|||||

RESULT 5
US-10-705-028-17
; Sequence 17, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-17

Query Match      96.6%; Score 28; DB 6; Length 6;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KIVFFA 6
|||||
Db      1 KIVFFA 6
|||||

RESULT 6
US-11-042-922-14
; Sequence 14, Application US/11042922
; GENERAL INFORMATION:
```

; APPLICANT: Fisher, Paul B.  
; APPLICANT: Kang, Dong-Chul  
; APPLICANT: Gopalakrishnan, Rahul V.  
; TITLE OF INVENTION: USE OF MDA-5 AS AN ANTIVIRAL AND  
; TITLE OF INVENTION: ANTIPROLIFERATIVE AGENT  
; FILE REFERENCE: A34614-A-PCT-USA-A-A (070050.2689)  
; CURRENT APPLICATION NUMBER: US/11/042,922  
; CURRENT FILING DATE: 2005-01-24  
; PRIOR APPLICATION NUMBER: 10/055,475  
; PRIOR FILING DATE: 2002-01-22  
; PRIOR APPLICATION NUMBER: PCT/US01/06960  
; PRIOR FILING DATE: 2001-02-28  
; PRIOR APPLICATION NUMBER: 09/515,363  
; PRIOR FILING DATE: 2000-02-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 14  
; LENGTH: 416  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-11-042-922-14

Query Match 96.6%; Score 28; DB 7; Length 416;  
Best Local Similarity 83.3%; Pred. No. 19;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 57 KVVFFA 62

RESULT 7  
US-11-042-922-13  
; Sequence 13, Application US/11042922  
; GENERAL INFORMATION:  
; APPLICANT: Fisher, Paul B.  
; APPLICANT: Kang, Dong-Chul  
; APPLICANT: Gopalakrishnan, Rahul V.  
; TITLE OF INVENTION: USE OF MDA-5 AS AN ANTIVIRAL AND  
; TITLE OF INVENTION: ANTIPROLIFERATIVE AGENT  
; FILE REFERENCE: A34614-A-PCT-USA-A-A (070050.2689)  
; CURRENT APPLICATION NUMBER: US/11/042,922  
; CURRENT FILING DATE: 2005-01-24  
; PRIOR APPLICATION NUMBER: 10/055,475  
; PRIOR FILING DATE: 2002-01-22  
; PRIOR APPLICATION NUMBER: PCT/US01/06960  
; PRIOR FILING DATE: 2001-02-28  
; PRIOR APPLICATION NUMBER: 09/515,363  
; PRIOR FILING DATE: 2000-02-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 13  
; LENGTH: 514  
; TYPE: PRT  
; ORGANISM: sus scrofa  
US-11-042-922-13

Query Match 96.6%; Score 28; DB 7; Length 514;  
Best Local Similarity 83.3%; Pred. No. 24;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 57 KVVFFA 62

RESULT 8  
US-10-937-758A-101  
; Sequence 101, Application US/10937758A  
; GENERAL INFORMATION:  
; APPLICANT: TERMAN, David S  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATMENT OF NEOPLASTIC DISEASE  
; FILE REFERENCE: FILE REFERENCE 650884

; CURRENT APPLICATION NUMBER: US/10/937,758A  
; CURRENT FILING DATE: 2004-09-08  
; PRIOR APPLICATION NUMBER: 09/650,884  
; PRIOR FILING DATE: 2000-08-30  
; NUMBER OF SEQ ID NOS: 121  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 101  
; LENGTH: 1144  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-10-937-758A-101

Query Match 96.6%; Score 28; DB 6; Length 1144;  
Best Local Similarity 83.3%; Pred. No. 57;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 514 KVVFFA 519

RESULT 9  
US-10-705-028-3  
; Sequence 3, Application US/10705028  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088CN  
; CURRENT APPLICATION NUMBER: US/10/705,028  
; CURRENT FILING DATE: 2003-11-11  
; PRIOR APPLICATION NUMBER: 09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-705-028-3

Query Match 93.1%; Score 27; DB 6; Length 6;  
Best Local Similarity 83.3%; Pred. No. 1.7e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 10  
US-10-705-028-11  
; Sequence 11, Application US/10705028  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088CN  
; CURRENT APPLICATION NUMBER: US/10/705,028  
; CURRENT FILING DATE: 2003-11-11  
; PRIOR APPLICATION NUMBER: 09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 11  
; LENGTH: 6  
; TYPE: PRT

```

; ORGANISM: Homo sapiens
US-10-705-028-11

Query Match      93.1%; Score 27; DB 6; Length 6;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
       |:|||||
Db      1 KLVFFA 6

RESULT 11
US-10-705-028-2
; Sequence 2, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-2

Query Match      93.1%; Score 27; DB 6; Length 7;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
       |:|||||
Db      2 KLVFFA 7

RESULT 12
US-10-705-028-18
; Sequence 18, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-18

Query Match      93.1%; Score 27; DB 6; Length 7;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
       |:|||||
Db      1 KLVFFA 6

RESULT 13
US-10-705-028-19
; Sequence 19, Application US/10705028
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; TITLE OF INVENTION: Compounds And Methods For Modulating
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy
; FILE REFERENCE: NBI-088CN
; CURRENT APPLICATION NUMBER: US/10/705,028
; CURRENT FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: 09/747,408
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-705-028-19

Query Match      93.1%; Score 27; DB 6; Length 7;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
       |:|||||
Db      1 KLVFFA 6

RESULT 14
PCT-US04-44093-51
; Sequence 51, Application PC/TUS0444093
; GENERAL INFORMATION:
; APPLICANT: Arumugham, Raaappa
; APPLICANT: Prasad, A. Krishna
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates
; FILE REFERENCE: 15270C-000110PC
; CURRENT APPLICATION NUMBER: PCT/US04/44093
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: US 60/530,481
; PRIOR FILING DATE: 2003-12-17
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 51
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: A-beta 16-22 + C
; NAME/KEY: misc feature
; LOCATION: (8)-(8)
; OTHER INFORMATION: CRM 197 added via terminal cysteine
PCT-US04-44093-51

Query Match      93.1%; Score 27; DB 1; Length 8;
Best Local Similarity 83.3%; Pred. No. 1.7e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
       |:|||||
Db      1 KLVFFA 6

RESULT 15
PCT-US04-44093-54
; Sequence 54, Application PC/TUS0444093
```

; GENERAL INFORMATION:  
; APPLICANT: Arumugham, Rasappa  
; APPLICANT: Prasad, A. Krishna  
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates  
; FILE REFERENCE: 15270C-000110PC  
; CURRENT APPLICATION NUMBER: PCT/US04/44093  
; CURRENT FILING DATE: 2004-12-17  
; PRIOR APPLICATION NUMBER: US 60/530,481  
; PRIOR FILING DATE: 2003-12-17  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 54  
; LENGTH: 8  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: C + A-beta 16-22 + C  
; NAME/KEY: misc.feature  
; LOCATION: (1)..(1)  
; OTHER INFORMATION: CRM 197 added via N-terminal cysteine  
PCT-US04-44093-54

Query Match 93.1%; Score 27; DB 1; Length 8;  
Best Local Similarity 83.3%; Pred. No. 1.7e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 2 KLVFFA 7

## RESULT 16

PCT-US04-44093-45  
; Sequence 45, Application PC/TUS0444093  
; GENERAL INFORMATION:  
; APPLICANT: Arumugham, Rasappa  
; APPLICANT: Prasad, A. Krishna  
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates  
; FILE REFERENCE: 15270C-000110PC  
; CURRENT APPLICATION NUMBER: PCT/US04/44093  
; CURRENT FILING DATE: 2004-12-17  
; PRIOR APPLICATION NUMBER: US 60/530,481  
; PRIOR FILING DATE: 2003-12-17  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 45  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: A-beta 16-23 + C  
PCT-US04-44093-45

Query Match 93.1%; Score 27; DB 1; Length 9;  
Best Local Similarity 83.3%; Pred. No. 1.7e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

## RESULT 17

PCT-US04-44093-48  
; Sequence 48, Application PC/TUS0444093  
; GENERAL INFORMATION:  
; APPLICANT: Arumugham, Rasappa  
; APPLICANT: Prasad, A. Krishna  
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates  
; FILE REFERENCE: 15270C-000110PC  
; CURRENT APPLICATION NUMBER: PCT/US04/44093  
; CURRENT FILING DATE: 2004-12-17

; PRIOR APPLICATION NUMBER: US 60/530,481  
; PRIOR FILING DATE: 2003-12-17  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 48  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: C + A-beta 16-23  
PCT-US04-44093-48

Query Match 93.1%; Score 27; DB 1; Length 9;  
Best Local Similarity 83.3%; Pred. No. 1.7e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 2 KLVFFA 7

## RESULT 18

US-10-705-028-20  
; Sequence 20, Application US/10705028  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088CN  
; CURRENT APPLICATION NUMBER: US/10/705,028  
; CURRENT FILING DATE: 2003-11-11  
; PRIOR APPLICATION NUMBER: 09/747,408  
; PRIOR FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 20  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-705-028-20

Query Match 93.1%; Score 27; DB 6; Length 9;  
Best Local Similarity 83.3%; Pred. No. 1.7e+05;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 4 KLVFFA 9

## RESULT 19

US-09-979-701-20  
; Sequence 20, Application US/09979701  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; APPLICANT: Neuralab Limited  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004753US  
; CURRENT APPLICATION NUMBER: US/09/979,701  
; CURRENT FILING DATE: 2002-03-13  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 2000-05-20  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20

```
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-20

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 5 KLVFFA 10

RESULT 20
US-09-979-701-21
; Sequence 21, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 2000-05-20
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/322,289
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-21

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 4 KLVFFA 9

RESULT 21
US-09-979-701-22
; Sequence 22, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 2000-05-20
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/322,289
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-22

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 4 KLVFFA 9

RESULT 22
US-09-979-701-23
; Sequence 23, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 2000-05-20
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/322,289
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-23

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 2 KLVFFA 7

RESULT 23
US-09-979-701-24
; Sequence 24, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
```

```
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-22

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 3 KLVFFA 8

RESULT 22
US-09-979-701-23
; Sequence 23, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 2000-05-20
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/322,289
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-979-701-23

Query Match          93.1%; Score 27; DB 5; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6
Db 2 KLVFFA 7

RESULT 23
US-09-979-701-24
; Sequence 24, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
```

; PRIOR FILING DATE: 2000-05-20  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-09-979-701-24

Query Match 93.1%; Score 27; DB 5; Length 10;  
Best Local Similarity 83.3%; Pred. No. 0.65;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
|:||||  
Db 1 KLVFFA 6

RESULT 24  
US-11-058-757-20  
; Sequence 20, Application US/11058757  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/11/058,757  
; CURRENT FILING DATE: 2005-02-14  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-11-058-757-20

Query Match 93.1%; Score 27; DB 7; Length 10;  
Best Local Similarity 83.3%; Pred. No. 0.65;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
|:||||  
Db 5 KLVFFA 10

RESULT 25  
US-11-058-757-21  
; Sequence 21, Application US/11058757  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/11/058,757  
; CURRENT FILING DATE: 2005-02-14  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-11-058-757-21

Query Match 93.1%; Score 27; DB 7; Length 10;  
Best Local Similarity 83.3%; Pred. No. 0.65;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
|:||||  
Db 4 KLVFFA 9

RESULT 26  
US-11-058-757-22  
; Sequence 22, Application US/11058757  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/11/058,757  
; CURRENT FILING DATE: 2005-02-14  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-11-058-757-22

Query Match 93.1%; Score 27; DB 7; Length 10;  
Best Local Similarity 83.3%; Pred. No. 0.65;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KIVFFA 6  
|:||||  
Db 3 KLVFFA 8

RESULT 27  
US-11-058-757-23  
; Sequence 23, Application US/11058757  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004760US  
; CURRENT APPLICATION NUMBER: US/11/058,757  
; CURRENT FILING DATE: 2005-02-14  
; PRIOR APPLICATION NUMBER: US/09/580,018  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289

```
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-11-058-757-23

Query Match          93.1%; Score 27; DB 7; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 28
US-11-058-757-24
; Sequence 24, Application US/11058757
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/11/058,757
; CURRENT FILING DATE: 2005-02-14
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-11-058-757-24

Query Match          93.1%; Score 27; DB 7; Length 10;
Best Local Similarity 83.3%; Pred. No. 0.65;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 29
US-09-979-701-75
; Sequence 75, Application US/09979701
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Vednock, Ted
; APPLICANT: Neuralab Limited
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004753US
; CURRENT APPLICATION NUMBER: US/09/979,701
; CURRENT FILING DATE: 2002-03-13
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 2000-05-20
```

```
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta 13-28
; OTHER INFORMATION: peptide with two Gly residues added and inserted
; OTHER INFORMATION: Cys residue
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (1)-
; OTHER INFORMATION: Xaa = N-acetyl His
US-09-979-701-75

Query Match          93.1%; Score 27; DB 5; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 30
US-11-058-757-75
; Sequence 75, Application US/11058757
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/11/058,757
; CURRENT FILING DATE: 2005-02-14
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Abeta 13-28
; OTHER INFORMATION: peptide with two Gly residues added and inserted
; OTHER INFORMATION: Cys residue
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (1)-
; OTHER INFORMATION: Xaa = N-acetyl His
US-11-058-757-75

Query Match          93.1%; Score 27; DB 7; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 31
US-09-908-943B-25
; Sequence 25, Application US/09908943B
; GENERAL INFORMATION:
; APPLICANT: Yan, Riqiang
; APPLICANT: Tomasselli, Alfredo G.
```



; APPLICANT: Gurney, Mark E.  
; APPLICANT: Emmons, Thomas L.  
; APPLICANT: Bienkowski, Mike J.  
; APPLICANT: Heinriksen, Robert L.  
; TITLE OF INVENTION: SUBSTRATES AND ASSAYS FOR BETA-SECRETASE ACTIVITY  
; FILE REFERENCE: 29915/00281A.US  
; CURRENT APPLICATION NUMBER: US/09/908,943B  
; CURRENT FILING DATE: 2001-07-19  
; PRIOR APPLICATION NUMBER: 60/219,795  
; PRIOR FILING DATE: 2000-07-19  
; NUMBER OF SEQ ID NOS: 199  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 25  
; LENGTH: 20  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
; OTHER INFORMATION: peptide sequence  
US-09-908-943B-25

Query Match 93.1%; Score 27; DB 5; Length 20;  
Best Local Similarity 83.3%; Pred. No. 1.4;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 14 KLVFFA 19

RESULT 32  
US-10-250-581A-20  
; Sequence 20, Application US/10250581A  
; GENERAL INFORMATION:  
; APPLICANT: Fraunhofer Society for Promotion of Applied...  
; TITLE OF INVENTION: Soluble cyclic analogs...  
; FILE REFERENCE: 25182  
; CURRENT APPLICATION NUMBER: US/10/250,581A  
; CURRENT FILING DATE: 2004-01-14  
; PRIOR APPLICATION NUMBER: DE 101 01 430 A1  
; PRIOR FILING DATE: 2001-01-13  
; NUMBER OF SEQ ID NOS: 21  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 20  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-250-581A-20

Query Match 93.1%; Score 27; DB 6; Length 28;  
Best Local Similarity 83.3%; Pred. No. 1.9;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 16 KLVFFA 21

RESULT 33  
PCT-US04-44093-21  
; Sequence 21, Application PC/TUS0444093  
; GENERAL INFORMATION:  
; APPLICANT: Arumugham, Rasappa  
; APPLICANT: Prasad, A. Krishna  
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates  
; FILE REFERENCE: 15270C-000110PC  
; CURRENT APPLICATION NUMBER: PCT/US04/44093  
; CURRENT FILING DATE: 2004-12-17  
; PRIOR APPLICATION NUMBER: US 60/530,481  
; PRIOR FILING DATE: 2003-12-17  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 21

; LENGTH: 42  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
PCT-US04-44093-21

Query Match 93.1%; Score 27; DB 1; Length 42;  
Best Local Similarity 83.3%; Pred. No. 3;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 16 KLVFFA 21

RESULT 34  
PCT-US04-44093-42  
; Sequence 42, Application PC/TUS0444093  
; GENERAL INFORMATION:  
; APPLICANT: Arumugham, Rasappa  
; APPLICANT: Prasad, A. Krishna  
; TITLE OF INVENTION: Methods of Producing Immunogenic A? Peptide Carrier Conjugates  
; FILE REFERENCE: 15270C-000110PC  
; CURRENT APPLICATION NUMBER: PCT/US04/44093  
; CURRENT FILING DATE: 2004-12-17  
; PRIOR APPLICATION NUMBER: US 60/530,481  
; PRIOR FILING DATE: 2003-12-17  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 42  
; LENGTH: 42  
; TYPE: PRT  
; ORGANISM: Mus musculus  
PCT-US04-44093-42

Query Match 93.1%; Score 27; DB 1; Length 42;  
Best Local Similarity 83.3%; Pred. No. 3;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 16 KLVFFA 21

RESULT 35  
US-09-979-701-42  
; Sequence 42, Application US/09979701  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; APPLICANT: Neuralab Limited  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004753US  
; CURRENT APPLICATION NUMBER: US/09/979,701  
; CURRENT FILING DATE: 2002-03-13  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 2000-05-20  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 42  
; LENGTH: 42  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: human Abeta42 beta-amyloid peptide  
US-09-979-701-42

Query Match 93.1%; Score 27; DB 5; Length 42;  
Best Local Similarity 83.3%; Pred. No. 3;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Query Match          93.1%; Score 27; DB 7; Length 42;
Best Local Similarity 83.3%; Pred. No. 3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 16 KLVFFA 21

RESULT 36
US-10-903-279-1
; Sequence 1, Application US/10903279
; GENERAL INFORMATION:
; APPLICANT: Monsonogo, Alon
; APPLICANT: Weiner, Howard
; APPLICANT: Selcoe, Dennis J.
; TITLE OF INVENTION: AMYLOID BETA-PEPTIDE AND METHODS OF USE
; FILE REFERENCE: 10286-016001
; CURRENT APPLICATION NUMBER: US/10/903,279
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/491,485
; PRIOR FILING DATE: 2003-07-30
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 42
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-903-279-1

Query Match          93.1%; Score 27; DB 6; Length 42;
Best Local Similarity 83.3%; Pred. No. 3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 16 KLVFFA 21

RESULT 37
US-11-021-951-190
; Sequence 190, Application US/11021951
; GENERAL INFORMATION:
; APPLICANT: HAUPT, Ulrich
; APPLICANT: KOLTERMANN, Andre
; APPLICANT: SCHEIDIG, Andreas
; APPLICANT: VOTSMER, Christian
; APPLICANT: Kettling, Ulrich
; APPLICANT: COCO, Wayne Michael
; TITLE OF INVENTION: New Biological Entities And The Pharmaceutical
; FILE REFERENCE: 04156.000205
; CURRENT APPLICATION NUMBER: US/11/021,951
; CURRENT FILING DATE: 2004-12-22
; PRIOR APPLICATION NUMBER: 10/872,198
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 60/543,518
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/524,960
; PRIOR FILING DATE: 2003-11-25
; PRIOR APPLICATION NUMBER: EP 04003058
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: EP 03025871
; PRIOR FILING DATE: 2003-11-11
; PRIOR APPLICATION NUMBER: EP 03025851
; PRIOR FILING DATE: 2003-11-10
; PRIOR APPLICATION NUMBER: EP 03013819
; PRIOR FILING DATE: 2003-06-18
; NUMBER OF SEQ ID NOS: 191
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 190
; LENGTH: 42
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-021-951-190

Query Match          93.1%; Score 27; DB 7; Length 42;
Best Local Similarity 83.3%; Pred. No. 3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 16 KLVFFA 21

RESULT 38
US-11-058-757-42
; Sequence 42, Application US/11058757
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/11/058,757
; CURRENT FILING DATE: 2005-02-14
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 42
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: human Abeta42 beta-amyloid peptide
US-11-058-757-42

Query Match          93.1%; Score 27; DB 7; Length 42;
Best Local Similarity 83.3%; Pred. No. 3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 16 KLVFFA 21

RESULT 39
US-60-647-493-7
; Sequence 7, Application US/60647493
; GENERAL INFORMATION:
; APPLICANT: Rubinstein, Amy
; TITLE OF INVENTION: TRANSGENIC ZEBRAFISH MODELS FOR
; FILE REFERENCE: 26007.0004U1
; CURRENT APPLICATION NUMBER: US/60/647,493
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 42
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence;/note =
; OTHER INFORMATION: Synthetic Construct
US-60-647-493-7

Query Match          93.1%; Score 27; DB 8; Length 42;
Best Local Similarity 83.3%; Pred. No. 3;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 16 KLVFFA 21
```

```
RESULT 40
US-10-250-581A-1
; Sequence 1, Application US/10250581A
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Society for Promotion of Applied...
; TITLE OF INVENTION: Soluble cyclic analogs...
; FILE REFERENCE: 25182
; CURRENT APPLICATION NUMBER: US/10/250,581A
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: DE 101 01 430 A1
; PRIOR FILING DATE: 2001-01-13
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 43
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-250-581A-1

Query Match      93.1%; Score 27; DB 6; Length 43;
Best Local Similarity 83.3%; Pred. No. 3.1;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      16 KLVFFA 21

RESULT 41
US-10-450-763-49442
; Sequence 49442, Application US/10450763
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc
; TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
; FILE REFERENCE: 790CIP3/US
; CURRENT APPLICATION NUMBER: US/10/450,763
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: PCT/US01/08631
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/540,217
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 09/649,167
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 60736
; SOFTWARE: Custom
; SEQ ID NO 49442
; LENGTH: 93
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: DOMAIN
; LOCATION: (45)..(59)
; OTHER INFORMATION: BETA-AMYLOID PEPTIDE (BETA-APP) SIGNATURE domain identified
; OTHER INFORMATION: by eMATRIX, accession number PR00204A, p-value=1.346e-19, raw score=1.346e-19
; OTHER INFORMATION: of 16.44
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(93)
; OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-49442

Query Match      93.1%; Score 27; DB 6; Length 93;
Best Local Similarity 83.3%; Pred. No. 7;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      57 KLVFFA 62

RESULT 42
US-11-031-175-13513
; Sequence 13513, Application US/11031175
```

```
; GENERAL INFORMATION:
; APPLICANT: Goldman, Barry S.
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Wiegand, Roger C.
; TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15849)B
; CURRENT APPLICATION NUMBER: US/11/031,175
; CURRENT FILING DATE: 2005-01-08
; PRIOR APPLICATION NUMBER: 60/217,883
; PRIOR FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 16825
; SEQ ID NO 13513
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Myxococcus xanthus
US-11-031-175-13513

Query Match      93.1%; Score 27; DB 7; Length 123;
Best Local Similarity 66.7%; Pred. No. 9.4;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      52 KLVFFA 57

RESULT 43
US-60-647-493-3
; Sequence 3, Application US/60647493
; GENERAL INFORMATION:
; APPLICANT: Rubinstein, Amy
; TITLE OF INVENTION: TRANSGENIC ZEBRAFISH MODELS FOR
; FILE REFERENCE: 26007.0004U1
; CURRENT APPLICATION NUMBER: US/60/647,493
; CURRENT FILING DATE: 2005-01-27
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 695
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:/note =
US-60-647-493-3

Query Match      93.1%; Score 27; DB 8; Length 695;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      612 KLVFFA 617

RESULT 44
US-60-651-509-336
; Sequence 336, Application US/60651509
; GENERAL INFORMATION:
; APPLICANT: RUBEN, Steven et al.
; TITLE OF INVENTION: BREAST DISEASE TARGETS AND USES THEREOF
; FILE REFERENCE: CL001578
; CURRENT APPLICATION NUMBER: US/60/651,509
; CURRENT FILING DATE: 2005-02-10
; NUMBER OF SEQ ID NOS: 1940
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 336
; LENGTH: 695
; TYPE: PRT
; ORGANISM: Homo sapiens
US-60-651-509-336
```

Query Match 93.1%; Score 27; DB 8; Length 695;  
Best Local Similarity 83.3%; Pred. No. 59;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 612 KLVFFA 617

RESULT 45  
US-60-651-509-340  
; Sequence 340, Application US/60651509  
; GENERAL INFORMATION:  
; APPLICANT: RUBEN, Steven et al.  
; TITLE OF INVENTION: BREAST DISEASE TARGETS AND USES THEREOF  
; FILE REFERENCE: CL001578  
; CURRENT APPLICATION NUMBER: US/60/651,509  
; CURRENT FILING DATE: 2005-02-10  
; NUMBER OF SEQ ID NOS: 1940  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 340  
; LENGTH: 695  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-60-651-509-340

Query Match 93.1%; Score 27; DB 8; Length 695;  
Best Local Similarity 83.3%; Pred. No. 59;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 612 KLVFFA 617

RESULT 46  
US-60-651-509-332  
; Sequence 332, Application US/60651509  
; GENERAL INFORMATION:  
; APPLICANT: RUBEN, Steven et al.  
; TITLE OF INVENTION: BREAST DISEASE TARGETS AND USES THEREOF  
; FILE REFERENCE: CL001578  
; CURRENT APPLICATION NUMBER: US/60/651,509  
; CURRENT FILING DATE: 2005-02-10  
; NUMBER OF SEQ ID NOS: 1940  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 332  
; LENGTH: 751  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-60-651-509-332

Query Match 93.1%; Score 27; DB 8; Length 751;  
Best Local Similarity 83.3%; Pred. No. 64;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 668 KLVFFA 673

RESULT 47  
US-60-651-509-339  
; Sequence 339, Application US/60651509  
; GENERAL INFORMATION:  
; APPLICANT: RUBEN, Steven et al.  
; TITLE OF INVENTION: BREAST DISEASE TARGETS AND USES THEREOF  
; FILE REFERENCE: CL001578  
; CURRENT APPLICATION NUMBER: US/60/651,509  
; CURRENT FILING DATE: 2005-02-10  
; NUMBER OF SEQ ID NOS: 1940  
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 339  
; LENGTH: 751  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-60-651-509-339

Query Match 93.1%; Score 27; DB 8; Length 751;  
Best Local Similarity 83.3%; Pred. No. 64;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 668 KLVFFA 673

RESULT 48  
US-10-287-436A-471  
; Sequence 471, Application US/10287436A  
; GENERAL INFORMATION:  
; APPLICANT: CHILDREN'S HOSPITAL MEDICAL CENTER  
; TITLE OF INVENTION: METHOD FOR DIAGNOSIS AND TREATMENT OF  
; TITLE OF INVENTION: RHEUMATOID ARTHRITIS  
; FILE REFERENCE: 10872.514696  
; CURRENT APPLICATION NUMBER: US/10/287,436A  
; CURRENT FILING DATE: 2002-10-31  
; PRIOR APPLICATION NUMBER: US 60/336,220  
; PRIOR FILING DATE: 2001-10-31  
; NUMBER OF SEQ ID NOS: 1446  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 471  
; LENGTH: 770  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-287-436A-471

Query Match 93.1%; Score 27; DB 6; Length 770;  
Best Local Similarity 83.3%; Pred. No. 66;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 687 KLVFFA 692

RESULT 49  
US-10-287-436A-1168  
; Sequence 1168, Application US/10287436A  
; GENERAL INFORMATION:  
; APPLICANT: CHILDREN'S HOSPITAL MEDICAL CENTER  
; TITLE OF INVENTION: METHOD FOR DIAGNOSIS AND TREATMENT OF  
; TITLE OF INVENTION: RHEUMATOID ARTHRITIS  
; FILE REFERENCE: 10872.514696  
; CURRENT APPLICATION NUMBER: US/10/287,436A  
; CURRENT FILING DATE: 2002-10-31  
; PRIOR APPLICATION NUMBER: US 60/336,220  
; PRIOR FILING DATE: 2001-10-31  
; NUMBER OF SEQ ID NOS: 1446  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 1168  
; LENGTH: 770  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-287-436A-1168

Query Match 93.1%; Score 27; DB 6; Length 770;  
Best Local Similarity 83.3%; Pred. No. 66;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KIVFFA 6  
|:||||  
Db 687 KLVFFA 692

RESULT 50  
US-10-903-279-2  
; Sequence 2, Application US/10903279  
; GENERAL INFORMATION:  
; APPLICANT: Monsonego, Alon  
; APPLICANT: Weiner, Howard  
; APPLICANT: Selkoe, Dennis J.  
; TITLE OF INVENTION: AMYLOID beta-PEPTIDE AND METHODS OF USE  
; FILE REFERENCE: 10286-016001  
; CURRENT APPLICATION NUMBER: US/10/903,279  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/491,485  
; PRIOR FILING DATE: 2003-07-30  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 770  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-903-279-2

Query Match 93.1%; Score 27; DB 6; Length 770;  
Best Local Similarity 83.3%; Pred. No. 66;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIVFFA 6  
|:||||  
Db 687 KLVFFA 692

Search completed: March 9, 2005, 07:30:19  
Job time : 9.30137 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:27:44 ; Search time 49.3151 Seconds  
(without alignments)  
40.034 Million cell updates/sec

Title: US-10-009-122-5

Perfect score: 29

Sequence: 1 AFFVLK 6

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1391452 seqs, 329044822 residues

Total number of hits satisfying chosen parameters: 1391452

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 65 summaries

Database : Published Applications AA:\*

1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/PCTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/1/pubpaa/US09A\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/1/pubpaa/US10D\_PUBCOMB.pep.\*  
17: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*  
19: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*  
20: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	6	9 US-09-867-847-14	Sequence 14, Appl
2	29	100.0	6	9 US-09-867-847-22	Sequence 22, Appl
3	29	100.0	6	9 US-09-915-092-4	Sequence 4, Appl
4	29	100.0	6	9 US-09-915-092-12	Sequence 12, Appl
5	29	100.0	6	10 US-09-747-408-5	Sequence 5, Appl
6	29	100.0	6	10 US-09-747-408-13	Sequence 13, Appl
7	29	100.0	88	17 US-10-472-928-3980	Sequence 3980, Ap
8	29	100.0	98	16 US-10-437-963-203341	Sequence 203341,
9	29	100.0	113	15 US-10-437-963-192576	Sequence 192576,
10	29	100.0	220	15 US-10-369-493-13359	Sequence 13359, A
11	28	96.6	106	15 US-10-264-049-2767	Sequence 2767, Ap
12	28	96.6	1095	15 US-10-369-493-2025	Sequence 2025, Ap
13	28	96.6	1896	15 US-10-296-734-393	Sequence 393, App

ALIGNMENTS

RESULT 1

US-09-867-847-14  
; Sequence 14, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lisa  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; PRIORITY FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29

Sequence 405, App  
Sequence 8703, Ap  
Sequence 195961,  
Sequence 192958,  
Sequence 222643,  
Sequence 160048,  
Sequence 162355,  
Sequence 283039,  
Sequence 63253, A  
Sequence 72133, A  
Sequence 17930, A  
Sequence 17429, A  
Sequence 137429,  
Sequence 3264, Ap  
Sequence 172128,  
Sequence 1207, Ap  
Sequence 1207, Ap  
Sequence 260161,  
Sequence 209666,  
Sequence 5193, Ap  
Sequence 223207,  
Sequence 53355, A  
Sequence 53434, A  
Sequence 148568,  
Sequence 156769,  
Sequence 118382,  
Sequence 195770,  
Sequence 266603,  
Sequence 256442,  
Sequence 261939,  
Sequence 175620,  
Sequence 39918, A  
Sequence 3814, Ap  
Sequence 195834,  
Sequence 234710,  
Sequence 238607,  
Sequence 264247,  
Sequence 235698,  
Sequence 231294,  
Sequence 279195,  
Sequence 18, Appl  
Sequence 123170,  
Sequence 158947,  
Sequence 161001,  
Sequence 226218,  
Sequence 152533,  
Sequence 21281,  
Sequence 152553,  
Sequence 185955,  
Sequence 51087, A  
Sequence 59186, A  
Sequence 44824, A

```

; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-09-867-847-14

Query Match      100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
   |||||
Db 1 AFFVLK 6

RESULT 2
US-09-867-847-22
; Sequence 22, Application US/09867847
; Patent No. US20020094335A1
; GENERAL INFORMATION:
; APPLICANT: Chalfour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xianqi
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; FILE REFERENCE: 14445-501 CIP
; CURRENT APPLICATION NUMBER: US/09/867,847
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
; NAME/KEY: MOD_RES
; LOCATION: (6)
; OTHER INFORMATION: AMIDATION
US-09-867-847-22

Query Match      100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
   |||||
Db 1 AFFVLK 6

RESULT 3
US-09-915-092-4
; Sequence 4, Application US/09915092
; Publication No. US20020115717A1
; GENERAL INFORMATION:
; APPLICANT: Gervais, Francine
; APPLICANT: Kong, Xianqi
; APPLICANT: Chalfour, Robert
; APPLICANT: Migneault, David
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND
; FILE REFERENCE: NEI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5

Query Match      100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
   |||||
Db 1 AFFVLK 6

RESULT 4
US-09-915-092-12
; Sequence 12, Application US/09915092
; Publication No. US20020115717A1
; GENERAL INFORMATION:
; APPLICANT: Gervais, Francine
; APPLICANT: Kong, Xianqi
; APPLICANT: Chalfour, Robert
; APPLICANT: Migneault, David
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND
; FILE REFERENCE: NEI-139
; CURRENT APPLICATION NUMBER: US/09/915,092
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/220,808
; PRIOR FILING DATE: 2000-07-25
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-092-12

Query Match      100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6
   |||||
Db 1 AFFVLK 6

RESULT 5
US-09-747-408-5
; Sequence 5, Application US/09747408
; Publication No. US20030003141A1
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NEI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5

```



; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-5

Query Match 100.0%; Score 29; DB 10; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||||  
Db 1 AFFVLK 6

## RESULT 6

US-09-747-408-13  
; Sequence 13, Application US/09747408  
; Publication No. US2003003141A1  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 13  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-13

Query Match 100.0%; Score 29; DB 10; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||||  
Db 1 AFFVLK 6

## RESULT 7

US-10-472-928-3980  
; Sequence 3980, Application US/10472928  
; Publication No. US20050020813A1  
; GENERAL INFORMATION:  
; APPLICANT: CHIRON Spa  
; TITLE OF INVENTION: THE INSTITUTE FOR GENOMIC RESEARCH  
; TITLE OF INVENTION: STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS  
; FILE REFERENCE: P026928W0  
; CURRENT APPLICATION NUMBER: US/10/472,928  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: GB-0107658.7  
; PRIOR FILING DATE: 2001-03-27  
; NUMBER OF SEQ ID NOS: 4979  
; SOFTWARE: SeqWin99, version 1.03  
; SEQ ID NO 3980  
; LENGTH: 88  
; TYPE: PRT  
; ORGANISM: Streptococcus pneumoniae  
; FEATURE:  
; OTHER INFORMATION: box element  
US-10-472-928-3980

Query Match 100.0%; Score 29; DB 17; Length 88;  
Best Local Similarity 100.0%; Pred. No. 68;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||||

Db 83 AFFVLK 88  
|||||

## RESULT 8

US-10-437-963-203341  
; Sequence 203341, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 203341  
; LENGTH: 98  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_98533C.1.pap  
US-10-437-963-203341

Query Match 100.0%; Score 29; DB 16; Length 98;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||||  
Db 90 AFFVLK 95

## RESULT 9

US-10-437-963-192576  
; Sequence 192576, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 192576  
; LENGTH: 113  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_88796C.1.pap  
US-10-437-963-192576

Query Match 100.0%; Score 29; DB 16; Length 113;  
Best Local Similarity 100.0%; Pred. No. 86;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||||

```
Db 100 AFFVLK 105
US-10-369-493-13359
RESULT 10
; Sequence 13359, Application US/10369493
; Publication No. US20030233675A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Yongwei
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Goldman, Barry S.
; APPLICANT: Chen, Xianfeng
; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF
; FILE REFERENCE: 38-10(52052)B
; CURRENT APPLICATION NUMBER: US/10/369,493
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/360,039
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 47374
; SEQ ID NO 13359
; LENGTH: 220
; TYPE: PRT
; ORGANISM: Aspergillus nidulans
; NAME/KEY: unsure
; LOCATION: (1)...(220)
; OTHER INFORMATION: unsure at all Xaa locations
US-10-369-493-13359
Query Match 100.0%; Score 29; DB 15; Length 220;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AFFVLK 6
Db 134 AFFVLK 139
US-10-264-049-2767
RESULT 11
; Sequence 2767, Application US/10264049
; Publication No. US20040005579A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA133PI
; CURRENT APPLICATION NUMBER: US/10/264,049
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/18569
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: US 60/209,467
; PRIOR FILING DATE: 2000-06-07
; NUMBER OF SEQ ID NOS: 4360
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 2767
; LENGTH: 106
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-264-049-2767
Query Match 96.6%; Score 28; DB 15; Length 106;
Best Local Similarity 83.3%; Pred. No. 1.3e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AFFVLK 6
Db 92 AFFVLK 97
US-10-369-493-2025
RESULT 12
; Sequence 2025, Application US/10369493
; Publication No. US20030233675A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Yongwei
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Goldman, Barry S.
; APPLICANT: Chen, Xianfeng
; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF
; FILE REFERENCE: 38-10(52052)B
; CURRENT APPLICATION NUMBER: US/10/369,493
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/360,039
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 47374
; SEQ ID NO 2025
; LENGTH: 1095
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-10-369-493-2025
Query Match 96.6%; Score 28; DB 15; Length 1095;
Best Local Similarity 83.3%; Pred. No. 1.2e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AFFVLK 6
Db 1082 AFFVLK 1087
US-10-296-734-393
RESULT 13
; Sequence 393, Application US/10296734
; Publication No. US200400054137A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Scott A
; APPLICANT: Ramshaw, Ian A
; TITLE OF INVENTION: Synthetic molecules and uses therefor
; FILE REFERENCE: Savine
; CURRENT APPLICATION NUMBER: US/10/296,734
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: AU PQ7761/00
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 1507
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 393
; LENGTH: 1896
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: HIV cassette A1
US-10-296-734-393
Query Match 96.6%; Score 28; DB 15; Length 1896;
Best Local Similarity 83.3%; Pred. No. 2e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AFFVLK 6
Db 1034 AFFVLK 1039
US-10-296-734-405
RESULT 14
; Sequence 405, Application US/10296734
; Publication No. US200400054137A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Scott A
; APPLICANT: Ramshaw, Ian A
; TITLE OF INVENTION: Synthetic molecules and uses therefor
; FILE REFERENCE: Savine
; CURRENT APPLICATION NUMBER: US/10/296,734
```

; CURRENT FILING DATE: 2003-08-04  
 ; PRIOR APPLICATION NUMBER: AU P07761/00  
 ; FILING DATE: 2000-05-26  
 ; NUMBER OF SEQ ID NOS: 1507  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 405  
 ; LENGTH: 5747  
 ; TYPE: PRT  
 ; ORGANISM: Artificial  
 ; FEATURE:  
 ; OTHER INFORMATION: HIV complete savine  
 US-10-296-734-405

Query Match 96.6%; Score 28; DB 15; Length 5747;  
 Best Local Similarity 83.3%; Pred. No. 5.7e+03;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 |||||  
 DB 1031 AFFILK 1036

RESULT 15  
 US-10-369-493-8703  
 ; Sequence 8703, Application US/10369493  
 ; Publication No. US20030233675A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Cao, Yongwei  
 ; APPLICANT: Hinkle, Gregory J.  
 ; APPLICANT: Slater, Steven C.  
 ; APPLICANT: Goldman, Barry S.  
 ; APPLICANT: Chen, Xianfeng  
 ; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF  
 ; FILE REFERENCE: 38-10(52052)B  
 ; CURRENT APPLICATION NUMBER: US/10/369,493  
 ; CURRENT FILING DATE: 2003-02-28  
 ; PRIOR APPLICATION NUMBER: US 60/360,039  
 ; FILING DATE: 2002-02-21  
 ; NUMBER OF SEQ ID NOS: 47374  
 ; SEQ ID NO 8703  
 ; LENGTH: 890  
 ; TYPE: PRT  
 ; ORGANISM: Ralstonia metallidurans  
 US-10-369-493-8703

Query Match 93.1%; Score 27; DB 15; Length 890;  
 Best Local Similarity 83.3%; Pred. No. 1.6e+03;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 |||||  
 DB 778 AFFVWK 783

RESULT 16  
 US-10-437-963-195961  
 ; Sequence 195961, Application US/10437963  
 ; Publication No. US20040123343A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: La Rosa, Thomas J.  
 ; APPLICANT: Kovalic, David K.  
 ; APPLICANT: Zhou, Yihua  
 ; APPLICANT: Cao, Yongwei  
 ; APPLICANT: Wu, Wei  
 ; APPLICANT: Boukharov, Andrey A.  
 ; APPLICANT: Barbazuk, Brad  
 ; APPLICANT: Li, Ping  
 ; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated with  
 ; FILE REFERENCE: 38-21(53221)B  
 ; CURRENT APPLICATION NUMBER: US/10/437,963  
 ; CURRENT FILING DATE: 2003-05-14

; NUMBER OF SEQ ID NOS: 204966  
 ; SEQ ID NO 195961  
 ; LENGTH: 1331  
 ; TYPE: PRT  
 ; ORGANISM: Oryza sativa  
 ; FEATURE:  
 ; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_91859C.1.pap  
 US-10-437-963-195961

Query Match 93.1%; Score 27; DB 16; Length 1331;  
 Best Local Similarity 83.3%; Pred. No. 2.4e+03;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 |||||  
 DB 298 AFFVIK 303

RESULT 17  
 US-10-437-963-192958  
 ; Sequence 192958, Application US/10437963  
 ; Publication No. US20040123343A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: La Rosa, Thomas J.  
 ; APPLICANT: Kovalic, David K.  
 ; APPLICANT: Zhou, Yihua  
 ; APPLICANT: Cao, Yongwei  
 ; APPLICANT: Wu, Wei  
 ; APPLICANT: Boukharov, Andrey A.  
 ; APPLICANT: Barbazuk, Brad  
 ; APPLICANT: Li, Ping  
 ; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated with  
 ; FILE REFERENCE: 38-21(53221)B  
 ; CURRENT APPLICATION NUMBER: US/10/437,963  
 ; CURRENT FILING DATE: 2003-05-14  
 ; NUMBER OF SEQ ID NOS: 204966  
 ; SEQ ID NO 192958  
 ; LENGTH: 64  
 ; TYPE: PRT  
 ; ORGANISM: Oryza sativa  
 ; FEATURE:  
 ; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_89141C.1.pap  
 US-10-437-963-192958

Query Match 89.7%; Score 26; DB 16; Length 64;  
 Best Local Similarity 83.3%; Pred. No. 2.2e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
 |||||  
 DB 38 AFFLLK 43

RESULT 18  
 US-10-424-599-222643  
 ; Sequence 222643, Application US/10424599  
 ; Publication No. US20040031072A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: La Rosa, Thomas J.  
 ; APPLICANT: Kovalic, David K.  
 ; APPLICANT: Zhou, Yihua  
 ; APPLICANT: Cao, Yongwei  
 ; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with  
 ; FILE REFERENCE: 38-21(53223)B  
 ; CURRENT APPLICATION NUMBER: US/10/424,599  
 ; CURRENT FILING DATE: 2003-04-28  
 ; NUMBER OF SEQ ID NOS: 285684  
 ; SEQ ID NO 222643  
 ; LENGTH: 69  
 ; TYPE: PRT  
 ; ORGANISM: Glycine max

;; FEATURE:  
;; NAME/KEY: unsure  
;; LOCATION: (1)..(69)  
;; OTHER INFORMATION: unsure at all Xaa locations  
;; FEATURE:  
;; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_43075C.1.pep  
US-10-424-599-222643

Query Match 89.7%; Score 26; DB 15; Length 69;  
Best Local Similarity 83.3%; Pred. No. 2.4e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||:|  
Db 62 AFFVVK 67

RESULT 19  
US-10-424-599-160048  
; Sequence 160048, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 160048  
; LENGTH: 78  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_115542C.1.pep  
US-10-424-599-160048

Query Match 89.7%; Score 26; DB 15; Length 78;  
Best Local Similarity 83.3%; Pred. No. 2.7e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||:|  
Db 32 AFFLLK 37

RESULT 20  
US-10-424-599-162355  
; Sequence 162355, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 162355  
; LENGTH: 139  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_117625C.1.pep  
US-10-424-599-162355

Query Match 89.7%; Score 26; DB 15; Length 139;

Best Local Similarity 83.3%; Pred. No. 4.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 AFFVLK 6  
|||:|  
Db 19 AFFLLK 24

RESULT 21  
US-10-424-599-283039  
; Sequence 283039, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 283039  
; LENGTH: 201  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_97606C.1.pep  
US-10-424-599-283039

Query Match 89.7%; Score 26; DB 15; Length 201;  
Best Local Similarity 83.3%; Pred. No. 6.6e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
|||:|  
Db 136 AFFLLK 141

RESULT 22  
US-10-282-122A-63253  
; Sequence 63253, Application US/10282122A  
; Publication No. US20040029129A1  
; GENERAL INFORMATION:  
; APPLICANT: Wang, Liangsu  
; APPLICANT: Zamudio, Carlos  
; APPLICANT: Malone, Cheryl  
; APPLICANT: Haselbeck, Robert  
; APPLICANT: Ohlsen, Kari  
; APPLICANT: Zyskind, Judith  
; APPLICANT: Wall, Daniel  
; APPLICANT: Trawick, John  
; APPLICANT: Carr, Grant  
; APPLICANT: Yamamoto, Robert  
; APPLICANT: Forsyth, R.  
; APPLICANT: Xu, H.  
; TITLE OF INVENTION: Identification of Essential Genes in Microorganisms  
; FILE REFERENCE: ELITRA 034A  
; CURRENT APPLICATION NUMBER: US/10/282,122A  
; CURRENT FILING DATE: 2003-02-20  
; PRIOR APPLICATION NUMBER: 60/191,078  
; PRIOR FILING DATE: 2000-03-21  
; PRIOR APPLICATION NUMBER: 60/206,848  
; PRIOR FILING DATE: 2000-05-23  
; PRIOR APPLICATION NUMBER: 60/207,727  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: 60/230,335  
; PRIOR FILING DATE: 2000-09-06  
; PRIOR APPLICATION NUMBER: 60/230,347  
; PRIOR FILING DATE: 2000-09-09  
; PRIOR APPLICATION NUMBER: 60/242,578  
; PRIOR FILING DATE: 2000-10-23

```
; PRIOR APPLICATION NUMBER: 60/253,625
; PRIOR FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 60/257,931
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/267,636
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/269,308
; PRIOR FILING DATE: 2001-02-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 78614
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 63253
; LENGTH: 428
; TYPE: PRT
; ORGANISM: Moraxella catarrhalis
US-10-282-122A-63253

Query Match      89.7%; Score 26; DB 15; Length 428;
Best Local Similarity 83.3%; Pred. No. 1.3e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      |||:|
Db      319 AFYVLK 324

RESULT 23
US-10-282-122A-72133
; Sequence 72133, Application US/10282122A
; Publication No. US20040029129A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Lianguo
; APPLICANT: Zamudio, Carlos
; APPLICANT: Malone, Cheryl
; APPLICANT: Haselbeck, Robert
; APPLICANT: Ohlsen, Kari
; APPLICANT: Zyskind, Judith
; APPLICANT: Wall, Daniel
; APPLICANT: Trawick, John
; APPLICANT: Cart, Grant
; APPLICANT: Yamamoto, Robert
; APPLICANT: Forsyth, R.
; APPLICANT: Xu, H.
; TITLE OF INVENTION: Identification of Essential Genes in Microorganisms
; FILE REFERENCE: ELITRA.034A
; CURRENT APPLICATION NUMBER: US/10/282,122A
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: 60/191,078
; PRIOR FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: 60/206,848
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/207,727
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 60/230,335
; PRIOR FILING DATE: 2000-09-06
; PRIOR APPLICATION NUMBER: 60/230,347
; PRIOR FILING DATE: 2000-09-09
; PRIOR APPLICATION NUMBER: 60/242,578
; PRIOR FILING DATE: 2000-10-23
; PRIOR APPLICATION NUMBER: 60/253,625
; PRIOR FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: 60/257,931
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/267,636
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/269,308
; PRIOR FILING DATE: 2001-02-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 78614
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 72133
; LENGTH: 544
; TYPE: PRT
```

```
; ORGANISM: Streptococcus mutans
US-10-282-122A-72133

Query Match      89.7%; Score 26; DB 15; Length 544;
Best Local Similarity 66.7%; Pred. No. 1.7e+03;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      |||:|
Db      183 AFFIMK 188

RESULT 24
US-10-369-493-17930
; Sequence 17930, Application US/10369493
; Publication No. US20030233675A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Yongwei
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Goldman, Barry S.
; APPLICANT: Chen, Xianfeng
; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF
; FILE REFERENCE: 38-10(52052)B
; CURRENT APPLICATION NUMBER: US/10/369,493
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/360,039
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 47374
; SEQ ID NO 17930
; LENGTH: 636
; TYPE: PRT
; ORGANISM: SPHINGOMONAS
US-10-369-493-17930

Query Match      89.7%; Score 26; DB 15; Length 636;
Best Local Similarity 83.3%; Pred. No. 1.9e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 AFFVLK 6
      |||:|
Db      120 AFFVLR 125

RESULT 25
US-10-437-963-137429
; Sequence 137429, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 137429
; LENGTH: 687
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_38914C.1.pcp
US-10-437-963-137429

Query Match      89.7%; Score 26; DB 16; Length 687;
```

```
Best Local Similarity 83.3%; Pred. No. 2.1e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 576 AFFMLK 581

RESULT 26
US-10-141-132-2
; Sequence 2, Application US/10141132
; Publication No. US2002013231A1
; GENERAL INFORMATION:
; APPLICANT: Wei et al.
; TITLE OF INVENTION: Human DNA Ligase IV
; FILE REFERENCE: PFI42P1D1
; CURRENT APPLICATION NUMBER: US/10/141,132
; CURRENT FILING DATE: 2002-05-09
; PRIOR APPLICATION NUMBER: 08/461,562
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: PCT/US94/12922
; PRIOR FILING DATE: 1994-11-08
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 911
; TYPE: PRT
; ORGANISM: human
US-10-141-132-2

Query Match 89.7%; Score 26; DB 13; Length 911;
Best Local Similarity 83.3%; Pred. No. 2.7e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 129 AFFVLK 134

RESULT 27
US-09-764-891-3264
; Sequence 3264, Application US/09764891
; Publication No. US20030077808A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC006
; CURRENT APPLICATION NUMBER: US/09/764,891
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 10231
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3264
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (3)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (4)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-891-3264

Query Match 86.2%; Score 25; DB 10; Length 40;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6
Db 13 FFVLK 17

RESULT 28
US-10-437-963-172128
; Sequence 172128, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 172128
; LENGTH: 41
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_70294C.1.pep
US-10-437-963-172128

Query Match 86.2%; Score 25; DB 16; Length 41;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6
Db 26 FFVLK 30

RESULT 29
US-09-764-877-1207
; Sequence 1207, Application US/09764877
; Patent No. US20020147140A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC005
; CURRENT APPLICATION NUMBER: US/09/764,877
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 4031
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1207
; LENGTH: 42
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-764-877-1207

Query Match 86.2%; Score 25; DB 9; Length 42;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6
Db 15 SFFVLK 20

RESULT 30
US-10-242-515-1207
; Sequence 1207, Application US/10242515
; Publication No. US20040009488A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC005C1
```

US-10-424-599-209666  
; Sequence 209666, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 209666  
; LENGTH: 51  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_31356C.1.pep  
US-10-424-599-209666

Query Match 86.2%; Score 25; DB 15; Length 42;  
Best Local Similarity 66.7%; Pred. No. 2.5e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
:|||||  
Db 15 SFFILK 20

RESULT 31  
US-10-424-599-260161  
; Sequence 260161, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 260161  
; LENGTH: 44  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_7694C.1.pep  
US-10-424-599-260161

Query Match 86.2%; Score 25; DB 15; Length 44;  
Best Local Similarity 66.7%; Pred. No. 2.6e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
:|||||  
Db 22 SFFILK 27

RESULT 32

US-10-424-599-209666  
; Sequence 209666, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 209666  
; LENGTH: 51  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_31356C.1.pep  
US-10-424-599-209666

Query Match 86.2%; Score 25; DB 15; Length 51;  
Best Local Similarity 100.0%; Pred. No. 3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6  
:|||||  
Db 40 FFVLK 44

RESULT 33  
US-09-764-891-5193  
; Sequence 5193, Application US/09764891  
; Publication No. US2003007808A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; FILE REFERENCE: PC006  
; CURRENT APPLICATION NUMBER: US/09/764,891  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 10231  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5193  
; LENGTH: 57  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-764-891-5193

Query Match 86.2%; Score 25; DB 10; Length 57;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6  
:|||||  
Db 16 FFVLK 20

RESULT 34  
US-10-424-599-223207  
; Sequence 223207, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28

; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 223207  
; LENGTH: 57  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_43587C.1.pep  
US-10-424-599-223207

Query Match 86.2%; Score 25; DB 15; Length 57;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 17 FFVLK 21

RESULT 35  
US-10-425-114-53355  
; Sequence 53355, Application US/10425114  
; Publication No. US20040034888A1  
; GENERAL INFORMATION:  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Screen, Steven E  
; APPLICANT: Tabaska, Jack E  
; APPLICANT: Cao, Yongwei  
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53313)B  
; CURRENT APPLICATION NUMBER: US/10/425,114  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 73128  
; SEQ ID NO 53355  
; LENGTH: 58  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 700558803\_FLI.pep  
US-10-425-114-53355

Query Match 86.2%; Score 25; DB 15; Length 58;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 38 FFVLK 42

RESULT 36  
US-10-425-114-53434  
; Sequence 53434, Application US/10425114  
; Publication No. US20040034888A1  
; GENERAL INFORMATION:  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Screen, Steven E  
; APPLICANT: Tabaska, Jack E  
; APPLICANT: Cao, Yongwei  
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53313)B  
; CURRENT APPLICATION NUMBER: US/10/425,114  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 73128  
; SEQ ID NO 53434  
; LENGTH: 58  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 700557013\_FLI.pep  
US-10-425-114-53434

; FEATURE:  
; OTHER INFORMATION: Clone ID: 700557013\_FLI.pep  
US-10-425-114-53434

Query Match 86.2%; Score 25; DB 15; Length 58;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 38 FFVLK 42

RESULT 37  
US-10-437-963-148568  
; Sequence 148568, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 148568  
; LENGTH: 58  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_48987C.1.pep  
US-10-437-963-148568

Query Match 86.2%; Score 25; DB 16; Length 58;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 1 FFVLK 5

RESULT 38  
US-10-437-963-156769  
; Sequence 156769, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 156769  
; LENGTH: 69  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 700558803\_FLI.pep  
US-10-425-114-53355

Query Match 86.2%; Score 25; DB 15; Length 57;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 17 FFVLK 21

RESULT 35  
US-10-425-114-53355  
; Sequence 53355, Application US/10425114  
; Publication No. US20040034888A1  
; GENERAL INFORMATION:  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Screen, Steven E  
; APPLICANT: Tabaska, Jack E  
; APPLICANT: Cao, Yongwei  
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53313)B  
; CURRENT APPLICATION NUMBER: US/10/425,114  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 73128  
; SEQ ID NO 53355  
; LENGTH: 58  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 700557013\_FLI.pep  
US-10-425-114-53434

Query Match 86.2%; Score 25; DB 15; Length 58;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||  
Db 38 FFVLK 42

RESULT 37  
US-10-437-963-148568  
; Sequence 148568, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 148568  
; LENGTH: 58  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_48987C.1.pep  
US-10-437-963-148568

Query Match 86.2%; Score 25; DB 16; Length 58;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_56405C.1.pep  
US-10-437-963-156769

Query Match 86.2%; Score 25; DB 16; Length 69;  
Best Local Similarity 100.0%; Pred. No. 4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||

Db 38 FFVLK 42

## RESULT 39

US-10-424-599-195770  
; Sequence 195770, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 195770  
; LENGTH: 70  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_18806C.1.pep  
US-10-424-599-195770

Query Match 86.2%; Score 25; DB 15; Length 70;  
Best Local Similarity 100.0%; Pred. No. 4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||

Db 59 FFVLK 63

## RESULT 40

US-10-437-963-118382  
; Sequence 118382, Application US/10437963  
; Publication No. US20040123343A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 118382  
; LENGTH: 70  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_2169C.1.pep  
US-10-437-963-118382

Query Match 86.2%; Score 25; DB 16; Length 70;  
Best Local Similarity 66.7%; Pred. No. 4e+02;

Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
:|:|

Db 39 SFFVLK 44

## RESULT 41

US-10-424-599-206603  
; Sequence 206603, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 206603  
; LENGTH: 76  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_28590C.1.pep  
US-10-424-599-206603

Query Match 86.2%; Score 25; DB 15; Length 76;  
Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||

Db 25 FFVLK 29

## RESULT 42

US-10-424-599-256442  
; Sequence 256442, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 256442  
; LENGTH: 77  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_73591C.1.pep  
US-10-424-599-256442

Query Match 86.2%; Score 25; DB 15; Length 77;  
Best Local Similarity 100.0%; Pred. No. 4.4e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
|||

Db 50 FFVLK 54

## RESULT 43

US-10-424-599-261939

; Sequence 261939, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 261939  
; LENGTH: 81  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_78553C.1.pap  
US-10-424-599-261939

Query Match 86.2%; Score 25; DB 15; Length 81;  
Best Local Similarity 66.7%; Pred. No. 4.6e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
:|||||  
Db 41 SFFVLK 46

RESULT 44  
US-10-424-599-175620  
; Sequence 175620, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 175620  
; LENGTH: 83  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_129602C.1.pap  
US-10-424-599-175620

Query Match 86.2%; Score 25; DB 15; Length 83;  
Best Local Similarity 100.0%; Pred. No. 4.7e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6  
:|||||  
Db 68 FFVLK 72

RESULT 45  
US-10-425-114-39918  
; Sequence 39918, Application US/10425114  
; Publication No. US20040034888A1  
; GENERAL INFORMATION:  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Screen, Steven E.  
; APPLICANT: Tabaska, Jack E.  
; APPLICANT: Cao, Yongwei

; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53313)B  
; CURRENT APPLICATION NUMBER: US/10/425,114  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 73128  
; SEQ ID NO 39918  
; LENGTH: 83  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 700899918\_FLI.pap  
US-10-425-114-39918

Query Match 86.2%; Score 25; DB 15; Length 83;  
Best Local Similarity 100.0%; Pred. No. 4.7e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 FFVLK 6  
:|||||  
Db 68 FFVLK 72

RESULT 46  
US-10-264-049-3814  
; Sequence 3814, Application US/10264049  
; Publication No. US20040005579A1  
; GENERAL INFORMATION:  
; APPLICANT: Birse et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PA133PI  
; CURRENT APPLICATION NUMBER: US/10/264,049  
; CURRENT FILING DATE: 2002-10-04  
; PRIOR APPLICATION NUMBER: PCT/US01/18569  
; PRIOR FILING DATE: 2001-06-07  
; PRIOR APPLICATION NUMBER: US 60/209,467  
; PRIOR FILING DATE: 2000-06-07  
; NUMBER OF SEQ ID NOS: 4360  
; SOFTWARE: Patent In Ver. 3.1  
; SEQ ID NO 3814  
; LENGTH: 87  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-264-049-3814

Query Match 86.2%; Score 25; DB 15; Length 87;  
Best Local Similarity 66.7%; Pred. No. 4.9e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFFVLK 6  
:|||||  
Db 53 AFFVLK 58

RESULT 47  
US-10-424-599-195834  
; Sequence 195834, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 195834  
; LENGTH: 93  
; TYPE: PRT  
; ORGANISM: Glycine max

; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_18864C.1.pap  
US-10-424-599-195834

Query Match 86.2%; Score 25; DB 15; Length 93;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
Db 7 FFVLK 11

RESULT 48  
US-10-424-599-234710  
; Sequence 234710, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 234710  
; LENGTH: 94  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_53971C.1.pap  
US-10-424-599-234710

Query Match 86.2%; Score 25; DB 15; Length 94;  
Best Local Similarity 100.0%; Pred. No. 5.3e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
Db 71 FFVLK 75

RESULT 49  
US-10-424-599-258607  
; Sequence 258607, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 258607  
; LENGTH: 98  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; NAME/KEY: unsure  
; LOCATION: (1)..(98)  
; OTHER INFORMATION: unsure at all Xaa locations  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_75547C.1.pap  
US-10-424-599-258607

Query Match 86.2%; Score 25; DB 15; Length 98;

Best Local Similarity 66.7%; Pred. No. 5.5e+02;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFFVLK 6  
Db 48 SFFVLK 53

RESULT 50  
US-10-424-599-264247  
; Sequence 264247, Application US/10424599  
; Publication No. US20040031072A1  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa Thomas J  
; APPLICANT: Kovalic David K  
; APPLICANT: Zhou Yihua  
; APPLICANT: Cao Yongwei  
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
; FILE REFERENCE: 38-21(53223)B  
; CURRENT APPLICATION NUMBER: US/10/424,599  
; CURRENT FILING DATE: 2003-04-28  
; NUMBER OF SEQ ID NOS: 285684  
; SEQ ID NO 264247  
; LENGTH: 101  
; TYPE: PRT  
; ORGANISM: Glycine max  
; FEATURE:  
; OTHER INFORMATION: Clone ID: PAT\_MRT3847\_80636C.1.pap  
US-10-424-599-264247

Query Match 86.2%; Score 25; DB 15; Length 101;  
Best Local Similarity 100.0%; Pred. No. 5.7e+02;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 FFVLK 6  
Db 96 FFVLK 100

Search completed: March 9, 2005, 07:40:30  
Job time : 51.3151 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:27:44 ; Search time 49.3151 Seconds  
(without alignments)  
40.034 Million cell updates/sec

Title: US-10-009-122-3

Perfect score: 29

Sequence: 1 KLVFFA 6

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1391452 seqs, 329044822 residues

Total number of hits satisfying chosen parameters: 1391452

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database : Published Applications\_AA.\*  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/PT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/PTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/1/pubpaa/US09A\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/1/pubpaa/US10D\_PUBCOMB.pep.\*  
17: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*  
19: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*  
20: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	29	100.0	6	9	US-09-867-847-7
2	29	100.0	6	9	US-09-867-847-20
3	29	100.0	6	9	US-09-972-475-9
4	29	100.0	6	9	US-09-915-092-10
5	29	100.0	6	9	US-09-915-092-28
6	29	100.0	6	9	US-09-956-625-25
7	29	100.0	6	10	US-09-747-408-3
8	29	100.0	6	10	US-09-747-408-11
9	29	100.0	6	15	US-09-867-847-9
10	29	100.0	7	9	US-09-867-847-12
11	29	100.0	7	9	US-09-867-847-27
12	29	100.0	7	9	US-09-867-847-28
13	29	100.0	7	9	US-09-972-475-7

14	29	100.0	7	9	US-09-915-092-2	Sequence 2, Appli
15	29	100.0	7	9	US-09-915-092-17	Sequence 17, Appli
16	29	100.0	7	9	US-09-915-092-18	Sequence 18, Appli
17	29	100.0	7	10	US-09-747-408-2	Sequence 2, Appli
18	29	100.0	7	10	US-09-747-408-18	Sequence 18, Appli
19	29	100.0	7	10	US-09-747-408-19	Sequence 19, Appli
20	29	100.0	7	15	US-10-463-729-7	Sequence 7, Appli
21	29	100.0	8	9	US-09-850-061A-44	Sequence 44, Appli
22	29	100.0	8	9	US-09-972-475-5	Sequence 5, Appli
23	29	100.0	8	14	US-10-235-483-1	Sequence 1, Appli
24	29	100.0	8	15	US-10-463-729-5	Sequence 5, Appli
25	29	100.0	8	16	US-10-281-092-42	Sequence 42, Appli
26	29	100.0	8	16	US-10-721-774-44	Sequence 44, Appli
27	29	100.0	9	9	US-09-867-847-9	Sequence 9, Appli
28	29	100.0	9	9	US-09-899-815-2	Sequence 2, Appli
29	29	100.0	9	10	US-09-747-408-20	Sequence 20, Appli
30	29	100.0	9	14	US-10-235-483-64	Sequence 64, Appli
31	29	100.0	9	15	US-10-619-454-3	Sequence 3, Appli
32	29	100.0	9	15	US-10-619-454-25	Sequence 25, Appli
33	29	100.0	9	15	US-10-619-454-28	Sequence 28, Appli
34	29	100.0	9	15	US-10-619-454-57	Sequence 57, Appli
35	29	100.0	9	15	US-10-619-454-157	Sequence 157, Appli
36	29	100.0	10	9	US-09-867-847-29	Sequence 29, Appli
37	29	100.0	10	9	US-09-915-092-19	Sequence 19, Appli
38	29	100.0	10	17	US-10-823-463-20	Sequence 20, Appli
39	29	100.0	10	17	US-10-823-463-21	Sequence 21, Appli
40	29	100.0	10	17	US-10-823-463-22	Sequence 22, Appli
41	29	100.0	10	17	US-10-823-463-23	Sequence 23, Appli
42	29	100.0	10	17	US-10-823-463-24	Sequence 24, Appli
43	29	100.0	11	9	US-09-988-842-9	Sequence 9, Appli
44	29	100.0	11	9	US-09-988-842-25	Sequence 25, Appli
45	29	100.0	11	14	US-10-235-483-14	Sequence 14, Appli
46	29	100.0	11	14	US-10-050-200-33	Sequence 33, Appli
47	29	100.0	11	16	US-10-237-673-20	Sequence 20, Appli
48	29	100.0	11	17	US-10-464-117-13	Sequence 13, Appli
49	29	100.0	12	9	US-09-867-847-8	Sequence 8, Appli
50	29	100.0	13	14	US-10-281-458-1	Sequence 1, Appli
51	29	100.0	14	9	US-09-992-800-5	Sequence 5, Appli
52	29	100.0	14	9	US-09-992-994-5	Sequence 5, Appli
53	29	100.0	14	15	US-10-385-065-5	Sequence 5, Appli
54	29	100.0	15	9	US-09-972-475-14	Sequence 14, Appli
55	29	100.0	15	9	US-09-996-357-9	Sequence 9, Appli
56	29	100.0	15	14	US-10-235-483-56	Sequence 56, Appli
57	29	100.0	15	14	US-10-235-483-57	Sequence 57, Appli
58	29	100.0	15	14	US-10-235-483-58	Sequence 58, Appli
59	29	100.0	15	14	US-10-235-483-60	Sequence 60, Appli
60	29	100.0	15	14	US-10-235-483-61	Sequence 61, Appli
61	29	100.0	15	14	US-10-235-483-63	Sequence 63, Appli
62	29	100.0	15	14	US-10-235-483-65	Sequence 65, Appli
63	29	100.0	15	15	US-10-463-729-14	Sequence 14, Appli
64	29	100.0	17	9	US-09-992-800-3	Sequence 3, Appli
65	29	100.0	17	9	US-09-992-994-3	Sequence 3, Appli

ALIGNMENTS

RESULT 1

US-09-867-847-7

; Sequence 7, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiangdi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29

```
; PRIOR APPLICATION NUMBER: 09/724,842
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-09-867-847-7

Query Match          100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
      |||||
Db      1 KLVFFA 6

RESULT 2
US-09-867-847-20
; Sequence 20, Application US/09867847
; Patent No. US20020094335A1
; GENERAL INFORMATION:
; APPLICANT: Chalfour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xiangi
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES
; FILE REFERENCE: 14445-501 CIP
; CURRENT APPLICATION NUMBER: US/09/867,847
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 20
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
; NAME/KEY: MOD_RES
; LOCATION: (6)
; OTHER INFORMATION: AMIDATION
US-09-867-847-20

Query Match          100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
      |||||
Db      1 KLVFFA 6

RESULT 3
US-09-972-475-9
; Sequence 9, Application US/09972475
; Patent No. US20020098173A1
; GENERAL INFORMATION:
; APPLICANT: Findels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
```

```
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/972,475
; FILING DATE: 04-Oct-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/617,267
; FILING DATE: <Unknown>
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-972-475-9

Query Match          100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
      |||||
Db      1 KLVFFA 6

RESULT 4
US-09-915-092-10
; Sequence 10, Application US/09915092
; Publication No. US20020115717A1
; GENERAL INFORMATION:
; APPLICANT: Gervais, Francine
; APPLICANT: Kong, Xiangi
; APPLICANT: Chalfour, Robert
; APPLICANT: Migneault, David
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND
; FILE REFERENCE: NBI-139
; CURRENT APPLICATION NUMBER: US/09/915,092
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/220,808
; PRIOR FILING DATE: 2000-07-25
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ-ID-NO: 10
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-092-10

Query Match          100.0%; Score 29; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 5  
US-09-915-092-28  
; Sequence 28, Application US/09915092  
; Publication No. US2002011571A1  
; GENERAL INFORMATION:  
; APPLICANT: Kong, Xiangi  
; APPLICANT: Gervais, Francine  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Migneault, David  
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND  
; TITLE OF INVENTION: USES THEREOF  
; FILE REFERENCE: NBI-139  
; CURRENT APPLICATION NUMBER: US/09/915,092  
; CURRENT FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/220,808  
; PRIOR FILING DATE: 2000-07-25  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 28  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: VARIANT  
; LOCATION: (1)...(6)  
; OTHER INFORMATION: D-amino acids  
US-09-915-092-28

Query Match 100.0%; Score 29; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 6  
US-09-956-625-25  
; Sequence 25, Application US/09956625  
; Patent No. US20020119926A1  
; GENERAL INFORMATION:  
; APPLICANT: Fraser, Paul  
; TITLE OF INVENTION: Inhibitors of IAPP Fibril Formation and Uses Thereof  
; FILE REFERENCE: 14445-503  
; CURRENT APPLICATION NUMBER: US/09/956,625  
; CURRENT FILING DATE: 2001-09-19  
; PRIOR APPLICATION NUMBER: 60/233,482  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 25  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial  
; OTHER INFORMATION: Sequence: Antifibrillogenic agents  
US-09-956-625-25

Query Match 100.0%; Score 29; DB 9; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 7  
US-09-747-408-3  
; Sequence 3, Application US/09747408  
; Publication No. US20030003141A1  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-3

Query Match 100.0%; Score 29; DB 10; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 8  
US-09-747-408-11  
; Sequence 11, Application US/09747408  
; Publication No. US20030003141A1  
; GENERAL INFORMATION:  
; APPLICANT: Green, Allan M.  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Compounds And Methods For Modulating  
; TITLE OF INVENTION: Cerebral Amyloid Angiopathy  
; FILE REFERENCE: NBI-088  
; CURRENT APPLICATION NUMBER: US/09/747,408  
; CURRENT FILING DATE: 2000-12-22  
; PRIOR APPLICATION NUMBER: 60/171,877  
; PRIOR FILING DATE: 1999-12-23  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 11  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-747-408-11

Query Match 100.0%; Score 29; DB 10; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 9  
US-10-463-729-9  
; Sequence 9, Application US/10463729  
; Publication No. US20040005307A1  
; GENERAL INFORMATION:  
; APPLICANT: Findis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP

STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/463,729  
FILING DATE: 17-JUNE-2003  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/617,267C  
FILING DATE: 14-MAR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/404,831  
FILING DATE: 14-MAR-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 6 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-10-463-729-9

Query Match 100.0%; Score 29; DB 15; Length 6;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 10  
US-09-867-847-12  
; Sequence 12, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; PRIOR FILING DATE: 2001-09-20  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 12  
; TYPE: PRT  
; ORGANISM: Artificial Sequence

; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-12

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 11  
US-09-867-847-27  
; Sequence 27, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 27  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-27

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

RESULT 12  
US-09-867-847-28  
; Sequence 28, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 28



LENGTH: 7  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
OTHER INFORMATION: or peptidomimetics  
NAME/KEY: MOD\_RES  
LOCATION: (7)  
OTHER INFORMATION: AMIDATION  
US-09-867-847-28

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

## RESULT 13

US-09-972-475-7  
Sequence 7, Application US/09972475  
Patent No. US20020098173A1  
GENERAL INFORMATION:  
APPLICANT: Findex, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSER: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA: US/09/972,475  
FILING DATE: 04-Oct-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/617,267  
FILING DATE: <Unknown>  
APPLICATION NUMBER: USN 08/475,579  
FILING DATE: 07-JUN-1995  
APPLICATION NUMBER: USN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 14  
US-09-915-092-2  
Sequence 2, Application US/09915092  
Publication No. US20020115717A1  
GENERAL INFORMATION:  
APPLICANT: Gervais, Francine  
APPLICANT: Kong, Xianqi  
APPLICANT: Chalifour, Robert  
APPLICANT: Migneault, David  
TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND  
FILE REFERENCE: NBI-139  
CURRENT APPLICATION NUMBER: US/09/915,092  
CURRENT FILING DATE: 2001-07-24  
PRIOR APPLICATION NUMBER: 60/220,808  
PRIOR FILING DATE: 2000-07-25  
NUMBER OF SEQ ID NOS: 28  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 2  
LENGTH: 7  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-915-092-2

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

## RESULT 15

US-09-915-092-17  
Sequence 17, Application US/09915092  
Publication No. US20020115717A1  
GENERAL INFORMATION:  
APPLICANT: Gervais, Francine  
APPLICANT: Kong, Xianqi  
APPLICANT: Chalifour, Robert  
APPLICANT: Migneault, David  
TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND  
FILE REFERENCE: NBI-139  
CURRENT APPLICATION NUMBER: US/09/915,092  
CURRENT FILING DATE: 2001-07-24  
PRIOR APPLICATION NUMBER: 60/220,808  
PRIOR FILING DATE: 2000-07-25  
NUMBER OF SEQ ID NOS: 28  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 17  
LENGTH: 7  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-915-092-17

Query Match 100.0%; Score 29; DB 9; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

## RESULT 16

US-09-915-092-18  
Sequence 18, Application US/09915092  
Publication No. US20020115717A1  
GENERAL INFORMATION:

```
; APPLICANT: Gervais, Francine
; APPLICANT: Kong, Xiandi
; APPLICANT: Chalfour, Robert
; APPLICANT: Migneault, David
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND
; FILE REFERENCE: NBI-139
; CURRENT APPLICATION NUMBER: US/09/915,092
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/220,808
; PRIOR FILING DATE: 2000-07-25
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-092-18

Query Match      100.0%; Score 29; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 17
US-09-747-408-2
; Sequence 2, Application US/09747408
; Publication No. US20030003141A1
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-2

Query Match      100.0%; Score 29; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 2 KLVFFA 7

RESULT 18
US-09-747-408-18
; Sequence 18, Application US/09747408
; Publication No. US20030003141A1
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
```

```
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-18

Query Match      100.0%; Score 29; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 19
US-09-747-408-19
; Sequence 19, Application US/09747408
; Publication No. US20030003141A1
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-088
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-747-408-19

Query Match      100.0%; Score 29; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 20
US-10-463-729-7
; Sequence 7, Application US/10463729
; Publication No. US20040005307A1
; GENERAL INFORMATION:
; APPLICANT: Fingels, Mark A. et al.
; TITLE OF INVENTION: Modulators of Amyloid Aggregation
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/463,729
; FILING DATE: 17-JUNE-2003
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/617,267C
```

RESULT 22  
US-09-972-475-5  
; Sequence 5, Application US/09972475  
; Patent No. US20020098173A1  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/972,475  
; FILING DATE: 04-Oct-2001  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/617,267  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-10-463-729-7

Query Match 100.0%; Score 29; DB 15; Length 7;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 21  
US-09-850-061A-44  
; Sequence 44, Application US/09850061A  
; Patent No. US20020094957A1  
; GENERAL INFORMATION:  
; APPLICANT: NORDSTEDT, Christer  
; APPLICANT: NASLUND, Jan  
; APPLICANT: THYBERG, Johan  
; APPLICANT: TJERNBERG, Lars O.  
; APPLICANT: TJERNBERG, Lars  
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA  
; FILE REFERENCE: 03315-002  
; CURRENT APPLICATION NUMBER: US/09/850,061A  
; CURRENT FILING DATE: 2001-05-08  
; PRIOR APPLICATION NUMBER: US 09/095,106  
; PRIOR FILING DATE: 1998-06-10  
; PRIOR APPLICATION NUMBER: PCT/SE96/01621  
; PRIOR FILING DATE: 1996-12-09  
; PRIOR APPLICATION NUMBER: SE 9504467-3  
; PRIOR FILING DATE: 1995-12-12  
; PRIOR APPLICATION NUMBER: US 60/009,386  
; PRIOR FILING DATE: 1995-12-29  
; NUMBER OF SEQ ID NOS: 44  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 44  
; LENGTH: 8  
; TYPE: PPT  
; ORGANISM: Amyloidosis  
US-09-850-061A-44

Query Match 100.0%; Score 29; DB 9; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
Db 1 KLVFFA 6

Query Match 100.0%; Score 29; DB 9; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KLVFFA 6  
Db 3 KLVFFA 8  
RESULT 23  
US-10-235-483-1  
; Sequence 1, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc  
; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASE  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEWMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.

```
/
/ COUNTRY: USA
/ ZIP: 20004
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/235,483
/ FILING DATE: 06-Sep-2002
/ CLASSIFICATION: <Unknown>
/ PRIORITY APPLICATION DATA:
/ APPLICATION NUMBER: US/08/766,596
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: US 08/630,645
/ FILING DATE: 10-APR-1996
/ APPLICATION NUMBER: US 08/478,326
/ FILING DATE: 06-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: YUN, Allen C.
/ REGISTRATION NUMBER: 37,971
/ REFERENCE/DOCKET NUMBER: SOTO-JARA-1A
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-628-5197
/ TELEFAX: 202-737-3528
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 8 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-235-483-1

Query Match 100.0%; Score 29; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
DB 1 KLVFFA 6

RESULT 24
US-10-463-729-5
/ Sequence 5, Application US/10463729
/ Publication No. US20040005307A1
/ GENERAL INFORMATION:
/ APPLICANT: Findels, Mark A. et al.
/ TITLE OF INVENTION: Modulators of Amyloid Aggregation
/ NUMBER OF SEQUENCES: 45
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: LAHIVE & COCKFIELD, LLP
/ STREET: 28 State Street
/ CITY: Boston
/ STATE: Massachusetts
/ COUNTRY: USA
/ ZIP: 02109-1875
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/463,729
/ FILING DATE: 17-JUNE-2003
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/617,267C
/ FILING DATE: 14-MAR-1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: USSN 08/404,831
/ FILING DATE: 14-MAR-1995
```

```
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: USSN 08/475,579
/ FILING DATE: 07-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: USSN 08/548,998
/ FILING DATE: 27-OCT-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: DeConti, Giulio A.
/ REGISTRATION NUMBER: 31,503
/ REFERENCE/DOCKET NUMBER: PPI-002CP2
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (617)227-7400
/ TELEFAX: (617)227-5941
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 8 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
US-10-463-729-5

Query Match 100.0%; Score 29; DB 15; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6
DB 3 KLVFFA 8

RESULT 25
US-10-281-092-42
/ Sequence 42, Application US/10281092
/ Publication No. US20040121947A1
/ GENERAL INFORMATION:
/ APPLICANT: Ghosh, Arun K.
/ APPLICANT: Tang, Jordan J.N.
/ APPLICANT: Bilcer, Geoffrey
/ APPLICANT: Chang, Wanpin
/ APPLICANT: Hong, Lin
/ APPLICANT: Koelsch, Gerald E.
/ APPLICANT: Loy, Jeffrey A.
/ APPLICANT: Turner, Robert T., III
/ APPLICANT: Devasumadrum, Thippeswamy
/ TITLE OF INVENTION: COMPOUNDS WHICH INHIBIT BETA-SECRETASE
/ TITLE OF INVENTION: ACTIVITY AND METHODS OF USE THEREOF
/ FILE REFERENCE: 2932.1001-004
/ CURRENT APPLICATION NUMBER: US/10/281,092
/ CURRENT FILING DATE: 2002-10-23
/ PRIOR APPLICATION NUMBER: US 10/032,818
/ PRIOR FILING DATE: 2001-12-28
/ PRIOR APPLICATION NUMBER: PCT US01/50826
/ PRIOR FILING DATE: 2001-12-28
/ PRIOR APPLICATION NUMBER: US 60/258,705
/ PRIOR FILING DATE: 2000-12-28
/ PRIOR APPLICATION NUMBER: US 60/275,756
/ PRIOR FILING DATE: 2001-03-14
/ PRIOR APPLICATION NUMBER: US 60/335,952
/ PRIOR FILING DATE: 2001-10-23
/ PRIOR APPLICATION NUMBER: US 60/333,545
/ PRIOR FILING DATE: 2001-11-27
/ PRIOR APPLICATION NUMBER: US 60/348,464
/ PRIOR FILING DATE: 2002-01-14
/ PRIOR APPLICATION NUMBER: US 60/348,615
/ PRIOR FILING DATE: 2002-01-14
/ PRIOR APPLICATION NUMBER: US 60/390,804
/ PRIOR FILING DATE: 2002-06-20
/ PRIOR APPLICATION NUMBER: US 60/397,557
/ PRIOR FILING DATE: 2002-07-19
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 59
/ SOFTWARE: FastSEQ for Windows Version 4.0
/ SEQ ID NO 42
```

```
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide
US-10-281-092-42

Query Match      100.0%; Score 29; DB 16; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      1 KLVFFA 6

RESULT 26
US-10-721-774-44
; Sequence 44, Application US/10721774
; Publication No. US20040157781A1
; GENERAL INFORMATION:
; APPLICANT: NORDSTEDT, Christer
; APPLICANT: NASLUND, Jan
; APPLICANT: THYBERG, Johan
; APPLICANT: TJERNBERG, Lars O.
; APPLICANT: TERENIUS, Lars
; TITLE OF INVENTION: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA
; FILE REFERENCE: 033315-002
; CURRENT APPLICATION NUMBER: US/10/721,774
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/095,106
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: PCT/SE96/01621
; PRIOR FILING DATE: 1996-12-09
; PRIOR APPLICATION NUMBER: SE 9504467-3
; PRIOR FILING DATE: 1995-12-12
; PRIOR APPLICATION NUMBER: US 60/009,386
; PRIOR FILING DATE: 1995-12-29
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 44
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Amyloidosis
US-10-721-774-44

Query Match      100.0%; Score 29; DB 16; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      1 KLVFFA 6

RESULT 27
US-09-867-847-9
; Sequence 9, Application US/09867847
; Patent No. US20020094338A1
; GENERAL INFORMATION:
; APPLICANT: Chalfour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xianci
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; FILE REFERENCE: 14445-501 CIP
; CURRENT APPLICATION NUMBER: US/09/867,847
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28

; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-09-867-847-9

Query Match      100.0%; Score 29; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      4 KLVFFA 9

RESULT 28
US-09-899-815-2
; Sequence 2, Application US/09899815
; Patent No. US20020162129A1
; GENERAL INFORMATION:
; APPLICANT: LANNFELT, Lars
; TITLE OF INVENTION: PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
; FILE REFERENCE: LANNFELT-1A
; CURRENT APPLICATION NUMBER: US/09/899,815
; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 60/217,098
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: EP 00202387.7
; PRIOR FILING DATE: 2000-07-07
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide (16-24 of SEQ ID NO:1)
US-09-899-815-2

Query Match      100.0%; Score 29; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 KLVFFA 6
Db      1 KLVFFA 6

RESULT 29
US-09-747-408-20
; Sequence 20, Application US/09747408
; Publication No. US20030003141A1
; GENERAL INFORMATION:
; APPLICANT: Green, Allan M.
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: Compounds And Methods For Modulating
; FILE REFERENCE: NBI-098
; CURRENT APPLICATION NUMBER: US/09/747,408
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/171,877
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
```

US-09-747-408-20

Query Match 100.0%; Score 29; DB 10; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|||||  
Db 4 KLVFFA 9

RESULT 30

US-10-235-483-64  
; Sequence 64, Application US/10235483  
; Publication No. US20030087407A1

GENERAL INFORMATION:

APPLICANT: SOTO-JARA, Claudio  
FRANGIONE, Blas  
BAUMANN, Marc

TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL

COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
DEPOSITS

NUMBER OF SEQUENCES: 69

CORRESPONDENCE ADDRESS:

ADDRESSEE: BROWDY AND NETMARK

STREET: 419 Seventh Street, N.W., Suite 400

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20004

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/235,483

FILING DATE: 06-Sep-2002

CLASSIFICATION: &lt;Unknown&gt;

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/766,596

FILING DATE: &lt;Unknown&gt;

APPLICATION NUMBER: US 08/630,645

FILING DATE: 10-APR-1996

APPLICATION NUMBER: US 08/478,326

FILING DATE: 06-JUN-1995

ATTORNEY/AGENT INFORMATION:

NAME: YUN, Allen C.

REGISTRATION NUMBER: 37,971

REFERENCE/DOCKET NUMBER: SOTO-JARA-1A

TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-628-5197

TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 64:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 64:

US-10-235-483-64

Query Match 100.0%; Score 29; DB 14; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|||||  
Db 2 KLVFFA 7

RESULT 31

US-10-619-454-3

; Sequence 3, Application US/10619454  
; Publication No. US20040091945A1

GENERAL INFORMATION:

APPLICANT: Mindset

APPLICANT: Fitzer Attas, Cheryl

APPLICANT: Chain, Daniel

TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES

TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

FILE REFERENCE: P-5202-US

CURRENT APPLICATION NUMBER: US/10/619,454

CURRENT FILING DATE: 2003-07-16

PRIOR APPLICATION NUMBER: US 60/396,245

PRIOR FILING DATE: 2002-07-17

NUMBER OF SEQ ID NOS: 187

SOFTWARE: PatentIn version 3.1

SEQ ID NO 3

LENGTH: 9

TYPE: PRT

ORGANISM: artificial sequence

FEATURE:

OTHER INFORMATION: algorithm generated

US-10-619-454-3

Query Match 100.0%; Score 29; DB 15; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.3e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 32

US-10-619-454-25

; Sequence 25, Application US/10619454

; Publication No. US20040091945A1

GENERAL INFORMATION:

APPLICANT: Mindset

APPLICANT: Fitzer Attas, Cheryl

APPLICANT: Chain, Daniel

TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES

TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED

FILE REFERENCE: P-5202-US

CURRENT APPLICATION NUMBER: US/10/619,454

CURRENT FILING DATE: 2003-07-16

PRIOR APPLICATION NUMBER: US 60/396,245

PRIOR FILING DATE: 2002-07-17

NUMBER OF SEQ ID NOS: 187

SOFTWARE: PatentIn version 3.1

SEQ ID NO 25

LENGTH: 9

TYPE: PRT

ORGANISM: artificial sequence

FEATURE:

OTHER INFORMATION: algorithm generated

US-10-619-454-25

Query Match 100.0%; Score 29; DB 15; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.3e+06;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6

Db 1 KLVFFA 6

RESULT 33

US-10-619-454-28

; Sequence 28, Application US/10619454

; Publication No. US20040091945A1

GENERAL INFORMATION:

```
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; TYPE: PRT
; LENGTH: 9
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-28

Query Match 100.0%; Score 29; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 34
US-10-619-454-57
; Sequence 57, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 57
; TYPE: PRT
; LENGTH: 9
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-57

Query Match 100.0%; Score 29; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 35
US-10-619-454-157
; Sequence 157, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
```

```
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 157
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-157

Query Match 100.0%; Score 29; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 36
US-09-867-847-29
; Sequence 29, Application US/09867847
; Patent No. US20020094335A1
; GENERAL INFORMATION:
; APPLICANT: Chalifour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xianqi
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES
; FILE REFERENCE: 14445-501 CIP
; CURRENT APPLICATION NUMBER: US/09/867,847
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; TYPE: PRT
; LENGTH: 10
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-09-867-847-29

Query Match 100.0%; Score 29; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 4 KLVFFA 9

RESULT 37
US-09-915-092-19
; Sequence 19, Application US/09915092
; Publication No. US20020115717A1
; GENERAL INFORMATION:
; APPLICANT: Gervais, Francine
; APPLICANT: Kong, Xianqi
; APPLICANT: Chalifour, Robert
; APPLICANT: Migneault, David
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND
; TITLE OF INVENTION: USES THEREOF
```

; FILE REFERENCE: NBI-139  
; CURRENT APPLICATION NUMBER: US/09/915,092  
; CURRENT FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/220,808  
; PRIOR FILING DATE: 2000-07-25  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 19  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-915-092-19

Query Match 100.0%; Score 29; DB 9; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||||  
Db 4 KLVFFA 9

RESULT 38  
US-10-823-463-20  
; Sequence 20, Application US/10823463  
; Publication No. US20050019328A1  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/10/823,463  
; CURRENT FILING DATE: 2004-04-14  
; PRIOR APPLICATION NUMBER: US/09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 20  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-10-823-463-20

Query Match 100.0%; Score 29; DB 17; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||||  
Db 5 KLVFFA 10

RESULT 39  
US-10-823-463-21  
; Sequence 21, Application US/10823463  
; Publication No. US20050019328A1  
; GENERAL INFORMATION:

; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/10/823,463  
; CURRENT FILING DATE: 2004-04-14  
; PRIOR APPLICATION NUMBER: US/09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-10-823-463-21

Query Match 100.0%; Score 29; DB 17; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFA 6  
|||||  
Db 4 KLVFFA 9

RESULT 40  
US-10-823-463-22  
; Sequence 22, Application US/10823463  
; Publication No. US20050019328A1  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/10/823,463  
; CURRENT FILING DATE: 2004-04-14  
; PRIOR APPLICATION NUMBER: US/09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 22  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:



; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-10-823-463-22

Query Match 100.0%; Score 29; DB 17; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;  
Matches 6; Conservative 0; Mismatches 0;

Qy 1 KLVFFA 6  
|||  
Db 3 KLVFFA 8

RESULT 41  
US-10-823-463-23  
; Sequence 23, Application US/10823463  
; Publication No. US20050019328A1  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/10/823,463  
; CURRENT FILING DATE: 2004-04-14  
; PRIOR APPLICATION NUMBER: US/09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 23  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-10-823-463-23

Query Match 100.0%; Score 29; DB 17; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;  
Matches 6; Conservative 0; Mismatches 0;

Qy 1 KLVFFA 6  
|||  
Db 2 KLVFFA 7

RESULT 42  
US-10-823-463-24  
; Sequence 24, Application US/10823463  
; Publication No. US20050019328A1  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Bard, Frederique  
; APPLICANT: Vasquez, Nicki  
; APPLICANT: Vednock, Ted  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004750UC  
; CURRENT APPLICATION NUMBER: US/10/823,463  
; CURRENT FILING DATE: 2004-04-14

; PRIOR APPLICATION NUMBER: US/09/580,015  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/322,289  
; PRIOR FILING DATE: 1999-05-28  
; PRIOR APPLICATION NUMBER: US 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; PRIOR APPLICATION NUMBER: US 60/067,740  
; PRIOR FILING DATE: 1997-12-02  
; NUMBER OF SEQ ID NOS: 77  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 10  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide  
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid  
; OTHER INFORMATION: peptide)  
US-10-823-463-24

Query Match 100.0%; Score 29; DB 17; Length 10;  
Best Local Similarity 100.0%; Pred. No. 7.4;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|||  
Db 1 KLVFFA 6

RESULT 43  
US-09-988-842-9  
; Sequence 9, Application US/09988842  
; Patent No. US20020143105A1  
; GENERAL INFORMATION:  
; APPLICANT: Johansson, Jan  
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION  
; TITLE OF INVENTION: OF AMYLOID FORMATION  
; FILE REFERENCE: 12125-002001  
; CURRENT APPLICATION NUMBER: US/09/988,842  
; CURRENT FILING DATE: 2001-11-19  
; PRIOR APPLICATION NUMBER: US 60/251,662  
; PRIOR FILING DATE: 2000-12-06  
; PRIOR APPLICATION NUMBER: US 60/253,695  
; PRIOR FILING DATE: 2000-11-20  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 9  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-9

Query Match 100.0%; Score 29; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.1;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
|||  
Db 2 KLVFFA 7

RESULT 44  
US-09-988-842-25  
; Sequence 25, Application US/09988842  
; Patent No. US20020143105A1  
; GENERAL INFORMATION:  
; APPLICANT: Johansson, Jan

;/ TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION  
;/ FILE REFERENCE: 12125-002001  
;/ CURRENT APPLICATION NUMBER: US/09/988,842  
;/ CURRENT FILING DATE: 2001-11-19  
;/ PRIOR APPLICATION NUMBER: US 60/251,662  
;/ PRIOR FILING DATE: 2000-12-06  
;/ PRIOR APPLICATION NUMBER: US 60/253,695  
;/ PRIOR FILING DATE: 2000-11-20  
;/ NUMBER OF SEQ ID NOS: 26  
;/ SOFTWARE: FastSeq for Windows Version 4.0  
;/ SEQ ID NO 25  
;/ LENGTH: 11  
;/ TYPE: PRT  
;/ ORGANISM: Artificial Sequence  
;/ FEATURE:  
;/ OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-25

Query Match 100.0%; Score 29; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.1;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 45  
US-10-235-483-14  
;/ Sequence 14, Application US/10235483  
;/ Publication No. US20030087407A1  
;/ GENERAL INFORMATION:  
;/ APPLICANT: SOTO-JARA, Claudio  
;/ BAUMANN, Marc  
;/ FRANGONE, Blas  
;/ TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
;/ COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
;/ ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
;/ DEPOSITS

NUMBER OF SEQUENCES: 69  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 400  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/235,483  
FILING DATE: 06-Sep-2002  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/766,596  
FILING DATE: <Unknown>  
APPLICATION NUMBER: US 08/630,645  
FILING DATE: 10-APR-1996  
APPLICATION NUMBER: US 08/478,326  
FILING DATE: 06-JUN-1995

ATTORNEY/AGENT INFORMATION:  
NAME: YUN, Allen C.  
REGISTRATION NUMBER: 37,971  
REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:

;/ LENGTH: 11 amino acids  
;/ TYPE: amino acid  
;/ STRANDEDNESS: single  
;/ TOPOLOGY: linear  
;/ MOLECULE TYPE: peptide  
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-10-235-483-14

Query Match 100.0%; Score 29; DB 14; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.1;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
Db 2 KLVFFA 7

RESULT 46  
US-10-050-200-33  
;/ Sequence 33, Application US/10050200  
;/ Publication No. US20030166037A1  
;/ GENERAL INFORMATION:  
;/ APPLICANT: Fourie, Anne  
;/ APPLICANT: Coles, Fawn  
;/ APPLICANT: Karlsson, Lars  
;/ TITLE OF INVENTION: Aggreanase-1 and -2 Peptide Substrates and Methods  
;/ FILE REFERENCE: ORT-1417  
;/ CURRENT APPLICATION NUMBER: US/10/050,200  
;/ CURRENT FILING DATE: 2002-01-16  
;/ NUMBER OF SEQ ID NOS: 60  
;/ SOFTWARE: PatentIn version 3.1  
;/ SEQ ID NO 33  
;/ LENGTH: 11  
;/ TYPE: PRT  
;/ ORGANISM: artificial sequence  
;/ FEATURE:  
;/ OTHER INFORMATION: peptide substrate  
US-10-050-200-33

Query Match 100.0%; Score 29; DB 14; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.1;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6  
Db 6 KLVFFA 11

RESULT 47  
US-10-237-673-20  
;/ Sequence 20, Application US/10237673  
;/ Publication No. US20040121398A1  
;/ GENERAL INFORMATION:  
;/ APPLICANT: FUJITSU LIMITED  
;/ APPLICANT: DAIICHI PHARMACEUTICAL CO., LTD.  
;/ TITLE OF INVENTION: Method for predicting protein-protein interactions  
;/ FILE REFERENCE: GP01-1001PCT  
;/ CURRENT APPLICATION NUMBER: US/10/237,673  
;/ CURRENT FILING DATE: 2002-09-10  
;/ PRIOR APPLICATION NUMBER: JP P2000-72485  
;/ PRIOR FILING DATE: 2000-03-10  
;/ NUMBER OF SEQ ID NOS: 21  
;/ SOFTWARE: PatentIn Ver. 2.1  
;/ SEQ ID NO 20  
;/ LENGTH: 11  
;/ TYPE: PRT  
;/ ORGANISM: Homo sapiens  
US-10-237-673-20

Query Match 100.0%; Score 29; DB 16; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.1;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 KLVFFA 6
Db 1 KLVFFA 6

RESULT 48
US-10-464-117-13
; Sequence 13, Application US/10464117
; Publication No. US20050014193A1
; GENERAL INFORMATION:
; APPLICANT: Palatin Technologies, Inc.
; APPLICANT: Sharma, Shubh D.
; APPLICANT: Shi, Yi-Qun
; TITLE OF INVENTION: Identification of Target-Specific Folding Sites in Peptides and
; Proteins
; FILE REFERENCE: 70025-UT-50075
; CURRENT APPLICATION NUMBER: US/10/464,117
; CURRENT FILING DATE: 2003-06-17
; PRIOR APPLICATION NUMBER: PCT/US01/50075
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: US 60/256,842
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 60/304,835
; PRIOR FILING DATE: 2001-02-13
; PRIOR APPLICATION NUMBER: US 60/327,835
; PRIOR FILING DATE: 2001-10-04
; NUMBER OF SEQ ID NOS: 171
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Amyloid beta-protein related peptide
US-10-464-117-13

Query Match 100.0%; Score 29; DB 17; Length 11;
Best Local Similarity 100.0%; Pred. No. 8.1;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 3 KLVFFA 8

RESULT 49
US-09-867-847-8
; Sequence 8, Application US/09867847
; Patent No. US20020094335A1
; GENERAL INFORMATION:
; APPLICANT: Chalfour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xiangi
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; DISEASE AND AMYLOID RELATED DISEASES
; FILE REFERENCE: 14445-501 CIP
; CURRENT APPLICATION NUMBER: US/09/867,847
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-09-867-847-8
```

```
Query Match 100.0%; Score 29; DB 9; Length 12;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 7 KLVFFA 12

RESULT 50
US-10-281-458-1
; Sequence 1, Application US/10281458
; Publication No. US20030108978A1
; GENERAL INFORMATION:
; APPLICANT: Gibbons, Ian
; APPLICANT: Ciambra, Gary J.
; TITLE OF INVENTION: Whole Cell Assay Systems for Cell
; Surface Proteases
; FILE REFERENCE: 50225-8093.US03
; CURRENT APPLICATION NUMBER: US/10/281,458
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: US 60/337,641
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 09/924,692
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-281-458-1
```

```
Query Match 100.0%; Score 29; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFA 6
Db 6 KLVFFA 11
```

Search completed: March 9, 2005, 07:40:27  
Job time : 50.3151 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 9, 2005, 06:11:37 ; Search time 261.397 Seconds  
(without alignments)  
31.278 Million cell updates/sec

Title: US-10-009-122-2

Perfect score: 34

Sequence: 1 KKLVFFA 7

Scoring table:

BLOSUM62

Gap 10.0 , Gapext 0.5

Searched: 6959266 seqs, 1168006243 residues

Total number of hits satisfying chosen parameters: 6959266

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 65 summaries

Database : Pending Patents AA Main:

- 1: /cgn2\_6/ptodata/1/paa/PCTUS COMB.pcp.\*
- 2: /cgn2\_6/ptodata/1/paa/US06 COMB.pcp.\*
- 3: /cgn2\_6/ptodata/1/paa/US07 COMB.pcp.\*
- 4: /cgn2\_6/ptodata/1/paa/US08 COMB.pcp.\*
- 5: /cgn2\_6/ptodata/1/paa/US081 COMB.pcp.\*
- 6: /cgn2\_6/ptodata/1/paa/US082 COMB.pcp.\*
- 7: /cgn2\_6/ptodata/1/paa/US083 COMB.pcp.\*
- 8: /cgn2\_6/ptodata/1/paa/US084 COMB.pcp.\*
- 9: /cgn2\_6/ptodata/1/paa/US085 COMB.pcp.\*
- 10: /cgn2\_6/ptodata/1/paa/US086 COMB.pcp.\*
- 11: /cgn2\_6/ptodata/1/paa/US087 COMB.pcp.\*
- 12: /cgn2\_6/ptodata/1/paa/US088 COMB.pcp.\*
- 13: /cgn2\_6/ptodata/1/paa/US089 COMB.pcp.\*
- 14: /cgn2\_6/ptodata/1/paa/US090 COMB.pcp.\*
- 15: /cgn2\_6/ptodata/1/paa/US091 COMB.pcp.\*
- 16: /cgn2\_6/ptodata/1/paa/US092 COMB.pcp.\*
- 17: /cgn2\_6/ptodata/1/paa/US093 COMB.pcp.\*
- 18: /cgn2\_6/ptodata/1/paa/US094 COMB.pcp.\*
- 19: /cgn2\_6/ptodata/1/paa/US095 COMB.pcp.\*
- 20: /cgn2\_6/ptodata/1/paa/US096 COMB.pcp.\*
- 21: /cgn2\_6/ptodata/1/paa/US097A COMB.pcp.\*
- 22: /cgn2\_6/ptodata/1/paa/US097B COMB.pcp.\*
- 23: /cgn2\_6/ptodata/1/paa/US098 COMB.pcp.\*
- 24: /cgn2\_6/ptodata/1/paa/US099A COMB.pcp.\*
- 25: /cgn2\_6/ptodata/1/paa/US099B COMB.pcp.\*
- 26: /cgn2\_6/ptodata/1/paa/US100 COMB.pcp.\*
- 27: /cgn2\_6/ptodata/1/paa/US101 COMB.pcp.\*
- 28: /cgn2\_6/ptodata/1/paa/US102 COMB.pcp.\*
- 29: /cgn2\_6/ptodata/1/paa/US103 COMB.pcp.\*
- 30: /cgn2\_6/ptodata/1/paa/US104 COMB.pcp.\*
- 31: /cgn2\_6/ptodata/1/paa/US105 COMB.pcp.\*
- 32: /cgn2\_6/ptodata/1/paa/US106 COMB.pcp.\*
- 33: /cgn2\_6/ptodata/1/paa/US107 COMB.pcp.\*
- 34: /cgn2\_6/ptodata/1/paa/US108 COMB.pcp.\*
- 35: /cgn2\_6/ptodata/1/paa/US109 COMB.pcp.\*
- 36: /cgn2\_6/ptodata/1/paa/US110 COMB.pcp.\*
- 37: /cgn2\_6/ptodata/1/paa/US60 COMB.pcp.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

ALIGNMENTS

Result No.	Score	Query Match	Length	DB	ID	Description
1	34	100.0	7	21	US-09-724-842-10	Sequence 10, Appl
2	34	100.0	7	21	US-09-724-842A-10	Sequence 10, Appl
3	34	100.0	7	23	US-09-867-847-12	Sequence 12, Appl
4	34	100.0	7	23	US-09-867-847A-12	Sequence 12, Appl
5	34	100.0	7	24	US-09-915-092-2	Sequence 2, Appl
6	34	100.0	7	26	US-10-009-122-2	Sequence 2, Appl
7	34	100.0	7	26	US-10-030-137A-5	Sequence 5, Appl
8	34	100.0	7	33	US-10-728-028-2	Sequence 2, Appl
9	34	100.0	7	34	US-10-825-958-10	Sequence 10, Appl
10	34	100.0	9	28	US-10-235-483-84	Sequence 64, Appl
11	34	100.0	10	37	US-60-603-403-1	Sequence 1, Appl
12	31	91.2	112	21	US-09-733-089-9030	Sequence 9030, Ap
13	31	91.2	112	23	US-09-816-660-9030	Sequence 9030, Ap
14	31	91.2	140	21	US-09-733-089-23062	Sequence 23062, A
15	31	91.2	140	23	US-09-816-660-23062	Sequence 23062, A
16	31	91.2	158	21	US-09-733-089-23064	Sequence 23064, A
17	31	91.2	158	23	US-09-816-660-23064	Sequence 23064, A
18	31	91.2	165	21	US-09-733-089-23060	Sequence 23060, A
19	31	91.2	165	23	US-09-816-660-23060	Sequence 23060, A
20	31	91.2	181	21	US-09-733-089-23063	Sequence 23063, A
21	31	91.2	181	23	US-09-816-660-23063	Sequence 23063, A
22	31	91.2	199	21	US-09-733-089-23065	Sequence 23065, A
23	31	91.2	199	23	US-09-816-660-23065	Sequence 23065, A
24	31	91.2	1640	30	US-10-437-963-109646	Sequence 109646, A
25	31	91.2	1640	30	US-10-438-246-24934	Sequence 24934, A
26	31	91.2	1764	27	US-10-155-881-25401	Sequence 25401, A
27	31	91.2	1764	27	US-10-155-881-28754	Sequence 28754, A
28	31	91.2	1764	30	US-10-438-246-17664	Sequence 17664, A
29	30	88.2	6	1	PCT-US02-26889-7	Sequence 7, Appl
30	30	88.2	7	9	US-08-548-998-6	Sequence 6, Appl
31	30	88.2	7	9	US-08-548-998A-6	Sequence 6, Appl
32	30	88.2	7	10	US-08-612-785-7	Sequence 7, Appl
33	30	88.2	7	10	US-08-616-081-7	Sequence 7, Appl
34	30	88.2	7	10	US-08-616-081A-7	Sequence 7, Appl
35	30	88.2	7	25	US-09-972-475-7	Sequence 7, Appl
36	30	88.2	7	25	US-09-972-475A-7	Sequence 7, Appl
37	30	88.2	7	30	US-10-463-729-7	Sequence 7, Appl
38	30	88.2	7	34	US-10-810-861A-128	Sequence 128, App
39	30	88.2	8	9	US-08-548-998-4	Sequence 4, Appl
40	30	88.2	8	9	US-08-548-998A-4	Sequence 4, Appl
41	30	88.2	8	10	US-08-612-785-5	Sequence 5, Appl
42	30	88.2	8	10	US-08-616-081-5	Sequence 5, Appl
43	30	88.2	8	10	US-08-616-081A-5	Sequence 5, Appl
44	30	88.2	8	25	US-09-972-475-5	Sequence 5, Appl
45	30	88.2	8	25	US-09-972-475A-5	Sequence 5, Appl
46	30	88.2	8	30	US-10-463-729-5	Sequence 5, Appl
47	30	88.2	9	3	US-07-877-675A-23	Sequence 23, Appl
48	30	88.2	9	3	US-07-877-675A-25	Sequence 25, Appl
49	30	88.2	9	23	US-09-867-847-9	Sequence 9, Appl
50	30	88.2	9	23	US-09-867-847A-9	Sequence 9, Appl
51	30	88.2	9	26	US-10-009-122-20	Sequence 20, Appl
52	30	88.2	9	28	US-10-235-483-54	Sequence 54, Appl
53	30	88.2	9	32	US-10-619-454-28	Sequence 28, Appl
54	30	88.2	10	19	US-09-580-015-20	Sequence 20, Appl
55	30	88.2	10	19	US-09-580-015-21	Sequence 21, Appl
56	30	88.2	10	19	US-09-580-015-22	Sequence 22, Appl
57	30	88.2	10	19	US-09-580-015-23	Sequence 23, Appl
58	30	88.2	10	19	US-09-580-019-20	Sequence 20, Appl
59	30	88.2	10	19	US-09-580-019-21	Sequence 21, Appl
60	30	88.2	10	19	US-09-580-019-22	Sequence 22, Appl
61	30	88.2	10	19	US-09-580-019-23	Sequence 23, Appl
62	30	88.2	10	21	US-09-723-544-20	Sequence 20, Appl
63	30	88.2	10	21	US-09-723-544-21	Sequence 21, Appl
64	30	88.2	10	21	US-09-723-544-22	Sequence 22, Appl
65	30	88.2	10	21	US-09-723-544-23	Sequence 23, Appl

RESULT 1  
US-09-724-842-10  
; Sequence 10, Application US/09724842  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiang  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501  
; CURRENT APPLICATION NUMBER: US/09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: Patent In Ver. 2.1  
; SEQ ID NO 10  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-724-842-10

Query Match 100.0%; Score 34; DB 21; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

RESULT 2  
US-09-724-842A-10  
; Sequence 10, Application US/09724842A  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiang  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501  
; CURRENT APPLICATION NUMBER: US/09/724,842A  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; NUMBER OF SEQ ID NOS: 63  
; SOFTWARE: Patent In Ver. 2.1  
; SEQ ID NO 10  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-724-842A-10

Query Match 100.0%; Score 34; DB 21; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

RESULT 3  
US-09-867-847-12

; Sequence 12, Application US/09867847  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiang  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: Patent In Ver. 2.1  
; SEQ ID NO 12  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-12

Query Match 100.0%; Score 34; DB 23; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

RESULT 4  
US-09-867-847A-12  
; Sequence 12, Application US/09867847A  
; GENERAL INFORMATION:  
; APPLICANT: Chalfour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiang  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: Vaccine for the Prevention and Treatment  
; TITLE OF INVENTION: of Alzheimer's and Amyloid Related Diseases  
; FILE REFERENCE: 50291/005001  
; CURRENT APPLICATION NUMBER: US/09/867,847A  
; CURRENT FILING DATE: 2001-05-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 12  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic, All D peptides or peptidomimetics  
US-09-867-847A-12

Query Match 100.0%; Score 34; DB 23; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVEFFA 7  
DB 1 KKLVEFFA 7

RESULT 5  
US-09-915-092-2

; Sequence 2, Application US/09915092  
; GENERAL INFORMATION:  
; APPLICANT: Gervais, Francine  
; APPLICANT: Kong, Xiangi  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Migneault, David  
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND  
; TITLE OF INVENTION: USES THEREOF  
; FILE REFERENCE: NBI-139  
; CURRENT APPLICATION NUMBER: US/09/915,092  
; CURRENT FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/220,808  
; PRIOR FILING DATE: 2000-07-25  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-915-092-2

Query Match 100.0%; Score 34; DB 24; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 KKLVEFA 7

RESULT 6  
US-10-009-122-2  
; Sequence 2, Application US/10009122  
; GENERAL INFORMATION:  
; APPLICANT: NEUROCHEM INC.  
; APPLICANT: CHALIFOUR, Robert  
; APPLICANT: Gervais, Francine  
; APPLICANT: GUPTA, Ajay  
; TITLE OF INVENTION: STERESELECTIVE ANTIFIBRILLOGENIC  
; TITLE OF INVENTION: PEPTIDES AND PEPTIDOMIMETICS THEREOF  
; FILE REFERENCE: 14228-1PCT  
; CURRENT APPLICATION NUMBER: US/10/009,122  
; CURRENT FILING DATE: 2001-11-05  
; PRIOR APPLICATION NUMBER: US/60/132,592  
; PRIOR FILING DATE: 1999-05-05  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 2  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: peptide having antifibrillogenic activity and/or  
; OTHER INFORMATION: neuroprotection  
US-10-009-122-2

Query Match 100.0%; Score 34; DB 26; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 KKLVEFA 7

RESULT 7  
US-10-030-137A-5  
; Sequence 5, Application US/10030137A  
; GENERAL INFORMATION:  
; APPLICANT: STOTT, KELVIN  
; TITLE OF INVENTION: PEPTIDES  
; FILE REFERENCE: P67518U50  
; CURRENT APPLICATION NUMBER: US/10/030,137A

; CURRENT FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: GB 9917724.8  
; PRIOR FILING DATE: 1999-07-28  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Homologous Sequence of SEQ ID NO.1  
US-10-030-137A-5

Query Match 100.0%; Score 34; DB 26; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 KKLVEFA 7

RESULT 8  
US-10-728-028-2  
; Sequence 2, Application US/10728028  
; GENERAL INFORMATION:  
; APPLICANT: Gervais, Francine  
; APPLICANT: KONG, Xiangi  
; APPLICANT: CHALIFOUR, Robert  
; APPLICANT: MIGNEAULT, David  
; TITLE OF INVENTION: AMYLOID TARGETING IMAGING AGENTS AND  
; TITLE OF INVENTION: USES THEREOF  
; FILE REFERENCE: NBI-139CP  
; CURRENT APPLICATION NUMBER: US/10/728,028  
; CURRENT FILING DATE: 2003-12-03  
; PRIOR APPLICATION NUMBER: 60/443291  
; PRIOR FILING DATE: 2003-01-29  
; PRIOR APPLICATION NUMBER: 09/915092  
; PRIOR FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/220808  
; PRIOR FILING DATE: 2000-07-25  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Construct  
US-10-728-028-2

Query Match 100.0%; Score 34; DB 33; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
DB 1 KKLVEFA 7

RESULT 9  
US-10-825-958-10  
; Sequence 10, Application US/10825958  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xiangi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES  
; FILE REFERENCE: 50291/004002  
; CURRENT APPLICATION NUMBER: US/10/825,958  
; CURRENT FILING DATE: 2004-04-16

;; PRIOR APPLICATION NUMBER: 09/724,842  
;; PRIOR FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: 60/168,594  
;; PRIOR FILING DATE: 1999-11-29  
;; NUMBER OF SEQ ID NOS: 63  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 10  
;; LENGTH: 7  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
;; OTHER INFORMATION: or peptidomimetics  
US-10-825-958-10

Query Match 100.0%; Score 34; DB 34; Length 7;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
|||  
Db 1 KKLVEFA 7

RESULT 10  
US-10-235-483-64  
;; Sequence 64, Application US/10235483  
;; GENERAL INFORMATION:  
;; APPLICANT: SOTO-JARA, Claudio  
;; BAUMANN, Marc  
;; FRANGIONE, Blas  
;; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
;; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
;; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
;; DEPOSITS  
;; NUMBER OF SEQUENCES: 69  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: BROWDY AND NEWMARK  
;; STREET: 419 Seventh Street, N.W., Suite 400  
;; CITY: Washington  
;; STATE: D.C.  
;; COUNTRY: USA  
;; ZIP: 20004  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/10/235,483  
;; FILING DATE: 06-Sep-2002  
;; CLASSIFICATION: <Unknown>  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/766,596  
;; FILING DATE: <Unknown>  
;; APPLICATION NUMBER: US 08/630,645  
;; FILING DATE: 10-APR-1996  
;; APPLICATION NUMBER: US 08/478,326  
;; FILING DATE: 06-JUN-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: YUN, Allen C.  
;; REGISTRATION NUMBER: 37,971  
;; REFERENCE/DOCKET NUMBER: SOTO-JARA-1A  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 202-628-5197  
;; TELEFAX: 202-737-3528  
;; INFORMATION FOR SEQ ID NO: 64:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 9 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide

;; SEQUENCE DESCRIPTION: SEQ ID NO: 64:  
US-10-235-483-64

Query Match 100.0%; Score 34; DB 28; Length 9;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
|||  
Db 1 KKLVEFA 7

RESULT 11  
US-60-603-403-1  
;; Sequence 1, Application US/60603403  
;; GENERAL INFORMATION:  
;; APPLICANT: Washington University St. Louis  
;; APPLICANT: Washington University St. Louis  
;; TITLE OF INVENTION: Blood Brain Barrier Permeation Peptides  
;; FILE REFERENCE: 6005161-0068  
;; CURRENT APPLICATION NUMBER: US/60/603,403  
;; CURRENT FILING DATE: 2004-08-20  
;; NUMBER OF SEQ ID NOS: 2  
;; SOFTWARE: PatentIn version 3.2  
;; SEQ ID NO 1  
;; LENGTH: 10  
;; TYPE: PRT  
;; ORGANISM: Artificial  
;; FEATURE:  
;; OTHER INFORMATION: BBB-permeant peptide sequence with ability to bind AB  
US-60-603-403-1

Query Match 100.0%; Score 34; DB 37; Length 10;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
|||  
Db 1 KKLVEFA 7

RESULT 12  
US-09-733-089-9030  
;; Sequence 9030, Application US/09733089  
;; GENERAL INFORMATION:  
;; APPLICANT: Dotson, Stanton B.  
;; APPLICANT: Kowalic, David K.  
;; APPLICANT: Liu, Jingdong  
;; APPLICANT: Lutfiyya, Linda L.  
;; APPLICANT: McIninch, James  
;; APPLICANT: Wu, Wei  
;; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With  
;; Transcription In Plants  
;; FILE REFERENCE: 38-21(15300)D  
;; CURRENT APPLICATION NUMBER: US/09/733,089  
;; CURRENT FILING DATE: 2000-12-11  
;; PRIOR APPLICATION NUMBER: US 09/474,435  
;; PRIOR FILING DATE: 1999-12-28  
;; PRIOR APPLICATION NUMBER: US 09/654,617  
;; PRIOR FILING DATE: 2000-09-05  
;; PRIOR APPLICATION NUMBER: US 09/620,392  
;; PRIOR FILING DATE: 2000-07-19  
;; NUMBER OF SEQ ID NOS: 24143  
;; SEQ ID NO 9030  
;; LENGTH: 112  
;; TYPE: PRT  
;; ORGANISM: Oryza sativa  
;; FEATURE:  
;; NAME/KEY: unsure  
;; LOCATION: (1)..(112)  
;; OTHER INFORMATION: unsure at all Xaa locations  
US-09-733-089-9030



```
Query Match          91.2%; Score 31; DB 21; Length 112;
Best Local Similarity 85.7%; Pred. No. 6.4e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVFPA 7
DB      20 KKVVFPA 26
      ||:|||||

RESULT 13
US-09-816-660-9030
; Sequence 9030, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/816,660
; PRIOR FILING DATE: 2001-03-26
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: )
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 9030
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(112)
; OTHER INFORMATION: unsure at all Xaa locations
US-09-816-660-9030

Query Match          91.2%; Score 31; DB 23; Length 112;
Best Local Similarity 85.7%; Pred. No. 6.4e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVFPA 7
DB      20 KKVVFPA 26
      ||:|||||

RESULT 14
US-09-733-089-23062
; Sequence 23062, Application US/09733089
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/733,089
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
```

```
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23062
; LENGTH: 140
; TYPE: PRT
; ORGANISM: Oryza sativa
US-09-733-089-23062

Query Match          91.2%; Score 31; DB 21; Length 140;
Best Local Similarity 85.7%; Pred. No. 7.8e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVFPA 7
DB      95 KKVVFPA 101
      ||:|||||

RESULT 15
US-09-816-660-23062
; Sequence 23062, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/816,660
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: )
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23062
; LENGTH: 140
; TYPE: PRT
; ORGANISM: Oryza sativa
US-09-816-660-23062

Query Match          91.2%; Score 31; DB 23; Length 140;
Best Local Similarity 85.7%; Pred. No. 7.8e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 KKLVFPA 7
DB      95 KKVVFPA 101
      ||:|||||

RESULT 16
US-09-733-089-23064
; Sequence 23064, Application US/09733089
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/733,089
```

```

; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23064
; LENGTH: 158
; TYPE: PRT
; ORGANISM: Oryza sativa
US-09-733-089-23064

```

```

Query Match          91.2%; Score 31; DB 21; Length 158;
Best Local Similarity 85.7%; Pred. No. 8.7e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 KKLVEFFA 7
    ||:||||
Db 113 KKVVEFFA 119

```

```

RESULT 17
US-09-816-660-23064
; Sequence 23064, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE OF INVENTION: Transcription In Plants
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/816,660
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: ) US 09/684,016
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23064
; LENGTH: 158
; TYPE: PRT
; ORGANISM: Oryza sativa
US-09-816-660-23064

```

```

Query Match          91.2%; Score 31; DB 23; Length 158;
Best Local Similarity 85.7%; Pred. No. 8.7e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 KKLVEFFA 7
    ||:||||
Db 113 KKVVEFFA 119

```

```

RESULT 18
US-09-733-089-23060
; Sequence 23060, Application US/09733089
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James

```

```

; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE OF INVENTION: Transcription In Plants
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/733,089
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23060
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(165)
; OTHER INFORMATION: unsure at all Xaa locations
US-09-733-089-23060

```

```

Query Match          91.2%; Score 31; DB 21; Length 165;
Best Local Similarity 85.7%; Pred. No. 9.1e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 KKLVEFFA 7
    ||:||||
Db 120 KKVVEFFA 126

```

```

RESULT 19
US-09-816-660-23060
; Sequence 23060, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE OF INVENTION: Transcription In Plants
; FILE REFERENCE: 38-21(15300)D
; CURRENT APPLICATION NUMBER: US/09/816,660
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: ) US 09/684,016
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23060
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(165)
; OTHER INFORMATION: unsure at all Xaa locations
US-09-816-660-23060

```

```

Query Match          91.2%; Score 31; DB 23; Length 165;
Best Local Similarity 85.7%; Pred. No. 9.1e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 KKLVEFFA 7

```

```
Db 120 KKVFFA 126
||:||||
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(181)
; OTHER INFORMATION: unsure at all Xaa locations
US-09-816-660-23063

Query Match 91.2%; Score 31; DB 23; Length 181;
Best Local Similarity 85.7%; Pred. No. 9.9e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7
||:||||
Db 136 KKVFFA 142

RESULT 22
US-09-733-089-23065
; Sequence 23065, Application US/09733089
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/733,089
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23063
; LENGTH: 181
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(181)
; OTHER INFORMATION: unsure at all Xaa locations
US-09-733-089-23063

Query Match 91.2%; Score 31; DB 21; Length 181;
Best Local Similarity 85.7%; Pred. No. 9.9e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7
||:||||
Db 136 KKVFFA 142

RESULT 21
US-09-816-660-23063
; Sequence 23063, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: )
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23063
; LENGTH: 181

US-09-733-089-23063
; Sequence 23063, Application US/09733089
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/733,089
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23063
; LENGTH: 181

US-09-816-660-23065
; Sequence 23065, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: US 09/733,089
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: )
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 09/620,392
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 24143
; SEQ ID NO 23065
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Oryza sativa
US-09-733-089-23065

Query Match 91.2%; Score 31; DB 21; Length 199;
Best Local Similarity 85.7%; Pred. No. 1.1e+03;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7
||:||||
Db 154 KKVFFA 160

RESULT 23
US-09-816-660-23065
; Sequence 23065, Application US/09816660
; GENERAL INFORMATION:
; APPLICANT: Dotson, Stanton B.
; APPLICANT: Kovalic, David K.
; APPLICANT: Liu, Jingdong
; APPLICANT: Lutfiyva, Linda L.
; APPLICANT: McIninch, James
; APPLICANT: Wu, Wei
; TITLE OF INVENTION: Nucleic Acid Molecules And Other Molecules Associated With
; FILE REFERENCE: 38-21(15300)D
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/474,435
; PRIOR FILING DATE: 1999-12-28
; PRIOR APPLICATION NUMBER: US 09/654,617
; PRIOR FILING DATE: 2000-09-05
```

; PRIOR APPLICATION NUMBER: US 09/733,089  
; PRIOR FILING DATE: 2000-12-11 US 09/684,016  
; PRIOR APPLICATION NUMBER: )  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 09/620,392  
; PRIOR FILING DATE: 2000-07-19  
; NUMBER OF SEQ ID NOS: 24143  
; SEQ ID NO 23065  
; LENGTH: 199  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
US-09-816-660-23065

Query Match 91.2%; Score 31; DB 23; Length 199;  
Best Local Similarity 85.7%; Pred. No. 1.1e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
||:||||  
Db 154 KKVVEFFA 160

## RESULT 24

US-10-437-963-109646  
; Sequence 109646, Application US/10437963

; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Cao, Yongwei  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; APPLICANT: Barbazuk, Brad

; APPLICANT: Li, Ping  
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated with  
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53221)B  
; CURRENT APPLICATION NUMBER: US/10/437,963  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 204966  
; SEQ ID NO 109646  
; LENGTH: 1640  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:

; OTHER INFORMATION: Clone ID: PAT\_MRT4530\_13784C.1.psp  
US-10-437-963-109646

Query Match 91.2%; Score 31; DB 30; Length 1640;  
Best Local Similarity 85.7%; Pred. No. 7.1e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
||:||||  
Db 1595 KKVVEFFA 1601

## RESULT 25

US-10-438-246-24934

; Sequence 24934, Application US/10438246  
; GENERAL INFORMATION:

; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Lutfiyya, Linda L.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; APPLICANT: Wu, Wei

; APPLICANT: Boukharov, Andrey A.  
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with  
; TITLE OF INVENTION: Transcription in Plants and Uses Thereof for Plant Improvement  
; FILE REFERENCE: 38-21(53333)B  
; CURRENT APPLICATION NUMBER: US/10/438,246

; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ ID NOS: 33516  
; SEQ ID NO 24934  
; LENGTH: 1640  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: TF\_Osc77457\_1.psp  
US-10-438-246-24934

Query Match 91.2%; Score 31; DB 30; Length 1640;  
Best Local Similarity 85.7%; Pred. No. 7.1e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
||:||||  
Db 1595 KKVVEFFA 1601

## RESULT 26

US-10-155-881-25401

; Sequence 25401, Application US/10155881  
; GENERAL INFORMATION:

; APPLICANT: Dotson, Stanton B.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Lutfiyya, Linda L.  
; APPLICANT: Mcininch, James

; APPLICANT: Mcininch, James  
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH  
; TITLE OF INVENTION: TRANSCRIPTION IN PLANTS

; FILE REFERENCE: 38-21(15300)J  
; CURRENT APPLICATION NUMBER: US/10/155,881  
; CURRENT FILING DATE: 2002-05-22  
; NUMBER OF SEQ ID NOS: 37595  
; SEQ ID NO 25401  
; LENGTH: 1764  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
US-10-155-881-25401

Query Match 91.2%; Score 31; DB 27; Length 1764;  
Best Local Similarity 85.7%; Pred. No. 7.6e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
||:||||  
Db 1719 KKVVEFFA 1725

## RESULT 27

US-10-155-881-28754

; Sequence 28754, Application US/10155881  
; GENERAL INFORMATION:

; APPLICANT: Dotson, Stanton B.  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Liu, Jingdong  
; APPLICANT: Lutfiyya, Linda L.  
; APPLICANT: Mcininch, James

; APPLICANT: Mcininch, James  
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED WITH  
; TITLE OF INVENTION: TRANSCRIPTION IN PLANTS

; FILE REFERENCE: 38-21(15300)J  
; CURRENT APPLICATION NUMBER: US/10/155,881  
; CURRENT FILING DATE: 2002-05-22  
; NUMBER OF SEQ ID NOS: 37595  
; SEQ ID NO 28754  
; LENGTH: 1764  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
US-10-155-881-28754

Query Match 91.2%; Score 31; DB 27; Length 1764;  
Best Local Similarity 85.7%; Pred. No. 7.6e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
||:||||  
Db 1719 KKVVEFA 1725

## RESULT 28

US-10-438-246-17664  
; Sequence 17664, Application US/10438246  
; GENERAL INFORMATION:  
; APPLICANT: La Rosa, Thomas J.  
; APPLICANT: Lutfiyeva, Linda L.  
; APPLICANT: Zhou, Yihua  
; APPLICANT: Kovalic, David K.  
; APPLICANT: Barbazuk, Brad  
; APPLICANT: Li, Ping  
; APPLICANT: Wu, Wei  
; APPLICANT: Boukharov, Andrey A.  
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with  
; FILE REFERENCE: 38-21(53333)B  
; CURRENT APPLICATION NUMBER: US/10/438,246  
; CURRENT FILING DATE: 2003-05-14  
; NUMBER OF SEQ. ID NOS: 33516  
; SEQ ID NO 17664  
; LENGTH: 1764  
; TYPE: PRT  
; ORGANISM: Oryza sativa  
; FEATURE:  
; OTHER INFORMATION: Clone ID: TF\_OSC401375j.C1.p5.fg  
US-10-438-246-17664

Query Match 91.2%; Score 31; DB 30; Length 1764;  
Best Local Similarity 85.7%; Pred. No. 7.6e+03;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
||:||||  
Db 1719 KKVVEFA 1725

## RESULT 29

PCT-US02-26889-7  
; Sequence 7, Application PC/TUS0226889  
; GENERAL INFORMATION:  
; APPLICANT: Stanley Stein  
; TITLE OF INVENTION: Application of Peptide Conjugates to  
; FILE REFERENCE: 2615-1-001PCT  
; CURRENT APPLICATION NUMBER: PCT/US02/26889  
; CURRENT FILING DATE: 2002-08-23  
; PRIOR APPLICATION NUMBER: 60/314,382  
; PRIOR FILING DATE: 2001-08-23  
; NUMBER OF SEQ ID NOS: 16  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 7  
; LENGTH: 6  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic  
PCT-US02-26889-7

Query Match 88.2%; Score 30; DB 1; Length 6;  
Best Local Similarity 100.0%; Pred. No. 6.4e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFF 6  
|||||  
Db 1 KKLVEFF 6

## RESULT 30

US-08-548-998-6  
; Sequence 6, Application US/08548998  
; GENERAL INFORMATION:  
; APPLICANT: Mark A. Findeis, Howard Benjamin, Marc B. Garnick,  
; APPLICANT: Malcolm L. Gelfer, Arvind Hundal, Laura Kasman,  
; APPLICANT: Gary Musso, Ethan R. Signer, James Wakefield,  
; APPLICANT: Michael Reed, Susan Molineaux, William Kubasek, Joseph  
; APPLICANT: Chin, Jung-Ja Lee and Michael Kelley.  
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "Symbol"}-Amyloid Peptide Aggrega  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/548,998  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hanley, Elizabeth A.  
; REGISTRATION NUMBER: 33,505  
; REFERENCE/DOCKET NUMBER: PPI-016  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-5940  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-548-998-6  
Query Match 88.2%; Score 30; DB 9; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
:|||||  
Db 1 QKLVEFA 7

RESULT 31  
US-08-548-998A-6  
; Sequence 6, Application US/08548998A  
; GENERAL INFORMATION:  
; APPLICANT: Mark A. Findeis, Howard Benjamin, Marc B. Garnick,  
; APPLICANT: Malcolm L. Gelfer, Arvind Hundal, Laura Kasman,  
; APPLICANT: Gary Musso, Ethan R. Signer, James Wakefield,  
; APPLICANT: Michael Reed, Susan Molineaux, William Kubasek, Joseph  
; APPLICANT: Chin, Jung-Ja Lee and Michael Kelley.  
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "Symbol"}-Amyloid Peptide Aggrega  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/548,998A
; FILING DATE: 21-OCT-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanley, Elizabeth A.
; REGISTRATION NUMBER: 33,505
; REFERENCE/DOCKET NUMBER: PPI-016
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-548-998A-6

Query Match      88.2%; Score 30; DB 9; Length 7;
Best Local Similarity 85.7%; Pred. No. 6.4e+06;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      1 QKLVFPA 7

RESULT 32
US-08-612-785-7
; Sequence 7, Application US/08612785
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,785
; FILING DATE: Herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/404,831
; FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/475,579
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-002CP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
```

```
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-612-785-7

Query Match      88.2%; Score 30; DB 10; Length 7;
Best Local Similarity 85.7%; Pred. No. 6.4e+06;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      1 QKLVFPA 7

RESULT 33
US-08-616-081-7
; Sequence 7, Application US/08616081
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of b-Amyloid Peptide Aggregation
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, Suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/616,081
; FILING DATE: Herewith
; CLASSIFICATION: 252
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/548,998
; FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: PPI-016CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-616-081-7

Query Match      88.2%; Score 30; DB 10; Length 7;
Best Local Similarity 85.7%; Pred. No. 6.4e+06;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KKLVFPA 7
Db      1 QKLVFPA 7

RESULT 34
US-08-616-081A-7
; Sequence 7, Application US/08616081A
; GENERAL INFORMATION:
; APPLICANT: Findeis, Mark A. et al.
; TITLE OF INVENTION: Modulators of (SYMBOL 98 \f "Symbol")-Amyloid Peptide Aggrega
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/616,081A  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION NUMBER: USN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-016CP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
MOLECULE TYPE: peptide  
US-08-616-081A-7

Query Match 88.2%; Score 30; DB 10; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
Db 1 QKLVEFFA 7

RESULT 35  
US-09-972-475-7  
Sequence 7, Application US/09972475  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/972,475  
FILING DATE: 04-Oct-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USN 08/617,267  
FILING DATE: 14-MAR-1996  
APPLICATION NUMBER: USN 08/404,831  
FILING DATE: 14-MAR-1995  
APPLICATION NUMBER: USN 08/475,579  
FILING DATE: 07-JUN-1995  
APPLICATION NUMBER: USN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2CN  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
MOLECULE TYPE: peptide  
US-09-972-475A-7

Query Match 88.2%; Score 30; DB 25; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
MOLECULE TYPE: peptide  
US-09-972-475-7

Query Match 88.2%; Score 30; DB 25; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFFA 7  
Db 1 QKLVEFFA 7

RESULT 36  
US-09-972-475A-7  
Sequence 7, Application US/09972475A  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/972,475A  
FILING DATE: 04-Oct-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USN 08/617,267  
FILING DATE: 14-MAR-1996  
APPLICATION NUMBER: USN 08/404,831  
FILING DATE: 14-MAR-1995  
APPLICATION NUMBER: USN 08/475,579  
FILING DATE: 07-JUN-1995  
APPLICATION NUMBER: USN 08/548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2CN  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
MOLECULE TYPE: peptide  
US-09-972-475A-7

Query Match 88.2%; Score 30; DB 25; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
:|||||  
Db 1 QKLVEFA 7

## RESULT 37

US-10-463-729-7  
; Sequence 7, Application US/10463729  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 32  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/463,729  
; FILING DATE: 17-Jun-2003  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/617,267  
; FILING DATE: 14-MAR-1996  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 7 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:  
US-10-463-729-7

Query Match 88.2%; Score 30; DB 30; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
:|||||  
Db 1 QKLVEFA 7

## RESULT 38

US-10-810-881A-128  
; Sequence 128, Application US/10810881A  
; GENERAL INFORMATION:  
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.  
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES  
; FILE REFERENCE: CEN5021 NP  
; CURRENT APPLICATION NUMBER: US/10/810,881A  
; CURRENT FILING DATE: 2004-03-26  
; PRIOR APPLICATION NUMBER: US 60/458,474

; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,469  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,509  
; PRIOR FILING DATE: 2003-03-28  
; PRIOR APPLICATION NUMBER: US 60/458,510  
; PRIOR FILING DATE: 2003-03-28  
; NUMBER OF SEQ ID NOS: 131  
; SOFTWARE: Patent in version 3.3  
; SEQ ID NO: 128  
; LENGTH: 7  
; TYPE: PRT  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: PEPTIDE  
US-10-810-881A-128

Query Match 88.2%; Score 30; DB 34; Length 7;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKLVEFA 7  
:|||||  
Db 1 QKLVEFA 7

## RESULT 39

US-08-548-998-4  
; Sequence 4, Application US/08548998  
; GENERAL INFORMATION:  
; APPLICANT: Mark A. Findeis, Howard Benjamin, Marc B. Garnick,  
; APPLICANT: Malcolm L. Getter, Arvind Hundal, Laura Kasman,  
; APPLICANT: Gary Musso, Ethan R. Signer, James Wakefield,  
; APPLICANT: Michael Reed, Susan Molineaux, William Kubasek, Joseph  
; APPLICANT: Chin, Jung-Ja Lee and Michael Kelley.  
; TITLE OF INVENTION: Modulators of [SYMBOL 98 \f "symbol"]-Amyloid Peptide Aggrega  
; TITLE OF INVENTION: Comprising an Ab Aggregation Core Domain  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/548,998  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hanley, Elizabeth A.  
; REGISTRATION NUMBER: 33,505  
; REFERENCE/DOCKET NUMBER: PPI-016  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-548-998-4

Query Match 88.2%; Score 30; DB 9; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;



QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

RESULT 40  
US-08-548-998A-4  
; Sequence 4, Application US/08548998A  
; GENERAL INFORMATION:  
; APPLICANT: Mark A. Findeis, Howard Benjamin, Marc B. Garnick,  
; APPLICANT: Malcolm L. Gafter, Arvind Hundal, Laura Kasman,  
; APPLICANT: Gary Musso, Ethan R. Signer, James Wakefield,  
; APPLICANT: Michael Reed, Susan Molineaux, William Kubasek, Joseph.  
; APPLICANT: Chin, Jung-Ja Lee and Michael Kelley.  
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "Symbol"}-Amyloid Peptide Aggrega  
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "Symbol"}-Amyloid Peptide Aggrega  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/548,998A  
; FILING DATE: 21-OCT-1995  
; CLASSIFICATION: 514  
; NAME: Hanley, Elizabeth A.  
; REGISTRATION NUMBER: 33,505  
; REFERENCE/DOCKET NUMBER: PPI-016  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-548-998A-4

Query Match 88.2%; Score 30; DB 9; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

RESULT 41  
US-08-612-785-5  
; Sequence 5, Application US/08612785  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 32  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-612-785-5

Query Match 88.2%; Score 30; DB 10; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

RESULT 42  
US-08-616-081-5  
; Sequence 5, Application US/08616081  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of b-Amyloid Peptide Aggregation  
; TITLE OF INVENTION: Comprising an Ab Aggregation Core Domain  
; NUMBER OF SEQUENCES: 32  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/616,081  
; FILING DATE: Herewith  
; CLASSIFICATION: 252  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-016CP  
; TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-616-081A-5

Query Match 88.2%; Score 30; DB 10; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

## RESULT 43

US-08-616-081A-5  
Sequence 5, Application US/08616081A  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Modulators of {SYMBOL 98 \F "Symbol"}-Amyloid Peptide Aggrega  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/616,081A  
FILING DATE: Herewith  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-016CP  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-616-081A-5

Query Match 88.2%; Score 30; DB 10; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

## RESULT 44

US-09-972-475-5  
Sequence 5, Application US/09972475  
GENERAL INFORMATION:

APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/972,475  
FILING DATE: 04-Oct-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/617,267  
FILING DATE: <Unknown>  
APPLICATION NUMBER: USSN 08/475,579  
FILING DATE: 07-JUN-1995  
APPLICATION NUMBER: USSN 08/548,998  
FILING DATE: 27-OCT-1995  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-972-475-5

Query Match 88.2%; Score 30; DB 25; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

## RESULT 45

US-09-972-475A-5  
Sequence 5, Application US/09972475A  
GENERAL INFORMATION:  
APPLICANT: Findeis, Mark A. et al.  
TITLE OF INVENTION: Modulators of Amyloid Aggregation  
NUMBER OF SEQUENCES: 45  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109-1875  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/972,475A  
FILING DATE: 04-Oct-2001  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US98/0617,267  
FILING DATE: 14-MAR-1996  
APPLICATION NUMBER: US98/0404,831  
FILING DATE: 14-MAR-1995  
APPLICATION NUMBER: US98/0475,579  
FILING DATE: 07-JUN-1995  
APPLICATION NUMBER: US98/0548,998  
FILING DATE: 27-OCT-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DeConti, Giulio A.  
REGISTRATION NUMBER: 31,503  
REFERENCE/DOCKET NUMBER: PPI-002CP2CN  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
US-09-972-475A-5.

Query Match 88.2%; Score 30; DB 25; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

RESULT 46  
US-10-463-729-5  
; Sequence 5, Application US/10463729  
; GENERAL INFORMATION:  
; APPLICANT: Fideis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 32  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 60 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; FILING DATE: 17-Jun-2003  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/10/463,729  
; FILING DATE: 14-MAR-1996  
; APPLICATION NUMBER: US98/0404,831  
; FILING DATE: 14-MAR-1995  
; APPLICATION NUMBER: US98/0475,579  
; FILING DATE: 07-JUN-1995  
; APPLICATION NUMBER: US98/0548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
US-10-463-729-5

Query Match 88.2%; Score 30; DB 30; Length 8;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 2 QKLVEFA 8

RESULT 47  
US-07-877-675A-23  
; Sequence 23, Application US/07877675A  
; GENERAL INFORMATION:  
; APPLICANT: Vitek Dr., Michael P.  
; APPLICANT: Jacobsen Dr., Jack S.  
; TITLE OF INVENTION: Novel Amyloid Precursor Proteins and  
; TITLE OF INVENTION: Methods of Using Same  
; NUMBER OF SEQUENCES: 25  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: 1937 West Main Street  
; CITY: Stamford  
; STATE: CT  
; COUNTRY: USA  
; ZIP: 06904-0060  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; FILING DATE: 19920501  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Lowney, Dr., Karen A.  
; REGISTRATION NUMBER: 31,274  
; REFERENCE/DOCKET NUMBER: 31844-00  
; TELEPHONE: 203-321-2361  
; TELEFAX: 203-321-2971  
; TELEX: 710-474-4059  
; INFORMATION FOR SEQ ID NO: 23:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: AMINO ACID  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-07-877-675A-23

Query Match 88.2%; Score 30; DB 3; Length 9;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVEFA 7  
Db 1 QKLVEFA 7

RESULT 48  
US-07-877-675A-25  
; Sequence 25, Application US/07877675A  
; GENERAL INFORMATION:  
; APPLICANT: Vitek Dr., Michael P.  
; APPLICANT: Jacobsen Dr., Jack S.

;; TITLE OF INVENTION: Novel Amyloid Precursor Proteins and  
;; TITLE OF INVENTION: Methods of Using Same  
;; NUMBER OF SEQUENCES: 25  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSES: American Cyanamid Company  
;; STREET: 1937 West Main Street  
;; CITY: Stamford  
;; STATE: CT  
;; COUNTRY: USA  
;; ZIP: 06904-0060  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/07/877,675A  
;; FILING DATE: 19920501  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Lowney, Dr., Karen A.  
;; REGISTRATION NUMBER: 31,274  
;; REFERENCE/DOCKET NUMBER: 31844-00  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 203-321-2361  
;; TELEFAX: 203-321-2971  
;; TELEX: 710-474-4059  
;; INFORMATION FOR SEQ ID NO: 25:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 9 amino acids  
;; TYPE: AMINO ACID  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-07-877-675A-25

Query Match 88.2%; Score 30; DB 3; Length 9;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
DB 1 QKLVFPA 7

RESULT 49  
US-09-867-847-9  
;; Sequence 9, Application US/09867847  
;; GENERAL INFORMATION:  
;; APPLICANT: Chalfour, Robert  
;; APPLICANT: Hebert, Lise  
;; APPLICANT: Kong, Xiangqi  
;; APPLICANT: Gervais, Francine  
;; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
;; FILE REFERENCE: 14445-501 CIP  
;; CURRENT APPLICATION NUMBER: US/09/867,847  
;; PRIOR FILING DATE: 2001-09-20  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: 60/168,594  
;; PRIOR FILING DATE: 2000-11-28  
;; NUMBER OF SEQ ID NOS: 65  
;; SOFTWARE: PatentIn Ver. 2.1  
;; SEQ ID NO 9  
;; LENGTH: 9  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
;; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-9

Query Match 88.2%; Score 30; DB 23; Length 9;

Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 KKLVFPA 7  
DB 3 QKLVFPA 9

RESULT 50  
US-09-867-847A-9  
;; Sequence 9, Application US/09867847A  
;; GENERAL INFORMATION:  
;; APPLICANT: Chalfour, Robert  
;; APPLICANT: Hebert, Lise  
;; APPLICANT: Kong, Xiangqi  
;; APPLICANT: Gervais, Francine  
;; TITLE OF INVENTION: Vaccine for the Prevention and Treatment  
;; FILE REFERENCE: 50291/005001  
;; CURRENT APPLICATION NUMBER: US/09/867,847A  
;; CURRENT FILING DATE: 2001-05-29  
;; PRIOR APPLICATION NUMBER: 09/724,842  
;; PRIOR FILING DATE: 2000-11-28  
;; PRIOR APPLICATION NUMBER: 60/168,594  
;; PRIOR FILING DATE: 1999-11-29  
;; NUMBER OF SEQ ID NOS: 65  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 9  
;; LENGTH: 9  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Synthetic, All D peptides or peptidomimetics  
US-09-867-847A-9

Query Match 88.2%; Score 30; DB 23; Length 9;  
Best Local Similarity 85.7%; Pred. No. 6.4e+06;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 KKLVFPA 7  
DB 3 QKLVFPA 9

Search completed: March 9, 2005, 07:28:33  
Job time : 262.397 secs